III

ETHIOPIAN MEDICINES FORMULARY

Second Edition
2013

Addis Ababa, Ethiopia

Contents

Pages

PREFACE -------------------------------------------------------------------- vii

ACKNOWLEDGEMENTS ------------------------------------------------- ix
ACRONYMS and ABBREVIATIONS ----------------------------------- xi
STRUCTURE and HOW to USE THE EMF--------------------------- xvi
Changes from the First Edition ------------------------------------------- xvi
How the EMF is developed ----------------------------------------------- xvi
Sources of EMF information ---------------------------------------------- xvi
How to Use and Search Information in EMF ---------------------------xvii
MEDICINES PRESCRIPTION, PRESCRIBING, DISPENSING,
and COUNSELING------------------------------------------------------- xix
Prescription Form --------------------------------------------------------- xix
Prescription Writing------------------------------------------------------- xx
Good Dispesing Practices ------------------------------------------------ xxix
Labeling of Medicines ---------------------------------------------------- xxix
Counseling of Patients ----------------------------------------------------- xxx
Adherence with Medicines Treatment ---------------------------------- xxxi
Monitoring drug treatment ---------------------------------------------- xxxii
ANTIMICROBIAL PRESCRIBING ------------------------------- xxxii
General antimicrobials prescribing practice -------------------------- xxxii
Antimicrobials Use for Surgical Prophylaxis----------------------- xxxviii
Antimicrobials Prophylaxis in Gynaecologic Procedures ----------- xliii
1. GASTROINTESTINAL SYSTEM MEDICINES -------------- 1
1.1. Antacids ------------------------------------------------------------------- 1
1.2. Anti-ulcer Agents ------------------------------------------------------- 8
1.5. Cathartics and Laxative --------------------------------------------- 41
1.6. Medicines Used in Diarrhea ---------------------------------------- 51
1.7. Antiflatulants ---------------------------------------------------------- 56
1.8. Digestants --------------------------------------------------------------- 57
1.9. Antihaemorrhoidal Agents------------------------------------------ 58
2. UROLOGICAL and RELATED MEDICINES ------------------ 62
2.1. Medicine used in benign prostatic hyperplasia ----------------- 62

ii

3. CARDIOVASCULAR MEDICINES ------------------------------- 71

3.1. Medicinesused for Congestive Cardiac failure ----------------- 71
3.2. Antiarrhythmics ------------------------------------------------------- 83
3.4. Medicines used for Angina/Ischemic Heart Disease ---------- 119
3.5. Antihypertensives ---------------------------------------------------- 129
3.6. Diuretics---------------------------------------------------------------- 160
3.7. Sclerosing Agents ---------------------------------------------------- 169
3.8. Medicines used in vascular shock -------------------------------- 171
3.9. Thrombolytic agent -------------------------------------------------- 177
4. RESPIRATORY MEDICINES ------------------------------------- 184
4.1. Antitussives/Expectorants/Mucolytics --------------------------- 184
4.2. Bronchodilators /Antiasthmatics --------------------------------- 190
5. CENTRAL NERVOUS SYSTEM MEDICINES ---------------- 211
5.1. Analgesics / Antipyretics ------------------------------------------- 211
5.3. Anxiolytics Sedatives, Hypnotics and Antipsychotics -------- 241
5.4. Antidepressants ------------------------------------------------------ 265
5.5. Mood Stabilizers ----------------------------------------------------- 278
5.6. Anticonvulsants ------------------------------------------------------ 280
5.7. Antiparkinson Agents ----------------------------------------------- 298
5.8. Medicines for Attention Deficit Disorder ----------------------- 305
6. MEDICINES USED in ANAESTHESIA ------------------------- 313
6.1. General Anaesthetics ------------------------------------------------ 313
6.2. Neuromuscular Blockers ------------------------------------------- 325
6.3. Anesthetic Adjuncts and Adjuvants ----------------------------- 330
6.4. Local Anesthetics----------------------------------------------------- 339
7. MEDICINES for MUSCLOSKELETAL and JOINT DISEASE345
7.1. Antirheumatics ------------------------------------------------------- 345
7.2. Medines used for Gout ---------------------------------------------- 357
7.3. Skeletal Muscle Relaxants ----------------------------------------- 362
7.4. Cholinergic and Anticholinesterase Agents -------------------- 368
7.5. Disease Modifying Antirheumatic Medicines ------------------ 372
7.6. Medicines for the relief of soft tissue inflammation ---------- 373
8. ANTI-INFECTIVES -------------------------------------------------- 378

iii

8.1. Antibacterials --------------------------------------------------------- 378

8.1.1. Penicillins ..................................................................................... 378
8.1.2. Cephalosporins, carbapenems, and other beta-lactams.......... 393
8.1.3.Macrolides ................................................................................... 412
8.1.4Aminoglycosides .......................................................................... 417
8.1.5. Quinolones ................................................................................. 420
8.1.6 Tetracyclines ............................................................................... 426
8.1.7.Chloramphenicols ....................................................................... 430
8.1.8.Miscellaneous.............................................................................. 432
8.1.9. Antituberculous drugs .................................................................. 441
8.1.10. Antileprotics ............................................................................... 459

8.2. Antifungals ------------------------------------------------------------ 462

8.3. Antivirals -------------------------------------------------------------- 474
8.3.1. Anti-Retroviral (ARV) Agents ...................................................... 474
8.3.3. Other Antivirals............................................................................ 501

8.4. Antiprotozoals -------------------------------------------------------- 509

8.4.1 Antimalarials ................................................................................. 509
8.4.2. Amoebicides and Antigiardial Agents ........................................... 523
8.4.3. Leshmaniacides............................................................................. 527
8.4.4. Trypanocides ................................................................................ 531
8.4.5. Medicines for Toxoplasmosis ........................................................ 533

8.5. Anthelmintics --------------------------------------------------------- 538

8.5.1. Filaricides ..................................................................................... 538
8.5.3. Other Anthelmintics ..................................................................... 544

9. MEDICINES for ENDOCRINE DISORDERS and

CONTRACEPTIVES ---------------------------------------------------- 552
9.1. Pituitary Hormone Preparations --------------------------------- 552
9.3. Thyroid Hormones and Antithyroid Agents ------------------- 564
9.4. Insulin and oral antidiabetic agents------------------------------ 569
9.5. Female Sex hormones and Combination preparations ------ 586
9.6. Male sex hormone Preparations and its antagonists --------- 594
9.7. Contraceptives -------------------------------------------------------- 596
9.7.1. Combined Oral Contraceptives ..................................................... 600
9.7.3. Contraceptive Devices, Barriers, and Spermicides ........................ 606

9.8. Medicines affecting Gonadotrophins ---------------------------- 610

9.9. Medicines used for impotence ------------------------------------- 611

iv

10. OBSTETRIC and GYNAECOLOGICAL MEDICINES --- 615

11. ANTINEOPLASTICS and ADJUVANTS ---------------------- 637
12. BLOOD PRODUCTS and MEDICINES ------------------------ 673
AFFECTING the BLOOD ---------------------------------------------- 673
12.1. Anticoagulants ------------------------------------------------------ 673
12.3. Hemostatic Agents ------------------------------------------------- 684
12.4. Antianemic Agents ------------------------------------------------- 685
12.5. Blood Substitutes and Plasma Expanders --------------------- 701
13.
MEDICINES
for
CORRECTING
WATER,
ELECTROLYTE and ACID-BASEDISTU RBANCES ---------- 708
13.1. Oral Electrolytes ---------------------------------------------------- 708
13.2. Parenteral Electrolyte --------------------------------------------- 717
14. VITAMINS ------------------------------------------------------------- 728
14.1. Vitamins, single ----------------------------------------------------- 730
14.2. Vitamins, Combinations ------------------------------------------ 744
14.2.1. Vitamin B complex preparations* ............................................... 744
14.2.2. Multivitamin preparations* ........................................................ 745
14.2.3. Multivitamin with minerals and/or extracts* ............................... 745

15. ANTIHISTAMINES and ANTIALLERGICS ----------------- 746

15.1. Antihistamines ------------------------------------------------------ 746
15.2. Medicines used in Allergic Emergencies ---------------------- 758
16. OPHTHALMIC AGENTS ----------------------------------------- 762
16.1. Antiglaucoma ----------------------------------------------------- 762
16.2. Mydriatics / Cycloplegics --------------------------------------- 776
16.3. Anti-infectives, Ophthalmic ------------------------------------ 781
16.3.1. Antibacterials.............................................................................. 781
16.3.2. Antivirals .................................................................................... 788
16.3.3. Antifungals ................................................................................. 792

16.4. Anti-inflammatories --------------------------------------------- 793

16.5. Anti-infective/Anti-inflammatory combination. ----------- 804
16.6. Anesthetics, Local ------------------------------------------------ 808
16.7. Diagnostics and Miscellaneous Agents ---------------------- 811
17. EAR, NOSE and THROAT PREPARATIONS ---------------- 821
17.1. Nasal and Oropharyngeal, Preparations ---------------------- 821

17.2. Otic Agents ----------------------------------------------------------- 834

18. DERMATOLOGICAL AGENTS --------------------------------- 841
18.1. Anti-infective, Topical --------------------------------------------- 841
18.2. Anti-Inflammatories, Topical ------------------------------------ 862
18.3. Anti-infective/Anti-inflammatory Combinations ------------ 868
18.4. Keratolytics/Caustics and Antiacne Agents ------------------ 872
18.5. Medicines for Psoriasis and Eczema --------------------------- 879
18.6. Antiprurities --------------------------------------------------------- 881
18.7. Depigmenting Agents --------------------------------------------- 883
18.9. Dermatological, systemic------------------------------------------ 885
18.10. Skin Disinfecting Agents ---------------------------------------- 890
18.11. Dermatologicals, Others ----------------------------------------- 893
19. ANTIDOTES and SUBSTANCES USED in POISONING -- 899
20. IMMUNOLOGICAL PREPARATIONS ----------------------- 915
21. MISCELLANEOUS ------------------------------------------------- 947
GLOSSARY ----------------------------------------------------------------- 954
APPENDIXES -------------------------------------------------------------- 967
APPENDIX I: Medicines Dose Calculation for Children ------------ 967
APPENDIX II: Body Weight to Surface Area------------------------- 968
APPENDIX III: Medicines Adverse Events ---------------------------- 969
APPENDIX IV: Medicines Storage Condition------------------------- 971
INDICES --------------------------------------------------------------------- 972

vi

PREFACE
An independent and up-to-date medicines information is
essentail for the safe and effective use of medicinces. In the
absence of such information resource, promotion of rational use
of medicines is at stake, which eventually harm the health of
indivuduals and affect the overall healthcare delivery system.
Recognising this unmet need on medicines information, the
Ethiopian Food, Medicine and Healthcare Administration and
Control Authority (EFMHACA) has been striving to develop
and make accessible medicines information materials including,
medicines formularies and standard treatment guidelines, good
prescribing and dispensing manuals, leaflets/posters in various
issues, bulletins, and others both in print copies and also
availing them in its website www.fmhaca.gov.et.
The EMF aims to provide unbiased and up-to-date information
on medicines. And it targets all health professionals involved in
patient care, training, research and others. Therefore the over all
goal of the EMF is to help health professionals base their
practice on solid information and knowledge to promote
rational use of medicines.
The second edition of the Ethiopian Medicines Formaulary
(EMF) is hereby revised based on the latest developments in the
fields of medicine and pharmacy. The second edition of the
EMF contains all the medicines included in the 6th edition and
its supplements of the Ethiopian Medicines List (EML). The
EMF contains key information on medicines which are essential
for medicines good prescribing, dispensing, adminstration and
use. It tries to address demands of all medicines prescribers,
dispensers and others who are involved in handling and use of
medicines.
vii

We hope that, this EMF will be of great help in providing useful

information to you in promoting the rational use of medicnes
and provision of quality health services for improved health
outcomes. It is of particular importance to those healthcare
providers working at health facilties who have little access to
adequate and up to date information on medicines.
Although the EMF has expnaded in its current volume; it still
will be used as digest for rapid reference and it may not always
include all the information needed for prescribing and
dispensing of medcines and also does not substitute standard
treatment guidelines.
Finally, I would like to express my gratitude to all those who
have directly or indirectly extended their helping hands in the
revision and printing of the EMF. I call upon all health
professionals and interested parties to continue their feedback
for the regular updating of the formulary by forwarding
comments and suggestions to:
FMHACA, P.O.Box 5681, Addis Ababa, Ethiopia
Fax: 251-115-521392
Free call line: 8482
E-mail: [email protected].
Yehulu Denekew
Director General, EFMHACA
May 2013

viii

ACKNOWLEDGEMENTS
This second edition of Ethiopian Medicines Formulary (EMF)
has passed intensive works starting from preparation of the draft
document by arranging monographs for each medicine to
preparing detailed document. It was commented by a national
workshop, by professional associations and by finalizing
technical working group emanated from different specialities
and finally edited and formated.
The Ethiopian Medicines Healthcare Adminstration and Control
Authrotiy (EFMHACA)would like to present heart felt
thanksall professional associations, national workshop
participants and members of finalizing technical working group,
and individuals mentioned below for sacrificing their time and
use their expertise for providing inputs to the enrichment of this
formaulary.
Our special gratitude goes to USAID/SIAPS for its continued
technical support and covering the printing and workshop costs
of thisformulary. The following experts are greately
acknowledged:
Editors:
Tenaw Andualem
Mamo Engdayehu
Debalke Fantaw
Memebers of Finalizing Technical Working Group:
Dr. Getnet Nigusie, ophthalmologist Minilik General Hospital,
Dr. Genet Getahun, Pediatrician, Yekatit General Hospital,
Dr. Beyene, Gynecologist, Bethel Teaching General Hospital,
Mr. Teshale Mekonone, School of pharmacy, AAU
Mr. Michael Awoke, AAU, Drug information Center
Mr.Yosef Wakwoya, MSH/SIAPS
Mr.Mulu Legesse, MSH/SIAPS, HealTB project
Mr. Said Ali, JHU, HIV program
Mr.Fekadu Demie, MSH/SIAPS, Malaria program
ix

Mr. K/Mariam G/Michael, FMHACA

Mr. Debalke Fantaw, FMHACA
Mr. Mamo Engdayehu, FMHACA
Mr. Tenaw Andualem, USAID/SIAPS
Ethiopian Medicines Formulary Workshop Participants:
Dr. Mesfin Hunegnaw, Dermato-venerologist, AAU
Dr. Aynalem Abraha, Oncologist, AAU
Mr. Workineh Getahun, MSH/SIAPS
Mr. Nathan Assefa, Ethiopian PharmaceuticalAssociation
Mr. Tenaw Andualem, MSH/SIAPS
Mr. Wondmagegn Tamiru, Gondar University
Mr. Binyam Kebede, GSK
Mr. Teshale Mekonnen, AAU, Drug Information Center
Dr. Sewagegn Yeshiwas, Ethiopian Pediatrics Society
Dr. Yeneneh Getachew, Ethiopian Medical Association
Mr. Andualem Mohammed, Sanofi
Mr. Nezif Hussien, Jimma University
Dr.Mohammed Hajihyder Ali, Amanuel Psychiatry Specialized
Hospital
Dr. Frehiwot Nigatu, FMOH
Mr. Desalegn G/yesus,MOH
W/t Hiwot Solomon, MOH
Dr. Mebratu Amogne, ACH
Dr. G/yusus Hagos, AAU, Medical Faculty
Mr.Sisay Tadele, Pharmaceutical Fund & Supply Agency
Mr. Hailemichael Zeru, Mekele University

AAU
ACE
ADR
AIDS
APD
ATP
AV
BMI
BMT
BPH
BSA
CAD
CCR5
CFC
cGMP
CHD
CHF
CHOP
CIU
CKD
Clcr
CMV
CML
CNS
COPD
CSF
CTC
CTCL
CVD

ACRONYMS and ABBREVIATIONS

Addis Ababa Univeristy
Angiotensin-converting enzyme
Adverse drug reaction
Acquired immuno deficiency syndrome
Action potential duration
Adenosine triphosphate
Atrioventricular
Body mass index
Bone marrow transplantation
Benign prostatic hyperplasia
Body surface area
Coronary artery disease
Chemokine receptor 5
Chlorofluorocarbon
Cyclic guanosine monophosphate
Coronary heart disease
Congestive heart failure
Cyclophosphamide,Hydroxydaunorubicin
(doxorubicin or Adriamycin), Oncovin
(Vincristine), Prednisone (Prednisolone).
Chronic idiopathic urticarial
Chronic kidney disease
Creatinine clearance
Cytomegalovirus
Chronic myeloid leukemia
Central nervous system
Chronic obstructive pulmonary disease
Cerebrospinal fluid
Common toxicity criteria
Cutaneous T-cell lymphoma
Cardiovascular disease
xi

CYP
D2
D5W
DIC
DME
DNS
DOT
DVT
DW
EEG
eGFR
EMF
EPTB
FDA
FDCs
FH
FIs
G6PD
G6PD
GABA
GAD
GERD
GFR
GI
GIT
GPP
GPP
GU
H.p.
H2
HAART
HDL

cytochrome P450
dopaminergic
Dextrose 5% in water
disseminated intravascular coagulation
diabetic macular oedema
Dextrose in normal saline
Direct observation of therapy
deep vein thrombosis
Dexstrose in water
Electro-encephalogram
estimated Glomerular Filtration Rate
Ethiopian medicines formulary
Extrapulmenary tuberculosis
Food and Drug Administration
Fixed dose combinations
Familial hypercholesterolemia
Fusion inhibitors
Glucose 6-phosphate dehydrogenase
G6PD glucose-6-phosphate dehydrogenase
Gamma aminobutyric acid
Generalized anxiety disorder
Gastro-oesphageal reflux disease
Glomerular filtration rate
Gastrointestinal
Gastrointestinal
Good dispensing practice
Good prescribing practice
Gastric ulcer
Helicobacter pylori
Histamine receptor
Higly active antiretrovial treatment
High density lipoproteins
xii

HeFH
HF
HFA
HIV
HMG-CoA
HRT
hs-CRP
HTN
5 HT3
IBD
IBS
ICD
IgE
IIs
IM
IO
IU
IUD
IV
Kg
LDL
LR
LVH
MAC
MAOI
MB
Mcg, mcg
MDI
MDR TB
MEOS
Mg, mg
mm Hg

Heterozygous familial hypercholesterolemia

Heart failure
Hydrofluoroalkane
Human immunodeficiency virus
Hydroxy-3-methyl glutaryl co enzyme A
Hormone replacement therapy
High-sensitivity C-reactive protein
Hypertension
5-hydroxytryptamine
Inflammatory bowel disease
Irritable bowel syndrome
Internationla classifaction of diseases
Immunoglobulin E
Intigerase inhibitors
Intramuscular
Intraosseous
International Units
Intrauterine device
Intravenous
Kilogram
Very low density lipoproteins
left ventricular hypertrophy
M. avium-intracellularecomplex
Monoamine oxidase inhibitor
Multibacillary leprosy
Microgram
Metered dose inhaler
Multi-drug resisitant tuberculosis
Microsomal enzyme oxidizing system
Milligram
millimeter mercury
xiii

MOPP
MRSA
MTCT
MU
NDRI
NIDDM
NNRTI
NRTIs
NS
NSAID
OCD
ORS
OTC
PAR
PAS
PB
PBPC
PCP
PDE5
PEP
pH
PI
PMTCT
PONV
PSVT
PTB
RBC
RDA
RVO
SA

Mustargen (Chlormethine), Oncovin (Vincristine),

Procarbazine, Prednisolone
Methicillin-resistant Staphylococcus aureus
Mother to child transmission
Million Units
Norepinephrine-dopamine reuptake inhibitor
Noninsulin dependent diabetes mellitus (type 2
diabetes mellitus)
Non nucleoside riverse transcriptase inhibitor
Nucleoside reverse transcriptase inhibitors
Normal saline (0.9% NaCl)
Non steroidal anti inflammatory drug
Obsessive-compulsive disorder
Oral Rehydration Salts
Over the counter
Perennial allergic rhinitis
Para-Amino Salicylic Acid
Paucibacillary leprosy
Peripheral blood progenitor cell
Pneumocystis carinii
Phosphodiesterase type 5 inhibitor
Post Expoure prophylaxis
Concentration of of hydrogen ion
Protease inhibitor
Prevention of mother to child transmission
Postoperative nausea and vomiting
Paroxysmal supraventricular tachycardia
Pulmonary tuberculosis
Red blood cells
Recommended dietary allowance
Retinal vein occlusion
Sinuatrial node
xiv

SAR
SBP
SC
SCN
SLE
SNRIs
SSRIs
STD
SVT
TC
TCAs
TG
TIA
TURP
ULN
URTI
UTI
VEGF
VF
VT
VTE
WPW

Seasonal allergic rhinitis

Spontaneous bacterial peritonitis
Subcutaneous
Severe chronic neutropenia
Systemic lupus erythematosus
Serotonin noradrenaline re-uptake inhibitors
Selective Serotonin Re-uptake Inhibitors
Sexually transmitted disease
Supraventricular tachycardia
Total cholesterol
Tricyclic Antidepressants
Triglycerides
Transient ischaemic attack
transurethral resection of the prostate
Upper Limit of Normal
Upper respiratory tract infection
Urinary tract infections
Vascular endothelial growth factor
Ventricular fibrillation
Ventricular tachycardia
Venous thromboembolism
Wolff-Parkinson-White

xv

STRUCTURE and HOW to USE THE EMF

Changes from the First Edition
This second edition of Ethiopia Medicines Formulary (EMF)is
revised based on the sixth edition of the Ethiopian Medicines
List, which incorporated more than 1140 medicines. It
incorporated monographs of more than 250 new medicines that
have been added to the edition of the List and that do not exist in
the first edition of the formulary.The formulary also links with
ongoing changes to the program medicines regimens and
treatment guidelines such as TB, HIV and malaria. It also
incorporated the new combination therapy regimens monographs
in addition to the single medicines monographs. There are also
deletions of some medicines. The users have to bear in mind that
there may also be changes to any of the components of the
monographs of the medicines (indications, cautions,
contraindications, side effects, dose and administration, etc)
incorporated in this formulary in contrast to the first edition based
on the product updates. Furthermore, this edition of the EMF
contains some additional useful topics at the beginning and
appendices that are useful to the readers and for promotion of
rational use of medicines.
How the EMF is developed
The EMF is based on the Ethiopian medicine list 6th edition 2010.
EMF has tried to bring together essential information; it has
brought together current and independent information on
medicines and also added additional information and guidance in
the appendices. All these are aimed at enabling healthcare
professionals to select safe and effective medicines for promoting
the rational use medicines and improved health outcomes for
individual patients and the community.
Sources of EMF information
In the revision of the second edition of EMF; a number of current
and independent information on medicines and diseases have
been consulted. It may not be possible to list all which are used
xvi

by the different contributors of the formulary; nevertheless we

have mentioned only some of those used in this EMF.
Literature and systematic reviews: Research papers and reviews
in some medical and pharmaceutical journals relating to drug
therapy are consulted.
Consensus guidelines: The information compiled in the EMF is
checked
against
consensus
guidelines.
Reference
sources:Textbooks and reference sources have provided valuable
information for the review of the EMF. These include but not
limited to the latest editions of Martindale: The Complete Drug
Reference,British National Formulary for adults and children,
Goodman & Gilman's The Pharmacological Basis of
Therapeutics, Harrison's Principles of Internal Medicine, AHFS
drug information, expert guidelines, and others.
How to Use and Search Information in EMF
The EMF has listed all the contributors in the development
process in the acknowledgment part.As much as possible
abbreviations and acronyms are minimized but when used will be
written in full the first time it is entered and abbreviated after
wards in the abbreviations and acronyms part of the EMF. These
facilitate reading and understanding in the text of the EMF. It is a
useful reference to cross-check.
There are useful guides before the main text of EMF such
as medicines prescription, prescribing, dispensing, labeling,
counseling, adherence to medcines, mintoring treatment, and
antimicrobial prescribing in general practice and for prophylaxis
use.The main contents of the EMF presented by body systems or
systemic disease categories and divided into 21 chapters. Each chapter
is then subdivided into subtopics. Each subsection begins with some
notes and then followed by description of the individual medicines. In
all medicines entries generic names/International Non-proprietary
names of medicines are used throughout the EMF. In this EMF the
following information about each medicine are included: Indications:
Cautions: Drug interactions: Contraindications: Side effects: Dose and
xvii

Administration (adult and child by age or by body weight); and

sometimes notes on the dosage and administration are added which
are useful to the health care providers and for patients; and finally
Storage of the dosage form.
The EMF has essential glossary and Appendices information
which have high relevance to the formulary and importance to
the readers.
The EMF is also indexed by medicines but left by disease for
now which will help to easily pinpoint the page in which the
medicine is cited.
Readers are kindly requested to provide their suggestions for the
improvement of the future editions of EMF at:
FMHACA,P.o.Box5681;Fax. 251-115-521392;Addis Ababa;
Free call line:8482
E-mail:[email protected]
Website:http://www.fmhaca.gov.et

xviii

MEDICINES PRESCRIPTION, PRESCRIBING,

DISPENSING, and COUNSELING
Prescription Form
The most important requirement is that the prescription be clear. It should be
legible and indicate precisely what should be given. The local language is
preferred. It should be legible and not ambiguous. A prescription should
contain the following details should be filled on the form:
Name, address, age body weight of the medicine consumer and Date of the
prescription; Diagnosis; Generic name, dosage form and strength and
directions for use of the medcines. The pharmaceutical form (for example
tablet, oral solution, eye ointment) should also be stated. The strength
of the drug should be stated in standard units using abbreviations that are
consistent with the Systme Internationale (SI). Microgram and
nanogram should not, however, be abbreviated. Also, units should not be
abbreviated. Avoid decimals whenever possible. If unavoidable, a zero
should be written infront of the decimal point.
Fill the diagnosis or ICD code for proper communication with the dispenser
and choice of the drug among the available generic options. Readers are
kindly requested to read Medicines Good Prescribing Practices (GPP)
manual 2012 edition.

xix

Prescription Writing
A prescription is an instruction from a prescriber to a dispenser.
The prescriber is not always a doctor but can also be a
paramedical worker, such as a medical assistant, a midwife or a
nurse. The dispenser is not always a pharmacist, but can be a
pharmacy technician, an assistant or a nurse. The following
guidelines will help to ensure that prescriptions are correctly
interpreted and leave no doubt about the intention of the
prescriber. The guidelines are relevant for primary care
prescribing; they may, however, be adapted for use in hospitals
or other specialist units.
A prescription is a written therapeutic transaction between the
prescriber and dispenser. It is a written order by the prescriber
to the dispenser on how the drug should be dispensed. It serves
as a means of communication among the prescriber, dispenser
and medicines consumer pertaining to treatment or prophylaxis.
A prescription should be written on a standard prescription
blank, in ink and in generics.
Directions for use: Directions specifying the route, dose and
frequency should be clear and explicit; use of phrases such as
take as directed or take as before should be avoided. For
preparations which are to be taken on an as required basis, the
minimum dose interval should be stated together with, where
relevant, the maximum daily dose. It is good practice to qualify
such prescriptions with the purpose of the medication (for
example every 6 hours as required for pain, at night as
required to sleep). It is good practice to explain the directions
to the patient; these directions will then be reinforced by the
label on the medicinal product and possibly by appropriate
counseling by the dispenser. It may be worthwhile giving a
written note for complicated regimens although it must be borne
in mind that the patient may lose the separate note.
Factors affecting Dose and Response
Success in drug treatment depends not only on the correct
choice of drug but on the correct dose regimen. Unfortunately
xx

drug treatment frequently fails because the dose is too small or

produces adverse effects because it is too large. However, the
use of standard doses in the marketing literature suggest that
standard responses are the rule, but in reality there is
considerable variation in drug response. As a result many
prescribed doses are far too low or too high, leading to
treatment failure or toxicity. There are many reasons for this
variation which include adherence (see below), drug
formulation, body weight and age, variation in absorption,
distribution, metabolism and excretion, variation in
pharmacodynamics,
disease
variables,
genetic
and
environmental variables.
Drug Formulation: Poorly formulated drugs may fail to
disintegrate or to dissolve. Enteric-coated drugs are particularly
problematic, and have been known to pass through the
gastrointestinal tract intact. Some drugs like digoxin or
phenytoin have a track record of formulation problems, and
dissolution profiles and can vary not only from manufacturer to
manufacturer but from batch to batch of the same company. The
problem is worse if there is a narrow therapeutic to toxic ratio,
as changes in absorption can produce sudden changes in drug
concentration. For such drugs quality control surveillance
should be carried out.
Body Weight and Age: Although the concept of varying the
dose with the body weight or age of children has a long
tradition, adult doses have been assumed to be the same
irrespective of size or shape. Yet adult weights vary two to
threefold, while a large fat mass can store large excesses of
highly lipid soluble drugs compared to lean patients of the same
weight. Age changes can also be important. Adolescents may
oxidize some drugs relatively more rapidly than adults, while
the elderly may have reduced renal function and eliminate some
drugs more slowly.
Physiological and Pharmacokinetic Variables: Drug
absorption rates may vary widely between individuals and
xxi

within the same individual at different times and in different

physiological states. Drugs taken after a meal are delivered to
the small intestine much more slowly than in the fasting state,
leading to much lower drug concentrations. In the case of drugs
like paracetamol with a high rate of metabolism on first pass
through the liver, this may render a standard dose completely
ineffective. In pregnancy gastric emptying is also delayed,
while some drugs may increase or decrease gastric emptying
and affect absorption of other drugs.
Drug Distribution: Drug distribution varies widely: fat soluble
drugs are stored in adipose tissue, water soluble drugs are
distributed chiefly in the extracellular space, acidic drugs bind
strongly to plasma albumin and basic drugs to muscle cells.
Hence variation in plasma albumin levels, fat content or muscle
mass may all contribute to dose variation. With very highly
albumin bound drugs like warfarin, a small change of albumin
concentration can produce a big change in free drug and a
dramatic change in drug effect.
Drug Metabolism and Excretion: Drug metabolic rates are
determined both by genetic and environmental factors. Drug
acetylation shows genetic polymorphism, whereby individuals
fall clearly into either fast or slow acetylator types. Drug
oxidation, however, is polygenic, and although a small
proportion of the population can be classified as very slow
oxidizers of some drugs, for most drugs and most subjects there
is a normal distribution of drug metabolizing capacity, and
much of the variation is under environmental control. Many
drugs are eliminated by the kidneys without being metabolized.
Renal disease or toxicity of other drugs on the kidney can
therefore slow excretion of some drugs.
Pharmacodynamic Variables: There is significant variation in
receptor response to some drugs, especially central nervous
system responses, for example pain and sedation. Some of this
is genetic, some due to tolerance, some due to interaction with
xxii

other drugs and some due to addiction, for example, morphine

and alcohol.
Disease Variables: Both liver disease and kidney disease can
have major effects on drug response, chiefly by the effect on
metabolism and elimination respectively (increasing toxicity),
but also by their effect on plasma albumin (increased free drug
also increasing toxicity). Heart failure can also affect
metabolism of drugs with rapid hepatic clearance (for example
lidocaine, propranolol). Respiratory disease and hypothyroidism
can both impair drug oxidation.
Enviromental Variables: Many drugs and environmental
toxins can induce the hepatic microsomal enzyme oxidizing
system (MEOS) or cytochrome P450 oxygenases, leading to
more rapid metabolism and elimination and ineffective
treatment. Environmental pollutants, anaesthetic drugs and
other compounds such as pesticides can also induce
metabolism. Diet and nutritional status also impact on
pharmacokinetics. For example in infantile malnutrition and in
malnourished elderly populations drug oxidation rates are
decreased, while high protein diets, charcoal cooked foods and
certain other foods act as metabolizing enzyme inducers.
Chronic alcohol use induces oxidation of other drugs, but in the
presence of high circulating alcohol concentrations drug
metabolism may be inhibited.
The Effect of Food on Drug Absorption: Food delays gastric
emptying and reduces the rate of absorption of many drugs; the
total amount of drug absorbed may or may not be reduced.
However, some drugs are preferably taken with food, either to
increase absorption or to decrease the irritant effect on the
stomach.
Drug Interactions: Though some drug interactions could be
beneficial most are harmful. Hence it is always important to
note the possible drug interactions prior to concomitant
drug/food or drink administration. Drug interactions could
occur at different levels including: Pharmaceutics, which are
xxiii

physicochemical interactions in an infusion or in the same

solution; Pharmacokinetics, which may take place at the level of
absorption, distribution, biotransformation or excretion;
Pharmacodynamics, which could occur directly at receptor level
or indirectly where a drug induced disease alters the response to
another drug. Drug interactions could be summation (the effect
is simple algebraic sum), synergism (the total effect is more
than the algebraic sum) potentiation (the effect of one drug
increases by the presence of another drug), or antagonism (the
effect of the agonist is blocked by the antagonist when given
together). Drug interactions are some of the most common
causes of adverse reactions. As drug reactions could also occur
between a drug and food or a drug and drink. We should always
inform our patients the type of food or drink which they have to
avoid while taking the drug.
Drug incompatibilities: Drugs should not be added to blood,
amino acid solutions or fat emulsions. Some drugs, when added
to IV fluids, may be inactivated due to change in pH, precipitate
formation or chemical reaction. For example, benzylepenicillin
and ampicillin loose potency after 6-8 hours if added to
dextrose solutions, due to the acidity of the solutions. Some
drugs, such as diazepam and insulin, bind to plastic containers
and tubing. Aminoglycosides are incompatible with penicillins
and heparin. Hydrocortisone is incompatible with heparin,
tetracycline and chloramphenicol.
Medicines use for elderly patients: There is no major
alteration in drug absorption in elderly patients. Conditions
associated with age may alter the rate of absorption of some
drugs. Such conditions include altered nutritional habits,
alteration in gastric emptying, which is often slower and the
concurrent administration of other drugs. Aged people have
reduced lean body mass, reduced body water and an increase in
fat as a percentage of body mass. There is a decrease in serum
albumin, and the ratio of bound to free drug is significantly
changed. There is a decline with age of the livers ability to
xxiv

recover from injury. Diseases that affect hepatic function like

congestive cardiac failure are more common in the elderly.
Severe nutritional deficiencies in the elderly may impair hepatic
function. Creatinine clearance declines in the elderly leading to
marked prolongation of the half life of drugs. The increased
incidence of active pulmonary disease in the elderly could
compromise drug elimination through exhalation. There is also
a change in the sensitivities of receptors to drugs in aged
people. The quality and quantity of life in elderly patients can
be improved by intelligent use of drugs. Compliance to the
doses is absolutely required in these patients. Unfortunately
patient noncompliance in the elderly is common because of
forgetfulness, confusion, deliberate skipping of doses and
physical disabilities as in the case of tremors which cause errors
in measurement by spoon.
Medicines use in renal failure: Many drugs are excreted
through the kidneys and impairment of renal function alters the
excretion of these drugs and may result in renal as well as
nonrenal toxicity unless doses are adjusted on the basis of the
degree of renal impairment. For dose adjustment in renal failure
it may occasionally be necessary to measure drug levels and
adjust doses accordingly. Factors that potentiate renal
dysfunction and contribute to the nephrotoxic potential of
renally excreted drugs include: intravascular volume depletion
either due to external losses or fluid sequestration (as in ascites
or edema); concomitant use of two or more nephrotoxic agents
e.g. Nonsteroidal anti-inflammatory agents, aminoglycosides,
radio contrast agents. In general in the presence of renal
impairment to avoid worsening of renal dysfunction: Avoid
potentially nephrotoxic drugs and use alternative drugs that are
excreted through other routes. If there are no alternative drugs
to use, adjust the dose. Dose adjustment may be accomplished
in three different ways: Decreasing each individual dose and
maintaining the same dose frequency; Maintaining the same
individual dose but administering each dose less frequently; and
xxv

Modifying both individual doses and the frequency of

administration, which is a combination method; Insure that the
patient is adequately hydrated; If the patient is on dialysis check
if the drug is eliminated by the specific dialysis modality and
consider administering a supplemental dose at the end of the
dialysis session; and Serially monitor kidney function.
Medicines use in liver disease: The liver is a site for the
metabolism and elimination of many drugs but it is only in
severe liver disease that changes in drug metabolism occur.
Unfortunately, routine determination of liver enzymes and other
tests of liver function cannot predict the extent to which the
metabolism of a certain drug may be impaired in an individual
patient. In general, drug prescription should be kept to a
minimum in all patients with severe liver disease. Major
problems occur in patients with advanced liver disease who
have ascites, jaundice or hepatic encephalopathy. The
hypoproteinemia in patients with severe liver disease is
associated with reduced protein binding and with increased
toxicity when highly protein bound drugs are used. One must
exercise caution in the use of some drugs like sedatives, opioids
and diuretics which may precipitate hepatic encephalopathy in
patients with advanced liver disease. It is always advisable to
consult tables in standard textbooks or drug formularies before
prescribing drugs for patients with severe liver disease.
Medicines use for pregnant women: The kinetics of drug is
altered during pregnancy. The rate of absorption decreases,
while volume of distribution, metabolism and glomerular
filtration rate increase during pregnancy. The embryonic
period, where, organogesis takes place, is the most susceptible
period of pregnancy to drug effects. Administration of drugs,
except those proved safe, in the first trimester, is therefore not
generally recommended. It is advisable not to prescribe any
drug during at any stage of pregnancy, if possible. This,
however, should not preclude the importance of prescribing in
life threatening conditions of the mother. Prior to prescribing
xxvi

any drug for pregnant women, the benefit risk ratio of

prescribing should be considered.
Medicines use for breast feeding mothers: Most drugs
administered are detectable in breast milk. The concentration,
however, is low. If the woman has to take the drug and the drug
is relatively safe, she should optimally take it 30-60 minutes
after nursing, and 3-4 hours before next feeding in order to
allow time for many drugs to be cleared from the mothers
blood, and the concentration in breast milk to be relatively low.
Drugs for which no data are available on safety during lactation
should be avoided or breast feeding discontinued while they are
being given. Most antibiotics taken by nursing mothers can be
detected in breast milk e.g., tetracycline and chloramphenichol.
Most sedative hypnotics achieve concentrations in breast milk.
Opioids also achieve concentrations in breast milk.
Antineoplastic drugs are contraindicated in breast feeding. So it
is worth noting not to prescribe drugs secreted in milk to the
nursing mother.
Prescribing for infants/children:Physiologic processes that
influence drug kinetics in the infant change significantly in the
first year of life, specially the first few months, while there is no
much difference in the dynamics but all the four parameters of
kinetics are, therefore, affected in children. So drugs, which are
partially or totally inactivated by the low pH of gastric content,
should not be administered orally. GI enzymes are lower in the
neonates than in adults. Neonates have less bile acid so that
absorption of lipid soluble drugs is less. Gastric emptying time
is prolonged in the first day. So drugs, which are absorbed
primarily in the stomach, may be absorbed more completely.
For drugs absorbed in the small intestine, therapeutic effects
may be delayed. Peristalsis in neonates is slow. More drugs,
therefore, will get absorbed from the small intestine. The
volume of distribution is low in children, and drug metabolizing
enzymes are not well developed. The glomerular filtration rate
is slower than adults (30-40%). So the clearance of drugs is
xxvii

slower in children than in adults. This definitely demands for

dose adjustment in this age group. Doses for children are
generally based on body-weight, age or body surface area
(Annex 3). The following age ranges are foten used: first month
(neonate); up to 1 year (infant); 16 years; and 612 years. For
most drugs the adult maximum dose should not be exceeded.
For example if the dose is stated as 8 mg/kg (max. 300 mg), a
child weighing 10 kg should receive 80 mg but a child weighing
40 kg should receive 300 mg (rather than 320 mg). Body
surface area (BSA) estimates are sometimes preferable to bodyweight for calculation of paediatric doses since many
physiological phenomena correlate better with body surface
area.
Narcotic Drugs and Psycotropic Substances use: The
prescribing of a medicinal product that is liable to abuse
requires special attention and may be subject to specific
statutory requirements. Practitioners may need to be authorized
to prescribe controlled substances; in such cases it might be
necessary to indicate details of the authority on the prescription.
In particular, the strength, directions and the quantity of the
controlled substance to be dispensed should be stated clearly,
with all quantities written in words as well as in figures to
prevent alteration. Other details such as patient particulars and
date should also be filled in carefully to avoid alteration.
Use of topical steroids: Absorption from the skin depends on
the sites (high at axilla, face and scalp; medium at limbs and
trunk; and low at palm, elbow and knee) and nature of lesion
(high in exfoliative dermatitis and low in hyperkeratinised
skin). Strong preparations should be avoided at highly
absorption sites and on acute lesions, they may, however, be
used for chronic lesions. Lotions/creams are better for exudative
lesions for they allow evaporation, have a cooling, drying and
antipruritic effect. Sprays and gels are good for hairy regions.
Ointments form occlusive film and are good for chronic scaly
conditions. Occlusive dressing enhances steroid absorption,
xxviii

retains moisture and results in maceration of horny layer.

Absorption is more in pediatric patients, hence milder
preparations should be used. Strong preparations should be
restricted for short term use only. Sudden withdrawal should be
avoided. Twice a day application is enough; do not exceed three
times application a day.
Good Dispesing Practices: Good dispensing practices ensure
that the correct drug is delivered to the right patient, in the
required dosage and quantities, with clear information, and in
package that maintains an acceptable potency and quality of the
drug. Dispensing includes all the activities that occur between
the times the prescription or oral request of the patient or care
provider is presented and the medicine is issued. This process
may take place in health institutions and community drug retail
outlets. It is often carried out by pharmacy professionals. No
matter where dispensing takes place or who does it, any error or
failure in the dispensing process can seriously affect the care of
the patient mainly with health and economic consequences.
Therefore, the dispenser plays a crucial role in the therapeutic
process. The quality of dispensing may be determined by the
training and supervision the dispenser has received. During
medcines dispensing and counseling the information mentioned
under prescribing above, theMedicines Good Dispensing
Practices manual 2012 edition and also medicines dispensing
and counseling guides are good resources to use. Finally, an
application of the professional code of ethics by pharmacy
professionals is an important issue that needs due consideration
particularly with respect to confidentiality of patient data,
withholding therapeutic interventions and varying cost of drug.
Labeling of Medicines: There is a legal requirement to be
added on the label of any prescribed or over the counter
medicine: Generic name, total quantity, directions for use, route
of administration, precautions relating to the use, and storage of
xxix

the medicine. If a product is dispensed in more than one

container, reference should be made to the amount in each
container; other common labeling words include: Keep out of
the reach of children when necessary 'For external use only';
expiry or end of use dates; Shake the bottle, Store in a cool
place, Discard . . . Days after opening and Do not use after . . .,
which apply particularly to antibiotic mixtures, diluted liquid
and topical preparations, and to eye-drops and name and
address of the person dispensing the medicine. A pharmacist
can add or modify to use more appropriate labeling and words
that corresponds with the individual medicine, patient, or
disease conditions. Avoid use of compound names or unofficial
abbreviations which may create confusion for the purposes of
generic prescribing and can be misinterpreted. Care should also
be exercised when writing sustained or extended release
preparations which may lead confusion between formulations
with different lengths of action.
Counseling of Patients: The prescriber and the patient should
agree on the health outcomes that the patient desires and on the
strategy for achieving them. Taking the time to explain to the
patient (and careers) the rationale and the potential adverse
effects of treatment may improve adherence. For some
medicines there is a special need for counseling (e.g.
appropriate posture during administration of doxycycline); this
is shown in counseling statements of the individual medicines.
Counseling should be tailored to the age, experience,
background, and understanding of the individual patient. The
pharmacist should ensure that the patient understands how to
take or use the medicine and how to follow the correct dosage
schedule, refer medicines dispesing and counsling guides. For
some preparations there is a special need for counselling, such
as an unusual method or time of administration or a potential
interaction with a common food or domestic remedy, and this is
indicated where necessary. Patients must be warned to keep all
xxx

medicines out of the reach of children. All solid dose and all
oral and external liquid preparations must be dispensed in a
reclosable child-resistant container unless: the medicine is in an
original pack or patient pack.
Adherence with Medicines Treatment: The health care
provider and the patient should agree on the health outcomes
that the patient desires and on the strategy for achieving them
(concordance). It is often assumed that once the appropriate
drug is chosen, the prescription correctly written and the
medication correctly dispensed, that it will be taken correctly
and treatment will be successful. Unfortunately, this is very
often not the case, and health care providers overlook one of the
most important reasons for treatment failurepoor adherence
(compliance) with the treatment plan. Patient compliance is the
extent to which the patient follows a prescribed drug regime,
while adherence is participation of patients in their care plan
resulting in understanding, consent and partnership with the
provider.The health care provider should be sensitive to
religious, cultural, and personal beliefs that can affect a patient's
acceptance of medicines. There are different factors which
contribute to patients non-adherence. These factors include:
purpose and instructions for administration not clear; perceived
lack of efficacy; real or perceived adverse effects; nature of
treatment, which in turn depends on the complexity of the
regime (more frequency of administration and more number of
drugs prescribed); characteristics of the patient such as
forgetfulness about taking the medication, unable to finish
because of feeling better, lack of understanding of the
prescription, fear of dependence, social or physical problems to
go to drug shops, unable to pay prescription charges,
inconvenience of taking drugs everyday; type of illness like
schizophrenia; health care system (long waiting times, uncaring
staff, uncomfortable environment, exhausted drug supply,
inaccessibility of the health institution); behavior of prescribers;
xxxi

not winning confidence of medicines consumers irrational

prescribing, giving inadequate information on the treatment,
poor attitude to patients, negligence, poor perception to team
work; physical difficulty in taking medicines (e.g. swallowing
the medicine, handling small tablets, or opening medicine
containers); and unattractive formulation (e.g. unpleasant taste).
Patient adherence can be improved by supervising drug
administration; simplifying therapeutic regime; educating
patients on the importance of adhering to the prescribed
medication; improving behavior of prescribers. Group of people
who adhere less to their medication include: Men, Youngsters,
Elderly patients, people living alone, etc.
Monitoring drug treatment: Patients should be monitored to
ensure they are achieving the expected benefits from drug
treatment without any unwanted side-effects.
ANTIMICROBIAL PRESCRIBING
General antimicrobials prescribing practice
Rates of Antimicrobial resistance are increasing in h e a l t h
f a c i l i t i e s a n d t h e c o m m un i t . The prevalence of
Antimicrobial resistance in any population is related to the
proportion of the population that receives Antimicrobial, and the
total Antimicrobial exposure. Increased Antimicrobial use leads to
more resistance.
Prescribing of antimicrobials requires knowledge of the
common causative pathogens and the local antimicrobials
resistance pattern/ level to choose the most appropriate
antimicrobial. Factors related to the patient which must be
considered include history of allergy, renal and hepatic
function, susceptibility to infection (i.e. whether immunocompromised), ability to tolerate drugs by mouth, severity of
illness, age, whether taking other medications and, if female,
whether pregnant, breast-feeding or taking oral contraceptive.
The known or likely organism and its antibacterial sensitivity,
xxxii

in association with the above factors, will suggest one or more

antibacterials; the final choice depends on the microbiological,
pharmacological, and toxicological properties.
Initially, when the infecting organism or the source of
infection is unknown, 'broad-spectrum' antimicrobial may be
appropriate. When a bacterial pathogen is isolated from a
clinical specimen and sensitivities are known, treatment will be
easy and should be adjusted to use the narrowest-spectrum
antimicrobial. This will reduce the likelihood of selection and
emerging bacterial resistance and other adverse effects. Other
factors that need to be considered in the selection of an
antibacterial are changing renal and hepatic function, and
information on side-effects. Duration of therapy, dosage, and
route of administration depend on site, type and severity of
infection and response. An example of a rational approach to
the selection of an antibacterial is treatment of a urinary-tract
infection in a patient complaining of nausea and symptoms of a
urinary tract infection in early pregnancy. The organism is
reported as being resistant to ampicillin but sensitive to
nitrofurantoin (can cause nausea), gentamicin (can be given
only by injection and best avoided in pregnancy), tetracycline
(causes dental discoloration) and trimethoprim (folate
antagonist, theoretical teratogenic risk). The safest antibiotics in
pregnancy are the penicillins and cephalosporins. The following
precepts
should be considered before prescribing
antimicrobials. Viral infections should not be treated with
antibacterials. However, antibacterials may be used to treat
secondary bacterial infection (e.g. bacterial pneumonia
secondary to influenza). Samples should be taken for culture
and sensitivity testing; blind antibacterial prescribing for
unexplained pyrexia usually leads to further difficulty in
establishing the diagnosis. Knowledge of prevalent organisms
and their current sensitivity is of great help in choosing an
antibacterial before bacteriological confirmation is available.
xxxiii

The dose of an antibacterial: varies according to a number of

factors including age, weight, hepatic function, renal function,
and severity of infection. The prescribing of the so-called
standard dose in serious infections may result in failure of
treatment or even death of the patient; therefore it is important
to prescribe a dose appropriate to the condition. An inadequate
dose may also increase the likelihood of antibacterial resistance.
On the other hand, for an antibacterial with a narrow therapeutic
index (toxic and therapeutic dose) (e.g. an aminoglycoside) it is
also important to avoid an excessive dose and the concentration
of the drug in the plasma may need to be monitored.
Duration of therapy: depends on the nature of the infection and
the response to treatment. Duration of treatment should not be
unduly prolonged because they encourage resistance, they may
lead to side-effects and they are costly. The prescription for an
antibacterial should specify the duration of treatment or the date
when treatment is to bestopped.
Route of Administration: The route of administration of an
antibacterial often depends on the severity of the infection. Lifethreatening
infections
require
intravenous
therapy.
Antibacterials that are well absorbed may be given by mouth
even for some serious infections. For a significant proportion of
patients, the oral route of administration will be appropriate
either on initiation or after 2 to 3 days of intravenous therapy.
Certain infections e.g. serious sepsis, bacterial meningitis and
neutropenic sepsis require intravenous antimicrobial for the full
period of treatment. Parenteral administration is also
appropriate when the oral route cannot be used (e.g. because of
vomiting) or if absorption is inadequate. Whenever possible,
painful intramuscular injections should be avoided in children.
All intravenous therapy should be reviewed ideally daily or at
least at 48 hours. A switch from intravenous to oral therapy
should be considered as soon as it is clinically appropriate with
the exception of patients with osteomyelitis, necrotising
fasciitis, septic arthritis and infections mentioned above. When
xxxiv

considering a switch from the intravenous to oral route:

Confirm that the oral route is suitable for the condition being
treated. Ensure that the oral dose is at the upper end of the oral
dose range to help maximize tissue antimicrobial
concentrations. Ensure that the patient is able to swallow.
Ensure the oral antibiotic is compatible with the feed and
administration route.
Recommendations for better outcomes
1. Documentation: The use of antimicrobial carries
significant risks to the patient and the community. The
decision to prescribe an antimicrobial should always be
justified following a risk-benefit assessment. All subsequent
decisions (the reasons) relating to antimicrobial therapy
should be documented clearly in the patients medical
record. All prescribers have a duty to comply with current
antimicrobial prescribing guidance available. Empirical
antimicrobial prescribing should be the last resort in
prescribing antimicrobials.
2. Microbiology Support for Antimicrobial Prescribing:
Appropriate microbiological samples will be taken prior to
the commencement of antimicrobial therapy. The results of
these cultures will be used to rationalise the empirical
prescription in the individual, to guide future empirical
therapy advice and for surveillance purposes. Appropriate
antimicrobial sensitivity testing will be carried out by the
laboratory on clinical specimens received.
3. Correct Dosing and Administration: Antimicrobials will
be administered at the most appropriate dose for treatment
of infection taking into account modifications required for
current clinical condition renal and/or liver dysfunction and
current medications and adjustments which may be required
for drug allergy or interactions. All aminoglycoside and
glycopeptide antimicrobials will be administered and
monitored according to guidelines. Oral administration is
xxxv

preferable to intravenous wherever possible to avoiding the

risks.
4. Preferential Use of Narrow Spectrum or Minimising the
use of broad-spectrum Antimicrobials: Antimicrobial
therapy should be targeted to treat the specific infection
using as narrow-spectrum an antimicrobial agent as
possible.
Prescribers should therefore avoid/minimize indescrimnate/
widespread use of cephalosporins, quinolones, broadspectrum
penicillins
(including amoxicillin) and
clindamycin unless there are clear clinical indications for
their use. In addition there is evidence to show an
association between total antimicrobial use and MRSA
prevalence. Broad-spectrum antibiotics should be restricted
to the treatment of serious infections when the pathogen is
not known or when other effective agents are unavailable.
5. Use of Oral Preparations and IV to Oral Switch Where
Appropriate: Intravenous therapy should only be used for
patients with severe infections, patients who have a focus of
infection requiring high doses of antimicrobials, patients
who are unable to take or absorb oral antimicrobials, and
when there are no alternative suitable agents.
IV
antimicrobials should be reviewed on a daily basis and, if
appropriate, the patient switched to an oral equivalent. Oral
therapy should be considered once patients are afebrile for
24hrs and improving, exceptions to this include some
serious infections or following microbiological advice.
6. Appropriate Duration of Therapy: Antimicrobials will be
prescribed for as short a time period as possible. The
duration of antimicrobial therapy depends on the infecting
organism(s), the site of the infection, the patients own
immune response and other additional features such as
surgical and medical interventions. Each antimicrobial
prescription needs to be assessed on a daily basis and the
review documented in the clinical notes.
xxxvi

7. Available Guidance for Antimicrobial Prescribing:

Antimicrobials will be prescribed following the standard
treatment guidelines which are available to the prescriber at
the point of care.
8. Support and Education for Management of Infection
Prevention and Control: All staff has a duty of care to the
patients and themselves to ensure they deliver high standards
of infection control practices including antimicrobial
prescribing practice at all times. Wherever there is deficiency
in their knowledge or experience this must be highlighted to
the department/ward head that is responsible for ensuring the
staff to receive the appropriate training, education or advice.
9. Antimicrobials allergy: Patients with a reported
antimicrobial allergy should have this clearly documented in
the appropriate section of the Patients Medication Record and
medical notes. The nature of the allergy should also be
recorded. Patients with such note should not the medcines.
10. Antimicrobials resistance: If a patient has been in hospital
for more than five days, has been previously colonized with
MRSA or is at risk of MRSA colonization, consider using
Vancomycin or Teicoplanin. If a patient has been previously
colonized or infected with Extended Spectrum BetaLactamase (ESBL) infection or is at risk of ESBL infection
(i.e. recurrent urinary tract infections, consider using an
alternative antibiotic regime.
11. Review of antibiotic treatment: It is important to develop
practice which includes daily review, appropriate deescalation from intravenous to oral therapy and setting a
maximum duration for treatment without repeat prescription,
unless there is a clear indication in the medical record that
antibiotics should be continued. Antibiotics should generally
be prescribed for a maximum of seven days or a shorter
period if this is clinically appropriate; however, some specific
conditions require a longer course (e.g. infective
endocarditis). Antibiotics prescribed empirically in lifexxxvii

threatening situations should be reviewed early in the light of

microbiological results and clinical progress, and where
necessary changed or discontinued as soon as is reasonable.
Individual patient and drug-specific factors to consider in all
cases include. Clinical Pharmacists will review all
prescription charts on a regular, mostly daily, basis.
Antimicrobials Use for Surgical Prophylaxis
The purpose of antibiotic prophylaxis in surgical procedures is
not to sterilize tissues but to reduce the colonization pressure of
microorganisms introduced at the time of operation to a level
that the patients immune system is able to overcome.
Prophylaxis does not prevent infection caused by postoperative
contamination. Prophylactic antimicrobial use differs from
treatment with antimicrobial in that the former is intended to
prevent infection, whereas the latter is intended to resolve an
established infection, typically requiring a longer course of
therapy. Prophylaxis is intended for elective procedures in
which the incision will be closed in the operating room.
Itmustbesafeandinexpensive, anditmust be effective against
organisms likely to be encountered in thesurgicalprocedure.
Theagentmustbeadministered in a way that ensures that serum
and tissue levels are adequate before anincisionismade andthat
therapeutic levels ofthe agent can be maintained in serum and
tissue. Prophylactic antimicrobial has an important part to play
in the prevention of post-operative wound and deep site
infections. The key principle is to have a high concentration of
the antimicrobial in the relevant tissues at the time of
operation, when bacteria may contaminate the tissues.
Whether antimicrobials are required and the antimicrobial
course length depends on the classification of the surgical
procedure and if any prosthetic material is being implanted.
Most clean-contaminated procedures require only a single dose
of the antimicrobial at induction of anaesthesia. Timing of
xxxviii

administration of prophylaxis is important to ensure that there

are maximum tissue levels at the time of first incision. Oral and
intramuscular antimicrobial should be given one hour and IV
antimicrobial given 30-40 minutes pre-operatively so that the
infusion or dose has just been completed at the time of incision.
Use of single dose for surgical prophylaxis: Prophylactic
antimicrobial use has an important part to play in the prevention
of post-operative wound and deep site infections. The key
principle in this use is to have a high concentration of the
antimicrobial agent in the relevant tissues at the time of the
operation, when bacteria may contaminate the tissues. For most
operations, this requires only a single dose of the antimicrobial
at induction of anaesthesia. If surgery is prolonged (over 4
hours) or there is excessive blood loss, a further dose of intraoperative antibiotics may be needed depending on the half-life
of the antimicrobial.
Dosageselection: It is generally accepted as good practice that
the dosage of anantimicrobial required for prophylaxis is the same
as that for the therapy of infection. A single standard therapeutic
dose of antibiotic is sufficient for prophylax is under most
circumstances.
Durationofprophylaxis: For many types of commonly
performed surgery there is consistent evidence that a single dose of
antimicrobial with a long enough half-life to achieve activity
throughout the operation is adequate. There is evidence for
prophylaxis during surgery that longer dosage duration has no
increased benefit over a short course.
RouteofAdministration:
Systemic
antimicrobial
prophylaxis, typically given by the parenteral intravenous route,
has historically proven to bear eliable and effective prophylaxis.
Oral Administration: Serum and tissue concentrations after
oral administration are determined in part by the rate of
absorption, which varies between individuals. There is relatively
little evidence about the effectiveness of orally administered
xxxix

antibioticprophylaxis. A further problem is that often the correct

time of administration is difficult to guarantee.
The use of antimicrobial prophylaxis has become an essential
component of the standard of care in virtually all surgical
procedures and has resulted in a reduced risk of postoperative
infection when sound and appropriate principles of prophylaxis
are applied which include: There is probable risk of infection in
the absence of a prophylactic agent. There must be knowledge
of the probable contaminating flora associated with the
operative wound or organ site. The activity of the chosen
prophylactic agent should encompass the majority of pathogens
likely to contaminate the wound or operative site. Single
antimicrobial agent is preferable. The prophylactic agent must
be administered in a dose which provides an effective tissue
concentration prior to intra-operative bacterial contamination.
Administration must occur 30-45 minutes prior to incision
(usually with the induction of anesthesia). The effective dose
should be governed by the patient's weight. In procedures
lasting 3 hour or less, a single prophylactic dose is usually
sufficient. Procedures lasting greater than three hours require an
additional effective dose. Procedures in which there is rapid
blood loss and/or fluid administration will dictate more frequent
prophylactic dosing. Under no circumstance should any
prophylactic agent be given on-call because it often results in
less than effective tissue levels at the time of incision.
Postoperative prophylaxis is strongly discouraged except in the
scenario of a bioprosthetic insertion in which case 2 or 3
additional prophylactic doses may be deemed. An effective and
thoughtful prophylactic regimen is no substitute for exquisite
surgical technique and competent postsurgical management.

xl

Antimicrobial Prophylaxis in Selected Surgeries

Type of procedure

Medicine

Route

Dosage

I. Clean surgery
a. Insertion of
synthetic
biomaterial device/
prosthesis
b. Patients with
impaired immunity

Cefazolin
IV
Or
Cefuroxime

750mg

II. Upper GIT and

elective bowel
surgeries (
stomach, small
bowel, pancreas,
hepatobilliary etc)
III. Large bowel
resection

Ciprofloxacin IV
Or
Cefazolin
IV
Plus
Metronidazol IV
e
Bisacodyl
Neomycin
Plus
Erythromycin
Cefazolin
Or
Ceftetan

400mg

Cefazolin
IV. Acute
Plus
appendicitis
Metronidazol
(Non-perforated)
In perforated or
e
gangrenous cases
treatment should
continue as clinically
indicated
V. Trauma surgery Ampicillin Or
Cefazolin
(penetrating
Plus
abdominal trauma)
metronidazol
e

Time of
administration
30-45min before
skin incision, 2nd
dose if procedure
lasts > 3hrs

Rationale (likely
infective agent)
Gm positive cocci
(S. aureus and
epidermidis), aerobic
coliforms
( E. coli)

30-45min before
skin incision,

Coliforms >
Enterococcus >
Streptococci>Aerobic>
Clostridia>PeptoStreptococci
Bacteriodes >Prevotella
Coliforms, enterococci,
Bacteriodes,
peptostreptococci,
Clostridia

750gm
500mg
PO

2tablets 2 days before

surgery1pm, 2pm
500mg and 10pm before
surgery
30-45min before
500mg
skin incision, 2nd
1-2gm
dose if procedure
1-2gm
lasts>3hrs
1gm
30-45min before
skin incision
500mg

PO
PO
IV
IV
IV
IV

IV
IV
IV

3gm
1-2gm
500mg

xli

30-45min before
skin incision, 2nd
dose if surgery
lasts> 3hrs

Coliforms, anaerobes

Coliforms and
anaerobes(gm positive
and negative)

Type of procedure

Medicine

VI. Gynecology and Ceftizoxime

Or
Obstetrics
a.Vaginal and
Cefazolin
abdominal
Ceftizoxime
hysterectomy
Or
including radical
Cefazolin
hysterectomy
b.Ceasarean section/
hysterectomy
Cefazolin
VII. Urology
Prostatectomy
Or
Ciprofloxacin
VIII. Head and
Cefazolin
neck
Or
surgery
Pencillin G
a. Clean procedure
(skin incision and Pencillin G
dissection)
Cefazolin
b. Mandibular
Or
fracture
Ceftizoxime
IX. Orthopedics
(Traumatic open
fractures)
X. Neurosurgery

Cefazolin

Route
IV

Dosage
1gm
1gm
1gm

1gm
IV

Time of
administration
30-45min before
skin incision
In high risk
patients 2gm may
be used after
clamping the
umbilical cord

Rationale (likely
infective agent)
Coliforms,
enterococci,
streprococci, clostridia,
bacteroides

30-45min before
skin incision

Coliforms,
staphylococci,
Pseudomonads

400mg
1gm

Staphylococci

IV
2-4MU
2-4MU
IV
2gms

Staphylococci
30-45min before
skin incision
Staphylococci

IV

IV

1gm

xlii

30-45min before
skin incision

Staphylococci

Antimicrobials Prophylaxis in Gynaecologic Procedures

Recommendations
1. All
women
undergoing
an
abdominal
or
vaginalhysterectomy should receive antibiotic prophylaxis.
2. All women undergoing laparoscopic hysterectomy or
laparoscopically assisted vaginal hysterectomy should
receive prophylactic antibiotics.
3. The choice of antibiotic for hysterectomy should be a single
dose of a first-generation cephalosporin. If patients are
allergic to cephalosporin, then clindamycin, erythromycin,
or metronidazole should be used.
4. Prophylactic antibiotics should be administered 15 to 60
minutes prior to skin incision. No additional doses are
recommended.
5. If an open abdominal procedure is lengthy (e .g.> 3 hours),
or if the estimated blood loss is > 1500 mL, an additional
dose of the prophylactic antibiotic may be given 3 to 4
hours after the initial dose.
6. Antibiotic prophylaxis is not recommended for laparoscopic
procedures that involve no direct access from the abdominal
cavity to the uterine cavity or vagina.
7. All women undergoing surgery for pelvic organ prolapse
and/or stress urinary incontinence should receive a single
dose of first- generation cephalosporin.
8. Antibiotic prophylaxis is not recommended for
hysteroscopic surgery.
9. All women undergoing an induced (therapeutic) surgical
abortion should receive prophylactic antibiotics to reduce
the risk of post- abortal infection.
10. Prophylactic antibiotics are not suggested to reduce
infectious morbidity following surgery for a missed or
incomplete abortion.
11. Antibiotic prophylaxis is not recommended for insertion of
an intrauterine device . However, health care professionals
xliii

could consider screening for sexually transmitted infections

in high-risk populations.
12. There is insufficient evidence to support the use of
antibiotic prophylaxis for an endometrial biopsy.
13. The
best
method
to
prevent
infection
after
hysterosalpingography is unknown. Women with dilated
tubes found at the time of hysterosalpingography are at
highest risk, and prophylactic antibiotics (e.g.,doxycycline)
should be given .
14. Antibiotic prophylaxis is not recommended for urodynamic
studies in women at low risk, unless the incidence of urinary
tract infection post-urodynamics is > 10%.
15. In patients with morbid obesity (BMI > 35 kg/m2), doubling
the antibiotic dose may be considered.
16. Administration of antibiotics solely to prevent endocarditis
is not recommended for patients who undergo a
genitourinary procedure.

xliv

1. Gastrointestinal Medicines

1. GASTROINTESTINAL SYSTEM MEDICINES

1.1. Antacids
Antacids are inorganic salts that dissolve in acid gastric
secretions releasing anions that partially neutralized gastric
hydrochloric acid.
Antacids (usually containing aluminium or magnesium
compounds) can often relieve symptoms in ulcer dyspepsia and
in non-erosive gastro-oesophageal reflux; they are also
sometimes used in non-ulcer dyspepsia but the evidence of
benefit is uncertain. Antacids also are used for the relief of, acid
indigestion, heart burn and sour stomach; for the prevention of
stress ulceration and gastrointestinal bleeding; and to reduce the
risk associated with gastric aspiration and for the management
of hyperphosphatemia.
Antacids are best given when symptoms occur or are
expected, usually between meals and at bedtime, 4 or more
times daily; additional doses may be required up to once an
hour.
Conventional doses, for example, 10 ml 3 or 4 times daily of
liquid magnesiumaluminium antacids promote ulcer healing,
but less well than antisecretory drugs (such as an H2-receptor
antagonist); proof of a relationship between healing and
neutralizing capacity is lacking. Liquid preparations are more
effective than solids.Aluminium- and magnesium-containing
antacids (for example aluminium hydroxide and magnesium
hydroxide), being relatively insoluble in water, are long-acting if
retained in the stomach. They are suitable antacids for most
purposes.
Aluminium and/or magnesium containing antacids are the
most commonly used and are often administered concurrently
or in commercially available combinations to control the
frequency and consistency of bowel movements.
1

1. Gastrointestinal Medicines

Aluminium salts tend to produce constipation and to delay

gastric emptying because of its astringent property, while
magnesium salts have the reverse effect; a combination of the
two may reduce adverse gastro-intestinal effects. Another
advantage of combined antacid formulations is that a slowacting antacid such as aluminium hydroxide may be combined
with a more rapidly acting agent such as magnesium hydroxide
to improve the onset and duration of effect.
Some of the antacid combinations contain other ingredients
that have no antacid properties. Simethicone, antiflatulent, has
been added as an aid in those conditions in which the retention
of gas may be a problem; however, in the treatment of peptic
ulcer disease, the advantage of using antacid and simethicone
combinations rather than antacids alone has not been clearly
established.
Alginate taken in combination with an antacid increases the
viscosity of stomach contents and can protect the osophageal
mucosa from acid reflux. Some alginate-containing preparations
form a viscous gel (raft) that floats on the surface of the
stomach contents, thereby reducing symptoms of reflux.
The role of calcium carbonate in the management of peptic
ulcer is controversial because this antacid may cause acid
rebound, which is especially important when the medicineis
administered at bedtime. However, it is useful because it has a
rapid onset of action, high acid effect and is relatively
inexpensive.
Antacids should not be given to young children (up to 6 years
of age) unless prescribed by a physician. Use of magnesiumcontaining antacids is contraindicated in very young children
because there is a risk of hypermagnesemia, especially in
dehydrated children or children with renal failure. Use of
aluminum-containing antacids is contraindicated in very young
children because there is a risk of aluminum toxicity, especially
2

1. Gastrointestinal Medicines

in dehydrated infants and children or infants and children with

renal failure.
Antacids interfere with the gastro-intestinal absorption of a
number of medicinestaken orally by forming insoluble
complexes, altering the gastric PH, or by effects on gastric
emptying rates (fluoroquinolones, isoniazid, ketoconazole,
tetracyclines, oral phosphates); changes in the urinary PH also
affect tubular reabsorption (mecamylamine, methenamine;
concurrent use is not recommended). Antacids may also damage
enteric coatings designed to prevent dissolution in the stomach.
The interaction between an antacid and another orally
administered medicinemay be minimized by giving the drug 2
to 3 hours before or after antacid administration.
Osteomalacia, encephalopathy, dementia, and microcytic
anaemia have been associated with aluminium accumulation in
patients with chronic renal failure. Patients with renal failure
taking aluminium compounds should avoid citrate - containing
preparations.
Use of magnesium-containing antacids is contraindicated in
patients with renal failure because of increased risk of
hypermagnesemia. Chronic administration of magnesium
trisilicate infrequently produces silica renal stones.
Aluminium Hydroxide
Mixture or Gel, 320 mg/5ml.
Suspension, 360mg/5ml.
Chewable tablet, 500mg
Indications: ulcer and non ulcer dyspepsia; gastro-oesphageal
reflux disease (GERD), hyperphosphatemia.
Cautions: See notes above, uremia, congestive heart failure,
renal failureandrenal dialysis, edema, cirrhosis, low sodium
diets, gastrointestinal hemorrhage, and elderly.
3

1. Gastrointestinal Medicines

Drug interactions: allupurinol, antibiotics (tetracycline,

quinolones, some cephalosporins), biphosphonate derivatives,
corticosteroids, cyclosporine, iron salts, imidazole antifungals,
isoniazide, phenytoin, phenothiazines- absorption will be
decreased; citric acid derivatives may decrease absorption of
aluminum hydroxide. See also notes above
Contraindications: see notes above, hypophosphatemia,
undiagnosed gastro intestinal or rectal bleeding; appendicitis;
porphyria.
Side effects: see notes above, constipation, stomach cramps,
fecal impaction, nausea, vomiting, and discoloration of feces,
hypophosphatemia, and hypomagnesemia.
Dose and Administration:Dyspepsia, gastro-oesophageal
reflux disease (GERD): Oral: Adult: 510 ml suspension 4
times daily between meals and at bedtime. Child: 612 years 5
ml up to three times daily
Hyperphosphatemia: Oral: Adult: 210 g daily in divided doses
with meals
Note: Do not take other medicines within 24 hours of aluminium
hydroxide preparations.

Storage: at room temperature, avoid freezing.

Aluminium Hydroxide and Magnesium Hydroxide
Suspension, 220mg+220mg/ 5 ml
Tablet (chewable), 400mg + 400mg
Indications, Cautions, Drug interactions, Contraindications,
Side effects and Storage; see under individual preparations and
notes above.
Note: a combination of Aluminium Hydroxide and Magnesium
Hydroxide may reduce adverse gastro-intestinal effects.
Another advantage of combined antacid formulations is that a

And any other combination ratio proven to be therapeutically effective can

be used

1. Gastrointestinal Medicines

slow-acting antacid aluminium hydroxide may be combined

with a more rapidly acting agent such as magnesium hydroxide
to improve the onset and duration of effect.
Dose and Administrations:Oral: shake the bottle well before
use. 5-10 ml (2 teasponfuls) or 1-2 tablets every 6 hours usually
between meals and at bedtime, or as required.
Storage: at room temperature.
Aluminium Hydroxide + Magnesium Hydroxide +
Simethicone
Suspension, 225mg+200 mg+25 mg/ 5 ml
Indications: temporary relief of hyperacidity associated with
gas; may also be used for indications associated with other
antacids.
Indications, cautions, drug interactions, contraindications
and side effects; see under individual preparations and notes
above.
Note: Simethicone, antiflatulent, has been added as an aid in those
conditions in which the retention of gas may be a problem.

Dose and Administration: Oral: Adult: 10-20ml 4-6 times /

day between meals and at bedtime; may be used every hour for
severe symptoms.
Storage: at room temperature.
Aluminium Hydroxide and Magnesium Trisilicate
Suspension, 310mg+620mg in 5ml
Tablet (chewable), 120 mg+250 mg; 250mg+500mg
Indications, cautions, drug interactions, contraindications,
and side effects; see under individual preparations and notes
above.

And any other combination ratio proven to be therapeutically effective can

be used

1. Gastrointestinal Medicines

Dose and Administrations:Oral:Adult: shake the bottle well

before use. 5-10 ml (2 teasponfuls) every 6 hours usually
between meals and at bedtime, or as required. Note: Chew 1 - 2
tablets when required.

Storage: at room temperature.

Note: Magnesim trisilicate is often given in conjunction with other
antacids in order to reduce adverse gastro-intestinal effects

Calcium Carbonate
Tablet, 350mg, 500mg, 700mg
Indications: used as an antacid, and treatment or prevention of
calcium deficiency or hyperphosphatemia.
Cautions: renal impairment; renal calculi; hypercalcemia;
hypophosphatemia.
Drug interactions: thiazide diuretics, levothyroxine, digoxin,
tetracycline, atenolol, iron, quinolones, sodium fluoride, and
verapamil.
Side effects: headache, hypophosphatemia, hypercalcaemia,
constipation, laxative effect, acid rebound, nausea, vomiting,
anorexia, abdominal pain, xerostomia, and flatulence.
Dose and Administration: Oral: Adult: Antacid: 1-2 tablets
every 2 hours; maximum 7000 mg per 24 hours.
Famotidine+calciumcarbonate+Magnesium hydroxide
Tablet, 10mg+800mg+165mg
Indications: to relieve heartburn associated with acid
indigestion and sour stomach
Caution: allergic to famotidine or other acid reducers, not
swallow tablet whole
Contraindications: trouble or pain swallowing food, vomiting
with blood, or bloody or black stools

1. Gastrointestinal Medicines

Dose and administration: adults and children 12 years and

over: to relieve symptoms, 1 tablet to be chewed before
swallowing; Maximum 2 chewable tablets in 24 hours.
Storage: store at 20-25C; protect from moisture
Magnesium Hydroxide
Suspension, 375 mg/5ml, 7.75 %
Tablet (chewable), 300 mg, 311 mg
Indications: ulcer and non-ulcer dyspepsia; GERD.
Cautions:
renal impairment, hypermagnesemia, hepatic
impairment, notes above.
Drug interactions: as for Aluminum hydroxide, also see notes
above.
Contraindications: see notes above, hypersensitivity to any
component of the formulation, severe renal impairment.
Side effects: diarrhoea, abdominal cramps, muscle weakness,
respiratory depression, hypermagnesemia and hypotension.
Dose and Administration: Tablet, Adult:Chew 2 - 4 tablets
repeated according to patients needs with maximum daily dose
of 16 tablets. Child (7-14 years): one tablet with maximum of 4
tablets per day. Mixture, Adult: 5 -15 ml repeated according to
patient's needs with maximum daily dose of 60 ml. Child: 2.55ml as needed up to 4 times /day.
Storage: at room temperature, avoid freezing.
Magnesium Trisilicate
Tablet (Chewable), 500 mg
Indications, Cautions, Drug interactions, Contraindications,
Storage, see notes above.
Side effects: see notes above, silica renal stones; diarrhea.
Dose and Administration: Oral, Chew 2 tablets as
required.Note: the antacid action is exerted slowly, so it does not
give such rapid symptomatic relief as magnesium hydroxide.
7

1. Gastrointestinal Medicines

Sodium
Alginate+Magnesium
Hydroxide+Aluminum
Hydroxide+Siimethicone
Oral suspension, 100mg+250mg+125mg+50mg in 5ml
Sodium bicarbonate+ Sodium Alginate+ Calcium carbonate
Tablet, 276mg+500mg+160mg
Alginate taken in combination with an antacid increases the
viscosity of stomach contents and can protect the oesophageal
mucosa from acid reflux. Some alginate-containing preparations
form a viscous gel (raft) that floats on the surface of the
stomach contents, thereby reducing symptoms of
reflux.Antacids may damage enteric coatings designed to
prevent dissolution in the stomach.
1.2. Anti-ulcer Agents
Anti-ulcer agents, used in the treatment and prophylaxis of
peptic ulcer disease, may be broadly divided into the
antisecretory agents which suppress the production of gastric
acid (e.g. cimetidine), and agents with cytoprotective or
mucosal protectant properties (e.g. sucralfate). Antacids (see
above) also play an adjuvant role in the symptomatic treatment
of peptic ulcer and therapy to treat Helicobacter pylori is
becoming more important.
H2-receptor antagonists
The H2-receptor antagonists, which include cimetidine,
ranitidine, nizatidine and famotidine, reduce acid secreation by
blocking the action of histamine at the H2-receptors in the
parietal cells of the stomach. Gastric acid secreation in response
to other secretagogues (e.g. acetylcholine, gastrin) is also
reduced. They are used in the management of peptic ulcer
disease, reflux oesophagitis and hypersecretory states such as
Zollinger-Ellison syndrome. High doses of H2-receptor
8

1. Gastrointestinal Medicines

antagonists have been used in ZollingerEllison syndrome, but

a proton-pump inhibitor is now preferred. H2-receptor
antagonists should be used with caution in renal impairment,
pregnancy and breast feeding.
Maintenance treatment with low doses of H2-receptor
antagonists has largely been replaced in Helicobacter pyloripositive patients by eradication regimens. Maintenance
treatment may occasionally be used for those with frequent
severe recurrences and for the elderly who suffer ulcer
complications. Treatment of undiagnosed dyspepsia with H2receptor antagonists may be acceptable in younger patients but
care is required in older people because their symptoms may be
caused by gastric cancer.
H2-receptor antagonist therapy can promote healing of
NSAIDs-associated ulcers (particularly duodenal). Treatment
also reduces the risk of acid aspiration in obstetric patients at
delivery (Mendelson syndrome).
Side-effects of the H2-receptor antagonists include diarrhoea,
headache, and dizziness. Rash (including erythema multiforme
and toxic epidermal necrolysis) occurs less frequently. Other
side-effects reported rarely or very rarely include hepatitis,
cholestatic jaundice, bradycardia, psychiatric reactions
(including confusion, depression, and hallucinations)
particularly in the elderly or the very ill, blood disorders
(including leucopenia, thrombocytopenia, and pancytopenia),
arthralgia, and myalgia. Gynaecomastia and impotence occur
occasionally with cimetidine and there are isolated reports with
the other H2-receptor antagonists.
Cimetidine is used in conditions where inhibition of gastric
acid secretion may be beneficial, such as duodenal and gastric
ulcers. Cimetidine binds to cytochrome P450 and inhibits the
breakdown of medicinesmetabolized by this system; many
interactions have been reported but only a few are of clinical
9

1. Gastrointestinal Medicines

significance. Ranitidine differs structurally from cimetidine; it

has been shown to be at least as effective as cimetidine as an
ulcer-healing medicine, and is less inclined to cross the bloodbrain barrier. Ranitidine and nizatidine do not appear to bind
microsomal cytochrome P450 and thus the potential for drug
interactions is lower. Unlike cimitidine, they have little or no
antiandrogenic effect. Famotidine has been shown to be 20-150
or 3-20 times as potent on a molar basis as cimetidine or
ranitidine, respectively, in inhibiting stimulated gastric acid
secretion.
Cimetidine
Injection, 200mg/ml in 2ml ampoule
Syrup, 200mg/5ml
Tablet, 200mg, 400mg, 800mg
Tablet, (chewable), 200mg
Indications: benign gastric and duodenal ulceration, stomach
ulceration, GERD, Zollinger-Ellison syndrome, and other
conditions where gastric acid reduction is beneficial.
Cautions: hepatic impairment; renal impairment; pregnancy;
breastfeeding; middle aged or older patients and in those whose
symptom change may mask gastric cancer; preferably avoid
intravenous injection (use intravenous infusion) particularly in
high dosage and in cardiovascular impairment (risk of
arrhythmias).
Drug interactions: tricyclic antidepressants, benzodiazepines,
metoprolol,
propranolol,
carbamazepine,
phenytoin,
procainamide, quinidine, theophylline, valproic acid, azole
antifungals and warfarin.
Contraindications: hypersensitivity to the drug.
Side effects: gastrointestinal disturbances, headache, dizziness,
somnolence, diarrhea, rash and tiredness; reversible confusional
states, gynaecomastia and impotence, hypersensitivity reactions
10

1. Gastrointestinal Medicines

(rare), less commonly tachycardia; rarely interstitial nephritis;

very rarely pancreatitis, galactorrhoea, vasculitis, alopecia.
Dose and Administration: Adult: Short-term treatment of
active ulcers: Oral: 300mg 4 times/day or 400mg twice daily or
800mg at bedtime for up to 8 weeks.
Note: Higher doses of 1600 mg at bedtime for 4 weeks may be
beneficial for a subpopulation of patients with larger duodenal ulcers
(>1 cm defined endoscopically) who are also heavy smokers (1
pack/day).

I.M, I.V: 200mg 4-6 hourly (for IV, dilute in 20ml 0.9% sodium
chloride solution and give slowly, over at least 2 minutes).
In cardiovascular disease or if a higher dose is required, IV
infusion is recommended: 400mg, diluted in 100ml 0.9%
sodium chloride and given over 0.5-1 hour, may be repeated 4-6
hourly; or continuous infusion at a rate of 50-100mg/hour;
maximum 2.4g/24 hours.
Duodenal ulcer prophylaxis: oral: 400mg-800mg at bed time.
Gastric hypersecretory conditions: Oral, I.M., I.V.; 300mg
600mg every 6 hours; dosage not to exceed 2.4g/day.
Child 12 years and Adult:Oral: heart burn, acid indigestion,
sour stomach: 200mg up to twice daily; may take 30 minutes
prior to eating foods or beverages expected to cause heart burn
or indigestion.
Child: Oral, I.M., I.V.: 20-40mg/kg/day in divided doses every
6 hours.
Note: Oral: Administer with meals so that the medicinespeak effect
occurs at the proper time. Peak inhibition of gastric acid secretion
occurs at 1 and 3 hours after dosing in fasting subjects and
approximately 2 hours in non fasting subjects; this correlates well
with the time food is no longer in the stomach offering a buffering
effect.

Renal Impairment: when Clcr 10-50 mL/minute: Administer

50% of normal dose. When Clcr <10 mL/minute: Administer
25% of normal dose
11

1. Gastrointestinal Medicines

Slightly dialyzable (5% to 20%); administer after dialysis.

Hepatic Impairment: Usual dose is safe in mild liver disease but
use with caution and in reduced dosage in severe liver disease.
Increased risk of CNS toxicity in cirrhosis suggested by
enhanced penetration of CNS.
Storage: store in airtight containers at a temperature of 15 to
30oc. Protect from light.
Famotidine
Tablet, 20 mg, 40 mg
Indications: maintenance therapy and treatment of duodenal
ulcer, gastric ulcer, to control gastric pH in critically-ill patients,
symptomatic relief in gastritis, GERD, active benign gastric
ulcer, and pathological hypersecretory conditions.
Caution: see under cimetidine.
Drug interactions: ketoconazole, itraconazole and ethanol; the
potential for drug interaction is much less than with cimetidine.
Contraindication: hypersensitivity to the medicine and other
H2 antagonists, or any component of the formulation.
Side effects: see under cimetidine; it has little if any antiandrogenic effect.
Dose and Administration: Oral: Adult: Duodenal ulcer:
Acute therapy: 40mg/day at bed time (or 20 mg twice daily) for
4-8 weeks. Maintenance therapy: 20mg/day at bedtime.Gastric
ulcer: Acute therapy: 40mg/day at bedtime.Hypersecretory
conditions: initial: 20mg every 6 hours; may increase in
increments up to 160mg every 6 hours. Gastro-oesophageal
reflux disease (GERD): 20mg twice daily for 6 weeks.Child:
Peptic ulcer: 1-16 years: 0.5mg/kg/day at bedtime or divided
twice daily (maximum dose: 40mg/day). GERD: <3 months:
0.5mg/kg once daily; 3 to 12 months: 0.5mg/kg twice daily; 1 to
16 years: 1mg/kg/day divided twice daily
(maximum dose:
40mg twice daily); Adult and Child 12 years: Heart burn,
12

1. Gastrointestinal Medicines

indigestion, sour stomach: 10-20mg every 12 hours; dose may

be taken 15-60 minutes before eating foods known to cause
heartburn.
Storage: store at room temperature; protect from moisture.
Nizatidine
Capsule, 150mg, 300mg
Injection, 25mg/ml
Indications: see under dose.
Cautions, Drug interactions, see under cimetidine above.
Side effects: sweating, rarely vasculitis, hyperuricaemia,
exfoliative dermatitis
Dose and Administration: Adult: Oral: Benign gastric,
duodenal or NSAID associated ulceration, treatment, 300mg in
the evening or 150 mg twice daily for 4-8 weeks; maintenance,
150mg at night;
Gastro-oesophageal reflux disease: 150-300mg twice daily for
up to 12 weeks.IV infusion: for short term use in peptic ulcer
hospital inpatients as alternative to oral route, by intermittent IV
infusion over 15 minutes, 100mg 3 times daily, or by
continuous IV infusion, 10mg/hour; max 480mg daily.Child not
recommended.
Ranitidine
Injection, 10 mg/ml in 5ml ampoule; 25mg/ml in 10ml ampoule
Tablet, 150 mg, 300mg
Indications: benign gastric and duodenal ulceration, GERD,
ZollingerEllison syndrome, other conditions where gastric acid
reduction is beneficial
Cautions, Side effects, see under cimetidine above.
Drug interactions: ranitidine does not appear to bind to
microsomal cytochrome P450 thus the potential for interactions
13

1. Gastrointestinal Medicines

is less than with cimetidine; sacralfate reduces absorption of

ranitidine.
Dose and Administration: Benign gastric and duodenal
ulceration: oral:Adult: 150 mg twice daily or 300 mg at night
for 48 weeks, up to 6 weeks in chronic episodic dyspepsia, and
up to 8 weeks in NSAID-associated ulceration (in duodenal
ulcer 300 mg can be given twice daily for 4 weeks to achieve a
higher healing rate); maintenance, 150 mg at night;
Child:(peptic ulcer) 24 mg/kg twice daily, maximum 300 mg
daily. Benign gastric and duodenal ulceration, reflux
oesophagitis, ZollingerEllison syndrome: IM: Adult: 50 mg
every 68 hours or by slow intravenous injection, 50 mg diluted
to 20 ml and given over at least 2 minutes, may be repeated
every 68 hours or by intravenous infusion, 25 mg/hour for 2
hours, may be repeated every 68 hours.Prophylaxis of NSAIDinduced duodenal ulcer: oral: Adult: 150 mg twice daily.
Reflux oesophagitis: oral:Adult: 150 mg twice daily or 300 mg
at night for up to 8 weeks, or if necessary 12 weeks (moderate
to severe, 150 mg 4 times daily for up to 12 weeks); long-term
treatment of healed oesophagitis, 150 mg twice daily.
ZollingerEllison syndrome: oral:Adult: 150 mg 3 times daily;
up to 6 g daily in divided doses has been used.Gastric acid
reduction (prophylaxis of acid aspiration) in obstetrics:
oral:Adult: 150 mg at onset of labour, then every 6 hours;
surgical procedures, IM or slow IV injection: Adult: 50 mg 45
60 minutes before induction of anaesthesia (intravenous
injection diluted to 20 ml and given over at least 2 minutes), or
orally, 150 mg 2 hours before induction of anaesthesia, and
also, when possible on the preceding evening.Prophylaxis of
stress ulceration: Adult: initial slow IV injection of 50 mg
diluted to 20 ml and given over at least 2 minutes then by
continuous IV infusion, 125250 micrograms/kg per hour (may
14

1. Gastrointestinal Medicines

be followed by 150 mg twice daily by mouth when oral feeding

commences).
Use half normal dose if eGFR less than 50 mL/minute/1.73 m2.
Storage: store injections between 4-30oC; and tablet between
15-30oC.
Misoprostol
Tablet, 20mcg, 40mcg
Indications: protection against NSAID associated gastric and
duodenal ulceration. Misoprostol is a synthetic prostaglandin E1
analogue used to inhibit gastric acid secreation by a direct action on
the parietal cells and also have mucosal protectant property.

Cautions: renal impairment and elderly, inflammatory bowel

disease (may exacerbate intestinal inflamation and produce
severe diarrhea); patients prone to dehydration or in whom its
consequence would be dangerous. Patients should understand
misoprostols abortifacient properties and attendant risks, and
that the medicineis intended only for their use for the specific
condition for which it was prescribed.
Drug interactions: oxytocin, diclofenac, phenylbutazone
Contraindications: pregnancy and allergy to prostaglandins.
Side effects:diarrhoea is the most common side effects (may
occasionally be severe and require withdrawal, reduced by
giving single doses not exceeding 200 micrograms and by
avoiding magnesium-containing antacids); abdominal pain,
dyspepsia, flatulence, and nausea and vomiting, increased utrine
contractility,
abnormal
viginal
bleeding
(including
intermenstrual bleeding, menorrhagia, and postmenopausal
bleeding), skin rashes, headache, dizziness, and constipation.
Dose and Administration: Adult: Oral: Prevention against
NSAID associated duodenal ulcer: 800 mcg/day in four divided
doses, with meals and at bedtime. Where appropriate, NSAIDs
should be taken simultaneously.
15

1. Gastrointestinal Medicines

Prevention against NSAID associated gastric ulcer: 200mcg

twice daily with food and the prescribed NSAID; increased to
200mcg three times daily (maximum 200 mcg 4 times daily) to
correspond with the NSAID administration schedule or if
clinically indicated. Misoprostol therapy should be started at the
onset of treatment with NSAIDs, and continue for the duration
of NSAIDs therapy. If required, antacids may be administered
before or after misoprostol for the relief of pain. However,
magnesium-containing antacids are not recommended since
they may aggravate misoprostol-induced diarrhea.
Storage: store at or below 25oC.
Note:Taking with food or milk will lessen adverse effects such as
loose stools, diarrhea, and abdominal cramping.

Proton pump inhibitors

The proton pump inhibitors, which include omeprazole,
esomeprazole and lansoprazole are the most potent suppressors
of gastric acid secreation. They inhibit gastric acid secretion by
blocking the hydrogen-potassium adenosine triphosphatase
enzyme system (the H+/K+ ATPase enzyme, the proton
pump) of the gastric parietal cell. They are indicated for short
term management of peptic ulcer disease and gastrooesophageal reflux disease (GERD), long-term prevention of
relapse of GERD, and as part of H. pylori eradication regimens.
Following endoscopic treatment of severe peptic ulcer bleeding,
an intravenous, high-dose proton pump inhibitor reduces the
risk of rebleeding and the need for surgery. In addition,
omeprazole is registered for the treatment of Zollinger-Ellison
syndrome, and the treatment and prevention of NSAIDassociated erosions. In patients who need to continue NSAID
treatment after an ulcer has healed, the dose of proton pump
inhibitor should normally not be reduced because asymptomatic
ulcer deterioration may occur. A proton pump inhibitor can be
16

1. Gastrointestinal Medicines

used to reduce the degradation of pancreatic enzyme

supplements in patients with cystic fibrosis.
Proton pump inhibitors may mask the symptoms of gastric
cancer; particular care is required in those presenting with
alarm features, in such cases gastric malignancy should be
ruled out before treatment. Patients at risk of osteoporosis
should maintain an adequate intake of calcium and vitamin D,
and, if necessary, receive other preventative therapy (see section
6.6). Measurement of serum-magnesium concentrations should
be considered before and during prolonged treatment with a
proton pump inhibitor, especially when used with other drugs
that cause hypomagnesaemia or with digoxin. A proton pump
inhibitor should be prescribed for appropriate indications at the
lowest effective dose for the shortest period; the need for longterm treatment should be reviewed periodically.
Side-effects of the proton pump inhibitors include gastrointestinal disturbances (including nausea, vomiting, abdominal
pain, flatulence, diarrhoea, constipation), and headache. Less
frequent side-effects include dry mouth, peripheral oedema,
dizziness, sleep disturbances, fatigue, paraesthesia, arthralgia,
myalgia, rash, and pruritus. Other side-effects reported rarely or
very rarely include taste disturbance, stomatitis, hepatitis,
jaundice, hypersensitivity reactions (including anaphylaxis,
bronchospasm), fever, depression, hallucinations, confusion,
gynaecomastia,
interstitial
nephritis,
hyponatraemia,
hypomagnesaemia (usually after 1 year of treatment, but
sometimes after 3 months of treatment), blood disorders
(including
leucopenia,
leucocytosis,
pancytopenia,
thrombocytopenia),
visual
disturbances,
sweating,
photosensitivity, alopecia, Stevens-Johnson syndrome, and
toxic epidermal necrolysis.

17

1. Gastrointestinal Medicines

By decreasing gastric acidity, proton pump inhibitors may

increase the risk of gastro-intestinal infections (including
Clostridium difficile infection).
Proton pump inhibitors can increase the risk of fractures,
particularly when used at high doses for over a year in the
elderly. Rebound acid hypersecretion and protracted dyspepsia
may occur after stopping prolonged treatment with a proton
pump inhibitor.
Esomeprazole
Capsule, 20mg
Tablet (e/c), 20mg, 40mg
Oral suspension (pediatric), 20mg, 40mg/sachet
Powder for injection, 20mg, 40mg/5ml vial
Indications: see under dose and administration.
Cautions, Drug interactions, Contraindications, Side effects
and Storage see under omeprazole.
Dose and Administration: Adult: Oral: Erosive reflux
oesophagitis: 40mg once daily for 4-8 weeks. Maintenance to
prevent relapse, 20mg once daily. GERD (without
oesophagitis):20mg once daily for 4 weeks. NSAID-associated
gastric ulcer: adult over 18 years, 20 mg once daily for 48
weeks; prophylaxis in patients with an increased risk of
gastroduodenal complications who require continued NSAID
treatment, 20 mg daily. ZollingerEllison syndrome: adult over
18 years, initially 40 mg twice daily, adjusted according to
response; usual range 80160 mg daily (above 80 mg in 2
divided doses). Eradication ofH. pylori: esomeprazole 20mg
plus amoxicillin 1g and clarithromycin 500mg, all twice daily
for 7 days.
IV over at least 3 minutes or by intravenous infusion, adult over
18 years, gastro-oesophageal reflux disease, 40 mg once daily;
18

1. Gastrointestinal Medicines

symptomatic reflux disease without oesophagitis, treatment of

NSAID-associated gastric ulcer, prevention of NSAIDassociated gastric or duodenal ulcer, 20 mg daily; continue until
oral administration possible. Severe peptic ulcer bleeding
(following endoscopic treatment), adult over 18 years, initial
intravenous infusion of 80 mg over 30 minutes, then by
continuous intravenous infusion 8 mg/hour for 72 hours, then
by mouth 40 mg once daily for 4 weeks
Lansoprazole
Capsule, 15mg, 30mg
Tablet, 15mg, 30mg (enteric coated)
Oral suspension (granule), 30mg/sachet
Indications: see under dose and administration.
Cautions, Drug interactions, Contraindications, Side effects
and Storage see under omeprazole. Contraindicated in liver
impairment.
Dose and Administration: Adult: Oral: 30mg daily for 2-8
weeks depending on the condition. Prevention of GERD: 15mg
daily for upto 1 year. No efficacy or safety data available for
therapy longer than 1 year. Functional dyspepsia: 15mg daily
for 2-4 weeks. Eradication of H. pylori: see under
omeprazole.Heartburn and hyperacidity: 15mg daily for up to
14 days
Omeprazole
Capsule (enclosing e/c granules), 20 mg
Tablet, 20mg (enteric coated)
Indications: management of gastric and duodenal ulcers, reflux
oesophagitis and Zollinger Ellison syndrome; also eradication
of H. Pylori in combination with appropriate antibiotics.
Cautions: pregnancy, lactating women, liver disease;
porphyria.
19

1. Gastrointestinal Medicines

Drug interactions: diazepam, warfarin, phenytoin, fluoxetin,

propranolol, indinavir, ketoconazole, and carbamazepine.
Contraindications: known hypersensitivity to the drug, exclude
malignancy.
Side effects: diarrhoea, headache, skin rashes, nausea,
vomiting, constipation, flatulence and abdominal pain, pruritus,
urticaria, dizziness.
Dose and Administration: Oral:Adult: Active duodenal ulcer:
20mg/day for 4-8 weeks. Gastric ulcers: 40mg/day for 4-8
weeks. NSAID-associated erosions: 20mg daily for 4-8 weeks.
Prevention, 20mg daily. Eradication of H.pylori: 20mg twice
daily or 40 mg once daily for 7-14 days in combination with
appropriate antibiotics (clarithromycin 500 mg twice daily,
amoxicillin 1 g twice daily, or as an alternative amoxicillin 1 g
twice daily, metronidazole 500 mg (or tinidazole 500mg) twice
daily). Zollinger-Ellison syndrome: initially 60mg once daily;
dosages range 20- 120mg/day, with doses over 80mg given in 2
divided doses. Gastric acid reduction during general anaesthesia
(prophylaxis of acid aspiration), 40 mg on the preceding
evening then 40 mg 26 hours before surgery.Child: Severe
ulcerative reflux oesophagitis: 10-20kg, 10mg once daily,
increased to 20mg daily if necessary; over 20kg, 20mg once
daily, increased to 40mg daily if necessary.
Storage: store at room temperature.
Note:-Taking the medication at least 1 hour before a meal will have
maximum benefit.

Pantoprazole
Tablet, 20mg, 40mg (enteric coated)
Indications: benign gastric ulcer, Gastro-oesophageal reflux
disease (GERD), duodenal ulcer, duodenal ulcer associated with
Helicobacter pylori, Prophylaxis of NSAID-associated gastric
or duodenal ulcer in patients with an increased risk of
20

1. Gastrointestinal Medicines

gastroduodenal complications who require continued NSAID

treatment,
ZollingerEllison
syndrome
(and
other
hypersecretory conditions).
Cautions: should be used with caution in patients with liver
disease, in pregnancy and in breast-feeding. May mask the
symptoms of gastric cancer; particular care is required in those
presenting with alarm features in such cases gastric malignancy
should be ruled out before treatment,renal impairment
Contraindications: sensitivity to pantoprazole, hepatic disease
Side effects: gastro-intestinal disturbances (including nausea,
vomiting, abdominal pain, flatulence, diarrhoea, constipation),
and headache. Less frequent side-effects include dry mouth,
peripheral oedema, dizziness, sleep disturbances, fatigue,
paraesthesia, arthralgia, myalgia, rash, and pruritus. And also
see the above note.
Dose and administration: benign gastric ulcer: oral:adultover
18 years, 40 mg daily in the morning for 4 weeks, continued for
further 4 weeks if not fully healed.
Gastro-oesophageal reflux disease (GERD): adult and child
over 12 years: 2040 mg daily in the morning for 4 weeks,
continued for further 4 weeks if not fully healed; maintenance
20 mg daily, increased to 40 mg daily if symptoms return.
Duodenal ulcer: adultover 18 years: 40 mg daily in the morning
for 2 weeks, continued for further 2 weeks if not fully
healed.Duodenal ulcer associated with Helicobacter pylori
(eradication): pantoprzole 40mg twice daily + clarithromycin
250mg twice daily+ metronidazole 400mg twice daily. If a
patient has been treated with metronidazole for other infections
pantoprzole 40mg twice daily +amoxicicilin 1g twice daily +
clarithromycin 500mg three times daily.Prophylaxis of NSAIDassociated gastric or duodenal ulcer in patients with an
increased risk of gastroduodenal complications who require
continued NSAID treatment: adult over 18 years: 20 mg daily.
21

1. Gastrointestinal Medicines

ZollingerEllison syndrome (and other hypersecretory

conditions): adultover 18 years: initially 80 mg once daily
adjusted according to response (elderly max. 40 mg daily); daily
doses above 80 mg given in 2 divided doses
Bismuth compounds
Bismuth compounds have been used for their antacid action and
for their mildly astringent action in various gastro-intestinal
disorders, including diarrhoea and dyspepsia. Tripotassium
dicitratobismuthate and the subsalicylate formulations are active
against H.Pylori and commonly used as part of a multi drug
regimen for H. Pylori eradication to reduce the risk of duodenal
ulcer recurrence. Excessive or prolonged use may lead to
bismuth accumulation and toxicity, including renal failure, liver
damage, and encephalopathy.
Bismuth subsalicylate
Liquid, 262 mg/15ml
Tablet, 300 mg
Indications: as part of a multidrug regimen for H.pylori
eradication to reduce the risk of duodenal ulcer recurrence.
Cautions: patients taking asprin, children < 3 years of age and
those with viral illness.
Drug interactions: warfarin, aspirin, hypoglycemics,
tetracyclines and uricosurics.
Contraindications: hypersensitivity to the medicine, severe GI
bleeding, history of coagulopathy, pregnancy (3rd trimester),
renal impairment.
Side effects: anxiety, confusion, headache, discoloration of the
tongue, grayish black stools, hearing loss, tinnitus, nausea and
vomiting.
Dose and Administration:Adult: Oral: 524mg four times/day
with meals and at bedtime; requires combination therapy.
22

1. Gastrointestinal Medicines

Storage: store in airtight containers and protect from light.

Tripotassium Dicitratobismuthate
Liquid, 120 mg/5ml
Tablet, 120 mg
Indications: used as a mucosal protectant for the treatment of
peptic ulcer disease; active against Helicobacter pylori and has
been used as triple therapy (with metronidazole and either
tetracycline or amoxicillin) to eradicate this organism and
therby prevent relapse of duodenal ulcer.
Cautions, Drug interactions, Contraindications, Side effects
and Storage see under bismuth subsalicylate.
Dose and Administration: Adult: Oral: Gastric and Duodenal
ulceration: 240mg twice daily or 120mg four times daily before
meals for 4 weeks, extended to 8 weeks if necessary. When
used as part of triple therapy 120mg 4 times daily for 2 weeks.
Storage: store in airtight containers and protect from light.
Sucralfate
Sucralfate, a sucrose hydrogen sulphate aluminium complex, is
a mucosal protective agent. It has a local protective action on
the ulcer base, without the side-effects that may occur with
other systemic agents. In the stomach a paste-like gel is formed
from a reaction with HCl, which adheres to the base of ulcer
craters (both in the stomach and duodenum), protecting ulcer
epithelium from ulcerogenic substances such as gastric acid,
pepsin and bile. It also directly adsorbs bile and pepsin.
Sucralfate requires a strict, frequent administration dosage
regimen which may produce problems with compliance, but if
used correctly, its efficacy compares favourably with that of
other ulcer-healing agents.
Sucralfate
Tablet, 1 g (Scored)
23

1. Gastrointestinal Medicines

Indications: for treatment of gastric and duodenal ulcers,

chronic gastritis and reflux oesophagitis.
Caution: renal impairment.
Drug interactions: other antacids, tetracyclines, phenytoin, oral
anticoagulants, digoxin, cimetidine.
Contraindications: hypersensitivity of the medicine.
Side effects: constipation, diarrhoea, nausea, abdominal
discomfort and indigestion.
Dose and Administration: Adult:Oral: 1g 4 times daily, 1
hour before meals and at bedtime. In duodenal ulcer, 2g twice
daily has also been shown to be effective.Maintenance 1g twice
daily, half an hour before morning and evening meals.
Storage: store at room tempertature.
1.3.Antispasmodics and other medicines altering gut
motility.
Antispasmodic medicines are used to treat symptoms such as
pain and spasm in irritable bowel syndrome (IBS). There are
two main types: Antimuscarinics such as hyoscine, atropine,
propantheline; and Smooth muscle relaxants (medines believed
to be direct relaxants of intestinal smooth muscles). Intestinal
antispasmodics have the major functions of muscle relaxation
and convulsion control, thus alleviating spasmodic pain. The
smooth muscle relaxant properties of antimuscarinics and other
antispasmodic medicines may be useful in IBS and diverticular
diseases. The Smooth muscle relaxant properties of
antimuscarinic (formerly termed 'anticholinergics') and other
antispasmodic medicines(e.g. Camylofin Hydrochloride) may be
useful in some forms of dyspepsia, in IBD and in diverticular
disease. Other indications of antimuscarinic medicinesinclude
arrhythmias, asthma and airways disease, motion sickness,
parkinsonism, urinary incontinence, mydriasis and cycloplegia,
premedication and as an antidote to organophosphorous
poisoning.
24

1. Gastrointestinal Medicines

Antimuscarinics that are used for gastro-intestinal

smooth muscle spasm include the tertiary amines atropine
sulphate and scopolamine (Hyoscine) hydrobromide and the
quaternary ammonium compounds scopolamine (Hyoscine)
butylbromide and propantheline bromide.
Antimuscarinics are commercially available in combination
with phenothiazines, or benzodiazepines or other anxiolytics
(e.g. chlordiazepoxide + clidinium bromide) for the benefit of
its supportive role in patients with IBD who respond to
sedatives or in some patients with peptic ulcer disease.
The side effects frequently associated with the use of
antimuscarinics include xerostoma (dry mouth), blurred vission,
cycloplegia, mydriasis, photophobia, anhidrosis, urinary
hesitancy and retention, tachycardia, palpitation, and
constipation. Side effects that occur occasionally include
confusion (particularly in elderly), nausea, vomiting and
giddiness.
Antimuscarinics should be used with caution in geriatricpatients, and children, and also in patients with
hyperthyroidism, hepatic or renal disease, or hypertension,
tachyarrhythmias, congestive heart failure, or coronary artery
disease; autonomic neuropathy, gastro-esophageal reflux,
known or suspected GI infections, diarrhea and mild to
moderate ulcerative colitis, and in patients who may be exposed
to elevated environmental temperatures or in patients who are
febrile.
The medicinesare contraindicated in patients with severe
ulcerative colitis, obstructive disease of the GI tract, paralytic
ileus, or intestinal atony, prostatic enlargement, known
hypersensitivity to the medicines, angle-closure glaucoma,
obstructive uropathy (caution for patients with partial
obstructive uropathy) and myasthenia gravis (unless the
25

1. Gastrointestinal Medicines

antimuscarinic is used to reduce adverse muscarinic effects of

an anticholinesterase agent).
The effect of antimuscarinic agents may be enhanced by the
concomitant
administration
of
other
medicineswith
antimuscarinic properties, such as amantadine, some
antimuscarinic, butyrophenones and phenothiazine, and tricyclic
antidepressants. The reduction in gastric motility caused by
antimuscarinic agents may affect the absorption of other
medicines.
Atropine Sulphate
Injection, 1 mg/ml in 1ml ampoule
Indications: dyspepsia, irritable bowel syndrome, diverticular
disease; preoperative medication to inhibit salivation and
secretions; mydriasis and cycloplegia; organophosphate or
carbamate insecticide poisoning (section 17); see also notes
above.
Cautions, Drug interactions, Contraindications, Side effects;
See notes above
Dose and Administration: Adult:IM, S.C., I.V: 0.4 - 0.6 mg
every four to six hours. Child:SC: 0.01 mg/kg of body weight,
not to exceed 0.4 mg, every four to six hours.
Storage: at room temperature, protect from freezing.
Chlordiazepoxide + Clidinium Bromide
Tablet, 5 mg + 2.5 mg
Indications: used in the treatment of functional disturbances of
GI motility such as irritable bowel syndrome, see also notes
above.
Cautions, Drug interactions,Contraindications, Side effects see notes above
The precautions and contraindications associated with
chlordiazepoxide must be considered (see section 4.2).
26

1. Gastrointestinal Medicines

Dose and Administrations: Adult: Oral: one or two tablets 3

or 4 times daily (i.e. 2.5 or 5 mg of Clidinium bromide 3 or 4
times a day)
Storage: store at room temperature in a tight, light resistant
container.
Drotaverine
Tablet, 40 mg
Injection, 40mg/2ml ampoule
Indications: smooth muscle spasm in connection with biliary
tract
diseases:
cholecystolithiasis,
cholangiolithiasis,
cholecystitis, pericholecystitis, cholangitis, and papillitis.
Smooth muscle spasm in connection with urinary tract diseases:
nephrolithiasis, ureterolithiasis, pyelitis, cystitis, and cramp of
urinary bladder.
Cautions: hypotension, people with lactase insufficiency,
galactosaemia.
Drug interactions: phosphodiesterase inhibitors like papverine
decrease the antiparkinsonian effect of levodopa.
Contraindications: hypersensitivity reactions; severe hepatic,
renal and cardiac insufficiency; children < 1 year of age.
Side effects: gastrointestinal disorders (nausea, constipation);
nervous system disorders (headache, dizziness, insomnia);
cardiovascular disorders (palpitation, hypotension).
Dose and Administration: Adult: the usual average daily dose
is 120-240 mg/day (in 2-3 divided doses).
Child > 1 year old: 40-120 mg/day divided in 2 to 3 doses
between 1 and 6 years. 80-200 mg/day divided in 2 to 5 doses
over 6 years.
Storage: store at a temperature not exceeding 25 oC.
Scopolamine (Hyoscine) Butylbromide
Drops, 5mg/5ml
27

1. Gastrointestinal Medicines

Injection, 20mg/ml
Tablet, 10mg
Suppository, 7.5mg, 10mg
Indications: symptomatic relief of visceral spasms of the
gastro-intestinal tract, painful spasm of the biliary and genitourinary system, bowel colic and excessive respiratory
secretions.
Cautions, Contraindications, Side effect; see notes above
Drug interactions: CNS depressants see also notes above.
Dose and Administrations: Adult:Oral: Smooth muscle
spasm: 20mg four times daily; IM or IV (acute spasm and
spasm in diagnostic procedures), 20 mg repeated after 30
minutes if necessary. (May be repeated more frequently in
endoscopy), maximum 100 mg daily.
Irritable bowel syndrome: 10 mg 3 times daily, increased if
required up to 20 mg 4 times daily.Child:Oral: 6-12 years,
10mg 3 times daily; parenteral use not recommended.
Storage: at room temperature, in a well-closed container.
Note: Scopolamine (hyoscine) hydrobromide should not be
interchanged with scopolamine butylbromide formulations. Dosages
are not equivalent.

Scopolamine (hyoscine) Hydrobromide

Injection, 0.4 mg/ml, 0.6 mg/ml in 1ml ampoule
Tablet, 0.6 mg
Indications: prevention and control of motion sickness, and
also used as an adjunct to anesthesia to inhibit salivation and
excessive respiratory secretions and to produce sedative and
amnesia; see also notes above. Not indicated for peptic ulcer.
Note: Hyoscine butylbromide is preferable to hyoscine hydrobromide
in the relief of visceral spasms of the gastro-intestinal tract and pain
associated with other smooth muscle spasm.

Cautions, Contraindications, Side effects; see notes above

28

1. Gastrointestinal Medicines

Drug interactions: CNS depression - producing medications;

see notes above.
Dose and Administration: Adult:Oral: 0.3 mg 30 minutes
before a journey to prevent motion sickness then 0.3 mg every 6
hours if required up to a maximum of 3 doses in 24 hours;IM,
IV, or SC, 0.3 to 0.6 mg; if necessary, the dose may be repeated
3 or 4 times daily.
Child: Oral: aged 4 to 10 years, 75 to 150 microgram and those
over 10 years, 150 to 300 microgram; IM, IV, or SC, 0.006
mg/Kg
Storage: store in a light - resistant container at room
temperature. Protect from freezing.
Propantheline Bromide
Tablet, 15 mg, 30 mg
Indications: adjunctive treatment of peptic ulcer, irritable
bowel syndrome, pancreatitis, ureteral and urinary bladder
spasm (urinary frequency); reduce duodenal motility during
diagnostic radiologic procedure, gustatory sweating.
Cautions, Drug interactions, Contraindications, Side effects;
see notes above.
Dose and Administration: Oral: Antisecretory: Adult: 15 mg
3 times/day before meals or food and 30mg at bedtime,
maximum 120 mg daily. Child: 1-2 mg/kg/day in 3-4 divided
doses. Elderly: 7.5 mg 3 times/day before meals and at
bedtime. Antispasmodic: Adult: 15mg 3 times/day before
meals or food and 30mg at bedtime max. 120 mg daily.Child:
2-3mg/kg/day in divided doses every 4-6 hours and at bedtime
Storage: at room temperature in a well closed container.
1.4. Antiemetics
Antiemetics are a diverse group of medicinesused to treat or
prevent nausea and vomiting, including that associated with
29

1. Gastrointestinal Medicines

cancer therapy, anaesthesia and surgery, and motion sickness.

Antiemetics described here include: the dopamine antagonists
such as metoclopramide and chlorpromazine hydrochloride;
antihistamines such as dimenhydrinate, meclizine hydrochloride
and promethazine hydrochloride; and the phenothiazine
thiethylperazine maleate.
The choice of medicinedepends partly on the cause of nausea
and vomiting. For example, hyoscine (see section 1.3.) or
antihistamines are used in motion sickness where as dopamine
antagonists, which act selectively on the chemoreceptor trigger
zone, are ineffective for the treatment of motion sickness.
Conversely, nausea and vomiting associated with cancer
chemotherapy is often hard to control and special regimens have
been devised including the use of metoclopramide in high doses
and more recently 5 HT3 antagonists such as ondanesetron.
The antihistamines may be slightly less effective than
hyoscine against motion sickness but are often tolerated.
There is no evidence that any one antihistamine is superior to
another but their duration of action and incidence of adverse
effects (drowsiness, and antimuscarinic effects) differ. For
example dimenhydrinate causes drowsiness more frequently;
meclizine has a longer duration of action than scopolamine and
most other antihistamines. If a sedative effect is desired
promethazine is useful. Promethazine is a phenothiazine that in
addition to D2 dopaminergic blockade, it has pronounced
histamine H1 and muscarinic receptor blocking properties. It is
effective in the prevention and treatment of vertigo and motion
sickness. Promethazine may be useful in the prevention and
treatment of postoperative and drug-induced nausea and
vomiting. It has limited effect on chemotherapy induced mild to
moderate emesis.
A popular choice of antiemetic is metoclopramide which is
effective against nausea and vomiting following surgery and
30

1. Gastrointestinal Medicines

chemotherapy. It is also effective against radiation-induced

nausea and vomiting. Metoclopramide is effective against
nausea and vomiting associated with gastrointestinal disorders
or migraine. Combining metoclopramide with corticosteroids
(such as dexamethasone) can improve its antiemetic effect in
chemotherapy-induced nausea and vomiting. Metoclopramide
may be useful in the management of gastro-oesophageal reflux
disease and gastroparesis, as well as preoperatively in the
prevention of aspiration syndromes. It is also used to facilitate
intubation of the small bowel during radiographic examinations.
Metoclopramide may cause acute dystonic reactions with facial
and skeletal muscle spasms and oculogyric crises. These
reactions are most common in the young (especially girls and
young women) and the elderly; they occur shortly after the start
of treatment and subside within 24 hours of
medicinewithdrawal.
Granisetron, ondansetron, and palonosetron are specific
5HT3-receptor antagonists which block 5HT3 receptors in the
gastro-intestinal tract and in the CNS. Granisetron and
ondansetron are of value in the management of nausea and
vomiting in patients receiving cytotoxics and in postoperative
nausea and vomiting. Palonosetron is licensed for prevention of
nausea and vomiting associated with moderately or highly
emetogenic cytotoxic chemotherapy.
Antiemetics are unnecessarily and sometimes harmful when
the cause can be treated, e.g. as in diabetic ketoacidosis, or in
excessive digoxin or antiepileptic dosage. Pregnancy induced
nausea and vomiting or morning sickness is common in the
first trimester, but generally does not require medicine therapy.
Dietary modification such as taking of small frequent
carbohydrate meals often helps. A few pregnant women may
require a short-term promethazine treatment.
31

1. Gastrointestinal Medicines

Chlorpromazine Hydrochloride
Drop, 25 mg/ml
Injection, 25mg/1ml, 25mg/2ml,50mg/2ml in 1ml and 2ml
ampoule
Syrup, 25 mg/5 ml
Tablet, 25 mg, 100 mg (film/sugar coated)
Indications: For the prevention and control of severe nausea
and vomiting, other indications (see section 4.2)
Note: It should not be used for motion sickness

Cautions, Drug interactions, Contraindications, and Side

effects; see section 4.2 under chlorpromazine
Dose and Administration: Adult: Oral: 12.5 25mg every 4
6 hours, as necessary. Slow, deep I.M: 25 mg as a single dose,
the dosage being increased to 25 50mg every 3 4 hours until
vomiting stops; it is then given orally if necessary. Child (6
month and over): Oral or slow, deep I.M: 0.55mg/kg every 6
8
hour
as
necessary.
.Storage: at room temperature. Protect from light and freezing.
Do not use if solution is markedly discolored or if a precipitate
is present.
Note: Patients should remain lying down for at least 30 minutes after
injection.

Dimenhydrinate
Tablet, 50 mg
Indications:prevention and treatment of nausea, vomiting
and/or vertigo associated with motion sickness; see also notes
above.
Cautions: as for meclizine hydrochloride; also pregnant and
nursing mothers.
Drug interactions: as for meclizine hydrochloride; ototoxic
drugs such as aminoglycoside antibiotics (dimenhydrinate may
mask the early symptoms of ototoxicity)
32

1. Gastrointestinal Medicines

Side effects: as for meclizine hydrochloride; also, tinnitus.

Dose and Administration: Adult:Oral, 50 to 100 mg every
four to six hours. Child:Oral, 6-12 Years of age, 25 to 50 mg
every six to eight hours as needed, not to exceed 150 mg per
day; 2-6 years of age, 12.5 to 25 mg every six to eight hours as
needed, not to exceed 75 mg per day.
Storage: at room temperature, in a well-closed container.
Note: Oral dosage forms used for motion sickness should be taken 30
minutes before motion

Domperidone
Tablets, 10 mg
Indications: nausea and vomiting, dyspepsia, gastrooesophageal reflux
Cautions: children, renal impairment, pregnancy, breast feeding
Drug
Interactions:
antimuscarinics,
bromocriptine,
cabergoline, erythromycin, ketoconazole, opioid analgesics,
telaprevir.
Contra-indications: prolactinoma; if increased gastro-intestinal
motility harmful, hepatic impairment
Side effects: gastro-intestinal disturbances (including cramps)
and hyperprolactinaemia; ventricular arrhythmias, agitation,
drowsiness, nervousness, seizures, extrapyramidal effects,
headache, and rashes; also reported QT-interval prolongation.
Dose and Administration: oral Adult and child body-weight
over 35 kg, 1020 mg 34 times daily; max. 80 mg daily; child
body-weight up to 35kg (nausea and vomiting only), 250500
micrograms/kg 34 times daily; max.2.4 mg/kg daily.
Granisetron Hydrochloride
Tablet, 2mg
Indications:prevention and treatment of nausea and vomiting
induced by cytotoxic chemotherapy or radiotherapy and
postoperative nausea and vomiting
33

1. Gastrointestinal Medicines

Drug Interactions: granisetron may enhance the hypotensive

effect of apomorphine.
Contraindications: hypersensitivity to medicine, other 5-HT3
receptor antagonists or any component of the formulation.
Sideeffects: constipation, nausea, diarrhoea, vomiting,
abdominal pain; headache, drowsiness, asthenia; fever; rarely
hepatic dysfunction, chest pain, arrhythmia; very rarely
anorexia, dizziness, insomnia, agitation, movement disorders,
and rash.
Dose and Administration: Nausea and vomiting induced by
cytotoxic chemotherapy or radiotherapy: Oral, 12 mg within 1
hour before start of treatment, then 2 mg daily in 12 divided
doses during treatment; when intravenous infusion also used,
maximum combined total 9 mg in 24 hours; CHILD:
20 micrograms/kg (maximum 1 mg) within 1 hour before start
of treatment, then 20 micrograms/kg (maximum 1 mg) twice
daily for up to 5 days during treatment. By intravenous injection
(diluted in 15 mL sodium chloride 0.9% and given over not less
than 30 seconds) or by intravenous infusion (over 5 minutes),
prevention, 3 mg before start of cytotoxic therapy (up to 2
additional 3-mg doses may be given within 24 hours);
treatment, as for prevention (the two additional doses must not
be given less than 10 minutes apart); max. 9 mg in 24 hours;
child, by intravenous infusion, (over 5 minutes), prevention,
40 micrograms/kg (max. 3 mg) before start of cytotoxic
therapy; treatment, as for preventionone additional dose of
40 micrograms/kg (max. 3 mg) may be given within 24 hours
(not less than 10 minutes after initial dose). Postoperative
nausea and vomiting: by intravenous injection (diluted to 5 mL
and given over 30 seconds), prevention, 1 mg before induction
of anaesthesia; treatment, 1 mg, given as for prevention;
maximum 2 mg in one day;
child: not recommended
34

1. Gastrointestinal Medicines

Storage: Store between 20-250C; Keep container closed tightly.

Protect from light
Meclizine Hydrochloride
Tablet, 12.5 mg, 25 mg
Indications: prevention and treatment of nausea, vomiting
and/or vertigo associated with motion sickness; see also notes
above.
Cautions: warn the patients not to perform hazardous activities
requiring mental alertness or physical condition; patients with
angle closure glaucoma or prostatic hypertrophy bladder neck
obstruction, coma, Jaundice; use with caution in hot weather,
and during exercise. Elderly may be at risk for anticholinergic
side effects
Drug interactions: alcohol, CNS depressants including
barbiturates, tranquillizers, medicineswith anti cholinergic
effects including tricyclic antidepressants.
Contraindications: hypersensitive to the medicine, pregnant
women, children younger than 12 years of age.
Side effects: drowsiness, fatigue and rarely blurred vision,
dryness of mouth, nose and throat, palpitations, thicknening of
bronchial secretions, increase appetite, weight gain, arthralgia,
and pharyngitis.
Dose and Administration: Adult and Child (>12 years of
age): Motion sickness (prophylaxis and treatment): Oral: 25 to
50 mg one hour before travel. Dose may be repeated every
twenty-four hours as needed. Vertigo (prophylaxis and
treatment): Oral: 25 to 100 mg a day as needed; in divided
doses.
Storage: at room temperature, in a well - closed container.
Metoclopramide Hydrochloride
Drop, 0.2 mg/drop
35

1. Gastrointestinal Medicines

Injection, 5 mg/ml, 5ml/2ml in 2 ml ampoule

Syrup, 5mg/5ml
Tablet, 10 mg
Indications: nausea and vomiting in gastrointestinal disorders
and treatment with cytotoxics or radiotherapy; gastrooesophageal reflux; gastroparesis; premedication and
postoperatively; aid to gastrointestinal intubation; nausea and
vomiting in migraine.
Cautions: elderly, children and young patients are at increased
risk of extrapyramidal reactions; hepatic and renal impairment;
may mask underlying disorders such as cerebral irritation, avoid
for 3 - 4 days after gastrointestinal surgery; pregnancy; breast
feeding; parkinson disease; depression; porphyria; patients
should be warned that the drug may impair their ability to
perform activities requiring mental alertness or physical
coordination.
Drug interactions: alcohol, barbiturates, CNS depressants;
phenothiazines and butyrophenones, lithium, antidepressants,
antiepileptics, and sympathomimetics; antimuscarinic agents
and opioid analgesics; digoxin, aspirin or paracetamol,
suxamethonium, bromocriptine.
Contraindications: convulsive disorders, gastrointestinal
hemorrhage,
mechanical
obstruction
or
perforation;
pheochromocytoma; 34 days after gastrointestinal surgery;
hypersensitivity to the medicine.
Side effects: extrapyramidal symptoms (especially in children
and young adults), tardive dyskinesia on prolonged use;
hyperprolactinaemia; drowsiness, restlessness, dizziness,
headache, diarrhoea, depression, hypotension and hypertension;
rarely, neuroleptic malignant syndrome; cardiac conduction
abnormalities following IV administration.
Dose and Administration: Nausea and vomiting, gastrooesophageal reflux, gastroparesis:
36

1. Gastrointestinal Medicines

Adult:Oral or IM, or slow IV injection: 10 mg 3 times daily;

young adult: 15 - 19 years (under 60 Kg) 5 mg 3 times daily;
Child:Oral, or IM, or slow IV injection: up to 1 year (up to 10
Kg) 1 mg twice daily, 1 - 3 years (10-14 Kg) 1 mg 2 - 3 times
daily, 3 - 5 years (15 - 19 Kg) 2 mg 2 - 3 times daily, 5 - 9 years
(20-28 Kg.) 2.5 mg 3 times daily, 9 - 14 years (30 Kg and over)
5 mg 3 times daily. (Usual maximum 500 micrograms/Kg daily,
particularly for children and young adults); Pre-medication:
Adult,by slow I.V., 10 mg as a single dose.
Aid to gastrointestinal intubation, Orally, or IM or by Slow
intravenous injection: Adult: 10 - 20 mg as a single dose 5 - 10
minutes before examination; Young Adult (15 - 19 years)
10mg; Child under 3 years 1 mg, 3 - 5 years 2 mg, 5 - 9 years
2.5 mg, 9 - 14 years 5 mg.
Storage:at room temperature, protect from light.
Ondansetrone
Solution for injection and Infusion, 4mg/2ml
Indications: For the prevention of nausea and vomiting
associated with moderately-to highly emetogenic cancer
chemotherapy, radiotherapy in patients receiving total body
irradiation or fractions to the abdomen and postoperation. Also
used for the treatment of postoperative nausea and vomiting.
Cautions: Avoid concomitant use of medicinesthat prolong QT
interval; sub acute intestinal obstruction; adenotonsillar
surgery,In patients with cardiac rhythm or conduction
disturbances, in patients treated with anti-arrhythmic agents or
beta-adrenergic blocking agents and in patients with significant
electrolyte disturbance, in patients with hepatic impairment,
pregnancy ,breast feeding.
Drug interactions:Apomorphine, CYP3A4-inducers (such as
aminoglutethimide, carbamazepine, nafcillin, nevirapine,
Phenobarbital, phenytoin and rifampicin), tramadol
37

1. Gastrointestinal Medicines

Contraindications: Hypersensitivity to medicine , other

selective 5-HT3 antagonists, or any component of the
formulation.
Side effects: Constipation; headache; flushing; injection sitereactions; less commonly hiccups, hypotension, bradycardia,
chest pain, arrhythmias, movement disorders, seizures; on
intravenous administration, rarely dizziness, transient visual
disturbances (very rarely transient blindness).
Dose
and
Administration:
Moderately emetogenic
chemotherapy or radiotherapy, Adults over 18 years, by
mouth, 8 mg 12 hours before treatment or by intramuscular
injection or slow intravenous injection, 8 mg immediately
before treatment then by mouth, 8 mg every 12 hours for up to 5
days or by rectum, 16 mg daily for up to 5 days. Severely
emetogenic chemotherapy: ADULT over 18 years, by
intramuscular injection or slow intravenous injection, 8 mg
immediately before treatment, where necessary followed by 2
further doses of 8 mg at intervals of 24 hours (or followed by
1 mg/hour by continuous intravenous infusion for up to 24
hours) then by mouth, 8 mg every 12 hours for up to 5 days or
by rectum, 16 mg daily for up to 5 days; Alternatively, by
intravenous infusion over at least 15 minutes, 32 mg
immediately before treatment or by rectum, 16 mg 12 hours
before treatment then by mouth, 8 mg every 12 hours for up to 5
days or by rectum, 16 mg daily for up to 5 days. Chemotherapyinduced nausea and vomiting: CHILD 6 months18 years: by
intravenous infusion over 15 minutes, 5 mg/m2 (max. 8 mg)
immediately before chemotherapy, then for body-surface area
less than 0.6 m2 2 mg by mouth every 12 hours for up to 5 days;
for body-surface area 0.6 m2 or greater 4 mg by mouth every 12
hours for up to 5 days; max. total daily dose 32 mg;
alternatively, by intravenous infusion over 15 minutes,
150 micrograms/kg (max. 8 mg) immediately before
38

1. Gastrointestinal Medicines

chemotherapy repeated at intervals of 4 hours for 2 further

doses, then for body-weight 10 kg or less 2 mg by mouth every
12 hours for up to 5 days; for body-weight over 10 kg 4 mg by
mouth every 12 hours for up to 5 days; maximum total daily
dose 32 mg. Prevention of postoperative nausea and vomiting:
by mouth, 16 mg 1 hour before anaesthesia or 8 mg 1 hour
before anaesthesia followed by 8 mg at intervals of 8 hours for
2 further doses; alternatively, by intramuscular or slow
intravenous injection, 4 mg at induction of anaesthesia; Child1
month18 years: by slow intravenous injection over at least 30
seconds, 100 micrograms/kg (max. 4 mg) before, during, or
after induction of anaesthesia. Treatment of postoperative
nausea and vomiting: by intramuscular or slow intravenous
injection, 4 mg; Child 1 month18 years, by slow IV injection
over at least 30 seconds, 100 micrograms/kg (max. 4 mg)
Storage: store between 2 and 30 0c
Promethazine Hydrochloride
Elixir, 5 mg/5 ml.
Injection, 25 mg/ml, 25/2ml in 1 ml and 2 ml ampoules
Suppository, 25 mg, 50 mg
Tablets, 10 mg, 25 mg (film/sugar coated)
Indications: control of nausea, vomiting, and vertigo of various
causes, as a sedative and hypnotic, and as a common ingredient
of cough and cold preparations; also see notes above.
Cautions: As for under Meclizine Hydrochloride, intravenous
injection of promethazine hydrochloride must be given slowly
and extreme care must be taken; should not be given by
subcutaneous injection, avoid in porphyria.
Drug interactions: As for meclizine hydrochloride;
epinephrine, extrapyramidal reaction causing medications,
levodopa, metrizamide and monoamine oxidase (MAO)
inhibitors including furazolidone, procarbazine, and selegiline.
39

1. Gastrointestinal Medicines

Contraindications:
patients
who
have
exhibited
hypersensitivity to the medicine; also in those who have
received large doses of CNS depressants and/or in those who
are comatose, in epileptic seizures.
Side effects: see under Meclizine Hydrochloride, and blood
dyscrasias, sedative effect is more pronounced.
Dose and Administration: Antiemetic:Oral: Adult: 25 mg
initially, then 10 to 25 mg every 4 - 6 hours as needed. Child
(>2 years of age): 0.25 to 0.5 mg per Kg of body weight every 4
to 6 hours or 10 to 25 mg every four to six hours as needed. IM
or IV: Adult: 12.5 to 25 mg every 4 hours as needed. Child (>
2 years of age): 0.25 to 0.5 mg per Kg of body weight every 4 to
6 hours as needed. Rectal: Adult: 25mg initially, then 12.5 to
25mg every 4 to 6 hours as needed. Child (> 2 years of age):
0.25 to 0.5mg per kg of body weight, or 12.5 to 25mg every 4 to
6 hours as needed.
Note: For motion sickness, the initial 25 mg dose should be taken one
half to one hour before travel, and the dose repeated 8 - 12 hours
later, if necessary.

Antivertigo agent: Oral: Adult: 25mg 2 times a day as needed.

Child (> 2 years of age): 0.5mg to 1mg per kg of body weight
or 10 to 25mg 2 times a day as needed.
Rectal: Adult: 25mg 2 times a day as needed. Child (> 2
years of age): 0.5mg per kg of body weight, or 12.5 to 25mg 2
times a day as needed.
Storage: Suppositories: store between 2 and 8oc, in a tight, light
-resistant container.Tablet & Injection - at room temperature
protect from light and from freezing.
Thiethylperazine Maleate
Injection, 6.5 mg/ ml
Suppository, 6.5 mg
Tablet, 6.5 mg (film/ sugar coated)
40

1. Gastrointestinal Medicines

Indications: for the control of nausea and vomiting associated

with surgical procedures and cancer therapy.
Cautions, Drug interactions, Contraindications, and Side
effects; as for Meclizine Hydrochloride
Dose and Administration: Adult:Oral, Rectal,IM, 10mg 1-3
times a day. Child: Safety and efficacy has not been
established.
Storage: protect from light. It should be stored in tight, lightresistant container at room temperature.
1.5. Cathartics and Laxative
Laxatives (purgatives or cathartics) promote defaecation and
are used in the treatment of constipation and for bowel
evacuation before investigational procedures, such as endoscopy
or radiological examination, or before surgery. Before
prescribing laxatives, it is important to be sure that the patient is
constipated and that the constipation is not secondary to an
underlying undiagnosed complaint. It is also important that the
patient understands that bowel habit can vary considerably in
frequency without doing harm. For example, some people
consider themselves constipated if they do not have a bowel
movement each day. A useful definition of constipation is the
passage of hard stools less frequently than the patients own
normal pattern; this should be explained to the patient since
misconceptions about bowel habits have led to excessive
laxative use, which in turn has led to hypokalaemia.
Laxatives should generally be avoided except where straining
will exacerbate a condition such as anginaor increase the risk of
rectal bleeding, as in haemorrhoids.
Laxatives are of value in medicine-induced constipation, for
the expulsion of parasites after anthelminthic treatment (section
6.1) and to clear the alimentary tract before surgery and
radiological procedures. Prolonged treatment of constipation is
41

1. Gastrointestinal Medicines

sometimes necessary. Laxatives are usually subdivided into

several categories including the bulk forming laxatives such as
cellulose derivatives, psyllium preparations; stimulant laxatives
(contact laxatives) that include antraquinone-containing agents
such as senna and cascara, diphenylmethane derivatives such as
bisacodyl and also other miscellaneous agent such as castor oil,
osmotic laxatives such as glycerin, lactulose and the saline
laxative such as magnesium sulphate are also included in this
group; faecal softeners (emollient laxatives) include sodium salt
of docusate and the lubricant laxative liquid paraffin. Bulk
forming laxatives relieve constipation by causing retention of
fluid and an increase in faecal mass resulting in stimulation of
peristalsis; the full effect may take some days to develop and
patients should be told this. They are of particular value in those
with small hard stools, but should not be required unless fiber
cannot be increased in the diet. They are useful in the
management of patients with colostomy, ileostomy,
haemarrhoids and fissure, chronic diarrhoea associated with
diverticular disease, irritable bowel syndrome and as adjuncts in
ulcerative colitis. Owing to their hydrophilic nature, bulk
laxatives may also be used to control acute diarrhoea and to
regulate the consistency of effluent in colostomy patients.
Adequate fluid intake must be maintained to avoid intestinal
obstruction. Unprocessed wheat bran taken with food or fruit
juice, is a most effective bulk forming preparation.
Methylcellulose is useful in patients who cannot tolerate bran.
Methylcellulose also acts as a faecal softener.
Stimulant laxatives which increase intestinal motility and
often cause abdominal cramp; they should be avoided in
intestinal obstruction. Prolonged use of stimulant laxatives can
precipitate the onset of an atonic non-functioning colon and
hypokalaemia; however, prolonged use may be justifiable in
some circumstances. Glycerin suppositories act as a rectal
42

1. Gastrointestinal Medicines

stimulant by virtue of the mildly irritant action of glycerin.

Powerful stimulants such as cascara and castor oil are obsolete.
Docusate sodium probably acts both as a stimulant and as a
softening agent. This group of laxatives is most commonly
associated with abuse. In general, use of stimulant laxatives
should be avoided in children younger than 6-10 years of age
unless prescribed by physician.
Faecal softeners such as liquid paraffin, which is the classical
lubricant, lubricate and soften impacted faeces. Bulk laxatives
and non-ionic surfactant 'wetting' agents e.g. docusate sodium
also have softening properties. Such medicines are useful for
oral administration in the management of haemorrhoids and anal
fissures.
Osmotic laxatives act by retaining fluid in the bowel by
osmosis or by changing the pattern of water distribution in the
faeces. Saline purgatives such as magnesium salts are useful
where rapid bowel evacuation is required. Lactulose is a semisynthetic disaccharide, which is not absorbed from the
gastrointestinal tract. It produces osmotic diarrhoea of low
faecal PH, and discourages the proliferation of ammonia
producing organisms. It is therefore useful in the treatment of
hepatic encephalopathy.
Bulk-forming laxatives, stool softeners, or miniral oil are
preferred to other laxatives in patients with conditions in which
straining at defecation should be avoided (e.g. myocardial
infarction, vascular diseases, diseases of the anus or rectum,
hernias, recent rectal surgery). Oral stool softeners or mineral oil
are preferred to bulk-forming laxatives to ease evacuation of
feces in patients with constipation associated with hard, dry
stools. Many clinicians consider the stool softeners to be the
treatment of choice in childhood constipation associated with
hard, dry stools and to be safer and more efficacious than
43

1. Gastrointestinal Medicines

mineral oil for conditions in which straining at defecation is to

be avoided.
Bulk-forming and stimulant laxatives have been used to treat
constipation that occurs following prolonged bed rest or
hospitalization.
Saline laxatives have been used to eliminate parasites and
toxic anthelmintics prior to and/or after therapy with some
anthelmintics. However, most clinicians agree that with the
newer anthelmintics use of laxatives to eliminate parasites or the
anthelmintic is not necessary, may complicate identification of
the parasite, and may be harmful to the patient.
Bisacodyl
Tablet, 5 mg
Suppository, 5 mg, 10 mg
Indications: constipation and for bowel evacuation.
Cautions: inflammatory bowel disease, the suppositories should
be used with caution in patients with rectal fissures or ulcerated
haemorrhoids; it should be preferably avoided in children. See
also notes above.
Contraindications: appendicitis, rectal bleeding, congestive
heart failure, hypertension, diabetes mellitus, intestinal
obstruction or undiagnosed abdominal symptoms. See also notes
above.
Side effects: abdominal discomfort (such as colic or cramp);
gripping (tablets); local irritation (suppositories). Diarrhoa with
excessive loss of water and electrolytes may occur on prolonged
use. See also notes above.
Dose and Administration: Oral:Adult and Child (>12 years):
5-15mg daily as a single dose and up to 30mg when complete
evacuation of bowel is required. Child (> 6 years): 5-10mg or
0.3 mg/kg daily as a single dose at bedtime or before breakfast.
Rectal: Adult and Child (>12 years): 10mg daily as a single
44

1. Gastrointestinal Medicines

dose. Child 2-11 years: 5-10mg daily given as a single dose.

Child (< 2 years of age): 5mg daily as a single dose.
Note: It is usually effective within 6 to 12 hours following oral
administration and within 15 to 60 minutes following rectal
administration. Oral bisacodyl should be administered the evening
before a morning bowl-movement is desired. Swallow the entericcoated bisacodyl whole and not crushed to avoid gastric irritation.
Take each dose with a full glass of water. Rectal bisacodyl
suppositories and enemas may be administered at the time a bowl
movement is desired.

Storage: at room temperature in a well-closed container.

Cascara Sagrada
Tablet, 125 mg
Indications: constipation
Cautions: care should be taken in patients with inflammatory
bowel disease prolonged use should be avoided, it should be
preferably avoided in children; avoid habitual use; See also
notes above.
Contraindications: see notes under bisacodyl
Side effects: mild abdominal discomfort, diarrhoea (prolonged
use), reversible melanosis coli, the urine may be coloured
yellowish brown or red and also see notes above.
Dose and Administrations: Adult and Child (10 years and
over): 0.3 - 1g, usually at bedtime. A laxative effect usually
occurs 6 to 8 hours after administration. As discussed above
such laxatives have a limited role in the management of
constipation.
Storage: at room temperature, in airtight container. Protect
from light.
Castor oil
Liquid, 30ml
45

1. Gastrointestinal Medicines

Indications: to facilitate defecation in geriatric patients with

diminished colonic motor response; constipation occurring
secondary to idiopathic slowing of transit time, to constipating
drugs or to irritable bowel or spastic colon syndrome; neurologic
constipation and to empty the bowel prior to surgery or
radiologic proctoscopic or sigmoidoscopic procedure.
Cautions: avoid prolonged use, and use in children up to six
years of age; elderly patient.
Drug interactions: avoid concomitant use of castor oil with
potassium sparing diuretics, potassium supplements.
Contraindications: pregnancy, acute abdominal pain, nausea,
vomiting or other symptoms of appendicitis or undiagnosed
abdominal pain, intestinal obstruction.
Side effects: abdominal discomfort, nausea, mild cramp,
gripping or faintness, excessive irritation of the colon, violent
purgation.
Dose and Administation:Oral: Constipation: Adult: 15 ml
daily; Child (< 2 years) 1-5 ml daily; (> 2 years) 5 - 15 ml
daily.For total colonic evacuation prior to surgery or radiologic
sigmoidoscopic or proctoscopic procedure administered as a
single dose about 16 hours before the procedures. Adult and
Child (12 years): 15 - 60 ml; Child, 2 - 11 years: 5 -15 ml; (<
2 years) 1 - 5 ml.
Storage: at room temperature in a tight container and in dry
place. Protect from freezing.
Note: Drink increased fluid. Take each dose with a full glass of water
or other liquid.

Dioctyl sodium Sulphosuccinate (Docusate Sodium)

Tablet, 50 mg, 100 mg
Syrup, 4 mg/ml
Indications: constipation and as an adjunct in abdominal
radiological procedure; prophylactically in patients who should
46

1. Gastrointestinal Medicines

not strain during defecation, such as those with an episiotamy

wounds, painful thrombosed hemorrhoids fissures or perianal
abscesses, body wall and diaphragmatic hernias, anorectal
stenosis, or postmyocardial infarction.
Cautions: do not give with liquid paraffin.
Drug interactions: potassium sparing diuretics, potassium
supplement, danthrol, mineral oil, phenolphthalein, aspirin.
Contraindications: symptoms of appendicitis, undiagnosed
rectal bleeding, congestive heart failure, hypertension, intestinal
obstruction, sensitivity to docusate.
Side effects: undetermined allergies (skin rash), stomach and/or
intestinal cramping.
Dose and Administration: Oral: Adult: up to 500 mg daily in
divided doses; Child over 6 months: 12.5 mg 3 times, daily; 2
12 years: 12.5 to 25 mg 3 times daily (use pediatric oral solution
only).
Note:Take each dose with a full glass of water or other liquid.

Storage: at room temperature, in a dry place and in a tight

container.
Glycerin (Glycerol)
Suppository, 1 g, 1.346 g, 2 g, 2.76 g
Indications: constipation, especially in children; see also notes
above.
Cautions: avoid habitual use.
Contraindications: as for bisacodyl
Side effects: rectal discomfort such as irritation, burning and
pain may occur rarely.
Dose and Administration: Rectal: Adult: 2 4g suppository;
Child: 2g suppository; Infant: 1g suppository.
Note: The suppositories should be moistened with water before
insertion.

Storage: In a cool place, in airtight containers.

47

1. Gastrointestinal Medicines

Lactulose
Enema
Syrup
Indications: constipation (may take up to 48 hours to act);
hepatic encephalopathy (portal systemic encephalopathy).
Cautions: lactose intolerance, diabetic patients (presence of
some free galactose and lactose)
Contraindications: as for bisacodyl; galactosaemia, intestinal
obstruction, hypersensitivity to lactulose.
Side effects: flatulence, cramps, and abdominal discomfort,
nausea & vomiting.
Dose and Administration:Adult: Constipation: Oral: Initially
10-20g (15-30ml) daily in single or 2 divided doses; increased
up to 40g (60ml) daily if necessary. Maintenance 7 to 10g (1015ml) daily.
Hepatic encephalopathy: Oral: initially 60-100g (90-150ml)
daily in 3-4 divided doses; doses should be adjusted after 1-2
days to produce 2-3 soft stools daily, or to keep the PH of the
stool at about 5.
Child: Constipation: Oral: under 1 year, 2.5ml; 1-5 year, 5ml; 612 years, 10ml twice daily, gradually reduced.
Storage: in airtight container preferably at a temperature
between 20c and 300c.
Liquid parafin, Heavy
Indication: constipation associated with stricture of colon.
Cautions: avoid prolonged use and caution should be taken in
children, pregnant women, elderly patients; caution is also
recommended with bedridden patients who may develop lipid
pneumonia from aspiration of miniral oil.
Drug interactions: avoid concomitant administration of the oil
with fat soluble vitamins (A, D, E, K), carotene, oral
48

1. Gastrointestinal Medicines

contraceptive,
cumarine
and
indandione
derivative
anticoagulants.
Contraindications: as for bisacodyl; also colostomy, ilestomy.
Side effects: seepage of mineral oil that may cause soiling of the
skin and clothing, anal irritation, pruritis, impair normal rectal
reflex mechanism, granulomatous reaction caused by absorption
of small quantities of liquid paraffin, lipoid pneumonia.
Dose and Administration: Oral: 5-20ml, when required.
Storage: at room temperature and protect from freezing.
Magnesium sulphate
Crystal
Indications: rapid bowel evacuation in preparations for rectal
and bowel examination, and selective colon surgery; to hasten
excretion of poisonous substances, except acids or alkalis, from
the G.I.T.
Cautions: care should be taken in patients with renal
impairment, hepatic impairment, in elderly and debilitated
patients.
Drug interactions: coumarin or indandione derivative
anticoagulants, digitalis glycoside, chlorpromazine, sodium
polystyrene sulfonate, and tetracycline.
Contraindications: as for bisacody; acute GI conditions,
colostomy, ileostomy, (increased risk of electrolyte or fluid
imbalance); dehydaration, renal impairment.
Side effects: colic, cramping, diarrhea, gas formation, increased
thirst, electrolyte imbalance (confusion, irregular heart beat,
muscle cramp, unusual tiredness or weakness).
Dose and Administration: Oral: Adult: 5 10 gm in a
tumberful of water preferably before breakfast (for rapid bowel
evacuation).

49

1. Gastrointestinal Medicines

Child: older than 6 years of age 5 10 gms dissolved in 120 ml

of water.Note: take each dose with a full glass of water. Dissolve or
mix in water or other liquid before taking.

Storage: at room temperature in a well-closed container.

Methyl Cellulose
Tablet, 500 mg
Indications: see note above, adjunct in obesity.
Cautions: see notes above: adequate fluid intake should be
maintained to avoid intestinal obstruction- it may be necessary
to supervise elderly or debilitated patients or those with
intestinal narrowing or decreased motility.
Contraindications: dysphagia, difficulty in swallowing,
intestinal obstruction, colonic atony, faecal impaction, and
infective bowel disease; see also under bisacodyl.
Side effects: flatulence, abdominal distensions, gastro-intestinal
obstruction or impaction, hypersensitivity reactions reported.
Dose and Administration: Adult and Child 12 and older: up
to 6 g daily given in divided doses of 0.43 - 3 g per dose. Child
6 - 11 years of age - up to 3g daily given in divided dose of 0.45
- 1 .5 g per dose.
Storage: at room temperature in a well-closed container.
Psyllium
Powder
Indications: Constipation, especially in diverticular disease and
irritable bowel syndrome, and when excessive straining at
stoolmust be avoided.
Cautions: avoid prolonged use; adequate fluid should be taken
to avoid intestinal obstruction. Caution on dispensing the
powder to avoid sensitization to air born particles of psyllium.
Drug interactions: tetracyclines.
Contraindications: see under bisacodyl; pre-existing faecal
impaction, intestinal obstruction or colonic atony.
50

1. Gastrointestinal Medicines

Side effects: hypersensitivity reactions; esophageal blockage or

intestinal impaction.
Dose and Administration: Oral: Adult and Child (12 years
and older): 30gm given daily in divided doses of 2.5 to 7.5gm
per dose; Children 6 to11 years old - 15gm daily given in
divided doses of 2.5-3.75gm per dose.
Storage: at room temperature in a tight container and in a dry
place.
Senna
Tablet (total sennosides), 7.5 mg
Indication: constipation and bowel evacuation.
Cautions: Pregnancy, breastfeeding, see also under Cascara
Sagrada
Contraindications:see under Cascara Sagrada
Side effects: see notes above.
Dose and Administrations: Oral: Adult: 15 - 30 mg, as a
single dose at bedtime. Child (over 6 years of age), one half of
the adult dose, and those aged 2 to 6 years are quarter the adult
dose.
Note: It is usually effective with in 6 to 12 hours.

Storage: at room temperature in a dry place. Protect from

freezing
1.6. Medicines Used in Diarrhea
Antidiarrheal medicinesare used as adjuncts in the
symptomatic treatment of diarrhea, although the main aim in the
management of acute diarrhoea is the correction of fluid and
electrolyte depletion with rehydration therapy; this is especially
important in infants and young children and antidiarrhoeal
agents are not generally recommended for this age group. Their
use is also limited in chronic diarrhea for treatment aimed at the
underlying disorder will often alleviate the diarrhoea.
51

1. Gastrointestinal Medicines

The main groups of antidiarrhoeal agents are the medicines

which reduce intestinal motility such as diphenoxylate, and
loperamide. Bulk laxatives (see section 1.5) may also be used in
the symptomatic treatment of diarrhoea.
Antimotility drugs (e.g. diphenoxylate, loperamide) are also
used for symptomatic treatment of mild or uncomplicated
travelers diarrhoea, including that occurring in adult travelers
with HIV infection. The most important measure in the
management of travelers diarrhoea is replacement of lost fluids
and electrolytes.
Antispasmodics are occasionally of value in treating
abdominal cramp associated with diarrhea but they should not
be used for primary treatment. Antispasmodics and antiemetics
should be avoided in young children with gastroenteritis because
they are rarely effective and have troublesome side effects.
Antibacterial medicines are generally unnecessary in simple
gastro-enteritis because the compliant usually resolves quickly
without them. Adsorbents such as kaolin are not recommended
for acute diarrhea.
Antidiarrhoeal agents, especially the adsorbents may interfere
with the absorption of other medicinesfrom the gastro-intestinal
tract if administered concomitantly.Adsorbents such as kaolin
are not recommended for acute diarrhea.
Diphenoxylate with Atropine Sulphate
Tablet, 2.5 mg + 0.05 mg
Indications: acute diarrhoea (adjunctive therapy)
Cautions: inflammatory bowel disease; severe colitis.
Drug interactions: CNS depressants (alcohol, phenobarbitone,
opioid analgesics), phenothiazines, tricyclic antidepressants,
antimuscaranics, MAO inhibitors.
Contraindications: severe hepatic disease, pseudomembranous
colitis and diarrhoea from infective aetiology; elderly and
52

1. Gastrointestinal Medicines

patients with glaucoma or prostate hypertrophy; children under

4 years.
Side effects: nausea, dizziness, drowsiness, fatigue, sensitivity
reactions include angioedema and giant urticaria, headache,
euphoria, respiratory and mental depression. Anticholinergic
symptoms such as dry mouth, fever, blurred vision; tachycardia
and urinary retention may be produced by the atropine in the
formulation, especially in children.
Dose and Administration: Oral: Adult: Diphenoxylate 5 mg 4
times/day until control achieved (maximum: 20 mg/day), then
reduce dose as needed; some patients may be controlled on
doses of 5 mg/day.Child: some authorities recommend that it
should be avoided in children under 12 years. However, in
certain circumstances the following doses have been used: 4 - 8
years, 2. 5 mg upto 3 times daily, 9 - 12 years, 2.5 mg upto 4
times daily, 13 - 16 years, 5 mg upto 3 times daily.
Storage: store at room temperature and protect from light.
Loperamide
Capsule, 2 mg
Indications: acute and chronic diarrhoea.
Cautions: dehydration, impaired hepatic function; children and
the elderly.
Drug interactions: opioid analgesics, CNS depressants (e.g.
alcohol).
Contraindications: pseudomembranous colitis, diarrhoea of
infective origin, or severe colitis from inflammatory bowel
disease, history of allergic reaction to loperamide, for children
under 2 years.
Side effects: Abdominal pains, nausea, constipation, dry mouth
and blurred vision, CNS reactions such as dizziness, headache
and fatigue, hypersensitivity reactions.
53

1. Gastrointestinal Medicines

Dose and Administration: Oral: Adult: Acute diarrhoea:

initially 4 mg, followed by 2 mg after each loose stool until
diarrhoea is controlled; maximum 16 mg/24 hours. Chronic
diarrhoea: usually 4 - 8 mg daily in divided doses. Child over
2 years: initially 1 mg/12.5 kg body mass, followed by 0.5 mg
/12.5 kg after each loose stool. Alternatively, 0.08 - 0.24
mg/kg/day in 2 - 3 divided doses.
Note: If no improvement has been observed after treatment with 16mg
daily for at least 10 days, further administration is unlikely to be of
benefit.

Storage: store at room temperature.

Oral Rehydration salt (ORS)
Powder, each sachet for 1 liter contains:
gm/liter
sodium chloride
2.6
Na+
potassium chloride
1.5
K+
sodium citrate
2.9
Cl
anhydrous glucose
13.5
citrate
glucose
Total Osmolarity

mmol/liter
75
20
65
10
75
245

Indications: replacement of fluid and electrolyte loss in

diarrhoea.
Cautions: ORS is not appropriate for patients with
gastrointestinal obstruction, inability to drink, oliguric or anuric
renal failure, or when parenteral rehydration therapy is indicated
as in severe dehydration or intractable vomiting.
Side effects: Vomiting can occur after administration of ORS,
the risk of hypernatremia or overhydration after administration
of ORS is low in patients with normal renal function.
Overdosage in patients with renal impairment may lead to
hypernatremia and hyperkalaemia.
54

1. Gastrointestinal Medicines

Dose and Administration: reconstitute one sachet by adding

sufficient water to make 1 liter Oral Rehydration Solution. Dose
- according to fluid loss, usually 200-400ml solution after ever
loose motion, child - 200ml after every loose motion, infant 1 1 times usual feed volume.
Storage: at room temperature.
Zinc Sulphate
Tablet (dispersible), 10mg, 20mg
Oral liquid, 10mg /unit
Indications: zinc deficiency or supplementation in zinc-losing
conditions
Cautions: acute renal failure (may accumulate), pregnancy
breast feeding
Contraindications: copper deficiency,high- density lipoprotein
Drug interactions: Quinolone antibiotics, tetracycline
derivatives, trientine.
Side effects: abdominal pain, dyspepsia, nausea, vomiting,
diarrhea, gastric irritation, gastritis; irritability, headache,
lethargy
Dose and administration: Zinc supplements should not be
given unless there is good evidence of deficiency
(hypoproteinaemia
spuriously
lowers
plasma-zinc
concentration) or in zinc-losing conditions. Zinc deficiency can
occur as a result of inadequate diet or malabsorption; excessive
loss of zinc can occur in trauma, burns, and protein-losing
conditions. A zinc supplement is given until clinical
improvement occurs, but it may need to be continued in severe
malabsorption, metabolic disease or in zinc-losing states.
adult and child over 30 kg, 1 tablet in water 13 times daily
after food; child under 10 kg, tablet daily; 1030 kg, tablet
13 times daily.
55

1. Gastrointestinal Medicines

1.7. Antiflatulants
Activated Charcoal
Tablet, 125 mg, 250mg
Indications: flatulence, indigestion and intestinal distention.
Cautions: advise patients not to take other medications orally
within two hours of the activated charcoal, except when
inactivation of the medication is desired.
Drug interactions: avoid simultaneous use of any other
medicineswith activated charcoal.
Side effects: vomiting, constipation, and pulmonary aspiration,
intestinal obstruction (with multiple dose administration); it
colours the stool black.
Dose and Administration: Orally with plenty of water chew a
tablet every 8 hours daily after meals.Note: FDA has classified
activated charcoal as lacking substaintial evidence of efficacy as an
antiflatulent or digestive aid.

Storage: at room temperature, in airtight containers.

Simethicone
Tablet (chewable), 60mg, 80mg, and 95mg
Capsule, 95 mg, 125 mg
Indications: treatment of conditions in which retention of a gas
may be a problem. It may be also be used as diagnostic aid as
anti-foaming agent during gastroscopy to enhance visualization
and prior to radiography of bowel to reduce gas shadows.
Cautions: simethicone is not recommended for the trestment of
infant colic because of limited information on its safety in
infants and children.
Contraindications: hypersensitivity to simethicone
Side effects: allergic reaction/rash, hives, itching, difficulty
breathing, tightness in the chest, swelling of mouth, face, lips,
or tongue.
56

1. Gastrointestinal Medicines

Dose and administration: chewable tablet: oral, 60 to 95 mg

four times a day after meals and at bed time or as needed or 150
mg three times a day after meals or as needed. Capsule: oral, 95
or 125mg four times a day after meals and bed time or as
needed.Note: Dose for pediatrics must be individualized by
physician.

Storage: store between 15-30oc, unless otherwise specified by

manufacturer. Store in a well-closed container.
1.8. Digestants
Pancreatic enzymes (as pancreatin or pancrelipase) hydrolyse
fats to glycerol and fatty acids break down protein into peptides,
proteoses and derived substances, and convert starch into
dextrins and sugars. They are given by mouth in conditions of
pancreatic exocrine deficiency such as pancreatitis and cystic
fibrosis.
Pancreatin
Tablet, 325 mg
Indications: replacement therapy in symptomatic treatment of
malabsorption syndrom due to cystic fibrosis and other
conditions associated with exocrine pancreatic insufficiency
Cautions: fibrotic strictures in the colon with high doses,
especially in children, nursing women, pregnancy.
Drug interactions: iron, absorption may be decreased.
Contraindications: hypersensitivity to hog protein.
Side effects: diarrhea or other transient intestinal upset,
hyperuricosuria and hyperuricemia, hypersensitivity reactions
(e.g. sneezing, lacrimation, rash). Retention of pancreatin
preparations in the mouth before swallowing may cause
irritation of the mucosa and has resulted in ulceration and
stomatitis.

57

1. Gastrointestinal Medicines

Dose and Administration: Adult: Oral: 1-3 tablets before,

during or one hour after meals, with an extra dose taken with
any food eaten between meals.
Storage: store at a temperature not exceeding 15OC and in
airtight containers.
1.9. Antihaemorrhoidal Agents
Haemorrhoids are enlarged or varicose veins of the tissues at
the anus or rectal outlet. They are the most frequent cause of
rectal bleeding. Anal and perianal pruritus, soreness and
excoriation occur commonly in patient suffering from
haemorrhoids, fistulas and proctitis. Careful local toilet with
attention to any minor, faecal soiling, adjustment of the diet to
avoid hard stools, the use of bulk forming materials such as
bran and a high residue diet are helpful.
Soothing preparations containing mild astringents such as
bismuth subgallate, zinc oxide, peru balsam and hamamelis
with lubricants, vasoconstrictors or mild antiseptics, in the form
of topical ointments, creams and suppositories, are used to
provide symptomatic relief. Local anesthetics may be included
to relieve pain, and corticosteroids may be used when infection
is not present; preparations containing either group of
medicinesare intended only for short term use after exclusion of
infections, such as herpes simplex; prolonged use can cause
atrophy of the anal skin.
Haemorrhoids in children are rare. Treatment is usually
symptomatic and the use of locally applied cream is appropriate
for short periods; however, local anaesthetics can cause stinging
initially and this may aggravate the child's fear of defecation.

58

1. Gastrointestinal Medicines

Bismuth Subgallate Compound (Bismuth Subgallate +

Bismuth Oxide +Peru Balsam + Zinc Oxide)
Ointment, 2.25% + 0.87% + 1.875% + 10.75%
Suppository, 5mg + 24mg + 49mg + 296mg
Indications: to relieve anal and perianal pain, itching and
soreness associated with hemorrhoids, anal fissures.
Cautions: advise patients to regulate their diet to produce soft
stools that pass through the anus with a minimum irritation.
Patients should be instructed to take hygienic measures after
defecation. Seenotes above.
Dose and Administration: Rectally, wash and dry the anal area
before application. Unless otherwise indicated; Ointment
Apply rectally night andmorning and after defecation.
Suppositories Insert in to the rectum night and morning and
after defection.
Storage: in a cool place.
Bismuth Subgallate Compound with Hydrocortisone
(Bismuth Subgallate + Bismuth Oxide + Peru Balsam + Zinc
Oxide + Hydrocortisone acetate + Benzyl Benzoate)
Ointment, 2.25% + 0.875% + 1.875% +10.75% + 0.25%
+1.25%
Suppository, 59mg + 24mg + 49mg +296mg + 10mg + 33mg
Indications: sameas Bismuth Subgallate Compound, and anal
inflammation in the absence of infection, see notes above.

Any antihaemorrhoidal preparation proven to be therapeutically effective

can be used.

Any antihaemorrhoidal preparation proven to be therapeutically effective

can be used

59

1. Gastrointestinal Medicines

Cautions: Same as Bismuth Subgallate Compound. Avoid this

preparation in the presence of an infection in the rectal area.
Contraindications: known hypersensitivity to the preparation,
untreated infection.
Side effects: worsening of untreated infection, and thinning of
the skin structure on prolonged use.
Dose and Administration:Rectally. Wash and dry the ectal area
before application. Unless otherwise indicated, Ointments
Apply rectally night and morning and after defection.
Suppositories Insert into the rectum night and morning and
after defection.
Storage: in a cool place.
Lidocaine + Aluminium Acetate + Zinc Oxide +
Hydrocortisone Acetate
Ointment, 50 mg + 35 mg + 180 mg + 2.5 mg
Suppository, 60 mg + 50 mg + 500 mg + 5 mg.
Indications: for treatment of hemorrhoids. They are suitable for
occasional short-term use after exclusion of infection, such as
herpes simplex.
Dose and Administration: Ointment Apply several times
daily, short term use; Suppositories insert 1 suppository at
night and after a bowel movement; short-term use only.
Lignocaine + Tribenoside
Suppository, 40mg + 400mg
Indications:for treatment of rectal Haemorrhoids
Cautions: Severe hepatic impairment, Pregnancy, avoid during
1st trimester, Lactation.
Side effects: Burning sensation, mild pain, increased bowel
motility, rash.

60

1. Gastrointestinal Medicines

Dose and Administration: Insert 1 suppository twice daily

until discomfort is relieved, and then reduce to once daily
Prednisolone Caproate + Dibucaine Hydrochloride +
Hexachlorophene + Clemizole undecenoate
Ointment, 0.19 % + 0.5 % + 0.5 % + 0.5 % + 1 %
Suppository, 1.3 mg + 1 mg + 2.5 mg + 5 mg.
Indications: short term symptomatic treatment of hemorrhoids.

Any antihaemorrhoidal preparation proven to be therapeutically effective

can be used.

61

2. Urological and Related Medicines

2. UROLOGICAL and RELATED MEDICINES

2.1. Medicine used in benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is a common condition
affecting men as they age. Stromal and glandular hyperplasia of
the prostate gland occurs as a result of the changing hormonal
environment in middle-aged men and is present in most men at
45 years of age; about 30% of these men will eventually require
treatment if their BPH causes lower urinary tract symptoms. It is
increasingly common for surgical treatment to be used only in
cases of failure of medical treatment or because of patient
preference.
Contraction of smooth muscle in the prostate and bladder neck
accounts for up to 40% of bladder outlet resistance. Alpha1
blockers treat the dynamic component of bladder outlet
obstruction. Those available include alfuzosin, prazosin,
doxazosin and tamsulosin. They are short acting and are given
once or twice daily. The most common side-effects of
alphablockers include dizziness, weakness, headaches, and
lightheadedness.
Dutasteride and finasteride are specific inhibitors of the
enzyme 5-reductase, which metabolizes testerone in to the more
potent androgen, dihydrotestesterone. This inhibition of
testosterone metabolism leads to reduction in prostate size, with
improvement in urinary flow rate and in obstructive symptoms.
They are alternatives to alpha-blockers particularily in men with
a significantly enlarged prostate.
Dutasteride and finasteride decrease serum concentration of
prostate cancer marker such as proste-specifi antigen factor;
reference value may need adjustment. Both drugs are excreted in
semen and use of condom is recommended if sexual partner is
pregnant or likely to become pregnant. Women with child bring
62

2. Urological and Related Medicines

potential should avoid handling crushed or brockrn tablets of

these finasteride and leackage capsules of dutasteride.
Alfuzosin
Tablet, 2.5mg, 5mg, 10mg
Indications: treatment of the functional symptoms of benign
prostatic hyperplasia (BPH).
Cautions: not intended for use as an antihypertensive drug.
Renal and hepatic impairment, angina, floppy iris syndrome,
orthostatic hypotension.
Drug
interactions:
azole
antifungals,
ciprofloxacin,
clarithromycin, diclofenac, doxycycline, erythromycin, isoniazid,
propofoll, protease inhibitors, quinidine, verapamil and other
CYP3A4 inhibitors; aminoglutethimide,
carbamazepine,
nafcillin, nevirapine, phenobarbital, phenytoin, rifamycins, and
other CYP3A4 inducers, alpha blockers, calcium channel
blockers, MAO inhibitors.
Contraindications: Hypersensitivity to alfuzosin or any
component of the formulation; moderate or severe hepatic;
concurrent use with potent CYP3A4 inhibitors (eg, itraconazole,
ketoconazole, ritonavir)
Side effects: dizziness, fatigue/ weakness, headache, abdominal
pain, constipation, dyspepsia, nausea, impotence, bronchitis, and
pharyngitis, orthostatic hypotension.
Dose and Administration:Adult: Oral:10 mg per day.
Storage: store at room temperature and protect from light and
moisture.
Doxazosin
Tablet, 1mg, 2mg, 4mg, 8mg
Indication: Treatment of urinary outflow obstruction and/or
obstructive and irritative symptoms associated with benign
63

2. Urological and Related Medicines

prostatic hyperplasia (BPH), particularly useful in patients with

troublesome symptoms who are unable or unwilling to undergo
invasive procedures, but who require rapid symptomatic relief;
can be used in combination with finasteride; for treatment and
management of mild to moderate hypertension.
Cautions: Since doxazosin is alpha1-selective alpha blockers
reduce blood pressure, patients receiving antihypertensive
treatment may require reduced dosage and specialist supervision.
Caution is required in the elderly and in patients undergoing
cataract surgery (risk of intra-operative floppy iris syndrome),
angina, orthostatic hypotension, hepatic impair.
Drug interaction: enhanced hypotensive effect with adrenergic
neurone blockers, diuretics, ACE inhibitors, calcium channel
blockers, other antihypertensive medications, sildenafil, tadalafil,
vardenafil, NSAIDs, alcohol, aldesleuk, alprostadil, anxiolytics
andhypnotics, baclofen,beta-blockers, hydralazine, MAOIs,
antipsychotics,
oestrogens,
Corticosteroids,
levodopa,
methyldopa.
Contraindications: Hypersensitivity to quinazolines (prazosin,
terazocin), doxazosin, or any component of the formulation.
Alpha-blockers should be avoided in patients with a history of
postural hypotension and micturition syncope.
Side effects:Drowsiness, hypotension (notably postural
hypotension), syncope, asthenia, dizziness, depression, headache,
dry mouth, gastro-intestinal disturbances, oedema, blurred vision,
rhinitis, erectile disorders, tachycardia, and palpitations.
Hypersensitivity reactions including rash, pruritus and
angioedema.
Dose and Administration: Initially 1 mg daily; dose may be
doubled at intervals of 12 weeks according to response, up to
maximum 8 mg daily; usual maintenance 24 mg daily. BPH: 464

2. Urological and Related Medicines

8mg/day, maximum dose: 8mg/day. Hypertension: maximum

dose: 16mg/day. Elderly: initial 0.5mg once daily
Note: Syncope may occur usually within 90 minutes of the initial dose.

Storage: Store in a dry place, at room temperature in a wellclosed container protected from light.
Dutasteride
Capsule, 0.5mg
Indication: For the treatment of symptomatic benign prostatic
hyperplasia (BPH) in men with an enlarged prostate gland to
improve symptoms, and reduce the risk of acute urinary retention
and the need for surgery.
Cautions: Patients with large residual urine volume and/or
severely diminished urinary flow should be carefully monitored
for obstructive uropathy. Dutasteride and finasteride decrease
serum concentration of prostate cancer markers such as prostatespecific antigen; reference values may need adjustment.
Dutasteride and finasteride are excreted in semen and use of a
condom is recommended if sexual partner is pregnant or likely to
become pregnant. No clinical benefit has yet been demonstrated
in patients with prostate cancer treated with dutasteride and
finasteride. Women of childbearing potential should avoid handling
crushed or broken tablets of finasteride and leaking capsules of
dutasteride.

Drug interaction: Diltiazem, Verapamil

Contraindications: for use in women of childbearing potential;
pregnancy, children and adolescents; for patients with known
hypersensitivity to dutasteride, other 5a-reductase inhibitors or
any component of the preparation.
Sideeffect: Breast tenderness or enlargement, decrease in sex
drive, difficulty ejaculating, and inability to have or maintain an
erection, rash, itching, urticaria, localized edema.
65

2. Urological and Related Medicines

Dose and Administration: The recommended dose dutasteride

is 0.5 mg taken orally once a day. The capsules should be
swallowed whole and not chewed or opened; as contact with the
contents may result in irritation of the oropharyngeal mucosa.
Dutasteride may be administered with or without food. Although
early improvement in symptoms may be seen, treatment for at
least six months may be necessary to assess whether a beneficial
response has been achieved. No dosage adjustment is necessary
for subjects with renal impairment or elderly. Due to the absence
of data in patients with hepatic impairment, no dosage
recommendation can be made.
Storage: Store at room temperature; protect from moisture.
Finasteride
Tablet, 5mg
Indications: Finasteride is indicated for the treatment and
control of benign prostatic hyperplasia (BPH) in patients with an
enlarged prostate to: cause regression of the enlarged prostate,
improve urinary flow and improve the symptoms associated with
BPH. Reduce the incidence of acute urinary retention and the
need for surgery including transurethral resection of the prostate
(TURP) and Prostatectomy.
Cautions: See under dutasteride
Drug interactions: Finasteride is a synthetic analog of
testosterone and inhibits an intracellular enzyme responsible for
converting testosterone to the potent androgen 5-dihydrotestosterone (DHT). Although finasteride appears to
interfere with the activation of testosterone to a more active form,
presumably blocking the effects of testosterone, it would be
illogical to administer finasteride concurrently with testosterone
or other androgens.
66

2. Urological and Related Medicines

Contraindications: Hypersensitivity to any component of this

medicine; women who are or may potentially be pregnant;
children and adolescents.
Side effect: Impotence, decreased libido, ejaculation disorders,
and breast tenderness and enlargement, testicular pain,
hypersensitivity reactions (including lip and face swelling,
pruritus and rash); male breast cancer.
Dose and Administration: Adult: one 5 mg tablet daily, taken
orally with or without food. Finasteride can be administered
alone or in combination with the alpha-blocker doxazosin.
Although early improvement in symptoms may be seen,
treatment for at least six months may be necessary to assess
whether a beneficial response has been achieved. Thereafter,
treatment should be continued long term. Clinical respose occur
within 12 weeks to 6 months of initiation of therapy. Therefore,
long term administration is recommended for maximal response.
No dosage adjustment is required in the elderly or in patients
with varying degrees of renal insufficiency (creatinine clearances
as low as 9 ml/min).
Prazosin Hydrochloride
Tablet, 1 mg, 2 mg, 5 mg
Indications:For treatment of benign prostatic hyperplasia and
hypertension, hypertension associated with pheochromocytoma.
Cautions: elderly patients, during pregnancy and breastfeeding,
angina pectoris, narcolepsy, and in those sensitive to the
medicine. First dose may cause collapse due to hypotension
(should be taken on retiring to bed); hepatic or renal function
impairment; advice patients not to do activities requiring
alertness.
Drug interactions: nifedipine, other antihypertensive agents or
nitrates, alcohol, beta blockers and calcium channel blockers.
67

2. Urological and Related Medicines

Contraindications: heart failure caused by mechanical

obstruction, for example aortic or mitral valve stenosis,
pulmonary embolism, and restrictive pericardial disease.
Side effects: dizziness, orthostatic hypotension, edema,
palpitations, dry mouth, urinary incontinence, angina, dyspnea,
and priapism, drowsiness, headache, lack of energy, and nausea.
Dose and Administration: Oral: Adult: 0.5 mg 23 times daily,
the initial dose on retiring to bed or night (to avoid collapse)
increased to 1 mg 2 3 times daily after 3 7 doses further
increased if necessary to maximum 20 mg daily. Child (under 7
years of age), initially 0.25 mg 2 3 times a day adjusted
according to response. 7 to 12 years of age, initially 0.5 mg two
or three times a day adjusted according to response.
Storage: at room temperature in a well-closed, light resistant
container.
Tamsulosin
Capsule, 0.4mg
Indications: Used in the treatment of signs and symptoms of
benign prostatic hyperplasia (reduction in urinary obstruction and
relief of associated manifestations such as hesitancy, terminal
dribbling of urine, interrupted or weak stream, etc,).
Contraindications: Hypersensitivity to the medicine or any
component of the formulation; in patients with a history of
postural hypotension and micturition syncope.
Cautions, Drug interactions and Side effects: see under
doxazosin
Dose and Administration: 0.4 mg PO daily 30 min after the
meal each day; if response is not satisfactory in 24 weeks,
dosage may be increased to 0.8 mg PO daily 30 min after the
meal each day. If therapy is interrupted for any reason for several
days, resume dosing at 0.4 mg PO daily.
68

2. Urological and Related Medicines

Storage: Store at room temperature; protect from moisture.

2.2 Medicines used for Urinary Incontinence
Urinary incontinence is loss of bladder control. Symptoms can
range from mild leaking to uncontrollable wetting. It can happen
to anyone, but it becomes more common with age. Treatment for
urge incontinence generally should include behavior therapy.
However, medications can be prescribed as an adjunct to
behavior therapy. Indeed, the combination of exercises and
medications results in better control of incontinence than either
treatment alone. Tolterodine, a selective anticholinergic agent,
has relatively more action on cholinergic receptors in the bladder
than in the salivary glands and other organs.
2.3. Ant-hyperphosphatemics
Sevelamer hydrochloride
Tablet: 400mg and 800mg
Indication: reduce serum phosphorus in patients with chronic
kidney
disease
who
are
undergoing
hemodialysis
(hyperphosphotemia)
Caution: breastfeeding, children younger than 18 years of age,
elderly.
Contraindications: hypophosphatemia or bowel obstruction,
known hypersensitivity to selvelamer hydrochloride or any
ingredient in the formulation.
Drug
interaction:
ciprofloxacin,
antiarrhythmics,
anticonvulsants
Side effects: diarrhea, constipation, dyspepsia, flatulence, nausea,
vomiting, hypertension, hypotension, thrombosis, infection
(nasopharyngitis, bronchitis, upper respiratory infection), cough,
dyspnea, headach, back pain.
69

2. Urological and Related Medicines

Dose and Administration: Serum phosphorus concentration 5.57.5mg/dl, should receive an initial sevelamer hydrochloride
dosage of 800mg 3 times daily. Serum phosphorus concentration
7.5-9mg/dl, should receive an initial sevelamer hydrochloride
dosage of 1.2g 3 times daily (3 tablets of 400mg). Serum
phosphorus concentration 9mg/dl, should receive an initial
sevelamer hydrochloride dosage of 1.6g 3 times daily (two tablets
of 800mg).

70

3. Cardiovascular Medicines

3. CARDIOVASCULAR MEDICINES
3.1. Medicinesused for Congestive Cardiac failure
Angiotensin-converting enzyme (ACE) inhibitors such
ascaptopril, enalapril, fosinopril and lisinoprilproduce clinical
benefit in all stages of chronic heart failure additional to that
obtained from diuretics. They relieve symptoms such as
dyspnoea and improve exercise tolerance. ACE inhibitors
improve survival and reduce the progression of mild or
moderate heart failure to more severe stages. ACE inhibitors
may also be beneficial in asymptomatic left ventricular
dysfunction. ACE inhibitors are recommended in all patients
with symptomatic heart failure due to left ventricular systolic
dysfunction, including those whose symptoms are controlled
with diuretic therapy. ACE inhibitors all appear to have a
similar spectrum of adverse effects although at one time some,
such as taste disturbance and skin reactions, were attributed to
the presence of a sulphydryl group (as in captopril) but have
now also been reported with ACE inhibitors; however, they
may be more common with captopril the most common adverse
effects are due to the vascular effects of ACE inhibitors and
include hypotension, dizziness, fatigue, headache, and nausea
and other gastrointestinal disturbances. Other side effects
include persistent cough and other upper respiratory tract
symptoms, and angioedema. All ACE inhibitors are
contraindicated in pregnancy; in patients with hypersensitivity
to ACE inhibitors; in known or suspected renovascular disease;
aortic stenosis or outflow tract obstruction.
Diuretics have been the mainstay in the treatment of heart
failure. They provide very effective symptomatic control in
patients with peripheral or pulmonary oedema and rapidly
relieve dyspnoea. If symptoms of fluid retention are only mild,
71

3. Cardiovascular Medicines

a thiazide diuretic such as hydrochlorthiazide may be adequate.

However, diuretics are not a sufficient treatment on their own
as clinical stability tends to deteriorte over time.
Cardiac glycosides the benefit of cardiac glycosides such as
digoxin in heart failure accompanied by atrial fibrillation is not
disputed although their role in patients with sinus rhythm has
been debated. There is evidence that withdrawal of digoxin
from patients receiving diuretics or ACE inhibitors carries a
considerable risk of clinical deterioration if they are stable on
such combination therapy. Digoxin, given in addition to
diuretics and ACE inhibitors, improved symptoms but had no
effect on mortality. Digoxin may therefore have a role in
patients who remain symptomatic despite ACE inhibitors,
diuretic, and beta-blocker therapy, and in those unable to
tolerate ACE inhibitors.
Beta-blockers unless otherwise contraindicated (by asthma,
2nd- or 3rd-degree atrioventricular block, or previous
intolerance), are an important addition to ACE inhibitors for
chronic systolic dysfunction in most patients, including the
elderly, and for diastolic dysfunction in hypertension and
hypertrophic cardiomyopathy. They are best started when the
patient has no evidence of pulmonary congestion. Some of
these drugs improve left ventricular ejection fraction, survival,
and other major cardiovascular outcomes in patients with
chronic systolic dysfunction, including those with severe
symptoms. -Blockers are particularly useful for diastolic
dysfunction because they reduce heart rate, prolonging diastolic
filling time, and possibly improve ventricular relaxation.
During a severe, acute decompensation, -blockers should not
be started until patients are stabilized and have little evidence of
fluid retention. For patients already taking a -blocker, the dose
may be temporarily reduced or, in severe decompensation,
72

3. Cardiovascular Medicines

temporarily withheld but restarted and titrated again when

patients are stable. For milder decompensations, the -blocker
dose should be continued with a temporary increase in diuretic
dose. The beta-blockers bisoprolol and carvedilol are of value
in any grade of stable heart failure due to left ventricular
systolic dysfunction; nebivolol is licensed for stable mild to
moderate heart failure in patients over 70 years. Beta-blocker
treatment should be started by those experienced in the
management of heart failure, at a very low dose and titrated
very slowly over a period of weeks or months. Symptoms may
deteriorate initially, calling for adjustment of concomitant
therapy.
Phosphodiesterase inhibitors have a dual action being both
positive inotropes and vasodilators. Although short-term
haemodynamic variables are improved, long-term oral use has
been associated either with an unacceptable incidence of
adverse effects (amrinone) or with an increased mortality rate
(milrinone). Thus, these phosphodiesterase inhibitors have been
reserved for heart failure unresponsive to other treatment.
Amrinone Lactate
Injection, 5mg/ml in 20ml ampoule
Indications: is used as a short-term therapy in patients with
intractable heart failure.Because of limited clinical experience
with the drug, it should be reserved in used for patients under
close monitoring.
Cautions: severe aortic or pulmonic valvular disease.
Drug interactions: diruretics (Furosemide), digitalis (digoxin).
Contraindications: gastrointestinal disturbances that may
necessitate withdrawal of of treatment, hypersensitivity reaction
to the medicine. Known hypersensitivity to sulfiting agents
73

3. Cardiovascular Medicines

(i.e., sulfur dioxide, potassium or sodium bisulfite, potassium or

sodium metabisulfite, sodium sulfite)
Side effects: arrhythmias, hypotension, thrombocytopenia,
chest pain, fever, hepatotoxicity, and hypersensitivity.
Dose and Administration:Adult and Child: 0.75 mg/kg IV
bolus over 2-3 minutes followed by maintenance infusion of 510 mcg/kg/minute; IV bolus may need to be repeated in 30
minutes.
Storage: See manufacturers recommendation.
Captopril
Tablet, 12.5 mg, 25 mg, 50 mg, 100 mg
Indications: treatment of congestive heart failure, management
of hypertension, left ventricular dysfunction after myocardial
infarction; diabetic nephrophaty.
Cautions: impaired renal function, patient with solitary kidney,
collagen-vascular
disease,
patients
receiving
immunosuppresants or other medicinesthat cause leukopenia or
agranulocytosis, coronary or cerebrovascular disease, severe
salt/volume depletion.
Drug interactions: potassium-sparing diuretics or potassium
supplements (ACE inhibitors are potassium-sparing agents);
aspirin, indomethacin and propably other NSAIDs, antacids,
digoxin and lithium, probenecid, food decreases absorption-take
30-60 minutes before meals.
Contraindications: hypersensitivity to ACE inhibitors,
idiopathic or hereditary angioedema; known or suspected
venovascular disease; aortic or bilateral renal artery stenosis,
outflow tract obstruction. ACEIs can cause injury and death to
the developing fetus when used in the second and third
trimesters. ACEIs should be discontinued as soon as possible
once pregnancy is detected.
74

3. Cardiovascular Medicines

Side effects: see notes above; slight increase in heart rate, first
dose hypotension, dizziness, fainting; rash (maculopapular or
urticarial), pruritus; hyperkalemia, neutropenia, proteinuria,
increased serum creatinine, cough, hypersensitivity reactions;
altered taste sensation.
Note:-In the treatment of heart failure severe first-dose
hypotension on introduction of an ACE inhibitor is common in
patients on loop diuretics.
Dose and Administration: Dosing: Adult Heart failure: Oral:
Initial dose: 6.25-12.5 mg 3 times/day in conjunction with
cardiac glycoside and diuretic therapy; initial dose depends
upon patient's fluid/electrolyte status. Target dose: 50 mg 3
times per day
Dosing: Pediatric Hypertension: Oral: Infants: Initial: 0.15-0.3
mg/kg/dose; titrate dose upward to maximum of 6 mg/kg/day in
1-4 divided doses
Children: Initial: 0.3-0.5 mg/kg/dose; titrate upward to
maximum of 6 mg/kg/day in 2-4 divided doses
Older Children: Initial: 6.25-12.5 mg/dose every 12-24 hours;
titrate upward to maximum of 6 mg/kg/day
Adolescents: Initial: 12.5-25 mg/dose; titrate to a maximum of
450 mg per day
Dosing: Renal Impairment, Adults: Clcr 10-50 mL/minute:
Administer at 75% of normal dose every 12-18 hours. Clcr<10
mL/minute: Administer at 50% of normal dose every 24 hours.
Prophylaxis after myocardial infarction (in clinically stable
patients): Oral:Adult: initially 6.25 mg gradually increased
over several weeks to 150 mg daily in divided doses.
Storage: at room temperature in a tight container.
Digoxin
Elixir, 0.05 mg/ml
75

3. Cardiovascular Medicines

Injection, 0.1 mg/ml in 1 ml ampoule; 0.25 mg/ml in 2 ml

ampoule
Tablet, 0.25 mg
Indications: Treatment of mild-to-moderate (or stage C as
recommended by the ACCF/AHA) heart failure (HF); atrial
fibrillation (rate-control). In treatment of atrial fibrillation (AF),
use is not considered first-line unless AF coexistent with heart
failure or in sedentary patients.
Cautions: patients with recent myocardial infarction, sick sinus
syndrome, hyporthyroidism, severe pulmonary disease; elderly
patients and in patients with renal function impairment where
dosage adjustment is necessary; breast-feeding; electrolyte
disturbances; Avoid rapid intravenous administration (nausea
and risk of arrhythmias)
Drug interactions: amiodarone, beta-adrenergic blocking
agents, (including atenolol, carvedilol, metoprolol and
propranolol), calcium channel blocking agents, especially
verapamil, potassium-depleting diuretics (such as bumetanide,
ethacrynic acid, furosemide, indapamide, mannitol, or thiazide),
propafenone, quinidine or quinine, sympathomimetics. Oral
aminoglycosides may decrease the serum concentration of
digoxin.
Contraindications: hypersensitivity to digoxin or digitoxin,
ventricular fibrillations, intermittent complete heart block,
second degree AV block, supraventiricular arrhythmias caused
by wolf Parkinson white syndrome, hypertrophic obstructive
cardiomyopathy toxic effects present from prior administration
of any digitalis preparation, ventricular fibrillation.
Side effects: anorexia, nausea, vomiting, lower stomach pain,
diarrhea, weakness, blurred or yellow vision, drowsiness,
confusion, mental depression, headache and hallucinations,
arrythmias, hypotension, AV block.
76

3. Cardiovascular Medicines

Dose and Administration: When changing from oral (tablets

or liquid) or I.M. to I.V. therapy, dosage should be reduced by
20% to 25%. Atrial fibrillation: (rate control) in patients with
heart failure: Loading dose: I.V.: 0.25 mg every 2 hours, up to
1.5 mg within 24 hours; for nonacute situations, may administer
0.5 mg orally once daily for 2 days followed by oral
maintenance dose. Maintenance dose: I.V., Oral: 0.125-0.375
mg once daily. Heart failure: Daily maintenance dose (Note:
Loading dose not recommended): Oral: 0.125-0.25 mg once
daily; higher daily doses (up to 0.5 mg/day) are rarely
necessary. If patient is >70 years of age, has impaired renal
function, or has a low lean body mass, low doses (eg, 0.125 mg
daily or every other day) should be used. Emergency control of
atrial fibrillation, IV infusion over at least 2 hours: Adult:
Initial total digitalizing dose 0.751.5 mg (I.V., I.M.: 0.5-1 mg
Daily maintenance dose: Oral: 0.125-0.5 mg once daily (I.V.,
I.M.: 0.1-0.4 mg once daily. Note: I.M. not preferred due to severe
injection site pain.Pediatric: Atrial dysrhythmias (rate control),
heart failure: When changing from oral (tablets or liquid) or
I.M. to I.V. therapy, dosage should be reduced by 20% to 25%.
See table below.

77

3. Cardiovascular Medicines

Storage: At room temperature in a tight container, protect from

freezing.
Enalapril Maleate
Tablet, 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg.
Indications: Treatment of hypertension; treatment of
symptomatic heart failure; treatment of asymptomatic left
ventricular dysfunction. To delay the progression of
nephropathy and reduce risks of cardiovascular events in
hypertensive patients with type 1 or 2 diabetes mellitus;
hypertensive crisis, diabetic nephropathy, hypertension
secondary to scleroderma renal crisis, diagnosis of
aldosteronism, idiopathic edema, Bartter's syndrome,
postmyocardial infarction for prevention of ventricular failure
Cautions, Drug interactions,Contraindications and Side
effects see under captopril and notes above
78

3. Cardiovascular Medicines

Dose and Administration: Adult: Oral: Congestive heart

failure: Oral: Initial: 2.5 mg once or twice daily (usual range:
5-40 mg/day in 2 divided doses); titrate slowly at 1- to 2-week
intervals. Target dose: 10-20 mg twice daily.
Storage: See manufacturers recommendation.
Enalapril Maleate + Hydrochlorothiazide
Tablet, 10 mg + 25 mg
Indications: see under Enalapril maleate
Cautions, Drug interactions, Contraindications; see
captopril above and hydrochlorothiazide.
Side effects: see notes above; chest pain, cholecystitis or
pancreatitis, hepatic function impairment, hyperuricemia or
gout, neutropenia or agranulocytosis, thrombocytopenia, and
electrolyte imbalance.
Dose and Administration: Oral: Congestive heart failure:
Adult: 1 tablet once or twice per day, as determined by
individual titration with the component agents, for a maximum
of 20 mg of Enalapril and 50 mg of Hydrochlorothiazide.
Child: as determined by individual titration with the
component agents. Enalapril: Oral, initially 0.1 mg per kg of
body weight per day, the dosage being adjusted as needed and
tolerated, up to a maximum of 0.5 mg per Kg of body weight
per day.Hydrochlorothiazide: Oral, 1 to 2 mg per kg of body
weight or 30 to 60 mg per square meter of body surface per day,
as a single dose or in two divided doses, the dosage being
adjusted according to response.
Hydralazine
Tablet, 10mg, 25mg, 50mg, 100mg
Powder for injection, 20mg/ml in 1 ml ampoule
79

3. Cardiovascular Medicines

Indication: Management of moderate-to-severe hypertension.

Heart
failure;
hypertension
secondary
to
preeclampsia/eclampsia.
Cautions: I.V. administration: Monitor blood pressure closely
following I.V. administration. Response may be delayed and
unpredictable in some patients; titrate cautiously to response.
Patient compliance: Patients may be poorly compliant because
of frequent dosing.
Drug interactions: May enhance the hypotensive effect of
other Antihypertensives. Nonsteroidal Anti-Inflammatory
Agents: May diminish the antihypertensive effect of
Hydralazine.
Contraindications: Hypersensitivity to hydralazine or any
component of the formulation; mitral valve rheumatic heart
disease. Hepatic impairment, renal impairment (dosage
adjustment). Avoid during first and second trimester, no report
on serious harm following use in third trimester.
Side effects: Angina pectoris, orthostatic hypotension,
peripheral edema, fluid retention (diuretics needed) tachycardia,
vascular collapse, pruritus, rash, urticarial, anorexia,
constipation, diarrhea, nausea and vomiting, agranulocytosis,
thrombocytopenia, conjunctivitis.
Dose and Administrations:Congestive heart failure: Oral:
Initial dose: 10-25 mg 3-4 times per day. Adjustment: Dosage
must be adjusted based on individual response. Target dose:
225-300 mg/day in divided doses; use in combination with
isosorbide dinitrate
Hydralazine +Isosorbide Dinitrate
Tablet, 37.5mg+20mg
Indication: Treatment of heart failure, adjunct to standard
therapy,
80

3. Cardiovascular Medicines

Cautions, Drug interactions, Contraindications, Side

effects: seeindividual medicine.
Dose and Administrations:Adult, Congestive heart failure:
Oral: Initial: 1 tablet 3 times/day; may titrate to a maximum
dose of 2 tablets 3 times/day
Isosorbide Dinitrate
Tablet, 5mg, 10mg, 20mg, 30mg, 40mg, 60mg
Sublingual Tablet, 2.5mg, 5mg, 10mg
Tablet/Capsule(s/r), 40mg
Indication: Isosorbide dinitrate (in combination with cardiac
glycosides and diuretics or with hydralazine) effective for the
treatment of CHF or other low cardiac output states.
Concomitant therapy with isosorbide dinitrate and hydralazine
may decrease mortality in patients with CHF; usually reserved
for patients who fail to respond to or are intolerant of first-line
therapy (e.g., ACE inhibitors) or in combination with such
therapy. Do not use isosorbide dinitrate as monotherapy for CHF.
Cautions: Severe hypotension (postural) can occur; paradoxical
bradycardia and increased angina pectoris can accompany
hypotension. Use with caution in volume depletion and
moderate hypotension, and use with extreme caution with
inferior wall MI and suspected right ventricular infarctions.
Nitrates may precipitate or aggravate increased intracranial
pressure and subsequently may worsen clinical outcomes in
patients with neurologic injury (eg, intracranial hemorrhage,
traumatic brain injury).
Drug interactions: May enhance the adverse/toxic effect of
other Hypotensive Agents. Phosphodiesterase 5 Inhibitors (e.g.,
sildenafil) may enhance the vasodilatory effect of Vasodilators
(Organic Nitrates). Caution with ethanol (may increase risk of
hypotension).
81

3. Cardiovascular Medicines

Contraindications: hypersensitivity to isosorbide dinitrate or

any component of the formulation; hypersensitivity to organic
nitrates; concurrent use with phosphodiesterase-5 (PDE-5)
inhibitors (sildenafil, tadalafil, or vardenafil)
Side effects: hypotension, orthostatic hypotension, rebound
hypertension, headache, methemoglobinemia
Dose and Administrations: Heart failure (unlabeled
use):Oral: Immediate release (Note: Use in combination with
hydralazine): Initial dose: 20 mg 3-4 times per day; Target
dose: 160 mg/day in 4 divided doses
Lisinopril
Tablet 2.5 mg, 5 mg, 10 mg, 20 mg
Indications: Treatment of hypertension, either alone or in
combination with other antihypertensive agents; adjunctive
therapy in treatment of heart failure (afterload reduction);
treatment of acute myocardial infarction within 24 hours in
hemodynamically-stable patients to improve survival; treatment
of left ventricular dysfunction after myocardial infarction.
Cautions, Drug interactions, Contraindications, Side
effects; see notes above and under Captopril.
Dose and Administrations: Adult Heart failure: Oral:
Initial: 2.5-5 mg once daily; thenincrease by no more than 10
mg increments at intervals no less than 2 weeks to a maximum
daily dose of 40 mg. Usual maintenance: 5-40 mg/day as a
single dose. Target dose: 20-40 mg once daily (ACC/AHA
2009 Heart Failure Guidelines)
Note: If patient has hyponatremia (serum sodium <130 mEq/L) or
renal impairment (Clcr<30 mL/minute or creatinine >3 mg/dL), then
initial dose should be 2.5 mg/day

Storage: at room temperature in a well-closed container.

82

3. Cardiovascular Medicines

3.2. Antiarrhythmics
Agents used in the management of cardiac arrhythmias form of
a diverse group of medicines. Many of them, such as beta
blockers, digoxin, lignocaine, magnesium and phenytoin have
important actions in addition to their antiarrhythmic properties
and thus, as well as being employed in the treatment of cardiac
arrhythmias, have a wide range of other clinical applications.
Management of arrhythmias
In general, medicine therapy of serious arrhythmias is
unsatisfactory and dangerous. Antiarrhythmics may suppress
arrhythmias successfully but paradoxically increase mortality.
Cardiac arrythmias can range from little more than
asymptomatic ECG abnormalities through to severe or lifethreatening events. In general, pharmacological therapy,
particularly chronic therapy, should be instituted only for
haemodynamically important, sustained arrhythmias after a
search for and correction of any simple precipitating factors and
consideration of alternative treatment (e.g. catheter ablation,
implantable cardioverter defibrillator). The inappropriate use of
an antiarrhythnic for a specific arrhythmia can not only be
ineffective but, in view of the proarrhythmic potential of most
of them, may even be deleterious.
Antiarrhythmics classes
Class I includes medicines, which directly interfere with
depolarization of the cell membrane (membrane-stabilising
drugs) by blocking the fast inward current of sodium into
cardiac cells; they also have local anaesthetic properties.
Class Ia agents, which prolong action potential duration (APD)
and include procainamide, disopyramide and quinidine.
Class Ib agents, shorten APD, includes lidocaine (lignocaine),
mexiletine.
83

3. Cardiovascular Medicines

Class Ic agents do not affect APD, which include propafenone

and flecainide. This class of medicines is not readily available in
Ethiopia.

Although they are effective antiarrhythmics, the use of many of

the class I agents is associated with an increased mortality
(compared with placebo).
Class II agents are characterized by beta-blocking activity,
leading to a reduction in heart rate, myocardial contractility, and
the rate of conduction of impulses through the conducting
system, and include propranolol, bretylium and others.
Class III includes those agents which prolong the duration of
cardiac action potential, e.g. amiodarone and sotalol.
Class IV agents block the slow inward calcium channel of the
SA and AV nodes, e.g. Adenosine, verapamil and diltiazem.
Adenosine
Injection 3mg/ml
Indications: treatment of paroxysmal supraventricular
tachycardia (PSVT) including that associated with accessory
bypass tracts (Wolff-Parkinson-White syndrome); when
clinically advisable, appropriate vagal maneuvers should be
attempted prior to adenosine administration; not effective for
conversion of atrial fibrillation, atrial flutter, or ventricular
tachycardia
Cautions: wide-complex tachycardia, electrolyte imbalance,
heart transplant recipient, pulmonary artery hypertension,
respiratory disease (e.g., asthma)
Drug interactions: carbamazepine, dipyridamole, theophylline
and caffeine (avoid food or drug with caffeine), digoxin,
nicotine
Contraindications: hypersensitivity to adenosine or any
component of the formulation; second- or third-degree AV
84

3. Cardiovascular Medicines

block, sick sinus syndrome, or symptomatic bradycardia (except

in patients with a functioning artificial pacemaker); use in
patients with atrial fibrillation/flutter with underlying WolffParkinson-White (WPW) syndrome
Side effects: transient new arrhtmia, headache, dizziness, GI
discomfort, dyspnea, hypotension, diaphoresis
Dose and Administration: Adult: Paroxysmal supraventricular
tachycardia: I.V. (rapid, over 1-2 seconds, via peripheral line;
see Note): Initial: 6 mg; if not effective within 1-2 minutes, 12
mg may be given; may repeat 12 mg bolus if needed (maximum
single dose: 12 mg). Follow each dose with 20 mL normal
saline flush. Note: Initial dose of adenosine should be reduced
to 3 mg if patient is currently receiving carbamazepine or
dipyridamole, has a transplanted heart or if adenosine is
administered via central line. Pharmacologic stress testing: I.V.:
Continuous I.V. infusion via peripheral line: 140 mcg/kg/minute
for 6 minutes using syringe or volumetric infusion pump; total
dose: 0.84 mg/kg. Thallium-201 is injected at midpoint (3
minutes) of infusion. Acute vasodilator testing in pulmonary
artery hypertension (unlabeled use). I.V.: Initial: 50
mcg/kg/minute increased by 50 mcg/kg/minute every 2 minutes
to a maximum dose of 500 mcg/kg/minute or to a maximum
dose of 250 mcg/kg/minute; acutely assess vasodilator response.
Child: Rapid I.V. push (over 1-2 seconds) via peripheral line,
followed by a normal saline flush: Paroxysmal supraventricular
tachycardia: Infants and Children: I.V.: Children <50 kg: Initial:
0.05-0.1 mg/kg (maximum initial dose: 6 mg). If conversion of
PSVT does not occur within 1-2 minutes, may increase dose by
0.05-0.1 mg/kg. May repeat until sinus rhythm is established or
to a maximum single dose of 0.3 mg/kg or 12 mg. Follow each
dose with normal saline flush. Children 50 kg: Refer to adult
dosing.Pediatric advanced life support: Treatment of SVT: I.V.,
85

3. Cardiovascular Medicines

I.O.: Initial: 0.1 mg/kg (maximum initial dose: 6 mg); if not

effective within 1-2 minutes, administer 0.2 mg/kg (maximum
single dose: 12 mg). Follow each dose with 5 mL normal
saline flush.
Storage: Store at controlled room temperature of 15C to 30C.
Do not refrigerate; crystallization may occur (may dissolve by
warming to room temperature).
Amiodarone
Tablet, 100mg, 200 mg, 400mg
Injection, 50mg/ml
Indications: Management of life-threatening recurrent
ventricular fibrillation (VF) or hemodynamically-unstable
ventricular tachycardia (VT) refractory to other antiarrhythmic
agents or in patients intolerant of other agents used for these
conditions
Cautions: heart failure and impaired liver function, avoid
exposure to sunlight. Arrhytmias, Hepatotoxicity, Proarrhytmic
effects, Pulmonary toxicity.
Drug interactions: amiodarone may interact with other drugs
for months after treatment is discontinued. It concentrates in the
liver and may interfere with the hepatic metabolism of many
drugs. Oral anticoagulants, other antiarrythmics, digoxin,
phenytoin; beta blockers, cimetidine and ritonavir.
Contraindications: Hypersensitivity to amiodarone, iodine, or
any component of the formulation; severe sinus-node
dysfunction; second- and third-degree heart block (except in
patients with a functioning artificial pacemaker); bradycardia
causing syncope (except in patients with a functioning artificial
pacemaker); cardiogenic shock
Side effects: frequent hyperor hypothyroidism, neurotoxicity
(including peripheral neuropathies), photosensitivity, headache,
86

3. Cardiovascular Medicines

nausea, vomiting, anorexia, constipation, fatigue and dizziness.

Less frequent - pulmonary fibrosis, interstitial or
hypersensitivity pneumonitis (include cough, dspnoea and slight
fever), skin discoloration, ocular toxicity, arrhythmias,
bradycardia, congestive cardiac failure.
Dose and Administration:Adult: Oral: Lower loading and
maintenance doses are preferable in women and all patients with
low body weight. Ventricular arrhythmias: Oral: 800-1600
mg/day in 1-2 doses for 1-3 weeks, then when adequate
arrhythmia control is achieved, decrease to 600-800 mg/day in
1-2 doses for 1 month; maintenance: 400 mg/day; lower doses
are recommended for supraventricular arrhythmias. Pulseless
VT or VF: I.V. push, I.O.: Initial: 300 mg rapid bolus; if
pulseless VT or VF continues after subsequent defibrillation
attempt or recurs, administer supplemental dose of 150 mg.
Note: In this setting, administering undiluted is preferred.
Upon return of spontaneous circulation, follow with an infusion
of 1 mg/minute for 6 hours, then 0.5 mg/minute for 18 hours
(mean daily doses >2.1 g/day have been associated with
hypotension). Breakthrough stable VT or SVT: 150 mg
supplemental doses in 100 mL D5W or NS over 10 minutes
(mean daily doses >2.1 g/day have been associated with
hypotension) I.V. to oral therapy conversion: Use the following
as a guide: <1 week I.V. infusion: 800-1600 mg/day; 1 to 3
weeks I.V. infusion: 600-800 mg/day; >3 weeks I.V. infusion:
400 mg.
Note: Conversion from I.V. to oral therapy has not been formally evaluated.
Some experts recommend a 1-2 day overlap when converting from I.V. to
oral therapy especially when treating ventricular arrhythmias.

Bretylium Tosylate
Injection, 50 mg/ml in 2 ml ampoule
87

3. Cardiovascular Medicines

Indications: Bretylium is used in ventricular arrhythmias

unresponsive to conventional therapy following acute
myocardial infarction. Bretylium has also proven effective in
the treatment of premature ventricular contractions, and in the
facilitation of countershock in ventricular fibrillation in cases
not responding to countershock alone or countershock with
other antiarrhythmics
Cautions: avoid in patients with fixed cardiac outputs (i.e.,
severe aortic stenosis or severe pulmonary hypertension); risk of
severe hypotension, digitalized patients, may aggravate digitalis
toxicity, geriatrics (hypotension), hyperthermia, hypotension,
repeated IM injections in same area may cause atrophy/necrosis,
renal impairment, transient hypertension or an increase in
arrhythmias possible on administration.
Drug interactions: catecholamines, digoxine, erythromycin,
class Ia and class III antiarrhythmics, specific quinolones.
Contraindications: all contraindications are relative to the
seriousness of the arrhythmia, digitalis-induced arrhythmias,
hypersensitivity to bretylium.
Side effects: hypotension, a transient initial increase in blood
pressure and heart rate, a worsening of cardiac arrhythmias,
nausea and vomiting, increased frequency of pulmonary
ventricular contractions, respiratory depression, exacerbation of
digitalis-induced arrhythmias.
Dose and Administration: Adult: I.M.: Ventricular
Arrhythmia; Treatment and Prophylaxis: do not dilute prior to
injection. Inject 5 to 10 milligrams/kilogram of body weight.
The dose may be repeated at 1 to 2 hour intervals if the
arrhythmia persists. Thereafter, administer the same dosage
every 6 to 8 hours. Intramuscular injection should not be made
directly into or near a major nerve and the site of injection
should be varied on repeated administration. I.V.: Ventricular
88

3. Cardiovascular Medicines

Arrhythmia; Treatment and Prophylaxis Ventricular Fibrillation:

Administer undiluted bretylium 5 milligrams/kilogram of body
weight by rapid intravenous injection. The usual
cardiopulmonary resuscitative measures, including electrical
cardioversion, should be employed prior to and following the
injection in accordance with good medical practice. If
ventricular fibrillation persists, the dosage may be increased to
10 mg/kg body weight and repeated as necessary. The
maximum loading dose should not exceed 30 mg/kg.
Storage: store at room temperature
Isoproterenol
Injection, 0.02mg/ml, 0.2mg/ml
Indications: Mild or transient episodes of heart block that do
not require electric shock or pacemaker therapy; serious
episodes of heart block and Adams-Stokes attacks (except when
caused by ventricular tachycardia or fibrillation); cardiac arrest
until electric shock or pacemaker therapy is available;
bronchospasm during anesthesia; adjunct to fluid and electrolyte
replacement therapy and other drugs and procedures in the
treatment of hypovolemic or septic shock and low cardiac
output states (eg, decompensated heart failure, cardiogenic
shock).
Cautions: elderly, diabetics, renal or cardiovascular disease,
distributive shock, seizure disorder or hyperthyroidism.
Drug interactions: sympathomimetic agents, general
anesthetics.
Contraindications: hypersensitivity, angina, pre-existing
cardiac arrhythmias, tachycardia.
Side effects: bradycardia, tachycardia, headache, nervousness,
nausea, vomiting, dyspnea.

89

3. Cardiovascular Medicines

Dose and Administration: I.V: Cardiac arrhythmias: Adult:

Bradyarrhythmias, AV nodal block, or refractory torsade de
pointes: Continuous I.V. infusion: Usual range: 2-10
mcg/minute; titrate to patient response.
Brugada syndrome with electrical storm (unlabeled use): I.V.
bolus: Initial: 1-2 mcg, followed by a continuous infusion of
0.15-0.3 mcg/minute for 1 day; may repeat sequence if
ventricular tachycardia/fibrillation recurs.
Child: Bradyarrhythmias, AV nodal block, or refractory torsade
de pointes: Continuous I.V. infusion: Usual range: 0.05-2
mcg/kg/minute; titrate to patient response. Patients may exhibit
dose-dependent vasodilation due to unopposed beta2-agonism
elicited by isoproterenol.
Storage: store at room temperature.
Lidocaine hydrochloride
Injection, 5 mg/ml, 10 mg/ml, 20 mg/ml in 20 ml vial
Indications: acute treatment of ventricular arrhythmias from
myocardial infarction or cardiac manipulation, cardiac
catheterization and those caused by digitalis intoxication
Cautions: lower dosage in congestive heart failure, bradycardia,
renal and hepatic impairment, marked hypoxia, severe
respiratory depression, following cardiac surgery and in elderly.
Drug interactions: other antiarrhythmics (e.g., amiodarone),
anticonvulsants, cimetidine, beta-blockers, saquinavir
Contraindications: sino-atrial disorder, any grade of
atrioventricular block or any other type of conduction
disturbances, severe myocardial depression, acute porphyria or
hypovolaemia, history of hypersensitivity to amide type local
anesthetics; pregnancy & children-safe use is not established.
90

3. Cardiovascular Medicines

Side effects: dizziness, paraesthesia, drowsiness, confusion,

apnoea, respiratory depression, coma, seizures, and convulsions,
hypotension, arrhythmias, heart block, cardiovascular collapse
and brady cardia (may lead to cardiac arrest), nystagmus often
an early sign of lidocaine overdosage.
Dose and Administration: Antiarrhythmic: Adult: VF or
pulseless VT (after defibrillation attempts, CPR, and
vasopressor administration) if amiodarone is not available: I.V.,
intraosseous (I.O.): Initial: 1-1.5 mg/kg. If refractory VF or
pulseless VT, repeat 0.5-0.75 mg/kg bolus every 5-10 minutes
(maximum cumulative dose: 3 mg/kg). Follow with continuous
infusion (1-4 mg/minute) after return of perfusion.
Reappearance of arrhythmia during constant infusion: 0.5 mg/kg
bolus and reassessment of infusion (Zipes, 2000).
Hemodynamically stable monomorphic VT: I.V.: 1-1.5 mg/kg;
repeat with 0.5-0.75 mg/kg every 5-10 minutes as necessary
(maximum cumulative dose: 3 mg/kg). Follow with continuous
infusion of 1-4 mg/minute (or 14-57 mcg/kg/minute).
Child: I.V., intraosseous (I.O.): Note: For use in VF or pulseless
VT if amiodarone is not available; give after defibrillation
attempts, CPR, and epinephrine: Loading dose: 1 mg/kg
(maximum: 100 mg); follow with continuous infusion; may
administer second bolus of 0.5-1 mg/kg if delay between bolus
and start of infusion is >15 minutes. Continuous infusion: 20-50
mcg/kg/minute. Per the manufacturer, do not exceed 20
mcg/kg/minute in patients with shock, hepatic disease, cardiac
arrest, or CHF.
Storage: store at room temperature.
Metoprolol
Injection, 1 mg/ml, 05ml/ml
Tablet, 50 mg, 100 mg, 200 mg (s/r.)
91

3. Cardiovascular Medicines

Indications: Treatment of angina pectoris, hypertension, or

hemodynamically-stable acute myocardial infarction. Treatment
of
angina
pectoris
or
hypertension;
to
reduce
mortality/hospitalization in patients with heart failure (stable
NYHA Class II or III) already receiving ACE inhibitors,
diuretics, and/or digoxin.
Cautions, Drug interactions, Contraindications, Side
effectsand Storage; see under propranolol.
Dose and Administration:Adult: Atrial fibrillation/flutter
(ventricular rate control), supraventricular tachycardia (SVT)
(acute treatment; unlabeled use; Antman, 2004; Fuster, 2006;
Neumar, 2010): I.V.: 2.5-5 mg every 2-5 minutes (maximum
total dose: 15 mg over a 10-15 minute period). Note: Initiate
cautiously in patients with concomitant heart failure; avoid in
patients with decompensated heart failure.
Maintenance: Oral (immediate release): 25-100 mg twice daily.
Hypertension/ventricular rate control: I.V. (in patients having
nonfunctioning GI tract): Initial: 1.25-5 mg every 6-12 hours;
titrate initial dose to response. Initially, low doses may be
appropriate to establish response; however, although not
routine, up to 15 mg administered as frequently as every 3 hours
has been employed in patients with refractory tachycardia.
Myocardial infarction: Acute: I.V.: 5 mg every 2 minutes for 3
doses in early treatment of myocardial infarction; thereafter,
give 50 mg orally every 6 hours beginning 15 minutes after last
I.V. dose and continue for 48 hours; then administer a
maintenance dose of 100 mg twice daily. Note: Do not initiate
this regimen in those with signs of heart failure, a low output
state, increased risk of cardiogenic shock, or other
contraindications (eg, second- or third-degree heart block). If
initial I.V. dosing is not tolerated, may give 25-50 mg orally
(depending on degree of intolerance) every 6 hours beginning
92

3. Cardiovascular Medicines

15 minutes after the last I.V. dose or as soon as clinical

condition permits.
Storage: at room temperature
Mexiletin Hydrochloride
Capsules, 50 mg, 200 mg
Injection, 25 mg/ml, in 10 ml ampoule
Indications: ventricular arrythmias, prevention of recurrent
cardiac arrests, suppression of paroxysmal ventricular
contractions.
Cautions: patients with sinus node dysfunction, conduction
defect, bradycardia, hypotension, cardiogenic shock, or cardiac
or hepatic failure.
Drug interactions: opioid analgesics, atropine, phenytoin,
rifampicin, cimetidine, lignocaine, phenobarbital.
Contraindications: hypersensitivity to mexiletin.
Side effects: nausea, vomiting, heart burn, tremor, confusion,
dizziness, and visual disturbances, hypotension, sinus
bradycardia, conduction defects and exacerbation of
arrhythmias.
Dose and Administration: Adult: Oral: Initial: 200 mg every 8
hours (may load with 400 mg if necessary); adjust dose every 23 days; usual dose: 200-300 mg every 8 hours; maximum: 1.2
g/day (some patients respond to every 12-hour dosing). When
switching from another antiarrhythmic, initiate a 200 mg dose 612 hours after stopping former agents, 3-6 hours after stopping
procainamide. IV injection: 100 to 250 mg at a rate of 25 mg per
minute, followed by an infusion at a rate of 250 mg over 1 hour,
250 mg over the next 2 hours, and then at about 0.5 mg per
minute for maintenance, according to patient response.
Storage: store in airtight containers.
93

3. Cardiovascular Medicines

Phenytoin (Diphenylhydantoin sodium)

Powder for injection, 250mg in vial
Indication: Phenytoin and phenytoin sodium are administered
orally. Phenytoin sodium also may be administered by slow IV
injection for the treatment of status epilepticus and by slow IV
or IM injection for the prophylaxis and treatment of seizures
during neurosurgery.Ref Because parenteral administration of
phenytoin is associated with more frequent and severe
complications, the oral route is preferred for maintaining
therapeutic concentrations of the drug during nonemergency
situations; patients receiving the drug parenterally should
routinely be assessed for feasibility of oral therapy.
Caution, contraindication, drug interaction, side effects (see
under antiepileptics)
Dose and Administration: IV injections of phenytoin sodium
should be made directly into a large vein through a large-gauge
needle or IV catheter. The drug must be injected slowly at rates
not exceeding 50 mg/minute in adults and 13 mg/kg per minute
in pediatric patients. Each injection of phenytoin sodium should
be followed by administration of sodium chloride injection
through the same needle or IV catheter to reduce local venous
irritation caused by the alkalinity of the injection solution.
Subcutaneous and perivascular injection of phenytoin sodium
should be avoided.
Procainamide hydrochloride
Injection, 100 mg/ml, 10-ml ampoule
Tablet, 250 mg,
Indications: Treatment of supraventricular arrhythmias. Note: In
the treatment of atrial fibrillation, use only when preferred treatment
is ineffective or cannot be used. Use in paroxysmal atrial tachycardia
when reflex stimulation or other measures are ineffective.
94

3. Cardiovascular Medicines

Cautions: elderly, renal and hepatic impairment, asthma,

pregnancy; breastfeeding, blood dyscrasias, drug induced lupus
erythematosus
Drug interactions: other antiarrhythmics, anticholinergics,
cimetidine, trimethoprim.
Contraindications: Hypersensitivity to procainamide, procaine,
other ester-type local anesthetics, or any component of the
formulation; complete heart block; second-degree AV block or
various types of hemiblock (without a functional artificial
pacemaker); SLE; torsade de pointes
Side effects: nausea, vomiting, diarrhoea, anorexia, severe
hypotension, ventricular fibrillation, pericarditis, rashes,
pruritus, urticaria, flushing, fever, and angioedema, depression,
dizziness, and psychosis; blood disorders include leukopenia,
haemolytic anemia and agranulocytosis after prolonged
treatment; lupus erythematosus-like syndrome.
Dose and Administration: Adult: Dose must be titrated to
patient's response. Antiarrhythmic: I.M.: 50 mg/kg/day divided
every 3-6 hours or 0.5-1 g every 4-8 hours. I.V.: Loading dose:
15-18 mg/kg administered as slow infusion over 25-30 minutes
or 100 mg/dose at a rate not to exceed 50 mg/minute repeated
every 5 minutes as needed to a total dose of 1 g.
Hemodynamically stable monomorphic VT or pre-excited atrial
fibrillation. Loading dose: Infuse 20-50 mg/minute or 100 mg
every 5 minutes until arrhythmia controlled, hypotension
occurs, QRS complex widens by 50% of its original width, or
total of 17 mg/kg is given. Follow with a continuous infusion of
1-4 mg/minute. Note: Not recommended for use in ongoing
ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT)
due to prolonged administration time and uncertain efficacy.

95

3. Cardiovascular Medicines

Maintenance dose: 1-4 mg/minute by continuous infusion.

Maintenance infusions should be reduced by one-third in
patients with moderate renal or cardiac impairment and by twothirds in patients with severe renal or cardiac impairment. Oral:
Sustained release formulation: Maintenance: 50 mg/kg/24 hours
given in divided doses every 6 hours. Child: Must be titrated to
patient's response: Arrhythmias: I.M.: 20-30 mg/kg/day divided
every 4-6 hours; maximum: 4 g/day. I.V.: Load: 3-6 mg/kg/dose
over 5 minutes not to exceed 100 mg/dose; may repeat every 510 minutes to maximum of 15 mg/kg/load. Maintenance as
continuous I.V. infusion: 20-80 mcg/kg/minute; maximum: 2
g/24 hours.
Storage: store in airtight containers and at room temperature.
Protect from light.
Propranolol
Injection, 1 mg/ml in 1 ml ampoule
Tablet, 10 mg, 40 mg
Indications: Management of hypertension; angina pectoris;
pheochromocytoma;
essential
tremor;
supraventricular
arrhythmias (such as atrial fibrillation and flutter, AV nodal reentrant tachycardias), ventricular tachycardias (catecholamineinduced arrhythmias, digoxin toxicity); prevention of
myocardial infarction; migraine headache prophylaxis;
symptomatic treatment of hypertrophic subaortic stenosis
(hypertrophic obstructive cardiomyopathy)
Cautions: peripheral arterial insufficiency, first degree
atrioventricular block, major surgery, renal & hepatic
impairment, diabetes, myasthenia gravis, pregnancy. Avoid
abrupt withdrawal.
Drug
interactions:
chlorpromazine,
phenothiazines,
thioxanthenes, lidocaine, cimetidine, hepatic enzyme inducers,
96

3. Cardiovascular Medicines

(barbiturates, phenytoin, rifampicin), non-steroidal antiinflammatory agents, digoxin, verapamil, neuromuscular

blocking agents, anaesthetic agents, insulin or oral antidiabetic
agents.
Contraindications: Hypersensitivity to propranolol, betablockers, or any component of the formulation; uncompensated
congestive heart failure (unless the failure is due to
tachyarrhythmias being treated with propranolol), cardiogenic
shock, severe sinus bradycardia or heart block greater than firstdegree (except in patients with a functioning artificial
pacemaker), severe hyperactive airway disease (asthma or
COPD).
Side effects: heart failure, heart block, hypotension,
bronchospasm, fatigue and coldness of the extremities,
headache, depression, dizziness, confusion and sleep
disturbances, dry mouth, nausea, vomiting, diarrhea, impotence
or decreased libido.
Dose and Administration: Oral: Adult: Tachyarrhythmias:
Oral: 10 to 30 mg/dose every 6-8 hours. I.V.: 1to 3 mg/dose
slow IVP; repeat every 2-5 minutes up to a total of 5 mg; titrate
initial dose to desired response or 0.5 to 1 mg over 1 minute;
may repeat, if necessary, up to a total maximum dose of 0.1
mg/kg. Note: Once response achieved or maximum dose
administered, additional doses should not be given for at least 4
hours.Thyroid storm: Oral: 60-80 mg every 4 hours; may

consider the use of an intravenous shorter-acting beta-blocker

(ie, esmolol). I.V.: 0.5-1 mg administered over 10 minutes every
3 hours.Thyrotoxicosis: Oral: 10-40 mg/dose every 6-8 hours;
may also consider administering extended or sustained release
formulations. Variceal hemorrhage prophylaxis (unlabeled
use)Oral: Primary prophylaxis: Initial: 20 mg twice daily; adjust
to maximal tolerated dose. Note: Risk factors for hemorrhage
97

3. Cardiovascular Medicines

include Child-Pugh class B/C or variceal red wale markings on

endoscopy.Secondary prophylaxis: Initial: 20 mg twice daily;
adjust to maximal tolerated dose 10 to 30mg/dose every 6-8
hours.Child: Initial: 0.5to 1mg/kg/day in divided doses every 68 hours; titrate dosage upward every 3-7 days; usual dose: 26mg/kg/day; higher doses may be needed; do not exceed
16mg/kg/day or 60mg/day.IV: Adult: 1mg/dose slow IV
injection; repeat every 5 minutes up to a total of 5mg.Child:
0.01-0.1mg/kg/dose slow IV injection over 10 minutes;
maximum dose: 1mg for infants; 3mg for children.
Storage:store at room temperature
Quinidine sulphate
Tablet, 200 mg
Indications: Quinidine sulfate salts: Conversion and prevention
of relapse into atrial fibrillation and/or flutter; suppression of
ventricular arrhythmias. Note: Due to proarrhythmic effects, use
should be reserved for life-threatening arrhythmias. Moreover,
the use of quinidine has largely been replaced by more
effective/safer antiarrhythmic agents and/or nonpharmacologic
therapies (eg, radiofrequency ablation).
Cautions:hepatotoxicity,
hypersensitivity
reactions,
proarrhythmic effects: disease-related concerns, atrial
fibrillation/flutter,
conduction
disturbances:
electrolyte
imbalance, G6PD deficiency, heart failure, concurrent drug
therapy issues (e.g.digoxin), elderly, do not interchange the
different salt products.
Drug interactions: digoxin, amiodarone, rifampicin,
Phenobarbital & phenytoin, nelfinavir & ritonavir, sodium
bicarbonate,
carbonic
anhydrase
inhibitors,
other
antiarrhythmics, phenothiazines, anticholinergics, reserpine, and
anticonvulsants.
98

3. Cardiovascular Medicines

Contraindications: complete heart block, digitalis overdosage.

Side effects: the elderly are particularly susceptible to adverse
nervous system effects and diarrhea, abdominal cramps, bitter
taste, nausea and vomiting. Hypersensitivity reactions may
occur, monitor patient after first dose. Acute hypotension,
cinchonism and, in severe toxicity, photophobia, confusion,
systemic lupus erythematosus and psychosis may occur.
Dose and Administration: Adult: Oral: Initial test dose of 200
mg to detect hypersensitivity to quinidine. Note: Dosage
expressed in terms of the salt: 267 mg of quinidine gluconate =
200 mg of quinidine sulfate.
Antiarrhythmic: Oral: Immediate release formulations:
Quinidine sulfate: Initial: 200-400 mg/dose every 6 hours the
dose may be increased cautiously to desired effect. Extended
release formulations:Quinidine sulfate: Initial: 300 mg every 812 hours; the dose may be increased cautiously to desired effect.
Quinidine gluconate: Initial: 324 mg every 8-12 hours; the dose
may be increased cautiously to desired effect.
Storage: store at room temperature and protect from light.
Sotalol
Tablet, 80mg, 120mg, 160mg, 240mg
Indications: Treatment of documented ventricular arrhythmias
(ie, sustained ventricular tachycardia), that in the judgment of
the physician are life-threatening; maintenance of normal sinus
rhythm in patients with symptomatic atrial fibrillation and atrial
flutter who are currently in sinus rhythm.
Contraindications: Hypersensitivity to sotalol or any
component of the formulation; bronchial asthma; sinus
bradycardia; second- or third-degree AV block (unless a
functioning pacemaker is present); congenital or acquired long
QT syndromes; cardiogenic shock; uncontrolled heart failure.
99

3. Cardiovascular Medicines

Dose and Administration: Adult: Baseline QTc interval and

creatinine clearance must be determined prior to initiation.
Sotalol should be initiated and doses increased in a hospital
with facilities for cardiac rhythm monitoring and assessment.
Proarrhythmic events can occur after initiation of therapy and
with each upward dosage adjustment. Conversion from oral
sotalol to I.V. sotalol:
80 mg oral equivalent to 75 mg I.V.
120 mg oral equivalent to 112.5 mg I.V.
160 mg oral equivalent to 150 mg I.V.
Ventricular arrhythmias:I.V.: Note: The effects of the initial I.V.
dose must be monitored and the dose titrated either upward or
downward, if needed, based on clinical effect, QTc interval, or
adverse reactions. Substitution for oral sotalol: Initial dose: 75
mg infused over 5 hours twice daily.Dose adjustment: If the
frequency of relapse does not reduce and excessive QTc
prolongation does not occur, may increase to 112.5 mg twice
daily. For ventricular arrhythmias, may increase dose every 3
days in increments of 75 mg/day.Dose range: Usual therapeutic
dose: 75-150 mg twice daily; maximum dose: 300 mg twice
daily.Hemodynamically stable monomorphic VT, ongoing
(unlabeled use): 1.5 mg/kg over 5 minutes. Note: Clinical trial
employed standard dose of 100 mg.Oral: Initial: 80 mg twice daily;
dose may be increased gradually to 240-320 mg/day; allow 3
days between dosing increments (to attain steady-state plasma
concentrations and to allow monitoring of QTc intervals). Usual
range: Most patients respond to 160-320 mg/day in 2-3 divided
doses. Maximum: Some patients, with life-threatening
refractory ventricular arrhythmias, may require doses as high as
480-640 mg/day; prescribed ONLY when the potential benefit
outweighs the increased of adverse events.
100

3. Cardiovascular Medicines

Atrial fibrillation or atrial flutter: I.V.: Note: The effects of the

initial I.V. dose must be monitored and the dose titrated either
upward or downward, if needed, based on clinical effect, QTc
interval, or adverse reactions. Substitution for oral sotalol:
Initial dose: 75 mg infused over 5 hours twice daily. Dose
adjustment: If the frequency of relapse does not reduce and
excessive QTc prolongation does not occur, may increase to
112.5 mg twice daily. For ventricular arrhythmias, may increase
dose every 3 days in increments of 75 mg/day. Dose range:
Usual therapeutic dose: 112.5 mg twice daily; maximum dose:
150 mg twice daily.
Dosing: Pediatric: Baseline QTc interval and creatinine
clearance must be determined prior to initiation. Sotalol should
be initiated and doses increased in a hospital with facilities for
cardiac rhythm monitoring and assessment. Proarrhythmic
events can occur after initiation of therapy and with each
upward dosage adjustment.
Note: The safety and efficacy of sotalol in children have not been established

Supraventricular arrhythmias: Oral: Note: Dosing per

manufacturer, based on pediatric pharmacokinetic data; wait at
least 36 hours between dosage adjustments to allow monitoring
of QTc intervals.
Children 2 years: Dosage should be adjusted (decreased) by
plotting of the child's age on a logarithmic scale; see graph or
refer to manufacturer's package labeling. Age factor nomogram:
Children >2 years: Initial: 90 mg/m2/day in 3 divided doses;
may be incrementally increased to a maximum of 180
mg/m2/day

101

3. Cardiovascular Medicines

Verapamil Hydrochloride
Injection, 2.5 mg/ml in 2 ml ampoule
Tablets, 40 mg, 80 mg, 120 mg
Indications: Oral: Treatment of hypertension; angina pectoris
(vasospastic, chronic stable, unstable); supraventricular
tachyarrhythmia (PSVT, atrial fibrillation/flutter [rate control]),;
I.V.: Supraventricular tachyarrhythmia (PSVT, atrial
fibrillation/flutter [rate control])
102

3. Cardiovascular Medicines

Cautions: first-degree atrioverntricular block; acute phase of

myocardial infarction; renal and hepatic impairment; children,
pregnancy, breast-feeding, muscular dystrophy, aortic stenosis
Drug interactions: beta blocking-agents; antiarrhythmics, other
highly protein-bound agents, carbamazepine, grape fruit juice,
digoxin, lithium & cyclosporine and calcium salts.
Contraindications: Hypersensitivity to verapamil or any
component of the formulation; severe left ventricular
dysfunction; hypotension (systolic pressure <90 mm Hg) or
cardiogenic shock; sick sinus syndrome (except in patients with
a functioning artificial ventricular pacemaker); second- or thirddegree AV block (except in patients with a functioning artificial
ventricular pacemaker); atrial flutter or fibrillation and an
accessory bypass tract (Wolff-Parkinson-White [WPW]
syndrome, Lown-Ganong-Levine syndrome), Additional
contraindications include concurrent use of I.V. beta-blocking
agents; ventricular tachycardia.
Dose and Administration: Adult Chronic atrial fibrillation
(rate-control), PSVT prophylaxis: Oral: Immediate release: 240480 mg/day in 3-4 divided doses; Usual dose range (Fuster,
2006): 120-360 mg/day in divided doses. SVT I.V.: 2.5-5 mg
over 2 minutes; second dose of 5-10 mg (~0.15 mg/kg) may be
given 15-30 minutes after the initial dose if patient tolerates, but
does not respond to initial dose; maximum total dose: 20-30 mg.
Dosing: Pediatric SVT: Note: Verapamil is no longer included
in the Pediatric Advanced Life Support (PALS) tachyarrhythmia
algorithm.
Children: 1-15 years: I.V.: 0.1-0.3 mg/kg/dose over 2 minutes;
maximum: 5 mg/dose, may repeat dose in 30 minutes if
inadequate response; maximum for second dose: 10 mg.

103

3. Cardiovascular Medicines

3.3. Antilipemic agents

Antilipemic agents are used to modify blood lipid
concentrations in the management of hyperlipidaemias and for
the reduction of cardiovascular risk. The principal groups of
lipid regulating medicines are the statins, fibrates, bile-acid
binding resins, nicotinates, and omega-3-triglycerides.
Statins: are inhibitors of 3-hydroxy-3-methyl glutaryl co
enzyme A (HMG-CoA) reductase, the rate determining enzyme
for cholesterol synthesis. These agents include simvastatin,
rosuvastatin, atrovastatin, fluvastatin and lovastatin. They are
potent reducers of plasma LDL cholesterol and triglyceride.
They are indicated in severe hypercholesterolaemia, and may
also be effective in some cases of mixedhyperlipidaemia and
even in mild hypertriglyceridaemia. They are regarded as the
medicines of choice for the management of most
dyslipidaemias. The commonest side effects of therapy with
statins are gastrointestinal disturbances. Myalgia, muscle
enzyme release, or both has been reported, especially in patients
taking statins concurrently with ciclosporin, fibric acid
derivatives, or nicotinc acid.
Fibrates inhibits the synthesis of cholesterol and bile acids, and
enhance the secretion of cholesterol in bile. These agents
include gemfibrozil, clofibrate, bezafibrate and tenofibrate. The
main effect is to reduce triglycerides by reducing the
concentration of VLDL; they also increase HDL-cholesterol
and have variable effects on LDL-cholesterol. They are used
mainly in patients with hypertriglyceridaemia. The most
common side effects of fibrates therapy are gastrointestinal
disturbances including anorexia, nausea, and gastric discomfort.
Fibrates therapy may be associated with myositis, myopathy,
rarely rhabdomyolysis and gallstones.
104

3. Cardiovascular Medicines

Bile-acid binding agents such as cholestyramine are basic

anion-exchange resins that bind bile acids in the gut, preventing
their enterohepatic recycling and causing the hepatocyte to
upregulate LDL receptors to obtain cholesterol for
compensatory increases in bile acid synthesis. It is not absorbed
and is effectively and safety combined with other agents in the
treatment of hypercholesterolaemia. As cholestyramine reduces
absorption, other medication should be taken at least an hour
before, or delayed for at least four hours after administration of
the resin.
Atorvastatin
Tablet, 10 mg, 20mg, 40mg, 80mg
Indications: Treatment of dyslipidemias or primary prevention
of cardiovascular disease (atherosclerotic) as detailed below:
Primary prevention of cardiovascular disease (high-risk for
CVD): To reduce the risk of MI or stroke in patients without
evidence of heart disease who have multiple CVD risk factors
or type 2 diabetes. Treatment reduces the risk for angina or
revascularization procedures in patients with multiple risk
factors. Secondary prevention of cardiovascular disease: To
reduce the risk of nonfatal MI, nonfatal stroke,
revascularization procedures, hospitalization for heart failure,
and angina in patients with evidence of coronary heart disease.
Treatment of dyslipidemias: To reduce elevations in total
cholesterol (C), LDL-C, apolipoprotein B, and triglycerides in
patients with elevations of one or more components, and/or to
increase low HDL-C as present in Fredrickson type IIa, IIb, III,
and IV hyperlipidemias, heterozygous familial and nonfamilial
hypercholesterolemia,
and
homozygous
familial
hypercholesterolemia. Treatment of heterozygous familial
hypercholesterolemia (HeFH) in adolescent patients (10-17
105

3. Cardiovascular Medicines

years of age, females >1 year postmenarche) having LDL-C

190 mg/dL or LDL-C 160 mg/dL with positive family
history of premature cardiovascular disease (CVD) or with two
or more CVD risk factors.
Cautions: hepatic disease or elevated serum transaminases.
Drug interactions: alcohol, warfarin, cholestyramine, digoxin,
drug which inhibit cytochrome P450 isoenzyme 3A4
(ciclosporin, macrolides, azoles, protease inhibitor; they
increase risk of myopathy), fibrates, nicotinic acid, propranolol.
Contraindications: known hypersensitivity to the drug; active
liver disease or unexplained persistently raised serumaminotransferase concentrations, pregnancy.
Side effects: abdominal pain, constipation, diarrhea, flatulence,
nausea, dyspepsia; myalgia associated with muscle stiffness or
weakness, or elevations of creatine kinase; plasma transaminase
elevation; headache, insomnia, skin rash, peripheral neuropathy
and a hypersensitivity syndrom with angioedema.
Rhabdomyolysis with renal failure has occurred. Incidence and
severity of myopathy are increased by drug interactions-see
above.
Dose and Administration: Adult: Primary prevention: Note:
Doses should be individualized according to the baseline LDLcholesterol concentrations, the recommended goal of therapy,
and patient response; adjustments should be made at intervals
of 2-4 weeks. Hypercholesterolemia (heterozygous familial
and nonfamilial) and mixed hyperlipidemia (Fredrickson
types IIa and IIb): Oral: Initial: 10-20 mg once daily; patients
requiring >45% reduction in LDL-C may be started at 40 mg
once daily; range: 10-80 mg once daily. Homozygous familial
hypercholesterolemia: Oral: 10-80 mg once daily. Secondary
prevention: Clinically evident coronary heart disease: Oral:
Initial: 80 mg once daily; adjust based on patient tolerability
106

3. Cardiovascular Medicines

and recommended goal LDL-C. Intensive lipid-lowering after

an ACS event regardless of baseline LDL (unlabeled use):
Oral: Initial: 80 mg once daily; adjust based on patient
tolerability and recommended goal LDL-C (Cannon, 2004;
Pederson, 2005; Schwartz, 2001).
Noncardioembolic
stroke/TIA (unlabeled use): Oral: Initial: 80 mg once daily;
adjust based on patient tolerability and recommended goal
LDL-C.
Dosage adjustment for atorvastatin with concomitant
medications: Clarithromycin, itraconazole, fosamprenavir,
ritonavir (plus darunavir, fosamprenavir, or saquinavir): Use
lowest effective atorvastatin dose (not to exceed 20 mg daily),
Nelfinavir: Use lowest effective atorvastatin dose (not to exceed
40 mg daily)
Pediatric Note: Doses should be individualized according to the baseline
LDL-cholesterol concentrations, the recommended goal of therapy, and
patient response; adjustments should be made at intervals of 4 weeks

HeFH: Children 10-17 years (females >1 year postmenarche):

Oral: 10 mg once daily (maximum: 20 mg/day). Dosage
adjustment for atorvastatin with concomitant medications:
Clarithromycin, itraconazole, fosamprenavir, ritonavir (plus
darunavir, fosamprenavir, lopinavir, or saquinavir): Lowest
effective atorvastatin dose (not to exceed 20 mg/day) should be
used. Nelfinavir: Lowest effective atorvastatin dose (not to
exceed 40 mg/day) should be used.
Storage: store in well-closed, light -resistant containers at 5
30oC
Cholestyramine
Powder, 4 g in 9g sachet

107

3. Cardiovascular Medicines

Indications: Adjunct in the management of primary

hypercholesterolemia; pruritus associated with elevated levels
of bile acids; regression of arteriolosclerosis.
Cautions: patients with constipation and phenylketoneuria, risk
of vitamin deficiencies in prolonged use.
Drug interactions: fat-soluble vitamins, warfarin, digoxin,
thiazides, barbiturates, aspirin, tetracyclines and thyroxine.
Contraindications: complete biliary and bowel obstruction,
active peptic, ulcer disease; sensitivity to tartrazine.
Side effects: frequently unpalatable or associated with bloated
feeling, nausea, vomiting, constipation occurs frequently,
headache
and
dizziness,
(<l%).
May
aggravate
hypertriglyceridaemia; see also notes above.
Note: constipation, most common side effect of cholestyramine, may
be, countered by increased fiber and water intake

Dose and Administration: Oral: Adult:Dyslipidemia: Oral:

Initial: 4 g 1 to 2 times/day; increase gradually over 1 month
intervals; maintenance: 8-16 g/day divided in 2 doses;
maximum: 24 g/day
Child: over 6 years, 240 mg/kg/day in divided doses has been
suggested.
Storage: store in airtight containers and at room temperature.
Ezetimibe
Tablet, 10mg
Indications: Use in combination with dietary therapy for the
treatment of primary hypercholesterolemia (as monotherapy or
in combination with HMG-CoA reductase inhibitors);
homozygous
sitosterolemia;
homozygous
familial
hypercholesterolemia (in combination with atorvastatin or
simvastatin); mixed hyperlipidemia (in combination with
fenofibrate).
108

3. Cardiovascular Medicines

Drug interactions: cholestyramine, ciclosporine

Contraindications: moderate to severe hepatic impairment;
children under 10 years of age.
Side effects: Common - headache, abdominal pain and
diarrhoea, rash & angioedema. Also, when combined with a
statin, constipation, flatulence, nausea, increased ALT/AST,
myalgia and rhabdomyolysis.
Dose and Administration: Adult: Oral: 10 mg daily. Children:
10 years, 10 mg daily.
Fenofibrate
Tablets, (micronised) 160 mg
Indications: Adjunct to dietary therapy for the treatment of
adults with elevations of serum triglyceride levels (types IV and
V hyperlipidemia); adjunct to dietary therapy for the reduction
of low density lipoprotein cholesterol (LDL-C), total cholesterol
(total-C), triglycerides, and apolipoprotein B (apo B), and to
increase high density lipoprotein cholesterol (HDL-C) in adult
patients with primary hypercholesterolemia or mixed
dyslipidemia (Fredrickson types IIa and IIb).
Cautions: liver function tests recommended every 3 months for
first year (discontinue treatment if significantly raised); Renal
impairment: reduce dose to 134 mg daily if eGFR less than 60
mL/minute/1.73 m2; reduce dose to 67 mg daily if eGFR less
than 20 mL/minute/1.73 m2; avoid if eGFR less than 15
mL/minute/1.73 m2; myositis-like syndrome, especially if renal
function is impaired. Also, combination of a fibrate with a statin
increases the risk of muscle effects (especially rhabdomyolysis)
Contraindications: gall bladder disease; pancreatitis (unless
due to severe hypertriglyceridaemia); photosensitivity to
ketoprofen; Hepatic impairment (avoid in severe liver disease),
Pregnancy, Breast-feeding
109

3. Cardiovascular Medicines

Druginteraction:
Ciclosporin,
Colchicine,
Coumarins,
Daptomycin, Ezetimibe, Insulin, Phenindione, Statins,
Sulfonylureas
Side effects: gastro-intestinal disturbances, anorexia; less
commonly cholestasis, weight gain, dizziness, headache,
fatigue, drowsiness, renal impairment, raised serum creatinine
(unrelated to renal impairment), erectile dysfunction,
myotoxicity (with myasthenia or myalgia)special risk in renal
impairment (see Cautions), urticaria, pruritus, photosensitivity
reactions.
Dose and Administration:Adult: oral, 160 mg daily (not
appropriate for children or in renal impairment)
Fluvastatin
Capsule, 20mg, 40mg
Tablet, 80mg
Indications: To be used as a component of multiple risk factor
intervention in patients at risk for atherosclerosis vascular
disease due to hypercholesterolemia. Adjunct to dietary therapy
to reduce elevated total cholesterol (total-C), LDL-C,
triglyceride, and apolipoprotein B (apo-B) levels and to
increase HDL-C in primary hypercholesterolemia and mixed
dyslipidemia (Fredrickson types IIa and IIb); to slow the
progression of coronary atherosclerosis in patients with
coronary heart disease; reduce risk of coronary
revascularization procedures in patients with coronary heart
disease.
Cautions: previous, liver disease or heavy ethanol use.
Treatment in patients < 18 years of age is not recommended.
Drug interactions: cimetidine, omeprazole, ranitidine and
ritonavir, erythromycin, gemfibrozil, digoxin, amiodarone,
fluoxetine, phenytoin, warfarin and others.
110

3. Cardiovascular Medicines

Contraindications: hypersensitivity reaction, active liver

disease, unexplained persistent elevations of serum
transaminses, pregnancy, breast-feeding.
Side effects: headache, fatigue, insomnia, dyspepsia, diarrhea,
abdominal pain, nausea, urinary tract infection, myalgia,
sinusitis, bronchitis.
Dose and Administration:Adult: Oral: Patients requiring
25%decrease in LDL-C: 40mg capsule or 80mg extended
release tablet once daily in the evening; may also use 40mg
capsule twice daily
Patients requiring < 25%decrease in LDL-C: 20mg capsule
once daily in the evening.
Note: Dosing range: 20-80 mg/day; adjust dose based on response to
therapy; maximum response occurs within 4-6 weeks.

Storage: store at 250C. Protect from light.

Gemfibrozil
Capsule, 300 mg
Indications: treatment of hypertriglyceridemia in WHO types
IV and V hyperlipidemia for patients who are at great risk for
pancreatitis and who have not responded to dietary
interventions.
Cautions: hyperthyroidism, gall bladder disorders, peptic ulcer,
hyperalbuminaemic states and cardiovascular disease.
Drug interactions: warfarin, HMG CoA reductase inhibitors,
phenytoin, sulphonylureas, and cholestyramine.
Contraindications: hypersensitivity to fibrates; renal or
hepatic failure; primary biliary cirrhosis; gallstones.
Side effects: gastrointestinal disturbances, myalgia/myosis like
syndrome, eczema, rash headache, dizziness, blurred vision;
transient leucopenia may occur; see also notes above.
111

3. Cardiovascular Medicines

Dose and Administration: Adult: Oral: Initially 300 mg twice

daily, increased to 600 mg twice daily, 30 minutes before the
morning and evening meals. Dosage range, 0.9-1.5 g daily in 2
divided doses.
Storage: store in airtight containers and at room temperature.
Lovastatin
Tablet, 20 mg
Indications: Adjunct to dietary therapy to decrease elevated
serum total and LDL cholesterol concentrations in primary
hypercholesterolemia. Primary prevention of coronary artery
disease (patients without symptomatic disease with average to
moderately elevated total and LDL-cholesterol and below
average HDL cholesterol); slow progression of coronary
atherosclerosis in patients with coronary heart disease and
reduce the risk of myocardial infarction, unstable angina, and
coronary revascularization procedures. Adjunct to dietary
therapy in adolescent patients (10-17 years of age, females >1
year
postmenarche)
with
heterozygous
familial
hypercholesterolemia having LDL >189 mg/dL, or LDL >160
mg/dL with positive family history of premature cardiovascular
disease (CVD), or LDL >160 mg/dL with the presence of at
least two other CVD risk factors.
Cautions, Drug interactions, Contraindications,Side effects
and Storage; see under simvastatin.
Dose and Administration: Adult: Oral: an initial dose of 10 to
20 mg daily in the evening with food, increased, if necessary, at
intervals of 4 weeks or more to 80 mg daily in single or divided
doses. In patients taking immunosuppressant drugs an initial
dose of 10 mg daily is recommended; the daily dose should not
exceed 20 mg.
112

3. Cardiovascular Medicines

Orlistat
Capsule, 120mg
Indication: Management of obesity, including weight loss and
weight management, when used in conjunction with a reducedcalorie and low-fat diet; reduce the risk of weight regain after
prior weight loss; indicated for obese patients with an initial
body mass index (BMI) 30 kg/m2 or 27 kg/m2 in the
presence of other risk factors (eg, diabetes, dyslipidemia,
hypertension).
Cautions: Epilepsy; pregnancy; breast-feeding; impair
absorption of fat soluble vitamins, children; If a multivitamin
supplement is required, it should be taken at least 2 hours after
orlistat dose or at bedtime.
Drug Interactions: Acarbose, Amiodarone, antiepileptics,
ciclosporin, coumarins, levothyroxine.
Contraindications: Orlistat is contraindicated in patients with
chronic malabsorption syndrome or cholestasis, and in patients
with known hypersensitivity to Orlistat or to any component of
this product.
Side effects: oily leakage from rectum, flatulence, faecal
urgency, liquid or oily stools, faecal incontinence, abdominal
distension and pain (gastro-intestinal effects minimised by
reduced fat intake), tooth and gingival disorders; respiratory
infections; fatigue, anxiety, headache; menstrual disturbances,
urinary-tract infection; hypoglycaemia; rarely rectal bleeding,
hypothyroidism; very rarely diverticulitis, cholelithiasis,
hepatitis, and bullous eruptions; oxalate nephropathy .
Dose and Administration: one capsule (120 mg) three times
daily. Adult over 18 years: 120 mg taken immediately before,
during, or up to 1 hour after each main meal (up to max.
360 mg daily); continue treatment beyond 12 weeks only if
weight loss since start of treatment exceeds 5% (target for
113

3. Cardiovascular Medicines

initial weight loss may be lower in patients with type 2

diabetes): administered orally with each main meal containing
fat; if a meal is missed by the patient or the meal contains no
fat, that dose may be omitted. Patients should be on a reducedcalorie diet with approximately 30% of the calories from fat.
Protein, carbohydrate, and fat intake should be balanced over 3
main meals. May decrease the absorption of some fat-soluble
vitamins (A, D, E, K) and beta-carotene. To ensure adequate
nutrition, patients should take a multivitamin supplement that
contains fat-soluble vitamins. The multivitamin supplement
should be taken orally once per day at least two hours before or
after administration (i.e. bedtime).Maximum Dosage Limits:
Adults: 360 mg/day PO.
Elderly: 360 mg/day PO.
Adolescents >= 12 years: 360 mg/day PO.
Storage: Store at room temperature
Rosuvastatin
Tablet, 5mg, 10mg, 20mg, 40mg

Indication: Treatment of dyslipidemias: Used with dietary

therapy for hyperlipidemias to reduce elevations in total
cholesterol (TC), LDL-C, apolipoprotein B, nonHDL-C, and
triglycerides
(TG)
in
patients
with
primary
hypercholesterolemia (elevations of 1 or more components are
present in Fredrickson type IIa, IIb, and IV hyperlipidemias);
increase HDL-C; treatment of primary dysbetalipoproteinemia
(Fredrickson type III hyperlipidemia); treatment of homozygous
familial hypercholesterolemia (FH); to slow progression of
atherosclerosis as an adjunct to diet to lower TC and LDL-C.
Heterozygous familial hypercholesterolemia (HeFH): In
adolescent patients (10-17 years of age, females >1 year
postmenarche) with HeFH having LDL-C >190 mg/dL or LDL
114

3. Cardiovascular Medicines

>160 mg/dL with positive family history of premature

cardiovascular disease (CVD), or 2 other CVD risk factors.
Primary prevention of cardiovascular disease: To reduce the
risk of stroke, myocardial infarction, or arterial
revascularization procedures in patients without clinically
evident coronary heart disease or lipid abnormalities but with
all of the following: 1) an increased risk of cardiovascular
disease based on age 50 years old in men and 60 years old in
women, 2) hsCRP 2 mg/L, and 3) the presence of at least one
additional cardiovascular disease risk factor such as
hypertension, low HDL-C, smoking, or a family history of
premature coronary heart disease. Secondary prevention of
cardiovascular disease: To slow progression of atherosclerosis
Cautions: In patients with risk factors for myopathy or
rhabdomyolysis (including personal or family history of
muscular disorders or toxicity), Hepatic impairment, renal
impairment, pregnancy, breast feeding. Safety and efficacy
have not been established in children.
Drug Interactions: Antacids (magnesium), atazanavir,
coumarins,
darunavir,
erythromycin,
ethinylestradiol,
fasamprenavir, indinavir, lopinavir, nelfinavir, norgestrel,
Chlchicine, cyclosporine, fibrate, gemfibrozil, tipranavir,
ritonavir, phenindione, saquinavir, daptomycin, nicotic acid,
niacin, warfarin, cholestyramine and colestipol, alcohol.
Contraindications: known hypersensitivity to any component
of this product; active liver disease or with unexplained
persistent elevations of serum transaminases.
Sideeffects:Headache,dizziness,depression,rash,abdomainalpai
n,constipation,nausea,vomiting,diarrhea,anemia, pain in the
muscles (myalgia), weakness or loss of strength (asthenia),
presence of protein in the urine.
Dosage and Administration: Dosing: Adult
115

3. Cardiovascular Medicines

Note: Doses should be individualized according to the baseline LDLcholesterol levels, the recommended goal of therapy, and patient response;
adjustments should be made at intervals of 4 weeks or more.

Hyperlipidemia, mixed dyslipidemia, hypertriglyceridemia,

primary dysbetalipoproteinemia, slowing progression of
atherosclerosis: Oral: Initial dose: General dosing: 10 mg once
daily; 20 mg once daily may be used in patients with severe
hyperlipidemia (LDL >190 mg/dL) and aggressive lipid targets
Conservative Dosing: Patients requiring less aggressive
treatment or predisposed to myopathy (including patients of
Asian descent): 5 mg once daily. Titration: After 2 weeks, may
be increased by 5 to 10 mg once daily; dosing range: 5 to 40
mg/day (maximum dose: 40 mg once daily).
Note: The 40 mg dose should be reserved for patients who have not
achieved goal cholesterol levels on a dose of 20 mg/day, including
patients switched from another HMG-CoA reductase inhibitor.

Homozygous familial hypercholesterolemia (FH): Oral:

Initial: 20 mg once daily (maximum dose: 40 mg/day). Dosage
adjustment with concomitant medications: Oral: U.S.
labeling: Cyclosporine: Rosuvastatin dose should not exceed 5
mg/day. Gemfibrozil: Avoid concurrent use; if unable to avoid
concurrent use, rosuvastatin dose should not exceed 10 mg/day
Atazanavir/ritonavir or lopinavir/ritonavir: Rosuvastatin dose
should not exceed 10 mg/day. Canadian labeling:Cyclosporine:
Concomitant use is contraindicated
Gemfibrozil: Rosuvastatin dose should not exceed 20 mg/day.
Dosage adjustment for hematuria and/or persistent,
unexplained proteinuria while on 40 mg/day: Reduce dose
and evaluate causes.
Dosing: Pediatric Note: Doses should be individualized according
to the baseline LDL-cholesterol levels, the recommended goal of
therapy, and patient response; adjustments should be made at
intervals of 4 weeks or more.
116

3. Cardiovascular Medicines

Heterozygous familial hypercholesterolemia (HeFH):

U.S. labeling: Children 10-17 years (females >1 year
postmenarche): Oral: 5-20 mg once daily; maximum: 20
mg/day. Dosage adjustment for rosuvastatin with concomitant
cyclosporine, atazanavir/ritonavir or lopinavir/ritonavir: Refer
to adult dosing.
Canadian labeling: Oral: 5-10 mg once daily; maximum: 10
mg/day. Dosing: Renal Impairment Mild to moderate
impairment: No dosage adjustment required.
Clcr<30 mL/minute/1.73 m2: Initial: 5 mg/day; do not exceed 10
mg once daily. Dosing: Hepatic Impairment U.S. labeling:Active
hepatic disease, including unexplained persistent transaminase
elevations: Use is contraindicated. Canadian labeling:Active
hepatic disease or unexplained persistent transaminase >3x
ULN: Use is contraindicated. Mild to moderate impairment: No
dosage adjustment required. Severe impairment: Initial: 5
mg/day; do not exceed 20 mg once daily.
Storage: Store it at room temperature.
Simvastatin
Tablets, 5mg, 10 mg, 20 mg, 40 mg
Indications: Used with dietary therapy for the following:
Secondary prevention of cardiovascular events in
hypercholesterolemic patients with established coronary heart
disease (CHD) or at high risk for CHD: To reduce
cardiovascular
morbidity
(myocardial
infarction,
coronary/noncoronary revascularization procedures) and
mortality; to reduce the risk of stroke.
Hyperlipidemias: To reduce elevations in total cholesterol
(total-C), LDL-C, apolipoprotein B, triglycerides, and VLDLC, and to increase HDL-C in patients with primary
hypercholesterolemia (elevations of 1 or more components are
117

3. Cardiovascular Medicines

present in Fredrickson type IIa, IIb, III, and IV

hyperlipidemias); treatment of homozygous familial
hypercholesterolemia.
Heterozygous
familial
hypercholesterolemia (HeFH): In adolescent patients (10-17
years of age, females >1 year postmenarche) with HeFH having
LDL-C 190 mg/dL or LDL-C 160 mg/dL with positive
family history of premature cardiovascular disease (CVD), or 2
or more CVD risk factors in the adolescent patient.
Cautions, Drug interactions, Contraindications, Side effects
and Storage; see under Atrovastatin
Dose and Administration: Adult: Oral: initially 10mg at night,
adjusted, if required, at intervals of 4 weeks or more. Maximum
80 mg/day. Severe renal impairment (creatinine clearance <30
ml/min): 10 mg/day. If higher doses are necessary, implement
with caution.
Ursodeoxycholic Acid
Capsule, 250mg
Indication: The medicine reduces cholesterol absorption and is
used to dissolve (cholesterol) gallstones in patients who want an
alternative to surgery.
Cautions: Pregnancy, breast-feeding, hepatic impairment
Drug Interactions: Ciclosporin, antacids, colestipol,
colestyramine, oestrogens, clofibrate, clomifene, conjugated
estrogens, diethylstilbestrol, estradiol, ethnyl estradiol,
fenofibrate, gemfibrozil.
Contraindications: Ursodeoxycholic acid will not dissolve
calcified cholesterol stones, radiopaque stones, or radiolucent
bile pigment stones. Hence, patients with such stones are not
candidates for ursodeoxycholic acid; Patients with compelling
reasons for cholecystectomy including unremitting acute
cholecystitis, non-functioning gall bladder, inflammatory
118

3. Cardiovascular Medicines

diseases and other conditions of the small intestine, cholangitis,

biliary obstruction, gallstone pancreatitis, or colon and liver
which interfere with entero-hepatic circulation of bile salts are
not candidates for Ursodeoxycholic acid therapy; Allergy to
bile acids.
Side-effects:
nausea,
vomiting, diarrhoea;
gallstone
calcification; pruritus.
Dose and Administration: Dissolution of gallstones, 8
12 mg/kg daily as a single dose at bedtime or in two divided
doses, for up to 2 years; treatment is continued for 34 months
after stones dissolve.
Storage: Store at room temperature.
3.4. Medicines used for Angina/Ischemic Heart Disease
Angina pectoris is a syndrome that arises from reduced
myocardial oxygen supply. The prominent symptom is transient
precordial distress ranging from discomfort to severe pain. The
three main types of angina are: stable angina: unstable angina,
and prinzmetal's angina. These should not be regarded as
discrete groups as more than one type is usually present in the
patient with angina.
Treatment depends on the type of angina and includes drug
therapy (nitrates, beta blockers and calcium channel blockers),
percutaneous coronary interventions, and coronary artery
bypass surgery. Antithrombotics are used in unstable angina
and include anticoagulants and antiplatelets.
Glyceryl trinitrate and other organic nitrates have a
vasodilator effect with venodilatation predominating over
dilatation of the arterioles and they have a useful role in angina.
Sublingual Glyceryl trinitrate is one of the most effective drugs
for providing rapid symptomatic relief of angina, but its effect
lasts only for 20 to 30 minutes. Duration of action may be
119

3. Cardiovascular Medicines

prolonged by modified - release and transdermal preparations

(but tolerance may develop)
A sublingual tablet of isosorbide dinitrate is more stable in
storage than glyceryl trinitrate and is useful in patients who
require nitrates infrequently; it has a slower onset of action, but
effects persist for several hours.
Beta-blockers, such as atenolol, block beta-adrenergic
receptors in the heart, and thereby decrease heart rate and
myocardial contractility and oxygen consumption, particularly
during exercise. Beta-blockers are first-line therapy for patients
with effort-induced chronic stable angina; they improve
exercise tolerance, relieve symptoms, reduce the severity and
frequency of angina attacks, and increase the anginal threshold.
Beta-blockers should be withdrawn gradually to avoid
precipitating an anginal attack; they should not be used in
patients with underlying coronary vasospasm (prinzmetal
angina).The different beta-blockers appear to be equally
effective in stable angina, although it has been suggested that
those with intrinsic sympathomimetic activity should be
avoided.
A calcium-channel blocker, such as verapamil, is used as an
alternative, particularly in patients unable to tolerate betablockers. Calcium-channel blockers interfere with the inward
movement of calcium ions through the slow channels in heart
and vascular smooth muscle cell membranes, leading to
relaxation of vascular smooth muscle. Calcium-channel
blockers are used to improve exercise tolerance in patients with
chronic stable angina due to coronary atherosclerosis or with
abnormally small coronary arteries and limited vasodilator
reserve. They can also be used in patients with unstable angina
with a vasospastic origin, such as Prinzmetal angina, and in
patients in whom alterations in cardiac tone may influence the
120

3. Cardiovascular Medicines

angina threshold. Care is required in selecting an appropriate

medicine since the properties of dihydropyridine calciumchannel blockers (such as nifedipine) and rate-limiting calcium
channel blockers (diltiazem and verapamil) are not the same.
Studies comparing long-acting calcium-channel blockers
(verapamil or modified-release nifedipine) with beta-blockers
have shown similar outcomes in terms of symptom control and
cardiovascular events. However, dihydropyridines may cause
tachycardia and are less suitable than rate limiting calciumchannel blockers for monotherapy; they should not be used with
out beta-blockers in unstable angina. Short-acting preparations
of nifedipine have been associated with increased mortality and
are not recommended.
Atenolol
Tablets, 50 mg, 100 mg
Indications: angina, Chronic Stable Angina: Unstable
Angina/Non-ST-Elevation Myocardial Infarction.
Cautions, Drug interactions, Contraindications, Side effects;
see section 3.2 under propranolol.
Dose and Administration: Oral: Angina: Adult Angina
pectoris: Oral: 50 mg once daily; may increase to 100 mg/day.
Some patients may require 200 mg/day.
Child: 0.8 to 1.5 mg/kg/day (maximum 2 mg/kg/day)
Storage: store at room temperature and protect from light.
Diltiazem Hydrochloride
Tablets,60 mg, 90 mg, 120 mg, 90 mg (s/r), 120 mg (s/r)
Indications: angina (including prinzmetal's angina),
hypertension, supraventricular arrhythmias.
Cautions, Drug interactions, Containdications and Side
effects; see section 3.2 under verapamil
121

3. Cardiovascular Medicines

Dose and Administration: Oral: Adult: Angina: Immediate

release: usual starting dose: 30mg 4 times/day; usual range:
180-360 mg/day in divided doses. Extended release: 180mg
once daily; may increase at 7-14 day intervals (maximum
recommended dose: 360mg/day).
Note: Do not crush long sustained release dosage forms.

Storage: store at room temperature.

Glyceryl trinitrate (Nitroglycerine)
Capsule (extended release), 2.5 mg, 6.5mg, 9mg
IV infusion, 0.1mg/ml, 0.2mg/ml, 0.4mg/ml
Injection, 5mg/ml
Ointment, 2%
Transdermal Patch, 0.1mg/hr, 0.2mg/hr, 0.4mg/hr
Transdermal Spray, 0.4mg/dose
Tablet (sublingual), 0.3mg, 0.4mg, 0.5 mg, 0.6mg
Tablet (Sustained released), 2.5 mg
Controlled release tablet, 2.6mg
Indications: prophylaxis and treatment of angina.
Cautions: severe hepatic or renal impairment; hypothyroidism,
malnutrition, or hypothermia, recent history of myocardial
infarction; conditions that cause dry mouth.
Drug interactions: alcohol, antihypertensive, vasodilators and
sildenafil.
Contraindications: hypersensitivity to nitrates; hypertensive
conditions and hypovolaemia; hypertrophic obstructive
cardiomyopathy, aortic stenosis, cardiac tamponade,
constrictive pericarditis, mitral stenosis; marked anaemia, head
trauma, cerebral haemorrhage, closed - angle glaucoma.
Side effects: Flushing of the face, dizziness, tachycardia, and
throbbing headache. Large doses cause vomiting, restlessness,
blurred vision, hypotension (which can be severe), syncope and
122

3. Cardiovascular Medicines

rarely cyanosis, and methaemoglobinaemia; impairment of

respiration and bradycardia may ensue.Contact dermatitis
(topical glyceryl trinitrate preparations), localized burning
sensation (sublingual tablets). Tolerance may develop from
uninterrupted, repeated use.
Note: tolerance may be managed by nitrate withdrawal (12-36 hours)
and reinstitution with the same agent. Doses may need to be reviewed
as tolerance develops.

Dose and Administrations: Adult: Sublingual: 0.3 to 0.6 mg

repeated at five-minute intervals for the maximum of 3 doses in
15 minutes, may also use prophylactically 5-10 minutes prior to
activities which may provoke an attack. Oral: 2.5 to 9mg 2-4
times/day (up to 26 mg 4 times/day). Ointment: topical to the
skin, 15 to 30 mg of nitroglycerin (contained in 2.5 to 5cm [1 to
2 inches] of ointment as squeezed from the tube) every eight
hours during the day and at bedtime. If angina occurs between
doses, frequency of application may be increased to every six
hours. Buccal: Initial: 1mg every 3-5 hours while awake
(3times/day); titrate dosage upward if angina occurs with tablet
in place. IV: 5mcg/minute, increase by 5mcg/minute every 3-5
minutes to 20mcg/minute; if no response at 20mcg/minute
increase by 10mcg/minute every 3-5 minutes, up to
200mcg/minute. Patch, transdermal: initial: 0.2 to 0.4 mg/hour
titrates to doses of 0.4-0.8mg/hour. Spray: 1to2 sprays into
mouth under tongue every 3 to 5 minutes for maximum of three
doses in 15 minutes. Dosage has not been established for pediatric
use.
Note1:Sublingual tablet: Instruct patient to sit or lie down upon first
indication of incoming angina pain and to place tablet under tongue
or in buccal pouch (hypotensive effect of drug is intensified in the
upright position). Instruct patient to allow tablet to dissolve naturally
and not to swallow until drug is entirely dissolved. Advise patient
123

3. Cardiovascular Medicines

with dry mouth to take a sip of water or place 1ml saline under the
tongue before taking the nitroglycerin tablet.
Note 2: Sustained-release tablet or capsule Take on an empty
stomack (1 hour before or 2 hours after meals), with a full glass of
water, and swallowes whole. Sustained release form helps to prevent
anginal attack, it is not intended for immediate relief of angina. Do
not crush or chew.
Note 3: Transdermal ointment: Ointment is applied in a thin, even
layer covering an area of the same size (measuring at least 2 by 3
inches) at each use, but it is not to be rubbed or massaged into the
skin. The site of ointment application may be the non-hairy skin of
the chest, stomach, front of the thighs, or any other accessible areas
of clean, dry skin. Application to the chest is commonly preferred
since the patient also benefits psychologically from applying
medication to the area where the pain is experienced. Keep ointment
container tightly closed and store in cool place.

Storage: nitroglycerin tablets for sublingual use may easily lose

half their potency in 24 hours if stored incorrectly. Tablets
should be kept in the original container, which should be kept
tightly Closed and closed immediately after use. Pateints should
keep the container in a cool place, e.g. handbag or outer
clothing Pocket. Discard 60 days after opening. No more than
100 tablets should be dispensed at one time
Isosorbide dinitrate
Tablets (sublingual), 5 mg, 10 mg
Indications: relief of acute anginal attacks and for management
of long-term angina pectoris; congestive cardiac failure.
Cautions, Drug interactions, Contraindications and Side
effects; see under glyceryl trinitrate.
Note: as with other long acting nitrates, tolerance develops rapidly.

Dose and Administration: Adult: Sublingually:Angina (acute

attack): 2.5 to 10 mg, if relief is not attained after a single dose,
additional doses may be given at 5-10 minute intervals; no more
124

3. Cardiovascular Medicines

than 3 doses should be given in a 15-30 minute period.Angina

prophylaxis: 2.5 - 10 mg 4-6 hourly.Congestive cardiac failure:
40mg 4 times daily. However, as 6 hourly administrations may
promote tolerance, 12 hourly dosage is preferable, alternatively
dosing with a nitrate-free night restores tolerance.
Storage: store at room temperature.
Isosorbide mononitrate
Tablet,10mg,20mg, 25mg(m/r), 40mg(m/r), 60mg(m/r)
Capsule(m/r), 40mg, 50mg
Indications:prophylaxis of angina; adjunct in congestive heart
failure
Cautions: pregnancy, renal and hepatic impairment,
hypothyroidism; malnutrition; hypothermia; recent history of
myocardial infarction; heart failure due to obstruction;
hypoxaemia or other ventilation and perfusion abnormalities;
susceptibility to angle-closure glaucoma; metal-containing
transdermal systems should be removed before magnetic
resonance imaging procedures, cardioversion, or diathermy;
avoid abrupt withdrawal
Drug interactions: enhanced hypotensive effect when given
with ACE inhibitors, Adrenergic neurone blockers, alcohol,
Alpha- blockers, Alprostadil, general anaesthetics, angiotensine
II receptor Antagonists
Contraindications: hypersensitivity to isosorbide mononitrate
or organic nitrates,hypotensive conditions and hypovolaemia;
hypertrophic cardiomyopathy; aortic stenosis; cardiac
tamponade; constrictive pericarditis; mitral stenosis; toxic
pulmonary oedema; raised intracranial pressure due to cerebral
haemorrhage or head trauma; marked anaemia, avoid
concomitant use with Sildenafil, Tadalafil and verdinafil
(hypotensive effects will be enhanced).
125

3. Cardiovascular Medicines

Side effects:Headache, rash, dizziness, upset stomach, flushing

Dose and Administration: Adult: Oral: 20mg 8-12 hourly. 20120mg/day in divided doses has been used.
Storage: store at room temperature
Metoprolol
Injection, 1mg/ml, 5mg/ml
Tablets, 50mg, 100 mg, 200mg(s/r)
Indications, Cautions, Drug interactions, Contraindications,
Side effects and Storage; see section 2.2, under metoprolol.
Dose and Administration:Oral:Angina: 50-100mg 2to 3 times
daily.
Nifedipine
Capsule,5mg,10mg,20mg,30mg (s/r); 20mg (soft gelatin)
Tablet, 10 mg, 20 mg,30mg, 40mg, 60mg, 90mg(m/r)
Indications: used alone or in combination with other agents for
treatment of hypertension and angina pectoris, Raynauds
phenomenon.
Cautions: aortic stenosis or hypertrophic obstructive
cardiomyopathy (may worsen cardiac failure or increase
outflow track obstruction); angina (may worsen symptoms);
nursing mother, renal & hepatic impairment.
Drug interactions: other antihypertensives, beta blockers (use
with special caution), digoxin, medicines that inhibit
cytochromeP4503A4 (cimetidine, erythromycine, fluoxetine,
protease inhibitors, ketoconazole, itraconazole, fluconazole),
medicines that induce cytochromeP450 3A4 (carbamzepine,
phenobarbital etc.), rifampicin, tacrolimus, valproic acid.
Contraindications: hypotension, unstable angina or acute
myocardial infarction (increased infarct rate and mortality) in
126

3. Cardiovascular Medicines

the absence of current beta blockade; cardiogenic shock. Avoid

sudden withdrawal.
Side effects: peripheral edema (swelling at ankles, feet, or
lower legs), dizziness or light headedness, flushing or feeling
of warmth, headache, nausea, congestive heart failure or
pulmonary edema (breathing difficulty, coughing, or wheezing),
tachycardia, constipation, unusual tiredness or weakness,
palpitation, increased frequency of micturation, eye pain, gum
hyperplasia, depression.
Dose and Administration:Oral:AdultDosage adjustments
should occur at 7 to 14days interval to allow for adequate
assessment of new dose; when switching from immediate
release to sustained release formulations, use same total daily
dose.Chronic stable or vasospastic angina: Oral: Immediate
release:Initial: 10 mg 3 times/day; usual dose: 10-20 mg 3
times/day; coronary artery spasm may require up to 20-30 mg 34 times/day. Single doses >30 mg and total daily doses >120 mg
are rarely needed; maximum: 180 mg/day.Note: Do not use for
acute
anginal
episodes;may
precipitate
myocardial
infarction.Extended release: Initial: 30 or60 mg once daily;

maximum: 120-180 mg/day.Child: dosage has not been

established
Storage: store between 15 and 25oc in a tight, light-resistant
container.
Nimodipine
Tablet, 30mg
Injection, 1mg/5ml
Indication: Prevention and treatment of ischaemic neurological
deficits following aneurysmal subarachnoid haemorrhage

127

3. Cardiovascular Medicines

Cautions: Hepatic impairment, renal impairment, pregnancy,

breast-feeding, cerebral oedema or severely raised intracranial
pressure; hypotension, heart attack, unstable angina.
Drug
interactions:Rifampicin,calcium-channel
blockers,
antihypertensive,
azoleantifungals,
hypnotics,
alcohol,
general anaesthetics, antipsychotics,anxiolytics & cimetidine,
corticosteroids, muscle relactant(non-depolarising),NSAIDs,
oestrogens, ritonavir, sodium nitroprusside, theophylline,
tizanidine.
Contraindications:Hypersensitivity to nimodipine or any
component of the formulation
Side-effects: Hypotension, variation in heart-rate, flushing,
headache, gastro-intestinal disorders, abdominal discomfort,
nausea, sweating and feeling of warmth; thrombocytopenia and
rash.
Dose and Administration: Subarachnoid hemorrhage: Oral: 60
mg every 4 hours for 21 days, start therapy within 96 hours after
subarachnoid hemorrhage.
Treatment, by intravenous infusion via central catheter, initially
1 mg/hour (up to 500 micrograms/hour if bodyweight is less
than 70 kg or if blood pressure unstable), increased after 2 hours
to 2 mg/hour if no severe fall in blood pressure; continue for at
least 5 days (maximum 14 days); if surgical intervention during
treatment, continue for at least 5 days after surgery; maximum
total duration of nimodipine use is 21 days. Dosage in renal and
hepatic impairment: the initial dosage of nimodipine in such
patients should be reduced to 30mg every 4 hours and blood
pressure and heart rate monitored closely.
Storage:Store it at room temperature and away from excess
heat and moisture.

128

3. Cardiovascular Medicines

Pentaerythritol Tetranitrate
Capsule, 80 mg
Tablet, 10 mg, 20 mg
Indications: angina pectoris.
Dose and Administration: Oral: Adult: up to 240mg daily, in
divided doses, before a meal.
Propranolol
Tablet, 10 mg, 40 mg
Indications, Cautions, Drug interactions, Contraindications,
Side effects and Storage; see section 3.2 under propranolol.
Dose and Administration: Adult: Oral:Post-MI mortality
reduction: Oral: 180-240 mg/day in 3-4 divided doses. Stable
angina: Oral: 80-320 mg/day in doses divided 2-4 times/day.
Initial: 80 mg once daily; maximum dose: 320 mg once daily
Trimetazidine
Controlled release tablet, 35mg
Indications: Long-term treatment of angina pectoris
Dose and Administration:Adult: oral: 35mg twice daily, in
the morning and evening with meals.
3.5. Antihypertensives
Management of hypertension
Since treatment for hypertension is often life-long, it is
important to integrate the treatment of hypertension into an
overall program of management of associated risk factors and
conditions, particularly in elderly patients who often have
multiple associated disorders.Mild hypertension is defined as
140 to 159 mmHg systolic blood pressure and 90 to 99 mmHg
diastolic blood pressure. Moderate hypertension 160 to 180
mmHg systolic and 100 to 109 mmHg diastolic and severe
129

3. Cardiovascular Medicines

hypertension more than 180 mmHg systolic and more than 110
mmHg diastolic.
Lifestyle changes should introduce for all patients; they include
weight reduction, reduction in alcohol intake, reduction of
dietary sodium, stopping tobacco smoking, and reduction in
saturated fat intake. The patient should eat a healthy nutritious
diet including adequate fruit and vegetables and should exercise
regularly.These measures alone may be sufficient in mild
hypertension with no target organ damage, but patients with
moderate to severe hypertension will also require specific
antihypertensive therapy.
Drug treatment of hypertension: The goal of treatment is to
obtain the maximum tolerated reduction in blood pressure.Five
classes of medicine are used for first-line treatment of
hypertension: Diuretics, Beta - adrenoceptor antagonists (beta
blockers), Angiotensin-converting enzyme (ACE) inhibitors,
calcium- channel blockers and alpha-adrenoceptor blocking
medicines (alpha blockers). All five classes are effective in
reducing blood pressure; thiazide diuretics and beta-blockers
have been shown to reduce mortality due to cardiovascular
complications of hypertension other classes of medicines may
be used in certain situations.
Thiazide diuretics, such as Hydrochlorothiazide have been used
as first-line antihypertensive therapy and are particularly
indicated in the elderly. They have few adverse effects in low
doses, but in large doses they may cause a variety of unwanted
metabolic effects (principally potassium depletion), reduced
glucose tolerance, ventricular ectopic beats and impotence; they
should be avoided in gout. These effects can be reduced by
keeping the dose as low as possible; higher doses do not
produce an increased reduction in blood pressure. Thiazides are
inexpensive and when used in combination, can enhance the
130

3. Cardiovascular Medicines

effectiveness of many other classes of antihypertensive

medicine.
Beta adrenoceptor antagonist (beta-blockers) such as
propranolol are effective in all grades of hypertension, and are
particularly useful in angina and following myocardial
infarction; they should be avoided in asthma, chronic
obstructive pulmonary disease, and heart block.
Angiotensinconverting enzyme inhibitors (ACE inhibitors) such
as captopril are effective and well tolerated by most patients
(see also section 2.1). They can used in heart failure, left
ventricular dysfunction and diabetic nephropathy, but should be
avoided in renovascular disease and in pregnancy. The most
common adverse effect is a dry persistent cough.
Calcium Channel blockers such as Nifedipine are effective
antihypertensives. Particularly for isolated systolic hypertension
and in the elderly when thiazides cannot be used. Short acting
formulations of nifedipine should be avoided as they may evoke
reflex tachycardia and cause large variations in blood pressure.
Alpha-adrenoceptor blocking medicines (alpha-blockers) such
as prazosin are effective in lowering blood pressure but remain
too expensive to be considered as first line therapy in many
countries. They are particularly useful in prostatism, but should
be avoided in urinary incontinence. They are usually used in
combination with other antihypertensives, the first dose being
given at bedtime, as profound hypotension may occur.
Medicines acting on the Central nervous system are also
effective antihypertensive medicines. In particular, methyldopa
is effective in the treatment of hypertension in pregnancy, and
may also be used in asthma and heart failure. Reserpine is also
used because of its effectiveness and low cost. It should be used
in combination with diuretics and prescribed in much lower
131

3. Cardiovascular Medicines

doses than were formerly used.Combining antihypertensive

medicines often produces a beneficial additive effect.
Hypertension in pregnancy
Medicine therapy for chronic hypertension during pregnancy
remains controversial. If diastolic blood pressure is greater than
95 mmHg. Methyldopa is the safer medicine. Beta-blockers
should be used with caution in early pregnancy. Since they
may retard fetal growth they are effective and safe in the third
trimester. ACE inhibitors are contraindicated in pregnancy
since they may damage fetal and neonatal blood pressure
control and renal function. Women who are taking these
medicines and become pregnant should have their
antihypertensive therapy changed immediately.Pre-eclampsia
and eclampsia. If pre-eclampsia or severe hypertension occurs
beyond the 36th week of pregnancy, delivery is the treatment of
choice. For acute severe hypertension in pre-eclampsia or
eclampsia, intravenous hydralazine can be used.
Amiloride and Hydrochlorthiazide
(Potassium-sparing diuretic; antihypertensive)
Oral solution, 5mg+50mg/5ml
Tablet, 2.5mg + 25 mg, 5mg + 50mg
Indications: hypertension, especially when a potassium-sparing
diuretic effect is desired.
Cautions: possibility of hypokalemia or hyperkalemia.
Drug interactions: chlorpropamide, carbenoxolone, see also
hydrochlorthiazide.
Side effects: hyponatraemia, constipation, allergic reactions,
cholecystitis or pancreatitis, gout or hyperuricemia, hepatic
function impairment, thrombocytopenia.
132

3. Cardiovascular Medicines

Dose and Administration: Oral: Adult: start with 5mg+50mg

per day, then may be increased to 10mg+100mg per day if
needed; given in a single dose.
Storage: at room temperature.
Amlodipine
Tablet 2.5 mg, 5 mg, 10 mg
Indications: Treatment of hypertension; treatment of
symptomatic chronic stable angina, vasospastic (Prinzmetal's)
angina (confirmed or suspected); prevention of hospitalization
due to angina with documented CAD (limited to patients
without heart failure or ejection fraction <40%).
Cautions, Drug interactions, Contraindications, Side
effects; see under Nifedipine below.
Dose and Administration:Hypertension: Oral: Adult: Initial
dose 2.5 mg twice daily (1.25 mg twice daily in elderly, hepatic
or renal impairment): increased if necessary after 3 - 4 weeks to
5 mg twice daily (exceptionally up to 10 mg twice daily);
maintenance 2.5 or 5 mg once daily may be sufficient
Storage: at room temperature in a tight, light resistant
container.
Atenolol
Tablet, 50mg, 100mg
Indication: treatment of hypertension, alone or in combination
with other agents; management of angina pectoris,
postmyocardial infraction patients.
Contraindication: Hypersensitivity to atenolol or any
component of the formulation; sinus bradycardia; node
dysfunction; heart block greater than first degree(except in
patients with a functioning artificial pacemaker); cardiogenic
133

3. Cardiovascular Medicines

shock; uncompensated cardiac failure; pulmonary edema;

pregenancy and breast feeding mother.
Drug interaction: digoxin, verapamil, diltiazem, alphablockers(prazosin,
terazosin),
alpha-adrenergic
stimulants(epinephrine,
phenylephrine),
insulin,
oral
hypoglycemic, clondine, beta-blockers,reserpine, aluminum
salts, barbiturates, calcium salts, chlolestyramine, colestipol,
NSAID, penicillins,rifampin,salicylates and sulfinpyrazone.
Dosage and administration: Dosing: AdultHypertension:
Oral: 25-50 mg once daily, may increase to 100 mg/day. Doses
>100 mg are unlikely to produce any further benefit. Pediatric:
Hypertension: Oral: Children: 0.5-1 mg/kg/dose given daily;
range of 0.5-1.5 mg/kg/day; maximum dose: 2 mg/kg/day up to
100 mg/day. Renal Impairment: Clcr 15-35 mL/minute:
Administer 50 mg/day maximum. Clcr<15 mL/minute:
Administer 50 mg every other day maximum.
Side effects: Persistent bradycardia, hypotension, chest pain,
edema, heart failure, dizziness, fatigue, insominia, lethargy,
confusion,headache, nightmares,constipation, diarrhea, nausea,
impotence,cold extremities.
Storage: store between 15 and 300C, in a well-closed container,
unless otherwise specified by manufacturer. Protect from light.
Candesartan
Tablet, 4mg, 8mg, 16mg,32mg
Indications: alone or in combination with other
antihypertensive agents in treating essential hypertension.
Cautions: pre-existing renal insufficiency.
Drug interactions: concurrent use with potassium sparing
diuretics (amiloride, spironolactone, triamterene), trimethoprim,
avoid garlic.
134

3. Cardiovascular Medicines

Contraindications: hypersensitivity to candesartan; bilateral

renal artery stenosis; pregnancy (2nd and 3rd trimesters)
Side effects: worsening of renal function in patients dependent
on
rennin-angiotensin-aldosterone
system.tachycardia,
dizziness, lightheadedness, drowsiness, headache, anxiety,
depression, somnolence, fever, rash, hyperglycemia,
hyperuricemia, dyspepsia, gastroenteritis, hematuria, dyspnea,
pharyngitis, and epistaxis.
Dose and Administration: Dosing: AdultHypertension: Oral:
Dosage must be individualized. Initial: 16 mg once daily; titrate
to response (within 2 weeks, antihypertensive effect usually
observed); usual range: 8-32 mg/day in 1-2 divided doses;
maximum daily dose: 32 mg/day.
PediatricHypertension: Oral: Children 1 to <6 years: Initial:
0.2 mg/kg/day in 1 to 2 divided doses; titrate to response
(within 2 weeks, antihypertensive effect usually observed);
usual range: 0.05 to 0.4 mg/kg/day; maximum daily dose: 0.4
mg/kg/day.
Children 6 to <17 years: <50 kg: Initial: 4 to 8 mg/day in 1to 2
divided doses; titrate to response (within 2 weeks,
antihypertensive effect usually observed); usual range: 2 to16
mg/day; maximum daily dose: 32 mg/day.
>50 kg: Initial: 8-16 mg/day in 1-2 divided doses; titrate to
response (within 2 weeks, antihypertensive effect usually
observed); usual range: 4-32 mg/day; maximum daily dose: 32
mg/day.
Renal Impairment: Children 1 to <17 years: No dosage adjustment
provided in manufacturers labeling. Children with GFR <30
mL/minute/1.73 m2 should not receive candesartan.
Adults: No initial dosage adjustment necessary; however, in
patients
with
severe
renal
impairment
(Clcr<30
135

3. Cardiovascular Medicines

mL/minute/1.73m2) AUC and Cmax were approximately

doubled after repeated dosing.
Hepatic Impairment: Mild impairment: No initial dosage
adjustment necessary.Moderate impairment: Consider initiation
at lower dosages (AUC increased by 145%).Severe impairment:
No dosage adjustment provided in manufacturers labeling.
Candesartan and Hydrochlorothiazide
Tablet, 16mg+ 12.5mg, 32mg+12.5mg
Indications: Treatment of hypertension; combination product
should not be used for initial therapy
Contraindication: with severe hepatic impairment and/or
cholestasis.
Dose and Administration: Dosing: AdultHypertension,
replacement therapy: Oral: Combination product can be
substituted for individual agents; maximum therapeutic effect
would be expected within 4 weeks. Usual dosage range:
Candesartan: 16-32 mg/day, given once daily or twice daily in
divided doses. Hydrochlorothiazide: 12.5 to 25 mg once daily
Geriatric:Refer to adult dosing.Renal Impairment:Serum
levels of candesartan are increased and the half-life of
hydrochlorothiazide is prolonged in patients with renal
impairment. Contraindicated with severe renal impairment
(Clcr<30 mL/minute). Hepatic Impairment:Use with caution
with moderate hepatic impairment.
Captopril
Tablet 12.5 mg, 25 mg, 50 mg, 100 mg
Indications, Cautions, Drug interactions, Contraindications,
Side effect; see section 3.1 and notes above
Dose and Administrations: Note: Titrate dose according to
patient's response; use lowest effective dose.
136

3. Cardiovascular Medicines

Adult: Acute hypertension (urgency/emergency): Oral: 12.5-25

mg, may repeat as needed (may be given sublingually, but no
therapeutic advantage demonstrated). Hypertension: Oral:
Initial dose: 25 mg 2-3 times/day (a lower initial dose of 12.5
mg 3 times/day may also be considered [VA Cooperative Study
Group, 1984]); may increase by 12.5-25 mg/dose at 1 to 2 week
intervals up to 50 mg 3 times/day; add thiazide diuretic, unless
severe renal impairment coexists then consider loop diuretic,
before further dosage increases or consider other treatment
options; maximum dose: 150 mg 3 times/day. Usual dose range
(JNC 7): 25-100 mg/day in 2 divided doses.
Geriatric: Refer to adult dosing. In the management of
hypertension, consider lower initial doses and titrate to
response.
Pediatric: Hypertension: Oral: Infants: Initial: 0.15-0.3
mg/kg/dose; titrate dose upward to maximum of 6 mg/kg/day in
1-4 divided doses. Children: Initial: 0.3-0.5 mg/kg/dose; titrate
upward to maximum of 6 mg/kg/day in 2-4 divided doses.
Older Children: Initial: 6.25-12.5 mg/dose every 12-24 hours;
titrate upward to maximum of 6 mg/kg/day. Adolescents:
Initial: 12.5-25 mg/dose; titrate to a maximum of 450 mg/day
Dosing: Renal ImpairmentManufacturers recommendations:
Reduce initial daily dose and titrate slowly (1 to 2weeks
intervals) with smaller increments. Slowly back titrate to
determine the minimum effective dose once the desired
therapeutic
effect
has
been
reached.Alternative
recommendations: Adults:Clcr 10-50 mL/minute: Administer at
75% of normal dose every 12-18 hours.Clcr<10 mL/minute:
Administer at 50% of normal dose every 24 hours.
Captopril + Hydrochlorthiazide
Tablet, 50 + 25 mg
137

3. Cardiovascular Medicines

See section 3.1.underCaptopril and Hydrochlorthiazide

Carvedilol
Tablet, 3.125 mg, 6.25 mg, 12.5 mg, 25 mg
Indications: hypertension; mild to moderate congestive heart
failure as an adjunct to standard therapy.
Cautions: sinus bradycardia and partial heart block.
Drug interactions: as for other beta-blockers.
Contraindications: as for other beta-blockers, hepatic
impairment.
Side effects: as for other beta-blockers; see atenolol, liver
function abnormalities.
Dose and Administration: Hypertension: Oral: Adult:
Initially 12.5 mg once daily; increased after 2 days to 25 mg
once daily; may be increased at intervals of at least 2 weeks up
to a maximum of 50mg/day in single or divided doses.Elderly:
12.5mg once daily, titrated at intervals of at least 2 weeks upto
25mg/day.
Storage: store at room temperature.
Clonidine Hydrocloride
Injection, 0.15 mg/ml in 1 ml ampoule
Tablet, 0.025 mg, 0.15 mg
Indications: management of mild to moderate hypertension
either used alone or in combination with other
antihypertensives.
Cautions: cardiovascular disease, ischaemic heart disease
including myocardial infarction, renal impairment, occlusive
peripheral vascular disorders such as raynauds disease, or
those with a history of depression; gradual withdrawal is
needed.
138

3. Cardiovascular Medicines

Note: it causes drowsiness and patients should not drive or operate

machinery where loss of attention could be dangerous. IV injection of
clonidine should be given slowly. Patients should be warned of the
risk of missing a dose or stoping the medicine as sudden
discontinuation may cause rebound hypertension.

Drug interactions: Alcohol and other CNS depressants,

tricyclic antidepressants, opiate analgesics, beta-blockers.
Contraindications:
hypersensitivity to clonidine or any
component of the formulation.
Side effects: drowsiness, dry mouth, dizziness, and headache,
constipation, depression, anxiety, fatigue, nausea, anorexia,
parotid pain, sleep disturbances, vivid dreams, impotence, loss
of libido, urinary retention or incontinence, slight orthostatic
hypotension, and itching, or burning sensation in the eye, fluid
retention, and sudden withdrawal of clonidine may produce
rebound hypertension.
Dose and Administration:Hypertension: OralAdult: initial
dose: 0.1 mg twice daily (maximum recommended dose
2.4mg/day); usual dose range 0.1 to 0.8mg/day in 2 divided
doses.
Child: initial dose 5 to 10 mcg/kg/day in divided doses every 8
to 12 hours, increase gradually at 5 to 7 day interval to 25
mcg/kg/day in divided doses every 6 hours, maximum:
0.9mg/day.Acute Hypertension Urgency: OralAdult: initial
dose 0.1-0.2 mg; may be followed by additional doses of 0.1mg
every hour, if necessary, to a maximum total dose of 0.6mg.
Storage: at room temperature in tightly closed container.
Diazoxide
Injection, 15 mg/ml in 20 ml ampoule
Indications: hypertensive crisis, commonly used with a diuretic
such as furosemide.
139

3. Cardiovascular Medicines

Caution: impaired cardiac or cerebral circulation and in

patients with aortic coarctation, arteriovenous shunt, heart
failure; impaired renal function, diabetes mellitus; during
labour, history of gout, uremia.
Drug interactions: hyperglycaemic, hyperuricaemic, other
antihypertensive or vasodilators; phenytoin.
Contraindications: hypersensitivity to diazoxide or to other
thiazides, cerebral bleeding, eclampsia.
Side effects: hypotension, hyperglycaemia, heart failure,
nausea, anorexia, and other gastrointestinal disturbances, mild
hyperuricaemia, extrapyramidal symptoms, eosinophilia,
dizziness, tinnitus and blurred vision; hypersensitivity reaction
such as rashes, leucopenia, & fever.
Dose and Administration: IV: Adult and Child: 1 to 3 mg/kg
up to a maximum of 150mg in a single injection; repeat dose in
5-15 minutes until blood pressure adequately reduced; repeat
administration at intervals of 4 to 24 hours; monitor the blood
pressure closely; do not use longer than 10 days.
Enalaprilat
Injection, 1.25 mg/ml
Indications, Cautions, Drug interactions, Contraindications,
Side effects and Storage; see section 3.1 under Enalaprilat and
notes above.
Dose and Administration: Hypertension: I.V: Adult: (over at
least five minutes), 1.25 mg every six hours.
Enalapril Maleate
Tablet, 2.5mg, 5mg, 10mg, 20mg, 40mg
Indications, Cautions, Drug interactions, Contraindications,
Side effects and Storage; see section 2.1 under Enalapril
maleate and notes above.
140

3. Cardiovascular Medicines

Dose and Administrations: Hypertension: Oral: Adult:

Used alone, initially 5 mg once daily. If used in addition to
diuretic in elderly patients, or in renal impairment, initially 2.5
mg daily, usual maintenance dose 10 mg - 20 mg once daily, in
severe hypertension may be increased to maximum 40 mg once
daily.
Enalapril Maleate and Hydrochlorothiazide
Tablet, 10 mg + 25 mg
Indications: hypertension; symptomatic heart failure (adjunct)
prevention of symptomatic heart failure in patients with
asymptomatic left ventricular dysfunction
Cautions, Drug interactions,dose, Contraindications, see
section under Enalapril Maleate and Hydrochlorothiazide
Fosinopril
Tablet, 10mg, 20mg
Indications:Treatment of hypertension, either alone or in
combination with other antihypertensive agents; treatment of
heart failure (HF)
Cautions, Drug interactions, Contraindications, Side
effects; see under captopril.
Dose and Administration: Dosing: AdultHypertension:
Oral:Initial: 10 mg/day; increase to a maximum dose of 80
mg/day. Most patients are maintained on 20-40 mg/day. May
need to divide the dose into two if trough effect is inadequate.
Discontinue the diuretic, if possible 2-3 days before initiation of
therapy. Resume diuretic therapy carefully, if needed.
Dosing: PediatricHypertension: Children 6 years and >50 kg:
Oral: Initial: 5 to 10 mg once daily (maximum: 40 mg/day).
Renal Impairment: None need since hepatobiliary elimination
141

3. Cardiovascular Medicines

compensates adequately diminished renal elimination. Hepatic

Impairment: Decrease dose and monitor effects
Hydralazine
Injection, 20 mg /ml in 1 ml ampoule
Tablet, 25 mg, 50 mg
Indications: moderate to severe hypertension (low doses used
in combination therapy, especially with beta blockers).
Cautions: pregnancy, breast-feeding, in elderly patients, in
patients with hepatic or renal impairment, with coronary artery
disease.
Drug interactions: other antihypertensive medicines, nitrates,
diazoxide.
Contraindications: coronary artery disease, rheumatic heart
disease (mitral valvular), cerebrovascular disease or accident,
idiopathic systemic lupus erythematosus, severe tachycardia,
high output heart failure, myocardial insufficiency due to
mechanical obstruction.
Side effects: tachycardia, palpitations, nausea, vomiting,
diarrhoea, anorexia, fluid retention, headache, systemic lupus
erythematosus like syndrome, fever, changes in blood count,
peripheral neuritis.
Dose and Administration: Dosing: AdultHypertension: Oral:
Initial: 10 mg 4 times/day; increase by 10-25 mg/dose every 2-5
days (maximum: 300 mg/day); usual dose range (JNC 7): 25100 mg/day in 2 divided doses. Acute hypertension: I.M., I.V.:
Initial: 10-20 mg/dose every 4-6 hours as needed, may increase
to 40 mg/dose; change to oral therapy as soon as possible.
Pre-eclampsia/eclampsia: I.M., I.V.: 5 mg/dose then 5-10 mg
every 20-30 minutes as needed.
Geriatric:Oral: Initial: 10 mg 2-3 times/day; increase by 10-25
mg/day every 2-5 days.
142

3. Cardiovascular Medicines

Pediatric:Hypertension: Oral: Initial: 0.75-1 mg/kg/day in 2-4

divided doses; increase over 3-4 weeks to maximum of 7.5
mg/kg/day in 2-4 divided doses; maximum daily dose: 200
mg/day
Acute hypertension: I.M., I.V.: 0.1-0.2 mg/kg/dose (not to
exceed 20 mg) every 4-6 hours as needed, up to 1.7-3.5
mg/kg/day in 4-6 divided doses
Renal Impairment: Clcr 10 to 50 mL/minute: Administer every 8
hours. Clcr<10 mL/minute: Administer every 8 to16 hours in
fast acetylators and every 12-24 hours in slow acetylators.
Hemodialysis effects: Supplemental dose is not necessary.
Peritoneal dialysis effects: Supplemental dose is not necessary.
Storage: at room temperature. Protect from freezing.
Hydrochlorothiazide
Tablet, 25mg
Indication: management of mild to moderate hypertension;
treatment of edema in congestive heart failure and nephritic
syndrome.
Contraindications: Hypersensitivity to the medicine or any
component of the formulation; thiazides, or sulfonamidederived drugs; anuuria; renal decompensation, pregenancy
Drug-interactions: furosemide, other loop diuretics, ACEinhibitor, beta- blockers, cyclosporine, digoxin,lithium,
neuromuscular
blocking
agents,
cholestyramine,
colestipol,NSAIDs.
Dosage and administration: Oral (effect of medicine may be
decreased when used every day):Children : <6 months: 2-3
mg/kg/day in 2 divided doses and >6 months: 2mg/kg/day in
divided doses.Adult: Edema: 25-100mg/day in 1-2 doses;
maximum: 200mg/day. Hypertension: 12.5-50mgmg/day:
minimal increase in response and more electrolyte disturbances
143

3. Cardiovascular Medicines

are seen with doses> 50mg/day. Elderly: 12.5-25mg once

daily(in pediatric patients, chlorothiazide may be preferred over
hydrochlorothiazide as there are more dosage formulations(eg.
suspensionavailable).
Indapamide
Film coated tablet 1.25mg, 2.5mg
Indications: Management of mild to moderate hypertension
Cautions: Diabetes, gout, and systemic lupus erythematosus,
renal impairment, nephrotic syndrome, hyperaldosteronism, and
malnourishment,mild to moderatehepatic impairment, in
patients with moderate or high cholesterol concentrations; also
acute porphyria.
Drug interactions: Furosemid and other loop diuretics, ACEinhibitors, cyclosporine, thiazide type diuretics, digoxin,
lithium,oral hypoglycemic, cholestyramine,colestipol and
NSAIDs.
Contra-indications: refractory hypokalaemia, hyponatraemia
and hypercalcaemia, symptomatic hyperuricaemia, severe
hepatic impairment, renal impairment if gullomulur filtration
rate (GFR) is less than 30 mL/minute/1.73 m2 ,and Addisons
disease; also hypersensitivity to sulfonamides and thiazides
Pregnancy, Breast-feeding, anuria.
Side-effects;mild gastro-intestinal disturbances, postural
hypotension, altered plasma-lipid concentrations, metabolic and
electrolyte
disturbances
including
hypokalaemia
hyponatraemia,
hypomagnesaemia,
hypercalcaemia,
hyperglycaemia, hypochloraemic alkalosis, hyperuricaemia,
and gout. Less common side-effects include blood disorders
such as agranulocytosis, leucopenia, and thrombocytopenia, and
impotence. Pancreatitis, intrahepatic cholestasis, cardiac
arrhythmias, headache, dizziness, paraesthesia, visual
144

3. Cardiovascular Medicines

disturbances, and hypersensitivity reactions (including

pneumonitis, pulmonary oedema, photosensitivity, and severe
skin reactions) have also been reported. Also palpitation,
diuresis with doses above 2.5 mg daily
Dose and Administration: 1.25mg in the morning may
increase to 5mg/day by increments of 1.25-2.5mg; consider
adding another antihypertensive and decreasing the dose if
response is not adequate.
Note: Administer early in day to avoid nocturia.

Irbesartan
Tablet, 75mg, 150mg, 300mg
Indications: treatment of hypertension alone or in combination
with other antihypertensives.
Cautions: safety and efficacy have not been established for
pediatric patients < 6 years of age.
Drug interactions: potassium salts, co-trimoxazole, ACE
inhibitors, potassium sparing diuretics, amiodarone, fluoxetine,
glipizide, phenytoin, rosiglitazone, warfarin, sertraline.
Contraindications: bilateral renal stenosis, pregnancy (2nd and
3rd trimesters)
Dose and Administration: Dosing: AdultHypertension: Oral:
150 mg once daily; patients may be titrated to 300 mg once
daily. Note: Starting dose in volume-depleted patients should
be 75 mg. Nephropathy in patients with type 2 diabetes and
hypertension: Oral: Target dose: 300 mg once daily.
Geriatric: Refer to adult dosing.
Pediatric:Hypertension: Oral: <6 years: Safety and efficacy
have not been established. 6-12 years: Initial: 75 mg once
daily; may be titrated to a maximum of 150 mg once daily; 1316 years: Refer to adult dosing.
145

3. Cardiovascular Medicines

Renal Impairment:No dosage adjustment necessary with mild

to severe impairment unless the patient is also volume depleted.
Isradipine
Tablet, 2.5 mg
Indications: treatment of hypertension.
Cautions, Drug interactions, Contraindication, Side effects;
see under Nifedipine.
Dose and Administration: Mild to moderate hypertension:
Oral:Adult: 2.5 mg twice daily; may be increased after 4 weeks
up to 5 mg twice daily. Hepatic or renal function impairment,
and the elderly; initially 1.25 mg twice daily.
Labetalol Hydrochloride
Tablets, 50 mg, 100 mg, 200 mg,300mg, 400 mg
Injection, 5mg/ml, 1000mg/20ml
Indications: Treatment of mild-to-severe hypertension; I.V. for
severe hypertension (eg, hypertensive emergencies).
Cautions: as for other beta-blockers, and also, hepatic disease
or treated heart failure.
Drug interactions: alcohol and anaesthetics; agents inhibiting
or inducing liver enzymes, other antihypertensives.
Contraindications: second or third degree atrioventricular
block, symptomatic heart failure, sinus bradycardia, or
cardiogenic shock; asthma, severe bronchospasm, history of
allergy.
Side effects: as for beta blockers; and it has also alpha blocking
activity which contributes to its adverse effects such as
orthostatic hypotension, impaired male sexual fuction to a
greater extent than with beta blockade alone; muscle weakness,
tremor, urinary retention, hepatitis and jaundice.
146

3. Cardiovascular Medicines

Dose and Administration:Adult: Hypertension: Oral: Initial:

100 mg twice daily, may increase as needed every 2-3 days by
100 mg twice daily (titration increments not to exceed 200 mg
twice daily) until desired response is obtained; usual dose: 100400 mg twice daily may require up to 2.4 g/day.
Acute hypertension (hypertensive emergency/urgency): I.V.
bolus: Per the manufacturer: Initial: 20 mg I.V. push over 2
minutes; may administer 40-80 mg at 10-minute intervals, up to
300 mg total cumulative dose; as appropriate, follow with oral
antihypertensive regimen. I.V. infusion (acute loading): Per the
manufacturer: Initial: 2 mg/minute; titrate to response up to 300
mg total cumulative dose (eg, discontinue after 2.5 hours of 2
mg/minute); usual total dose required: 50-200 mg; as
appropriate, follow with oral antihypertensive regimen
Arterial hypertension in acute ischemic strokeI.V. to oral
conversion: Upon discontinuation of I.V. infusion, may initiate
oral dose of 200 mg followed in 6-12 hours with an additional
dose of 200-400 mg. Thereafter, dose patients with 400-2400
mg/day in divided doses depending on blood pressure response.
Pediatric: Note: Due to limited documentation of its use, labetalol should
be initiated cautiously in pediatric patients with careful dosage adjustment
and blood pressure monitoring.
Hypertension: Oral:Hypertension (unlabeled use): Initial: 1to 3

mg/kg/day, in 2 divided doses; maximum: 10 to12 mg/kg/day,

up to 1200 mg/day. I.V.: Intermittent bolus doses of 0.3-1
mg/kg/dose have been reported. Pediatric hypertensive
emergencies: Initial continuous infusions of 0.4-1 mg/kg/hour
with a maximum of 3 mg/kg/hour have been used;
administration requires the use of an infusion pump.
Lisinopril
Tablet 2.5 mg, 5 mg, 10 mg, 20 mg
147

3. Cardiovascular Medicines

Indications, Cautions, Drug interactions, Contraindications,

Side effects and Storage; see section 3.1 and notes above
Dose and Administration:Hypertension, initially 2.5 mg daily
including patients with renal impairment, the elderly or those
who receiving a diuretic; if possible, the diuretic should be
withdrawn 2 or 3 days before Lisinopril is started and resumed
later if required and usual maintenance dose 10 - 20 mg daily,
maximum 40 mg daily.
Lisinopril and Hydrochlorothiazide
Tablet, 10mg + 12.5mg
Indications: treatment of hypertension
Dose and Administration: Adult:Oral: Dosage is
individualized; doses >80mg/day lisinopril or > 50mg/day
hydrochlorothiazide are not recommended.
Losartan
Tablet, 25mg, 50mg, 100mg
Indications: Treatment of hypertension (HTN); treatment of
diabetic nephropathy in patients with type 2 diabetes mellitus
(noninsulin dependent, NIDDM) and a history of hypertension;
stroke risk reduction in patients with HTN and left ventricular
hypertrophy (LVH).
Drug interactions: potassium sparing diuretics or potassium
supplements.
Contraindications: bilateral renal stenosis, pregnancy (2nd and
3rd trimesters)
Side effects: dizziness, headache, skin rash, urticaria, cough,
myalgia, GI effect, angio edema, hyperkalaemia.
Dose and Administration: AdultHypertension: Oral: Usual
starting dose: 50 mg once daily; can be administered once or
twice daily with total daily doses ranging from 25-100 mg.
148

3. Cardiovascular Medicines

Usual initial doses in patients receiving diuretics or those with

intravascular volume depletion: 25 mg once daily. Nephropathy
in patients with type 2 diabetes and hypertension: Oral: Initial:
50 mg once daily; can be increased to 100 mg once daily based
on blood pressure response. Stroke reduction (HTN with LVH):
Oral: 50 mg once daily (maximum daily dose: 100 mg); may be
used in combination with a thiazide diuretic.
Pediatric: Hypertension: Oral: Children 6-16 years: 0.7 mg/kg
once daily (maximum: 50 mg/day); doses >1.4 mg/kg
(maximum: 100 mg) have not been studied.
Renal Impairment: Children: Use is not recommended if GFR
<30
mL/minute/1.73
m2. Adults:
No
adjustment
necessary.Hepatic Impairment: Adults: Reduce the initial
dose to 25 mg/day
Methyldopa
Tablet, 250 mg, 500mg
Indications: hypertension in pregnancy, moderate to severe
hypertension.
Cautions: renal or hepatic impairment, or with a history of
haemolytic anaemia, liver disease, or depression; Parkinsonism.
Drug interactions: alcohol, CNS depression producing
medications, monoamine oxidase inhibitors including
furazolidine, paragyline, procarbazine; cocaine, norepinephrine,
phenylepinephrine, anaesthetics, and lithium, diuretics, other
antihypertensives, antipsychotics.
Contraindications: depression, active liver disease,
phaeochromocytoma, haemolytic anemia.
Side effects: dry mouth, sedation, depression, drowsiness,
diarrhoea, fluid retention, failure of ejaculation, liver damage,
haemolytic anaemia, lupus erythematosus like syndrome,
149

3. Cardiovascular Medicines

parkinsonism, rashes, nasal stuffiness edema (swelling of feet

or lower legs), gynaecomastia.
Dose and Administration: Oral:Adult: 250mg 2-3 times daily
gradually increased at intervals of two or more days to
maximum daily dose 3gm.
Elderly: 120mg twice daily initially, gradually increased,
maximum daily dose 2gm.
Storage: at room temperature.
Metoprolol Tartrate
Injection, 1mg/ml, 5mg/ml
Tablets, 50mg, 100 mg, 200mg(s/r)
Indications, Cautions, Drug interactions, Contraindications,
Side effects and Storage; see section 2.2 under metoprolol.
Dose and Administration: Oral:Adult:initial dose 100mg
daily, increased weekly according to response to 400mg daily.
Maintenance dose 100 to 200mg daily.
Elderly: 25mg daily, usual range 25-300mg/day.
Nicardipine
Injection, 0.1mg/ml
Indications: used alone or in combination with other agents for
treatment of hypertension and chronic stable angina pectoris.
Cautions: hepatic dysfunction, renal dysfunction, pregnancy,
breastfeeding mother, cardiac heart failure, pheochromocytoma,
patient with portal hypertension, avoid systemic hypotension
when administering the drug to patients who have sustained an
acute cerebral infarction or hemorrhage.
Drug interactions: Cimitidine, digoxin, Fentanyl anesthesia,
cyclosporine, azole antifungals, clarithromycin, diclofenac,
doxycycline, erythromycin, isoniazid, nefazodone, propofol,
protease inhibitors, quinidine, telithromycin, verapamil,
150

3. Cardiovascular Medicines

aminoglutethimide, carbamazepine, nevirapine, Phenobarbital,

phenytoin, rifamycins.
Contraindications: It is contraindicated in patients with known
hypersensitivity to the medicine and also in patients with
advanced aortic stenosis, severe hypotension, cardiogenic
shock, ventricular tachycardia.
Side effects: Hypotension, headache, tachycardia, palpitation,
perpherial edema, nausea, vomiting, weakness.
Dose and Administration: Acute Hypertension: Intial:
5mg/hour increased by 2.5my/hour every 15 minutes to a
maximum of 15mg/hour; consider reduction to 3mg/hour after
response is achieved.Monitor and titrate to lowest dose
necessary to maintain stable blood pressure.Substitution for oral
therapy (approximate eqivalents):20mg every 8 hours oral,
equivalent to 0.5mg/hour IV infusion; 30mg every 8 hours oral,
equivalent to 1.2mg/hour IV infusion; 40mg every 8 hours oral,
equivalent to 2.2mg/hour IV infusion.
Storage:Store at room temperature 20 to 25C
Nifedipine
Capsule, 5 mg, 10 mg, 20 mg 30mg (s/r)
Tablet, 10 mg, 20 mg,30mg, 40mg, 60mg, 90mg(m/r)
Indications: used alone or in combination with other agents for
treatment of hypertension and angina pectoris, Raynauds
phenomenon.
Cautions: aortic stenosis or hypertrophic obstructive
cardiomyopathy (may worsen cardiac failure or increase
outflow track obstruction); angina (may worsen symptoms);
nursing mother, renal & hepatic impairment.
Drug interactions: other antihypertensives, beta blockers (use
with special caution), digoxin, medicines that inhibit
cytochrome P450 3A4 (cimetidine, erythromycine, fluoxetine,
151

3. Cardiovascular Medicines

protease inhibitors, ketoconazole, itraconazole, fluconazole),

medicines that induce cytochrome P450 3A4 (carbamzepine,
phenobarbital e.t.c.), rifampicin, tacrolimus, valproic acid.
Contraindications: hypotension, unstable angina or acute
myocardial infarction (increased infarct rate and mortality) in
the absence of current beta blockade; cardiogenic shock. Avoid
sudden withdrawal.
Side effects: peripheral edema (swelling at ankles, feet, or
lower legs), dizziness or light headedness, flushing or feeling
of warmth, headache, nausea, congestive heart failure or
pulmonary edema (breathing difficulty, coughing, or
wheezing), tachycardia, constipation, unusual tiredness or
weakness, palpitation, increased frequency of micturation, eye
pain, gum hyperplasia, depression.
Dose and Administration: Oral:Adult: 10 to 20mg three times
daily up to 180mg/day or 30 to 90mg sustained release once per
day.Child: dosage has not been established
Note:Short acting preparation is not recommended for the management of
hypertension.

Storage: store between 15 and 25oc in a tight, light-resistant

container.
Phenoxybenzamine Hydrochloride
Capsule, 10 mg
Indications: symptomatic management of pheochromocytoma,
treatment of hypertensive crisis caused by sympathomimetic
amines.
Cautions: renal impairment, cerebral or coronary
arteriosclerosis, elderly, heart failure and ischaemic heart
disease, it aggravates the symptoms of respiratory infections.
Drug interactions: beta-blockers, sildenafil, tadalafil, and
adrenaline
152

3. Cardiovascular Medicines

Contraindications: instances when fall in blood pressure

would be dangerous; compensated congestive failure.
Side effects: postural hypotension, tachycardia, shock,
headache, confusion, fatigue, dry mouth, dizziness, miosis,
nasal congestion, inhibition of ejaculation.
Dose and Administration: Oral:Pheochromocytoma:
Adult: initial: 10mg twice daily, increase by 10mg every other
day until optimum dose is achieved; usual range: 20-40mg 2-3
times/day.Child: initial: 0.2mg/kg (maximum: 10mg) once
daily, increase by 0.2mg/kg increments; usual maintenance
dose: 0.4-1.2mg/kg/day every 6-8 hours, higher doses may be
necessary.
Storage: store at room temperature.
Phentolamine mesilate
Injection, 10 mg/ml in 1ml
Indications: Diagnosis of pheochromocytoma and treatment of
hypertension associated with pheochromocytoma or other forms
of hypertension caused by excess sympathomimetic amines;
treatment of dermal necrosis after extravasation of drugs with
alpha-adrenergic effects (ie, dopamine, epinephrine,
norepinephrine, phenylephrine).
Cautions: gastritis or peptic ulcer.
Drug interactions: adrenaline, ethanol, sildenafil, and tadalafil.
Contraindications: as phenoxybenzamine & also angina
pectoris or other evidence of ischemic heart disease.
Side effects: tachycardia, angina pain, arrhythmia, flushing,
sweating, feeling of apprehension, orthostatic hypotension,
dizziness, nausea, vomiting, diarrhea, nasal congestion,
pulmonary
hypertension,
myocardial
infarction
&
cerebovascular spasm or occlusion.
153

3. Cardiovascular Medicines

Dose and Administration: Surgery for pheochromocytoma

hypertension: I.M. I.V.:Adult: Treatment of alpha-adrenergic
agonist drug extravasation: SubQ: Infiltrate area with a small
amount (e.g. 1 ml) of solution (made by diluting 5 to10 mg in
10 ml of NS) within 12 hours of extravasation; in general, do
not exceed 0.1 to 0.2 mg/kg (5 mg total); typically doses of 5
mg are effective; a case using 50 mg for a large extravasation
has been reported.
Diagnosis of pheochromocytoma: I.M., I.V.: 5 mg Surgery for
pheochromocytoma: Hypertension: I.M., I.V.: 5 mg given 1 to
2 hours before procedure and repeated as needed every 2-4
hours Hypertensive crisis: I.V.: 5-20 mg Treatment of
pralidoxime-induced hypertension: I.V.: 5 mg.
Child: 0.05-0.1mg/kg/dose given 1-2 hours before procedure;
repeat as needed every 2-4 hours until hypertension is
controlled; maximum single dose: 5mg.
Storage: store powder for injection at room temperature.
Reconstituted solution is stable for 48 hours at room
temperature and 1 week when refrigerated.
Prazosin Hydrochloride
Tablet, 1 mg, 2 mg, 5 mg
Indications: hypertension, hypertension associated with
pheochromocytoma.
Cautions: elderly patients, during pregnancy and breastfeeding,
angina pectoris, narcolepsy, and in those sensitive to the drug.
First dose may cause collapse due to hypotension (should be
taken on retiring to bed); hepatic or renal function impairment;
advice patients not to do activities requiring alertness.
Drug interactions: nifedipine, other antihypertensive agents or
nitrates, alcohol, beta blockers and calcium channel blockers.
154

3. Cardiovascular Medicines

Contraindications: heart failure caused by mechanical

obstruction, for example aortic or mitral valve stenosis,
pulmonary embolism, and restrictive pericardial disease.
Side effects: dizziness, orthostatic hypotension, edema,
palpitations, dry mouth, urinary incontinence, angina, dyspnea,
and priapism, drowsiness, headache, lack of energy, and
nausea.
Dose and Administration: Oral:Adult: 0.5 mg 23 times
daily, the initial dose on retiring to bed or night (to avoid
collapse) increased to 1 mg 2 3 times daily after 3 7 doses
further increased if necessary to maximum 20 mg daily.Child
(under 7 years of age), initially 0.25 mg 2 3 times a day
adjusted according to response. 7 to 12 years of age, initially
0.5 mg two or three times a day adjusted according to response.
Storage: at room temperature in a well-closed, light resistant
container.
Propranolol
Injection, 1mg/ml in 1ml ampoule
Tablet, 10mg, 40mg
Indications, Cautions, Drug interactions, Contraindications,
Side effects and Storage; see section 2.2 under propranolol.
Dose and Administration: Hypertension: Oral: 80mg twice
daily increased at weekly intervals as required, maintenance
160-320mg daily.I.V. injection: 1.3mg administered at a rate
not to exceed 1mg/minute, repeated after two minutes and again
after four hours if necessary (for Antiarrhythmic).
Ramipril
Capsule, 1.25mg, 2.5mg, 5mg, 10mg
Indications: treatment of hypertension, either alone or in
combination with other antihypertensive agents.
155

3. Cardiovascular Medicines

Contraindications: bilateral renal stenosis, pregnancy (2nd and

3rd trimesters)
Dose and Administration: Oral: Adult: 2.5-5mg once daily,
maximum: 20mg/day.
Reserpine
Tablet, 0.1mg, 0.25mg
Injection, 1mg/ml in 1ml ampoule
Indications: mild to moderate hypertension.
Cautions: debilitated or elderly patients, during breastfeeding,
in those patients with cardiac arrhythmias, myocardial
infarction, severe cardiac damage, renal insufficiency,
gallstones, epilepsy, or allergic conditions such as bronchial
asthma.
Note: Advice patients not to operate machineries or drive vehicles

Drug interactions: diuretic and hypotensive agents, cardiac

glycosides or quinidine, monoamine oxidase inhibitors, CNS
depressants.
Contraindications: mental depression, active peptic ulcer, with
ulcerative colities and in patients receiving electroconvulsive
therapy.
Side effects: nasal congestion, CNS symptoms including
depression, drowsiness, lethargy, nightmares, diarrhoea,
abdominal cramp; nausea, vomiting and anorexia, respiratory
distress, cyanosis, breast enlargement and galactorrhoea,
gynaecomastia, decreased libido, impotence, sodium retention,
oedema, weight gain, miosis, dry mouth, sialorrhoea, dysuria,
rashes, thrombocytopenia purpura..
Dose and Administration: Oral: Adult: initially 0.05 0.125mg once daily; this may be increased gradually to an
accepted maximum of 0.25mg daily. The lowest effective dose
should be used.Child: 0.005 to 0.02mg per kg of body weight a
156

3. Cardiovascular Medicines

day in one or two divided daily doses.Note: Take with meals or

milks.

Storage: at room temperature, in tight, light-resistant

containers.
Sodium Nitroprusside
Powder for injection, 50 mg in ampoule.
Indications:Management of hypertensive crises; acute
decompensated heart failure (HF); used for controlled
hypotension to reduce bleeding during surgery.
Cautions: impaired pulmonary function; hypothyroidism; renal
impairment; ischaemic heart disease; impaired cerebral
circulation; hyponatraemia; raised intracranial pressure; elderly;
hypothermia; monitor blood pressure and blood-cyanide
concentration, also blood thiocyanate concentration if given
for more than 3 days; avoid sudden withdrawal (reduce infusion
over 15 - 30 minutes to avoid rebound effects); pregnancy;
breast feeding.
Drug interactions: other antihypertensives; acetazolamide,
alcohol.
Contraindications: severe hepatic impairment; compensatory
hypertension; severe vitamin B12 deficiency; hereditary optic
atrophy or increased intracranial pressure
Side effects: nausea and vomiting, headache, apprehension,
restlessness, palpitations, dizziness and abdominal pain,
convulsions, confusion and hyperreflexia.
Dose and Administration: Hypertensive crisis: IV infusion:
Adult: Initially 0.3 mcg/kg/minute; usual maintenance dose 0.5
- 6 mcg/kg/minute; maximum dose 8mcg/kg/minutes; stop
infusion if no response after 10 minutes at maximum dose.
Lower doses in patients already being treated with
antihypertensives.
157

3. Cardiovascular Medicines

Storage: store at room temperature.

Tolazoline
Injection, 25mg/ml in 10ml ampoule
Indications: persistent pulmonary vasoconstriction and
hypertension of the newborn (persistent fetal circulation),
peripheral vasospastic disorders.
Caution: mitral stenosis. Note:pretreatment of infants with antacid
may prevent gastrointestinal bleeding

Drug interactions: ischaemic heart disease, hypotension or

after a cerebrovascular accident; peptic ulcer disease.
Side effects: piloerection, headache, flushing, tachycardia,
cardiac arrhythmias, tingling, chilliness, shivering, sweating,
nausea, vomiting, diarrhoea, and epigastric pain, orthosatic
hypotension or marked hypertension with large doses; peptic
ulcer disease, oliguria, haematuria, myocardial infarction,
gastrointestinal haemorrhage, thrombocytopenia and other
blood dyscrasias.
Dose and administration: Adult: peripheral vasospastic
disorder: IM, IV, SC: 10-50mg 4 times/day.
Neonates: Initial: IV: 1-2mg/kg over 10-15minutes via scalp
vein or upper extremity; Maintenance: 1 to 2mg/kg/hour; use
lower maintenance doses in patients with decreased renal
function.
Valsartan
Tablet, 40mg, 80mg, 160mg, 320mg
Indications: treatment of hypertension alone or in combination
with other antihypertensives. Treatment of heart failure.
Contraindications: bilateral renal stenosis, pregnancy (2nd and
3rd trimesters)
158

3. Cardiovascular Medicines

Dose and Administration: Oral: Adult: Initial: 80 mg once

daily; maximum recommended dose: 320mg/day
Heart failure: initial: 40mg twice dsily; titrate dose to 80-160
mg twice daily, maximum daily dose 320mg.Note: Do not use
with ACE inhibitors and beta blockers.
Valsartan +Hydrochlorthiazide
Tablet, 80mg+12.5mg, 160mg+12.5mg, 160mg+25mg,
320mg+12.5mg, 320mg+25mg
Indication: inadequately controlled hypertension with single
therapy of ether valsartan or hydrochlorothiazide; or patients
adequately controlled hypertension with hydrochlorothiazide
experiencing hypokalemia.
Cautions: hepatic problem, driving or other activities need
alertness, surgery, alcohol use, sunlight, diabetic patients
Contraindications: Pregnancy, breast feeding, hypersensitivity
to valsartan, hydrochlorothiazide or other sulfonamide derived
substances, anuria. Risk benefit should be evaluated for the
following cases: Congestive heart failure, atherosclerosis or
hyperlipidemia, diabetes mellitus, gout, hepatic function
impairment, renal function impairment
Drug interactions: barbiturates, opoid analgesics, oral
antdiabetic agents or insulin, NSAIDs, corticosteroids, lithium,
tubocurarine
Side effects: dizziness, fatigue, pharyngitis, headache, viral
infection, abdominal pain, allergic reaction, hypotension,
jaundice, anxiety neutropenia, cough, impotence, libido
photosensitivity
Dose and administration: adult: oral: the usual starting dose
for patients taking usual dose of valsartan as a single therapy
and uncontrolled blood pressure is 80mg/12.5mg valsartan/
hydrochlorothiazide combination therapy and the usual starting
159

3. Cardiovascular Medicines

dose forpatients taking 25 mg hydrochlorothiazide as a single

therapy with uncontrolled blood pressure or patients taking
hydrochlorothiazide experiencing hypokalemia is 80mg/12.5mg
valsartan/ hydrochlorothiazide once daily.Titrate the dose to
160 mg/25 mg valsartan/ hydrochlorothiazide combination once
daily if the blood pressure remains uncontrolled.
Verapamil
Injection, 2.5 mg/ml in 2ml ampoule
Tablets, 40 mg, 80 mg, 120 mg
Cautions, contraindication, side effects: See section 3.2.
Under Verapamil
Dosing: AdultHypertension:Oral: Initial: 80 mg or 160 mg
once daily (in patients who are not volume depleted); dose may
be increased to achieve desired effect; maximum recommended
dose: 320 mg/day
Pediatric: Hypertension: Oral: Children 6-16 years: Initial: 1.3
mg/kg once daily (maximum: 40 mg/day); dose may be
increased to achieve desired effect; doses >2.7 mg/kg
(maximum: 160 mg) have not been studied.
Renal Impairment: Clcr 30 mL/minute: No dosage adjustment
necessary.Clcr<30 mL/minute: No dosage adjustment provided
in manufacturers labeling; safety and efficacy has not been
established.
3.6. Diuretics
Diuretics promote the excretion of water and electrolytes by the
kidneys. They are used in the treatment of heart failure or in
hepatic, renal, or pulmonary disease when salt and water
retention has resulted in oedema or ascites. Diuretics are also
used, either alone, or in association with other agents, in the
treatment of hypertension. Low dose diuretics are
160

3. Cardiovascular Medicines

recommended first-line therapy in uncomplicated cases of

hypertension, especially in black patients and elderly patients
with isolated systolic hypertension. High doses are not
recommended because of biochemical repercussions, including
an adverse lipid profile, hyperuricaemia and impaired glucose
control.
The principal groups of diuretics are Low-ceiling diuretcs,
'Loop' or 'high - ceiling' diuretics, potassium sparing diuretics,
osmotic diuretics, mercurial diuretics and carbonic anhydrase
inhibitors.Low-ceiling
diuretcs:
The
thiazides,
e.g.
hydrochlorothiazide, are used as initial therapy for mild
congestive heart failure and mild to moderate hypertension.
Low doses are well tested in mild hypertension and in systolic
hypertension, and should not exceed 25mg.The low-ceiling
diuretics do not induce a diuresis at low creatinine clearances.
In hypertension, diuretics may be used alone or in combination
with potassium-sparing diuretics or other antihypertensive
agents.They are also used for the management of oedema
associated with nephritic syndrome, liver cirrhosis (usually
preceded by spironolactone) and heart failure, idiopathic
hypercalciuria, nephrogenic diabetes insipidus (where they have
an antidiuretics effect) and to help prevent osteoporosis.
High-ceiling diuretics: loop diurectics, e.g. furosemide, are used
in the initial therapy of severe heart failure. Furosemide is
effective in high doses even if there is severe impairment of
renal function. Furosemide is similar chemically to the thiazide
diurectics. It has prompt onset of diuretic action and acts
primarily by inhibiting chloride and sodium reabsorption over
the entire length of the thick ascending limb of the loop of
henle.The intravenous route is very fast-acting in emergency
situations such as pulmonary oedema. In such circumstances it
161

3. Cardiovascular Medicines

has an acute haemodynamic effect, i.e. venodilation with

reduced venous return.
The oral form may be used for hypertension, either alone or in
combination with other antihypertensive agents, but the
thiazide-type diurects are preferred unless there is renal
impairment or cardiac failure.
Potassium-sparing diuretics: these include the aldosterone
antagonists, e.g. spiranolactone, which should only be used
where specifically indicated.
Others are amiloride and triamterene. Amiloride inhibits
sodium reabsorption in the distal tubule and is a weak diuretic
when administered alone. It also has some antihypertensive
activity. Its potassium and magnesium-sparing properties are
useful if combined with a potassium-depleting diuretic, e.g.
hydrochlorothiazide. It is the drug of chice in Liddles
syndrome and is an altenetive to spironolactone in patients with
primary aldosteronism, who experience adverse effects.
The adverse effects of diuretic therapy are mainly due to the
fluid and electrolyte imbalance induced by the drugs.
Hyponatraemia is an adverse effect of all diuretics. The risk of
hypokalaemia, which may occur with both thiazide and loop
diuretics, depends more on the duration of action than on
potency and is thus greater with thiazides than with loop
diuretics (when given in equipotent doses). Potassium-sparing
diuretics can cause hyperkalaemia.
Other electrolyte
disturbances include hypercalcaemia (thiazides), hypocalcaemia
(loop diuretics) and hypomagnesaemia (thiazide and loop
diuretics).
Symptoms of fluid and electrolyte imbalance include dry
mouth, thirst, gastrointestinal disturbances (including nausea,
vomiting), weakness, lethargy, drowsiness, restlessness
seizures, confusion, headache, muscle pains or cramps,
162

3. Cardiovascular Medicines

hypotension (including postural hypotension), oliguria,

arrhythmias.
The elderly are more susceptible to electrolyte imbalance than
younger patients; treatment should begin with a lower initial
dose of the diuretic (commonly about 50 % of the adult dose)
and then adjusted carefully according to renal function, plasma
electrolytes and diuretic response.
Amiloride
Tablet, 5mg
Indications: counteracts potassium loss induced by other
diuretics in the treatment of hypertension or oedematous
conditions
including
CHF,
hepatic
cirrhosis,
and
hypoaldosteronism.
Cautions: diabetes mellitus, elderly, pregnancy and breastfeeding.
Drug interactions: ACE inhibitors, potssium supplements and
salt substitutes, NSAIDs.
Contraindications: hyperkalaemia, renal failure, and
hypersensitivity; see also Hydrochlorothiazide
Side effects: except for hyperkalaemia serious adverse effects
are uncommon; nausea, anorexia, abdominal pain and
flatulence, headache, weakness and dizziness. Rarely - visual
disturbances, blood dyscrasias, skin rashes, pruritus, bladder
spasm, muscle cramps and jaundice.
Dose and Administration: Edema: Oral: Adult: 5-10mg/day
(up to 20mg). Elderly: initial: 5mg once daily or every other
day.
Storage: store at room temperature
Amiloride and Hydrochlorthiazide
Oral solution, 5mg + 50mg/5ml
163

3. Cardiovascular Medicines

Tablet, 2.5mg + 25mg; 5mg + 50mg

See section 2.5 under Amiloride and hydrochlorthiazide
Furosemide
Elixir, 10 mg/ml
Injection, 10 mg/ml in 2 ml ampoule
Tablet, 40 mg, 80mg
Indications: edema of cardiac, hepatic or renal origin, oliguria
due to renal failure; mild to moderate hypertension, usually in
combinations with other antihypertensive agents and as adjunct
in the treatment of hypertensive crisis and for the treatment of
hypercalcemia.
Cautions: children, elderly patients, pregnancy (not used to
treat hypertension in pregnancy) and breast feeding;
hypotension; correct hypovolaemia before using in oliguria. It
may cause hypokalaemia and hyponatraemia, aggravates
diabetes mellitus and gout, liver failure, renal impairment,
prostatic enlargement, porphyria.
Drug interactions: antigout, potassium-depleting agents,
cephalosporins, NSAIDs, thiazide diuretics.
Contraindications: patients with precomatose states associated
with liver cirrhosis, renal failure with anuria.
Side effects: hyponatraemia, hypokalaemia, hypomagnesaemia,
hypochloraemic alkalosis, increased calcium excretion,
hypotension, less commonly nausea, gastro-intestinal
disturbances, hyperuricemia and gout, hyperglycemia,
temporary increase in plasma cholesterol and triglyceride
concentrations, photosensitivity and bone marrow depression,
pancreatitis, tinnitus and deafness, orthostatic hypotension as a
result of massive diuresis (dizziness or light-headedness when
getting up from sitting position).
164

3. Cardiovascular Medicines

Dose and Administration:Edema: Oral:Adult: initially 40 mg

daily on rising, maintenance, 20 mg daily or 40 mg on
alternate days, may be increased to 80 mg daily in resistant
oedema;
Child: 1 to 3 mg/Kg body weight daily (maximum 40 mg
daily).Acute Pulmonary edema: Slow IV injection:
Adult: 20 to 50 mg, if necessary increase by 20 mg steps every
2 hours; if effective single dose is more than 50 mg, consider
using slow intravenous infusion at a rate not exceeding 4
mg/minute.
Child: 0.5 to1.5 mg/kg body weight daily (maximum 20 mg
daily).Oliguria (glomerular filtration rate less than 20
ml/minute): Slow IV infusion of a rate not exceeding
4mg/minute:Adult: initially 250 mg over 1 hour; if urine output
not satisfactory during hour after first dose, infuse 500 mg over
2 hours then, if no satisfactory response during hour after
second dose, infuse 1 g over 4 hours; if no response after third
dose, dialysis probably necessary.Hypertension:Oral: initially
40mg two times a day; the dosage being adjusted according to
patients need. IV: hypertensive crisis in patients with normal
renal function, IV 40 to 80mg. Hypertensive crisis accompanied
by pulmonary edema or acute renal failure IV 100-200
mg.Antihypercalcemic:Oral: 120mg a day a single dose or
divided into two or three doses; IM or IV: Adult: 80-100mg in
severe cases, the dosage being repeated if necessary every one
to two hours until the desired response is obtained. In less
severe cases smaller doses may be given every two or four
hours. Child: IM or IV: 25 to 50mg, the dosage being repeated
if necessary every four hours until the desired response is
obtained.
Storage: Store at room temperature in a well closed container,
protect from freezing and light.
165

3. Cardiovascular Medicines

Hydrochlorothiazide
Tablet, 25 mg
Indications: oedema, hypertension and cardiac failure.
Cautions: paediatrics, elderly patients, during pregnancy and
breast-feeding, heart failure, aggravates diabetes and gout, and
may exacerbate systemic lupus erythematosus, dyslipidaemia.
Drug interactions: lithium, antidiabetic agents, hypotensive
agents, NSAIDs, drugs causing potassium depletion, digoxin,
cholestyramine.
Contraindications: refractory hypokalaemia, hyponatraemia,
hypercalcemia, severe renal and hepatic impairment, and
symptomatic hyperuricemia, Addisons disease, anuria.
Side effects: postural hypotension and mild gastrointestinal
effects,
impotence
(reversible),
hypokalaemia,
hypomagnesaemia,
hyponatraemia,
hypercalcemia,
hypochloraemic alkalosis, hyperuricemia, gout, hyperglycemia,
and increased in plasma cholesterol concentrations, less
commonly rashes, photosensitivity, blood disorders (including
neutropenia and thrombocytopenia), pancreatitis, intrahepatic
cholestasis, hypersensitivity reaction.
Dose and Administration:Hypertension: Oral:Adult: 12.5, 25
mg daily; elderly initially 12.5 mg daily.
Edema: Oral:Adult: initially 25 mg daily on rising increasing to
50 mg daily if necessary, elderly initially 12.5 mg daily.Severe
Oedema in patients unable to tolerate loop diuretics: Oral:
Adult: up to 100 mg either daily or on alternate days
(maximum 100 mg daily).
Nephrogenic diabetes insipidus: Oral: Adult: initially up to 100
mg daily.
Mannitol
Injection,25 % in 50 ml, 20 % in 250 ml, 10 % in 500 ml
166

3. Cardiovascular Medicines

Indications: oliguria due to acute renal failure; reduction of

intracranial pressure - cerebral oedema; reduction of intraocular
pressure - for angle closure glaucoma.
Cautions:
extravasation
causes
inflammation
and
thrombophlebitis.
Drug interactions: digitalis glycosides, lithium.
Contraindications: cardiac failure, pulmonary oedema, well
established anuria caused by severe renal disease or impaired
renal functions who do not respond to a test dose, severe
dehydration, metabolic edema, intracranial bleeding.
Side effects: chest pain or fast heartbeat, chills or fever, head
ache, convulsions, difficulty in urination, electrolyte imbalance
(confusion, irregular heartbeat, muscle cramps or pain,
numbness, tingling, pain or weakness in hands or feet),
pulmonary congestion, thrombophlebitis (redness or swelling or
pain at injection site).
Dose and Administrations:Test dose (to assess adequate renal
function), by intravenous infusion, as a 20 % solution, 200
mg/kg body weight infused over 3-5 minutes, repeat test dose if
urine output less than 30 - 50 ml/hour; if response inadequate
after second test dose, re-evaluate patient.Raised intracranial or
intraocular pressure: I.V infusion: as a 20 % solution infused
over 30 - 60 minutes, 0.25 - 2g/kg body weight.Cerebral
Oedema: I.V infusion: as a 20 % solution infused rapidly,
1g/kg body weight.
Storage: at room temperature protect from freezing.
Metolazone
Tablet, 2.5 mg, 5 mg, 10 mg
Indications: management of mild to moderate hypertension;
treatment of edema in congestive heart failure and nephritic
syndrome, impaired renal function.
167

3. Cardiovascular Medicines

Cautions: as for Hydrochlorothiazide.

Drug
interactions:
furosemide,
see
also
under
hydrochlorothiazide.
Contraindications: as for hydrochlorothiazide.
Side effects:as for hydrochlorothiazide, and also palpitation,
chest pain, and chills.
Dose and Administration: Oral: Adult: Edema: 5-20mg/dose
every 24 hours.Hypertension: 2.5-5mg/dose every 24 hours.
Storage: store at room temperature.
Spironolactone
Tablet, 25 mg, 100 mg
Syrup, 5mg 10mg, 25mg, 50mg,100mg/5ml
Indications: oedema and ascites in cirrhosis of the liver,
malignant ascites, nephritic syndrome, congestive heart failure;
primary hyperaldosteronism.
Cautions: renal and hepatic function impairment, diabetes
mellitus, pregnancy, breast feeding, elderly, monitor
electrolytes (discontinue if hyperkalaemia)
Drug interactions: Angiotensin - converting enzyme (ACE)
inhibitors, cyclosporin, diuretics, potassium containing
medications, potassium supplements or substances containing
high levels of potassium, lithium, digoxin, NSAIDs, warfarin.
Contraindications: hyperkalaemia, hyponatraemia, pregnancy
and
breast-feeding,
Addisons
disease.
Side effects: gastro-intestinal disturbances; impotence,
gynaecomastia, menstrual irregularities; lethargy, headache,
confusion; rashes, hyperkalaemia (discontinue), hyponatraemia,
hepatotoxicity, osteomalacia, and blood disorders reported.
Dose and Administration: Oral:Oedema: Adult: 100 - 200 mg
daily, increased if necessary to 400 mg daily in resistant
oedema, usual maintenance dose 75 - 200 mg daily. Child:
168

3. Cardiovascular Medicines

initially 3 mg/kg body weight daily in divided doses.Primarily

hyperaldosteronism: Adult: diagnosis, 400 mg daily for 3 - 4
weeks; preoperative management, 100 - 400 mg daily; if not
suitable for surgery, lowest effective dose for long term
maintenance.Adjunct in severe heart failure: Adult: usually 25
mg daily.Note: Take with meals or milk.
Storage: at room temperature in a tight, light - resistant
container
3.7. Sclerosing Agents
Sclerosants are used in the managment of varicosities including
varicose veins and oesophageal varices when their capacity to
damage veins is apparently put to good use. The mechanisms
by which injection sclerotherapy works are not completely
understood but are thought to involve damage to the intima,
intraluminal thrombosis, and intravascular fibrous organisation.
Sclerosants used include: ethanolamine oleate, sodium
tetradecyl sulphate and sodium morrhuate.
Ethanolamine Oleate
Injection, 5 % in 2 ml ampoule
Indications: treatment of varicose veins and oesophageal
varices.
Cautions: fatal anaphylactic shock has been reported following
administration; use with caution and decrease dose in patients
with significant liver dysfunction, with concomitant
cardiorespiratory disease, or in the elderly or critically ill.
Contraindications: varicose veins of the legs in patients with
thrombosis or a tendency to thrombosis; acute phlebitis, marked
arterial, cardiac, or renal disease; local or systemic infections;
or uncontrolled metabolic disorders such as diabetes
mellitus.Known hypersensitivity to the agent or oleic acid.
169

3. Cardiovascular Medicines

Side effects: irritant to skin and mucus membranes; local

injection may cause sloughing, ulceration, and in severe cases,
necrosis and pain may occur at the site of injection. Patients
receiving treatment for oesophageal varices may develop
pleural effusion or infiltration. Hypersensitivity reactions have
been reported.
Dose and Administration: IV: Adult: Varicose veins: 2 to 5
ml of a 5 % solution of ethanolamine oleate is injected into
empty isolated sections of veins, divided between 3 or 4 sites.
Injection into full veins is also possible.Oesophageal varices:
1.5 to 5 ml of a 5 % solution per varix to a maximum total dose
of 20 ml per treatment session.
Storage: protect from light.
SodiumMorrhuate
Injection, 5% in 5ml ampoule
Indications: treatment of small, uncomplicated varicose veins
of the lower extremities.
Cautions: should only be administered when adequate
facilities,
drugs
(e.g.
epinephrine,
antihistamines,
corticosteroids), and personnel are available for the treatment of
anaphylactic reactions.
Contraindications: hypersensitivity reactions to the medicine
or to the fatty acids of cod liver oil. thrombophlebitis; arterial
disease, varicosites caused by abdominal and pelvic tumors,
uncontrolled diabetes mellitus, thyrotoxicosis, tuberculosis,
neoplasms, asthma, sepsis, blood dyscrasias, acute respiratory
or skin diseases; and in bedridden patients.
Side effects: thrombosis, valvular incompetency, vascular
collapse, drowsiness, headache, dizziness, urticaria, nausea,
vomiting, burning at the site of injection, severe extravasation
effects, asthma, anaphylaxis, weakness.
170

3. Cardiovascular Medicines

Dose and Administration:IV: Adult: Small veins: 50-100mg

(1-2ml or 5% injection). Large veins: 150-200 mg (3-5ml or 5%
injection).
Storage: store at room temperature and protect from light.
Sodium Tetradecyl Sulphate
Injection, 1%, 3 %
Indications: varicose veins, management of bleeding
oesophageal varices.
Cautions, Contraindications and Side effects; as for
ethanolamine oleate.
Dose and Administration: IV: Test dose: 0.5ml given several
hours prior to administration of larger dose; 0.5-2ml (preferred
maximum: 1ml) in each vein, maximum: 10ml per treatment
session; 3% solution reserved for large varices.
Storage: store at a temperature not exceeding 25oC. Protect
from light.
3.8. Medicines used in vascular shock
Shock is a complex clinical syndrome of multiple aetiologies
but the common factor in all types of shock is a failure of the
circulatory system to maintain celluar perfusion and
function.Cardiac shock usually results from acute failure of the
heart, leading to an inadequate stroke volume and reduced
cardiac output. It has a number of causes, but is most
commonly associated with acute myocardial infarction.
Successful correction of hypovolaemia may alleviate
hypotension in some cases, but cardiac out put may remain
depressed and signs of impaired organ perfusion may persist,
necessitating additional therapy.

171

3. Cardiovascular Medicines

In cardiogenic shock cardiac output is usually low but

peripheral resistance is high and drugs that have predominantly
inotropic effects are most suitable.
Dopamine or dobutamine are often chosen. Dopamine has
been widely used in all forms of shock, often in combination
with other inotropes. At low doses it causes peripheral
vasodilation, which was thought to protect renal perfusion;
however, any clinical benefit is unclear and at higher doses it
causes vasoconstriction and is useful where hypotension is not
significant. Noradrenaline causes peripheral vasoconstriction
and should be reserved for severe hypotension. It is particularly
useful in septic shock where the cardiac output is usually high
but peripheral resistance is low. Adrenaline has also been used
alone but renal artery vasoconstriction may limit its use, and it
has also been reported to cause lactic acidosis.In cardiogenic
shock associated with myocardial infarction, specific therapy to
restore myocardial perfusion is also indicated.
Adrenaline (Epinephrine)
Injection, 0.1 %, 1:1000 1mg/ml
Indications:
Anaphylactic
shock,
cardiac
arrest;
bronchospasms; open angle (chronic simple) glaucoma; added
to local anaesthatics.
Cautions: hyperthyroidism, hypertension, diabetes mellitus,
ischaemic heart disease, arrhythmias, cerebrovascular disease,
and elderly, cerebral arteriosclerosis, pankinsons , rapid IV
infusion amy cause death from cerebrovascular hemorrhage or
cardiac arrhythmias.
Drug interactions: other sympathomimmetic agents (additive
effects), alpha-adrenergic blocking agents, anaesthetics

172

3. Cardiovascular Medicines

(volatile), beta blockers, digoxin, theophylline, tricycluc

antidepressants, monoamine oxidaze inhibitors.
Contraindications:
asymmetric
septal
hypertrophy,
pheochromacytoma, tachyarrhytmias.
Side effects: tachycardia and arrhythmia, hypertension,
hypotension, tremor, anxiety, sweating, nausea, vomiting,
weakness, dizziness, pulmonary oedema, headache, peripheral
vasoconstriction.
Dose and Administration:The 1:1000 (1mg/ml) concentration
of epinephrine injection must be diluted before administering
intravenously.Adult: vasopressor-intravenous infusion, 1mcg
per minute. The dose may be titrated up to 2 to 10microgram
per minutes for desired hemodynamic response.
Storage: at room temperature. Protect from light and freezing.
Dobutamine
Powder for injection, 250 mg
Indications: inotropic support in cardiogenic shock, acute
myocardial infarction, post-cardiac surgery and septic shock
after adequate volume replacement; management of refractory
cardiac failure.
Cautions: pregnancy, severe hypotension, hypovolaemia
should be corrected before treatment.
Drug interactions: beta-blocking agents; anaesthetic agents
(eg, halothane); MAO inhibitors.
Contraindications: idiopathic hypertrophic cardiomyopathy
with outflow obstruction.
Side effects: palpitations, ectopic heartbeats and, rarely,
ventricular tachycardia, angina, increase in systolic blood
pressure (10 - 20 mmHg, in most patient, but may be more
dramatic, particularly in the presence of preexising
173

3. Cardiovascular Medicines

hypertension), nausea, vomiting, headache, paraesthesia and

dyspnoea may occur.
Dose and Administation: Adult:IV infusion: initially, 2.5-10
mcg/kg/minute, increasing gradually in increments of 2.5
mcg/kg/minute up to 15 mcg/kg /minute. Usually not > 20
mcg/kg/ minute are needed. May be infused for up to 72 hours,
provide the patient is carefully monitored; thereafter
intermittently.
Storage: store at room temperature.
Dopamine Hydrochloride
Injection, 40 mg/ml
Indications: cardiogenic shock in infarction or cardiac surgery,
renal failure or septicaemia after adequate volume replacement;
short-term management of refractory cardiac failure and
treatment of acute hypotension.
Cautions: hypovolaemia; low dose in shock due to acute
myocardial infarction, hypoxia, hypercapnia, and metabolic
acidosis before or at some time as starting treatment, history of
peripheral vascular disease, elderly.
Note: hypovolaemia should be corrected before dopamine is used in
shocked patients.

Drug interactions: halogenated anaesthetics (such as

cyclopropane, halothane); monoamine oxidase inhibitors,
betablockers, digoxin, ergotamine/ergotamine, tricyclic
antidepressants.
Contraindications: tachyarrhythmias, ventricular fibrillation,
ischaemic heart disease, Pheochromocytoma; hyperthyroidism.
Side effects: nausea and vomiting, peripheral vasoconstriction,
hypotension with dizziness, fainting, flushing, tachycardia,
ectopic beats, palpitations, anginal pain; headache dyspnoea,
hypertension.
174

3. Cardiovascular Medicines

Dose and Administration: Cardiogenic shock: I.V infusion

into large vein: Adult: initially 2 - 5 micrograms/Kg/minutes;
gradually increased by 5 - 10 micrograms/Kg/minutes
according to blood pressure, cardiac output and urine output;
seriously ill patients up to 20 - 50 micrograms/Kg
minutes.Child: IV same as for adults.
Storage: at room temperature protect from freezing.
Isoprenaline (Isoproproterenol) hydrochloride
Injection, 0.02 mg/ml, 0.2mg/ml
Indications: severe bradycardia, unresponsive to atropine;
short-term emergency treatment of heart block; ventricular
arrhythmias secondary to atrioventricular nodal block.
Cautions, Drug interactions, Contraindications and Side
effects; as for adrenaline above.
Dose and Administration:Adult: Emergency treatment: Slow
IV bolus: 0.01 to 0.06 mg (10 - 60 mcg), with subsequent doses
ranging from 0.01 to 0.2 mg.IV infusion: initially 1
mcg/minute, adjusted according to response.Child: IM or SC:
0.2 mg as a single dose. IV: 0.02 mg as a single dose. IV
infusion: 0.2 mg (1ml) in 200 ml 5 % dextrose water; rate
depends on size of patient and situation.
Storage: store in tight, light-resistant containers.
Levarterenol (Noradrenaline) Tartarate
Tartrate Injection, 8mg/ml in 1ml ampoule
Injection, 1:1000
Indications: treatment of shock which persists after adequate
fluid volume replacement.
Cautions: never use leg veins for infusion sites, monitor blood
pressure closely and adjust infusion rate, hypoxia or
hypercapnia.
175

3. Cardiovascular Medicines

Drug interactions: tricyclic antidepressants, MAO inhibitors,

antihistamines, beta-blockers (nonselective), ergot alkaloids,
reserpine, and methyldopa, alpha-blockers.
Contraindications: hypersensitivity to the drug, pregnancy,
during anesthesia with cyclopropane or halothane anesthesia
(risk of ventricular arrhythmias)
Side effects: bradycardia, arrhythmia, peripheral ischemia,
headache, anxiety, and dyspnea, skin necrosis, respiratory
difficulty.
Dose and Administration:Vasopressor: Adult: initial, I.V
infusion, 0.5 to 1mcg (base) per minute; the dosage being
adjusted gradually to achieve desired blood pressure.
Maintenance: Intravenous infusion, 2 to 12 mcg (base) per
minute.Child: IV, 0.1mcg (base) per kg of body weight per
minute; the dosage being adjusted gradually to achieve desired
blood pressure, up to 1mcg per kg of body weight per minute.
Note: Noradrenaline is administered only by intravenous infusion.
Subcutaneous or intramuscular administration is not recommended
because of the potent vasoconstrictor effect of norepinephrine.

Storage: store at room temperature.

Phenylephrine Hydrochloride
Injection, 10 mg/ml in 1 ml ampoule
Indications: treatment of vascular failure, unresponsive to
adequate fluid volume replacement, in shock, shock like states,
drug induced hypotension, or hypersensitivity.
Cautions: late pregnancy and during labour, diabetes mellitus,
cerebral arterioscerosis, bradycardia, elderly patients.
Drug interactions: alpha adrenergic blocking agents such as
labetalol; phenoxy benzamine; phentolamine; prazosin,
anaesthetics, tricyclic antidepressant, ergotamine, B-blockers,
MAO inhibitors
176

3. Cardiovascular Medicines

Contraindications:
hypertension,
hyperthyroidism
or
myocardial disease or tachycardia.
Side effects: chest discomfort, pain, dizziness, nervousness,
restlessness, trembling, troubled breathing, unusual paleness,
and unusual weakness.
Dose and Administration:Adult: IM, SC: 2-5 mg/dose every
1-2 hours as needed (initial dose should not exceed 5 mg). IV.
bolus: 0.1-0.5 mg/dose every 10 -15 minutes as needed (initial
dose should not exceed 0.5 mg).Child: IM, SC: 0.1mg/kg/dose
every 1-2 hours as needed (maximum: 5 mg). IV. bolus: 5-20
mcg/kg/dose every 10-15 minutes as needed. IV. infusion: 0.10.5 mcg/kg/minute.
Storage: at room temperature and protect from light and
freezing.
3.9. Thrombolytic agent
Antithrombic enzymes convert plasminogen to plasmin, which
inturn degrades fibrin thrombi and fibrinogen. The most
generally accepted indication for the use of antithrombic
enzymes is in the treatment of selected cases of acute
myocardial infarction. Other indications include acute severe
pulmonary thromboembolism; acute arterial thrombosis and
thromboembolism; severe deep-vein thrombosis; and clearance
of ateriovenous catheters and cannulae. Thrombolytic agents
should not be used to treat superficial thrombophlebitis.
Alteplase
Powder for injection, 50mg, 100mg /vial
Indications: management of acute occulisve myocardial
infarction for the lysis of thrombi in coronary arteries;
management of acute massive pulmonary embolism (PE) in
adults.
177

3. Cardiovascular Medicines

Cautions: refractory hypertension, traumatic resuscitation, noncompressible vascular punctures, transient ischaemic attack
(TIA) in preceding 6 months, warfarin therapy, recent retinal
laser treatment.
Drug interactions: aminocaproic acid, oral anticoagulants,
heparin, non steroidal ant inflammatory medicines,
nitroglycerin.
Contraindications: cerebrovascular accident, or history of
recent major trauma, surgery or head injury (within the
preceding month); gastrointestinal bleeding within the last
month; dissecting aneurysm, intracranial aneurysm, active
bleeding or known bleeding disorder.
Side effects: hypotension, fever, bruising, GI hemorrhage,
nausea, vomiting, GU hemorrhage, bleeding.
Dose and Administration: Acute myocardial infarction: IV:
Adult: 15mg bolus, then 0.75mg/kg over 30 minutes, followed
by 0.5mg/kg over 60 minutes. Total dose should not exceed
100mg.
Storage: store at room temperature or under refrigeration; once
reconstituted it must be used within 8 hours.
Fondaparinux
Injection, 2.5mg/0.5ml, 7.5mg/0.6ml injection
Indications:prophylaxis of venous thromboembolism in
medical patients immobilised because of acute illness, and
patients undergoing major orthopaedic surgery of the hip or leg,
or abdominal surgery; treatment of deep-vein thrombosis,
superficial-vein thrombosis, and pulmonary embolism;
treatment of unstable angina or non-ST-segment elevation
myocardial infarction; treatment of ST-segment elevation
myocardial infarction.

178

3. Cardiovascular Medicines

Cautions:bleeding disorders, active gastro-intestinal ulcer

disease; recent intracranial haemorrhage; brain, spinal, or
ophthalmic surgery; spinal or epidural anaesthesia (risk of spinal
haematomaavoid if using treatment doses); risk of catheter
thrombus during percutaneous coronary intervention; low bodyweight; elderly patients; concomitant use of drugs that increase
risk of bleeding,Hepatic impairment,Renal impairment; for
treatment of venous thromboembolism use if eGFR 3050
ml/minute/1.73 m2.
Contra-indications:active bleeding; bacterial endocarditis,
Renal impairment: treatment of acute coronary syndromes avoid
if eGFR less than 20 ml/minute/1.73 m2; for treatment of venous
thromboembolism avoid if eGFR less than 30 ml/minute/1.73
m2, for prophylaxis of venous thromboembolism and treatment
of superficial-vein thrombosis reduce dose to 1.5 mg daily if
eGFR 2050 mL/minute/1.73 m2, avoid if eGFR less than 20
mL/minute/1.73 m2;Pregnancy, Breast-feeding
Side-effects:bleeding, purpura, anaemia; less commonly gastrointestinal disturbances, oedema, hepatic impairment, chest pain,
dyspnoea, thrombocytopenia, thrombocythaemia, rash, pruritus;
rarely hypotension, flushing, cough, vertigo, dizziness, anxiety,
drowsiness,
confusion,
headache,
hypokalaemia,
hyperbilirubinaemia, injection-site reactions; also reported atrial
fibrillation, tachycardia, and pyrexia.
Dosage and Administration:Prophylaxis of venous
thromboembolism after surgery, by subcutaneous injection,
2.5 mg 6 hours after surgery then 2.5 mg once daily.Prophylaxis
of venous thromboembolism in medical patients, by
subcutaneous injection, 2.5 mg once daily.Treatment of
superficial-vein thrombosis, by subcutaneous injection, adult
body-weight over 50 kg, 2.5 mg once daily for at least 30 days
(maximum 45 days if high risk of thromboembolic
179

3. Cardiovascular Medicines

complications); treatment should be stopped 24 hours before

surgery and restarted at least 6 hours post operatively.
Unstable angina and non-ST-segment elevation myocardial
infarction, by subcutaneous injection, 2.5 mg once daily for up
to 8 days (or until hospital discharge if sooner); treatment
should be stopped 24 hours before coronary artery bypass graft
surgery (where possible) and restarted 48 hours post
operatively.
ST-segment elevation myocardial infarction, initially by
intravenous injection or infusion, 2.5 mg for first day, thereafter
by subcutaneous injection 2.5 mg once daily for up to 8 days (or
until hospital discharge if sooner); treatment should be stopped
24 hours before coronary artery bypass graft surgery (where
possible) and restarted 48 hours post operatively.
Treatment of deep-vein thrombosis and of pulmonary embolism,
by subcutaneous injection, adult body-weight under 50 kg, 5 mg
every 24 hours; body-weight 50100 kg, 7.5 mg every 24 hours;
body-weight over 100 kg, 10 mg every 24 hours.
Note: Child under 17 years not recommended.An oral anticoagulant
(usually warfarin,) is started at the same time as fondaparinux
(fondaparinux should be continued for at least 5 days and until INR
2 for at least 24 hours

Reteplase
Powder for injection, 10.4u
Indications: management of acute myocardial infarction
(AMI); improvement of ventricular function; reduction of the
incidence of CHF and the reduction of mortality following AMI.
Caution, Drug interactions and Contraindications; see under
alteplase.
180

3. Cardiovascular Medicines

Side effects: bleeding, anemia.

Dose and Administration: Adult: 10 units IV over 2 minutes,
followed by a second dose 30 minutes later of 10 units IV over
2 minutes.
Storage: store at 2-250C.
Rivaroxaban
Tablet, 10mg, 15mg and 20mg
Indication:prophylaxis of venous thromboembolism in adults
after hip or knee replacement surgery; Rivaroxaban does not
require therapeutic monitoring.
Cautions: bleeding disorders; concomitant use of drugs that
increase risk of bleeding; severe hypertension; active or recent
gastro-intestinal ulceration; vascular retinopathy; anaesthesia
with postoperative indwelling epidural catheter (risk of
paralysismonitor neurological signs and wait at least 18 hours
after rivaroxaban dose before removing catheter and do not give
next dose until at least 6 hours after catheter removal); recent
surgery; Hepatic impairment; Renal impairment.
Drug interaction: tazanavir, Darunavir, Fosamprenavir,
Indinavir, Itraconazole, Ketoconazole, Lopinavir, Nelfinavir,
Posaconazole, Rifampicin, Ritonavir, Saquinavir, Tipranavir,
Voriconazole, Diclofenac, Ketorolac. Renal impairment use
with caution if eGFR 1529 mL/minute/1.73 m2 or if eGFR 30
49 mL/minute/1.73 m.
Contraindications:active bleeding; Renal impairment avoid if
eGFR less than 15 mL/minute/1.73 m2, Pregnancy, Breastfeeding
Side-effects: nausea; haemorrhage; less commonly constipation,
diarrhoea, dyspepsia, dry mouth, vomiting, hypotension,
oedema, tachycardia, thrombocythaemia, syncope, dizziness,

181

3. Cardiovascular Medicines

headache, renal impairment, pain in extremities, pruritus, and

rash; jaundice also reported
Dose
and
Administration:Prophylaxis
of
venous
thromboembolism following knee replacement surgery, adult
over 18 years, 10 mg once daily for 2 weeks starting 610 hours
after surgery.Prophylaxis of venous thromboembolism
following hip replacement surgery, adult over 18 years, 10 mg
once daily for 5 weeks starting 610 hours after surgery
Tenecteplase
Powder for injection, 50mg
Indications: management of acute myocardial infarction (AMI)
Caution and Contraindications see under alteplase.
Side effects: hematoma, bleeding, stroke, GI hemorrhage,
epistaxis, GU bleeding.
Dose and Administration: Adult: Acute myocardial infarction:
IV bolus over 10 seconds, 30-50 mg according to body weight;
maximum 50mg.
Storage: store at room temperature or under refrigeration 2-80C.
If reconstituted and not used immediately, store in refrigerator
and use within 8 hours.
3.9. Diagnostic Agents
Iohexol
Injection, 140mg/ml, 180mg/ml, 200mg/ml, 240mg/ml,
300mg/ml,3500mg
Indications: for intrathecal administration in adults including
myelography (lumbar, thoracic, cervical, total columnar) and in
contrast enhancement for computerized tomography
(myelography, cisternography, ventriculography).
Contraindications:known
hypersensitivity
to
iohexol.
Myelography should not be performed in the presence of
182

3. Cardiovascular Medicines

significant local or systemic infection where bacteremia is

likely. Intrathecal administration of corticosteroids with iohexol
is contraindicated. Because of the possibility of overdosage,
immediate repeat myelography in the event of technical failure
is contraindicated

183

4. Respiratory Medicines

4. RESPIRATORY MEDICINES
4.1. Antitussives/Expectorants/Mucolytics
Cough is an important physiological protective mechanism,
but may also occur as a symptom of an underlying disorder such
as asthma, gastro-oesophageal reflux disease, and postnasal
drip. Treatment of the disorder often alleviates the cough, but
there are times when symptomatic treatment is appropriate. The
treatment chosen depends on whether the cough is productive or
non-productive.
A non-productive cough such as that often seen with the
common cold serves no useful purpose for the patient, and
cough suppressants may provide some relief, particularly if
given at night. Of the commonly used cough suppressants,
pholcodine and dextromethorphan are considered to have fewer
adverse effects than codeine. However, there is little evidence
that these drugs are effective in severe cough. Codeine or
similar opioids are not generally recommended as cough
suppressants in children, and should be avoided altogether in
those under 1 year of age.
A productive cough is characterized by the presence of
sputum and may be associated with conditions such as chronic
bronchitis, bronchiectasis, or cystic fibrosis. Cough suppressants
are inappropriate, since the cough serves the purpose of clearing
the airways; expectorants such as guaifenesin have been used on
the grounds that increasing the volume of secretions in the
respiratory tract facilitates removal by ciliary action and
coughing. Mucolytics such as carbocisteine have been shown to
affect sputum viscosity and structure and patients with
productive cough have reported alleviation of their symptoms,
but no consistent improvement has been demonstrated in lung
function.
184

4. Respiratory Medicines

Acetaminophen+Pseudoephedrine
Hydrochloride+Chlorpheniramine
Tablet, 325mg +15mg +1mg
Indications: Temporary reliefs of running nose, sneezing,
minor aches and pains headache, fever and nasal congestion
associated with the common cold
Caution: avoid concomitant use of other paracetamol
containing medicines, should be given with caution for patients
with impaired kidney function or liver function and to patients
with alcohol dependence, Pseudoephedrine is distributed in to
breast milk and hence use by nursing mothers is not
recommended,Chlorpheniramine causes drowsiness do not
drive or operate machinery while taking and avoid alcohol
Contraindications, side effects: see individual preparations
Dose and administration: oral:Analgesic: Based on
Acetaminophen component:Children: 10-15 mg/kg/dose every
4-6 hours as needed; do not exceed 5 doses in 24 hours.Adult:
325-650mg every 4-6 hours as needed; do not exceed
4g/day.Based on Chlorpheniraminecomponent: Children: 2-6
years: 1mg every 4-6 hours (maximum: 6mg/24hrs); 6-12 years:
2mg every 4-6 hrs (maximum: 12mg/24hrs); Children > 12
years and Adult: 4mg every 4-6 hrs (maximum: 24mg/24hrs).
Decongestant: Based on Pseudoephedrine component:Children;
2-6 years: 15 mg every 4 hrs (max 90mg/24hrs); 6-12 years: 30
mg every 4 hrs (max 180mg/24hrs); Children > 12 years and
Adult: 60mg every 4 hrs (maximum: 360mg/24hrs)
Bromhexine Hydrochloride
Elixir, 4mg/ml
Syrup, 5mg/5ml
Indications: acute and chronic bronchopulmonary diseases
associated with abnormal mucous secretion and impaired
mucous transport.
185

4. Respiratory Medicines

Cautions: history or symptoms of peptic ulceration, severe

hepatic and renal impairment
Contraindications: known hypersensitivity or idiosyncratic
reaction to bromhexine hydrochloride (or any of the other
ingredients in the product).
Side effect: gastrointestinal effects may occur; and transient
elevation in serum aminotransferase has been reported.
Dose and administration: Oral: Child (<2 years): 1mg 3
times/ day; Child (2 to 6 years): 4mg twice daily or 2mg 3
times/ day; Child (6 to 12 years):4 mg 3 times/day; Child (>12
years) and Adults: 8mg 3 times/day.
Storage: keep in a cool dry place where the temperature stays
below 30C.
Carbocisteine
Syrup, 2% (2gm/100ml), 5 %( 5gm/100ml) in 125 ml
Indications: for respiratory disorders associated with
productive cough.
Cautions: history of peptic ulcer disease.
Contraindications: active peptic ulceration.
Side effects: headache, GIT disturbances such as nausea,
diarrhea and gastrointestinal bleeding, and skin rashes.
Dose and Administration: Oral: Adult: initially 750 mg 3
times daily, reduced to 1.5 g/day in divided doses, as soon as a
response is obtained.Child: 6-12 years, 250 mg 3 times daily; 25 years, 62.5-125 mg 4 times daily.
Storage: at room temperature.
Codeine Phosphate
Tablet, 30 mg
Linctus, 15 mg/5ml
Indications: Antitussive in lower doses; treatment of mild to
moderate pain.
186

4. Respiratory Medicines

Cautions: patients with asthma, hepatic and renal impairment,

history of drug abuse and also in children, hypersensitivity
reactions to other phenanthrene derivative opioid agonists.
Drug interactions: alcohol, CNS depressants, buprenorpine,
monoamine
oxidase
(MAO)
inhibitors,
naltrexone,
antidiarrhoeal agents.
Contraindications: children under 1 year old, productive
cough, elderly, respiratory depression, head injury, acute
alcoholism, acute asthma, heart failure secondary to chronic
lung disease.
Side effects: constipation particularly troublesome in long term
use; dizziness, nausea, vomiting; difficulty with micturation;
ureteric or biliary spasm; dry mouth, headaches, sweating, facial
flushing; dependence, euphoria, sedation, respiratory
depression, circulatory collapse, anaphylactoid reaction.
Dose and Administration:Tablet, Adult: 10-20mg every 4 -6
hours. Maximum, 120mg in twentyfour hours.Child: (6-12
years of age), Oral, 5 to 10mg every four to six hours, not to
exceed 60mg per day. Linctus, Adult: 5-10ml 3 - 4 times
daily.Child (but not generally recommended) 5-12 years, 2.5 5ml 3-4 times daily.
Storage: at room temperature in a well-closed container.
Dexchlorpheniramine
Syrup, 2mg/5ml
Tablet, 2mg, 4mg, 6mg
Indication: perennial and seasonal allergic rhinitis and other
allergic symptoms including urticaria
Cautions: history of bronchial asthma; glaucoma or increased
intraocular pressure;a stomach ulcer; an enlarged prostate,
bladder problems, or difficulty urinating; hyperthyroidism;
cardiovascular disease; hypertension;
187

4. Respiratory Medicines

Drug interaction: monoamine oxidase inhibitor such as

isocarboxazid, phenelzine, or tranylcypromine, alcohol and
other sedatives.
Contraindications: pregnancy; breast feeding; Lower
Respiratory Disease; Hypersensitivity to Dexchlorpheniramin or
other antihistamines; Monoamine oxidase inhibitor therapy
Side effect: allergic reactions;dryness of mouth, nose, and
throat; anorexia; nausea; vomiting; diarrhea; constipation;
dizziness or drowsiness, tachycardia; hypotension, thickening of
bronchial secretions, tightness of chest and wheezing,
Hemolytic anemia, thrombocytopenia, agranulocytosis; change
in vision
Dose and administration: Oral: Adult 2mg 3-4 times daily;
Child (6-12 years) 1mg 3-4 times/day, Child (2-5 years) 0.5mg
3-4 times/day
Storage: Store at room temperature between 15 and 30 degrees.
Protect from light and moisture
Dexchlorpheniramine+Guaifenesin+Pseudoephedrine
Syrup, 2mg +100mg + 20mg/5ml
Indication: Treatment of cough, nasal congestion, and
associated aches, and general discomfort due to colds, flu, or
allergy
Cautions and side effects: Dexchlorpheniramine, Guaifenesin
and Pseudoephedrine (see Sections 4.1, 4.2, 17.1), respectively.
Dextromethorphan Hydrobromide
Tablet, 15mg
Syrups, 5mg/5ml, 7.5mg/5ml, 15mg/5ml
Drops, 15mg/ml
Indications: symptomatic relief of non-productive cough due to
minor throat and bronchial irritation occurring with colds or
inhales irritants.
Cautions: as for pholcodine
188

4. Respiratory Medicines

Drug interactions: CNS depressants, monoamine oxidase

inhibitors including furazolidine and procarbazine, amiodarone,
fluoxetine, haloperidol, quinidine, thioridazine.
Contraindications: respiratory failure, acute asthma, in
children up to two years of age.
Side effects: mild dizziness, mild drowsiness, nausea or
vomiting, stomach pain.
Dose and Administration:Oral: Adult: 10 to 20 mg every 4
hours, or 30 mg every 6 to 8 hours, to a usual maximum of 120
mg in 24 hours. Child (6-12 years), 5 to 10 mg every 4 hours or
15 mg every 6 to 8 hours to a maximum of 60mg in 24 hours,
and children (2 to 6 years) 2.5 to 5 mg every 4 hours, or 7.5
every 6 to 8 hours, to a maximum of 30 mg in 24 hours.
Storage: at room temperature in a well-closed container.
Guaifenesin
Tablet, 100mg, 200mg
Capsules, 200mg
Syrup, 100mg/5ml
Indications: symptomatic relief of productive cough due to
colds and minor upper respiratory infections.
Cautions: persistent or chronic cough such as that occurring
with smoking, asthma, chronic bronchitis, or emphysema, or for
cough accompanied by excessive phlegm.
Drug interaction: heparin
Contraindications: sensitive to Guaifenesin.
Side effects: diarrhoea, drowsiness, nausea or vomiting,
stomach pain.
Dose and Administration: Oral: Adult: 200-400mg every 4
hours. Child (6 to 12 years), 100 to 200mg every 4 hours, and
children (2 to 6 years), 50 to 100mg every 4 hours.
Storage: at room temperature in a tight container
189

4. Respiratory Medicines

Pholcodine
Syrup, 0.06%, 0.12%
Indications: dry cough
Cautions: asthma; chronic, persistent, or productive cough,
renal impairment
Contraindications: chronic bronchitis, chronic obstructive
pulmonary disease, bronchiectasis, patients at risk of respiratory
failure, hepatic impairment, severe renal impairment
Drug interactions: phenothiazines, benzodiazepines and TCAs.
Side effects: nausea, vomiting, constipation, sputum retention,
drowsiness, dizziness, excitation, confusion, rash
Dose and Administration: Oral:Adult: 5-10mg 3-4 times
daily.Child: over 5 years, 2.5-5mg 3-4 times daily; 1-5 years, 22.5 mg 3 times daily.
4.2. Bronchodilators /Antiasthmatics
Management of Asthma
Asthma is a chronic inflammatory disease in which the patient
suffers episodes of reversible airways obstruction due to
bronchial hyper responsiveness; in a few patients, inflammation
may lead to irreversible obstruction. Common precipitating
factors include exposures to cold weather, upper respiratory
tract infections, bad smells, exercise, ingestion of drugs like
aspirin and beta blockers etc,.The course of acute asthmatic
attack is often unpredictable and is potentially life threatening.
Concerning the chronic form of the disease, one should always
try to classify the disease based on severity before initiating
treatment. Accordingly, it is classified as intermittent or
persistent asthma. The later is again divided into mild, moderate
and severe persistent asthma.Management of asthma involves
prophylactic measures to reduce inflammation and airways
resistance and to maintain airflow, as well as specific regimens
for the treatment of acute attacks.
190

4. Respiratory Medicines

The standard drugs used for the management of asthma are the
beta2 agonists and corticosteroids. Therapy is preferably given
by inhalation to deliver the drug to the desired site of action.
This permits smaller dosages than would be required with oral
administration with a consequent reduction in side effects.
Pregnancy:Poorly controlled asthma in pregnant women can
have and adverse effect on the fetus, resulting in perinatal
mortality, increased prematurity and low birth - weight. For this
reason using medications to obtain optimal control of asthma is
justified. Administration of drugs by inhalation during
pregnancy has the advantage that plasma drug concentrations
are not likely to be high enough to have an effect on the fetus.
Acute exacerbations should be treated aggressively in order to
avoid fetal hypoxia.
Management of Chronic Obstructive Pulmonary Disease
(COPD)
COPD is a common disorder frequently associated with
cigarette smoking, infections, environmemntal pollution, and
occupation dust exposure may also have an aetiological role.
The most important therapeutic intervention is encouraging
those patients who smoke to stop; psychological support and
adjunctive drug therapy may be required. Drug treatment is
primarily symptomatic and palliative using bronchodilators,
corticosteroids, and oxygen therapy. First-line drug therapy for
the treatment of COPD consists of bronchodilators to alleviate
bronchospam and any reversible component of the airways
obstruction.
For mild disease, bronchodilators such as beta2 agonists,
ipratropium bromide or combination of both may be useful.
Regular oral theopylline may be added, bearing in mind the risk
of adverse events.For moderate to severe cases a trial of oral
191

4. Respiratory Medicines

corticosteroid therapy should be considered.The use of

mucolytics or expectorants is controversial.
Selective Beta2 agonist, inhaled and systemic
Beta2 agonists relax the bronchial smooth muscle to produce
bronchodilatation by selectively stimulating beta2-adrenergic
receptors. Short-acting beta2 agonists such as salbutamol or
terbutaline are the initial drugs of choice for acute
bronchospasm; if inhaled, they can have an almost immediate
bronchodilating effect. Simultaneous administration of more
than one drug within this group is hazardous.
Short-acting betta2 agonists should not be used on a regular
basis, but only as required. Patients requiring beta2 agonists
more than twice a week should be commenced on inhaled
steroids.
Salmeterol and formoterol are selective beta2 agonists with a
prolonged duration of action. These agents are indicated for
maintenance therapy in chronic persistent asthma, and COPD.
Salmeterol has a delayed onset of action and is not suitable for
treatment of an acute exacerbation. Various formulations and
routes of administration are available.
Inhalation: Aerosol inhalers(metered dose) are highly effective
and preferred to oral medication for mild to moderate attacks of
bronchospasm. Bronchodilator response is rapid and is sustained
for 4 hours or longer, depending on the severity of the asthma
and the dose administered. Compared with oral preparations, the
dose delivered is small and side effects are few.
Note:
Use of the inhaler should be demonstrated carefully tothe patient and
technique checked at subsequent visits. The importance of breathing out
first, then inhaling slowly and holding the breath for 10 seconds after
inhalation should be stressed. Some patients, especially the elderly,
arthritic, and young children, may be unable to use metered-dose
inhalers with out spacers.

192

4. Respiratory Medicines
Use of one of the various spacer devices, preferably large volume
(500ml), will often improve delivery of aerosol, eliminating the need for
precise co-ordination of activation and inhalation.
The maximum dose per 24-hour period and the number of inhalations
permissible at one time should be explained carefully to the patient and
that if relief is not obtained with the prescribed dose, medical advice
should be sought.
When a patient requires a beta2 agonist more than twice a week, add
inhaled corticosteroids. Inhaled corticosteroids increase response to
beta2 agonist.
Dry powder inhalers are useful when patients cannot use pressured
aerosols correctly, as they are activated by the patients inspiration.
Oral:Oral beta2 agonists should rarely be prescribed. Onset of action is
slower than inhaled therapy and incidence of side-effects significantly
higher, but the action is slightly more prolonged than with aerosol inhalers.
The slow-release preparations may be of value in patients with nocturnal
asthma.
Intravenous:Intravenous beta2 agonists, used in severe asthma, possess
bronchodilator potency comparable to that of aminophylline and are
probably safer to use if blood level measurement of the latter is not possible.

Glucocorticoids, inhaled
Inhaled corticosteroids reduce airways inflammation and are
very effective in the prophylactic management of chronic
persistent asthma. They must be used regularly for maximum
benefit.Beclometasone, budesonide and fluticasone are equally
effective if used in equivalent doses. There appears to be a
relatively flat dose response within the high-dose range.
Suppression of the adrenohypophyseal axis has been reported
with high doses, especially with fluticasone. Chlorofluorocarbon
(CFC) propellants in aerosol metered-dose inhalers are being
replaced by hydrofluoroalkane (HFA) propellants, and doses
may differ.
Anticholinergics, inhaled
An antimuscarnic may be the bronchodilator of choice in the
management of chronic obstructive pulmonary disease. In
193

4. Respiratory Medicines

patients with asthma they are usually reserved for use in lifethreatening acute asthma exacerbations.
Ipratropium bromide an atropine derivative anticholinergic
agent, is a potent inhibitor of vagus meiated bronchoconstriction
and has significant bronchodilator capacity, exerted by blocking
vagal influences on bronchomotor tone.
Xanthines
These agents have a narrow therapeutic index with significant
toxicity.Theophylline, a methylxanthine derivative, is`used
primarily for the relief of bronchospasm. Recent evidence
indicates that thephyllines have some anti-inflammatory effect.
Once daily administration in lower doses, previously considered
to be sub-therapeutic, may be of some benefit.
Other effects include CNS stimulation, increased gastric
secretion, vasodilation and mild diuresis; increased rate and
depth of respiration, an increase in diaphragmatic contractility,
and positive inotropic and chronotropic effects on the
heart.Aminophylline is a combination of theophylline with
ethylenediamine which dissociates in the stomach to be
absorbed as theophylline. (Aminophylline 1.27g is equivalent to
about 1g theophylline). Aminophylline is more water soluble
than theophylline and may be given parenterally.IV infusion has
not been shown to be beneficial in acute asthma or
exacerbations of COPD when added to corticosteroids and
nebulized bronchodilators.
Compound bronchodilator preparations
Most compound bronchodilator preparations have no place in
the management of patients with airways obstruction.In general,
patients are best treated wth single-ingredient preparation, such
as a selective beta2 adrenoceptor stimulant or ipratropium
bromide, so that the dose of each drug can be adjusted. This
flexibility is lost with combinations, although those in which
194

4. Respiratory Medicines

both components are effective may occasionally have a role

when compliance is a problem.
Adrenaline (Epinephrine)
Injection, 0.1 % in 1 ml ampoule
Indications: for acute bronchial asthma, and acute anaphylactic
reactions; see section 2.8. under Adrenaline.
Cautions, Drug interactions, Contraindications, Side effects;
see section 2.8.under Adrenaline.
Dose and Administration: Acute bronchial asthma: S.C or
I.M:Adult:S.C. initially, 0.2 0.5mg (0.20.5ml), repeated
every 20 minutes as necessary up to 3 doses or IV (slow &
cautions), 0.1 to 0.25mg. Child:S.C. 0.01mg (0.01ml)/ kg of
body weight, up to a maximum of 0.3mg (0.3ml)/dose. The dose
may be repeated every 15 minutes for 3 or 4 doses as necessary.
Note: only a 1: 10, 000 epinephrine solution should be used for
intravenous administration.

Storage: at room temperature, in a light resistant container.

Aminophylline (Theophylline and Ethylenediamine)
Tablet, 100mg, 200mg
Tablet (m/r), 100mg, 225mg, 350mg
Injection, 250mg/10ml, 10ml, in 10 and 20ml
Indications: reversible airways obstruction, acute severe
asthma.
Cautions: as for theophyline, and also, IV injection must be
administered very slowintravenous injection (over at least 20
minutes) to prevent dangerous CNS and cardiovascular side
effects.
Drug interactions, Contraindications; see under theophylline
Side effects: as for theophylline; also allergy to
Ethylenediamine can cause urticaria, erythema, and exfoliative
dermatitis.
195

4. Respiratory Medicines

Dose and Administration: Tablet,Oral: Adult, 100-300mg, 3-4

times daily, after food.Tablet (m/r, 225mg), 1 tablet twice daily
initially, increased after 1 week to 2 tablets twice daily. Tablet
(m/r, 350mg) is for smokers and other patients with decreased
theophylline half-life. Tablet (m/r, 100mg), children over 3
years, 6mg/kg twice daily initially, increased after 1 week to
12mg/kg twice daily; some children with chronic asthma may
require 13-20mg/kg every 12 hours.Slow I.V injection or
preferably by slow I.V infusion. Avoid rapid intravenous
injection.It should be given cautiously, particularly in patients
who have previously been taking theophylline and/or
ephedrine.Adult: Slow, I.V., 250500mg (5mg/kg) over 20
minutes,
or
diluted
with
10ml
of
water
for
injection.MaintenanceIf required, 0.5mg/kg of body weight
per hour by slow I.V. infusion for a period of 24 hours
only.Child: Slow I.V. 5mg/kg of body weight; Maintenance-If
required, 6 months-9 years-1mg/kg of body weight per hour by
slow intravenous infusion.10 to 16 years0.8mg/kg of body
weight per hour by slow intravenous infusion.
Storage: at room temperature protect from light.
Beclomethasone Dipropionate
Oral inhalation (aerosol), 50 mcg/dose, 100 mcg/dose
Indications: chronic persistent asthma.
Cautions: active or quiescent pulmonary tuberculosis;
pregnancy, particular care is required when patients are
transferred from systemic corticosteroid to inhaled products;
diabetes, hypertension, osteoporosis, peptic ulcer, glaucoma,
cataracts, hepatic impairment, withdrawal should be slowly.
Drug interactions: salmeterol
Contraindications: bronchiectasis (moderate to severe),
sensitivity to the drug or any ingredient (e.g. fluorocarbons,
oleic acid) in the formulation; not to be used in status
196

4. Respiratory Medicines

asthmaticus or for the relief of acute bronchospasm; children

less than 6 years of age.
Side effects: oral candidiasis (creamy white, curd like patches
inside mouth); cough without symptoms of infection; rarely skin
rash and difficulty in swallowing; hoarseness.
Dose and Administration:Adult: 200 micrograms twice daily
or 100 micrograms three or four times daily. Severe cases 600
800 micrograms daily;Child: 50 100 micrograms two to four
times daily.Note: Gargling and rinsing the mouth with water after each
dose is recommended to help prevent hoarseness, throat irritation, and oral
candidiasis. The use of a spacing device may also greatly decrease the
incidence of these local adverse effects.

Storage: at room temperature

Budesonide
Suspension: 0.25, 0.5mg/ml
Indications: prophylaxis of asthma
Cautions: breast feeding, systemic infection (e.g. tuberculosis),
Paradoxical bronchospasm
Drug Interactions: Itraconazole, Ketoconazole, Nelfinavir,
Ritonavir, Telaprevir
Contraindication: allergic to budesonide or components of the
formulation
Side effects: adrenal suppression, adrenal crisis and coma in
children; excessive doses should be avoided, High doses have
been associated with lower respiratory tract infections, including
pneumonia, in older patients with chronic obstructive
pulmonary disease, Bone mineral density may be reduced
following long-term inhalation of higher doses, predisposing
patients to osteoporosis
Anxiety, depression, sleep
disturbances, and behavioral changes including hyperactivity,
irritability, and aggression (particularly in children),
hyperglycemia, cataracts, skin thinning and bruising .
197

4. Respiratory Medicines

Dose and administration:Budesonide Inhalation Suspension is

indicated for the maintenance treatment of asthma and as
prophylactic therapy in children 12 months to 8 years of age.
Dosing recommendations based on previous therapy are as
follows:Bronchodilators alone: 0.25 mg twice daily; Inhaled
corticosteroids: 0.25 mg twice daily up to 0.5 mg twice daily;
Oral corticosteroids: 0.5 mg twice daily.In all patients, it is
desirable to downward-titrate to the lowest effective dose once
asthma stability is achieved.
Budesonide + Formoterol Fumarate
Aerosol, 80mcg + 4.5mcg, 160mcg + 4.5mcg
Cautions, Drug interactions, Contraindications and Side
effects; see under Salmeterol and Fluticasone.
Dose and Administration:Adult: 1-2 inhalations twice daily;
may be temporarily increased to a maximum of 4 inhalations
twice daily. When control has been achieved, titrate to lowest
dose at which effective control is maintained. Child: over 12
years, as for Adults.
Ephedrine sulphate
Injection, 50mg/ml
Indications: treatment of bronchial asthma, nasal congestion,
acute bronchospasm, idiopathic orthostatic hypotention,
anesthesia-induced hypotension
Cautions:blood volum depletion should be corrected before
ephedrine therapy is instituted; use caution in patients with
unstable vasomotor symptoms diabetes, hyperthyroidism,
prostatic hyperplasia, a history of seizures or those on other
symptomimetic agents; also use caution in the eldery and those
patients with cardiovascular disorders, such as coronary artery
disease, artrhythmias, and hypertention. Ephdrine may cause
hypertantion resulting in intracania.Alpha-adrenergic blocking
198

4. Respiratory Medicines

agents may reduce the vasopressor response to ephedrine by

causing vasodilation. Beta-adrenergic blocking drugs may block
the cardiac and bronchodilating effects of ephedrine.
Drug interactions: -blockers: Atropine sulfate, blockers,Cardiac
glycosides,
Ergotamine,
ergometrine,
methylergometrine,
oxytocin,Guanethidine,
Hydrocarbon
inhalation
anaesthetics,
such
as
cyclopropane,
halothane,Methyldopa,MAO
Inhibitors,
Reserpine,
Sympathomimetic Agents, Tricyclic antidepressants, Clonidine,
Urinary Alkalinizers, such as acetazolamide, dichlorphenamide,
sodium bicarbonate and sodium citrate, Theophylline:
Contraindications: closed angle glaucoma, patients with
pheochromocytoma, patients with asymmetric septal
hypertrophy (idiopathic hypertrophic subaortic stenosis) ,
patients undergoing therapy MAO inhibitors, or within 14 days
of ceasing such therapy, since MAO inhibitors may prolong and
intensify the cardiac and pressor effects of ephedrine,patients
undergoing general anaesthesia with cyclopropane or halothane
or
other
halogenated
hydrocarbons,
patients
with
tachyarrhythmias or ventricular fibrillation, patients with
hypersensitivity to ephedrine and in patients with
psychoneurosis.
Dose and Administration: Adults: I.M, SC: 25-50mg,
parenteral adult dose shoud not exceed 150 mg in 24
hours.I.V:5-25 mg/dose slow I.V. push repeated after 5-10
minutes as needed, then every 3-4 hour not to exceed 150 mg/24
hours. Child: I.M: slow I.V push: 0.2-0.3mg/kg/dose every 4-6
hours.
Storage: protect from light
Ephedrine + Theophyline
Tablet, 11mg + 120mg
Elixir, 6mg + 30mg in each 5ml
Syrup, 2.24% + 0.30%
199

4. Respiratory Medicines

Indications: symptomatic relief of chronic bronchial asthma;

asthmatic bronchitis; and other bronchospastic disorders;
prophylactically use to stop or decrease asthmatic attacks.
Drug interactions, Contraindications, Side effects:See
Ephedrine and Theophyline
Dose and Administration:Child (> 25kg): to 1 regular
release tablet 3to 4 times/day or at first sign of an asthmatic
attack. Adult: 1 to 2 regular release tablets 3-4 times/ day or at
first sign of an asthmatic attack.
Storage: at room temperature
Fluticasone furoate
Nasal spray, 27.5mcg
Indication:treatment of symptoms of seasonal and perennial
allergic rhinitis in adults and children 2 years.
Cautions: epistaxis, nasal ulceration, Candida albicans
infection, nasal septal perforation, impaired wound healing.
Avoid use in patients with recent nasal ulcers, nasal surgery, or
nasal trauma. Development of glaucoma or posterior
subcapsular cataracts. Monitor patients closely with a change in
vision or with a history of increased intraocular pressure,
glaucoma, and/or cataracts, immunosuppression.
Drug interactions:ritonavir, potent CYP 3A4 inhibitors, such
as ketoconazole.
Contraindications: Hypersensitivity to the medicines and any
component of the formulation.
Side-effect: headache, epistaxis, pharyngolaryngeal pain, nasal
ulceration, back pain, pyrexia, and cough.
Dose and Administration: For intranasal use only.
Usual starting dosages: Adults and adolescents 12 years: is
110 mcg once daily administered as 2 sprays (27.5 14
mcg/spray) in each nostril. Children 2-11 years: is 55 mcg once
daily administered as 1 spray (27.5 mcg/spray) in each nostril.
200

4. Respiratory Medicines

Salmeterol + Fluticasone
Powder for oral inhalation, 50mcg + 100mcg, 50mcg +
250mcg, 50mcg + 500mcg
Indications: maintenance treatment of asthma in adults and
children 4 years; not for use for relief of acute bronchospasm;
maintenance treatment of COPD associated with chronic
bronchitis.
Cautions: see under beclomethasone and salbutamole.
Drug interactions: diuretics (loop, thiazide); CYP3A4
inhibitors (e.g. azole antifungals, ciprofloxacin); MAO
inhibitors, TCAs (wait at least 2 weeks after discontinuing these
agents); beta-adrenergic blockers (e.g. propranolol), beta2
agonists.
Contraindications: hypersensitivity to salmeterol or
fluticasone; status asthmaticus; acute episodes of asthma.
Side effects: headache, hyperglycaemia, hypokalaemia,
pharyngitis, upper respiratory tract infection, diarrhea, GI
pain/discomfort,
oral
candidiasis,
nausea/vomiting,
musculoskeletal pain, bronchitis, cough, dysphonia, sinusitis,
upper respiratory tract inflammation, viral respiratory tract
infection.
Dose and Administration: Oral inhalation:COPD:Adult:
50/250 mcg twice daily, 12 hours apart.Asthma:Adult and
Child 12: One inhalation twice daily, morning and evenening,
12 hours apart.Child 4-11 years: 50/250 mcg twice daily, 12
hours apart.
Note: Do not use to transfer patients from systemic corticosteroid therapy.
This drug is available in 3 strengths; initial dose prescribed should be based
upon previous asthma therapy. Dose should be increased after 2 weeks if
adequate response is not achieved. Patients should be titrated to lowest
effective dose once stable. (Because each strength contains salmeterol
50mcg/inhalation, dose adjustments should be made by changing inhaler
strength. No more than 1 inhalation of any strength should be taken more
than twice a day). Maximum dose: 50/500 mcg, one inhalation twice daily.

201

4. Respiratory Medicines
Patients not currently on inhaled corticosteroids: 50/100 mcg. Patients
currently using inhaled beclomethasone dipropionate: 420 mcg/day: 50/100
mcg. 462-840 mcg/day: 50/250 mcg

Storage: store at room temperature.

Formoterol fumarate
Inhalational powder, 12mcg/dose
Indications: maintenance treatment of asthma and prevention of
bronchospasm in patients 5years of age with reversible
obstructive airway disease, including patients with symptoms of
nocturnal asthma, who require regular treatment with inhaled,
short-acting beta2 agonists; maintenance treatment of
bronchoconstriction in patients with COPD; prevention of
exercise-induced bronchospasm in patients 5 years of age.
Cautions: do not use as a component of chronic therapy without
an anti-inflammatory agent; do not exceed recommended dose;
cardiovascular disease, convulsive disorders, diabetes,
glaucoma, hyperthyroidism or hyperkalemia. Safety and
efficacy have not been established in children < 5 years of age.
Drug interactions: adrenergic agonists, antidepressants
(tricyclic), beta-blockers, corticosteroids, diuretics, MAO
inhibitors, theophyline derivatives.
Contraindications: hypersensitivity reactions.
Side effects: children are more likely to have infection,
inflammation, abdominal pain, nausea and dyspepsia. Serum
glucose increased, serum potassium decreased, chest pain,
tremor, dizziness, insomnia, dysphonia, rash, bronchitis,
infection, dyspnea, tonsillitis.
Dose and Administration:Relief of bronchoconstriction:Child
12 years and Adult: 6mcg or 12mcg as a single dose
(maximum dose: 72 mcg in any 24-hour period). The prolonged
use of high dosage (48 mcg/day for 3 consecutive days) may
202

4. Respiratory Medicines

be a sign of suboptimal control, and should prompt the reevaluation of therapy.

Storage: prior to dispensing, store in refrigerator at 2 to 8oC;
after dispensing store at room temperature.
Ipratropium Bromide
Aerosol Solution, 20mcg/metered
Inhalation; 400mcg/metered inhalation
Indications: relief of bronhospasm in reversible air ways
obstruction, especially COPD and in elderly patients, it has also
been used in cystic fibrosis.
Cautions: prostatic hypertrophy; pregnancy; acute angle closure
glaucoma.
Drug interactions: anticholinergics.
Side effects: dry mouth occasionally reported, rarely urinary
retention,
constipation,
tachycardia,
palpitations
and
arrhythmias, hypersensitivity reactions, including uriticaria,
angioedema, anaphylaxis.
Dose and Administration:Chronic asthma or chronic
obstructive pulmonary disease:Aerosol inhalation: Adult: 2040 micrograms, in early treatment up to 80 micrograms at a
time, 3-4 times daily; Child: up to 6 years, 20 micrograms 3
times daily; 6 to 12 years, 20-40 micrograms 3 times
daily.Inhalers:Adult: 40 micrograms 3 times daily; if necessary,
a second dose may be inhaled 5 minutes after the first.
Storage: at room temperature protect from freezing. Protect
from light.
Isoprenaline Sulphate
Tablet (Sublingual), 5mg, 10mg
Injection, 2.5mg/2ml
Indications: symptomatic treatment of bronchial asthma and
reversible bronchospasm which may occur association with
203

4. Respiratory Medicines

chronic bronchitis, pulmonary emphysema, bronchiectasis and

other chronic obstructive pulmonary diseases.
Cautions, Cotraindications, Side effects - see under
Adrenaline, sec. 2.8
Drug interactions: see under Adrenaline and also beta1
agonists such as Adrenaline: -dryness or irritation of mouth or
throat, nervousness, or restlessness, pinkish to red coloration of
saliva, insomnia, anxiety, tension, fear, or excitement, chest
discomfort or pain, dizziness or light headedness, continuing
fast heartbeat, continuing or severe headache.
Dose and Administration: Sublingual,Adult: 10-20mg, not to
exceed 60mg;Child: 5-10mg, not to exceed 30mg.
Storage: at room temperature in a well closed, light resistant
container.
Montelukast
Oral granules (sparkles):4mg
Tablets, Chewable: 4mg, 5mg
Tablets, film coated: 10mg
Indications: prophylaxis and chronic treatment of asthma;
relief of symptoms of seasonal allergic rhinitis and perennial
allergic rhinitis.
Caution: pregnancy and lactation
Drug interactions: CYP2C8/9 inducers may decrease effects of
montelukast (e.g. carbamazepine, Phenobarbital, phenytoin,
rifampin). CYP3A4 inducers may decrease effects of
montelukast (e.g carbamazepine, nevirapine, Phenobarbital,
phenytoin)
Contraindications: hypersensitivity to Montelukast or any
component of the formulation.
Side effects: cough, nasal congestion, flu like symptoms,
dizziness, fever, fatigue, rash, abdominal pain, dental pain,
dyspepsia
204

4. Respiratory Medicines

Dose and Administration:Children 6 to 23 months: perennial

allergic rhinitis: 4 mg (oral granules) once daily.12 to 23
months: Asthma: 4 mg (oral granules) once daily, taken in the
evening. 2 to 5 years: Asthma, seasonal or perennial allergic
rhinitis: 4mg (chewable tablet or oral granules) once daily,
taken in the evening.6 to 14 years: Asthma, seasonal or
perennial allergic rhinitis: chew one 5mg chewable tablet per
day, taken in the evening. Adults and children >15 years:
Asthma, seasonal or perennial allergic rhinitis: tablet: 10
mg/day, taken in the evening.
Storage: store at 200c to 250c.
Salbutamol (Albuterol)
Tablet, 2mg, 4mg, 4mg (s/r)
Syrup, 2mg/5ml
Oral inhalation (aerosol), 0.1mg per dose
Nebulizer Solution, 2.5mg/2.5ml
Indications: asthma and other conditions associated with
reversible airways obstruction.
Cautions:
hyperthyroidism,
myocardial
insufficiency,
arrhythmias, susceptibility to QT-interval prolongation,
hypertension, elderly.Note: it is important that asthma be well controlled
throughout pregnancy. Inhaled administration is particularly advantageous
as therapeutic action can be achieved at lower plasma levels with very little
risk to the fetus.

Drug interactions: corticosteroids, cardiacglycosides, diuretics,

xanthines and antidepressants.
Contraidications: eclampsia and severe pre-eclampsia, intrauterine infection, intra-uterine fetal death, antepartum
haemorrhage (which requires immediate delivery), placenta
praevia, and cord compression; threatened miscarriage.
Side effects: fine tremor, nervousness, headache, dizziness,
cardiac stimulation with tachycardia & palpitations (infrequent
205

4. Respiratory Medicines

with aerosol inhalation) are usually dose-related. High doses

may cause nausea & vomiting, and prolonged use has led to
reversible hypertrichosis. Hypersensitivity reactions are rare.
Dose and Administration:Tablets: Oral: Adult:2 to 6mg
(base) - three or four times a day initially, the dosage being
increased and tolerated up to a maximum of 8mg four times a
day. Child (6-12 years): 2mg (base) - three or four times a day
initially, the dosage being increased and tolerated up to a
maximum of 24mg per day in divided doses.Syrup: Oral:Adult:
2mg to 6mg (base)- three or four times a day initially, the
dosage being increased as needed and tolerated up to a
maximum of 8mg four times a day.Child (2 to 6years): 0.1mg
(base) per kg of body weight three times a day initially, the
dosage being increased as needed and tolerated up to 0.2mg per
kg of body weight, not to exceed 4mg three times a day.Child
(6 to 14 years): 2mg (base)- three or four times a day initially,
the dosage being increased as needed and tolerated up to a
maximum of 24mg per day in divided doses.Inhalation
(aerosol): Oral inhalation: Adult: 0.18 to 0.2mg (1 to 2
inhalations/puffs) every four to six hours as required
Note: Shake well before use.

Nebulizer solution: 2ml of 0.5% solution (10mg) given over 3

minutes up to 4 times daily or continuous inhalation of 50100mcg/ml (1 in 100 or 1 in 50 dilution)
Note: nebulizer: may be used in sever and unresponsive asthma.

Storage: Aerosol - store at room temperature away from heat

and direct sunlight.Syrup, Tablet - store between 2 and 300c, in
a well-closed container, protect from light and from freezing.
Salbutamol + Bromhexine + Guaifenesine + Menthol
Syrup,
2mg
+
4mg
+
100mg
+
1mg,
2mg+4mg+100mg+1mg/10ml, 1mg+2mg+50mg+0.5mg/5ml
206

4. Respiratory Medicines

Indications: for symptomatic management of all productive

including asthmatic coughs.
Cautions: cardiovascular disorders like ischemic heart disease,
hypertension and cardiac arrhythmias; hyperthyroidism,
diabetes, those who are unusually responsive to
sympathomimetics or who have convulsive disorders.
Pregnancy and lactation.Peptic ulceration, severe hepatic and
renal dysfunction. Menthol containing products should be
avoided in those with hiatal hernia, gallstones and in near-term
pregnant females.
Drug interactions: sympathomimetics, beta blockers, MAOIs,
nonpotassium-sparing
diuretics,
digoxin
tricyclic
antidepressants to cause untoward reactions.
Contraindications: hypersensitivity reaction.
Side effects: nausea, vomiting, skin rashes, headache, and
dizziness may rarely occur.
Storage: store below 25C in a dry place, protected from light.
Sodium Cromoglycate
Capsules with inhaler, 20 mg
Indications: Indicated as a prophylaxis and in the management
of bronchial asthma
It is also indicated to prevent bronchospasm induced by exercise
or by exposure to allergens, cold dry air, environmental
pollutants, or other known precipitating factors when exposure
is either episodic or continuous.
Cautions: nursing women, pediatric and geriatric patients.
Caution should also be used when decreasing the dosage of
cromolyn or discontinuing the drug in patients with asthma.
Contraindications: sensitivity to cromolyn, coronary artery
disease or history of cardiac arrhythmias.

207

4. Respiratory Medicines

Side effects: wheezing, nasal congestion, cough, hoarseness,

irritation of the throat and trachea, bronchospasm, nausea,
headache, dizziness, unpleasant taste, joint pain and swelling.
Dose and Administration: Adult and Child 2 years and
older: Asthma, bronchial (prophylaxis):Oral inhalation: 20 mg
(1 capsule) four times a day at regular intervals, the dosage
being adjusted as needed and tolerated.Bronchospasm
(prophylaxis):Oral inhalation: 20 mg (1capsule) as a single
dose just prior to exposure to the precipitating factor; or, if used
chronically, 20 mg (1 capsule) four times a day at regular
intervals, the dosage being adjusted as needed and
tolerated.Child up to 2 years of age:The capsule for inhalation
should not be used.
Storage: at room temperature in tight, light-resistant containers.
Theophylline
Tablet (anhydrous theophylline),100mg, 200mg, 200mg (s/r)

Elixir, 33mg in each 15 ml (anhydrous theophylline)

Indications: treatment of acute, severe and chronic persistant
asthma and other conditions associated with reversible
bronchospasm; COPD.
Cautions: peptic ulcer, hyperthyroidism, hypertension, cardiac
arrhythmias or other cardiovascular disease, or epilepsy; heart
failure, hepatic dysfunction or chronic alcoholism, acute febrile
illness, and to neonates and the elderly (since in all of these
circumstances theophylline clearance may be decreased)
Drug interactions: other xanthine medications, allopurinol,
antiarrhythmics,
cimetidine,
disulfiram,
fluvoxamine,
interferon-alfa, macrolide antibacterials and quinolones, oral
contraceptives, phenytoin, alcohol, ritonavir, rifampicin,
sulfinpyrazone,
smoking,
sympathomimetic
agents,
corticosteroids, diuretics, halothane or ketamine, lithium, beta
blockers.
208

4. Respiratory Medicines

Contraindications: hypersensitivity to theophylline or xanthine

derivatives; coronary artery disease (when, in the physician's
judgment, myocardial stimulation might prove harmful).
Side effects: tachycardia, palpitations, nausea, gastro-intestinal
disturbances, headache, insomnia, arrhythmias.
Dose and Administration: Adult: as anhydrous theophylline,
Oral: general range 6-18mg/kg/day.
Chronic bronchospasm: sustained-release formulations; initially
the usual daily dose is 12mg/kg or 400mg (whichever is less)
divided into 2-3 doses 8-12 hourly; dose may be increased by 23mg/kg/day at 3-day intervals.Addition as a once-daily slowrelease formulation at night may ameliorate night dipping.The
general therapeutic range is 10-20mcg/ml (55-110mcmol/l),
although benefit may be seen at sub-therapeutic doses.
Child: Oral: 1-9 years, 20mg/kg/day; 9-12 years,
16mg/kg/day.The total daily dose is divided into 2-3 doses for
8-12 hourly administration of sustained release preparations, or
into 4 doses for 6 hourly administrations of short-acting
preparations.Because of a general higher metabolic rate of
theophylline in children, the sustained-release agents often have
to be given 8 hourly.Both the final maintenance dose and the
dose interval should be guided by serum levels obtained after
steady state has been achieved.Note: patients should not be
transferred from one modified release theophylline or aminophylline
preparation to another without clinical assessment and the
measurement of serum-theophylline concentrations because of
bioavailability.

Storage: store in a well-closed container at room temperature.

Theophylline and Guaifenesin
Tablet 150mg + 90mg
Capsule, 150mg + 90mg; 300mg + 180mg
Elixir, 150mg + 90mg/15ml
209

4. Respiratory Medicines

Indications: for relief and/or prevention of symptoms of

bronchial asthma and reversible bronchospasm associated with
chronic bronchitis and pulmonary emphysema.
Cautions, Drug interactions and Contraindications;see notes
under theophylline and guaifenesin
Side effects: gastroesophageal reflux: see notes under
theophylline & guaifenesin.
Dose and Administration:Adult:Oral: 16mg/kg/day or 400mg
per day, in divided doses, every 6-8 hours.
Note:complete prescribing information for this medication should be
consulted for additional detail.

Storage: Guaifenesin preparations should be stored in tight

containers at room temperature.

210

6. Medicines Used In Anaesthesia

5. CENTRAL NERVOUS SYSTEM MEDICINES

5.1. Analgesics / Antipyretics
Pain is not only associated with physical suffering or hurting but
has an emotional or mental component, hence it is defined as an
unpleasant sensory and emotional experience associated with
actual or potential tissue damage, or described in terms of such
damage.
Pain can be classified as acute or chronic. Acute pain is usually
of short duration and the cause often identifiable (disease
trauma). Chronic pain persists after healing is expected to be
complete, or is caused by a chronic disease. Pain may be
modified by psychological factors and attention to these is
essential in pain management. Drug treatment aims to modify
the peripheral and central mechanisms involved in the
development of pain.
Non-opioid analgesics are particularly suitable for pain in
musculoskeletal conditions whereas the opioid analgesics are
more suitable for moderate to severe visceral pain. Those nonopioid analgesics which also have anti-inflammatory actions
include salicylates and NSAIDS (Nonsteroidal antiinflammatory drugs), they can reduce both pain and
inflammation of chronic inflammatory disorders such as
rheumatoid arthritis, but they do not alter or modify the disease
process itself.
Fever (pyrexia) is defined as an increase in body temperature
due to an elevated thermoregulatory set-point temperature.
Common causes of fever include infections, inflammatory
disorders, neoplastic disease, and some drug treatment.
Methods for reducing body temperature in fever include the use
211

6. Medicines Used In Anaesthesia

of antipyretic drugs and/or physical means. Antipyretic agents

used include paracetamol, salicylates and some other NSAIDs.
Non - opioid analgesics
Paracetamol, aspirin, and other non-steroidal anti-inflammatory
drugs (NSAIDs) are the first choice for treating mild or
moderate pain and are used in moderate or severe pain to
potentate the effects of opioids. They are suitable for use in
acute or chronic pain.
Acetylsalicylic acid (Aspirin) is indicated for headache,
transient musculoskeletal pain, dysmenorrhoea and pyrexia. In
inflammatory conditions, most physicians prefer antiinflammatory treatment with another NSAID which may be
better tolerated and more convenient for patient. Acetylsalicylic
acid is also used for its anti-platelet properties.
Adverse effects with analgesic doses are generally mild but
include a high incidence of gastro-intestinal irritation with slight
blood loss (Minimized by taking the dose after food, or enteric
coated preparations), bronchospasm and skin reactions in
hypersensitive patients, and increased bleeding time. Antiinflammatory doses are associated with a much higher incidence
of adverse reactions, and they also cause mild chronic salicylism
which is characterized by tinnitus and deafness. Its use is not
advisable in the latter stage of pregnancy, or in children because
of an association with Reye syndrome (encephalopathy and liver
damage).
Paracetamol:is similar in analgesic and antipyretic efficacy to
acetylsalicylic acid. Unlike acetyl salicylic acid and other
NSAIDs, paracetamol has little anti-inflammatory activity
which limits its usefulness for long-term treatment of pain
associated with inflammation; however it is useful in the
management of osteoarthritis, a condition with only a small
212

6. Medicines Used In Anaesthesia

inflammatory component.Since paracetamol does not have

aspirin's hypersensitivity hematological or gastro-intestinal
adverse effects, it is particularly useful in patients in whom
salicylates or other NSAIDs are contraindicated, such as
asthmatics and those with a history of peptic ulcer, or for
children under the age of 12 years in whom salicylates are
contraindicated because of the risk of Reye syndrome. However
large doses of paracetamol can produce severe or sometimes
fatal hepatotoxicity; patients with cachexia or those with
existing liver disease may be more susceptible.
Non-steroidal anti-inflammatory drugs(NSAIDs): Many of the
effects of non-steroidal anti-inflammatory drugs (NSAIDS)
appear to be due to their inhibitory action on cyclo-oxygenases
which are involved in the biosynthesis of prostaglandins.
Prostaglandins have an important role in the production of pain,
inflammation, and fever and NSAIDs therefore find their main
use as analgesics, anti-inflammatory agents, and antipyretics.
Administered as a single dose or in short-term intermittent
therapy they provide adequate analgesia to relieve mild to
moderate pain. However, it may take several days to two weeks
of use before their anti-inflammatory effects become evident.
The combined analgesic and anti-inflammatory effects of
NSAIDs make them particularly useful for the symptomatic
relief of painful and/or inflammatory conditions including
musculoskeletal and joint disorders.
Differences in anti-inflammatory activity between different
NSAIDs are small, but there is considerable variation in
individual patient tolerance and response. The main differences
between NSAIDs are in the incidence and type of side effects.
Before treatment is started the prescriber should weigh efficacy
against possible side effects.
213

6. Medicines Used In Anaesthesia

Side effects:The commonest side-effects occurring during

therapy with NSAIDs are generally gastrointestinal disturbances;
these are usually mild and reversible but in some patients peptic
ulcer and severe gastro-intestinal bleeding have been reported;
CNS related side effects include headache, dizziness,
nervousness, tinnitus, depression, drowsiness, and insomnia;
hypersensitivity reactions may occur occasionally and include
fever, asthma, and rashes. Hematological adverse effects of
NSAIDs include anaemias, thrombocytopenia, neutropenia,
eosinophilia, and agranulocytosis. Fluid retention may occur
(rarely precipitating congestive heart failure in elderly patients).
Renal failure may be provoked by NSAIDs especially in
patients with pre-existing renal impairment. Rarely, papillary
necrosis or interstitial fibrosis associated with NSAIDs may lead
to renal failure. Hepatic damage alveolitis, pulmonary
eosinophilia, pancreatitis, eye changes, Stevens Johnson
syndrome and toxic epidermal necrolysis are other rare side
effects. Induction of or exacerbation of colitis has been reported.
Aseptic meningitis has been reported rarely with NSAIDs.
Patients with connective tissue disorders such as systemic lupus
erythematosus may be especially susceptible.
Cautions and contraindications:NSAIDs should be used with
caution in the elderly (risk of serious side effects and fatalities),
in allergic disorders (they are contraindicated in patients with a
history of hypersensitivity to aspirin or any other NSAID.
Which include those in whom attacks of asthmas, angioedema,
urticaria or rhinitis have been precipitated by aspirin or any
other NSAID), during breast-feeding and pregnancy and in
coagulation.In patients with renal, cardiac, or hepatic
impairment caution is required since the use of NSAIDs may
result in deterioration of renal function; the dose should be kept
as low as possible and renal function should be monitored.
214

6. Medicines Used In Anaesthesia

NSAIDs should not be given to patients with active peptic

ulceration. While it is preferable to avoid them in patients with
current or previous gastro-intestinal ulceration or bleeding, and
to withdraw them if gastro-intestinal lesions develop,
nevertheless patients with serious rheumatic diseases (e.g.
rheumatoid arthritis) are usually dependent on NSAIDs for
effective relief of pain and stiffness.
In general caution should be taken in patient with renal
impairment; hepatic impairment; cardiac disease; elderly;
pregnancy and breastfeeding; coagulation defects; allergic
disorders.
Aceclofenac
Tablet, 100mg
Indications: pain and inflammation in rheumatoidarthritis,
osteoarthritis and ankylosingspondylitis
Cautions: acute prophyrias
Contraindications: hyper sensitivity to diclofenac; aspirin;
other NSAIDs or any compononents of the formulation
pregnancy [3rd trimester]
Dose and Administration: Adult, oral100 mg twice daily
(reduce to 100mg daily initially in hepatic impairment); child
not recommended
Storage: store at room temperature.
Acetylsalicylic acid (Aspirin)
Tablet,75mg, 81mg, 100mg (soluble); 300mg, 324mg
(microfined); 500 mg (enteric coated)
Indications:relief of mild to moderate pain, pyrexia;
prophylaxis of platelet aggregation; treatment of rheumatic
fever, and acute and chronic inflammatory disorders.
215

6. Medicines Used In Anaesthesia

Cautions: caution in patients with gastritis, peptic ulcer, elderly,

lactation (high dose)
Drug interactions: antidiabetic agents, including insulin;
agents inhibiting platelet aggregation (e.g. penicillins,
dipyridamole and valproic acid); thrombolytic agents and
heparin; agents causing gastric irritation; methotrexate,
probenecid; zidovudine.
Contraindications: history of severe sensitivity reaction to
acetylsalicylic acid, bleeding ulcers or other hemorrhagic states,
nasal polyps associated with asthma, febrile and dehydrated
children (especially with viral infections).
Side effects: gastrointestinal irritation causing abdominal pain,
nausea, vomiting and occult or overt mucosal bleeding. Chronic
administration of high doses may cause gastric erosion and
acute haemorrhage, potentiated by alcohol.Pseudo-allergic
reactions such as bronchospasm, rhinitis, urticaria, angioedema
and anaphylaxis like shock may occur, most frequently in
asthmatics, or in patients with nasal polyps or severe atopy.
True hypersensitivity reactions may also occur. Tinnitus and
decreased hearing, impaired renal function, decreased
prothrombin time and hepatotoxicity are more likely when
serum levels are > 200mcg/ml, but may be caused by low doses,
epecially in the elderly.
Dose and Administration:Oral:Adult: Analgesic and
antipyretic: 325-650mg every 4-6 hours up to 4g/day.Antiinflammatory: initial: 2.4-3.6g/day in divided doses; usual
maintenance: 3.6-5.4 g/day. Child:Analgesic and antipyretic:
10-15mg/kg/dose every 4-6 hours, up to a total of 4g/day.Orally,
preferably with or after food with a full glass of water. Child
should not take more than 5 doses/day or for longer than 10
days at a time, and adult should not take for longer than 10 days
at time.
216

6. Medicines Used In Anaesthesia

Note:Aspirin tablets or dispersible aspirin tablets are adequate for

most purposes as they act rapidly. Enteric-coated tablets are
beneficial in minimizing gastric irritation effect of aspirin, but have a
slow onset of action and are therefore unsuitable for single-dose
analgesic use (though their prolonged action may be useful for night
pain).Acetylsalicylic acid preparations should not be used if a strong
vinegar-like odor is present.

Storage: at room temperature, in a tight container. Protect from

heat.
Celecoxib
Capsule, 100mg, 200mg
Indications: reliief of the signs and symptoms of osteoarthritis,
ankylosing spondylitis, and rheumatoid arthritis; management of
acute
pain;
treatment
of
primarydysmenorrhea.
Cautions: consider BP before and after treatment and during
treatment, patients with thrombotic events ( e.g myocardial
infraction and stroke), hypertension, cardiac failure, edema,
patients with a prior history of peptic ulcer or gastrointestinal
bleeding especially in elderly or debilitated patients; patients
with impaired renal function, heart failure, liver dysfunction,
elderly; considerable dehydration; late pregnancy; breast
feeding; Safety and effectiveness in pediatric patients below the
age of 18 years have not been evaluated.
Drug interactions: ACE-inhibitors, Fluconazole, Lithium,
Warfarin, Glyburide, ketoconazole, methotrexate, phenytoin,
and tolbutamide.
Contraindications:known hypersensitivity to Sulfonamides;
allergic reactions to sulfonamides and aspirin or other NSAIDs;
asthma, urticarial, ischemic heart diseases, cerebrovascular
diseases, peripheral arterial diseases, and moderate to severe
heart failure.
217

6. Medicines Used In Anaesthesia

Side effects: Celecoxib is generally well tolerated. It has lower

incidence of stomach side effects irritation, ulcers, and even
bleeding than other anti-inflammatory drugs.
Dose and administration:Adult: Oral: Acute pain or primary
dysmenorrheal: Intial dose: 400mg, followed by an additional
200mg if needed on day 1; maintainance dose: 200mg twice
daily as needed
Ankylosing spondylitis: 200mg/day as a single dose or in
divided doses twice daily; if no effect after 6 weeks, may
increase to 400mg/day. If no response following 6 weeks of
treatment with 400mg/day, consider discontinuation and
alternative treatment.Osteoarthritis: 200mg/day as a single dose
or in divided dose twice daily.Rheumatoid arthritis: 100-200mg
twice daily
Storage: store at room temperature between 15 and 30 degrees
Diclofenac Sodium
Capsule (S/R), 75 mg
Injection, 25mg/ml in 3ml ampoule, 75mg/ml
Tablet (e/c), 25mg, 50mg, 75mg(s/r), 100mg(s/r)
Suppository, 12.5mg, 25mg, 50mg, 100mg
Indications: pain and inflammation in rheumatic disease
(including
juvenile
idiopathic
arthritis)
and
other
musculoskeletal disorders; acute gout; post operative pain.
Cautions: should be used with caution in the elderly (risk of
serious side effects and fatalities) during pregnancy and breastfeeding and in coagulation defects. Long-term use of some
NSAIDs is associated with reduced female fertility, which is
reversible on stopping treatment. In patients with renal, cardiac,
or hepatic impairment caution is required since NSAIDs may
impair renal function; the dose should be kept as low as possible
and renal function should be monitored.
218

6. Medicines Used In Anaesthesia

Drug interactions: Alendronate, lithium, methotrexate,

increased risk of methotrexate toxicity), rifampin,
timolol,warfarin,
cumarine
or
indandione
derivative
anticoagulants,
heparin,
or
thrombolytic
agents,
antihypertensives or diuretics, especially triamterene; aspirin
and anti-inflammatory, blood dyscrasia causing medications and
bone marrow depressants, radiation therapy, colchicine,
probenecid
Contraindications:Its contra-indicated in patients with a
history of hypersensitivity to aspirin or any other NSAID
which includes those in whom attacks of asthma, angioedema,
urticaria or rhinitis have been precipitated by aspirin or any
other NSAID. All NSAIDs are contra-indicated in severe heart
failure.
Side effects:Gastro-intestinal discomfort, nausea, diarrhoea, and
occasionally bleeding and ulceration occur, hypersensitivity
reactions, headache, dizziness, nervousness, depression,
drowsiness, insomnia, vertigo, hearing disturbances such as
tinnitus, photosensitivity, and haematuria,blood disorders, fluid
retention, increased blood pressure, hepatic damage, alveolitis,
pulmonary eosinophilia, pancreatitis, eye changes, StevensJohnson syndrome and toxic epidermal necrolysis are other rare
side effects.
Dose and Administration: Oral:75150 mg daily in 23
divided doses. Rectal: suppositories, 75150 mg daily in
divided doses. Children 112 years, juvenile arthritis, orally or
rectal , 13 mg/kg (max. 150 mg) daily in divided doses (25 mg
e/c tablets, 12.5 mg and 25 mg suppositories only). Children 6
12 years, postoperative pain, rectally, 1 2 mg/kg (max. 150 mg)
daily in divided doses (12.5 mg and 25 mg suppositories only)
for max. 4 days.
219

6. Medicines Used In Anaesthesia

Storage: store at room temperature in a well-closed, light

resistant container. Protect from freezing.
Diclofenac sodium + misoprostol
Tablet, 75mg+200
Indications: the diclofenac component is indicated for the
treatment of asteoarthritis and rheumatoid arthritis, the
misoprostol component is indicated for the prophylaxis of
NSAID-induced gastric and duodenal ulceration.
Caution: renal impairment
Contraindications: pregnancy
Dose and Administration: oral:Adult: osteoarthritis: 1 tablet 23 times/ day. Rheumatoid arthritis: 1 tablet 3to 4 times/day. If
not tolerated by patients, the dose may be changed to one tablet
twice daily.
Storage: store at room temperature
Ibuprofen
Capsule, 300 mg
Soft gelatin capsule, 400mg
Tablet, 200 mg, 400 mg (enteric coated,optional)
Syrup, 100mg/5ml
Suspension,100mg/5ml
Indications:pain and inflammation in rheumatic disease
(including juvenile arthritis) and other musculoskeletal disorders;
mild to moderate pain including dysmenorrhoea, postoperative
analgesia; migraine; fever and pain in children.
Cautions: see notes above
Drug interactions: cumarine or indandione derivative
anticoagulants,
heparin,
or
thrombolytic
agents,
antihypertensives or diuretics, especially triamterene; aspirin
and anti-inflammatory, blood dyscrasia causing medications and
220

6. Medicines Used In Anaesthesia

bone marrow depressants, radiation therapy, colchicine, lithium,

methotrexate, probenecid.
Contraindications: see notes above
Side effects: see notes above
Dose and Administration:Adult: Antirheumatic: Oral: 1.2 to
3.2gms a day in three or four divided doses.After a satisfactory
response has been obtained, the dosage should be reduced to the
lowest maintenance dose that provides continuing control of
symptoms. Note: Higher doses are generally required in rheumatoid
arthritis than in osteoarthritis.Analgesia/pain/fever/dysmenorrhea:
200-400 mg/dose every 4-6 hours (maximum daily dose: 1.2g,
unless directed by physician).OTC labeling (analgesic,
antipyretic): 200mg every 4-6 hours as needed (maximum: 1200
mg/24 hours). Child: Antirheumatics: (1-12 years of age): Oral:
initially 30 to 40mg per kg of body weight a day in three or four
divided doses then reduced to the lowest dose needed to control
disease activity.
Storage: store at room temperature in a well-closed, light
resistant container. Protect from freezing.
Ketoprofen
Topical gel, 25mg
Indications: Symptomatic relief of pain in such conditions as
soft tissue injuries, including sport injuries, sprains, strains,
musculo-tendonitis, swelling, backache and rheumatic pain
musculoskeletal disorders, and after orthopaedic surgery.
Cautions: Elderly, connective-tissue, for topical use only; The
appearance of cutaneous eruption following application of the
gel requires interruption of treatment. Hands should be washed
thoroughly before use and immediately after each application of
product (unless they are being treated).It is recommended to
protect treated areas by wearing clothing during all the
221

6. Medicines Used In Anaesthesia

application of the product and two weeks following its

discontinuation to avoid the risk of photosensitization. Not for
use with occlusive dressing. Topical application of large
amounts may result in systemic effects including
hypersensitivity and asthma, cardiac impairment, uncontrolled
hypertension, heart failure, ischaemic heart disease, peripheral
artery disease, cerebrovascular disease, Crohns disease or
ulcerative colitis, hepatic impairment, renal impairment.
Drug interaction: Methotrexate ,Probenecid ACE Inhibitors,
Adrenergic Neurone Blockers, Aliskiren,Alpha-blockers,
Angiotensin-II Receptor Antagonists, Antidepressants, SSRI,
Aspirin, Baclofen, Beta-blockers, Calcium-channel Blockers,
Cardiac Glycosides, Ciclosporin, Clonidine, Clopidogrel,
Corticosteroids, Coumarins, DabigatranEtexilate, Diazoxide,
Diuretics, Diuretics, Potassium-sparing and Aldosterone
Antagonists, Erlotinib, Heparins, Hydralazine, Iloprost,
Ketorolac, Lithium, Methotrexate, Methyldopa, Mifamurtide,
Minoxidil, Moxonidine, Nitrates, NSAIDs, Penicillamine,
Pentoxifylline, Phenindione, Potassium Canrenoate, Prasugrel,
Quinolones, Ritonavir, Sodium Nitroprusside, Sulfonylureas,
Tacrolimus, Venlafaxine, Zidovudine.
Contraindications:Known hypersensitivity reactions, such as
symptoms of asthma, allergic rhinitis to ketoprofen, fenofibrate,
tiaprofenic acid, acetylsalicylic acid, or to other NSAIDs
(including when taken by mouth), Children under 15 years.
Side effects: Local skin reactions such as erythematous, pruritis
and burning sensations.
Dose and Administration:For cutaneous use: Penetration of
the gel by gentle and prolonged massage on the painful or
inflamed surface for up to seven days. Two to four daily
applications of approximately 2 to 4g gel, representing
222

6. Medicines Used In Anaesthesia

approximately 5 to 10cm. The usual maximum dose is 15g per

day.
Storage: at room temperature, avoid freezing.
Mefenamic Acid
Tablet, 500mg,
Dispersible tablet, 100mg
Indications: pain and inflammation in rheumatoid arthritis and
osteoarthritis; postoperative pain; mild to moderate pain;
dysmenorrhoea and menorrhagia
Cautions: elderly, connective-tissue disorders, cardiac
impairment, uncontrolled hypertension, heart failure, ischaemic
heart disease, peripheral artery disease, cerebrovascular disease,
Crohns disease or ulcerative colitis, Hepatic impairment, Renal
impairment,epilepsy, acute porphyria, fluid retention
Drug interactions: Anticoagulants (e.g warfarin and heparin),
other antiplatelet medicines(e.g clopidogrel, asprin),
CYP2C8/9substrates (e.g amiodarone, fluoxetine, glimepiride),
NSAIDs, lithium, cyclosporine, ACE-inhibitors, angiotension
antagonists, diuretics, hydralizine, chlolestyramine and
colestipol.
Contraindication: allergic disorders, (they are contra-indicated
in patients with a history of hypersensitivity to aspirin or any
other NSAIDwhich includes those in whom attacks of
asthma, angioedema, urticaria or rhinitis have been precipitated
by aspirin or any other NSAID), coagulation defects, severe
heart failure, active gastro-intestinal ulceration or bleeding or
perforation, Pregnancy, Breast-feeding, severe liver disease,
renal disease, perioperative pain in the setting of coronary
artery bypass surgery
Side-effects:
Gastro-intestinal
disturbances
including
discomfort, nausea, diarrhoea, and occasionally bleeding and
223

6. Medicines Used In Anaesthesia

ulceration occur (see also NSAIDs and Gastro-intestinal Events,

Systemic as well as local effects of NSAIDs contribute to
gastro-intestinal
damage,
hypersensitivity
reactions
(particularly rashes, angioedema, and bronchospasm, headache,
dizziness, nervousness, depression, drowsiness, insomnia,
vertigo, hearing disturbances such as tinnitus, photosensitivity,
and haematuria, Blood disorders, Fluid retention, blood
pressure may be raised; suppositories may cause rectal
irritation; of worsening of asthma, Hepatic damage, alveolitis,
pulmonary eosinophilia, pancreatitis, visual disturbances,
Stevens-Johnson syndrome, and toxic epidermal necrolysis
Dose and Administration:Adult over 18 years, 500 mg 3
times daily. Child 1218 years, acute pain including
dysmenorrhoea, menorrhagia, 500 mg 3 times daily
Naproxen + Esomeprazole
Tablet, 500mg+20mg
Indications: pain and inflammation in rheumatic disease
(including
juvenile
idiopathic
arthritis)
and
other
musculoskeletal disorders; dysmenorrhoea; acute gout
Cautions: elderly, connective-tissue disorders, cardiac
impairment, uncontrolled hypertension, heart failure, ischaemic
heart disease, peripheral artery disease, cerebrovascular disease,
Crohns disease or ulcerative colitis, Hepatic impairment, renal
impairment
Drug interaction: Methotrexate ,Probenecid ACE Inhibitors,
Adrenergic Neurone Blockers, Aliskiren,Alpha-blockers,
Angiotensin-II Receptor Antagonists, Antidepressants, SSRI,
Aspirin, Baclofen, Beta-blockers, Calcium-channel Blockers,
Cardiac Glycosides, Ciclosporin, Clonidine, Clopidogrel,
Corticosteroids, Coumarins, DabigatranEtexilate, Diazoxide,
Diuretics, Diuretics, Potassium-sparing and Aldosterone
224

6. Medicines Used In Anaesthesia

Antagonists, Erlotinib, Heparins, Hydralazine, Iloprost,

Ketorolac, Lithium, Methotrexate, Methyldopa, Mifamurtide,
Minoxidil, Moxonidine, Nitrates, NSAIDs, Penicillamine,
Pentoxifylline, Phenindione, Potassium Canrenoate, Prasugrel,
Quinolones, Ritonavir, Sodium Nitroprusside, Sulfonylureas,
Tacrolimus, Venlafaxine, Zidovudine
Contraindication: pregnancy(third trimester), breast feeding,
allergic disorders, attacks of asthma, angioedema, urticaria or
rhinitis, coagulation defects, severe heart failure, active gastrointestinal ulceration or bleeding or perforation, Pregnancy,
Breast-feeding, severe liver disease, Renal impairment avoid if
eGFR less than 30 mL/minute/1.73 m2
Side effects: Gastro-intestinal disturbances including
discomfort, nausea, diarrhoea, and occasionally bleeding and
ulceration occur (see also NSAIDs and Gastro-intestinal Events,
Systemic as well as local effects of NSAIDs contribute to
gastro-intestinal damage; taking oral formulations with milk or
food, or using enteric-coated formulations, or changing the route
of administration may only partially reduce symptoms such as
dyspepsia, hypersensitivity reactions (particularly rashes,
angioedema, and bronchospasm, headache, dizziness,
nervousness, depression, drowsiness, insomnia, vertigo, hearing
disturbances such as tinnitus, photosensitivity, and haematuria,
Blood disorders, Fluid retention, blood pressure may be raised;
suppositories may cause rectal irritation; of worsening of
asthma, Hepatic damage, alveolitis, pulmonary eosinophilia,
pancreatitis, visual disturbances, Stevens-Johnson syndrome,
and toxic epidermal necrolysis
Dose and Administration: Adult:Rheumatic disease, 0.5 to 1g
daily in 12 divided doses; Acute musculoskeletal disorders and
dysmenorrhoea: 500 mg initially, then 250 mg every 68 hours
as required; maximum dose after first day 1.25 g daily. Acute
225

6. Medicines Used In Anaesthesia

gout: 750 mg initially, then 250 mg every 8 hours until attack

has passed; child under 16 years not recommended
Children:Pain and inflammation in musculoskeletal disorders,
dysmenorrhea-oral: Child 1 month18 years - 5 mg/kg twice
daily (maximum 1 g daily). Juvenile idiopathic arthritisoral:Child 218 years 57.5 mg/kg twice daily (max. 1 g daily)
Paracetamol
Tablet, 100mg, 500mg
Suppository, 125mg, 250mg
Syrup, 120mg/5ml, 250mg/5ml
Drops, 100mg/ml
Injection, 1g in 100ml
Indications: mild to moderate pain or pyrexia.
Cautions: caution in alcoholics, and in patients with hepatic
diseases, and severe renal function impairment, anaemia and
other disorders of the haemopoietic system.
Drug interactions: avoid simultaneous use of single toxic doses
or long-term high doses of paracetamol with alcohol, or
phenobarbitone; oral anticoagulants.
Contraindications: severe hepatic or renal disease.
Side effects: rare in therapeutic doses. Allergic reactions such as
skin rashes, neutropenia and thrombocytopenia may occur rarely.
Dose and Administration:Mild to moderate pain, pyrexia, Oral:
Adult: 0.5 to 1g every 4-6 hours, maximum 4g daily. Child: 3
months-1 year 60-125mg, 1-5 years 120 - 250mg, 6-12 years
250 - 500mg these doses may be repeated every 4 - 6 hours if
necessary (maximum 4 doses in 24 hours).Rectum: Adult: 0.5 1g, every 4-6 hours, maximum 4g daily.Child: 1 - 5 years 125 250mg, 6 - 12 years 250 - 500mg; doses inserted every 4 - 6
hours if necessary, maximum 4 doses in 24 hours.Postimmunization pyrexia: Oral: infant 2-3 months, 60mg followed
226

6. Medicines Used In Anaesthesia

by a second dose if necessary 4-6 hours later; warn parents to

seek medical advice if pyrexia persists after second
dose.Injection: Adult and Adolescents > 50 kg: 1g per
administration (100ml vial), up to 4 times a day. Maximum
daily dose not exceed 4g.Child weighing more than 33 kg
(approximately 11 years old), adolescents and adults weighing
less than 50 kg: 15 mg/kg per administration, i.e. 1.5 ml
solution per kg up to 4 times a day. The minimum interval
between each administration must be 4 hours. The maximum
daily dose must not exceed 60 mg/kg (without exceeding 3
g).Children weighing more than 10 kg (approximately 1 year
old) and less than 33 kg: 15 mg/kg per administration, i.e. 1.5
ml solution per kg up to 4 times a day. The minimum interval
between each administration must be 4 hours. The maximum
daily dose must not exceed 60mg/kg (not exceeding 2 g).
Storage: at room temperature
Paracetamol + Pseudoephedrine Hydrochloride +
Chlorpheniramine
Tablet, 325mg + 15mg +1mg
Syrup, 160mg+15mg+1mg/5ml
Indications, Caution, Contraindications, side effects and
Dose and administration: see section 3 (respiratory medicines).
Opioid analgesics
The opioid analgesics may be usually classified as lowefficacy opioids (e.g. codeine) and high-efficacy opioids (e.g.
morphine, methadone and pethidine).Codeine may effectively
relieve mild to moderate pain not responding to aspirin or
paracetamol. It has useful antitussive activity at doses lower
than those required for analgesia, and is also effective in
controlling diarrhoea. Because of their different mechanisms of
227

6. Medicines Used In Anaesthesia

action, codeine has additive analgesic effects with paracetamol,

aspirin or other non-steroidal anti-inflammatory agents, and
such combinations can be used beneficially. Combination with
other opioids should be used with caution. It is much less potent
than morphine and much less liable, in normal doses, to produce
adverse effects including dependency. It is effective for mild to
moderate pain but is too constipating for long-term use.
Morphine and Pethidine are opioid analgesics which are
effective in relieving moderate to severe pain, particularly of
visceral origin; there is a large variation in patient response.
Weaker opioids such as codeine are suitable for mild to
moderate pain. Pethidine produces prompt but short-acting
analgesia, it is less constipating than morphine, but even in high
doses it is less effective.
Morphine remains one of the most valuable opioid analgesics.
Its euphoriant action can be a useful property for providing a
sense of well-being in patients with severe pain. It is used to
relieve severe acute pain, or chronic pain, e.g. in terminally ill
patients. It is also used for pre-operative sedation, as a
supplement to anaesthesia and in acute pulmonary oedema
secondary to left ventricular failure, and is the choice to relieve
pain in acute ischaemic myocardial conditions.
A neurotoxic metabolite, norpethidine, accumulates during
repeated administration and can cause central nervous system
excitation, including myoclonus and seizures. These adverse
effects together with the short duration of analgesic action make
pethidine unsuitable for severe, continuing pain. It is used for
analgesia in labor; however other opioid analgesics such as
morphine are often preferred.
Pethidine is preferred to morphine in certain clinical situation,
e.g. during labour, in biliary, bowel or ureteric colic. It is less
bronchospasmogenic than morphine.
228

6. Medicines Used In Anaesthesia

Methadone as an antitussive linctus, it may be used to control

non-productive cough in special cases, e.g. lung cancer. It may
be used in the management of opioid dependence and
withdrawal; prolonged therapy may be required, with carefully
adjusted, individualized doses.
Other agent such as tramadol is an atypical opioid structurally
akin to tilidine, but apart from its morphine-receptor agonist
action, it inhibits neuronal reuptake of serotonin and
noradrenaline. It does not appear to release histamine.
Pentazocine has both agonist and antagonist properties and
precipitates withdrawal symptoms, including pain in patients
dependent on other opioids. By injection it is more potent than
dihydrocodeine or codeine, but hallucinations and thought
disturbances may occur. It is not recommended and, in
particular, should be avoided after myocardial infarction as it
may increase pulmonary and aortic blood pressure as well as
cardiac work.Note:
Opioid analgesics have neither antipyretic nor anti-inflammatory activity.
The risk of dependency with the weaker opioids is lower than with the
high-effecacy opioids, but a considerable potential may exist in patients
with a history of drug abuse or patients who are dependence-prone.
Tolerance to the analgesic efficacy of opioids may develop with repeated
and prolonged administration, and dependence and abuse are further
problems. However, in the management of chronic pain in terminal
illness the dependence-producing potential is of less importance, and
doses should be titrated up wards until adequate analgesia is provided.
Their tendency to cause respiratory depression should also be noted.
The low-efficacy opioids also have a tendency to suppress respiration,
and in overdosage they are marked respiratory depressants. Toxicity is
aggravated by alcohol or other CNS depressants.
The opioids all have, in varying degrees, the potential to cause
constipation, urinary retention, nausea, vomiting and cough
suppression; combinations of opioids should be avoided.

229

6. Medicines Used In Anaesthesia

Opioids should be used with caution in hypotensive states, in impaired

hepatic function, when decreased respiratory reserve is present, and in
combination with certain drugs such as MAO inhibitors.
Morphine should be used with caution in asthmatic patients.
At higher doses, all opioids may cause muscle rigidity.
Prolonged administration of opioids and addiction during pregnancy
may cause dependence and withdrawal in the neonate.

Codeine Phosphate
Tablet, 30mg
Injection, 30mg/ml in 1ml ampoule
Indications: mild to moderate pain, also used in the
symptomatic relief of non-productive cough (section 3.1)
Cautions: renal and hepatic impairment, dependence; and also
see section 3.1
Drug interactions: see section 3.1, under codeine phosphate
Contraindications: respiratory depression, obstructive airways
disease, acute asthma attack; where risk of paralytic illus.
Side effects: see section 3.1, under codeine phosphate
Dose and Administration:Mild to moderate pain:
Oral: Adult: 30 - 60 mg every 4 hours when necessary to a
maximum of 240mg, daily. Injection: I.M: 30-60mg every 4
hours when necessary. Children: oral:1-12 years, 3mg/kg daily
in divided doses.
Storage: at room temperature
Fentanyl
Injection, 50mcg/ml
Indications: relief of pain,
Cautions, Drug interactions, Contraindications, Side effects
andStorage, see above
Dose and Administration: Acute pain management: Adult:
Severe: I.M, I.V: 50-100 mcg/dose every 1-2hours as needed;
230

6. Medicines Used In Anaesthesia

patients with prior opiate exposure may tolerate higher initial

doses. Patient-controlled analgesia (PCA): I.V.: Usual
concentration: 10mcg/ml. Demand dose: Usual: 10mcg; range:
10-50mcg. Lockout interval: 5-8 minutes. Mechanicallyventilate patients (based on 70 kg patient): Slow I.V.: 0.351.5mcg/kg every 30-60 minutes as needed; infusion: 0.710mcg/kg/hour
Methadone hydrochloride
Injection, 10 mg/ml, 20mg/ml in 1 ml ampoule
Tablet, 5 mg
Indications: for relief of severe pain, cough suppressant, opioid
dependence.
Cautions: as for morphine. Methadone has a long half-life and
accumulation may occur with repeated doses, especially in
elderly or debilitated patients; caution in hepatic and renal
impairment.
Drug interactions: as for morphine, and also fluconazole,
zidovudine.
Contraindications: as for morphine, see notes above.
Side effects: as for morphine. Methadone has a more prolonged
effect than morphine and readily accumulates with repeated
doses. It may have a relatively greater respiratory depressant
effect than morphine and, although reported to be less sedating,
repeated doses of methadone may result in marked sedation. It
causes pain at injection sites; subcutaneous injection causes
local tissue irritation and induration.
Dose and Administration: Adult:Analgesia: Oral: 2.5-10mg
every 3-4 hours as needed.IV: initial: 2.5-10mg every 8-12
hours in opioid-naive patients also be administered by SC or IM
injection.
Storage: store at room temperture.
231

6. Medicines Used In Anaesthesia

Morphine Sulphate
Tablets, 5mg, 10 mg, 15mg, 20mg, 30mg
Oral solution, 5mg/5ml, 20mg/5ml,50mg/5ml
10 mg/5ml,100 mg/5ml
Suppository, 10mg, 15mg, 20mg, 30mg
Granules for oral suspension, 30mg, 60mg, 100mg, 200mg per
sachet
Capsule (modified release), 20mg, 50mg, 100mg, 200mg
Injection (as hydrochloride), 10 mg/ml, 20mg/ml in 1ml
ampoule
Indications: analgesic, antidiarrhoeal, anaesthesia adjunt and
antitussive; see also notes above.
Cautions: renal and hepatic impairment; elderly and debilitated,
dependence; hypothyroidism; convulsive disorders; decreased
respiratory reserve and acute asthma; hypotension, prostatic
hypertrophy; pregnancy and breastfeeding, adrenocortical
insufficiency, obstructive bowel disorders, myasthenia gravis,
withdraw gradually, not drive or operate machinery; see also
notes above.
Drug interactions: CNS depressants; e.g alcohol, anaesthetic
agents; antidiarrheals; anticholinergics, antihypertensives;
cimetidine; metoclopramide; MAO inhibitors.
Contraindications: acute respiratory depression, acute
alcoholism, where risk of paralytic ileus; raised intracranial
pressure or head injury; avoid injection in phaeochromocytoma;
during labour, diarrhea caused by poisons, antibiotic-associated
pseudomembranous enterocolitis, acute abdominal conditions
and biliary colic; see also notes above.
Side effects: nausea, vomiting, constipation, drowsiness, also
dry mouth, anorexia, spasm of urinary and biliary tract,
bradycardia, tachycardia, palpitations, euphoria, decreased
libido, rash, urticaria, pruritus, sweating, headache, facial
232

6. Medicines Used In Anaesthesia

flushing, vertigo, postural hypotension, hypothermia,

hallucinations, confusion, tolerance & dependence, miosis,
larger doses produce respiratory depression and hypotension.
Dose and Administration: Adult:IM or SC: 5 -15mg (usually
10 mg initially, based on an adultweighing 70 Kg); repeated 3-4
hourly as required. IV: 2.5 mg increments every 5 - 10 minutes,
up to a maximum of 15 mg.Oral: 5 - 20 mg 4 hourly. When
changing to a controlled release formulation, give the current
total 24 - hour requirement in 2 divided doses.Controlled release
tablets: Initially 10 - 20 mg twice daily, increasedaccording to
individual requirements.
Child: IM or SC: over one month old, 0.1-0.2 mg/kg.
Neonates: IM or SC: 0.1mg/kg.Note: Facilities must be available
to provide ventilatory support if necessary.

Storage: store at room temperature.

Pentazocine
Tablet, 50mg
Injection, 30mg/ml in 1ml ampoule
Indications: moderate to severe pain.
Cautions: as for morphine; pentazocine has weak opioid
antagonist actions and may precipitate withdrawal symptoms if
given to patients who are physically dependent on opioids.
Drug interactions: see under pethidine Hydrochloride.
Contraindications: see under Pethidine Hydrochloride and
notes above; patients dependent on opioids; arterial or
pulmonary hypertension, heart failure.
Side effects: as for morphine; also hallucinations, nightmares,
thought
distriburbances,
hypertension,
tachycardia,
agranulocytosis, toxic epidermal necrosis.
Dose
and
Administration:Oral:Adult:
Pentazocine
hydrochloride 50mg every 3 - 4 hours preferably after food
233

6. Medicines Used In Anaesthesia

(range 25 - 100mg); maximum 600mg daily; Child 6 - 12 years

25 mg every 3-4 hours.SC, IM, or IV injections:Adult:
moderate pain, 30mg; severe pain 45 - 60 mg every 3 - 4 hours
when necessary; Child over 1 year, by S.C or IM injection, up
to 1mg/kg, by IV injection up to, 500 micrograms/kg.
Storage: at room temperature in a tight, light resistant container.
Protect from freezing (Injection).
Pethidine Hydrochloride
Tablet, 50mg
Injection, 50mg/ml in 1 and 2ml ampoules
Indications: analgesia in moderate to severe pain including
labour, anaesthesia adjunct; see also introduction notes.
Cautions: as for morphine above, also atrial fibrillation or other
cardiac diseases where tachycardia might pose a problem.
Drug interactions: as for morphine, also MAO inhibitors, and
cimetidine
Contraindications: as for morphine above, also renal failure or
severe hepatic disease.
Side effects: as for morphine above; the effect on smooth
muscle may be relatively less intense than with morphine and
constipation occurs less frequently. Local reactions often follow
injection of pethidine; general hypersensitivity reactions occur
rarely. Pethidine given intravenously may increase the heart rate.
Dose and Administration: Adult:Oral: 50 - 150mg every 4
hours.IM (preferred), SC: 50 -150mg (usually 100mg) every
three to four hour as needed; Child: Oral or IM: 0.52.0mg/kg/dose, repeated 8 hourly if required. Maximum
6mg/kg/day.
Storage: store at room temperature protect from light and from
freezing.
234

6. Medicines Used In Anaesthesia

Phenazopyridine
Tablet, 100 mg
Indications: symptomatic relief of urinary burning, itching in
association with urinary tract infection.
Cautions: G6PD deficiency or discontinue if the skin or sclerae
become discolored.
Contraindications: allergic reaction tophenazopyridine;
hepatitis, impaired renal function.
Side effects: anemia, aseptic meningitis, dermatitis, allergic,
hepatotoxicity, methemoglobinemia, renal function impairment
or failure, dizziness, headache, indigestion, pruritus, stomah
cramps or pain.
Dose and Administration:Oral:Adult: 100-200 mg 3 times
/day, after meals for up to 2 days when it is used concomitantly
with an antibacterial agent.
Child: 12 mg/kg/day in 3 divided doses administered after
meals for 2 days.
Storage: store at rom temperature in a tight container.
Tramadol
Tablet/Capsule,50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 300 mg
Oral drops, 100 mg/ml (40 drops)
Nasal spray, 20 mg/0.1ml
Injection, 50 mg/ ml
Indications: moderate to severe pain.
Cautions: hepatic or renal impairment, and when risk of
seizures exists.
Drug interactions: carbamazepine, CNS depressants,
anaesthetics, alcohol, MAO inhibitors.
Contraindications: increased intracranial pressure or head
injury, respiratory depression.
235

6. Medicines Used In Anaesthesia

Side effects: as for morphine, but less potential for abuse,

respiratory depression, or constipation.
Dose and Administration: Adult:Oral: 50 - 100 mg 4 - 6
hourly, maximum 400 mg/day.
Sustainedrelease formulation, initially 100 mg twice daily,
increased to 150 mg or 200 mg twice daily.Drops: initially 50
mg (20 drops or 0.5 ml), repeated in 30-60 minutes if analgesia
is not achieved; maximum 400 mg/day (160 drops).IV: over 2 3 minutes or by infusions, IM or SC, 50-100 mg 4 - 6 hourly;
maximum 400 mg/day.Elderly>75 years: Oral: 50-100 mg
every 4-6 hours (not exceed 300 mg/day)
Storage: store at room temperature.
5.2. Antimigraine Headache Medicines
Migraine is characterized by recurrent attacks of headache
which may take up to 72 hours to resolve. Treatment of
migraine attacks may be successfully carried out with nonopioid analgesics such as aspirin, other NSAIDs, or paracetamol
(preferably in a soluble or dispersible form) taken at the earliest
signs of an attack concomitant anti-emetic treatment may be
required.
Attacks which do not respond to non-opioid
analgesics may be treated with ergot preparations such as
Ergotamine Tartrate. But the value of ergotamine for migraine is
limited by difficulties in absorption and by its side effects,
particularly nausea, vomiting, abdominal pain, and muscular
cramps; it is best avoided. The recommended doses of
ergotamine preparations should not be exceeded and treatment
should not be repeated at intervals of less than 4 days.
To avoid habituation the frequency of administration of
ergotamine should be limited to no more than twice a month. It
should never be prescribed prophylactically but in the
236

6. Medicines Used In Anaesthesia

management of cluster headache a low dose is occasionally

given for 1 to 2 weeks.
An alternative to ergot compounds for the acute treatment of
migraine is the selective serotonin agonist sumatriptan succinate,
this drug act by constricting dilated cranial blood vessels and
inhibiting release of sensory neuropeptides from the
perivascular trigeminal afferents, thereby blocking the
consequences of trigeminovascular activation. Sumatriptan is
relatively safe and well tolerated but should be avoided in
patients with known, or at risk of, cardiovascular disease.
Paracetamol+Acetylsalycilic acid+Caffeine
Tablet, 250mg+250mg+65mg, 400mg+250mg+65mg
Indications: relief of mild to moderate pain; mild to moderate
pain associated with migraine headache.
Dose and Administration: Oral: Adult:Based on
acetaminophen component:Mild to moderate pain: 325-650mg
every 4-6 hours as needed; do not exceed 4 g/day
Mild to moderate pain associated with migraine headache:
500mg/dose (in combination with 500mg aspirin and 130mg
caffeine) every 6 hours while symptoms persist; do not use for
longer than 48 hours
Based on aspirin component:Mild to moderate pain: 325-650mg
every 4-6 hours as needed; do not exceed 4 g/day.Mild to
moderate pain associated with migraine headache: 500mg/dose
(in combination with 500mg acetaminophen and 130mg
caffeine) every 6 hours; do not use for longer than 48 hours.
Ergotamine Tartrate
Tablet, 1mg, 2mg (sublingual)
Injection 0.25 mg/ml in 1ml ampoule
237

6. Medicines Used In Anaesthesia

Indications: as single agent or in combination with caffeine to

prevent or abort migraine, cluster headache (histamine
cephalagia), and other vascular headaches. Not recommended
for migraine prophylaxis because of the possibility of adverse
effects.
Cautions: risk of peripheral vasospasm (stop medication
immediately if numbness or tingling in extremities or anginal
pain develops, may aggravate MI, or aggravate intermittent
claudication), elderly, daily rebound headaches indicative of
ergotamine dependence; discontinuation after regular normal
dosage may result in withdrawal headache; See also notes above.
Drug interactions: beta blockers, macrolide antibiotics,
sumatriptan containing preparation, sympathomimetic agents
such as adrenaline; vasoconstrictor - containing local anesthetic,
systemic
vasoconstrictors,
ciprofloxacin,
diclofenac,
doxycycline, quinidine, verapamil, MAO inhibitors.
Contraindications: hypersensitivity to ergotamine, pregnancy
and breastfeeding, children, peripheral vascular disorders,
coronary artery disease, obliterative vascular disease and
Raynaud Syndrome, severe hypertension, sepsis, severe renal or
hepatic dysfunction; hyperthyroidism, prolonged use of
excessive dosage
Side effects: nausea, vomiting, vertigo, abdominal pain,
diarrhea, muscle cramps, increased headache; pericardial pain,
myocardial ischaemia; rarely myocardial infarction; repeated
high dosage may cause ergotism with gangrene and confusion;
pleural and peritoneal fibrosis may occur with excessive use.

238

6. Medicines Used In Anaesthesia

Dose and Administration:Treatment of acute migraine

attack:Sublingual:Adult: 2mg under tongue at the start of the
attack, repeated at intervals of at least thirty minutes, if
necessary, up to a total of 6mg per day.
Oral:Adult: 1- 2 mg at first sign of attack, maximum 4mg in 24
hours; do not repeat at intervals of less than 4 days maximum
8mg in any one week; not to be used more than twice in any 1
month.
Note:**Ergotamine Tartrate was formerly given by subcutaneous or
IM injection but dihydroergotamine mesylate is generally used if
parenteral administration is necessary.

Storage: at room temperature in a well closed, light resistant

container.
Ergotamine Tartrate + Caffeine1
Tablet, 1mg + 100mg
Suppository, 2mg + 100mg
Indications: as for ergotamine.
Cautions: as for ergotamine; and also, breast-feeding women.
Drug interactions: as for ergotamine, also CNS stimulant,
MAO inhibitors.
Contraindications: as for ergotamine, also anxiety disorders,
insomnia, peptic ulceration, and severe cardiac disease.
Side effects: as for ergotamine above, also insomnia.
Dose and Administration:Oral: Adult: 1 - 2 tablets at onset;
maximum 4 tablets in 24 hours; not to be repeated at intervals of
less than 4 days; maximum 8 tablets in one week; child not
recommended.Rectal: 1 suppository at onset; maximum 2 in 24
hours; not to be repeated at intervals of less than 4 days;
maximum 4 suppositories in one week.

And any other combination ratio proven to be therapeutically effective can be used

239

6. Medicines Used In Anaesthesia

Ergotamine Tartrate + Cyclizine Hydrochloride + Caffeine

Hydrate 2
Tablet, 2 mg + 50mg + 100mg
Indication: as for ergotamine and caffeine above.
Cautions: as for ergotamine and caffeine, also pediatrics,
geriatrics.
Drug interactions: as for ergotamine and caffeine, also drugs
with anticholinergic effect.
Contraindications: as for ergotamine and caffeine, also
patients which may adversely affected by anticholinergic effects.
Side effects: as for ergotamine and caffeine, also cyclizine has
antihistaminic, anticholinergic, and CNS depressant effects.
Dose and Administration:Oral:Adult: 1 tablet at onset,
followed after 30 minutes by - 1 tablet, repeated every 30
minutes if necessary; maximum 4 tablets per attack and 6 tablets
in one week, child not recommended.
Propranolol
Tablets, 10 mg, 20 mg, 40mg, 60mg, 80mg
Indications, cautions, Drug interactions, contraindications, side
effects and storage; see section 3.2 under propranolol
Dose and Administration: Initial dose: 80 mg/day orally in
divided doses.Maintenance dose: 160 to 240 mg/day.The dosage
may be increased gradually to achieve optimum migraine
prophylaxis. If a satisfactory response is not obtained within 4 to 6
weeks after reaching the maximum dose, propranolol therapy
should be discontinued.
Sumatriptan
Tablets, 50 mg, 100 mg
Injection, 12 mg/ml
2

And any other combination ratio proven to be therapeutically effective can be used

240

6. Medicines Used In Anaesthesia

Nasal spray, 20 mg/0.1ml

Indications: treatment of acute migraine attacks with or without
aura, clster headache.
Cautions: patients with a history of seizure disorder, impaired
hepatic or renal function, nursing mothers, pregnancy; safety
and effectiveness in children have not been established.
Drug interactions: ergotamine, MAO inhibitors, selective
serotonin re-uptake inhibitors, lithium.
Contraindications: hypersensitivity to the drug, IV use,
coronary artery disease (CAD); risk factor for CAD such as
hypertension, hypercholesterolemia, obesity, diabetes, smoking,
and strong family history.
Side effects: chest pain, heaviness or tightness, transient
increase in blood pressure, bronchospasm, flushing, tingling,
dizziness, dysphagia, muscle cramps and weakness; transient
pain at injection site, nausea and vomiting; vertigo.
Dose and Administration:Adult:Oral: initially 50 mg;
depending on response, this may be increased to 100 mg. If
symptoms recur after an initial beneficial response, the dose
may be repeated after 2 - 4 hours; maximum 300 mg in 24 hours.
SC: 6 mg. If symptoms recur after an initial beneficial response,
6 mg may be repeated after at least 1 hour; maximum 12 mg/24
hours.
Nasal spray; Intranasal: 20 mg administered in one nosetril. If
symptoms recur, the dose may be repeated after a minimum of 2
hours; Maximum 40 mg/24 hours.
Storage: store at 2-30 oC; protect from light.
5.3. Anxiolytics Sedatives, Hypnotics and Antipsychotics
5.3.1. Anxiolytics
Benzodiazepine therapy
241

6. Medicines Used In Anaesthesia

The benzodiazepines are primarily indicated for the treatment

of anxiety states and as hypnotics.Other indications
include:Peri-operative- as premedication; Management of
alcohol withdrawal (delirium treatments)- attenuating the acute
withdrawal symptoms; Treatment of seizure disorders; Muscle
relaxant.
All benzodiazepines act by facilitating the action of gammaaminobutyric acid (GABA) which is the major inhibitory
neurotransmitter in the CNS. Benzodiazepine receptors have
been identified in the brain, located in close proximity to GABA
receptors. Activation of the benzodiazepine receptors promotes
the activity of the GABA receptors.
The benzodiazepines may be divided into four groups on the
basis of the elimination half-lifes of the parent compound and
the active metabolites (if any):Ultra short-acting (half life < 6
hours); Midazolam; Short-acting (half life 6-12 hours);
oxazepam, temazepam; Intermediate-acting (half life 12-24
hours); Alprazolam, bromazepam; Long-acting (half life > 24
hours); chlordiazepoxide, diazepam, medazepam, flurazepam
Duration of action of a drug is dependent on many factors other
than elimination half-life. This system of classification may thus
not always accurately predict the duration of clinical effect.
Alprazolam
Tablet, 0.25mg, 0.5mg, 1mg
Indication: treatment of anxiety, panic disorder with or without
agoraphobia; anxiety associated with depression.
Cautions, Drug interactions, Contraindications, Side effects;
see under diazepam and also notes above.
Dose and Administration: Oral:Adult: 0.25 - 0.5mg 3 times
daily (elderly or debilitated 0.25 mg 2-3 times daily), increased
if necessary to a total of 3mg daily.
242

6. Medicines Used In Anaesthesia

Storage: store at room temperature in a tight, light resistant

container.
Bromazepam
Tablet, 1.5mg, 3mg, 6mg
Indications: anxiety (short - term use, not more than two weeks)
Cautions, Drug interactions, Contraindications, Side effects;
see under diazepam, and also notes above.
Dose and Administration: Oral:Adult: 6 to 18mg daily in
divided doses; elderly (or debilitated) half adult dose; maximum
(in exceptional circumstances in hospitalized patients) 60mg
daily in divided doses.
Storage: store at room temperature in a well-closed container.
Chlordiazepoxide
Tablet, 5mg, 10mg, 25mg
Indications: anxiety (short - term use); adjunct in acute alcohol
withdrawal.
Cautions, Drug interactions, Contraindications, Side effects;
see under diazepam, and also notes above.
Dose and Administration: Anxiety: Oral:Adult:10mg 3 times
daily increased if necessary to 60 - 100mg daily in divided
doses; elderly (or debilitated) half adult dose.
Note:the doses stated above refer equally to chlordiazepoxide and to
its hydrochloride.

Storage: store at room temperature in a tight, light resistant

container.
Diazepam
Tablet, 2mg, 5mg, 10mg
Suppository, 5mg, 10mg
Syrup, 2mg/5ml
243

6. Medicines Used In Anaesthesia

Injection, 5mg/ml in 2ml ampoule

Indications: short-term treatment of anxiety or insomnia;
adjunct in acute alcohol withdrawal; status epilepticus; febrile
convulsions; muscle spasm; peri-operative use.
Cautions: elderly, in patients with impaired liver or kidney
function, muscle weakness; elderly or debilitated patients;
respiratory disease, history of alcohol abuse, marked personality
disorder; pregnancy; breastfeeding; avoid prolonged use and
abrupt withdrawal; porphyria.
Note:- drowsiness may affect performance of skilled tasks (e.g.
driving); effects of alcohol enhanced.
Drug interactions: alcohol, antidepressants, antihistamines,
antipsychotics, sedative, general anaesthetics, other hypnotics or
sedatives, and opioid analgesics (sedation or respiratory and
cardiovascular depression may be enhanced); fluvoxamine,
ketoconazole, nefazodone (concurrent use may inhibit the
hepatic metabolism of benzodiazepines that are metabolized by
oxidation); plastic infusion tubing (diazepam may adheres to
plastic infusion tubing), zidovudine, aminophylline.
Contraindications: preexisting CNS depression or coma, acute
pulmonary insufficiency, or sleep apnoea, severe hepatic
impairment; myasthenia gravis; respiratory depression;
diazepam should not be used for the treatment of chronic
psychosis or for phobic or obsessional states. Avoid injections
containing benzyle alcohol in neonates.
Side effects: drowsiness and light headedness the next day;
confusion and ataxia (especially in the elderly); amnesia;
dependence; paradoxical increase in aggression; muscle
weakness; occasionally headache, vertigo, salivation changes,
gastrointestinal disturbances, visual disturbances, dysarthria,
tremor, changes in libido, incontinence, urinary retention, blood
244

6. Medicines Used In Anaesthesia

disorders and jaundice, skin reactions raised liver enzymes, on

IV injection, pain, thrombophlebitis and rarely apnea.
Dose and Administration:Oral:Adult: Anxiety: 2mg 3 times
daily increased if necessary to 15 - 30 mg daily in divided doses;
elderly (or debilitated) half adult dose.
Insomnia associated with anxiety: 5- 15 mg at bedtime.
Child: night terrors and somnambulism: 1 - 5 mg at bedtime.IM
or slow IV injection (into a large vein, at a rate of not more than
5mg/minute): for severe acute anxiety, control of acute panic
attacks, and acute alcohol withdrawal, 10mg, repeated if
necessary after not less than 4 hours.Note: Only use intramuscular
route when oral and intravenous routes not possible.

Rectum as suppositories: anxiety when oral route not

appropriate, 10 to 30mg (higher dose divided), dosage form not
appropriate for less than 10mg.
Storage: at room temperature in light resistant container protect
from freezing.
Flurazepam
Capsule, 15 mg, 30 mg
Indications: short-term treatment of insomnia.
Cautions: elderly, pregnancy and children < 15 years.
Drug
interactions: azole antifungals, ciprofloxacin,
clarithromycin,
diclofenac,
doxycycline,
erythromycin,
isoniazide, protease inhibitor, quinidine, verapamil, cimetidine,
clozapine, CNS depressants, digoxin, disulfiram, metoprolol.
Contraindications: narrow angle glaucoma, pregnancy.
Side effects: chest pain, constipation, drowsiness, memory
impairment, hangover effect, euphoria, hallucinations, rash,
vomiting, diarrhea, nausea, blurred vision, tinnitus, and apnea.
Dose and Administration: Oral: Adult: 15-30 mg at
beditme.Elderly: 15mg at bedtime; avoid use if possible
245

6. Medicines Used In Anaesthesia

Storage: store in light-resistant containers and at room

temperature.
Medazepam
Capsule, 5mg, 10mg
Medazepam is a long acting benzodiazepine with properties
similar to those of diazepam.
Indications: used for short-term treatment of anxiety disorders.
Cautions, Drug interactions, Contraindications, Side effects;
see under diazepam, and also notes above.
Dose and Administration: Oral:Adult:10-30mg daily in
divided doses; in severe conditions up to 60mg daily has been
given.
Storage: store at room temperature.
Midazolam Hydrochloride
Injection, 1mg/ml, 2 mg/ml in 5ml ampoule, 5 mg/ml in 2ml
ampoule
Syrup, 2mg/ml
Tablet, 10 mg
Indications: preoperative sedation and provides conscious
sedation prior to diagnostic or radiographic procedures;
intravenous anesthesia (induction and maintenance).
Cautions, Drug interactions, Contraindications and Side
effects; see under diazepam.
Dose and Administration: Adult:Preoperative sedation: IM:
0.07 to 0.08 mg/kg 30-60 minutes prior to surgery/procedure;
usual dose: 5mg.IV: 0.02-0.04mg/kg; repeat every 5 minutes as
needed to desired effect or up to 0.1-0.2mg/kg.Conscious
sedation: IV: initial; 0.5-2mg slow IV over at least 2 minutes;
slowly titrate to effect by repeating doses every 2-3 minutes if
needed; usual total dose: 2.5-5mg; use decreased doses in
246

6. Medicines Used In Anaesthesia

elderly.Anesthesia:IV: Induction: Unpremedicated patients: 0.30.35mg/kg (up to 0.6mg/kg in resistant cases). Premedicated
patients: 0.15-0.3 mg/kg.Maintenance: 0.05 to 0.3mg/kg as
needed or continuous infusion 0.25 to 1.5mcg/kg/minute.
Conscious sedation for procedures or preoperative
sedation:Oral: 0.25-0.5 mg/kg as a single dose procedure, up to
a maximum of 20 mg; administer 30-45 minutes prior to
procedure. Child< 6 years or less- cooperative patients may
require as much as 1 mg/kg as a single dose; 0.25 mg/kg may
suffice for child 6-16 years of age.
Storage: store at room temperature.
Oxazepam
Tablet, 10 mg
Indications: short-term management and relief of anxiety.
Cautions, Drug interactions, Contraindications, Side effects;
see under diazepam, and also notes above.
The elderly are more sensitive to CNS effects, use the smallest
effective dose.
Dose and Administration: OralAdult: Anxiety: 10 - 15 mg 2 4 times daily.Insomnia: 5 - 30 mg 1 - 2 hours before
bedtime.Psychotic patients and alcoholics: 30 mg 3 to 4 times
daily may be required.
Note: if used as hypnotic, it should be administered at least 1to 2
hours before bed time as absorption is slower than with diazepam.

Storage: store at room temperature

Temazepam
Capsules, 10mg, 15mg, 20mg, 30mg
Indications: short-term treatment of insomnia.
Cautions: elderly or debilitated patients; respiratory disease,
renal and hepatic impairment.
247

6. Medicines Used In Anaesthesia

Drug interactions: narcotic analgesics, barbiturates,

phenothiazins, MAO inhibitors, cimetidine, ciprofloxacin,
clozapine, and oral contraceptive.
Contraindications: narrow-angle glaucoma, pregnancy.
Side effects: confusion, dizziness, drowsiness, anxiety,
headache, hangover, euphoria, rash, decreased libido, diarrhea,
blurred vision, diaphoresis.
Dose and Administration:Adult: 15-30mg at bedtime.
Elderly or debilitated patients: 15mg
Storage: store at room temperature.
Zolpidem
Tablet, 10mg
It is an imidazopyridine, chemically distinct from the
benzodiazepines, but exhibiting selective high affinity for a
benzodiazepine receptor subtype. Its sedative action
predominates over its muscle relaxant and anticonvulsant
activity (in contrast to the benzodiazepines), and its indication is
for the treatment of insomnia.
Dose and Administration: Oral: Adult: 10mg at bedtime.
Hepatic impairment and the elderly: 5 mg.
5.3.2. Hypnotics
These agents act by depressing the central nervous system.
Although widely prescribed, both physical and psychological
dependence, as well as tolerance, occur. They have no analgesic
effects, and in the presence of pain, adequate analgesia is
desirable. Anterograde amnesia has been described even with
single doses of hypnotics.
Chloral Hydrate
Capsule, 500 mg
248

6. Medicines Used In Anaesthesia

Suppository, 60 mg
Syrup, 250 mg/5ml, 500 mg/5ml, 1 g/ml
Indications: short term sedative and hypnotic (< 2 weeks),
sedative / hypnotic for diagnostic procedures; sedative prior to
EEG evaluations.
Cautions: respiratory disease, pregnancy and breast-feeding,
neonates.
Drug interactions: CNS depressants, warfarin, IV furosemide,
benzodiazepine.
Contraindications: hepatic or renal impairment; cardiac disease,
gastritis or ulcers.
Side effects: gastric irritation with nausea and vomiting, ataxia,
headache, malaise, nightmares and delirium; eosinophpilia,
reduction in white cell count; dependence with prolonged use.
Dose and Administration:Adult: Oral, Rectal:Sedation,
anxiety: 250 mg 3 times / day. Hypnotic: 500 - 1000 mg at bed
time or 30 minutes prior to procedure, not to exceed 2 g/24
hours.Child: Sedation or anxiety: Oral, Rectal: 5 - 15
mg/kg/dose every 8 hours (maximum: 500 mg/dose). Prior to
EEG: Oral, Rectal: 20 - 25 mg/kg/dose, 30-60 minutes prior to
EEG; may repeat in 30 minutes to maximum of 100 mg/kg or 2
g total.Hypnotic: Oral, Rectal: 20 - 40 mg/kg/dose up to a
maximum of 50 mg/kg/24 hours or 1 g/dose or 2 g/24 hours.
Conscious sedation: Oral: 50 - 75 mg/kg/dose 30 - 60 minutes
prior to procedure; may repeat 30 minutes after initial dose if
needed, to a total maximum dose of 120 mg/kg or 1 g total.
Storage: store in light resistant, airtight container and at room
temperature.
Pentobarbitone (pentobarbital)
Capsule, 50mg, 100mg
Suppository (Sodium), 30mg, 60mg
249

6. Medicines Used In Anaesthesia

Injection (sodium), 50mg/ml in 50ml

Indications: sedative/hypnotic; preanesthetic; high-dose
barbiturate coma for treatment of increased intracranial pressure
or status epilepticus unresponsive to other therapy.
Cautions: elderly, debilitated, renally impaired, hepatic
dysfunction, or paediatric patients. Patients with depression or
suicidal tendencies.
Drug interactions: other CNS depressants, ethanol, narcotic
analgesics,
antidepressants,
or
benzodiazepines,
chloramphenicol, MAO inhibitors, valproic acid, griseofulvin,
clarithromycin, cyclosporine, erythromycin, nevirapine,
protease inhibitors, rifampin, oral contraceptives, oral
anticoagulants.
Contraindications: hypersensitivity to barbiturates; hepatic
impairment; dyspnea or airway obstruction; porphyria;
pregnancy.
Side effects: bradycardia, hypotension, drowsiness, CNS
excitation or depression, lethargy, headache, insomnia, anxiety,
dizziness,
rash,
nausea,
vomiting,
constipation,
thrombocytopenia.
Dose and Administration:Adult: Hypnotic: IM: 150-200mg.
IV: initial: 100mg, may repeat every 1-3 minutes up to 200-500
mg total dose.Preoperative sedation: IM: 150-200mg. Child:
Hypnotic: IM: 2-6 mg/kg; maximum 100mg/dose. Preoperative
sedation: 6 months: IM: 2-6mg/kg; maximum: 100mg/dose.IV:
1-3mg/kg to a maximum of 100mg until asleep.
Storage: at room temperature in air tight container.
Phenobarbitone (Phenobarbital)
Tablet 10mg, 15mg, 30mg, 60mg, and 100mg
Elixir, 20mg/ 5ml
250

6. Medicines Used In Anaesthesia

Injection (Sodium), 25mg/ml in 1ml ampoule, 100mg/ml in 1ml

ampoule, 4%
Indications: sedative-hypnotic.
Cautions: pediatric, elderly, and debilitated patients.
Drug
interactions:
alcohol,
CNS
depressants,
adrenocorticoids,glucocorticoids and mineralocorticoids; or
chloramphenicol; corticotropin; cumarin or indandione derivative anticoagulants, carbamazepine, estrogen-containing
contraceptives; valproic sodium or valproic acid; vitamin D;
xanthines such as aminophylline, caffeine, oxtriphylline,
theophylline, rifampin; monoamine oxidase inhibitors including
furazolidone, paragyline and procarbazine; doxycycline.
Contraindications: pregnancy and breastfeeding, and in
patients with acute intermittent or variegated or history of
porphyria, insomnia caused by pain, drug abuse or dependence
(history of), hepatic coma or hepatic function impairment, acute
or chronic pain; respiratory disease involving dyspnea or
obstruction, particularly status asthmaticus; sensitivity to
barbiturates.
Side effects: Common: drowsiness (especially with initiation of
therapy).Uncommon: ataxia and nystagmus (usually doserelated), dizziness and psychomotor impairment.Rare: skin
reactions,
including
Stevens-Johnson
syndrome,
photosensitivity; folic acid deficiency and megaloblastic
anaemia. Prolonged use may lead to dependence, with a
withdrawal syndrome on termination of treatment; also rickets
and osteomalacia due to vitamin D deficiency,
hypoprothrombinaemia and hepatitis.
Dose and Administration:Hypnotic: Adult:Oral: 100 to
320mg (base) at bedtime;IM or IV: 100 to 325mg.
Child: dosage must be individualized by physician.
251

6. Medicines Used In Anaesthesia

Sedative: Oral:Adult: daytime- 30-120mg (base) in two or three

divided doses a day;Child: daytime, 2mg (base)/kg of body
weight three times a day; Preoperative, 1 to 3mg (base) per kg
of body weight. IM or IV: Adult:daytime, 30 to 120mg a day in
two or three divided doses, preoperative (IM), 130-200mg sixty
to ninety minutes before surgery. Child: preoperative, 1 to 3mg
per kg of body weight, sixty-ninety minutes prior to surgery.
Storage: at room temperature in a tight container protect from
freezing.
Promethazine
Tablet, 25mg
Indications: night sedation and insomnia or it is indicated as
sedative hypnotic.
Cautions: epilepsy, prostatic hypertrophy, urinary retention,
glaucoma, hepatic disease, jaundice, also during pregnancy and
breast-feeding, in children and elderly. It causes drowsiness.
Patients should be advised to avoid car driving, machine
operating
or
doing
activities
requiring
alertness.
Drug interactions: alcohol, CNS depressants, anticholinergics,
antithyroid, epinephrine, extrapyramidal reaction causing
medication, levodopa, metrizamide, monoamine oxidase
inhibitors including furazolidone and procarbazine.
Contraindication: hypersensitivity to promethazine; coma;
treatment of lower respiratory tract symptoms, including asthma;
children < 2 years of age.
Side effects: drowsiness, headache, psychomotor impairment,
urinary retention, dry mouth, blurred vision, gastrointestinal
disturbances, rashes, photosensitivity reactions, palpitation, and
arrhythmias, hypersensitivity reaction (including bronchospasm,
angioedema, and anaphylaxes), convulsions, sweating, myalgia,
paraesthesia, blood disorders, tremor, liver dysfunction, sleep
252

6. Medicines Used In Anaesthesia

disturbance, depression, hypotension, and hair loss, extra

pyramidal effects.
Dose and Administration: Adult:Oral: 25mg at bed time,
increased to 50mg if necessary.Child (2-5 years): 15 to 20mg;
5-10 years: 20 to 25mg at bed time.
Storage: at room temperature in a tight, light-resistant container.
5.3.3. Antipsychotics
Antipsychotics may be used in a wide variety of psychotic
disorders including schizophrenia, Delirum and dementia, the
manic phase of bipolar disorder (manic depressive illness),
psychotic depression, and other acute psychotic illnesses.
Buspirone
Tablet, 5mg, 10mg
Indications: management of generalized anxiety disorder (GAD)
Cautions: hepatic or renal impairment; does not prevent or treat
withdrawal from benzodiazepines.
Drug interactions: MAOinhibitors, trazodone, warfarin,
grapefruit juice, erythromycin, clarithromycin, diclofenac,
doxycycline, itraconazole, nefazodone, rifampin and verapamil.
Contraindications: Hypersensitivity to buspirone
Side effects: Commonly dizziness, nausea, headache,
nervousness, lightheadedness, and excitement; less frequently
unsteady gait, diarrhea, weakness, hostility, skin rash, and
tremors.
Dose and Administration: Oral: Child and Adolescents: Initial:
5mg daily; increase in increments of 5mg/day at weekly
intervals as needed, to a maximum dose of 60mg/day divided
into 2-3 doses. Adult: 15mg/day (7.5mg twice daily); may
increase in increments of 5mg/day every 2-4 days to a
maximum dose of 60mg/day; target dose for most people is
30mg/day (15mg twice daily). Elderly: Initial 5mg twice daily,
253

6. Medicines Used In Anaesthesia

increase by 5mg/day every 2-3 days as needed up to 20-30

mg/day; maximum daily dose: 60mg/day.
Storage: store at room temperature
Chlorpromazine Hydrochloride
Tablet, 25 mg, 50mg, 100mg
Oral Drop, 25mg/ml in 10ml bottle, 40mg/ml in 10ml and 30ml
bottles
Syrup, 25mg/5ml
Injection, 25mg/ml in 1 and 2ml ampoules, 50mg/ml in 2ml
ampoule
Indications: symptomatic management of psychotic disorders
in patients with and for the management of excessive anxiety,
tension, and agitation.
Cautions: cardiovascular and cerebrovascular disease,
respiratory disease, parkinsonism, epilepsy, acute infection,
pregnancy, breast-feeding, renal and hepatic impairment, history
of jaundice, leucopenia, hypothyroidism, myasthenia gravis,
prostatic hypertrophy, closed-angle glaucoma. Caution also in
elderly particularly in very hot or cold weather.
Note: Avoid abrupt withdrawal. Avoid direct contact with
chlorpromazine for it causes contact sensitization. Advice patients not
to drive cars or operate machineries or do activities requiring
alertness

Drug interactions: alcohol, CNS depressants, tricyclic

antidepressants such as amitriptyline, antithyroid agents,
epinephrine, extra pyramidal reaction causing medication,
hypotension producing medication, levodopa, lithium,
metrizamide,
amphetamines,
anticonvulsants
including
barbiturates.
Contraindications: severe cardiovascular disease, severe CNS
depression, and comatose states.
254

6. Medicines Used In Anaesthesia

Side effects: akathisia (restlessness or need to keep moving),

blurred vision associated with anticholinergic effects; deposition
of opaque material in lens, cornea and retina (blurred vision),
dystonic extrapyramidal effects (muscle spasms of the face,
neck, and back; tic-like or twitching movements; twisting
movements of the body; inability to move eyes; weakness of
arms and legs), parkinsonian extrapyramidal effects (difficulty
in speaking or swallowing; loss of balance control; mask like
face; shuffling walk; stiffness of arms or legs; trembling and
shaking of hands and fingers); hypotension (fainting),
pigmentary retinopathy (blurred vision, defective colour vision,
difficulty seeing at night); tardive dyskinesia (lip smacking or
packering; putting of cheeks, rapid or worm-like movements of
tongue; uncontrolled chewing movements; uncontrolled
movements of arms and legs); ammenorrhea and gallactorrhea
(female), gynecomastia and impotence (in male), hypothermia
(decrease body temperature below Normal); dry mouth;
tachycardia, urinary retention; increased appetite and weight
gain, cholestatic jaundice, corneal opacity.
Dose and Administration:Adult: Psychotic disorder:
Oral: initially 25 to 200 mg (base) two or four times a day, the
dosage being increased by 20 to 50mg a day over 3 or 4 days as
needed or tolerated. Maximum 1000mg/day.IM: (severe) 25 to
50mg (base), the dosage being repeated in one hour if needed
and every three to twelve hours thereafter as needed and
tolerated. The dosage may be gradually increased over several
days as needed and tolerated.Child (6 years and older): Oral:
0.5mg per kg of body weight every four to six hours, the dosage
being adjusted as needed and tolerated.IM: 0.55 mg per kg of
body weight one or two hours before surgery.
Storage: At room temperature. Protect from light and freezing
255

6. Medicines Used In Anaesthesia

Clozapine
Tablet, 25 mg, 50 mg, 100 mg
Indications: schizophrenia, in patients unresponsive toor,
intolerant of, conventional antipsychotic medicine.
Cautions: it causes severe agranulocytosis and neutropenia, so
it should be prescribed strictly where there is central monitoring
unit. Intiailly complet bood count should be monitored weekly
for 18 weeks, if it is stable, then every 2 weeks. If Leukocyte
count is less than 3,000/mm3 or absolute neutropenia less than
1500/mm3 medication should be discontinued. Prostatic
enlargment, narrow-angle glaucome, history of seizures.
Drug interactions: benzodiazepines, risperidone, amiodarone,
ciprofloxacin,
ketoconazole,
norfloxacin,
lidocaine,
dextrometorphan, lidocaine, amphetamines, codein, tramadol,
and phenobarbital.
Contraindications: history of drug-induced agranulocytosis,
bone marrow disorders, severe liver, renal or cardiac disease,
toxic or alcoholic psychoses, uncontrolled epilepsy.
Side effects: drowsiness, sedation, fatigue, orthostatic
hypotension, dizziness, headache, dry mouth, blurred vision,
hypersalivation (common), weight gain, nausea, vomiting,
constipation, urinary incontinence and retention, increase in
hepatic enzymes. Risk of agranulocytosis and neutropenia is far
greater than with other neuroleptics.Fatal myocarditis and
cardiomyopathy.
Dose and Administration: Oral:Adult:Initially 12.5 to 25 mg
daily gradually increased in 25 to 50 mg increments to achieve
therapeutic doses in 2 to 3 weeks. Usual range 200 to 450
mg/day in divided doses; up to 600 mg/day may be required.
Maximum 900 mg/day.
Storage: store in tight containers at a temperature not exceeding
30oC.
256

6. Medicines Used In Anaesthesia

Fluphenazine decanoate
Depot injection,25 mg/ml in 1ml and 2ml ampoules and in 10ml vial.

Indications: psychotic disorders, particularly chronic

schizophrenia who are non compliant patient
Cautions: cardiovascular and cerebrovascular disorders,
respiratory disease, epilepsy, acute infections, pregnancy,
breastfeeding, renal and hepatic impairment, history of jaundice,
leukopenia, hypertrophy, angle-closure glaucoma, elderly.
Drug
interactions:
anticholinergics,
antiepileptics,
antihypertensives, antiparkinsonian agents, CNS depressants,
metabolic enzyme inducers, antacids.
Contraindications: children, confusional states, impaired
consciousness due to CNS depression, parkinsonism,
intolerance to antipsychotics, depression, bone-marrow
depression, and phaechromocytoma.
Side effects: extrapyramidal side effects, especially in the
elderly; anticholinergic effects, hypotension and sedation;
photosensitivity, effects on the heart, jaundice and blood
dyscrasias. Increased risk of extrapyramidal reactions with
depot injections. Pain may occur at the injection site, and
occasionally erythema, swelling and nodules.
Dose and Administration:Adult:Deep IM: initially 12.5 mg;
subsequent doses determined by individual response. Usual
range 6.25 - 25 mg every 2 - 4 weeks. Higher doses (up to 50
mg per 2 weeks) are rarely required.Elderly: Doses at the lower
end of the range should be used.
Storage: store at room temperature.
Fluphenazine Hydrochloride
Tablet, 1mg
257

6. Medicines Used In Anaesthesia

Indications: schizophrenia, mania, severe anxiety, and other

psychoses.
Cautions: pregnancy, breast-feeding, cardiovascular and
cerebrovascular disease, parkinsonism, epilepsy, acute
infections, history of jaundice, leucopenia, liver and kidney
disease,hypothyroidism,
myasthenia
gravis,
prostatic
hypertrophy, closed angle glaucoma and elderly patients
particularly in very hot or very cold weather
Drug interactions: alcohol, CNS depression producing
medications, tricyclic anti-depressants, anti-thyroid agents,
epinephrine, extrapyramidal reaction causing medications,
hypotensionproducing medications, levodopa, lithium,
metrizamide, fluoxetine, fluvoxamine, paroxetine, maprotiline,
astemizole, terfenadine sotatol.
Contraindications: severe CNS depression, comatose states,
active alcoholism, blood dyscrasias, hepatic function
impairment, Reyes syndrome, bone marrow disorders, history
of cardiac arrhythmias, congential long QT syndrome, marked
cerebral atherosclerosis.
Side effects: extrapyramidal symptoms, akathisia, tardive
dyskinesia, blurred vision, hypothermia, drowsiness, apathy,
pallor, night mares, insomnia, depression and more rarely
agitation, EEG changes, convulsions; anti muscarnic and
cardiovasucular symptoms.
Dose and Administration:Adult: Initial: Oral: 2.5 to 10 mg a
day in divided doses every six to eight hours, the dosage being
gradually increased as needed and tolerated.Maintenance: Oral:
1 to 5 mg a day as a single dose or in divided doses. Usual adult
prescribing limits: - up to 20 mg a day.
Note: Emaciated or debilitated patients usually require a lower initial
dosage (1 to 2.5 mg daily), the dosage being gradually increased as
needed and tolerated.
258

6. Medicines Used In Anaesthesia

Child:Oral: 250 to 750 mcg (0.25 to 0.75 mg) one to four times
a day.Elderly: Oral: 1 to 2.5 mg a day, the dosage being
gradually increased as needed and tolerated.
Storage:
in a tight, light-resistant container at room
temperature.
Haloperidol
Tablet, 1mg, 2mg, 5mg
Oral liquid, 2ml/ml
Injection, 5mg/ml in 1ml ampoule
Indications: schizophrenia and other psychotic disorders, mania,
psychomotor agitation and violent behaviour; adjunct in severe
anxiety.
Cautions: cardiovascular and cerebrovascular disorders,
respiratory disease, parkinsonism, epilepsy, acute infections,
pregnancy, breastfeeding, renal and hepatic impairment (avoid
if severe), history of jaundice, leucopoenia (blood counts if
unexplained fever or infection); hypothyroidism, myasthenia
gravis, prostatic hypertrophy, angle-closure glaucoma; elderly
(particularly in very hot or very cold weather); children and
adolescents; avoid abrupt withdrawal; patients should remain
supine and the blood pressure monitored for 30 minutes after
intramuscular injection; see also interactions.
Drug interactions: amitriptyline, carbamazepine, clomipramine,
ether (anaesthetic),ethosuximide, halothane, ketamine, nitrous
oxide, phenobarbital, phenytoin, procainamide, quinidine,
rifampicin, ritonavir, thiopental, valproic acid.
Contraindications: impaired consciousness due to CNS
depression; bone-marrow depression; phaeochromocytoma;
porphyria, basal ganglia disease.
Side effects: see notes above and under chlorpromazine; but
less sedating and fewer antimuscarinic or hypotensive
259

6. Medicines Used In Anaesthesia

symptoms; pigmentation and photosensitivity reactions rare;

extrapyramidal symptoms, particularly dystonic reactions and
akathisia especially in thyrotoxic patients; rarely weight loss,
hypoglycaemia, inappropriate antidiuretic hormone secretion.
Dose and Administrations:Oral:Adult: initially 1.5 to 3mg, 2
to 3 times daily or 3 to 5mg 2 to 3 times daily in severely
affected or resistant patients (up to 30mg daily in resistant
schizophrenia);
Elderly (or debilitated) initially half adult dose;
Child initially 25 to 50 micrograms/kg daily in 2 divided dose
(maximum 10mg daily).
Acute psychotic conditions: deep IM injection:Adult: two
10mg, subsequent doses every 4 to 8 hours according to
response (up to every hour if necessary) to total maximum of 18
mg; Child not recommended.
Storage: at room temperature in light resistant container.
Protect from freezing.
Haloperidol Decanoate
Injection (Depot Oily), 50mg/ml, 100mg/ml in 1ml
Indications: maintenance in schizophrenia and other psychoses.
Cautinos, Contraindications, and Side effects see under
haloperidol.
Dose and Administration: Adult: deep I.M injection: initially
50mg every 4 weeks, if necessary increasing by 50 mg
increments to 300 mg every 4 weeks; higher doses may be
needed in some patients. Elderly: initially 12.5 to 25 mg every
4 weeks. Adult: Psychosis: Oral: 0.5 to 5mg, 2 to 3 times/day;
usual maximum: 30 mg/day
IM (as decanoate): initial; 10 to 20 times the daily oral dose
administered at 4 week intervals.
260

6. Medicines Used In Anaesthesia

Olanzapine
Tablet, 5mg
Indications: schizophrenia.
Cautions: hepatic impairment, diabetes mellitus; porphyria.
Contraindications: narrow-angle glaucoma.
Side effects: somnolence, agitation, dizziness, asthenia, weight
gain, constipation, dry mouth, rhinitis, headache, fever, myalgia
and musculoskeletal pains, neck rigidity, orthostatic
hypotension, tachycardia, peripheral oedema, raised hepatic
enzymes, hypertriglyceridaemia.
Dose and Administration: Oral: Adult: initially 5-10 mg once
daily. Usual therapeutic dose, 10 mg.
Storage: store at room temperature and protect from light and
moisture.
Pimozide
Tablet, 2mg, 4mg, 10mg
Indications: suppression of severe motor and phonic tics in
patients with Tourettes disorder who have failed to respond
satisfactorily to standard treatment.
Caution: neuroleptic malignant syndrome; renal or hepatic
impairment.
Drug interactions: barbiturates, alcohol, analgesics.
Contraindications: treatment of simple tics, patient with severe
toxic CNS depression, hypersensitivity to the drug.
Side effects: amenorrhea, dysmenorrheal, vomiting, anorexia,
rash and urticaria.
Dose and Administration: Tourettes disorder: Oral:
Adult and Child >12 years: initial: 1 to 2mg/day in divided
doses, then increase dosage as needed every other day; range is
usually 7 to 16 mg/day, maximum dose: 10mg/day or
261

6. Medicines Used In Anaesthesia

0.2mg/kg/day are not generally recommended.Child 12 years:

initial: 0.05mg/kg preferably once at bed time; may be increased
every third day; usual range: 2 to 4 mg/day; do not exceed
10mg/day (0.2mg/kg/day).
Storage: store at room temperature.
Risperidone
Tablets, 1 mg, 2 mg, 3 mg, 4 mg, 6 mg
Oral solution, 1 mg/ml
Indications: for acute and chronic schizophrenic psychoses
with positive and/or negative symptoms, or when affective
symptoms are prominent. It is also used for the management of
behavioural symptoms (aggression, wandering, and agitation)
and psychosis associated with dementia.
Cautions: Parkinsons disease, cardiovascular disease, and
hepatic or renal impairment.
Drug interactions: chlorpromazine, fluoxetine, miconazole,
quinidine, quinine, ritonavir, clozapine, metoclopramide,
levodopa, carbamazepine.
Contraindications: hypersensitivity to risperidone.
Side effects: are similar to those of chlorpromazine; it has a
lower tendency to induce extrapypramidal symptoms than the
classic neuroleptics, although extrapypramidal phenomena,
tardive dyskinesia and the neuroleptic malignant syndrome have
all been reported. Orthostatic hypotension has been observed,
particularly with high initial doses. It can induce a dose
dependent increase in plasma prolactin concentration. Weight
gain may be notable.
Dose and Administration: Oral:Adult: 2 mg/day on the 1stday,
4 mg/day on the 2nd day, 6 mg/day on the 3rd day; then
individualised if necessary. Usual range 4 to 8 mg/day. Elderly
(or in renal or hepatic impairment): initially 1 mg/day, increased
262

6. Medicines Used In Anaesthesia

by 1 mg/day up to 2 to 4 mg/day. Note: Doses > 10 mg/day do not

appear to produce increased efficacy, and may cause increased side
effects.
Storage: protect from light.
Thioridazine Hydrochloride
Tablet, 10mg, 25mg, 100mg
Indications: under specialist supervision, second line treatment
of schizophrenia in adults (see notes above).
Cautions: see under chlorpromazine; ECG screening and
electrolyte measurement before treatment, after each dose
increase and at 6 month intervals; also monitor for visual defects
on prolonged use; avoid in porphyria.
Drug interactions: antiepileptics (except carbamazepine),
barbiturates, antihypertensives and B-blockers, anticoagulants;
anaesthetics, analgesics, anti-arrhythmics, antibacterials,
antidepressants, antifungals, antihistamines, antimalarials, other
antipsychotics, antivirals, diuretics, litium, pentamidine
isetionate, sibutramine
Contraindications: in patients with:Clinically significant
cardiac disorders (e.g. cardiac failure, angina, cardiomyopathy
or left ventricular dysfunction; QTc interval prolongation (see
cautions & Drug interactions); a history of ventricular
arrhythmias or Torsades de pointes; Bradycardia or 2nd or 3rd
degree heart block; A family history off QTc interval
prolongation; Uncorrected hypokalaemia or hypomagnesaemia
Side effects: see under chlorpromazine; less sedating then
chlorpromazine, and extrapyramidal symptoms and hypothermia
rarely occur; more likely to induce hypotension and increased
risk of cardiotoxicity and prolongation of QT interval,
pigmentary retinopathy (with reduced visual acuity, brownish
colouring of vision, and impaired night vision) occurs rarely
263

6. Medicines Used In Anaesthesia

with high doses; sexual dysfunction, particularly retrograde

ejaculation may occur.
Dose and Administration: Oral: Adult: 50 to 300 mg daily
(initially in divided doses): Maximum 600 mg daily (in hospital
patients only); child not recommended.
Storage: at room temperature in a tight, light resistant container.
Trifluoperazine hydrochloride
Tablets, 1 mg, 5 mg
Capsules, 2 mg, 10 mg
Syrup, 1 mg/5 ml
Injection, 1 mg/ml; 2 mg/ml
Indications: treatment of schizophrenia and for management of
psychotic disorders.
Cautions: cardiovascular disease, seizures, hepatic dysfunction,
narrow-angle glaucoma, or bone marrow suppression,
myasthenia gravis or parkinsons disease.
Drug interactions: aminoglutethimide, carbamazepine,
nevirapine, phenobarbital, phenytoin, azole antifungals,
ciprofloxacin, clarithromycin, diclofenac, doxycycline, isoniazid
and protease inhibitors.
Contraindications: severe CNS depression; bone marrow
suppression; blood dyscrasias, coma.
Side effects: hypotension, cardiac arrest, extrapyramidal
symptoms, dizziness, headache, constipation, stomach pain,
vomiting, hepatotoxicity, dizziness, and headache.
Dose and Administration: Adult: Oral: initially 5 mg twice
daily or 10 mg daily in modified - release form, increased by 5
mg after 1 week, then at intervals of 3 days, according to the
response. I.M: 1to 2 mg every 4-6 hours as needed up to 10
mg/24 hours maximum; for elderly 1 mg every 4 to 6 hours;
increase at 1 mg increments; do not exceed 6 mg/day. Child up
264

6. Medicines Used In Anaesthesia

to 12 years: Oral: initially up to 5 mg daily in divided doses,

adjusted according to response, age, and body weight.I.M: 1 mg
twice daily.Short term adjunctive management of severe anxiety:
Oral:Adult: 2 - 4 mg daily in divided doses or 2 - 4 mg daily in
modified-release form, increased if necessary to 6 mg
daily;Child 3 - 5 years, up to 1 mg daily, 6 - 12 years, up to 4
mg daily.
Storage: store at room temperature.
5.4. Antidepressants
The major classes of Antidepressants include the tricyclic and
related antidepressants, the Selective Serotonin Re-uptake
Inhibitors (SSRIs), and the Mono-Amine Oxides Inhibitors
(MAOIs); and a range of other compounds not usually
categorized in to groups.
This section covers Tricyclic Antidepressants (TCAs), SSRIs
and Serotonin noradrenaline re-uptake inhibitors (SNRIs)and
Norepinephrine-dopamine reuptake inhibitor (NDRI).
TCAs are most effective for treating moderate to severe
endogenous depression associated with psychomotor and
physiological changes such as loss of appetite and sleep
disturbances; improvement in sleep is usually the first benefit of
therapy. Since there may be an interval of 2 weeks before the
antidepressant action takes place electroconvulsive treatment
may be required in severe depression when delay is hazardous
or intolerable. Some tricyclic antidepressants are also effective
in the management of panic disorder.
TCAs are also important in some forms of neuralgia; and in
nocturnal enuresis in children. Tricyclic and related
antidepressant drugs can be roughly divided in to those with
additional sedative properties and those, which are less so.
265

6. Medicines Used In Anaesthesia

Amitriptyline: it is tertiary amine tricyclic antidepressants.

Agitated and anxious patients tend to respond best to this drug
because of its additional sedative property. Though amitriptyline
can be sedating, it is not recommended for use purely as a
sedative - hypnotic, as other agents have greater efficacy with
fewer adverse effects.
Amitriptyline and imipramine are well established and
relatively safe and effective, but nevertheless have more marked
antimuscrinic and cardiac side effects than other TCAs.
SSRIs which include fluoxetine, fluvoxamine, sertraline,
escitalopram and others have minimal anticholinergic effects
and are less cardiotoxic than the TCAs. Recent evidence
suggests that there is an increased risk of suicidality in
depressed children and adolescents given antidepressant
medications, and SSRIs in particular. This increased risk has not
been identified with SSRI treatment for anxiety
disorders.Serotonin and noradrenaline re-uptake inhibitors
(SNRIs), e.g. duloxetine, have tolerability profiles comparable
to those of SSRIs. Duloxetine weakly inhibits dopamine reuptake with no significant affinity for histaminergic,
dopaminergic, cholinergic or adrenergic receptors.
NDRI, e.g., Bupropion, for the treatment of depression, it is
often used in conjunction with an SSRI. It is one of the few
antidepressants that do not have sexual side effects, and it is
sometimes used to counteract the loss of libido and other sexual
side effects caused by SSRIs. Bupropion has many uses besides
treatment of depression, used in a smoking cessation (see
section 4.7).
5.4.1. Tricyclic Antidepressants
Amitriptyline
Tablet, 10mg, 25mg, 50mg
266

6. Medicines Used In Anaesthesia

Indications: depressive illness, particularly where sedation is

required; nocturnal enuresis in children.
Cautions: cardiac disease (Particularly with arrhythmias),
history of epilepsy, pregnancy and breastfeeding, elderly,
hepatic impairment (avoid if severe), thyroid disease,
phaeochromocytoma, history of mania, psychoses (may
aggravate psychotic symptoms) angle closure glaucoma, history
of urinary retention, concurrent electro-convulsive therapy; if
possible avoid abrupt withdrawal; anaesthesia (increased risk of
arrhythmias and hypotension); porphyria
Drug interactions: alcohol, other CNS depressants, antithyroid
agents, phenothiazine, cimetidine, clonidine, guanadrel,
guanethidine, extrapyramidal reaction causing medications,
metrizamide, MAO inhibitors and sympathomimetics.
Contraindications: recent myocardial infarction, arrhythmias
(particularly heart block), not indicated in manic phase, severe
liver disease.
Side effects: dry mouth, sedation, blurred vision (disturbance of
accommodation, increased intraocular pressure), constipation,
nausea, difficulty with micturation; cardiovascular.Side effects
such as ECG changes, arrhythmias, postural hypotension,
tachycardia, syncope, particularly with high doses; sweating,
tremor, rashes and hypersensitivity reactions (including urticaria,
photosensitivity), behavioural disturbances (particularly
children), hypomania or mania, confusion (particularly elderly),
interference with sexual function, blood sugar changes;
increased appetite and weight gain (occasionally weight loss),
endocrine side effects such as testicular enlargement,
gynaecomastia, galactorrhoea; also convulsions, movement
disorders and dyskinesias, fever, agranulocytosis, leucopoenia,
eosinophilia, purpura, thrombocytopenia, hyponatraemia (may
267

6. Medicines Used In Anaesthesia

be due to inappropriate antidiuretic hormone secretion),

abnormal liver function tests (jaundice);
Dose and Administration: OralAdult:Depression: initially 5075 mg (elderly and adolescents 30 - 75 mg) daily in divided
doses or as a single dose at bedtime increased gradually as
necessary to 150 - 200 mg;
Child: under 16 years not recommended for depression;
Nocturnal enuresis:Child 7 to 10 years, 10 to 20 mg, 11 to 16
years, 25 to 50mg at night; maximum period of treatment
(including gradual withdrawal) 3 months full physical
examination before further course.
Storage: at room temperature in a well closed container.
Amitriptyline + Chlordiazepoxide
Capsule, 12.5mg + 5mg; 25mg + 10mg
Indications: treatment of moderate to severe anxiety and/or
agitation and depression.
Dose and Administration: Oral: 3-4 tablets in divided doses;
this may be increased to 6 tablets/day as required; some patients
respond to smaller doses and can be maintained on 2 tablets.
Clomipramine Hydrochloride
Capsules, 10mg, 25mg, 50mg
Indications: phobic and obsessional states, panic attacks.
Cautions: cardiac disease, history of epilepsy, pregnancy,
breastfeeding, elderly, hepatic impairment, thyroid disease,
phaeochromocytoma, history of mania, psychoses, angleclosure glaucoma, history of urinary retention, concurrent
electroconvulsive therapy, avoid abrupt withdrawal, anaesthesia.
Drug interactions: alcohol, artemether + Lumefantrine,
carbamazepin, chlorpromazine, epinephrine, ethosuximide,
268

6. Medicines Used In Anaesthesia

fluphenazine,
haloperidol,
phenobarbital,
phenytoin,
procainamide, quinidine, ritonavir, valproic acid.
Contraindications: recent myocardial infarction, arrhythmias
(especially heart block); manic phase in bipolar disorders,
severe liver disease; children, porphyria.
Side effects: sedation, dry mouth, blurred vision, constipation,
nausea, difficulty in micturition; cardiovascular adverse effects
particularly with high dosage including ECG changes,
arrhythmias, postural hypotension, tachycardia, syncope,
sweating, tremor, rash and hypersensitivity reactions, behavioral
disturbances, hypomania or mania, confusion, interference with
sexual function, blood sugar changes, increased appetite and
weight gain, endocrine adverse effects, convulsions, movement
disorders and dyskinesias, fever, agranulocytosis, leukopenia,
eosinophilia, purpura, thrombocytopenia, hyponatraemia,
abnormal liver function test.
Dose and Administration: Oral:Adult: initially 50 to
75mg/day, increased gradually to 150 mg/day if
necessary.
May be given as a single dose at night or in 2 to 3 divided
doses.Elderly: initially 10mg/day, increasing carefully to 30 50mg/day.
Obsessive-Compulsive disorder: Dosage may have to be
increased beyond those generally used, e.g. to more than
200mg/ day; maximum 250mg/day.
Child: initially 10/mg/day, increased gradually to 20mg for 5-7
years old, and to 20 to 50 mg for 8 - 14 year olds. Alternatively,
18 - 23kg, 0.5 to 0.9 mg/kg/day; 25 - 48 kg, 0.8 to 1.1mg/kg/day
Storage: store at room temperature.
Imipramine
Tablet, 10mg, 25mg
269

6. Medicines Used In Anaesthesia

Indications: management of depressive illness. Nocturnal

enuresis (adjunctive therapy) in children over 6 years of age,
after exclusion of organic pathology; adjuvant to pain relief in
chronic pain syndromes, also drug management of panic
disorders.
Cautions: hyperthyroidism (or on thyroxin therapy),
arrhythmias, epilepsy, prostatic enlargement, closed-angle
glaucoma or impaired liver function.
Drug interactions: antihistamines, antipsychotics and anticholinergic type antiparkinsonian agents, cimetidine, fluoxetine,
paroxetine and steroids, hepatic enzyme-inducing agents, MAO
inhibitors.
Contraindications: early post myocardial infarction period and
heart block.
Side effects: dry mouth, blurred vision, constipation, and
difficulty with micturition. Blood pressure changes, syncope,
tachycardia, arrhythmias, precipitation of epileptic seizures,
sedation, excessive sweating, muscle tremors, restlessness,
weakness, interference with sexual function and confusional
states, especially in the elderly, extrapyramidal symptoms,
allergic skin reactions and, rarely, cholestatic jaundice and
blood disorders, including agranulocytosis. Occasionally
produce agitation and insomnia.
Dose and Administration:Oral:Adult:Depression: initial:
25mg 3-4 times/day, increase dose gradually, total dose may be
given at bedtime; maximum: 300mg/day.Elderly: initially 1025mg at bedtime; increasing up to 100mg/day as required and if
tolerated.
Child:Nocturnal enuresis: 6 - 7 years, 10 - 25mg; 8 - 11 years,
25 - 50mg; > 11 years, 25 - 75mg; given as a single dose after
the evening meal.
Storage: store at room temperature.
270

6. Medicines Used In Anaesthesia

Nortriptyline
Tablet, 10mg, 25mg
Indications: Depressive illness; nocturnal enuresis in children;
neuropathic pain
Cautions:bipolar disorder; schizophrenia; pregnancy; a history
of seizures, bladder problems, or glaucoma; hyperthyroidism;
diabetes.
Drug interactions: Anticholinergic medications (e.g., atropine,
benztropine,
pinaverium),
carbamazepine,
certain
antiarrhythmic medications (e.g., propafenone, flecainide,
encainide), cimetidine, fluoxetine, guanethidine, other
antidepressants especially MAO inhibitors (e.g., phenelzine,
tranylcypromine),
phenothiazines
(e.g.,
perphenazine,
chlorpromazine), quinidine, reserpine, sympathomimetic
medications (e.g., epinephrine)
Contra-indications: Hepatic impairment, Pregnancy; use only
if potential benefit outweighs risk, Breast-feeding
Side-effects:
abdominal
pain,
stomatitis,
diarrhoea,
hypertension, oedema, flushing, restlessness, fatigue, and
mydriasis.
Dose and Administration:Adults:Depression: 25 mg 3 or 4
times daily; dosage should begin at a low level and be increased
as required (max. 150 mg daily); Adolescent and elderly 30 to
50 mg daily in divided doses; child not recommended for
depression.
Nocturnal enuresis: child 7 years 10 mg, 8 to11 years 10 to
20 mg, over 11 years 25 to 35 mg, 30 minutes before bedtime;
max period of treatment (including gradual withdrawal) 3
monthsfull physical examination and ECG before further course.
Neuropathic pain [unlicensed]:initially 10 mg daily at night,
gradually increased if necessary to 75 mg daily; higher doses
under specialist supervision
271

6. Medicines Used In Anaesthesia

5.4.2. Selective Serotonin Re-uptake Inhibitors (SSRIs)

Escitalopram
Tablet, 5mg, 10mg, 20mg
Indications: treatment of major depressive disorder;
generalized anxiety disorder (GAD).
Cautions: previous seizure disorder, monitor worsening of
depression or suicidality.
Drug interactions: non selective MAO inhibitors (phenelizine),
fluconazole, fluvoxamine, gemfibrozil, isoniazid, omeprazole,
ciprofloxacin,
clarithromycin,
diclofenac,
doxycycline,
erythromycin, protease inhibitors, quinidine and verapamil.
Combined use of sumatriptan; NSAIDs, asprin. Carbamazepine,
phenytoin, rifampin, nevirapine, phenoarbital, phenytoin and
rifamycins
Contraindications:hypersensitivity reaction, concomitant use
or within 2 weeks of MAO inhibitors.
Side effects: headache, somnolence, insomnia, nausea, chest
pain, hypertension, palpitation, dizziness, fatigue, dreaming
anormal, concentration impaired, fever, irritability, lethargy,
lightheadedness, migraine, vertigo, yawning, rash, hot flashes,
libido decreased, anorgasmia, menstrual cramps, menstrual
disorder,diarrhea, xerostomia, appetite decreased, constipation,
indigestion, abdominal pain, abdominal cramps, appetite
increased, flatulence, heartburn, toothache, vomiting, weight
gain/loss, impotence, urinary tract infection, blurred vision,
sinusitis, cough.
Dose and Administration: Depression, GAD:Oral:Adult:
initial: 10mg/day; dose may be increased to 20mg/day after at
least 1 week. Elderly: 10mg/day; bioavailability and half-life
are increased by 50% in the elderly
Storage: store at room temperature.
272

6. Medicines Used In Anaesthesia

Fluoxetine
Capsule, 20mg
Indications: depressive disorders, bulimia nervosa; obsessivecompulsive disorder (OCD).
Cautions: hepatic or renal impairment, epilepsy and diabetes.
Drug interactions: flecainide, metoprolol, nifedipine,
diclofenac, omeprazole, clozapine, fluphenazine, haloperidol,
risperidone, antidepressants, terfenadine, carbamazepine and
phenytoin; CNS depressants, diazepam and alprazolam; highly
protein- bound drugs; lithium, MAO inhibitors; moclobemide,
serotonergic agents.
Side effects: headache and gastrointestinal disturbances, CNS
effects; mania or hypomania may be precipitated in some
patients. Seizure threshold may be lowered, predisposing to
epilepsy. Skin rashes have been reported and may be a warning
of a serious systemic reaction, possibly related to vasculitis.
Decreased libido and sexual dysfunction, weight loss, asthenia,
hypoglycemia, hyponatraemia, and elevated transaminase levels.
Altered platelet function and abnormal bleeding.
Dose and Administration:Oral:Adult:Depression: 20mg/day.
May be increased by 20mg/day, if required; maximum 60 mg/day.
The elderly: use the lowest effective dose.Bulimia nervosa: increase
up to 60mg/day. OCD: 20-60mg/day; maximum 80 mg/day.

Child:Depression: 8-18 years: 10-20 mg/day; lowerweight

children can be started at 10mg/day, may increase to 20 mg/day
after 1 week if needed.OCD: 7-18 years: initial: 10mg/day; in
adolescents and higher-weight children, dose may be increased
to 20mg/day after 2 weeks. Range: 10-60 mg/day.
Storage: store at controlled room temperature.
Fluvoxamine maleate
Tablets, 40 mg, 100 mg
273

6. Medicines Used In Anaesthesia

Indications: Major depressive disorders, especially where

sedation is undesirable; panic disorder; obsessive-compulsive
disorder, social phobia.
Cautions: mania, epilepsy, cardiac disease, hepatic or renal
impairment.
Drug interactions: MAO inhibitors, cimetidine, lithium,
phenytoin,
serotonergic
agents,
sumatriptan,
TCAs,
phenothiazine neuroleptics, antiarrhythmics class Ic (e.g.
propafenone), warfarin.
Contraindications: hypersensitivity to fluvoxamine.
Side effects: nausea, somnolence, sweating, tremor, dry mouth,
asthenia, insomnia, constipation, dizziness, sexual dysfunction,
dyspepsia, vomiting, diarrhea, anxiety, decreased appetite and
headache.Extrapyramidaleffects have been reported, also skin
rashes, bruising and elevations of hepatic enzymes, with isolated
reports of serious liver function abnormalities. Hyponatraemia
has been reported, especially in the elderly.
Dose and Administration:Oral:Adult:Depression: initially
100mg daily as a single dose in the evening, increased if
necessary; usual range 100 - 200 mg/day; maximum 300mg/day.
Doses above 150mg/day should be given in 2-3 divided
doses.OCD: initially 50mg daily for 3- 4 days, increased
gradually; usual range 100-200mg/day; maximum 300mg/day.
If no improvement within 10 weeks, treatment should be
reconsidered.Child:OCD: 8-17 years: initial: 25mg at bedtime;
adjust in 25 mg increments at 4-7 day intervals, as tolerated, to
maximum therapeutic benefit: Range: 50-200mg/day.
Maximum: 8-12 years: 200mg/day, adolescents: 300mg/day;
lower doses may be effective in female versus male patients.
Storage: store at room temperature.

274

6. Medicines Used In Anaesthesia

Paroxetine
Tablet, 20mg
Indications: Major depression, obsessive-compulsive disorder,
panic disorder; social anxiety disorder; post-traumatic stress
disorder; generalised anxiety disorder
Cautions: Also achlorhydria or high gastric pH (reduced
absorption of oral suspension)
Contraindications:Hepatic impairment, Renalimpairment,
Pregnancy and Breast-feeding
Side effects: also yawning; abnormal dreams; raised cholesterol;
less commonly arrhythmias, confusion, urinary incontinence;
rarely panic attacks and paradoxical increased anxiety during
initial treatment of panic disorder (reduce dose),
depersonalisation, and neuroleptic malignant syndrome-like
event; rarely restless legs syndrome; very rarely peripheral
oedema, acute glaucoma, hepatic disorders (e.g. hepatitis), and
priapism; also reported tinnitus, extrapyramidal reactions
(including orofacial dystonias) and withdrawal reactions
Dose and Administration: Major depression, social anxiety
disorder, post-traumatic stress disorder, generalised anxiety
disorder:Adult over 18 years: usually 20 mg each morning,
higher doses on specialist advice only; maximum 50 mg daily
(elderly 40 mg daily); child under 18 years not recommended.
Obsessive-compulsive disorder: Adult over 18 years: initially
20 mg each morning increased gradually in steps of 10 mg to
usual dose of 40 mg daily, higher doses on specialist advice
only; max. 60 mg daily (elderly 40 mg daily).Panic
disorder:Adult over 18 years: initially 10 mg each morning
increased gradually in steps of 10 mg to usual dose of 40 mg
daily, higher doses on specialist advice only; maximum 60 mg
daily (elederly 40 mg daily).
275

6. Medicines Used In Anaesthesia

Sertraline hydrochloride
Tablets, 50mg, 100mg
Indications, Cautions, Drug interactions and Side effects;
see under fluvoxamine.
Dose and Administration: Oral:Adult:Depression: initially
50mg daily, usual range 50 - 100 mg/day. May be increased, if
necessary, by 50mg over several weeks up to a maximum of 200
mg/day.OCD: the minimum effective dose is 50mg/day.
Increase, if necessary, in 50mg increments over several weeks
up to a maximum of 200mg/day.Panic disorder: initially 25mg
daily, increased to 50mg/day after 1 week, and thereafter, if
necessary, in 50mg increments up to a maximum of
200mg/day.Child: OCD: 6-12 years: initial: 25mg once daily;
13-17 years: initial: 50mg once daily.
Storage: store at controlled room temperature.
5.4.3. Serotonin and noradrenaline re-uptake inhibitors
(SNRIs)
Duloxetin
Tablet, 30mg, 40mg, 60mg
Indications: treatment of major depressive disorder.
Cautions: renal impairment or with concomitant CNS
depressants.
Drug interactions: MAO inhibitors, TCAs, buspirone, SSRIs,
tramadol,
amiodarone,
chlorpromazine,
ciprofloxacin,
delavirdine, fluvoxamine, fluoxetine, ketoconazole, miconazole,
norfloxacin, ofloxacin, aminoglutethimide, carbamazepine,
phenobarbital, and rifampicin.
Contraindications: hypersensitivity to the drug, concomitant
use or within 2 weeks of MAO inhibitors; uncontrolled narrow
angle glaucoma.
276

6. Medicines Used In Anaesthesia

Side effects: insomnia, somnolence, dizziness, headache, nausea,

xerostomia, constipation, appetite decreased.
Dose and Administration: Oral: Adult: initial: 40-60 mg/day;
dose may be divided (i.e., 20 or 30 mg twice daily) or given as a
single dose of 60mg; maximum dose: 60 mg/day.Elderly:
treatment or major depressive disorder; initial dose; 20mg 1-2
times/day; increase to 40-60mg/day as a single daily dose or in
divided dose.
Storage: store at room temperature.
5.4.4. Norepinephrine-dopamine reuptake inhibitor
Bupropion
Tablet, 75mg, 100mg
Indications: treatment of depression; adjunct in smoking
cessation.
Caution: elderly; predisposition to seizures (prescribe only if
benefit clearly outweighs risk) including concomitant use of
drugs that lower seizure threshold, alcohol abuse, history of
head trauma, and diabetes; measure blood pressure before and
during treatment.
Drug interactions:prochlorperazine, chlorpromazine, and other
antipsychotic medications of the phenothiazine class.
Additionally,
persons
who
are
withdrawing
from
benzodiazepines [for example, diazepam, alprazolam ] are at
increased risk for seizures. Carbamazepine, MAO inhibitors,
warfarin
Contraindications: Acute alcohol or benzodiazepine
withdrawal; severe hepatic cirrhosis; CNS tumour; history of
seizures, eating disorders, or bipolar disorder
Side effects: dry mouth, gastro-intestinal disturbances, taste
disturbance; agitation, anxiety, dizziness, depression, headache,
277

6. Medicines Used In Anaesthesia

impaired concentration, insomnia (reduced by avoiding dose at

bedtime), tremor; fever; pruritus, rash, sweating; less commonly
chest pain, flushing, hypertension, tachycardia, anorexia,
asthenia, confusion, tinnitus, and visual disturbances; rarely
hepatitis, jaundice, palpitation, postural hypotension,
vasodilatation,
abnormal
dreams,
ataxia,
dystonia,
depersonalisation, hallucinations, hostility, incoordination,
irritability, impaired memory, paraesthesia, seizures, twitching,
blood-glucose changes, urinary frequency, urinary retention,
exacerbation of psoriasis, and Stevens-Johnson syndrome; very
rarely aggression, delusions, paranoid ideation, and restlessness;
also reported suicidal ideation
Dose and Administration: Adult: over 18 years, start 12
weeks before target stop date, initially 150 mg daily for 6 days
then 150 mg twice daily (max. single dose 150 mg, max. daily
dose 300 mg; minimum 8 hours between doses); period of
treatment 79 weeks; discontinue if abstinence not achieved at 7
weeks; consider max. 150 mg daily in patients with risk factors
for seizures; Elderly max. 150 mg daily
Storage: at room temperature, 15-25 C.
5.5. Mood Stabilizers
Lithium is regarded as a mood stabilizer, with antimanic and
antidepressant effects. Primary use is as a prophylactic agent in
bipolar affective disorders, where it has been shown to reduce
chiefly the manic, but also the depressive relapses. It is also
useful in treating the acute manic stage, but is rarely
recommended for depressive illnesses of the unipolar type.
Lithium carbonate
Tablet, 300 mg, 400 mg
278

6. Medicines Used In Anaesthesia

Indications: treatment and prophylaxis of mania, prophylaxis of

bipolar disorder and recurrent depression.
Cautions: measure serum-lithium concentration about 4 days
after starting treatment, then weekly until stabilized, then at
least every 3 months, monitor thyroid function and renal
function, maintain adequate fluid and sodium intake, reduction
of dose or discontinuation may be necessary, in diarrhoea,
vomiting and intercurrent infection, pregnancy, breastfeeding,
elderly, diuretic treatment, myasthenia gravis, surgery, if
possible, avoid abrupt withdrawal.
Drug interactions: combination of lithium with other drugs,
including over-the-counter medicines, should be carefully
monitored, ACE inhibitors, antithyroid agents of iodides,
neuroleptics, non-steroidal anti-inflammatory agents, thiazide
and loop diuretics, xanthines.
Contraindications: cardiac disease, renal impairment or urinary
retention, CNS disorders, e.g. epilepsy.
Side effects: gastrointestinal disturbances, fine tremor, polyuria,
polydipsia, weight gain and oedema; signs of intoxication
include blurred vision, muscle weakness, increasing
gastrointestinal disturbances, increased CNS disturbances and
require withdrawal of treatment, with severe overdosage,
hyperreflexia and hyperextension of the limbs, convulsions,
toxic psychoses, syncope, oliguria, circulatory failure, coma,
occasionally death, goitre, raised antidiuretic hormone
concentration, hypothyroidism, hypokalaemia, ECG changes,
exacerbation of psoriasis and kidney changes may occur.
Dose and Administration: Oral:Adult: initially 20 mg/kg/day
in divided doses, adjusting the dose, if necessary, to achieve a
plasma concentration of 0.4 - 0.8 millimol/L. Sustained - release
preparations are given once or twice daily.
Storage: store in a well-closed container at room temperature.
279

6. Medicines Used In Anaesthesia

5.6. Anticonvulsants
Treatment should always be started with a single drug, but the
choice of an anticonvulsant can only be made on an individual
basis and will depend on the efficacy of the drug and the
patients tolerance of treatment. If a drug fails to control the
seizures after it has been used in full therapeutic dosage for an
adequate period, or if it is not tolerated, it should be gradually
substituted with another with the first drug being withdrawn
only when the new regimen is mainly established. If
monotherapy is ineffective, two drugs should be given in
combination and several regimens may need to be tried before
the most appropriate is found.
Carbamazepine is used as a first-line drug in the treatment of
partial seizures with or without secondary generalization and
tonic-clonic seizures; it is also effective in other forms of
epilepsy. It may exacerbate absence and myoclonic seizures,
and may cause deterioration of juvenile myoclonic epilepsy if
used to treat tonic-clonic seizures occurring within the
syndrome. Carbamazepine is often preferred in children because
it lacks the dysmorphic adverse effects associated with
phenytoin. However, carbamazepine does posses some unique
pharmacokinetic characteristics, particularly in children and
manipulation of dosage forms and schedules to accommodate
individual needs may be necessary. Carbamazepine elimination
is more rapid in children and accumulation of the active
metabolite is often higher than in adults.
Phenytoin is used as a first-line drug in the treatment of partial
and tonic-clonic seizures; it may also be used in other forms of
epilepsy, with the exception of absence and myoclonic seizures.
The non-linear pharmacokinetics of phenytoin make it difficult
to use, particularly at higher doses, because small increases in
doses may produce large rises in plasma concentrations.
280

6. Medicines Used In Anaesthesia

Phenytoin may be unsuitable in adolescents and women because

of potential coarsening of the facial features, acne, or hirustism.
Gingival hyperplasia and tenderness can also be a problem. The
potential effects of phenytoin on cognition may make it less
suitable in young children.
Valproic acid or valproate is used as a first-line drug in the
treatment of absence, tonic-clonic, and myoclonic seizures. It
may also be used for partial seizures and is effective in some
epileptic syndromes.
Phenobarbitone is used in all forms of epilepsy with the
exception of absence seizures. It has been widely used in
children and neonates in particular, perhaps because of
convenient of administration and linear phramcokinetics, but
there is concern about its effects on cognition.
The use of benzodiazepines for the long-term treatment of
epilepsy is limited by problems of tolerance, sedation, and the
development of dependence; withdrawal seizures are also a
problem. Diazepam is not used in the prophylaxis of epileptic
seizures but is of value in the treatment of febrile convulsions
Withdrawal: Treatment is normally continued for a minimum of
two years after the last seizure. Withdrawal should be extended
over a period of several months since abrupt withdrawal can
lead to complications such as status epilepticus. Abrupt
discontinuation is therefore never warranted. Many adult
patients relapse once treatment is withdrawn and it may be
justified to continue treatment indefinitely, particularly when the
patient's livelihood or lifestyle can be endangered by recurrence
of a seizure.
Pregnancy and Breastfeeding: There is an increased risk of birth
defects with the use of anticonvulsants, particularly
carbamazepine, valproate and phenytoin. However, if there is
good seizure control, there is probably no advantage in changing
281

6. Medicines Used In Anaesthesia

pregnant patients' antiepileptic drugs. In view of the risks of

neural tube and other defects, patients who may become
pregnant should be informed of the risks and referred for advice,
and pregnant patients should be offered counseling and
antenatal screening. To counteract the risk of neural tube
defects, adequate foliate supplements are advised for women
before and during pregnancy. In view of the risk of neonatal
bleeding associated with carbamazepine, phenobarbital and
phenytoin, prophylactic phytomenadione (vitamin k1) is
recommended for the neonatal and the mother before delivery.
Antiepileptic drugs can be continued during breastfeeding.
Acetazolamide
Tablet, 125 mg, 250 mg
Indications: treatment of centrencephalic epilepsies.
Cautions, Drug interactions, Contraindications, Side effects
and Storage; see section 2.6.under acetazolamide.
Dose and Administration: Oral:Adult: 8-30mg/kg/day in 1-4
divided doses.
Child: 8-30 mg/kg/day in 1-4 divided doses, not to exceed
1g/day.
Carbamazepine
Tablet, 100mg, 200mg
Syrup, 100mg/5ml
Indications: partial and secondary generalized tonic-clonic
seizures, some primary generalized seizures; trigeminal
neuralgia, prophylaxis of bipolar disorder unresponsive to
lithium.
Cautions: hepatic or renal impairment; cardiac disease (see also
contraindications). Skin reactions, history of hematological
reactions to other drugs; glaucoma; pregnancy (see notes above),
282

6. Medicines Used In Anaesthesia

breastfeeding (see notes above); avoid abrupt withdrawal (see

notes above); see also interactions
Drug interactions: acetazolamide, amitriptyline, chloroquine,
chlorpromazine, ciclosporin, cimetidine, clomipramine,
clonazepam, oral contraceptives, dexamethasone, erythromycin,
ethosuximide, fludrocortisone, fluphenazine, haloperidol,
hydrocortisone,
isoniazide,
levonorgestrel,
medroxyprogesterone,
mefloquine,
norethisterone,
phenobarbital, phenytoin, prednisolone, valproic acid, verapamil,
warfarin.
Contraindications: atrioventricular conduction abnormalities;
history of bone marrow depression; porphyria.
Side effects: dizziness, drowsiness, headache, ataxia, blurred
vision, diplopia (may be associated with high plasma levels);
gastrointestinal intolerance including nausea and vomiting,
anorexia, abdominal pain, dry mouth, diarrhea or constipation;
commonly, mild transient generalized erythematous rash
(withdraw if worsens or is accompanied by other symptoms);
leukopenia
and
other
blood
disorders
(including
thrombocytopenia, agranulocytosis and aplastic anemia);
cholestic jaundice, hepatitis, acute renal failure, Stevens
Johnson syndrome (erythema multiform), toxic epidermal
necrolysis, alopecia, thromboembolism, arthralgia, fever,
proteinuria, lymphnode enlargement, arrhythmias, heart block
and heart failure, dyskinesias, parasthesia, depression,
impotence, male infertility, gynaecomastia, galactorrhoea,
aggression, activation of psychosis, photosensitivity, pulmonary
hypersensitivity, hyponatraemia, oedema, disturbances of bone
metabolism with osteomalacia also reported; confusion and
agitation in elderly.
Dose and Administration: Adult:Oral: Epilepsy: initially, 100
- 200 mg twice daily, with increments of 100-200mg/day at
283

6. Medicines Used In Anaesthesia

weekly intervals according to seizure control and adverse

symptoms.Maintenance range (i.e. minimum effective dosage)
is generally 600-1200 mg/day in divided doses, but up to
1.6g/day may occasionally be necessary. Elderly: start with
100mg twice daily and increase as required. Trigemial
neuralgia and pain syndromes: initially 100mg twice daily,
increased by 100mg every 12 hours until pain is relieved
(maximum 1.2g/day). Once pain is controlled, the dose may be
decreased over a period of a few weeks to a maintenance dose,
usually 400-800 mg/day.
Prophylaxis of bipolar disorder unresponsive to lithium:
initially 400mg daily in divided doses increased until symptoms
controlled; usual range 400 - 600mg daily; max. 1.6 g
daily.Mood stabilizer: Dosage as for epilepsy (usually 400600mg/day). Response usually takes 7-10 days to become
evident.Child:Epilepsy: 12-15 years, as for adults but maximum
1g/day.6-12 years, initially 100mg twice daily, increasing by
100mg/day at weekly intervals until optimal response and
plasma levels are obtained.Usual maintenance, 400-800 mg/day
(maximum 1g/day).Under 6 years, initially 10-20mg/kg/day in
2-3 divided doses, increasing by up to 100mg/day at weekly
intervals as needed. Usual maintenance 200-350 mg/day,
maximum 400 mg/day; under 1 year, 100-200 mg/day.
Storage: at room temperature in a tight, light-resistant container.
Protect from freezing (syrup).
Clonazepam
Injection, 1 mg/ml in 1ml ampoule
Tablet, 0.5 mg, 1mg, 2 mg
Indications: management of myoclonic and atonic/ akinetic
seizures in children, and as an adjuvant agent in the
management of other forms of epilepsy. It is used as an
284

6. Medicines Used In Anaesthesia

alternative to diazepam in the emergency treatment of status

epilepticus.
Cautions: respiratory disease; hepatic impairment, renal
impairment; elderly and debilitated; pregnancy; breastfeeding;
avoid sudden withdrawal, porphyhria.
Drug interactions: acetazolamide, alcohol, carbamazepine,
phenobarbital, phenytoin, ritonavir.
Contraindication: hypersensitivity to clonazepam.
Side effects: frequently - fatigue, drowsiness, ataxia and
clumsiness, especially early in treatment. Paradoxical
hyperkinesis, excitability, aggressiveness and other behavioral
problems may occur, particularly in children with pre-existing
brain damage or in patients with a history of aggressiveness.
Other effects include headache and muscle weakness.
Dose and Administration: Adult: Oral: start with small doses
and increase gradually to an optimum dose according to
individual response. Initially 1mg at night for 4 nights,
increased over 2 - 4 weeks to usual maintenance of 4 - 8
mg/day.Status epilepticus: IV: 1mg injected slowly, over 30
seconds; may be repeated as required.Child:Oral: initially
0.05mg/kg/day in 3 divided doses, increased slowly if needed to
a maximum of 0.3 mg/kg/day. Usual maintenance: < 1 year, 0.5
- 1mg/day; 1 - 5 years, 1 - 3mg/day; 5 - 12 years, 3 - 6mg/day,
in 3 divided doses.Status epilepticus:IV: 0.5mg by slow
injection.
Storage: store tablets at room temperature.
Diazepam
Suppository, 5mg, 10mg
Injection, 5mg/ml in 2ml ampoule
Indications: It is indicated as adjunct in static epilepticus and
severe recurrent convulsive seizures.
285

6. Medicines Used In Anaesthesia

Cautions, Drug interactions, Contraindications, and Side

effects; see notes on diazepam under 4.2.
Dose and Administration:Adult:anticonvulsants:IV: 5-10mg
initially, the dosage being repeated, if necessary, at 10-15
minutes
interval
up
to
a
maximum
dose
of
30mg.Child:Anticonvulsant: status epilepticus and severe
recurrent convulsive seizures.Infants over 30 days of age and
children up to 5 years of age:IV (slow): 0.2 to 0.5 mg every 2-5
minutes
up
to
a
maximum
of
5mg. If necessary, therapy should be continued.Child 5 and
older: IV (slow): 1mg every two to five minutes up to a
maximum of 5mg. If necessary, therapy may be repeated in two
or four hours. Elderly:Anticonvulsant:IM or IV, initially, 2 to 5
mg per dose, the dosage being increased gradually as needed
and tolerated.
Storage: store at room temperature. Protect from light and
freezing.
Diphenylhydantoin (Phenytoin)
Tablet, 50 mg, 100mg
Capsule, 50 mg, 100 mg
Suspension, 30 mg/ 5 ml
Powder forinjection (sodium), 250 mg in vial
Injection, 50mg/ml in 5ml vial (Sodium salt)
Indications: generalized tonic-clonic seizures; partial seizures;
status epilepticus.
Cautions: renal and hepatic function impairment (reduce dose),
porphyria, blood dyscrasias, and during pregnancy, breast
feeding; avoid sudden withdrawal; blood counts should be
determined prior to and during therapy with these drugs.
Caution for sensitive to hydantoin anticonvulsants.
Drug interactions:alcohol, CNS depressant, chloramphenicol,
antituberculosis agents, amiodarone, corticosteroids, cimetidine,
286

6. Medicines Used In Anaesthesia

calcium, diazoxide (oral), antacids (aluminium-magnesium

containing and calcium carbonate containing), anticoagulants
(coumarin or indandione derivative), disulfiram,
contraceptives, fluconazole, intraconazole, ketoconazole,
miconazole, estrogen, progestins, felbamate, fluoxetine,
lidocaine, phenacenide, methadone, sucralfate, valproic acid,
theophylline.
Contraindications: cardiac function impairment, such as
Adams- stokes syndrome, second and third degree AV block,
sino-atrial block, and sinus bradycardia (parenteral Phenytoin
administration may affect ventricular automaticity and result in
ventricular arrhythmias).
Side effects:nausea, vomiting, mental confusion, dizziness,
headache, tremor, transient nervousness, insomnia occur
commonly; rarely dyskinesias, peripheral neuropathy; ataxia,
slurred speech, nystagmus and blurred vision are signs of
overdosage; rashes (discontinue, if mild re-introduce cautiously
but discontinue immediately if recurrence), coarse facies, acne
and hirsutes, fever and hepatitis, lupus erythematosus, erythema
multiforme, toxic epidermal necrolysis, poly arteritis nodosa
lymphadenopathy; gingival hypertrophy and tenderness ; rarely
haemataological effects, including megaloblastic anaemia,
leucopenia, thrombocytopenia, agranulocytosis and aplastic
anaemia; plasma calcium may be lowered (rickets and
osteomalacia).
Dose and Administration: Generalized tonic-clonic seizures,
partial seizures: Oral: Adult: initially 3-4 mg/kg daily (as a
single dose or in 2 divided doses), increased gradually at
intervals of 2 weeks as necessary (with plasma- phenytoin
concentration monitoring); usual dose 200 500 mg daily.
Child: initially 5 mg/kg daily in 2 divided doses; usual dose
range 4-8 mg/kg daily (maximum 300 mg).
287

6. Medicines Used In Anaesthesia

Note. Plasma concentration for optimum response 10-20 mg/litre (4080 micromol/litre).Patient advice: Preferably taken with or after food.
Status epilepticus: Slow IV injection or by IV infusion (with blood
pressure and ECG monitoring),

Adult: 15 mg/kg at rate of not more than 50 mg/minute, as a

loading dose; maintenance doses of about 100mg by mouth or
by slow IV injection should be given thereafter at intervals of 68 hours, monitored by measurement of plasma concentrations;
rates and dose reduced according to weight. Child: 15 mg/kg as
loading dose at rate of 1 mg/kg/minute (not exceeding 50
mg/minute). Neonate: 15-20 mg/kg as a loading dose at rate of
1-3 mg/kg/minute.
Storage: store in a well-closed container at room temperature,
protect from freezing.
Ethosuximide
Capsule, 250 mg,
Syrup, 250 mg/5ml
Indications: Management of absence (petitmal) epilepsy.
Cautions: hepatic or renal impairment; blood counts and
hepatic and renal function tests recommended; pregnancy;
breastfeeding; avoid sudden withdrawal; porphyria.Note: patients
or their carers should be told how to recognize signs of blood
disorder, and advised to seek immediate medical attention if
symptoms such as fever, sore throat, mouth ulcers, bruising or
bleeding develop.May impair ability to perform skilled tasks, for
example operating machinery, driving.

Drug interactions: other antiepileptics, CNS depressants.

Contraindications: hypersensitivity to the drug.
Side effects: frequently- gastrointestinal disturbances, causing
anorexia, diarrhoea, epigastric pain, nausea and vomiting.Less
frequently - adverse CNS effects including drowsiness,
headache, dizziness, euphoria, ataxia and depression.Rarely 288

6. Medicines Used In Anaesthesia

haematopoietic
disorders
(leucopenia,
agranulocytosis,
pancytopenia, aplastic anaemia), psychotic states.Skin reactions,
including Stevens - Johnson syndrome, may occur.
Dose and Administration: Oral:Adult: initially 500mg daily,
increased according to need by 250mg every 4 - 7 days to a
maximum of 1.5g/day, in divided doses.
Child: 3 - 6 years, initially 250mg daily; > 6 years, 500mg daily;
adjust according to plasma levels and clinical response.
Doses exceeding 1.5g/day (in divided doses), should be used
only under strict supervision.
Note: Daily doses of 1 g and above should be taken as 2 or more
divided doses.Plasma concentration for optimum response 40100mg/litre (300-700 micromol/litre)

Storage: store at room temperature.

Lamotrigine
Tabelet, 25mg, 50mg, 100mg, 200mg
Indications: Monotherapy and adjunctive treatment of focal
seizures and generalised seizures including tonic-clonic seizures;
seizures
associated
with
Lennox-Gastaut
syndrome;
monotherapy of typical absence seizures in children; prevention
of depressive episodes associated with bipolar disorder
Cautions: Closely monitor and consider withdrawal if rash,
fever, or other signs of hypersensitivity syndrome develop;
avoid abrupt withdrawal (taper off over 2 weeks or longer)
unless serious skin reaction occurs; myoclonic seizures (may be
exacerbated); Parkinsons disease (may be exacerbated). Blood
disorders (Be alert for symptoms and signs suggestive of bonemarrow failure such as anaemia, bruising, or infection. Aplastic
anaemia, bone-marrow depression and pancytopenia have been
associated rarely with lamotrigine).
289

6. Medicines Used In Anaesthesia

Drug
interactions:
Antidepressant,
Antiepileptics,
Antimalarials,
Barbiturates,
Oral
contraceptives
and
Paracetamol.
Contraindications: impaired renal or hepatic function.
Side-effects: nausea, vomiting, diarrhoea, dry mouth,
aggression, agitation, headache, drowsiness, dizziness, tremor,
insomnia, ataxia, back pain, arthralgia, nystagmus, diplopia,
blurred vision, rash ; rarely conjunctivitis; very rarely hepatic
failure, aseptic meningitis, movement disorders, unsteadiness,
increase in seizure frequency, exacerbation of Parkinsons
disease, confusion, hallucination, blood disorders (including
anaemia, leucopenia, thrombocytopenia, pancytopeniasee
Blood Disorders, above), hypersensitivity syndrome (possibly
including rash, fever, facial oedema, lymphadenopathy, hepatic
dysfunction, disseminated intravascular coagulation, and multiorgan dysfunction). Serious skin reactions including StevensJohnson syndrome and toxic epidermal necrolysis have
developed especially in children; most rashes occur in the first 8
weeks. Rash is sometimes associated with hypersensitivity
syndrome and is more common in patients with history of
allergy or rash from other antiepileptic drugs. Consider
withdrawal if rash or signs of hypersensitivity syndrome
develop. Factors associated with increased risk of serious skin
reactions include concomitant use of valproate, initial
lamotrigine dosing higher than recommended and more rapid
dose escalation than recommended.
Dose and Administration:Monotherapy, initialy 25mg daily
for 14 days, increased to 50mg daily for further 14 days, and
then increased by max. Of 50-100mg every 7-14 days; usual
maintenance as montherapy, 100-200mg daily in 1-2 divided
doses (up to 500mg daily has been required). Adjunctive
therapy with valproate, initially 25mg every other day for 14
290

6. Medicines Used In Anaesthesia

days then 25mg daily for furthuer 14 days, thereafter increased

by max. Of 25-50mg evry 7-14 days; usual maintenance, 100200 mg daily in 1-2 divided doses.Adjunctive therapy (with
enzyem inducing drug) without valproate, intially 50mg daily
for 14 days then 50mg twice daily for further 14 days, thereafter
increased by maximum of 100mg every 7-14 days; usual
maintenance 200-400mg daily in 2 divided doses (up to 700mg
daily has been required).
Child: under 12 years, monotherapy, not recommended.
Child: 2-12 years, adjunctive therapy with valproate, initially
150 microgram/kg daily for 14 days (thos weighing 17-33kg
may receive 5mg on alternate days for first 14 days) then 300
micrograms/kg daily for furthur 14 days, thereafter increased by
300 microgram/kg every 7-14 days; usul maintenance 1-5mg/kg
daily in 1-2 divided doses.Child: 2-12 years adjunctive therapy
(with enzyme including drugs) without valproate, initialy 600
microgram/kg daily in 2 divided doses for 14 days then
1.2mg/kg daily in 2 divded doses for furthur 14 days, therearfter
increased by 1.2mg/kg every 7-14 days; usual maintenance 5-15
mg/kg daily in 2 divided doses.
Lorazepam
Tablet (Sublingual), 1mg, 2mg
Injection, 1mg, 4mg
Indications: conscious sedation for procedures; premedication;
short-term use in anxiety or insomnia; status epilepticus, perioperative febrile convulsions; convulsions due to poisoning.
Cautions: see under Diazepam; short acting; when given
parenterally, facilities for managing respiratory depression with
mechanical ventilation must be available
Drug interactions: see under Diazepam
291

6. Medicines Used In Anaesthesia

Contraindications: Hypersensitivity to lorazepam or any

component of the formulation (cross-sensitivity with other
benzodiazepines may exist); acute narrow-angel glaucoma;
sleep apnea (pareteral); intra-arterial injection of parenteral
formulation; several respiratory insufficiency (expect during
mechanical ventilation); pregnancy
Side effects: see under Diazepam
Dose and Administration:Adult: By mouth, anxiety, 14 mg
daily in divided doses.
Adult: Insomnia associated with anxiety, 12 mg at bedtime.
Adult: By intramuscular or slow intravenous injection (into a
large vein), acute panic attacks, 2530 micrograms/kg (usual
range 1.52.5 mg), repeated every 6 hours if necessary. Child
under 12 years: not recommended.
Magnesium Sulfate
Injection, 50% in 20 ml
Indications: prevention of recurrent seizures in eclampsia, as
seizure prophylaxis in sever pre-eclampsia
Cautions: hepatic impairment, renal failure.
Drug interactions: alcuronium, nifedipine, suxamethonium,
vacuronium.
Contraindications: heart block, serious renal impairment,
myocardial damage, hepatitis, Addisons disease.
Side effects: hypermagnesaemia, nausea, vomiting, thirst,
flushing of skin, hypotension, arrhythmias, respiratory
depression, drowsiness, confusion, less of tendon reflexes,
muscle weakness.
Dose and Administration: Adult:IV injection, initially 4g over
5 - 10 minutes followed by IV infusion at a rate of 1g every hour
for at least 24 hours after the last seizure, recurrence of seizures
may require additional IV bolus of 2g.
292

6. Medicines Used In Anaesthesia

Storage: store at room temperature.

Paraldehyde
Injection, in 2ml, 5ml and 10ml ampoules
Indications: used to control status epilepticus resistant to
conventionaltreatment.
Cautions:bronchopulmonary disease or hepatic impairment.
Plastic syringes should be avoided.
Drug interactions: CNS depressants (alcohol, barbiturates, and
other sedatives).
Contraindications: hypersensitivity to the drug.
Side effects: tissue necrosis, sterile abscesses, and nerve
damage.
Dose and Administration: IM: AdultIM 5-10 ml. IV 5 ml
diluted with at least 100 ml of 0.9% of NaCl at a rate not
exceeding 1ml/min. Rectal 10-20 ml. Pediatric: IM 0.15ml/kg
of body weight or 6ml/m2 of body surface area. IV 0.1-0.15 ml/
kg of body weight diluted with 0.9% of NaCl administered
slowly.
Storage: store in small well-filled airtight containers. Protect
from light.
Phenobarbitone (Phenobarbital)
Tablets 15mg, 30mg, 60mg, 100mg
Elixir, 20mg/5ml
Injection (sodium), 25mg/ml in 1ml ampoule, 100mg/ml in 2ml
ampoule; 4%
Indications: for the control of seizures (epilepsy).Long acting
barbiturate is indicated as long-term anticonvulsant therapy for
the treatment of generalized tonic-clonic and simple partial
(cortical focal) seizures.
293

6. Medicines Used In Anaesthesia

Cautions: liver or renal diseases, acute or chronic pain, in weak

patients, in children and the elderly, during pregnancy, labour,
delivery, and breast-feeding.It has a sedative effect, and driving
and operating machines should be avoided. Also treatment
should not be stopped abruptly as rebound seizures may occur.
Drug interactions:central nervous system (CNS) depressants
(e.g. alcohol), paracetamol, isoniazid, choramphenicol, and oral
contraceptives containing estrogens.
Contraindications: respiratory depression.
Side effects: drowsiness or sedation, respiratory depression, and
a hangover effect may occur more frequently. Unusual
excitement may occur in children, the elderly, and in patients
with severe pain. It should be discontinued if severe skin
reactions with fever occur.
Continued use may result in psychic or physical dependence.
With excessive doses in coordination of muscular motion and
continuous rolling movement of eyeball may also occur.
Dose and Administration: Oral: Several weeks (2 to 3) of
therapy may be required to achieve maximum antiepileptic
effect.Adult: Oral: 50 100 mg every 12 hours daily.Child:
Oral: 15 50 mg every 12 hours daily. Or 1 2 mg/kg of body
weight every 8 hours daily
Anticonvulsant:Adult: Oral: 60-250 mg per day as a single dose
- or in divided dose; IV -100-320 mg, repeated if necessary up to
a total dose of 600 mg during a 24 hour period. Child: Oral: 1
to 6 mg per kg of body weight per day as a single dose or in
divided doses.
Status epilepticus:IV (slow): 10 to 20 mg per kg of body weight,
repeated, if necessary.
Storage: at room temperature, in a well-closed container.

294

6. Medicines Used In Anaesthesia

Primidone
Tablet, 250 mg
Indications: management of grandmal, psychomotor, and focal
seizures.
Cautions: renal and hepatic impairment, pulmonary
insufficiency.
Drug interactions: narcotic analgesics, antidepressants,
chloramphenicol, MAO inhibitors, valproic acid, phenobarbitol.
Contraindications: pregnancy, porphyria.
Side
effects:
drowsiness,
vertigo,
ataxia,
fatigue,
hyperirritability, rash, nausea, vomiting, anorexia, impotence,
agranulocytopenia, anemia, diplopia, nystagmus.
Dose and Administration:Oral:Adult: initial: 125-250mg/day
at bed time; increase by 125-250mg/day every 3-7 days; usual
dose: 750-1500mg/day in divided doses 3-4 times/day with
maximum dosage of 2g/day.
Child: initial: 50-125mg/day given at bed time; increase by 50125mg/day increments every 3-7 days; usual dose: 1025mg/kg/day in divided doses 3-4 times/day.
Storage: store at room temperature.
Sodium Valproate
Tablet, 200mg, 500mg
Syrup, 200mg/5ml
Indications: for all forms of epilepsy
Cautions: patients under 3 years of age, especially those with
congenital metabolic disorders, organic brain disease, or mental
retardation may be at particular risk of hepatotoxicity (liver
function test should be carried out in those at risk). The drug
should be discontinued if signs of liver dysfunction occur;
bruising, or bleeding (withdraw or reduce the dose); systemic
lupus erythematosus, care in withdrawing the therapy; renal
295

6. Medicines Used In Anaesthesia

impairment, breastfeeding, pregnancy, false - positive urine tests

for ketenes, interactions restrictions on driving in patients with
epilepsy
Drug interactions: amitriptyline, carbamazepine, chloroquine,
chlorpromazine, cimetidine, clomipramine, ethosuximide,
fluphenazine, haloperidol, mefloquine, phenobarbital, phenytoin.
Contraindications: pre-existing liver disease or a family
history of severe hepatic dysfunction, pancreatitis; porphyria.
Side effects: gastrointestinal disturbances, particularly an
initiation of therapy (use of entericoated formulations,
administration with meals, and commencement of therapy with
low dose may minimize symptoms); increased appetite and
weight gain, tremor, drowsiness, ataxia, confusion, headache,
reversible prolongation of bleeding time and thrombocytopenia;
liver dysfunction (necessitates valproate withdrawal), elevation
of liver enzyme values, hyperammonaemia, pancreatitis,
leucopenia and bone marrow depression.
Dose and Administration:Oral:Adult:initially, 600mg daily
given in 2 divided doses, preferably after food, increasing by
200mg/day at 3 days intervals to a maximum of 2.5g daily in
divided doses, usual maintenance 1 - 2gdaily (20 - 30 mg/kg
daily).
Child up to 20kg, initially 20mg/kg daily in divided doses, may
be increased provided plasma concentrations monitored (above
40mg/kg daily also monitor clinical chemistry and
haematological parameters); over 20kg, initially 400mg daily in
divided doses increased until control (usually in range of 20 - 30
mg/kg daily ); maximum 35mg/kg daily.
Storage: at room temperature in a tight container. Protect from
freezing.

296

6. Medicines Used In Anaesthesia

Topiramate
Tablet, 25mg, 50mg, 100mg
Indications: in adults and paediatric patients, adjunctive
therapy for partial onset seizures and adjunctive therapy of
primary generalized tonic-clonic seizures; treatment of seizures
associated with Lennox-Gastaut syndrome; prophylaxis of
migraine headache.
Cautions: hepatic, respiratory, or renal impairment.
Drug interactions: concomitant administration with other CNS
depressants
and
anticholinergic
drugs;
phenytoin,
carbamazepine, digoxin, ethinyl estradiol.
Contraindications: hypersensitivity reactions.
Side effects: dizziness, ataxia, somnolence, nervousness, speech
problems, fatigue, nausea, tremor, abnormal vision, upper
respiratory infection.
Dose and Administration: adjunctive therapy for partial onset
seizures and adjunctive therapy of primary generalized tonic-clonic seizures:

Adult: Initial: 25-50mg/day; titrate in increments of 25-50mg

per week until an effective daily dose is reached; the daily dose
may be increased by 25mg at weekly intervals for the first 4
weeks; thereafter, the daily dose may be increased by 25-50mg
weekly to an effective daily dose (usually at least 400mg); usual
maximum dose: 1600mg/day
Child 2-16 years: Initial dose titration should begin at 25mg (or
less, based on a range of 1-3mg/kg/day) nightly for the first
week; dosage may be increased in increments of 1-3mg/kg/day
(administer in 2 divided doses) at 1 or 2 week intervals to a total
daily dose of 5-9 mg/kg/day.
Adult:Migraine prophylaxis: Initial: 25mg/day, titrated at
weekly intervals in 25mg increments, up to the recommended
total daily dose of 100mg/day given in 2 divided doses.
Storage: store at room temperature.
297

6. Medicines Used In Anaesthesia

5.7. Antiparkinson Agents

Antimuscarinic agents are used in Parkinsons disease
(idiopathic or primary Parkinsonism) and drug - induced
Parkinsonism. Those commonly used are the tertiary amine,
benzhexol hydrochloride, benztropine mesylate, orphenadrine
hydrochloride, and procyclidine hydrochloride.
In Parkinson's disease, antimuscarinics are generally used in the
early stages when the condition is mild and tremor is the
predominant symptom as they provide little benefit in
bradykinesia. They can also reduce the diarrhoea experienced
by patients with this disease.
The most effective form of therapy is a combination of levodopa
and peripheral dopa-decarboxylase inhibitor, such as carbidopa.
The response to levodopa with carbidopa is a compromise
between increased mobility and adverse effects. Dyskinesias
may be dose limiting and increasingly frequent with increased
duration of treatment. Many factors including tolerance and
progression of the disease may result in complications after 2-5
years of treatment. End-of-dose deterioration occurs when
there is a reduced duration of benefit from a dose, resulting in
disability and dystonias. The on-off phenomenon is
characterized by sudden swings from mobility to episodes of
akinesia, tremor and rigidity lasting from a few minutes to
several hours. Amelioration of these effects can sometimes be
achieved by administering levodopa in a sustained-release
preparation or in a greater number of fractionated dose
throughout the day. Psychatric symptoms inducing disruption of
sleep, vivid dreams and hallucinations are characteristic adverse
effects that may occur at any time, especially in the elderly, and
may require dose reduction or withdrawal of levodopa.

298

6. Medicines Used In Anaesthesia

Amantadine Hydrochloride
Capsule, 100mg
Indications: Parkinsons disease (not for drug - induced
Parkinson like syndromes); influenza prophylaxis.
Cautions: epilepsy, confusional or hallucinational states,
history of eczema, congestive heart failure and/or peripheral
oedema, orthostatic hypotension; renal or liver impairment.
Drug interactions: agents with anticholinergic effects, alcohol,
CNS stimulants, hydrochlorothiazide and triamterene.
Contraindication: hypersensitivity to amantadine.
Side effects: livedo reticularis (skin discolouration) mainly of
the legs; oedema of the legs. CNS reactions (psychotic episodes,
convulsions and nausea),especially when doses exceed 200
mg/day. Mild headache, constipation, insomnia, nervousness,
urinary retention, dry mouth, blurred vision as well as
neutropenia and skin rashes have occurred.
Dose and Administration:Oral:Adult: initially 100mg daily,
increased to 100mg twice daily after 7 days, maximum
400mg/day.Elderly (> 65 years): Maximum 100mg daily.
Storage: store at room temperature.
Benzhexol (Trihexyphenidyl Hydrochloride)
Tablet, 2mg, 5mg
Indications: Parkinsonism; drug induced extrapyramidal
symptoms (but not tardive dyskinesia).
Cautions: as antimuscarinics in general (see section 1.3), and
cardiovascular disease, hepatic or renal impairment; elderly,
avoid abrupt discontinuation of treatment; liable to abuse (may
produce euphoric effect)
Drug interactions: as antimuscarinics (section 1.3);
antipsychotics, TCAs, antihistamins, amantadine, alcohol, CNS
depressants, levodopa.
299

6. Medicines Used In Anaesthesia

Contraindications: untreated urinary retention, angle-closure

glaucoma, gastrointestinal obstruction, myasthenia gravis.
Side effects: as antimuscarinics (see section 1.3); Common anticholinergic symptoms such as dry mouth, blurred vision,
dizziness, mild nausea or nervousness, CNS stimulation (dose
related and in the elderly), manifested by restlessness, confusion,
hallucinations or euphoria, amnesia and impaired recall.
Constipation and urinary retention or hesitancy may occur,
particularly in the elederly. Other effects include tachycardia,
drowsiness and raised intraocular pressure. Rare - psychiatric
disturbances such as excitation, mania and delusions.
Dose and Administration: Oral:Adult: initially, 1-2mg daily
with increments of 2 mg every 3-5 days, as required, to 6-10
mg/day in 3-4 divided doses (maximum 15mg/day).
Concomitant with levodopa: usually 1-2 mg 3 times daily is
adequate.
Drug-induced Parkinsonism: Effective dosage range varies
widely from 1-15mg/day.
Storage: at room temperature in a tight container.
Bromocriptine
Tablet, 2.5mg, 5mg
Indications: treatment of Parkinsons diseases.
Cautions: monitors for pituitary enlargement, particularly
during pregnancy; monitor visual field to detect secondary field
loss in macroprolactinoma; contraceptive advice if appropriate
(oral contraceptives may increase prolactin concentration).
Drug interactions: inhibutor include azole antifungals,
clarithromycin, diclofenac, doxycyclin, erythromycin, isonized,
nefazodone, nicardipine, propofol, protease inhibitor, quinidine,
telitromycin, and varapamil. Concurrent use of bromocriptin
with antihypertensive agents may increase the risk of
300

6. Medicines Used In Anaesthesia

hypotention. Concurrent use of levodopa may increase the risk

of hallucinations
Contraindications: also hypertension in postpartum women or
in puerperium, Hepatic impairment; dose reduction may be
necessary, Pregnancy, Breast-feeding; suppresses lactation;
avoid breast feeding for about 5 days if lactation prevention fails
Side effects: drowsiness, nasal congestion; less commonly
vomiting, postural hypotension, fatigue, dizziness, dry mouth;
also, particularly with high doses, confusion, psychomotor
excitation, hallucinations; rarely diarrhoea, gastro-intestinal
bleeding, gastric ulcer, abdominal pain, tachycardia, bradycardia,
arrhythmia, insomnia, psychosis, visual disturbances, tinnitus;
very rarely vasospasm of fingers and toes particularly in patients
with Raynauds syndrome, and effects like neuroleptic
malignant syndrome on withdrawal; urinary incontinence,
leucopenia, thrombocytopenia, hyponatraemia, reversible
hearing loss, increased libido, and hypersexuality also reported
Dose and Administration: Parkinsonism: 1.25mg twice daily,
increased by 2.5mg/day in 2 to 4 week intervals (usual dose
range is 30-90mg/day in 3 divided doses), though elderly
patients can usually be managed on lower doses.
Diphenhydramine Hydrochloride
Tablet, 250mg, 500mg
Indications: control of Parkinsonism.
Cautions, Drug interactions; Contraindications and Side
effects: see section 14.1
Dose and Admininistration:50mg2 to 4 times daily
Benztropine Mesylate
Tablet, 2mg
Injection, 1mg/ml in 2ml ampoule
301

6. Medicines Used In Anaesthesia

Indications, Caution, Drug interactions; see under

Trihexyphenidyl hydrochloride.
Contraindications: see Trihexyphenidyl Hydrochloride; avoid
in children less than 3 years.
Side effects: see trihexypenidyl Hydrochloride, but causes
sedation rather than stimulation.
Dose and Administration: Adult:Oral: 0.5 1 mg daily
usually at bedtime, generally increased, max. 6 mg daily; usual
maintenance dose 1 4 mg daily in single or divided dose;
elderly preferably lower end of range
IM or IV: 1 to 2 mg repeated if symptoms reappear; Elderly
preferably lower end of range.
Storage: at room temperature in a well-closed container.
Protect from freezing.
Levodopa
Tablet, 250mg, 500mg
Indications: Parkinson's disease (not for drug-induced
parkinson like syndromes).
Cautions: asthmatics, patients with chronic obstructive airway
disease, renal, hepatic or endocrine diseases, a history of peptic
ulceration, open - angle glaucoma, and diabetics
Drug interactions: MAO inhibitors, antipsychotic agents,
metoclopramide, antihypertensive agents.
Contraindications: closed-angle glaucoma, a history of
malignant melanoma, patients younger than 25 years, psychosis,
history of myocardial infarction, particularly residual
arrhythmias; convulsive disorders.
Side effects: gastric intolerance, nausea, vomiting, anorexia,
peptic ulceration and gastrointestinal bleeding may occur; also
psychiatric disturbances including nervousness, mild anxiety
and depression to overt psychotic reactions. Complex
302

6. Medicines Used In Anaesthesia

involuntary movements.Postural hypotension and dizziness are

common during the first few months of therapy. Cardiac
arrhythmias, hypertension may occur.
Urinary frequency or retention, visual abnormalities, flushing,
blood dyscrasias (thrombocytopenia), raised liver enzymes,
increased urea and uric acid serum concentrations, and the
development of a scleroderma-like illness.
Dose and Admininistration: Oral: Adult: 500mg to 1g daily
administered in 2 or more equally divided doses. Daily dosage
may be increased by 100-750mg every 3-7 days until a
maximum response is achieved; the maximum recommended
daily dosage is 8 g.
Storage: store at room temperature.
Levodopa + benserazide
Tablets, 50mg+12.5mg, 100mg+25mg, 200mg+50mg
Capsules, 50mg+12.5mg, 100mg+25mg, 200mg+50mg
Dose and Administration: Adult: Initially 25/100mg 3 times
daily, increased by 25/100mg weekly until desired response is
obtained. Usual effective range 100/400 - 200/800 mg/ day
Levodopa + Carbidopa
Tablets, carbidopa 10mg+ levodopa 100mg; carbidopa 25mg+
levodopa 250mg
Dose and Administration: Adult: 10/100 tablets: initially 50 100 mg (with carbidopa 10) 3-4 times daily, increased by 50 100 mg daily or alternate days according to response, up to 800
mg (with carbidopa 80) daily in divided doses.
25/250 tablets: initially 12.5/125mg (half a tablet) once or twice
daily, increased gradually by 12.5/125mg every day or alternate
day. Maximum 200/2000 mg/day (8 tablets).
303

6. Medicines Used In Anaesthesia

Orphenadrine hydrochloride
Tablet, 50mg
Indications: Parkinson's disease and drug induced
extrapyramidal reactions (but not tardive dyskinesia).
Cautions, Drug interactions, Contraindication and Side
effects; see under trihexyphenidyl.
Dose and Administration: Adult: Oral: initially 50mg 3 times
daily, increased gradually according to the individual response.
Usual range, 150 - 250 mg/day (maximum 400mg)
Storage: store at room temperature.
Procyclidine
Injection, 5 mg/ml; 2ml ampoule
Indications: relieves symptoms of parkinsonian syndrome and
drug induced extrapyramidal symptoms.
Cautions: tachycardia, cardiac arrythmia, hypertension,
hypotension, liver or kidney disorder, prostatic hyperplasia,
elderly.
Drug interactions: amantadine, narcotic analgesics,
phenothiazines, TCA, antiarrythmics, quinidine, levodopa,
digoxin.
Contraindications: angle-closure glaucoma, myasthenia gravis.
Side effects: tachycardia, palpitation, confusion, drowsiness,
headache, loss of memory, fatigue, constipation, nausea,
vomiting, difficult urination, increased intraocular pain, blurred
vision, mydriasis, epigasric stress.
Dose and Administration: Adult: IM: 5-10mg may be given as
a single injection, repeated if necessary after 20 minutes to a
maximum of 20mg daily. Parenteral doses are usually effective
within 5 to 10 minutes but may need 30 minutes to produce
relief.
304

6. Medicines Used In Anaesthesia

5.8. Medicines for Attention Deficit Disorder

Registered medicines in this group include methylphenidate,
atomoxetine and dextroamphetamine. They are indicated in
attention deficit hyperactivity disorder. Owing to their
dependence-producing liability, these drugs should not be used
for the relief of fatigue or in the treatment of debility or
depression. They should only be used for their specific
indications and after careful diagnosis.
Atomoxetine
Capsule, 5mg, 10mg, 18mg, 25mg, 40mg, 60mg
Indications: attention deficit/hyperactivity disorder in children,
adolescents and adults.
Cautions: liver dysfunction.
Drug interactions: beta2 agonists (e.g. salbutamol), pressor
agents and drugs that affect noradrenaline; drugs that induce or
inhibit CYP2D6; drugs metabolized by CYP3A4, e.g.
midazolam; MAO inhibitors.
Contraindications: uncontrolled hypertension, hepatic
impairment, narrow angle glaucoma.
Side effects: Children- abdominal discomfort, nausea and
vomiting, decreased appetite, dizziness, somnolence, irritability,
mood swings and pruritis.
Adult - dry mouth, sinus, headache, nausea, constipation, loss of
appetite and weight, insomnia, palpitations, sweating, fatigue,
hot flushes and urogenital dysfunction.
Dose and Administration: Adult and (Child/Adolescent 70
kg): initiate at 40 mg/day for 7 days and titrate gradually up to a
maximum of 80mg/day.Child and (Adolescent < 70kg): 0.5
mg/kg/day for 7 days followed by gradual titration up to a
maximum of 1.2 mg/kg/day.
Storage: store at room temperature.
305

6. Medicines Used In Anaesthesia

Dextroamphetamine
Tablet, 5mg, 10mg
Indications:
narcolepsy;
refractory
attention
deficit
hyperactivity disorder (under specialist supervision)
Cautions: anorexia; mild hypertension (contra-indicated if
moderate or severe); psychosis or bipolar disorder; monitor for
aggressive behaviour or hostility during initial treatment; history
of epilepsy (discontinue if convulsions occur); tics and Tourette
syndrome (use with caution)discontinue if tics occur; monitor
growth in children; susceptibility to angle-closure glaucoma;
avoid abrupt withdrawal; data on safety and efficacy of longterm use not complete; acute porphyria;
Special cautions in children: Monitor height and weight as
growth restriction may occur during prolonged therapy (drugfree periods may allow catch-up in growth but withdraw slowly
to avoid inducing depression or renewed hyperactivity);
Driving
Contraindications: cardiovascular disease including moderate
to severe hypertension, structural cardiac abnormalities,
advanced arteriosclerosis, hyperexcitability or agitated states,
hyperthyroidism, history of drug or alcohol abuse, Renal
impairment, Pregnancy, Breast-feeding
Side effects: insomnia, restlessness, irritability and excitability,
night terrors, euphoria, tremor, dizziness, aggression, paranoia,
anxiety, confusion, depression, fatigue, headache; seizures (see
also Cautions); dependence and tolerance, psychosis; anorexia,
gastro-intestinal symptoms, growth restriction in children (see
also under Cautions); dry mouth, sweating, tachycardia (and
anginal pain), palpitation, myocardial infarction, hypertension,
hypotension; impotence; visual disturbances; alopecia, rash;
cardiomyopathy reported with chronic use; cardiovascular
collapse; cerebral vasculitis; central stimulants have provoked
306

6. Medicines Used In Anaesthesia

choreoathetoid movements and dyskinesia, tics and Tourette

syndrome in predisposed individuals (see also Cautions); very
rarely angle-closure glaucoma.
Dose and Administration: Narcolepsy, initially 10 mg (elderly
5 mg) daily in divided doses increased at weekly intervals by
10 mg (elderly 5 mg) daily to a max. of 60 mg daily.Refractory
attention deficit hyperactivity disorder, adult over 18 years
[unlicensed use], initially 5 mg twice daily, increased at weekly
intervals according to response; max 60 mg daily; child 618
years, initially 510 mg daily, increased if necessary at weekly
intervals by 5 mg daily, usual max. 1 mg/kg (up to 20 mg) daily
(40 mg daily has been required in some children).
Note: Maintenance dose given in 24 divided doses.

Methylphenidate
Tablets, 5 mg, 10 mg, 20 mg
Indications: attention deficit hyperactivity disorders in children;
narcolepsy.
Cautions: hypertension, vocal or motor tics, epilepsy.
Drug interactions: barbiturates, primidone, phenytoin, phenyl
butazone, tricylic antidepressants, warfarin, and MAO inhibitors.
Contraindications: absolute-history of schizophrenia, drug
dependence or personality disorders; patients with glaucoma,
thyrotoxicosis, tachyarrhythmias, anxiety, tension or ischaemic
heart disease.
Side effects: nervousness, insomnia; wight loss and growth
retardation may occur (particularly in children receiving > 30
mg/day for prolonged periods); changes in blood pressure and
pulse rate, nausea, drowsiness, dyskinesia, tremor, skin rash and
dependence, especially if predisposed.
Dose and Administration: Oral:Adult: usually 10 mg 2 to 3
times daily; maximum 60mg/day.Child over 6 years: initially
307

6. Medicines Used In Anaesthesia

5mg twice daily (at breakfast and lunch), increased at weekly

intervals, if necessary, to 20-30mg/day; maximum 1mg/kg/day.
Storage: store in airtight container and at room temperature.
5.9. Medicines for substance Abuse and Dependence
Bupropion
Tablet, 75mg, 100mg
Indications, Cautions, Drug interactions, Contraindications,
Side-effects, Dose and Administration and Storage: see
section 4.3

Disulfiram
Tablet, 200 mg, 250 mg, 500 mg
Indications: adjunctive treatment of chronic alcoholism.
Cautions: epilepsy, diabetes mellitus, renal or hepatic disease.
Drug interactions: cumulative benzodiazepines such as
diazepam and chlordiazepoxide; isoniazid; metronidazole;
phenytoin and warfarin; amitriptyline.
Contraindications: cardiac failure, coronary artery disease,
psychosis and drug addiction.
Side effects: In the absence of alcohol - drowsiness, headache,
an unpleasant taste, impotence, and mild gastrointestinal
disturbances, allergic dermatitis.The alcohol - disulfiram
reaction may be manifested by facial flushing, throbbing
headache, tachycardia and nausea and vomiting. During severe
reactions there may be respiratory depression, cardiovascular
collapse, arrhythmias, seizures, coma and sudden death.
Dose and Administration:Oral: 200 - 400 mg daily or 400 mg
on alternate days.
Storage: store at room temperature.
308

6. Medicines Used In Anaesthesia

Methadone
Tablet, 50mg, 10mg, 40mg
Concentrated for oral liquid, 5mg/ml, 10mg/ml (Hydrochloride)
Oral liquid, 5mg/5ml, 10mg/5ml
Indications: adjunct in treatment of opioid dependence
Cautions: history of cardiac conduction abnormalities, QT
interval prolongation
Contraindications: Opioid analgesics should be avoided in
patients with acute respiratory depression and when there is a
risk of paralytic ileus. They are also contra-indicated in
conditions associated with raised intracranial pressure and in
head injury (opioid analgesics interfere with pupillary responses
vital for neurological assessment). Comatose patients should not
be treated with opioid analgesics.
Side effects: QT interval prolongation, torsade de pointes,
hypothermia, restlessness, raised intracranial pressure,
dysmenorrhoea, dry eyes, and hyperprolactinaemia
Dose and Administration: Oral or SC or IM: 510 mg every
68 hours, adjusted according to response; on prolonged use not
to be given more frequently than every 12 hours. Note Child not
recommended

Naltrexone Hydrochloride
Tablet, 50mg
Injection, 380mg/vial
Indications: adjunct to prevent relapse in formerly opioiddependent patients (who have remained opioid-free for at least
710 days)
Cautions: liver function tests needed before and during
treatment; test for opioid dependence with naloxone before
treatment; avoid concomitant use of opioids but increased dose
309

6. Medicines Used In Anaesthesia

of opioid analgesic may be required for pain (monitor for opioid

intoxication)
Note: Patients should be warned that an attempt to overcome the
blockade of opioid receptors by overdosing could result in acute
opioid intoxication
Contraindications: patients currently dependent on opioids,
Hepatic impairment, renal impairment, Pregnancy, Breastfeeding
Side effects:nausea, vomiting, abdominal pain, diarrhoea,
constipation, reduced appetite, increased thirst; chest pain;
anxiety, sleep disorders, headache, reduced energy, increased
energy, irritability, emotional lability, dizziness; chills; urinary
retention; delayed ejaculation, decreased potency; arthralgia,
myalgia; increased lacrimation; rash, and increased sweating;
rarely hepatic dysfunction, suicidal ideation, and speech
disorders; very rarely hallucinations, tremor, and idiopathic
thrombocytopenia
Dose and Administration: Adult over 18 years (initiate in
specialist clinics only), 25 mg initially then 50 mg daily; total
weekly dose (350 mg) may be divided and given on 3 days of
the week for improved compliance (e.g. 100 mg on Monday and
Wednesday, and 150 mg on Friday)
Nicotine replacement therapy (NRT)
Chewing Gum, 2mg, 4mg
Transdermal patch, 5mg-30mg/16hrs, 7mg-21mg/24hrs
Indications: treatment to aid smoking cessation for the relief of
nicotine withdrawal symptoms (including nicotine craving)
Cautions: severe or unstable cardiovascular disease (including
hospitalisation for severe arrhythmias, recent myocardial
infarction, or recent cerebrovascular accident)initiate under
medical supervision; uncontrolled hyperthyroidism; diabetes
310

6. Medicines Used In Anaesthesia

mellitus (monitor blood-glucose concentration closely when

initiating treatment); phaeochromocytoma; oral preparations,
oesophagitis, gastritis, peptic ulcers; patches, skin disorders
(patches should not be placed on broken skin); hepatic
impairment; renal impairment; pregnancy; breast-feeding.
Note: Most warnings under Cautions also apply to continuation of
cigarette smoking

Side effects: gastro-intestinal disturbances (including nausea,

vomiting, dyspepsia); headache, dizziness; influenza-like
symptoms; dry mouth; rash; lessfrequently palpitation; rarely
atrial fibrillation; with nasal spray, sneezing, epistaxis, watering
eyes, ear sensations; with lozenges, thirst, paraesthesia of mouth,
tastedisturbances; with patches, skin reactions (discontinue if
severe)vasculitis also reported, blood pressurechanges; with
patches or lozenges, sleepdisturbances, nightmares, chest pain;
with gum or lozenges, mouth ulceration, increased salivation;
with gum, lozenge, sublingual tablets, or inhalator, hiccups,
throat irritation.
Dose and Administration:Chewing gum: smoking cessation,
individuals smoking 20 cigarettes or less daily, initially chew
one 2-mg piece slowly (chew gum until taste becomes strong,
then rest gum between cheek and gum, when taste fades start
chewing again) for approx. 30 minutes when urge to smoke
occurs; individuals smoking more than 20 cigarettes daily or
needing more than 15 pieces of 2-mg gum daily should use the
4-mg strength; max. 15 pieces of 4-mg strength daily; withdraw
gradually after 3 months; review treatment if abstinence not
achieved within 9 months; Child 1218 years, treatment
continued for up to 8 weeks followed by gradual reduction over
4 weeks; review treatment if abstinence not achieved within 3
months Smoking reduction, chew 1 piece when urge to smoke
occurs between smoking episodes; reduce smoking within 6
311

6. Medicines Used In Anaesthesia

weeks and attempt smoking cessation within 6 months; review

treatment if abstinence not achieved within 9 months Note:
Children under 18 years should consult a healthcare professional
before
starting
smoking-reduction
regimen.
Topical:Transdermal patch:Dose smoking cessation, Adult over
18 years, apply to dry, nonhairy skin site, removing after 24
hours and siting replacement patch on a different area (avoid
using same area for 24 hours); individuals smoking less than 20
cigarettes daily, initially 14-mgor 21-mg patch daily
(depending on severity of withdrawal symptoms); individuals
smoking 20 or more cigarettes daily, initially 21 mg patch
daily; withdraw gradually, reducing dose every 34 weeks;
review treatment if abstinence not achieved within 3 months;
maximum period of treatment should not exceed 6 months.

312

6. Medicines Used In Anaesthesia

6. MEDICINES USED in ANAESTHESIA

6.1. General Anaesthetics
General anesthetics are a diverse group of drugs that produce
reversible state of unconsciousness (amnesia), analgesia, and
muscle relaxation to allow the performance of surgery or
interventional procedures. An ideal anesthetic agent would
produce unconsciousness, analgesia, and muscle relaxation
suitable for all surgical procedures and be metabolically inert
and rapidly eliminated. No single agent in safe concentrations
fulfills all these requirements and it is customary to employ a
number of agents to produce the required conditions
The goal of anesthesia is to provide the desired combination of
analgesia, amnesia, and optimal operating conditions while
ensuring physiologic homeostasis. The types of anesthesia
include general anesthesia, neuraxial anesthesia (spinal and
epidural), peripheral nerve blocks, and monitored anesthetic
care (sedation). The course of general anesthesia can be divided
into three distinct phases: induction, maintenance, and
emergence. Induction and Maintenance of anesthesia can be
achieved with IV orvolatile anesthetics agents. Induction of
general anesthesia for adults is usually achieved with the
injection of intravenous medications while inhalation
anesthetics are particularly useful in the induction of pediatric
patients.
Maintenance of anesthesia can be achieved with
volatile or IV anesthetics. Volatile agents remain a popular
because of their ease of delivery, reliable recovery, excellent
safety profile, and modest cost.Emergence or "waking up" from
general anesthesia is a crucial time in which the patient back to
a restored state of consciousness. With this return of
consciousness there is a short period of time in which the
patient's body is aware of the emergence without a full return to
consciousness. This results in autonomic hyper-responsiveness
313

6. Medicines Used In Anaesthesia

which may manifest as hypertension, tachycardia,

bronchospasm, or laryngospasm. Short acting narcotics, beta
blockers, or lidocaine can blunt these responses in patients,
when these responses may be harmful (eg ischemic heart
disease).
Intravenous anaesthetics: Intravenous anesthetics may be used
either to induce anesthesia or for maintenance of anesthesia
throughout surgery. Induction of general anesthesia is usually
achieved with the injection of intravenous medications such as
propofol, thiopental sodium, etomidate, ketamine and narcotics.
Propofol is the most commonly used induction agent because of
its favorable recovery profile and short elimination half-life
(resulting in less prolonged sedation and less nausea than
sodium pentothal, a barbiturate induction agent). When used for
induction,
propofol
causes
bradycardia
and
hypotension .Thiopental sodium is a widely used intravenous
anesthetic in our country, but it has no analgesic properties.
Induction is generally smooth and rapid, but owing to its narrow
therapeutic margin, over dosage with cardiorespiratory
depression may occur. The reconstituted solution is highly
alkaline and therefore irritant on misplaced injection outside the
vein; arterial injection is particularly dangerous. Thiopental is
contraindicated in porphyria.
Awakening from a moderate dose of thiopental is rapid due to
redistribution of the drug in the whole body tissue. Metabolism
is, however, slow and some sedative effects may persist for 24
hours. Repeated doses have a cumulative effect.
Ketamine is a phencyclidine derivative and rapid acting
dissociative general anesthetic. The benefits of ketamine include
significant analgesia and preservation of respiratory drive. It
may be used as the sole agent for diagnostic and for painful
procedures of short duration such as the dressing of burns, radio
314

6. Medicines Used In Anaesthesia

therapeutic procedures, bone marrow sampling and minor

orthopedic procedures. It is of particular value in children, it
also causes bronchodilation, which may be beneficial in patients
with reactive airways. Used alone, it may have cardiovascular
stimulant properties and/or unpleasant emergence reactions such
as hallucinations, vivid dreams, or delirium. Benzodiazepines
can be used in combination with ketamine to reduce these side
effects.
Etomidate is used as induction agent. It has minimal respiratory
and cardiovascular depressant properties, while causing little
hangover effect or histamine release. It has no analgesic
properties. A significant cautionary drawback to the use of
etomidate is that even a single dose can cause transient adrenal
insufficiency.
Opioid analgetics are used in nearly every facet of modern
anesthesia practice. They are used as premedicants or sedatives,
intravenous anesthetics postoperativeanalgetics, and intraspinal
analgetics. Unfortunately, they are also abused by patients and
physicians.
Opioids may be divided into three groups based upon their
pharmacodynamic activity: pure agonists (morphine, fentanyl,
etc.), pure antagonists (naloxone, naltrexone), and mixed
agonist-antagonists (nalbuphine, butorphanol, etc,.
Opioids may also be grouped on the basis of their chemical
groups or their postulated interactions with opioid receptor
subtypes (mu, kappa, delta, sigma, episilon, etc.). Opium is a
complex mixture of alkaloids obtained from the seed pods of
Papaver somniferum, the opium poppy. The two naturally
occurring opiate analgetics are the phenanthrene alkaloids,
morphine and codeine. The term opioid applies to any natural or
synthetic compound that has morphinelike properties. All the
clinically available opioids are structurally related to morphine.
315

6. Medicines Used In Anaesthesia

Etomidate
Injection, 20 mg/ml in 10ml and 20ml ampoules
Indications: induction agent for general anaesthesia.
Cautions: porphyria, should not be given in repeated doses
because it causes adrenal insufficency
Drug interactions: CNS depressants including alcohol;
ketamine.
Contraindication: hypersensitivity to etomidate.
Side effects: pain on injection, a high incidence of involuntary
muscle movements (may be reduced by premedication with
diazepam or one of the opiates), post-operative nausea and
vomiting and brief periods of apnoea. Rare - laryngospasm, skin
rashes,
Dose and Administration:Dose should be individualized.Adult:
Induction: I V: 0.2 - 0.3mg/kg slowly over 30 - 60 seconds.
Smaller doses may be used as supplements for other anaesthetic
agents.
Storage: store at room temperature.
Ketamine Hydrochloride
Injection, 10 mg/ml in 20ml, 50 mg/ml in 20 ml
Indications:
Induction,
maintenance,
analgesia.
Cautions: warn the patient not to drive or operate machinery for
about 24 hours of postanaesthesia or avoiding alcohol and other
CNS depressants with in 24 hours following anaesthesia;
pregnancy.
Drug interactions: anaesthetics such as enflurane, isoflurane,
methoxyflurane, antihypertensives; CNS depressants, thyroid
hormones.
Contraindications: ketamine is contraindicated in any
condition in which significant elevation of blood pressure would
be hazardous such as severe cardiovascular disease, Heartfailure, severe-hypertension, myocardial infarction, stroke
316

6. Medicines Used In Anaesthesia

(history); cerebral trauma, Intracerebrial mass or hemorrhage;

eye injury, increased cerebrospinal fluid pressure and increased
intraocular pressure; psychiatric disorders such as schizophrenia
or acute psychosis, thyrotoxic states.
Side effects: increased blood pressure, tachycardia, tonic or
clonic muscle movements, emergence reaction (alteration in
mood or body image, delirium, dissociative or floating
sensation), vivid dreams or illusions, visual hallucinations.
Dose and Administration:Adult:Induction: IV: 1 to 2mg per
kg of body weight administered as a single dose or by IV
infusion at a rate of 0.5mg per kg of body weight per minute. IM:
5-10mg per kg of body weight.
Maintenance: IV: 0.01-0.05mg (base) per kg of body weight by
continuous infusion at a rate of 1-2mg per minute.Child and
Elderly: Same as adult
Storage: at room temperature, protect from light and heat and
from freezing.
Propofol
Injection (emulsion), 10mg/ml in 20ml ampoule
Indications: intravenous anaesthesia (both induction and
maintenance).
Cautions: cardiac, respiratory, renal or hepatic function
impairment, epilepsy, elderly and hypovolaemic or debilitated
patients.
Drug interactions: benzodiazepines, opiates, ethanol, narcotics,
phenothiazines, fluconazole, ketoconazole, NSAIDs.
Contraindications: hypersensitivity to propofol.
Side effects: hypotension and transient apnoea, bradycardia;
headache during recovery; involuntary muscle movements in
unpremedicated patients; seizures.
317

6. Medicines Used In Anaesthesia

Dose and Administration:Adult: Induction: Slow IV

injectionor infusion, titrated against the response obtained from
40mg every 10 seconds. Most adult patients under 55 years
require 1.5 to 2.5mg/kg.Maintenance: continuous infusion, the
rate varying from4 to 12 mg/kg/hour. Alternatively, a
techniqueof repeat bolus injections may be used: increments of
25 - 50mg may be given at intervals determined by clinical
signs of lightening anaesthesia (usually every 6 minutes).
Note: Patients over 55 years and high risk patients may require less than the
usual doses. For induction: 1- 1.5 mg/kg may be adequate.Maintenance: 2 6 mg /kg hour.

Child: over 3 years: Induction: 2.5 mg/kg adjusted as

necessary.Maintenance: IV infusion, 9 - 15 mg/kg/hour.
Storage: store at room temperature.
Thiopental sodium
Powder for injection, 0.5 g and 1 g in ampoule
Indications: induction of general anesthesia; anaesthesia of
short duration; control of convulsions (especially in status
epilepticus).
Cautions: reduce induction dose in severe liver disease.
Extreme care is required in surgery of the mouth, pharynx, or
larynx and in patients with acute circulatory failure (shock) or
fixed cardiac out put, dehydration, hypovolaemia, severe
anaemia, hyperkalaemia, toxaemia, myasthenia gravis,
myoedema or in severe renal disease.Caution should be taken
during pregnancy, in geriatric and patients sensitive to any one
of barbiturates.
Drug interactions: alcohol, CNS depressant, dopaminergics,
antihypertensives, especially diazoxide or ganglionic blockers,
& hypotension producing medication, aspirin, probenecid.
318

6. Medicines Used In Anaesthesia

Contraindications: porphyria (thiopental sodium may

aggravate symptoms by inducing enzymes responsible for
porphyria in synthesis).
Side effects: apnea, hypotension, allergic reaction, cardiac
arrhythmias, circulatory depression, emergence delirium, and
thrombophlebitis.
Dose and Administration:Dosage must be individualized;
however, as a general guideline the following can be used.
Adult:Induction: IV: 50 to 100 mg (2 to 4 ml of a 2.5 %
solution) as require; or 3 to 5mg per Kg of body weight as a
single dose.Maintenance: IV (Intermittent) 50 to 100 mg (2 to 4
ml of a 2.5 % solution) as required.Status epilepticus refractory
to other treatment:IV, 2 to 4mg/kg bolus over 20 seconds, then
further 50mg boluses every 2-3 minutes until seizures are
controlled; then infusion to maintain 1-5 mg/kg/hour using EEG
control if possible.Child up to 15 years of age: Induction: IV: 3
to 5 mg per Kg of body weight.Maintenance: IV: (intermittent),
about 1 mg per Kg of body weight as required.
Storage: prior to reconstitution, store at room temperature,
unless otherwise specified by manufacturer.
Volatile inhalation agents
The most commonly used inhaled anesthetics in modern
anesthesia include a single gas (nitouse oxide) and volatile
liquids (halothane,isoflurane desflurane and sevoflorane). One
of the volatile anesthetics, (with or without nitrous oxide), can
be used for induction when intravenous agents are
contraindicated and particularly when intubations is likely to be
difficult.
If intubation is likely to be difficult, halothane is preferred. It
does not augment salivary or bronchial secretions and the
incidence of postoperative nausea and vomiting is low. Severe
319

6. Medicines Used In Anaesthesia

hepatitis, which may be fatal, sometimes occurs; it is more

likely in patients who are repeatedly anaesthetized with
halothane with in a short period of time.
Isoflurane is an isomer of enflurane. It is more irritant to the
airway than halothane and thus unsuitable for inhalational
induction. In comparison with the other two, induction of
anaesthesia is more rapid, and it is less arrhythmogenic. It is a
potent vasodilator with minimal cardiac depressant effect. It is
used in neurosurgical anaesthesia because it causes less increase
in intracranial blood flow and a smaller subsequent rise in
intracranial pressure. Sevoflurane is nanpurgency and rapid
increase in alveolar anesthetic concentration make it an
excellent choice for smooth and rapid inhalation induction in
pediatric and adult patients.
Nitrous oxide is used for the maintenance of anesthesia. It is
too weak to be used alone, but it allows the dosage of other
anesthetic agents to be reduced. It has a strong analgesic action.
Enflurane
Inhalation, 250ml
Indications: Induction and maintainance of general anaesthesia.
Cautions: increased intracranial pressure, epilepsy, elderly,
porphyria
Drug interactions: as for halothane; isoniazid, nondepolarizing muscle relaxants.
Contraindications: history of malignant hyperthermia, or
jaundice/hepatic dysfunction (for which no other cause could be
established) after exposure to a volatile agent; renal failure.
Side effects: hypotension and tachycardia may occur.
Respiratory depression, an increase in salivation and bronchial
secreations, and hepatic impairment have been reported.
320

6. Medicines Used In Anaesthesia

Malignant hyperthermia may be precipitated in susceptible

patients.
Dose and Administration: Adult: Maintenance range 1-3%.
Child: not used for inhalational induction. Maintenance range 13 %.
Ether, anesthetic
Inhalation, 100gm, 250gm
Indications: general anesthesia before surgery.
Cautions: ether is explosive. Mixture of its vapor with oxygen,
nitrous oxide or air at certain concentration causes explosion
and hence it should be avoided. It should not be used in the
presence of open flame or any electrical appliances liable to
produce a spark.
Premedication with atropine is necessary to inhibit bronchial
and gastric secretion induced by ether.
Drug interactions: avoid concomitant use of ether with
competitive muscle relaxants.
Contraindications: diabetes mellitus, impaired kidney function,
severe liver disease.
Side effects: irritation on the mucous membrane of the
respiratory tract, pharyngeal spasm, decreased blood pressure,
capillary bleeding, malignant hyperpyrexia (in some
individuals), convulsions in children and young adults.
Dose and Administration:Inhalation: Induction: Adult and
Child: up to 15 % in impaired gases. Maintenance of light
anesthesia, 3 to 5 % in air (with or without muscle relaxants); up
to 10 % for deep anesthesia.
Halothane
Inhalation, 250 ml
Indications: induction and maintenance of anesthesia in major
surgery often combined with nitrous oxide/oxygen mixtures.
321

6. Medicines Used In Anaesthesia

Cautions: during pregnancy, breast-feeding, in children and

elderly patients.
Drug
interactions:
sympathomimetics,
especially
cathecolamenis such as dopamine, epinephrine, norepinephrine;
or cocaine, ephedrine, levodopa, metraminol, methenamine,
nephrotoxic agents, xanthines; alcohol, aminoglycosides;
capreomycin,
citrate-anticoagulated
blood,
lincomycin
(systemic), neuromuscular blocking agents (non depolarizing),
polymyxins (systemic). Amiodarone, cumarine or indandione
derivative
anticoagulants;
antihypertensives,
especially
diazoxide or ganglionic blockers such as guandrel, guanethidine,
mecamylamine
or
trimethaphan,
neostigimine
and
pyridostigmine.
Contraindications: malignant hyperthermia, biliary tract
disease or hepatic function impairment, jaundice or acute
hepatic damage; cardiac arrhythmias, head injury or increased
intracranial pressure, myasthenia gravis, pheochromocytoma,
sensitivity to halothane.
Side effects: hepatotoxicity, impairment of psychomotor skills,
emergence delirium (postanaesthesia), shivering or trembling,
nausea or vomiting (mild).
Dose and Administration:inhalationdult: Induction: Increase
gradually to 2-3% in oxygen or nitrous oxide/oxygen mixture.
Maintenance range 0.5-1.5%
Child: Induction: 1.5-2%, though up to 3% may be required.
Maintenance: 0.5 to 2%
Storage: at room temperature in a tight, light-resistant container.
Isoflurane
Inhalation, 100 ml
Indications: Inhalational anaesthesia.
Cautions: debilitated patients, elderly, ischaemic heart disease.
322

6. Medicines Used In Anaesthesia

Drug interactions: sympathomimetics and xanthines,

anticonvulsants, non - depolarizing muscle relaxants, blood
pressure lowering agents.
Contraindications: history of malignant hyperthermia
Side effects: respiratory depression and airway irritation (may
result in retardation of inhaltional induction due to
breathholding or coughing if the inspired concentration is
increased too rapidly). Increase in heart rate and significant
hypotension with increasing concentrations.
Malignant hyperthermia may be precipitated in susceptible
patients.
Dose and Administration:Adult and Child: Maintenance
range usually 0.75 to 1.5%.
Storage: store at room temperature.
Nitrous oxide
Inhalation
Indications: maintenance of anaesthesia and, in sub-anaesthetic
concentrations, for analgesia.Nitrous oxide is used for the
maintenance of anesthesia. It is too weak to be used alone, but it
allows the dosage of other anesthetic agents to be reduced. It has a
strong analgesic action.

Cautions: caution is needed in the presence of air-enclosing

cavities (such as pulmonary, renal or occluded middle ear air
cysts or air embolism).
Drug interactions: alcohol; alfentanil, fentanyl, sufentanil;
amiodarone, anticoagulants (coumarin-or indandione
derivative); antihypertensive agents, especially diazoxide or
ganglionic blockers; chlorpromazine; diuretics; CNS depressant,
methyldopa, xanthines.
Contraindications: pneumothorax, head injury or increased
intracranial pressure, pre-existing or intracranial lesions, space
323

6. Medicines Used In Anaesthesia

occupying or tumors, history of sensitivity to the anaesthetic

being considered for use.
Side effects: mild nausea or vomiting and rarely respiratory
depression, neurologic injury, malignant hyperthermic crisis,
megaloblastic anaemia.
Dose
and
Administration:Adult:Inhalation:Anaesthetic
(general): Induction: 70 % with 30 % of oxygen. Maintenance:
30 to 70 % with oxygen.For obstetrics or procedures not
requiring loss of consciousness: 25 to 50 % with oxygen.Child:
Dosage must be individualized.
Storage: store at room temperature, unless otherwise specified
by manufacturer.
Sevoflurane
Inhalation, 250ml
Indications: Inhalational anaesthesia
Cautions: porphyria, paediatics, pregnancy.
Drug interactions: non-depolarizing muscle relaxants, nitrous
oxide, opioids and benzodiazepines.
Contraindications: known sensitivity to halogenated agents;
history of malignant hyperthermia; liver dysfunction,
unexplained fever or leucocytosis occurring after a previous
halogenated anaesthetic.
Side effects: may cause dose-dependent cardiorespiratory
depression. Malignant hyperthermia may be precipitated in
susceptible patients.
Dose and Administration: Adult: Induction: In adults inspired
concentrations of up to 5% usually produce surgical anaesthesia
in < 22 minutes. A short acting intravenous induction agent may
be used prior to inhalation. Maintainance: Surgical levels of
anaesthesia may be sustained with concentrations of 1-3%
sevoflurane, with or without the concomitant use of nitrous
324

6. Medicines Used In Anaesthesia

oxide. Child: Inspired concentrations of up to 6% usually

produce surgical anaesthesia in < 2 minutes. Maintenance: 2-3%.
Trichloroethylene
Inhalation
Indications: used for maintenance of light anaesthesia.
Cautions: it should not be used in closed-circuit apparatus.
Drug interactions: sympathomimetics such as adrenaline;
alchol.
Side effects: acute exposure leads to dizziness, lightheadedness,
lethargy, nausea and vomiting and hepatic and renal
dysfunction. Chronic poisoning may result in visual
disturbances, impairment of performance, hearing defects,
neuralgia and mild liver function.
Dose and Administration: administered by inhalation.
6.2. Neuromuscular Blockers
One of the most important requirements for optimal operating
conditions is that the patient remains still during surgery. This
goal can be achieved using different techniques, the most
popular of which is neuromuscular blockade. Neuromuscular
blocking agents block the acetylcholine receptors at the
neuromuscular junctions of striated muscle to provide
"relaxation" of the major muscle groups in the body.
These drugs are used as adjuncts to general anesthesia,
particularly to enable adequate muscle relaxation. There are 2
main types of neuromuscular blocking agents: competitive or
non-depolarizing agents and depolarizing agents.
Generally, the competitive neuromuscular blocking agents,
having a longer duration of action, are used in major operations,
while the depolarizing agents, with a much shorter effects, are
used for minor operations or manipulations and particularly for
325

6. Medicines Used In Anaesthesia

intubations. Following administration of a depolarizing agent,

such as suxamethonium, to aid intubation, a longer acting
competitive agent may be given to maintain muscle relaxation
throughout an operation.
Suxamethonium is the only widely used depolarizing muscle
relaxant. It produces rapid, complete paralysis, which is very
short-lasting in most patients and is of particular value for
laryngoscopy and intubation. Prolonged paralysis may occur in
those with low or atypical plasma cholinesterase. Assisted
ventilation should be continued until muscle function is restored.
Suxamethonium normally produces a phase I (depolarizing)
neuromuscular block. After high dose or prolonged use, the
nature of the block changes to a phase II (non-depolarizing)
block; this phase II block (also known as dual block) is
associated with prolonged neuromuscular blockade and apnoea.
Non-depolarizing (competitive) muscle relaxants include
atracurium besylate, pancuronium bromide, and vecuronium
bromide. These agents compete with acetylcholine at the
neuromuscular receptor sites. Their action is reversible by
anticholinesterase agents, which allow the concentration of
acetylcholine to increase at these receptor sites and displace the
blocker.
6.2.1. Non-depolarizing muscle relaxants
Atracurium Besylate
Powder for Injection, 10mg/ml in 2.5, 5ml, 25ml ampoules
Indications: adjunct to general anesthesia to facilitate
endotracheal intubation and to relax skeletal muscles during
surgery.
Cautions: previous anaphylactic reaction.

326

6. Medicines Used In Anaesthesia

Drug
interactions:
aminoglycosides,
beta-blockers,
clindamycin, calcium channel blocker, ketamine, lidocaine, loop
diuretics, theophyline, and sympathomimetics.
Side effects: flushing, bronchial secretion, erythema, itching,
wheezing.
Dose and Administration: Adult:IV: usual range initially 0.3
0.6 mg/kg, depending on the duration of block required, with
supplementary doses of 0.08- 0.2 mg/kg as needed.
Storage: store in refrigeration.
Cisatracurium
Injection, 2mg/ml in 10ml ampoule
Indications: neuromuscular blockade (intermediate duration)
for surgery or during intensive care
Cautions: lactation; burn Patients; safety and efficacy have not
been determined in children less than 2 years of age.
Side effects: Bradycardia, hypotension, flushing, bronchospasm,
rash.
Dose and Administration: IV:Intubation: Adult and Child over
1 month: initially 150 micrograms/kg; maintenance, 30
micrograms/kg approx. every 20 minutes; Child 212 years, 20
micrograms/kg approx. every 9 minutes; or maintenance, Adult
and Child over 2 years, initially, 3 micrograms/kg/minute, then
after stabilisation, 12 micrograms/kg/minute; dose reduced by
up to 40% if used with isoflurane. Intensive care: Adult: 0.5
10.2 micrograms/kg/minute (usual dose 3 micrograms/kg/
minute).
Note: Lower doses can be used for children over 2 years when not for
intubation. To avoid excessive dosage in obese patients, dose should be
calculated on the basis of ideal body-weight.

Pancuronium bromide
Injection, 2mg/ml in 2ml ampoule
327

6. Medicines Used In Anaesthesia

Indications: management of mechanically ventilated patients

and used for surgery.
Cautions: renal and hepatic disease.
Drug interactions: aminoglycosides, clindamycin, lincomycin,
polymyxin antibiotics, tetracyclines, quinidine, lignocaine,
verapamil, lithium, magnesium salts, anaesthetic agents such as
enflurane and ether, and potasium - depleting drugs such as
amphotericin B and diuretics; digoxin, phenytoin and
carbamazepine.
Contraindications: conditions in which tachycardia would be
undesirable.
Side effects: tachycardia and a dose - related elevation in blood
pressure (due to vagolytic and indirect sympathomimetic effects
on the cardiovascular system).
Rarely - hypersensitivity reactions.
Dose and Administration: IV:Adult: initially: 0.04 - 0.1mg/kg;
further doses of 0.01 - 0.02 mg/kg may be given as required.In
intensive care: 0.06 mg/kg every 1 - 1.5 hours.Following
administration of suxamethonium, dose should be reduced; 0.02
to 0.06 mg/kg may be adequate for the initial dose.Child: over 2
months: 0.04 - 0.1mg/kg; increments of 0.01 - 0.02 mg/kg if
required.
Neonates: 0.03 - 0.04 mg/kg with increments of 0.01 to 0.02
mg/kg if needed. Should be used with extreme caution.
Storage: store in refrigerator. Stable at room temperature up to
6 months.
Vecuronium Bromide
Powder for Injection, 10mg in vial
Indications: muscle relaxant during surgery.
Cautions: renal impairment, hepatic impairment, electrolyte
disturbances, asthma, pregnancy and breastfeeding.
328

6. Medicines Used In Anaesthesia

Drug interactions: carbamazepine, clindamycin, gentamicin,

lithium, neostigmine, nifedipine, phenytoin, procainamide,
propranolol, pyridostigmine, quinidine, streptomycin, verapamil.
Contraindications:respiratory insufficiency or pulmonary
disease; dehydrated or severely ill patients; myasthenia gravis or
other neuromuscular disorder.
Side effects:hypersensitivity reactions including bronchospasm,
hypotension, tachycardia, oedema, erythema, pruritus.
Dose and Administration:IV: Intubation:Adult and Child over
5 months: 80-100 mcg/kg; maintenance of relaxation 20-30
mcg/kg.Child under 4 months: initially 10-20mcg/kg, followed
by increments according to response.IV infusion: Adult: initial
bolus 40-100mcg/kg then 0.8-1.4mcg/kg/minute.
Storage: store at room temperature.
6.2.2. Depolarizing muscle relaxant
Suxamethonium Chloride (succinylcholine)
Powder for injection, 50 mg, 100 mg, 500 mg in vial
Injection, 50mg/ml
Indications: rapid and complete depolarizing muscle relaxation
of short duration; used mainly for endotracheal intubation.
Cautions: children, during pregnancy, and cardiovascular
function impairment. Caution is also required: in conditions
that may be adversely affected by increased potassium
concentrations (severe burns, digitalis toxicity, or recent
digitalization, degenerative or dystrophic neuromuscular disease,
paraplegia, pre-existing hyperkalemia, spinal cord injury, severe
trauma).Conditions that may lead to low plasmapseudocholine
esterase activity (severe anemia, dehydration, exposure to
neurotoxic insecticides or other cholinesterase inhibitors, severe
hepatic disease or cirrhosis, malnutrition, recessive hereditary
trait).Conditions that may be adversely affected by increase in
329

6. Medicines Used In Anaesthesia

intraocular pressure (open eye injury, glaucoma, occular

surgery).Fracture or muscle spasm and malignant hypertheimia.
Drug interactions: cholinesterase inhibitor specially
echothiopate, demecarium, isoflurophate, cyclophosphamide.
Avoid exposure to insecticides such as Malathion. Avoid also
simultaneous use of digitalis glycosides, procainamide,
physiostigmine, calcium salts, and succinylcholine.
Contraindications: allergic to succinylcholine, pulmonary
function impairment or respiratory depression, renal function
impairment.
Side effects: increased intra ocular pressure, muscle pain and
stiffness (postoperative), excessive salivation, cardiac
arrhythmias, bradycardia.
Dose and Administration:Adult:IV injection: initially 0.61mg/kg (range 20-100 mg). Subsequent doses must be
individualized according to the patients needs.IV infusion, as a
0.1% solution, 2-5 mg/minute for up to 1 hour.Child: IV: 1-12
years, 1mg/kg; under 1 year, 2mg/kg.
Storage: store between 2 and 80c. Protect from freezing.
6.3. Anesthetic Adjuncts and Adjuvants
A balance combination of agents with different actions is often
used to provide the various components of general anesthesia
including hypnosis muscle relaxation. This technique has been
reported to minimize intra-operative cardiovascular depression,
to facilitate a rapid return of consciousness, and to have a low
incidence of postoperative adverse effects such as nausea, and
vomiting, and excitation.
Antimuscarinics,
including
atropine,
hyoscine,
and
glycopyrronium, have been used as pre-operative medication to
inhibit salivation and excessive secretions of the respiratory
tract. This use is less important now that less irritating
330

6. Medicines Used In Anaesthesia

anesthetics are used. Atropine, hyoscine and glycopyrronium

are also given as premedications to reduce intra-operative
bradycardia and hypotension induced by agents such as
suxamethonium, halothane, or following vagal stimulation.
At the end of surgery drugs are sometimes administered to
accelerate recovery from the effects of the various agents used
during anesthesia. Non-depolarizing muscle relaxants may be
reversed with anticholinesterases such as neostigmine but
concomitant administration of atropine or glycopyrronium is
required to prevent bradycardia and other muscarinic actions
developing.
Oxygen should be added routinely during anesthesia with
inhalational agents, even when air is used as the carrier gas, to
protect against hypoxia.
Atropine is now rarely used for premedication but still has an
emergency role in the treatment of vagotonic side effects.
Hyoscine effectively reduces secretion and also provides a
degree of amnesia, sedation and anti-emesis. Unlike atropine it
may produce bradycardia rather than tachycardia. In some
patients, especially the elderly, hyoscine may cause the central
anti-cholinergic syndrome (excitement, ataxia, hallucinations,
behavioral abnormalities and drowsiness) glycopyrronium
produces good drying of salivary secretions. When given
intravenously it produces less tachycardia than atropine. It is
widely used with neostigmine for reversal of non-depolarizing
muscle relaxants.
Neostigmine is the specific drug for reversal of nondepolarizing (competitive) blockade. It acts with in one minute
of intravenous injection and lasts for 20 to 30 minutes; a second
dose may then be necessary.
Atropine or preferably
glycopyronium should be given before or with neostigmine in
331

6. Medicines Used In Anaesthesia

order to prevent bradycardia, excessive salivation; and other

muscarinic actions of neostigmine.
Atropine Sulphate
Injection, 1 mg/ml in 1 ml ampoule
Indications: as antisialagogue pre-anaesthetic medication to
prevent or reduce salivation and respiratory tract secretions.
Cautions: pregnancy, breastfeeding, in children and elderly
patients. Caution is also needed in patients with
hyperthyroidism, hepatic or renal disease, hypertension,
tachyarrhythmias, congestive heart failure, coronary artery
disease, gastric ulcer, esophageal reflex, and cardiac
insufficiency. Extreme caution is required in patients with
known or suspected GI-infection and with autonomic
neuropathy. There should be caution also in debilitated patients
with
chronic
pulmonary
disease.
Advise patients not to drive vehicle or operate machineries
Drug interactions: atropine with antacids, antidiarrhoeals
(adsorbent), other anticholinergic, cyclopropane anaesthesia,
ketoconazole.
Contraindications: severe ulcerative colitis, obstructive disease
of the GI tract e.g. pylorodeudonal stenosis, achalasia,
cardiospasm, paralytic ileus or intestinal atony (especially in
geriatric or debilitated patients), known hypersensitivity, angleclosure glaucoma, obstructive uropathy, myasthenia gravis.
Side effects: dryness of mouth, nose and throat, skin;
constipation decreased sweating, redness or other signs of
irritation at injection site, blurred vision, decreased salivary
secretion (difficulty in swallowing), mydriatic effect (increased
sensitivity of eyes to light), increased intraocular pressure,
bradycardia followed by tachycardia, palpitation and
arrhythmias.
332

6. Medicines Used In Anaesthesia

Dose and Administration:Adult:IV: 0.3-0.6mg immediately

before induction of anaesthesia.IM: 0.3 to 0.6mg, 30-60 minutes
before induction.
Child:IM: 20 micrograms per kg of body weight
Storage: store at room temperature protect from freezing.
Droperidol
Injection, 2.5 mg/ml
Indications: antiemetic in surgical and diagnostic procedures;
preoperative medication in patients when other treatments are
ineffective or inappropriate.
Cautions: hypokalemia, hypomagnesemia, pheochromocytoma,
alcoholism (acute), Parkinsonism
Drug interactions: anesthetics, bromocriptine, levodopa, CNS
depression
producing
medications,
epinephrine,
extrapyramidal reaction, hypotension- producing medications,
propofol.
Contraindications: hypersensitivity to droperidol.
Side effects: akathisia, anxiety, hypertension, dystonia,
hyperpyrexia, oculogyric crisis, hypotension, tachycardia,
excessive sedation.
Dose and Administration: Nausea and Vomiting: IM, IV:Adult:
initial; 2.5mg; additional doses of 1.25mg may be administered
to achieve desired effect; administer additional doses with
caution.
Child 2-12 years: 0.05-0.06mg/kg (maximum initial dose:
0.1mg/kg).
Storage: store at room temperature.
Fentanyl
Injection, 0.05mg/ml in 2ml ampoule
333

6. Medicines Used In Anaesthesia

Indications: general or local adjunct anesthesia, pain of labor

and vaginal delivery.
Cautions: cardiac bradyarrhythmias, hepatic impairment,
hypothyroidism, renal functions impairment, respiratory
impairment, elderly.
Drug
interactions:
antihypertensives,
diuretics,
benzodiazepines, cimetidine, erythromycin, CNS depressionproducing medications, MAO inhibitors, nalbuphine,
pentazocine, naloxone, naltrexone, neuromuscular blocking
agents, nitrous oxide, phenothiazines.
Contraindications: hypersensitivity reaction to fentanyl.
Side effects: drowsiness, nausea or vomiting, brady cardia,
hypotension, respiratory depression, cardiac arrythmia, biliary
spasm, changes in vision, chills, constipation, ureteral spasm,
urinary retention.
Dose and Administration: IV:Adult: Spontaneous respiration:
initially 50 - 200mcg, and 50mcg as supplements when
needed.Assisted respiration: Initially 300-3500mcg (up to
50mcg/kg), then 100-200mcg as required.Child over 2 years:
Spontaneous respiration: 1-3mcg/kg in small increments, and
supplements of 1mcg/kg as required.
Assisted respiration: initially 10 - 15 mcg/kg, followed by 1 - 3
mcg/kg as required.
Storage: store at room temperature and protect from light.
Glycopyrronium Bromide (Glycopyrrolate)
Injection, 0.2 mg/ml in 1 ml and 3 ml ampoules
Indications: as antisialagogue in preanesthesia. Also, indicated
as anti-arrhythmic in pre-anesthesia, anesthesia, and surgery. In
addition, indicated to prevent aspiration pneumonitis during
anesthesia. May be used as antidiarrheal and for cholinesterase
inhibitor toxicity
334

6. Medicines Used In Anaesthesia

Cautions: close supervision is recommended for infants,

children and geriatric patients. Cardiovascular disease, prostatic
enlargement, ulcerative colitis, and pyloric stenosis; pregnancy
and breast-feeding.
Drug
interactions:
anti-cholinergics,
cyclopropane,
ketoconazole (Note: patients should be advised to take this
medication at least two hours after ketoconazole), potassium
chloride (especially wax matrix preparations).
Contraindications: symptomatic reflux, paralytic ileus,
glaucoma, cardiac disease, hemorrhage, myasthenia gravis,
prostate hypertrophy.
Side effects: constipation; blurrred vision; clumsiness or
unsteadiness, confusion; difficulty in breathing; dryness of
mouth, nose, or throat; drowsiness; muscle weakness; tiredness;
tachycardia, hesitate micturation
Dose and Administration:Adult:Anticholinergic prophylaxis
of excessive salivation and respiratory tract secretions, in
anesthesia; and prophylaxis of gastric hypersecretory
conditions, in anesthesia:IM: 4.4 mcg (0.004mg) per kg of body
weight one-half to one hour before induction of anesthesia or at
the time the preanesthetic narcotic and/or sedative are
administered.
Antiarrhythmic, in anesthesia; or Antiarrhythmic, in
surgery:IV: 100 mcg (0.1mg), the dosage being repeated if
necessary at two to three minute intervals.
Cholinergic adjunct (curariform block):IV: 200mcg (0.2 mg) for
each 1 mg of neostigmine or 5 mg of pyridostigmine given
simultaneously; may be mixed in the same syringe.
Note: Geriatric patients may be more sensitive to the effects of the
usual adult dose.

Child: AnticholinergicProphylaxis of excessive salivation and

respiratory tract secretions, in anaesthesia; and Prophylaxis of
335

6. Medicines Used In Anaesthesia

gastric hypersecretory conditions, in anestheesia;IM, 4.4 to 8.8

mcg (0.0044 to 0.0088 mg) per kg of body weight one half to
one hour before induction of anesthesia or at the time the
preanesthetic narcotic and/or sedative are administered
Antiarrhythmics, in anesthesia; or Antiarrhythmics, in
surgery:IV: 4.4 mcg (0.0044 mg) per Kg of body weight up to a
maximum of 100 mcg (0.1 mg) the dosage being repeated, if
necessary, at two-to three minute intervals.
Cholinergic adjunct (curariform block) IV the same as usual
adult and adolescent dose.
Storage: store at room temperature unless otherwise specified
by manufacturer.
Hyoscine Hydrobromide
Injection, 0.4 mg/ml, 0.6 mg/ml, 1mg/ml in 1 ml ampoule
Indications: as antisialogogue pre anaesthetic medication to
prevent or reduce salivation and respiratory tract secretion.
Parentral administration of scopolamine in combination with
morphine or mepridine is indicated in pre-anaesthesia to reduce
excitement and produce amnesia.
Cautions: pregnancy and breast-feeding, in children and elderly
patients. Advice patients to avoid alcohol, driving vehicle and
operating machineries.
Drug interactions: antacids, antidiarrhoeals (adsorbents), other
anticholinergics, cyclopropane anaesthesia, CNS depressants.
Contraindications: angle closure glaucoma, pyloric obstruction,
urinary bladder neck obstruction, tachycardia, paralytic ileus,
hypersensitivity to the drug, ulcerative colitis.
Side effects:constipation decreased sweating, drowsiness,
dryness of mouth, skin, throat and nose, loss of memory,
redness or other signs of irritation at injection site.
336

6. Medicines Used In Anaesthesia

Dose and Administration:Adult: Prophylaxis of excessive

salivation and respiratory tract secretion in anaesthesia: IM
0.2-0.6mg, 30 minutes to 1 hour before induction of
anaesthesia.Anaesthetic Adjunct - sedation - hypnosis: IM, IV or
SC: 0.6mg three or four times a day.Amnesia:IM, IV, SC: 0.32
to 0.05mg. Child: Prophylaxis of excessive salivation and
respiratory tract secretion in anaesthesia: IM: administered 45
minutes - 1 hour before induction of anaesthesia. Child (4-7
months) 0.1mg. Child (7months - 3 years) - 0.15mg, Child (3-8
years) - 0.2mg, Child (8-12 years) 0.3mg.
Storage: store at room temperature in light-resistant container,
protect from light.
Neostigmine
Injection (Methylsulphate), 0.5 mg/ml, 2.5 mg/ml in 1 ml
ampoule
Indications: for reversal of the effects of Non-depolarizing
Neuromuscular blocking agents (e.g. tubocurarine, metocurine,
gallamine or pancuronium) after surgery; in the treatment of
post-operative non-obstructive urinary retention; for prevention
and treatment of post-operative gastro intestinal ileus and
prevention of postoperative distention and urinary retention.
Cautions: caution should be taken during near term pregnancy,
in elderly and in those patients with epilepsy, bronchial asthma,
bradycardia,
recent
coronary
occlusion,
vagotonia,
hyperthyroidism, cardiac arrhythmias, or peptic ulcer.
Drug interactions: anticholinergics especially atropine and
related compounds, local and some general anaesthetics such as
chloroform, cyclopropane, enflurane, halothane, lidocaine;
systemic aminoglycosides, succinylcholine or decamythonium;
other cholinesterase inhibitors including demecarium,
echothiopate isophlurophate, edrophonium; ganglionic blocking
337

6. Medicines Used In Anaesthesia

agents such as guanethidine, mecamylamine, trimethaphan;

procainamide.
Contraindications: intestinal or urinary tract obstruction
(mechanical), hypersensitivity to the drug or bromide,
peritonitis, urinary tract infection.
Side effects: diarrhoea, increasing sweating, increasing of
watering of mouth, nausea, vomiting, stomach cramp, frequent
urge to urinate, increased bronchial secretion, miosis,
bradycardia, bronchospasm, weakness, muscle cramp,
fasciculation, hypotension.
Dose and Administration:Adult: Antidote (to nondepolarizing neuromuscular blocking agents) after surgery: IV:
0.5mg - 2mg administered slowly, repeated as required up to a
total dose of 5mg.
Note: 0.6mg to 1.2mg of atropine is administered prior to or
concurrently with neostigmine to counteract its muscarinic side
effect.Prevention of post-operative distention or retention:IM or
SC 0.25mg immediately following surgery, repeated every four
to six hours for 2 or 3 days.Prevention of post-operative
distention:IM or SC- 0.5mg as needed.
Prevention of urinary retention:IM or SC - 0.5mg; dose
repeated every 3 hours for at least five doses after patient has
voided or the bladder has been emptied.
Note: If urination doesnt occur within one hour following the initial
0.5mg per dose, the patient should be catheterized.

Child:Antidote (to non-depolarizing neuromuscular blocker)

after surgery:IV,0.04mg per kg of body weight administered
with 0.02mg of atropine per kg of body weight.
Storage: at room temperature. Protect from freezing and light.
Oxygen (white-colored cylinder)
Indications: oxygen is given by inhalation to correct hypoxia in
conditions causing under ventilation of the lungs, such as
338

6. Medicines Used In Anaesthesia

exacerbations of chronic bronchitis, pneumonia, or pulmonary

oedema, where bronchospasm causes hypoxia, as in asthma, in
extensive fibrosing alveolitis after general anaesthesia and in
conditions where the oxygen content of the air breathed is
inadequate as at high altitudes.
Cautions: any fire or spark is highly dangerous in the presence
of increased oxygen concentrations especially when oxygen is
used under pressure.
Metal cylinders containing oxygen should be fitted with a
reducing valve by which the rate of flow can be controlled.
Side effects: CNS, toxicity (nausea, mood change, vertigo,
twitching, convulsions, loss of consciousness), pulmonary
toxicity (decrease in vital capacity, cough, substernal distress,
and later atelectasis), retinopathy of prematurity.
Dose and Administration: by inhalation. It is administered by
means of nasal catheter, facemask, endotracheal tube, or oxygen
tent.
Concentration of oxygen in inspired anesthetic gases should
never be less than 29-30% and use sodaline (carbondioxide
absorbent).
Soda lime, Carbon Dioxide Adsorbent
Used to absorb carbondioxide, for instance in closed-cicuit
anaesthetic apparatus.
6.4. Local Anesthetics
The local anesthetics are compounds which produce reversible loss of
sensation by preventing or diminishing the conduction of sensory
nerve impulses near to the site of their application or injection. Local
anesthetics could also be described as local analgesics as they are
most often used to produce loss of pain without loss of nervous
control. Also because their mode of action is to decrease permeability
of the nerve cell membrane to sodium ions they are considered to
339

6. Medicines Used In Anaesthesia

have a membrane stabilizing effect.Local anesthetics are used very

widely in dental practice, for brief and superficial interventions for
obstetric procedures, and for specialized techniques of regional
anesthesia calling for highly developed skills. Where patient
cooperation is required the patient must be psychologically prepared
to adopt the proposed procedure. Facilities and equipment for
resuscitation should be readily available at all times. Care must
always be taken to avoid inadvertent intravascular injection.The drugs
used vary widely in their potency, toxicity, duration of action, stability
in water, and ability to penetrate mucous membranes. These
variations determine their suitability for use by various routes, e.g.
topical (surface), infiltration, plexus, epidural (extradural) or spinal
block.The cold sensation produced by ethyl chloride spray is used to
test the onset of regional anaesthesia.
Local infiltration anesthesia. Many simple surgical procedures that
neither involve the body cavities nor require muscle relaxation can be
performed under local infiltration anesthesia. Lower segment
caesarean section can also be performed under local infiltration
anesthesia. The local anesthetic drug of choice is lidocaine 0.5 %
with or without epinephrine. No more than 4 mg/Kg of plain
lidocaine or 7 mg/kg of lidocaine with epinephrine should be
administered on any one occasion. The addition of epinephrine
(adrenaline) diminishes localblood flow, slows the rate of absorption
of the local anesthetic, and prolongs its effect. Care is necessary
when using epinephrine for this purpose since, in excesses, it may
produce ischaemic necrosis. And should not be injected with
epinephrine at end arterial sites (Finger, earlobe, penis, etc).
Surface anesthesia: Topical preparations of lidocaine are available
and topical eye drop solutions of tetracaine are used for local
anaesthesia of the cornea and conjunctiva.
Regional Block: A regional nerve block can proceed safe and
effective anesthesia but its execution requires considerable training
and practice. Nevertheless, where the necessary skills are available,
techniques such as axillarys, ankle block, etc can be invaluable.
340

6. Medicines Used In Anaesthesia

Either lidocaine 1 % or bupivacaine 0.5 % is suitable. Bupivacaine

has the advantage of a longer duration of action.
Spinal Anesthesia: This is one of the most useful of all anaesthetic
techniques and can be used widely for surgery of the abdomen and the
lower limbs. It is a major procedure requiring considerable training
and practice. Either lidocaine 5 % in glucose or bupivacaine 0.5 % in
glucose can be used but the latter is often chosen because of its longer
duration of action.Epidural anesthesia and analgesia: Local
anesthetic agents are popular alone or with opioids or epidural
anesthesia and analgesia in suitable surgical procedures and laboring
mother.

Bupivacaine
Injection, 0.25%, 0.5%
Indications: the 0.5% solution is chiefly indicated for
peripheral nerve blocks, eye blocks, spinal and epidural
(including caudal) anesthesia. Diluted solutions (0.25%) have
been used for local infiltration.Bupivacaine is particularly useful
for producing prolonged analgesia during labour, where the
interval between doses is usually 2-3 hours.
Cautions: respiratory impairment; hepatic impairment; epilepsy;
porphyria; myasthenia gravis; pregnancy and breastfeeding.
Drug interactions: hyaluronidase.
Contraindications: adjacent skin infection, inflamed skin,
concomitant anticoagulant therapy, severe anaemia or heart
disease; spinal or epidural anaesthesia in dehydrated or
hypovolaemic patient.
Side effects: cardiac arrest, hypotension, bradycardia, seizures,
restlessness, anxiety, dizziness, nausea, vomiting, blurred vision,
tinnitus and apnea.
Dose and Administration:Adult:Dosage depends on site of
injection, procedure used, and the status of the patient:Not more
than 2mg/kg (with or without adrenaline) should be
341

6. Medicines Used In Anaesthesia

administered in any 4 hour period, and in 24 hours the total

amount should not exceed 400mg.Child: Local infiltration:
2mg/kg. Regional anaesthesia: 2.5mg/kg
Storage: store at room temperature.
Cocaine Hydrochloride
Topical solution, 4% (40mg/ml), 10 %( 100mg/ml)
Indications: provide local anesthesia and vasoconstriction of
accessible mucous membranes, especially in the oral, laryngeal,
and nasal cavities
Cautions: Pregnancy, breast feeding and severely traumatized
mucosa and sepsis.
Contraindications: known history of hypersensitivity to the
drug or to the components of the topical solution.
Side effects: nausea, nervousness, unusual feelings of wellbeing, or restlessness
Dose and Administration: The dosage varies and depends upon the
area to be anesthetized, vascularity of the tissues, individual tolerance, and
the technique of anesthesia. The lowest dose needed to provide effective
anesthesia should be administered. Dose should be reduced for children and
for elderly and debilitated patients. Cocaine hydrochloride topical solution
can be administered by means of cotton applicators or packs, instilled into a
cavity, or as a spray.

Storage: Store at room temperature.

Ethyl Chloride
Spray, 50ml
Indications: as a local anaesthetic in minor operative
procedures such as incision of boils and removal of localized
growths.
Cautions: during application, the skin adjacent to the area being
treated should be covered with vaseline to protect against tissue
sloughing. Inhalation of ethyl chloride should be avoided.
Contraindications: broken skin or mucous membrane.
342

6. Medicines Used In Anaesthesia

Side effects: freezing may injure cells, decrease resistance to

infections, and delay healing. The frozen tissue may be painful, as
it gets warm. And cutaneous sensitization may occur rarely.
Dose and Administration: the container should be held about 12
inches (30 cm) from the area being treated and the spray directed
downward until light frosting appears. Because the local
anaesthetic effect is very brief, incision should be made as soon as
the tissue become white.
Storage: at room temperature, in tight containers, away from fire.
Protect from light.
Lidocaine Hydrochloride
Ointment, 5 % in 10 g; Jelly, 2% in 30 ml; Cartridge, 2% in 1.8 ml
ampoule; Spray, 2%, 4 %, 10 % in 80 g; Viscous, 2 % in 100 ml;
Injection, 0.5 %, 1 %, 2 % , 5 %
Indications: surface anaesthesia of mucous membranes;
infiltration anesthesia; peripheral and sympathetic nerve block;
dental anaesthesia; spinal anaesthesia; intravenous regional
anaesthesia; arrhythmias.
Cautions: caution in patients with inflammation and/or infections
at site of injection, and in very young, the elderly, acutely ill, or
weak patients.
Drug interactions: avoid simultaneous use of lidocaine with
vasoconstrictors (e.g. adrenaline) on the extremities such as the
finger, toes etc.
Contraindications: known hypersensitivity.
Side effects: a transient burning sensation may occur at the site of
injection.
Dose and Administration:Note: Intradermally, subcutaneously, or
submucosally (local infiltration). Inject indirectly into the tissue to be
incised or in the immediate surgery area. It should be injected slowly,
with frequent aspirations before and during the injection, to reduce
the risk of inadvertent intravascular administration.
343

6. Medicines Used In Anaesthesia

The total dose should not exceed 300mg/dose (4.5mg/kg of

body weight). Children should receive smaller amounts of
lidocaine, generally in lower concentration than adults.By
injection, infiltration anesthesia, according to patients weight
and nature of procedure, max, 300 mg.
Ointment,
Topical,Adult and Child 2 years of age and older as a 5 %
ointment, to the affected area three or four times a day as
needed.Jelly, Topical, Adult, to the affected area three or four
times a day as needed. Spray, Topical, Adult, sprayed and/or
applied to affected area three or four times a day as needed.
Storage: at room temperature. Protect from freezing.
Lidocaine Hydrochloride and Adrenaline
Injection, 1 % + 1:200,000 in 30 ml Vial
Injection, 2 % + 1:200,000 in 20 ml vial
See under Lidocaine Hydrochloride
Dose and Administrations: Dental Anaesthesia (for infiltration or
nerve block). Adult: 20 to 100 mg (1 to 5 ml) of lidocaine
hydrochloride as 2 % solution with epinephrine 1:2000,000; Child,
4 to 5 mg of Lidocaine Hydrochloride per kg of body weight or
100 to 150 mg as a single dose.Local infiltration or nerve block 7
mg of lidocaine hydrochloride per kg of body weight as a 0.25 to 1 %
solution with epinephrine 1:200,000.
Storage: at room temperature protect from light and freezing.
Tetracaine hydrochloride
Injection, 0.5%, 2%, 4% in 2ml vial
Indications: spinal anesthesia.
Dose and Administration: Adult: Subarachnoid injection: 520mg.

344

7. Medicines Used In Musculoskeletal And Joint Disease

7. MEDICINES for MUSCLOSKELETAL and JOINT

DISEASE

7.1. Antirheumatics
Many different drugs have been used for rheumatoid arthritis.
The choice of drugs for relief of pain depends up on the severity
of symptoms. In mild cases an analgesic alone may be all that is
required but most patients need the additional anti-inflammatory
effect provided by a NSAID (see also notes in section5.1).
Acemetacin
Capsule, 30mg, 60mg 90mg, (D/R)
Indications: pain and inflammation in rheumatic disease and
other musculoskeletal disorders; postoperative analgesia.
Cautions and Side effects: see under Indometacin and notes in
section 5.1
Drug interactions: cumarine or indandione derivative
anticoagulants,
heparin
or
thrombolytic
agents,
antihypertensives or diuretics, especially triamterene; aspirin
and anti-inflammatory, blood dyscrasias causing medications
and bone marrow depressants, radiation therapy, colchicine,
lithium, methotrexate, probenecid.
Contraindications: see notes in section 5.1
Dose and Administration: 120 mg daily in divided doses with
food, increased if necessary to 180 mg daily; child not
recommended.
Acetylsalicylic acid
Tablet, 75 mg, 100 mg (soluble), 300 mg, 324 mg (microfined),
500 mg (enteric coated)
Indications, Cautions, Drug interactions, Contraindications, Side
effects, Dose and Administration and Storage: see section 5.1
345

7. Medicines Used In Musculoskeletal And Joint Disease

Acetylsalycilic acid + Caffeine + Paracetamol

Tablet, 250mg+65mg+250mg
Indications: temporary relief of the pain of headache, mild to
moderate pain associated with migraine headache, pain due to
sinusitis or colds, muscular aches, pain of menstrual discomfort,
toothaches and minor arthritis pain and pain accompanied by
fever.
Cautions: see notes above, also in dehydrated patients,
particularly children, gout, coagulation or platelet function
disorder.
Drug
interactions:
anticoagulants,
anti-inflammatory,
phenothiazines, oral hypoglycemic, insulin, sulfinpyrazone,
urinary alkalinizers and acidifiers, diuretics, bronchodilators,
caffeine containing beverages.
Contraindications: hypersensitivity (including asthma,
angioedema, urticaria, or rhinitis) to acetylsalicylic acid or any
other NSAID; active peptic ulceration.
Dosage and Administration: see section 5.1. Adults and
Children over 12 Years of Age: 2 tablet with a full glass of
water after meal every 6 hours while symptoms persist, not to
exceed 8 tablets in 24 hours.Note: The patient should be instructed
not to lie down for 15-30 minutes following drug intake in order to
reduce the risk of esophageal irritation and ulceration.

Diclofenac Diethylamine
Gel, 1%, 30gm
Indications: For the relief of aches and pain associated with
acute, localized muscle or joint injuries such as sprains, strains
or sports injuries (e.g. sprain of ankle, strain of shoulder or back
muscles). Rest may also be helpful to assist the relief of
associated discomfort.
Cautions, Contraindicationsand Side effects: see section 5.1
346

7. Medicines Used In Musculoskeletal And Joint Disease

Drug interactions: anticoagulants (blood thinners), or heparin

or thrombolytic agents, antihypertensives, oral antidiabetic
agents, fluoroquinolone antibiotics (ofloxacin) aspirin and antiinflammatory, colchicine, lithium, methotrexate, probenecid.
See section 5.1
Dose and Administration:Adults and adolescents 16 years and
older: apply Diclofenac diethylamine gel 3 to 4 times a day.
Gently rub a small amount of Diclofenac diethylamine gel into
the skin where you have pain or swelling. The amount needed
will vary depending upon the size of the painful or swollen area.
Usually, a strip approximately 2 cm long will be sufficient to
cover a 200cm2 area. Wash your hands after rubbing in
Diclofenac diethylamine gel, unless of course they are the site
being treated. The gel should not be used for more than 7 days
for muscle and joint injuries, unless recommended.
Diclofenac sodium
Capsule(S/R), 75mg
Injection, 25 mg/ml in 3 ml ampoule, 75mg/ml
Tablet (e/c), 25 mg, 50 mg
Tablet 75mg (S/R) ,100mg(S/R)
Sachet, 50mg (as potassium)
Suppository, 12.5mg, 25mg, 50mg, 100 mg
Gel, 1%, 3%
Indications: pain and inflammation in rheumatic disease
(including juvenile arthritis) and other musculoskeletal
disorders; acute gout; postoperative pain.
Cautions: See notes in section 5.1
Drug interactions: cumarine or indandione derivative
anticoagulants, or heparin or thrombolytic agents,
antihypertensives or diuretics, especially triamterene, aspirin
and anti-inflammatory, blood dyscrasia causing medications and
347

7. Medicines Used In Musculoskeletal And Joint Disease

bone marrow depressants, radiation therapy, colchicine, lithium,

methotrexate, probenecid.
Contraindications: See also notes in section 5.1, porphyria.
Side effects: see notes above; suppositories may cause rectal
irritation, injection site reactions.
Dose and Administration:Adult: Oral: Rheumatoid arthritis:
150-200mg per day in three or four divided doses, initially.
After a satisfactory response has been obtained, dosage should
be reduced to the minimum dose that provides continuing
control of symptoms, usually 75 100 mg a day in 3 divided
doses.
Deep IM injection into the gluteal muscle: acute exacerbations
and post- operative: 75 mg once daily (twice daily in severe
cases) for maximum of 2 days.
Ureteric colic: 75 mg then a further 75 mg after 30 minutes if
necessary.IV infusion (in hospital setting), 75 mg repeated if
necessary after 4 6 hours for maximum 2 days.Prevention of
postoperative pain, initially after surgery 25 to 50 mg over 15
60 minutes then 5 mg/hour for maximum 2 days.Rectum in
suppositories, 75 to 150 mg daily in divided doses.Maximum
total daily dose by any route 150 mg.Child 1 12 years,
juvenile arthritis, Oral or rectum: 1 3 mg/kg daily in divided
doses (25 mg e/c tablets, 12.5 mg and 25 mg suppositories
only).
Storage: at room temperature in a tight container, protect from
moisture.
Diclofenac sodium + Misoprostol
Tablet, 50mg + 200mcg, 75mg+200mcg
Indications: the diclofenac component is indicated for the
treatment of osteoarthritis and rheumatoid arthritis; the
348

7. Medicines Used In Musculoskeletal And Joint Disease

misoprostol component is indicated for the prophylaxis of

NSAID-induced gastric and duodenal ulceration.
Dose and Administration:Oral:Adult: Osteoarthritis: 50
mg/200 mcg three times daily. For patients experiencing
intolerance, 50 mg/200 mcg or 75 mg/200 mcg twice daily can
be used, but is less effective at preventing ulcers. Dosages of
diclofenac higher than 150 mg/day and misoprostol 800 mcg/day in
osteoarthritis are not recommended.Rheumatoid arthritis: 50

mg/200 mcg three or four times daily. For patients experiencing

intolerance, 50 mg/200 mcg or 75 mg/200 mcg twice daily can
be used, but is less effective at preventing ulcers.
Etofenamate
Gel, 5%, 10%
Cream, 10%
Lotion, 10%
Spray, 100mg/ml (18mg/dose)
Indications: treatment of soft tissue rheumatic disorders of
musculoskeletal system: muscular rheumatism muscle
hardening which occurs with frozen shoulder (periarthritis of the
shoulder),lumbago , sciatica, tenosynovitis, bursitis, disorders
caused by overstraining and erosion of the spinal column or
joints (spondylosis ,osteoarthritis) ,treatment of blunt injuries
(sport injuries such as bruises, sprains and strains)
Caution: do not apply to damaged, eczematous inflamed skin,
to the mucus membranes, to the eyes and any other open skin
Contraindications:
hyepersinsitivity
to
etofenamate,
flufenamic acid, or any other NSAID pregnancy and breast
feeding, children
Side effects: reddening of the skin, allergic skin reactions
(intense itching, rashes, erythema, swelling, blistering.
Dose and administration: for rheumatic disorders, apply strip
of gel 5 to 10 cm long (corresponding to approximately 1.7 to
349

7. Medicines Used In Musculoskeletal And Joint Disease

3.3 mg per administration three to four times a day for 3 to 4

weeks and for sports injuries up to 2 weeks depending on the
size of the painful areas and rub over in over as large as an area
of the skin as possible
Storage: do not store above 25 oC
Ibuprofen
Capsule, 300 mg
Tablet, 200 mg, 400 mg (enteric coated,optioal)
Syrup, 100mg/5ml
Indications, Cautions Drug interactions, Contraindications
Side effects and Dose and Administration: see section 5.1.
Indomethacin
Capsule, 25 mg, 50mg, 75mg
Suppository, 100 mg
Syrup, 25mg/5ml, 100mg/5ml
Tablet, 25mg (enteric coated, optional)
Indications: acute or chronic rheumatoid arthritis, for relief of
acute or chronic osteoarthritis and for relief of acute or chronic
ankylosing spondylitis; acute gout (section 6.2). It is also
indicated for relief of acute or chronic juvenile arthritis and in
the treatment of psoriatic arthritis.
Cautions: see notes above, also epilepsy, Parkinsonism,
psychiatric disturbances, during prolonged therapy ophthalmic
and blood examinations particularly advisable; avoid rectal
administrations in proctitis and haemorrhoids. Dizziness may
affect performance of skilled tasks (e.g. driving)
Drug interactions: cumarine or indandione derivative
anticoagulants,
heparin
or
thrombolytic
agents,
antihypertensives or diuretics, especially triamterene; aspirin
and anti-inflammatory, blood dyscrasias causing medications
350

7. Medicines Used In Musculoskeletal And Joint Disease

and bone marrow depressants, radiation therapy, colchicine,

lithium, methotrexate, probenecid.
Contraindications: see notes above
Side effects: see notes above; frequently gastrointestinal
disturbances (including diarrhea, headache, dizziness, and light headedness; also gastro-intestinal ulceration and bleeding;
rarely, drowsiness, confusion, insomnia, convulsions,
psychiatric disturbances, depression, syncope, blood disorders
(particularly thrombocytopenia), hypertension, hyperglycaemia,
blurred vision, corneal deposits, peripheral neuropathy, and
intestinal strictures; suppositories may cause rectal irritation and
occasional bleeding.
Dose and Administration: Adult: Anti-rheumatic:Oral:
initially 25 to 50mg two or four times a day, if well tolerated,
the dosage per day may be increased by 25 or 50mg at weekly
intervals until a satisfactory response is obtained or up to a
maximum dose of 200mg per day.Rectal: 50mg four times a
day. Child: Anti-rheumatic:Oral: 1.5 to 2.5mg per kg of body
weight, per day, administered in three or four divided doses, up
to a maximum of 4mg per kg of body weight per day or 150 to
200mg per day, which ever is less.Rectal: same as oral (for
children).
Storage: store at room temperature in a well-closed container.
Leflunomide
Tablet, 10mg, 20mg, 100mg
Indications: treatment of active rheumatoid arthritis; indicated
to reduce signs and symptoms, and to retard structural damage
and improve physical function.
Cautions: hepatic disease, patients with severe immune
deficiency, uncontrolled infection; hematologic abnormalities;
renal impairment.
351

7. Medicines Used In Musculoskeletal And Joint Disease

Drug interactions: NSAIDs, methotrexate, rifampin.

Contraindications: pregnancy, hypersensitivity reaction.
Side effects: diarrhea, respiratory tract infection, hypertension,
chest pain, headache, dizziness, fever, sleep disorder, rash,
alopecia, eczema, nausea, weight loss, anorexia, vomiting,
bronchitis, cough.
Dose and Administration:Oral:Adult: Initial: 100mg/day for 3
days, followed by 20mg/day; dosage may be decreased to 10
mg/day in patients who have difficulty tolerating the 20mg dose.
Storage: store at room temperature and protect from light.
Meloxicam
Tablet, 7.5mg, 15mg
Indications: Pain and inflammation in rheumatic disease;
exacerbation of osteoarthritis (short-term); ankylosing
spondylitis
Cautions: renal impairment; hepatic impairment; cardiac
disease; elderly; pregnancy and breastfeeding; coagulation
defects; allergic disorders.
Drug interactions: cumarine or indandione derivative
anticoagulants,
heparin
or
thrombolytic
agents,
antihypertensives or diuretics, especially triamterene; aspirin
and anti-inflammatory, blood dyscrasias causing medications
and bone marrow depressants, radiation therapy, colchicine,
lithium, methotrexate, probenecid,sulfonylurea antidiabetic
agents.
Contraindications: hypersensitivity (including asthma,
angioedema, urticaria, orrhinitis) to acetylsalicylic acid or any
other NSAID; active peptic ulceration.
Side effects: Gastro-intestinal disturbances including
discomfort, nausea, diarrhoea, and occasionally bleeding and
ulceration occur. Systemic as well as local effects of NSAIDs
352

7. Medicines Used In Musculoskeletal And Joint Disease

contribute to gastro-intestinal damage; taking oral formulations

with milk or food, or using enteric-coated formulations, or
changing the route of administration may only partially reduce
symptoms such as dyspepsia.Other side-effects include
hypersensitivity reactions (particularly rashes, angioedema, and
bronchospasm), headache, dizziness, nervousness, depression,
drowsiness, insomnia, vertigo, hearing disturbances such as
tinnitus, photosensitivity, and haematuria. Blood disorders have
also occurred. Fluid retention may occur (rarely precipitating).
Dose and Administration: Oral:Osteoarthritis: Adult and
child over 16 years: 7.5 mg once daily, increased if necessary to
max.15 mg once daily.
Rheumatoid arthritis, ankylosing spondylitis: Adult and Child
over 16 years: 15 mg once daily, may be reduced to 7.5 mg once
daily; elderly 7.5 mg daily; Child 12-18 years and body weight
under 50kg 7.5mg once daily;Child 12-18 years and body
weight over 50kg 15mg once daily.
Storage: store it at room temperature and away from excess
heat and moisture
Naproxen
Tablet, 200mg, 220mg, 250mg, 375mg, 500mg
Suspension, 125/5ml
Indications: pain and inflammation in rheumatic disease
(including
juvenile
idiopathic
arthritis)
and
other
musculoskeletal disorders; dysmenorrhoea; acute gout.
Cautions, Drug interactions, Contraindications and Side
effects: See under meloxicam.
Dose and Administration: Undesirable effects may be
minimised by using the lowest effective dose for the shortest
duration necessary to control symptoms.
353

7. Medicines Used In Musculoskeletal And Joint Disease

Rheumatic disorders the usual initial dose of naproxen is 250

mg, twice daily, adjusted to 500 mg to 1g daily in two divided
doses. Acute gout, an initial dose of 750 mg followed by 250
mg every 8 hours has been suggested; while in dysmenorrhoea
500 mg may be given initially, followed by 250 mg every 6 to 8
hours. A dose of 10 mg per body weight daily, in two divided
doses has been used in children over 5 years of age with
juvenile rheumatoid arthritis. The elderly are at increased risk of
the serious consequences of adverse reactions. If NSAID is
considered necessary, the lowest effective dose should be used
and for the shortest possible duration. The patient should be
monitored regularly for GI bleeding during NSAID therapy.
Storage: store in a dry place below 25C. Protect from light.
Keep container tightly closed.
Nimesulide
Tablet, 100mg, 200mg
Indications: treatment of acute pain, symptomatic treatment of
painful osteoarthritis, primary dysmenorrhea
Cautions: Nimesulide containing medical products should be
use for the shortest possible duration as required by the clinical
situation. May cause hepato toxicity, gastrointestinal bleeding or
ulceration, may interfere with platelet function, and may impair
female fertility, co administration of NSAIDs or other
analgesics with Nimesulide is not recommended.
Contraindication: known hypersensitivity to Nimesulide,
history of hypersensitivity reactions to other NSAIDs, history of
hepatic reactions to Nimesulide, active gastric or duodenal
ulcer,severe coagulation disorders, severe heart failure, sever
renal impairment, and sever renal impairment, children under 12
years old.
354

7. Medicines Used In Musculoskeletal And Joint Disease

Piroxicam
Capsule, 10 mg, 20 mg
Tablet, 10 mg, 20 mg
Suppository, 20 mg
Indications: pain and inflammation in rheumatic disease
(including juvenile arthritis) and other musculoskeletal
disorders; acute gout.
Cautions: CHF, hypertension, dehydration, history of GI
disease.
Drug interactions: lithium, methotrexate, amiodarone,
fluoxetine, glimepiride, glipizide, phenytoin, sertraline,
warfarin, and other CYP2C8/9 substrates; diuretics; betablockers; aspirin; antacids, and cholestyramine.
Contraindications: hypersensitivity to piroxicam, aspirin or
other NSAIDs; active GI bleeding; pregnancy (3rd trimester or
near term).
Side effects: dizziness, rash, abdominal cramps, heartburn,
indigestion, nausea, headache, nervousness, itching, fluid
retention, vomiting and tinnitus.
Dose and Administration: Oral, Rectum: Adult: Rheumatic
disease: initially 20 mg daily, maintenance 10 - 30 mg daily, in
single or divided doses.
Childover 6 years: Oral: juvenile arthritis, less than 15 kg, 5
mg daily; 16 - 25 kg, 10 mg; 26-45 kg, 15mg; over 46kg, 20 mg.
Acute musculoskeletal disorders:Adult: 40 mg daily in single or
divided doses for 2 days, then 20 mg daily for 7 - 14 days.Acute
goute:Adult: 40 mg initially, then 40 mg daily in single or
divided doses for 4 - 6 days.
Sulphasalazine
Tablet (e/c), 500mg
Indications: severe rheumatoid arthritis.
355

7. Medicines Used In Musculoskeletal And Joint Disease

Cautions: renal or hepatic impairment, or urinary tract

obstruction, pregnancy and breast-feeding, glucose-6-phosphate
dehydrogenase(G6PD) deficiency, intestinal obstruction, blood
dyscrasias, porphyria.
Drug interactions: digoxin, diuretics, oral contraceptives, oral
antidiabetic agents, phenytion or phenobarbital, pyrimethamine,
warfarin, zidovudine and lamivudine.
Contraindications: hypersensitivity to salicylates and
sulphonamides; child under 2 years of age.
Side effects: nausea, vomiting, diarrhea and anorexia; reversible
oligospermia and infertility are common in males;
haematological disturbances, hypersensitivity reactions and
hepatic function disturbances. Photosensitivity may occur.
Dose and Administration:Adult:Oral: initially 500mg daily,
increased by 500mg at intervals of 1 week to a maximum of 23g daily in divided doses.
Storage: protect from light.
Tenoxicam
Tablet, 20mg
Suppository, 20mg
Indications: symptomatic management of osteoarthritis and
rheumatoid arthritis and also in the short term management of
soft-tissue injury.
Cautionsand Side effects: as for non-steroidal antiinflammatory drug in general.
Drug interactions: see under indomethacin
Dose and Administrations: Oral: as a single daily dose usually
of 20mg. In acute skeletal disorders treatment for up to 7 days is
usually sufficient but in severe cases it may be given for up to a
maximum of 14 days. Dose similar to those given by mouth
have been given by rectal suppository. Child not recommended.
356

7. Medicines Used In Musculoskeletal And Joint Disease

Tolmetin sodium
Capsule, 200 mg, 400 mg
Tablet, 200 mg
Indications: treatment of rheumatoid arthritis and osteoarthritis,
juvenile rheumatoid arthritis.
Cautions: as piroxicam.
Drug interactions: digoxin, methotrexate, cyclosporine,
Contraindications: hypersensitivity to tolmetin, aspirin, or
other NSAIDs, pregnancy (3rd trimester or near term).
Side effects: chest pain, hypertension, edema, headache,
dizziness, drowsiness, depression, skin irritation, weight
gain/loss, heartburn, abdominal pain, diarrhea, flatulence,
vomiting, constipation, gastritis, peptic ulcer, nausea, urinary
tract infection, visual disturbances, tinnitus.
Dose and Administration: Oral:Adult: 400 mg 3 times /day;
usual dose: 600 mg to 1.8 g/day; maximum; 2 g/day.Child 2
years:Anti-inflammatory: initial: 20 mg/kg/day in 3 divided
doses, then 15-30 mg/kg/day in 3 divided doses.Analgesic: 5-7
mg/kg/dose every 6-8 hours.
7.2. Medines used for Gout
It is important to distinguish drugs for the treatment of acute
attacks of gout from those used in the long-term control of the
disease.The latter exacerbate and prolong the acute
manifestations if started during attack.
Acute gout: Acute attacks of gout are usually treated with high
doses of NSAIDs such as indomethacin (150 - 200 mg daily in
divided doses), ibuprofen has weaker anti-inflammatory
properties than other NSAIDs and is therefore unsuitable for
treatment of gout. Salicylates, including acetylsalicylic acid are
also not suitable because they may increase plasma-urate
357

7. Medicines Used In Musculoskeletal And Joint Disease

concentrations. Colchicine is an alternative for those patients in

whom NSAIDs are contraindicated. Its use is limited by
toxicity with high doses. It does not induce fluid retention and
can therefore be given to patients with heart failure; it can also
be given to patients receiving anticoagulants.
Chronic gout: For long-term control of gout in patients who
have frequent attacks, the xanthine oxidase inhibitor allopurinol
may be used to reduce production of uric acid. It should not be
used to treat an acute attack since it may prolong it indefinitely.
Treatment for chronic gout should not be started until after an
acute attack has completely subsided, usually 2 - 3 weeks. The
initiations of allopurinol treatment may precipitate an acute
attack therefore colchicines or a suitable NSAIDs should be
used as a prophylactic and continued for at least one month after
the hyperuricaemia has been corrected. If an acute attack
develops during treatment for chronic gout, then allopurinol
should continue at the same dosage and the acute attack should
be treated in its own right. Treatment for chronic gout must be
continued indefinitely to prevent further attacks of gout.
Note: Administer, prophylactic colchicine or non-steroidal antiinflammatory drugs (not aspirin or salicylates) until at least 1 month
after hyperuricemia corrected, ensure adequate fluid intake (2
liters/day). In neoplastic conditions treatment with allopurinol should
be commenced before cytotoxic drugs are given.

Allopurinol
Tablet, 100 mg
Indications: long-term management of hyperuricemia
associated with primary or secondary gout; to control
hyperuricemia secondary to blood dyscrasias such as
polycythemavera myeloid metaplasia, or their treatment.
358

7. Medicines Used In Musculoskeletal And Joint Disease

Note: Allopurinol is not effective in the treatment of acute gout

attacks because it has no anti-inflammatory action, and may
intensify and prolong inflammation during the acute phase.
Cautions: renal and hepatic function impairment, diabetes
mellitus, and hypertension
Drug interactions: cumarine or indandione derivative
anticoagulants, mercaptopurine, alcohol, xanthenes such as
aminophylline
oxtriphylline,
theophylline,
furosemide,
diazoxide, ethacrinic acid and thiazide diuretics.
Contraindications: sensitivity to allopurinol, acute gout.
Side effects: dermatitis allergic (skin rash, hives or itching,
agranulocytosis (chills, fever or sore throat), angitis (vasculitis),
hypersensitivity (chills, fever, sore throat muscle ache, pain or
weakness, shortness of breath, troubled breathing, tightness in
chest, wheezing), diarrhoea, drowsiness, headache.
Dose and Administration:Adult: Antigout: Initial - Oral,
100mg once a day, to be increased by 100mg per day at one
week intervals until the desired serum uric acid concentration is
attained. Maximum - 800mg per day. Maintenance -Oral, 100 200mg two or three times a day or 300mg as a single dose once
a day.
Child: Antihyperuricemic, in neoplastic disease therapy:
Child (up to 6 years)- Oral, 50mg three times a day; 6-10 years
of age, oral, 100mg three times a day or 300mg as a single dose
once a day.
Note: Drink large amounts of fluids.

Storage: at room temperature in a well-closed container.

Colchicine
Injection, 0.5 mg/ml in 2 ml ampoule
Tablet, 0.5mg
359

7. Medicines Used In Musculoskeletal And Joint Disease

Indications: acute gout, short-term prophylaxis during initial

therapy with allopurinol and uricosuric drugs; prophylaxis of
familial Mediterranean fever (recurrent polyserositis).
Cautions: elderly, gastro-intestinal disease, cardiac, hepatic and
renal impairment
Drug interactions: cyclosporin
Contraindications: pregnancy and breast-feeding
Side effects: most common are nausea, vomiting, and
abdominal pain, excessive doses may also cause profuse
diarrhea, gastro-intestinal hemorrhage, rashes, renal and hepatic
damage. Rarely peripheral neuritis, myopathy, alopecia, and
blood disorder with pronged treatment.
Dose and Administration:Acute gout: Oral: 0.5 - 1mg initially,
followed by 500 micrograms every 2 - 3 hours until relief of
pain is obtained, or vomiting or diarrhea occurs; maximum total
dose 6 mg, the course should not be repeated within 3
days.Prevention of gout attacks during initial treatment with
allopurinol, 500 micrograms 2 - 3 times daily continuing for at
least 1 month after hyperuricaemia has been corrected.
Storage: at room temperature. Protect from freezing. Protect
from light.
Ibuprofen
Tablet, 200 mg, 400 m g(enteric coated, optional)
Indications: for relief of the pain and inflammation of acute
gout arthritis.
Cautions, Drug Interactions, Contraindications, Side effects,
Storage; See section 6.1 under Ibuprofen.
Dose and Administrations:Treatment of acute migraine attack:
Oral: preferably with or after food,
Adult: 400600 mg at first sign of attack may be repeated every
68 hours if necessary, maximum 2.4 g daily;Children: 812
360

7. Medicines Used In Musculoskeletal And Joint Disease

years 200 mg at first sign of attack, may be repeated every 68

hours if necessary
Indomethacin
Capsule, 25 mg
Suppository, 100 mg
Indications: for relief of the pain and inflammation of acute
gouty arthritis.
Cautions, Drug interactions, Contraindications, Side effect,
and Storage; see section 6.1, under indomethacin.
Dose and Administration: Adult: Antigout: Oral: 100mg
initially, then 50mg three times a day until pain is relieved, with
the dosage then being reduced until medication is
discontinued.Rectal: the total daily dose may be given as 100mg
in the morning and at night. The total daily combined dose by
mouth and by rectum should not exceed 200mg. In acute gout
the daily dose is 150-200mg in divided doses until all symptoms
and signs subside. In Child dose not recommended.
Probenecid
Tablet, 500 mg
Indications: long-term management
associated with chronic gout.

of

hyperuricemia

Note: It is not effective in the treatment of acute gout attacks and does
not eliminate the need to use colchicine or non-steroidal antiinflammatory drugs to relieve an attack.

Cautions: children (younger than 2 years of age), in patients

with peptic ulceration, renal function impairment, blood
dyscrasias.
Drug interactions: antineoplastic (rapidly cytolytic),
zidovudine, indomethacin, ketoprofen, aspirin or other
361

7. Medicines Used In Musculoskeletal And Joint Disease

salicylates (including bismuth subsalicylate), cephalosporines or

penicillines, heparin, and nitrofurantoin.
Contraindications: probenecid is contraindicated in any
condition in which there is an increased risk of uric acid renal
calculi formation or urate nephropathy such as cancer
chemotherapy with rapidly cytolytic antineoplastic agents,
radiation therapy for malignancy, moderate to severe renal
function impairment, history of blood dyscrasias nephrolithiasis,
porphyria, acute gout attacks.
Side effects: acute gout, arthritis attack (joint pain, redness,
swelling) headache, loss of appetite, nausea or vomiting (mild),
dizziness, flushing or redness of face, urinary frequency, sore
gums, aplastic anaemia, nephrotic syndrome (cloudy urine,
swelling of face).
Dose and Administration:Adult: Antigout: Oral: Initial
250mg two times a day for one week. Maintenance 500mg two
times a day.
Child: dosage has not been established.
Storage: at room temperature in a well-closed container.
7.3. Skeletal Muscle Relaxants
Centrally acting muscle relaxants have a selective action on the
central nervous system and are used in the management of
spasticity due to neuromuscular and musculoskeletal disorders
and for relief of painful muscle spasm. Diazepam and baclofen
are effective for the control of muscle spasm in a variety of
disorders. The efficacy of agents such as methocarbamol and
orphenadrine is controversial; they may be no more clinically
useful than adequate analgesia alone. Significant adverse effects
(e.g. sedation, hepatotoxicity, immunological reactions) may
occur.Dantrolene acts uniquely outside the CNS and used in the
362

7. Medicines Used In Musculoskeletal And Joint Disease

treatment of malignant hyperthermia and in slected instances of

skeletal muscle spasticity.
Muscle relaxants should be used with caution if muscle
spasticity plays a role in sustaining upright posture and balance.
A reduction in muscle tone may cause a loss of the splinting
action of the spastic muscles and lead to increased disability and
instability.
Baclofen
Tablet, 5mg, 10mg
Indications: relief of muscle spasiticity due to spinal cord
injury or disease, especially multiple sclerosis; pain relief in
trigeminal neuralgia; stiff - man syndrome.
Cautions: epilepsy, peptic ulcer disease, renal impairment,
cerebrovauscular disease or pre - existing psychiatric
disturbances.
Drug interactions:other CNS depressants; antihypertensive
agents. Contraindications: hypersensitivity to baclofen.
Side effects: drowsiness, dizziness, ataxia, nausea, constipation
or diarrhea, confusion, hypotension, allergic skin reactions;
psychiatric disturbances (e.g. depression, hallucinations,
euphoria) occur occasionally in the elderly or in patients with
psychiatric or brain disorders.
Dose and Administration:Oral:Adult: initially 5mg 3 times
daily; preferably with meals, increased by 5mg /dose every 3
days until the desired response is obtained, usually with 30 75mg/day. Maximum 100 mg/day.
Child: 1 to 1.5mg/kg daily. Maximum doses: 2 - 7 years, 30 40 mg/day; over 8 years, 60mg/day.
Storage: store at room temperature.

363

7. Medicines Used In Musculoskeletal And Joint Disease

Chlormezanone + Paracetamol
Tablet, 100mg + 450mg
Indications: relief of generalized pain associated with tension.
Cautions: do not use continuously for more than 10 days
without consulting your doctor; liver or kidney disease.
Drug interactions: other tranquilizers or antidepressants.
Contraindications: sensitivity to Paracetamol. Safety in
pregnancy and lactation has not been established.
Side effects: sensitivity reactions resulting in reversible skin
rash or blood disorders; drowsiness, weakness, nausea,
dizziness, flushing of the skin, excitement, depression, skin
rash, confusion, dryness of the mouth and difficulty in
micturition; cholestatic jaundice may occur. The patient should
not drive a vehicle or operate machinery, if dizziness or
drowsiness
occurs.
Dose and Administration:Adult: 1 tablet 3-4 times daily as
required. Child 9-12 years: tablet 3 - 4 times daily as
required. Not for children under 9 years of age.
Storage: store below 25C. Protect from light.
Dantrolene sodium
Capsule, 25mg, 50mg
Indications: treatment of spasticity associated with spinal cord
injury, stroke, cerebral palsy, or multiple sclerosis; treatment of
malignant hyperthermia.
Cautions: impaired cardiac function or pulmonary functions;
hepatic disease.
Drug interactions: estrogens, CNS depressants, MAO
inhibitors, phenothiazines, clindamycin, verapamil, warfarin,
clofibrate, tolbutamide, azole antifungals, ciprofloxacin,
clarithromycin,
diclofenac,
doxycycline,
erythromycin,
364

7. Medicines Used In Musculoskeletal And Joint Disease

aminoglutethimide, carbamazepine, nafcillin, nevirapine,

phenobarbital, phenytoin and rifamycins.
Contraindications: active hepatic disease; should not be used
where spasticity is used to maintain posture or balance.
Side effects: drowsiness, dizziness, lightheadedness, fatigue,
rash, diarrhea, vomiting, muscle weakness, chills, fever,
headache, insomnia, nervousness, mental depression,
constipation, anorexia, stomach cramps, blurred vision,
respiratory depression.
Dose and Administration: Oral: Spasticity:Adult: 25mg/day to
start, increase frequency to 2 - 4 times/day, then increase dose
by 25mg every 4 - 7 days to a maximum of 100mg 2 - 4 times /
day or 400mg/day.
Child:initial 0.5mg/kg/dose twice daily, increase frequency to 3
- 4 times/day at 4 - 7 day intervals, then increase dose by
0.5mg/kg to a maximum of 3mg/kg /dose 2 - 4 times/day up to
400mg/day.
Malignant hyperthermia:
Adult and Child: preoperative prophylaxis:4 to 8 mg/kg/day in
4 divided doses, begin 1 to 2 days prior to surgery with last dose
3 - 4 hours prior to surgery.
Storage: store at room temperature.
Diazepam
Tablet, 2 mg, 5 mg, 10 mg
Syrup, 2 mg / 5 ml
Injection, 10 mg/ml, in 2 ml ampoule
Indications: muscle spasm of varied etiology, including
tetanus; other indications (section 4.2, section 4.4).
Cautions: see section 4.2; special precautions for intravenous
injection.
365

7. Medicines Used In Musculoskeletal And Joint Disease

Contraindications, Side effects, see section 4.2; also

hypotonia.
Dose and Administration:Oral: 2 - 15 mg daily in divided
doses, increased if necessary in spastic conditions to 60 mg
daily according to response.
Cerebral spasticity in selected cases:
Child: 2 - 40 mg daily in divided doses.IM or slow IV injection
(into a large vein at a rate of not more than 5 mg/minute), in
acute muscle spasm, 10 mg repeated if necessary after 4
hours.Tetanus: Adult and Child: IV injection: 100 - 300
micrograms/kg repeated every 1 - 4 hours; IV infusion (or by
nasoduodenal tube): 3 - 10 mg/kg over 24 hours, adjusted
according to response.Note: Only use IM route when oral and IV
routes not possible.

Methocarbamol
Injection, 1g in 10ml vial
Tablet, 500mg
Indications: treatment of muscle spasm associated with acute
painful musculo skeletal conditions; supportive therapy in
tetanus.
Cautions: renal or hepatic impairment, seizures.
Drug interactions: CNS depressants, ethanol.
Contraindications: hypersensitivity to methocarbamol.
Side effects: flushing of face, bradycardia, hypotension,
syncope, drowsiness, dizziness, lightheadedness, convulsion,
vertigo, headache, fever, amnesia, confusion, insomnia,
sedation, allergic dermatitis, urticaria, pruritus, rash, nausea,
vomiting, metallic taste, dyspepsia, leukopenia, jaundice,
thrombophlebitis,
blurred
vision,
renal
impairment,
conjunctivitis and nasal congestion.
366

7. Medicines Used In Musculoskeletal And Joint Disease

Dose and Administration:Muscle spasm: Adult and Child >

16 years:Oral: 1.5g 4 times /day for 2 -3 days (up to 8g/day
may be given in severe conditions) then decrease to 4 4.5 g
/day in 3 - 6 divided doses.
I.M, I.V: 1 g every 8 hours if oral not possible; injection should
not be used for more than 3 consecutive days. If condition
persists, may repeat course of therapy after a drug- free interval
of 48 hours.
Elderly: oral: initial: 500mg 4 times /day.
Storage: Store at controlled room temperature.
Orphenadrine Citrate
Tablet, 100 mg
Drop, 2.5 mg/ml
Injection, 30 mg/ml
Indications: to relieve pain due to spasm of skeletal muscle (see
notes above).
Cautions, Drug interactions, Contraindications, Side effects;
see section 4.5 under orphenadrine hydrochloride.
Dose and Administration:Adult: Oral: 100 mg twice daily IM
or slow IV (over a period of 5 minutes) injection in a dose of 60
mg which is repeated every 12 hours, as needed.
Storage: at room temperature, protect from light and freezing.
Other centrally acting muscle relaxants include
Orphenadrine citrate + Paracetamol
Tablet, 35mg + 450mg
Indications: generalised pain and the relief of muscle spasm
associated with acute painful musculo-skeletal conditions.
Cautions: cardiac disease or arrhythmias, especially
tachycardia.
367

7. Medicines Used In Musculoskeletal And Joint Disease

Drug interactions: orphenadrine may increase central nervous

system depression if taken concurrently with alcohol or central
nervous system depressants. Anticholinergic effects may be
intensified if orphenadrine is taken concurrently with
anticholinergics or medication with anticholinergic effects.
Contraindications: hypersensitivity to any of the ingredients;
severe liver function impairment; prostatic enlargement,
achalasia, bladder neck obstruction, glaucoma, myasthenia
gravis, peptic ulcer or stenosing and pyloric or duodenal
obstruction; safety in pregnancy and lactation has not been
established;
porphyria.
Side effects: see under individual preparations.
Dose and Administration:Adult: 2 tablets 3 times a day. Do
not
exceed
the
recommended
dosage.
Storage: store below 25C. Protect from light.
7.4. Cholinergic and Anticholinesterase Agents
Parasympathomimetics may be classified into 2 distinct
pharmacological groups. Cholinergic agonists, such as
bethanechol, which act directly on effector cells to mimic the
effects of acetylcholin.Anticholinesterases (neostigmine,
pyridostigmine and edrophonium) which inhibit the enzymic
hydrolysis of acetylcholin by acetylcholinesterase and other
cholinesterases, thereby prolonging and enhancing its actions in
the body.
Bethanechol
Tablet, 10mg, 25mg
Injection (chloride), 5 mg/ml in 1 ampoule
Indications: nonobstructive urinary retention and retention due
to neurogenic bladder.
368

7. Medicines Used In Musculoskeletal And Joint Disease

Cautions: hyperthyroidism, peptic ulcer disease, epilepsy,

obstructive pulmonary disease, bradycardia, vasomotor
instability, atrioventricular conduction defects, hypotension, or
Parkinsonism.
Drug interactions: procainamide, quinidine, atropine,
anthistamines, TCAs, phenothiazines.
Contraindications: hypersensitivity to bethanechol; mechanical
obstruction of the GI or GU tract.
Side effects: hypotension, tachycardia, bradycardia, flushed
skin, head ache, malaise, abdominal cramps, diarrhea, nausea,
vomiting, salivation, eructation, urinary urgency, lacrimation,
miosis, asthmatic attacks, branchial constriction, diaphoresis.
Dose and Administration:
Adult: urinary retention, neurogenic bladder, and/or bladder
atony: Oral: initial, 10 50 mg 2- 4 times/day. To determine
effective dose, may initiate at a dose of 5 - 10mg, with
additional doses of 5 - 10 mg hourly until an effective
cumulative dose is reached.
SC: Initial: 2.575mg, may repeat in 15 - 30 minutes; (maximum
cumulative initial dose: 10.3mg); subsequent doses may be
given 3 - 4 times daily as needed.
Storage: store at room temperature.
Edrophonium
Injection, 10mg/ml in 1ml ampoule
Indications: diagnosis of myasthenia gravis, differentiation of
cholinergic crises from myasthenia crises, reversal of non
depolarizing neuromuscular blockers, adjunct treatment of
respiratory depression caused by curare overdose.
Cautions: bronchial asthma and those receiving a cardiac
glycoside; atropine sulfate should always be readily available as
an antagonist.
369

7. Medicines Used In Musculoskeletal And Joint Disease

Drug interactions: digoxin, succinylcholine, decamethonium,

pancuronium, vecuronium, acetazolamide, neostigmine,
physostigmine, atropin, nondepolarizing muscle relaxants,
procainamide, and quinidine.
Contraindications: hypersensitivity to edrophonium, GI or GU
obstruction.
Side effects: bradycardia, hypotension, decreased carbon
monoxide, tachycardia, convulsions, dizziness, loss of
consciousness,
drowsiness,
headache,
skin
rash,
thromophlebitis, urticaria, hyperperistalsis, nausea, vomiting,
salivation, diarrhea, stomach cramps, dysphagia, flatulence,
urinary urgency, muscle cramps, spasms, small pupils,
lacrimation, increased bronchial secreations, laryngospasm,
respiratory muscle paralysis, dyspnea, bronchospasm.
Dose and Administration: Adult: Diagnosis:IV: 2 mg test dose
administered over 15 - 30 seconds; 8 mg given 45 seconds
later if no response is seen; test dose may be repeated after 30
minutes.I.M: Initial: 10mg, if no cholinergic reaction occurs;
administer 2mg 30 minutes later. Titration of oral
anticholinestrase therapy: 1 - 2mg 1 hour after oral dose of
anticholinesterase.Reversal of non-depolarizing neuromuscular
blocking agents:I V: 10mg over 30 - 45 seconds, may repeat
every 5 - 10 minutes up to 40mg.Termination of paroxysmal
atrial tachycardia: IV rapid injection: 5- 10mg.Differentiation
of cholinergic from myasthenic crisis: IV: 1mg; may repeat after
1 minute.Child: Diagnosis:Initial; 0.04 mg/kg over 1 minute
followed by 0.16 mg/kg if no response, to a maximum total
dose of 5mg for children < 34kg, or 10mg for children > 34kg.
Titration of oral anticholinesterase therapy: 0.04 mg/kg once
given 1 hour after oral intake of the drug being used in
treatment.
370

7. Medicines Used In Musculoskeletal And Joint Disease

Infant: IM: 0.5 to 1 mg. I.V: Initial 0.1 mg, followed by 0.4mg
if no response; total dose to 0.5mg.
Storage: protect from light.
Neostigmine
Tablet (Bromide), 15 mg
Injection (Methylsulphate), 0.5 mg/ml, 2.5 mg/ml in 1 ml
ampoules
Indications: in the treatment of conditions such as myasthenia
gravis and to reverse muscle relaxation produced by competitive
(non-depolarizing) muscle relaxant.
Cautions, Contraindications, Drug interactions, Side effects;
see section 5.3 under neostigmine.
Dose and Administrations:Oral: as neostigmine bromide,
Adult: 15 to 30 mg at suitable intervals throughout day, total
daily dose 75 - 300 mg; but doses above 180 mg daily not
usually tolerated.
Child: up to 6 years, initially 7.5 mg, 6 12 years, initially 15
mg, total daily dose usually 15 90 mg in divided doses at
appropriate intervals.
SC or IM injection: as neostigmine methylsulphate,
Adult: 0.5 to 2.5 mg as required, total daily dose 5 to 20 mg.
Neonate: 50 - 250 micrograms 30 minutes before feeds (not
usually required beyond 8 weeks of age);
Child: 200 - 500 micrograms as required.
Pyridostigmine bromide
Tablet, 10mg, 25mg, 60mg, 180mg (sustained release)
Injection, 1mg/ml, 5mg/ml in 1ml ampoule
Indications: myasthenia gravis.
Cautions: asthma, urinary tract infection, cardiovascular
disease including arrhythmias, hypotension, peptic ulcer,
371

7. Medicines Used In Musculoskeletal And Joint Disease

epilepsy, parkinsonism, avoid intravenous injection, renal

impairment, pregnancy and breastfeeding.
Drug
interactions: alcuronium, atropine, biperiden,
chloroquine, clindamycin, gentamicin, lithium, procainamide,
propranolol,
quinidine,
streptomycin,
suxamethonium,
vecuronium.
Contraindications: recent intestinal or bladder surgery,
mechanical intestinal or urinary tract obstruction, after
suxamethonium, pneumonia, and peritonitis.
Side effects: muscaranic effects generally weaker than with
neostigmine, increased salivation and bronchial secretions,
sweating, nausea and vomiting, abdominal cramps, diarrhoea,
miosis, muscle spasm, bradycardia, bronchospasm, allergic
reactions, hypotension, cholinergic crisis on overdosage,
thrombophlebitis, and rash associated with bromide salt.
Dose and Administration: Oral: Adult: 30 - 120mg at 4 - 6
hourly intervals, total daily dose 120 -720mg, adjusted to
individual response. Child: 7mg/kg/ day in 5-6 divided
doses.I.M: Adult: 2mg every 2 - 3 hours;
Neonate:50 to 150 micrograms before feeds (but neostigmine
usually preferred). Child: total daily dose 1 to 12 mg given in
divided doses at appropriate intervals.
Storage: store at room temperature and protect from light.
7.5. Disease Modifying Antirheumatic Medicines
Leflunomide
Tablet, 10mg, 20mg, 100mg
(See section 6.1)
Methotrexate
Tablet, 2.5mg, 5mg, 7.5mg,
10mg, 15mg
Powder for Injection, 5mg,
50mg in vial (See section antineoplastic)
372

7. Medicines Used In Musculoskeletal And Joint Disease

7.6. Medicines for the relief of soft tissue inflammation

Enzymes
Hyaluronidase is used to render the tissues more easily
permeable to injected fluids, e.g. for introduction of fluids by
subcutaneous infusion (termed hypodermoclysis).
Hyaluronidase
Powder for injection, 1500 units in ampoule
Indications: enhance permeation of subcutaneous or
intramuscular injections, local anesthetics and subcutaneous
infusions; promote resorption of excess fluids and blood.
Cautions: infants or elderly (control speed and total volume and
avoid overhydration especially in renal impairment).
Contraindications: do not be apply direct to cornea; avoid sites
where infection or malignancy; not for anaesthesia in
unexplained premature labour; not to be used to reduce swelling
of bites or stings; not for intravenous administration.
Drug interactions: anticoagulants, antiplatelate.
Side effects: edema, flushing, hypotension, dizziness, headache,
itching, rash, local (erythema, pain, rash, swelling).
Dose and Administration:SC or IM: 1500 units dissolved
directly in solution to be injected (ensure compatibility) with
local anaesthetics, 1500 units mixed with local anaesthetic
solution (ophthalmology, 15 units/ml).Hypodermoclysis, 1500
units dissolved in 1 mL water for injections or 0.9% sodium
chloride injection, administered before start of 500-1000mL
infusion fluid. Extravasation or haematoma, 1500 units
dissolved in 1mL water for injections or 0.9% sodium chloride
injection, infiltrated into affected area (as soon as possible after
extravasation).
Storage: store at 2o C to 80 C.
373

7. Medicines Used In Musculoskeletal And Joint Disease

7.7. Bone modulating Medicines

Alendronate Sodium
Tablet, 70mg
Indications: Treatment of postmenopausal osteoporosis and
osteoporosis in men, Prevention of postmenopausal
osteoporosis, Prevention and treatment of corticosteroid-induced
osteoporosis
Cautions: upper gastro-intestinal disorders (dysphagia,
symptomatic oesophageal disease, gastritis, duodenitis, or
ulcerssee also under Contra-indications and Side-effects);
history (within 1 year) of ulcers, active gastro-intestinal
bleeding, or surgery of the upper gastro-intestinal tract; renal
impairment; correct disturbances of calcium and mineral
metabolism (e.g. vitamin-D deficiency, hypocalcaemia) before
starting and monitor serum-calcium concentration during
treatment; consider preventive dental treatment before initiating
bisphosphonate (risk of osteonecrosis of the jaw, see notes
above); exclude other causes of osteoporosis; atypical stress
fractures reported (discontinue unless benefits of continued
treatment clearly outweigh risks)
Contraindications: abnormalities of oesophagus and other
factors which delay emptying (e.g. stricture or achalasia),
hypocalcaemia, pregnancy and breast-feeding.
Side effects: oesophageal reactions (see below), abdominal pain
and distension, dyspepsia, regurgitation, melaena, diarrhoea or
constipation, flatulence, musculoskeletal pain, headache; rarely
rash, pruritus, erythema, photosensitivity, uveitis, scleritis,
transient decrease in serum calcium and phosphate; nausea,
vomiting, gastritis, peptic ulceration, hypersensitivity reactions
(including urticaria and angioedema), and atypical stress
fractures with long-term use also reported; myalgia, malaise,
374

7. Medicines Used In Musculoskeletal And Joint Disease

and fever at initiation of treatment; very rarely severe skin

reactions (including Stevens-Johnson syndrome), osteonecrosis.
Oesophageal reactions: Severe oesophageal reactions
(oesophagitis, oesophageal ulcers, oesophageal stricture and
oesophageal erosions) have been reported; patients should be
advised to stop taking the tablets and to seek medical attention if
they develop symptoms of oesophageal irritation such as
dysphagia, new or worsening heartburn, pain on swallowing or
retrosternal pain.
Drug interactions: Aminoglycosides, NSAIDs, bisphosphate
derivatives, antacids (Aluminum, Calcium, magnesium) oral
calcium salts, oral iron salts and oral magnesium salt.
Dose and Administration:Treatment of postmenopausal
osteoporosis and osteoporosis in men, 10 mg daily or (in
postmenopausal osteoporosis) 70 mg once weekly. Prevention
of postmenopausal osteoporosis, 5 mg daily.Prevention and
treatment of corticosteroid-induced osteoporosis, 5 mg daily
(postmenopausal women not receiving hormone replacement
therapy, 10 mg daily).Note: Tablets should be swallowed whole
with plenty of water while sitting or standing; to be taken on an empty
stomach at least 30 minutes before breakfast (or another oral
medicine); patient should stand or sit upright for at least 30 minutes
after taking tablet.

Ibandronate
Tablet, 2.5mg, 50mg, 150mg
Indications: reduction of bone damage in bone metastases in
breast cancer and treatment of postmenopausal osteoporosis.
Cautions: consider preventive dental treatment before initiating
bisphosphonate (risk of osteonecrosis of the jaw, see notes
above); renal impairment; monitor renal function and serum
calcium, phosphate and magnesium; cardiac disease (avoid fluid
overload).
375

7. Medicines Used In Musculoskeletal And Joint Disease

Contra-indications: pregnancy; breastfeeding

Drug interactions: see under Alendronate Sodium
Side effects: hypocalcaemia, hypophosphataemia, influenzalike symptoms (including fever, chills, and muscle pain), bone
pain; oesophageal reactions (see below), diarrhoea, nausea,
vomiting, gastritis, abdominal pain, dyspepsia, pharyngitis;
headache, asthenia, rash; rarely anaemia, hypersensitivity
reactions (pruritus, bronchospasm and angioedema reported);
urticaria; injection-site reactions; very rarely osteonecrosis.
Oesophageal reactions Severe oesophageal reactions reported
with all oral bisphosphonates; patients should be advised to stop
tablets and seek medical attention for symptoms of oesophageal
irritation such as dysphagia, pain on swallowing, retrosternal
pain, or heartburn
Dose and Administration: Reduction of bone damage in bone
metastases in breast cancer: Oral: 50 mg daily
Treatment of postmenopausal osteoporosis: Oral: 150 mg once
a month.Child: not recommended
Note: Tablets should be swallowed whole with plenty of water while
sitting or standing in an empty stomach at least 30 minutes (tablets,
50 mg) or 1hour (tablets, 150 mg) before breakfast or another oral
medicine; patient should continue to fast, and stand or sit upright for
at least 30 minutes (50-mg tablet) or 1 hour (150-mg tablet) after
taking tablet

Pamidronate
Injection, 30mg, 90mg
Indications: Treatment of hypercalcemia associated with
malignancy; treatment of osteolytic bone lesions associated with
multiple myeloma or metastatic breast cancer; moderate to
severe Pagets disease of bone.
Cautions: Invasive dental procedures should be avoided during
treatment ,renal impairment and avoid in severe renal
376

7. Medicines Used In Musculoskeletal And Joint Disease

impairment, patients with pre-existing anemia leucopenia, or

thrombocytopenia, monitor serum electrolytes especially in the
elderly,severe bone,joint and muscle pain.
Drug interactions: See under Alendronate Sodium
Contraindication: Hypersensitivity to pamidronate, other
bisphosphonates, or any component of the formulation;
pregnancy.
Side effects: fatigue, fever, headache, anxiety, insomnia,
hypophosphatemia, nausea, vomiting, abdominal pain,
leucopenia, myalgia, arthralgia, dyspnea, cough, constipation,
back pain, painful or swollen gums, loosening of the teeth,
numbness or heavy feeling in the jaw, poor healing of the jaw,
bloody or black and tarry stools, shortness of breath, fast
heartbeat, numbness or tingling around the mouth, eye pain or
tearing.
Dose and Administration:Drug must be diluted properly
before administration and infused intravenously slowly.Due to
risk of nephrotoxicity, doses should not exceed 90mg.IV.Adult:
Hypercalcemia of malignancy:
Moderate cancer-related Hypocalcaemia (corrected serum
calcium:12-13.5mg//dL):60-90mg, as single dose.
Severe cancer- related Hypocalcaemia (corrected serum
calcium :> 13.5mg//dL): 90mg, as single dose.A period of 7
days should elapse before the use of second course; repeat
infusions every 2-3 weeks have been suggested, however, could
be administered every 2-3 months according to the degree and
of severity of hypercalcemia and/or the type of
malignancy.Osteolytic bone lesions with multiple myeloma:
90mg monthly.Osteolytic bone lesions with metastatic breast
cancer: 90mg repeated every 3-4weeks.Pagets disease: 30mg
for 3 consecutive days. Elderly: Begin at lower end dosing
range.
377

8. Anti-Infectives

8. ANTI-INFECTIVES
8.1. Antibacterials
8.1.1. Penicillins
Penicillins can be classified into four broad categories, each
covering a different spectrum of activity. The natural penicillins
(penicillin G and penicillin V) have activity against many grampositive organisms, gram-negative cocciand some other gramnegative organisms. The aminopenicillins (ampicillin and
amoxicilline) have activity against penicillin-sensitive gram
positive bacteria, as well as Escherchia coli, Proteus mirabilis,
Salmonella sp., Shigella sp. and Haemophilus influenza. The
antistaphylococcal penicillins (cloxacillin, dicloxacillin, etc) are
also active against beta lactamase producing staphylococci.
The antipseudomonal penicillins have less activity against
gram-positive organisms than the natural penicillins or
aminopenicillins.
Benzylpenicillin can be considered the parent compound of the
penicillins and is inactivated by penicillinase producing bacteria
and because of its instability in gastric acid it is usually injected.
Long acting preparations include procaine penicillin and
benzanthine penicillin which slowly release benzylpenicillin
after injection. Phenoxymethyl penicillin is acid stable and
therefore given by mouth but it is also inactivated by
penicillinase. It is generally used for relatively mild infections.
The isoxazolyl penicillins such as cloxacillin, dicloxacillin are
resistant to penicillinase& gastric acid.
Ampicillin has a broader spectrum of activity than
benzylpenicillin; although generally less active against grampositive bacteria, some gram-negative organisms including
Escherichia coli. Haemophilus influenzae, and Salmonlella
spp. are sensitive although resistance is being reported
increasingly, Pseudomonas spp are not sensitive. Ampicillin is
378

8. Anti-Infectives

acid stable and can be given by mouth but is destroyed by

penicillinase. Amoxycillin, only differs from ampicillin by the
addition of a hydroxyl group, but is better absorbed from the
gastro-intestinal tract.
The most important side effect of the penicillins is
hypersensitivity reaction which cause rashes and anaphylaxis,
which can be fatal.
Individuals who have experienced
anaphylaxis, urticaria, or rash immediately after penicillin
administration are at increased risk of immediate
hypersensitivity to penicillin; these individuals should not
receive a beta-lactam antibiotic. Patients who are allergic to one
penicillin will be allergic to all because the hypersensitivity is
related to the basic penicillin structure.
A rare but serious toxic effect of the penicillins is
encephalopathy due to cerebral irritation. This may result from
excessively high doses or in patients with severe renal failure.
The penicillins should not be given by intrathecal injection
because they can cause encephalopathy which may be fatal.
Another problem relating to high doses of penicillin, or normal
dose given to patients with renal failure, is the accumulation of
electrolyte since most injectable penicillins contain either
sodium or potassium.
Diarrhea frequently occurs during oral penicillin therapy. It is
most common with broad- spectrum penicillins, which can also
cause antibiotic associated colitis.
Amoxicillin
Tablet, 500 mg
Capsule, 250 mg, 500 mg
Injection, 250 mg, 500 mg in vial
Syrup, 125mg/5ml, 250 mg/5ml
379

8. Anti-Infectives

Indications: urinary tract infections, upper respiratory tract

infections, bronchitis, pneumonia, otitis media, dental abscess,
osteomyelitis, Lyme disease in children, endocarditis
prophylaxis, post-splenectomy prophylaxis, gynaecological
infections, gonorrhea, and Helicobacter pylori eradication
(section 1.2)
Cautions: history of allergy, renal impairment, erythematous
rashes common in glandular fever, chronic lymphatic
leukaemia, and possibly HIV infection.
Drug interactions: probenecid (except in cases of gonorrhea
and other STD), allopurinol, oral contraceptives, methotrexate,
warfarin.
Contraindications: known hypersensitivity (allergy) to any
penicillines.
Side effects: allergic reaction, specifically anaphylaxis
(bronchospasm, sudden or severe decrease in blood pressure),
skin rash, joint pain, fever, GIT reaction (mild diarrhoea,
nausea, vomiting), oral candidiasis (sore mouth or tongue),
pseudomembraneous colitis (severe abdominal or stomach
cramps and pain, abdominal tenderness, watery and severe
diarrhoea).
Dose and Administrations:Infections due to sensitive
organisms: Oral:Adult and Child over 10 years, 250 mg every
8 hours, doubled in severe infections; Child up to 10 years,
125mg every 8 hours, doubled in severe infections. Severe or
recurrent purulent respiratory-tract infections:Oral:Adult: 3 g
every 12 hours.Pneumonia:Oral:Adult: 0.5 to 1 g every 8
hours. Short Course Oral therapy.Dental abscess:Adult: 3 g
repeated after 8 hours. Urinary tract infections:Adult: 3 g
repeated after 10 12 hours.Otitis media: Child 3 10 years,
750 mg twice daily for 2 days.IM: 500 mg every 8 hours; Child,
50 to 10 mg/kg daily in divided doses.IV injection or infusion:
380

8. Anti-Infectives

500 mg every 8 hours increased to 1g every 6 hours. Child, 50

to 100 mg/kg daily in divided doses
AdultsMeningitis (in combination with another antibiotic if
necessary):IV infusion: 2 g every 4 hours for at least 5 days in
meningococcal disease or for 10 14 days in listerial
meningitis.Enterococcal endocarditis (in combination with
another antibiotic if necessary): IV infusion: 2 g every 4 hours.
Storage: at room temperature in a tight container; oral
suspension remains stable for 14 days at room temperature or if
refrigerated.
Note: Reconstitution and
manufacturers directions.

Administration:

According

to

Amoxicilline and Clavulanic acid

Tablet (Chewable), 125 mg + 31.25 mg, 250mg +62.5 mg, (film
coated), 250 mg + 125 mg, 500 mg + 125 mg
Capsule, 500mg +125mg, 875mg +125mg
Oral Suspension, 125 mg + 31.25 mg in each 5 ml, 250 mg +
62.5 mg in each 5 ml, 228mg/5ml ,457mg/5ml
Injection, 500 mg + 100mg, 1 g + 200 mg
Indications: infection due to beta-lactamase-producing bacteria
including respiratory tract infections, genito-urinary and
abdominal infections, cellulites, animal bites, severe dental
infections, and surgical prophylaxis.
Cautions: during pregnancy, hepatic impairment and nursing
women, history of allergy, renal impairment, erythematous
rashes common in glandular fever, chronic lymphatic leukemia
& HIV infection.
Drug interactions: allopurinol, disulfiram, probenecid,
anticoagulants, anti-inflammatory drugs, platelet aggregation
inhibitor, contraceptives, heparin, thrombolytic agents,
sulfinpyrazone.
381

8. Anti-Infectives

Contraindications: penicillin hypersensitivity, history of

amoxicilline + clavulanic acid associated or penicillin
associated jaundice or hepatic dysfunction.
Side effects: diarrhea, nausea, vomiting, abdominal discomfort,
anorexia and flatulence, rash and urticaria, pseudomembraneous
colitis, headache, dizziness.
Dose and Administration: Note: All doses expressed as
amoxicillin. Infections due to susceptible beta-lactamase
producing organisms: Oral: Adult and Child over 12 years,
250mg every 8 hours, doubled in severe infections; Childunder
1 year, 20mg/kg daily in 3 divided doses; Child 1-6 years,
125mg every 8 hours; 6-12 years, 250mg every 8 hours.Severe
dental infections: Oral:Adult 250mg every 8 hours for 5
days.Infections due to susceptible beta-lactamase producing
organisms: slow IV injection:Adult and Child over 12 years,
1g every 8 hours, increased to 1g every 6 hours in severe
infections; Neonate and Premature Infant 25mg/kg every 12
hours; Infant up to 3 months, 25mg/kg every 8 hours; Child 3
months to 12 years, 25mg/kg every 8 hours increased to 25
mg/kg every 6 hours in more severe infections.Surgical
prophylaxis:IV injection: Adult 1g at induction, with up to 2 to
3 further doses of 1g every 8 hours (if increased risk of
infection).
Storage: in tight containers at a temperature less than 24oC;
exposure to excessive humidity should be avoided. Following
reconstitution, oral suspension of amoxicillin and clavulanate
potassium should be stored at 2 8 oC, and unused suspension should
be discarded after 10 days.

Ampicillin
Capsule, 250 mg, 500 mg
Oral suspension; 125 mg/5ml, 250 mg/5ml
382

8. Anti-Infectives

Drop, 100 mg/ml

Injection, (sodium), 250 mg, 500 mg, 1 g in vial
Indications: broad spectrum activity against several Grampositive organisms, Gram-negative cocci and some bacilli. Used
in respiratory tract infections, cholecystitis and gastrointestinal
tract infections, including typhoid
Cautions, Drug interactions, Contraindications and Side
effects; see under Amoxicillin and see notes above.
Dose and Administration:Adult:Oral:250-500mg 6 hourly (up
to 1g 6 hourly for severe infections).IM: 500mg 6 hourly. IV: by
slow injection or infusion over 30-60 minutes, 500mg 4-6
hourly
(up
to
12g
daily
for
severe
infections).Meningitis/septicaemia:IV: 1-2g 3-4 hourly;
maximum 300 mg/kg/day or 16g.Renal impairment: GFR 10 to
50ml/min, dose interval 6-12 hours; GFR <10ml/min, 12-24
hours.Child: Oral, IM or IV: under 20kg, 10-25 mg/kg/dose 6
hourly; over 20kg, as for adults.Meningitis or severe
infections:IV:50mg/kg dose 6 hourly. Neonates:IM or IV:
50mg/kg/dose (meningitis 100mg/kg/dose) 12 hourly in the first
week of life, 8 hourly from 1-3 weeks old, 6 hourly thereafter.
Storage: at room temperature; after reconstitution oral
suspension is stable for 7 days at room temperature or for 14
days under refrigeration.Note: Reconstitution and Administration:
According to manufacturers directions.

Ampicillin sodium and sulbactam sodium

Injection, 1 g + 0.5g, 2 g + 1 g
Indications: in the treatment of intra abdominal infections such
as abscess, female pelvic infections & infections caused by
ampicilline susceptible organisms and as a secondary agent in
the treatment of genito-urinary tract infections, skin and soft
383

8. Anti-Infectives

tissue infections, including burn wound infections, and bone and

joint infections.
Cautions: renal function impairment, congestive heart failure,
and gastrointestinal disease.
Drug interactions: see notes under amoxicilline and clavulanic
acid.
Contraindications: Allergy of penicillines, infectious
mononucleosis.
Side effects: allergic reactions, specially anaphylaxis; serum
sickness like reactions (skin rash, joint pain, fever), chest pain
pseudomembraneous colitis, oral candidiasis, vaginal
candidiasis, clostridium difficile colitis, dysuria, edema,
erythemamultiforme, hepatic dysfunction, glossitis, leukopenia,
platelet dysfunction and seizures.
Dose and Administration:Adult: IM or IV: 1.5 to 3 grams (1 to
2 grams, Ampicillin and 500 mg to 1 gram, sulbactam) every six
hours.
Gonorrhea: IM: 1.5 grams (1 gram of Ampicilline and 500 mg
of sulbactam) as a single dose with 1 gram of oral
probenecid.Note: Adults with impaired renal function may require a
reduction in dose.Usual adult prescribing limits up to a maximum
of 4 grams (sulbactam) daily.
Child: Dosage has not been established in children up to the age
of 12 years. However, doses of 200 to 400mg per kg of body
weight of ampicillin and 100 to 200 mg per kg of body weight
of sulbactam per day, administered in divided doses, have been
used.
Storage:Prior to reconstitution, do not store above 30oC, unless
otherwise specified by the manufacturers.
Carbenicillin
Tablet (Indanyl sodium), 382 mg
384

8. Anti-Infectives

Injection 1g, 5 g in vial

Indications: treatment of serious urinary tract infections and
prostatitis caused by susceptible gram-negative aerobic bacilli.
Cautions: impaired renal and/or hepatic function.
Drug interactions: heparin or oral anticoagulants,
aminoglycosides,
methotrexate
probenecid,
disulfiram,
tetracyclines.
Contraindications: hypersensitivity to carbenicillin, penicillins,
or any component of the formulation.
Side effects: diarrhea, nausea, bad taste, vomiting, flatulenc,
glossitis, anemia, epigastric distress, headache, hematuria,
hypersensitivity reactions, hyperthermia, hypokalemia, rash,
thrombocytopenia and urticaria.
Dose and Administration: Urinary tract infections:
Oral:Adult: 1 - 2 tablets every 6 hours for urinary tract
infections or 2 tablets every 6 hours for prostatitis.
Child: 30 - 50 mg/kg/day divided every 6 hours; maximum
dose: 2 - 3 g/day.IM:Adult: 1 to 2g every 6 hours. Child: 50100mg/kg daily in divided doses.
Storage: temperature not exceeding 30oC and injections at 28oC.
Cloxacillin sodium
Capsule, 250mg, 500mg
Syrup, 125mg, 250mg in each 5ml
Injection, 250mg, 500mg in vial
Indications: infections due to beta-lactamase-producing
staphylococci including impetigo, cellulitis and other soft-tissue
infections; staphylococcal endocarditis, septicaemia, pneumonia
and osteomyelitis.
Cautions: history of allergy, renal and hepatic function
impairment, GIT disease especially ulcerative colitis, and
385

8. Anti-Infectives

regional enteritis, antibiotic associated colitis, heart failure;

pregnancy and breastfeeding.
Drug
interactions:
probenecid,
chloramphenicol,
erythromycin, sulfonamide, and tetracyclines.
Contraindications: known hypersensitivity or allergy to
penicillines.
Side effects: nausea and vomiting, diarrhea, hypersensitivity
reactions including urticaria, fever, joint pain, rashes,
angioedema, anaphylaxis, serum sickness-like reactions,
haemolytic anaemia, interstitial nephritis; neutropenia,
thrombocytopenia, coagulation disorders; antibiotic-associated
colitis; hepatitis and cholestatic jaundice may be delayed in
onset; electrolyte disturbances; pain, inflammation, phlebitis or
thrombophlebitis at injection sites.
Dose and Administration:Adult: Oral: 250 to 500mg (base)
every six hours. Maximum dose up to 6 gm (base) a day.IV 250
to 500mg (base) every six hours maximum 6gms (base)
daily.Child: Infants and children up to 20kg of body weights:
Oral: 6.25 to 12.5mg (base) per kg of body weight every six
hours or IV: 6.25 to 12.5mg (base) per kg of body weight every
six hours.Note: continue medicines for full time of treatment and take
on empty stomach.

Storage: store at room temperature. After reconstitution, solutions

retain their potency for 14 days if refrigerated.
Flucloxacillin
Capsule, 250 mg, 500 mg
Injection, 250 mg, 500 mg in vial
Syrup, 125 mg/5ml
Indications: for treatment of infections due to staphylococci
resistant to benzylpenicillin these include bone and joint
386

8. Anti-Infectives

infections, endocarditis, peritonitis, pneumonia, skin infections,

surgical infection and toxic shock syndrome.
Cautions: older patients and those receiving fluoxacillin for
more than 2 weeks.
Drug interactions:see benzylpenicillin.
Side effects: hepatitis, cholestatic jaundice, agranulocytosis and
neutropenia occur.
Dose and Administration:Adult: Oral, IM: 250mg four times
daily.It is given intravenously in a dose of 0.25 to 1 g four times
daily by slow injection over 3 to 4 minutes or by IV infusion.
Storage: store at room temperature.
Mezlocillin
Powder for injection, 0.5 g, 1g, 2 g, 3 g, 4 g, /vial
Intravenous (IV) infusion, 2 g, 3 g, 4 g
Indications: treatment of infections caused by susceptible gram
negative aerobic bacilli (Klebsiella, Proteus, Eschericia coli,
Enterobacter, Pseudomonas aeruginosa, Serratia) involving the
skin and skin structure, bone and joint, respiratory tract, urinary
tract, gastrointestinal tract, as well as septicemia.
Cautions: hypersensitivity to mezlocillin, any component, or
penicillins.
Drug interactions: as for benzylpenicillin. Clavulanic acid,
methotrexate, probenecid
Side effects: as for carbenicillin.
Dose and Administration:Adult:Serious infection: IV: 200 to
300mg/kg daily in divided doses, for lifethreatening
infections, up to 350mg/kg daily may be used, but total dose
should not exceed 24g.Urinary- tract infection: IM or IV: 1.5 to
2g every 6 hours.
Storage: store in airtight container.
387

8. Anti-Infectives

Penicillin G, Benzathine
Injection, 0.6, 1.2, 2.4 million IU in Vial
Indications: streptococcal pharyngitis, diphtheria carrier state,
syphilis and other treponemal infections (yaws, pinta, bejel);
rheumatic fever prophylaxis.
Cautions: history of allergy (see notes above); renal failure;
pregnancy and breast feeding
Drug interactions: methotrexate
Contra indications: see under penicillin G, sodium crystalline;
and neurosyphilis
Side effects: see under penicillin G, sodium crystalline
Dose and Administrations: deep IM injection.Streptococcal
pharyngitis: primary prophylaxis of rheumatic fever: Adult and
Child over 30 Kg body-weight, 900 mg as a single dose. Child
under 30 Kg body weight, 450 675 mg as a single dose.
Secondary prophylaxis of rheumatic fever:Adult and Child over
30 Kg body-weight, 900 mg once every 3 4 weeks; Child
under 30 Kg body-weight, 450 mg once every 3 4
weeks.Early syphilis: Adult 1.8 g as a single dose, divided
between 2 sites.Late syphilis: Adult 1.8 g divided between two
sites, once weekly for 3 consecutive weeks.Congenital syphilis
(where no evidence of CSF involvement):Child up to 2 years,
37.5 mg/kg as a single dose.Yaws, Pinta, and bejel: Adult: 900
mg as a single dose; Child 450 mg as a single dose.
Reconstitution and Administration.According to manufacturers
directions.

Storage: store between 2 and 8oc.

Penicillin G, Sodium crystalline
Injection, 1 million IU, 10 million IU, 20 million IU in vial. 1
million unit equivalent to 600 mg
388

8. Anti-Infectives

Indications: throat infections, pneumonia, otitis media, lyme

disease in children; streptococcal endocarditis; meningococcal
disease; necrotizing enterocolitis, necrotizing fascitis;
leptospirosis, neurosyphilis, anthrax; actinomycosis; brain
abscess; gas gangrene; cellulitis; osteomyelitis.
Cautions: history of allergy (see notes under 8.1.1); renal
failure; heart failure; pregnancy and breastfeeding.
Drug interactions: methotrexate, probenecid (decrease renal
tubular secreation of the penicillins), aminoglycosides
(inactivated by high doses of IV benzylpenicillin; should not be
administered in same giving set).
Contraindications: penicillin hypersensitivity (see notes under
8.1.1); avoid intrathecal route
Side effects: hypersensitivity reactions including urticaria,
fever, joint pains, rashes, angioedema, anaphylaxis, serum
sickness like reactions, hemolytic anemia and interstitial
nephritis; neutropenia, thrombocytopenia, coagulation disorders
and central nervous system toxicity including convulsions
reported (especially with high doses or in severe renal
impairment), paraesthesia with prolonged use; diarrhea and
antibiotic associated colitis; see also notes above.
Dose and Administration:Mild to moderate infections due to
sensitive organisms: IM or slow IV injection or infusion:Adult:
0.6 2.4 g daily in 2 4 divided doses, with higher doses in
severe infections and duration of treatment depending on
disease.Neonate: 50 mg/kg daily in 2 divided doses;Infant 1 to
4 weeks, 75 mg/kg daily in 3 divided doses; Child 1 month to
12 years, 100 mg/kg daily in 4 divided doses, with higher doses
in severe infections.Bacterial endocarditic: slow IV injection or
infusion: Adult up to 7.2g daily in 6 divided
doses.Meningococcal meningitis: slow IV injection or
infusion:Adult up to 14.4 g daily in divided doses;
389

8. Anti-Infectives

Premature infant and Neonate 100 mg/kg daily in 2 divided

doses; Infant 150 mg/kg daily in 3 divided doses; Child 1 month
to 12 years, 180 300 mg/kg daily in 4 6 divided
doses.Suspected meningococcal disease (before transfer to
hospital): IM or slow IV injection: Adult and Child over 10
years, 1.2 g; Child 1 to 9 years, 600 mg; Child less than 1 year,
300 mg.Neurosyphilis: slow IV injection: Adult: 1.8 2.4 g
every 4 hours for 2 weeks.Congenital syphilis,IM or slow IV
injection: Child up to 2 years, 30 mg /kg daily in 2 divided
doses for 10 days, Child over 2 years, 120 180 mg/Kg (to
maximum of 1.44g) daily in divided doses for 14 days.
Reconstitution and Administration: According to manufacturers
directions

Storage: at room temperature. Prior to reconstitution

Phenoxymethyl Penicillin
Tablet, 125 mg, 250 mg, 500,000 IU
Oral suspension, 125 mg/5ml, 50000 IU/ml
250mg = 400,000 units
Indications: streptococcal pharyngitis; otitis media; erysipelas;
mouth infection; secondary prophylaxis of rheumatic fever;
post-splenectomy prophylaxis.
Cautions, Contraindications, Drug interactions, Side effects;
see under penicillin G, sodium crystalline
Dose and Administration:Infections due to sensitive organisms:
Oral:Adult: 500 mg every 6 hours increased up to 1 g every 6
hours in severe infections;Child up to 1 year, 62.5 mg every 6
hours; Child 1 5 years, 125 mg every 6 hours; Child 6 12
years, 250 mg every 6 hours.Secondary prophylaxis of
rheumatic fever:Oral: Adult: 500 mg twice daily; Child 1 5
years, 125 mg twice daily; Child 6 12 years, 250 mg twice
daily.
390

8. Anti-Infectives

Patient advice: Phenoxymethyl penicillin should be taken at

least 30 minutes before or 2 hours after food.
Storage: at room temperature in a tight container.
Phenoxymethyl penicillin, potassium
Tablet, 390 mg
Suspension, 195 mg/5ml
See under Phenoxymethyl penicillin
Piperacillin
Powder for injection (as sodium salt), 1g, 2g in vial
Indications: infections due to P. aeruginosa - usually in
combination with an aminoglycoside for synegistic effect.
Cautions: known hypersensitivity to any penicillin or
cephalosporin.
Drug interactions: probenecid, aminoglycosides, oral
contraceptives.
Side effects: the high sodium content may cause fluid retention
and hypokalaemia. Piperacillin has a potential for provoking a
bleeding
diathesis.
Neutropenia,
leucopenia
and
thrombocytopenia have been reported. Other effects include
thrombophlebitis at the injection site, neuromuscular excitability
with high doses, cholestatic jaundice, bloody diarrhea, and
reversible elevation of serum urea and creatinine levels.
Dose and Administration: Adult:IV: usually 2-4g, 6 - 8 hourly,
injected over 3-5 minutes, or infused over 20 - 40 minutes;
maximum 24 g/day.IM: 2g, 8 - 12 hourly (i.e. 4 to 6
g/day).Single doses over 2g must be given intravenously; the IV
route is preferred in severe infections.Child: IV: 2 months - 12
years, 50 - 100mg/kg/dose 6-8 hourly (Maximum dose 2 4g).
Give 12 hourly in the first week of life.
Storage: store in airtight containers.
391

8. Anti-Infectives

Procaine Penicillin, Fortified

Injection (buffered), 4,000,000 IU
Indications: for the treatment of respiratory infections (e.g.
pneumonia), acute otitis media, skin structure infections,
uncomplicated urogenital gonorrhea, and syphilis.
Cautions: same as penicillin G benzathine and also caution in
the treatment of gonococcal infections during pregnancy and in
children.
Drug interactions: see under penicillin G, sodium crystalline
Contraindications: known hypersensitivity to any penicillin
and/ or procaine.
Side effects: hypersensitivity reactions such as skin rash, fever,
joint pains, edema and anaphylaxis may occur.
Dose and Administration:IM injection only.Adult:
Gonorrhea (acute, uncomplicated): 4,800,000 IU (2,400,000 IU
in each buttock). Repeat the same dose next day.Syphilis
Primary, secondary, or latent (of not more than 2 years
duration): 600,000 IU daily for 8 days. Tertiary (2 year and
more)- 600,000 IU daily for 10-15 days.Pneumonia, acute otitis
media, skin or skin structure infections:Adult and child (12
years and over): 600,000-1,200,000 IU daily for 5- 7days.
Maximum dose 100,000 IU of penicillin G /kg of body weight
in divided doses.Child (below 12 years): Treatment is given
daily for 5 to 7 days: 1-5 months of age, (3-5kg)100,000 IU
daily; 6-12 months of age, (6-10kg) 200,000 IU daily; 1- 6 years
of age, (11-20kg) 300,000 IU daily; 1-5 years of age, (21-30kg)
400,000 IU daily. Note: Remember to treat always the sexual
partner.

Storage: At room temperature. After reconstitution, it should be

used within 14 days provided it is stored between 2-4oc or
within 4 days at about 20oc.
392

8. Anti-Infectives

Sultamicillin (Ampicillin Sodium and Sulbactam Sodium

double ester)
Tablet, 375 mg, 750mg
Indications;
Cautions;
Drug
interactions;
Contraindications; Side effects: see under Ampicillin sodium
+ Sulbactam sodium.
Dose and Administration: Oral: 375-750mg twice daily.
8.1.2. Cephalosporins, carbapenems, and other beta-lactams
Cephalosporins: 1st, 2nd, 3rd, 4th
Cephalosporins are bactericidal and they act by inhibiting
synthesis of the bacterial cell wall. The most widely used
system of classification of cephalosporins is by generations and
is based on the general features of their antibacterial activity.
First generation cephalosporins: They usually are active
against a wide spectrum of Gram-positive bacteria including
penicillinase-producing and non penicilinase producing
organisms. But not active against enterococci including
oxacilline-resistant staphylococci (formaerly known as
meticillin-resistant staphylococci).Their activity against Gramnegative bacteria is modest.Cefadroxil and cefalexin are
available in oral formulations, while cefazolin is administered
parenterally and widely used for surgical prophylaxis.
Second generation cephalosporins: They have similar or
slightly less activity than first generations against Gram-positive
bacteria, but greater stability to hydrolysis by beta lactamases
produced by Gram-negative bacteria and inhanced activity
against many of the Enterobacteriaceae and Haemophilus
influenzae (including ampicillin-resistant strains). Cefaclor,
Cefprozil
and
Cefuroxime
are
second-generation
cephalosporins.
393

8. Anti-Infectives

Third generation cephalosporins: They are sometimes

referred to as extended-spectrum cephalosporins. Compared
with the earlier generations of cephalosporins they have a wider
spectrum and greater potency of activity against Gram-negative
organisms,
including
most
clinically
important
Enterobacteriaceae. Their activity against Gram-positive
bacteria is said to be less than that of the first-generation drugs,
but they are very active against streptococci.Cefotaxime has
good activity against most Gram-positive and Gram-negative
organisms. It is useful in treating infection due to H. influenzae
(including beta-lactamase-producing strains), Salmonella spp
and N. gonorrhoeae. It is ineffective against P.aeruginosa.
Ceftazidime is effective against many strains of P.aeruginosa. It
is
not
adequate
for
S.pneumoniae
or
other
streptococci.Ceftriaxone has activity similar to that of
cefotaxime. Its longer half-life allows once or twice daily
dosing. There is concern that widespread use of these agents
could lead to increasing resistance, particularly among
pneumococci.
Fourth generation Cephalosporins: Cefepime,classified as a
fourth-generation cephalosporin, has an extended spectrum of
activity against both gram-positive and gram-negative
organisms, including P aeruginosa.
First Generation Cephalosporins
Cefadroxil
Capsule/ Tablet, 500mg, 1gm
Oral suspension, 125mg/5ml, 250mg/5ml
Indications: treatment of susceptible bacterial infections,
including those caused by group A beta-hemolytic
Streptococcus; prophylaxis against bacterial endocarditis in
394

8. Anti-Infectives

patients who are allergic to penicillin and undergoing surgical or

dental procedures.
Cautions: severe renal impairment, history of penicillin allergy.
Drug interactions: probenecid, anticoagulants.
Contraindications: hypersensitivity to cefadroxil or other
cephalosporins.
Side effects: diarrhea, abdominal pain, agranulocytosis,
anaphylaxis, angioedema, arthralgia, cholestasis, dyspepsia,
erythema multiforme, fever, nausea, neutropenia, pruritus,
pseudomembranous colitis, rash, serum sickness, StevensJohnson syndrome, thrombocytopenia, transaminases increased,
urticaria, vaginitis, vomiting.
Dose and Administration: Oral:Adult: 1-2 g/day in 2 divided
doses.Child: 30 mg/kg/day divided twice daily up to a
maximum
of
2g/day.Prophylaxis
against
bacterial
endocarditis:Adult: 2g 1 hour prior to the procedure.Child:
50mg/kg 1 hour prior to the procedure.
Storage: store at room temperature.
Cephalexin
Capsule, 250 mg, 500 mg
Syrup, 125 mg/5ml
Indications: treatment of susceptible bacterial infections
including respiratory tract infections, otitis media, skin and skin
structure infections, bone infections and genitourinary tract
infections, including acute prostatitis, alternative therapy for
acute bacterial endocarditis prophylaxis.
Cautions: severe renal impairment, penicillin allergy.
Drug interactions: probenecid, aminoglycosides.
Contraindications: hypersensitivity to cephalexin or other
cephalosporins.
395

8. Anti-Infectives

Side effects: agitation, confusion, dizziness, fatigue,

hallucinations, headache, angioedema, erythema multiforme,
rash, Stevens-Johnson syndrome, urticaria, abdominal pain,
diarrhea, dyspepsia, gastritis, pseudomembranous colitis, genital
pruritus, genital moniliasis, vaginitis, vaginal discharge,
thrombocytopenia; arthritis, joint- disorder.
Dose and Administration: Oral:Adult: 250 to 1000 mg every
6 hours; maximum: 4 g/day.Streptococcal pharyngitis, skin
infections: 500 mg every 12 hours.
Uncomplicated cystitis: 500 mg every 12 hours for 7 - 14
days.Prophylaxis of bacterial endocarditis: 2g 1 hour prior to
procedure.Neonates: 25mg/kg, every 6 - 12 hours.Child 1
month to 1 year: 125mg every 12 hours.
Child > 1 year: 25 to 50 mg/kg/day every 6 - 8 hours, more
severe infections; 50 - 100 mg/kg/day in divided doses every 6 8 hours; maximum: 4 g/24 hours.
Otitis media: 75 to 100mg/kg/day in 4 divided doses.
Streptococcal pharyngitis, skin infections: 25-50 mg/kg /day
divided every 12 hours.Uncomplicated cystitis:Child >15
years: Refer to Adults dosing.Prophylaxis of bacterial
endocarditis: 50 mg/kg 1 hour prior to procedure (maximum: 2
g).
Storage: store capsules and powder for oral suspension at room
temperature. After reconstitution of oral suspension store in
airtight containers at 2-8 oC and discard if not used within 2
weeks.
Cephazoline Sodium
Injection, 250 mg, 500 mg, 1g in vial
Indications: treatment of respiratory tract, skin and skin
structure, genital, urinary tract, biliary tract, bone and joint
infections, septicemia, preoperative prophylaxis.
396

8. Anti-Infectives

Cautions: severe renal impairment, history of penicillin allergy.

Drug interactions: probenecid, aminoglycosides, warfarin.
Contraindications: hypersensitivity to cefazolin sodium or
other cephalosporins.
Side effects: fever, seizure, rash, pruritus, Stevens-Johnson
syndrome, diarrhea, nausea, vomiting, abdominal cramps,
anorexia, pseudomembranous colitis, oral candidiasis, vaginitis,
hepatitis,
eosinophilia,
neutropenia,
thrombocytopenia,
leukopenia, thromboytosis, pain at injection site, phlebitis, renal
failure; BUN increased, serum creatinine increased.
Dose and Administration:IM, IV:Adult: 250 mg to 2 g every 6
- 12 (usually 8) hours, depending on severity of infection;
maximum dose: 12g/day.Child>1 month: 25 - 100 mg/kg/day
divided every 6 - 8 hours; maximum: 6 g/day.
Storage: store intact vials at room temperature and protect from
temperature exceeding 40oC.
Cephradine
Capsule, 250 mg, 500 mg
Intravenous (I.V) Infusion, 2g, 4g/100ml
Powder for injection, 250mg, 500mg, 1g/vial
Syrup, 125 mg/5ml; 250 mg/5ml
Indications: treatment of infections when caused by susceptible
strains in respiratory, genitourinary, gastrointestinal, skin, bone
and joint infections; treatment of susceptible gram-positive
bacilli and cocci; some gram-negative bacilli.
Cautions: renal impairment, penicillin allergy.
Drug interactions: probenecid, aminoglycosids.
Contraindications: hypersensitivity to cephradine or other
cephalosporins.

397

8. Anti-Infectives

Side effects: dizziness, rash, pruritus, diarrhea, nausea,

pseudomembranous
colitis,
leukopenia,
neutropenia,
eosinophilia, joint pain, BUN increased, creatinine increased.
Dose and Administration: Adult: Oral: 250 to 500 mg every 6
- 12 hours.In severe infection: deep IM or IV by slow injection
over 3-5 minutes or by infusion, in doses of 2-4 g daily in 4
divided doses; up to 8g daily.Child 1 - 8 months: 12.5mg/kg
twice daily ( total daily dose may alternatively be given in 3-4
divided doses). Child 9 months: Oral: Usual dose: 25 - 50
mg/kg/day in divided doses every 6 hours. Otitis media: 75 -100
mg/kg/day in divided doses every 6 or 12 hours (maximum:
4g/day).Injection: 50-100mg/kg daily may be given in 4 divided
doses, increasing to 300mg/kg daily in severe infections.
Storage: store at controlled room temperature.
Second Generation Cephalosporins
Cefaclor
Capsules, 250 mg, 500 mg
Suspension, 125 mg/5ml, 250 mg/5ml
Indications: treatment of susceptible bacterial infections
including otitis media, lower respiratory tract infections, acute
exacerbations of chronic bronchitis, pharyngitis and tonsillitis,
urinary tract infections, skin infections.
Cautions: severe renal impairment, history of penicillin allergy.
Drug interactions: probenecid, furosemide, aminoglycosides.
Contraindications: hypersensitivity to cefaclor or other
cephalosporins.
Side effects: rash, diarrhea, vaginitis, eosinophilia,
transaminases
increased,
agitation,
agranulocytosis,
anaphylaxis, angioedema, aplastic anemia, cholestatic jaundice,
CNS irritability, confusion, dizziness, hallucinations, hemolytic
anemia, hepatitis.
398

8. Anti-Infectives

Dose and Administration:Oral:Adult: 250 - 500 mg every 8

hours. Child>1 month: 20 - 40 mg/kg/day divided every 8 - 12
hours; Maximum dose: 1 g/day.
Otitis media: 40 mg/kg/day divided every 12 hours
Pharyngitis: 20 mg/kg/day divided every 12 hours.
Storage: store at controlled room temperature. Refrigerate
suspension after reconstitution and discard after 14 days. Do not
freeze.
Cefprozil
Tablet, 500mg, 1g
Oral solution, 125mg/5ml, 250mg/5ml
Indications: treatment of otitis media, infections involving
respiratory tract and skin and skin structure; active against
methicillin sensitive staphylococci, many streptococci, and
various gram-negative bacilli including E.coli, some
Klebsiella,P. mirabilis, H. influenzae and Moraxella.
Cautions: severe renal impairment, history of penicillin allergy.
Drug interactions: probenecid, furosemide, aminoglycosides.
Contraindications: cephalosporin hypersensitivity.
Side effects: dizziness, diaper rash, diarrhea, nausea, vomiting,
abdominal pain, vaginitis, transaminases increased, and
superinfection.
Dose and Administration: Oral:Pharyngitis/tonsillitis:
Adult and Child >13 years: 500 mg every 24 hours for 10
days.Children 2-12 years: 7.5 to 15 mg/kg/day divided every
12 hours for 10 days; maximum: 1 g/day.
Uncomplicated skin and skin structure infections:
Adult and Child >13 years: 250mg every 12 hours, or 500 mg
every 12-24 hours for 10 days.Child 2-12 years: 20mg/kg every
24 hours for 10 days; maximum: 1 g/day.Secondary bacterial
infection of acute bronchitis or acute bacterial exacerbation of
399

8. Anti-Infectives

chronic bronchitis: 500mg every 12 hours for 10 days. Infants

and Child > 6 months to 12 years: Otitis media: 15mg/kg
every 12 hours for 10 days.
Storage: store at room temperature.
Cefuroxime
Tablet, 125 mg, 250 mg
Powder for injection, 250 mg/vial, 750 mg/vial, 1.5 g/vial, Oral
suspension, 125mg/ml
Indications: bone and joint infections; upper respiratory tract
infections (pneumonia or bronchitis) caused by S.Pyogenes,
H.influenza (beta-lactamase negative and beta-lactamase
positive strains), sinusitis caused by M. Catarrhalis,
S.Pneumonia or H.Influenzae, Lower respiratory tract infections
(pneumonia or bronchitis), skin structure infections caused by
S.Aureus, S.Pyogenes or S.Agalactiae; Gonorrhea
Cautions: penicillin sensitivity; renal impairment; pregnancy
and breast feeding (but appropriate to use); false positive
urinary glucose (if tested for reducing substances) and false
positive coombs' test.
Drug interactions: anticoagulants
Contraindications: cephalosporin hypersensitivity; porphyria.
Side effects: diarrhea and rarely antibiotic associated colitis,
nausea and vomiting, abdominal discomfort, headache, allergic
reactions including rashes, pruritus, urticaria, serum sickness
like reactions with rashes, fever and arthralgia, and anaphylaxis,
erythema multiforme, toxic epidermal necrolysis, transient
hepatitis and cholestatic jaundice, eosinophilia and blood
disorders
(including
thrombocytopenia,
leucopenia,
agranulocytosis,
aplastic
anaemia
and
hemolytic
anaemia),reversible
interstitial
nephritis,
hyperactivity,
400

8. Anti-Infectives

nervousness, sleep disturbances, confusion, hypertonia, and

dizziness.
Dose and Administration:Oral:(as cefuroxime axetil), 250 mg
twice daily in most infections including mild to moderate lower
respiratory tract infections (e.g. bronchitis); doubled for more
severe lower respiratory-tract infections or if pneumonia
suspected.Urinary-tract infection, 125 mg twice daily, doubled
in pyelonephritis.
Gonorrhoea, 1 g as a single dose; Child over 3 months, 125 mg
twice daily, if necessary doubled in child over 2 years with otitis
media.Lyme disease,Adult and Child over 12 years, 500 mg
twice daily for 20 days.
IM or IV injection or infusion: 750 mg every 6 8 hours; 1.5 g
every 6 8 hours in severe infections; single doses over 750 mg
intravenous route only. Child usual dose 60 mg/kg daily (range
30 100 mg/Kg daily) in 3- 4 divided doses (2- 3 divided doses
in neonates).Gonorrhoea, 1.5 g as a single dose by
intramuscular injection (divided between 2 sites). Surgical
prophylaxis, 1.5 g by intravenous injection at induction; may be
supplemented with 750mg intramuscularly 8 and 16 hours later
abdominal, pelvic, and orthopedic operations) or followed by
750 mg intramuscularly every 8 hours for further 24 48 hours
(cardiac,
pulmonary,
oesphageal,
and
vascular
operations).Meningitis, 3 g intravenously every 8 hours; Child,
200 to 240 mg/kg daily (in 3 4 divided does) reduced to 100
mg/kg daily after 3 days or on clinical improvement; Neonate,
100 mg/kg daily reduced to 50 mg/kg daily.
Storage: at room temperature.
Third Generation Cephalosporins
Cefditoren
Tablet, 200mg, 400mg
401

8. Anti-Infectives

Indications: acute bacterial exacerbation of chronic bronchitis,

community-acquired pneumonia, pharyngitis/tonsillitis, and
uncomplicated skin and skin-structure infections
Cautions: pregnancy and lactation, renal impairment, hepatic
impairment
Contraindications:
known
hypersensitivity
reaction
tocefditoren or any other cephalosporin, carnitine deficiency,
milk protein hypersensitivity (not lactose intolerance), children
younger than 12 years of age,
Drug interactions: antacids and H2 receptor antagonists,
probenecid, oral contraceptives
Dose and Administration: orally with meals (to enhance GI
absorption). Adults: Pharyngitis and Tonsillitis: 200 mg twice
daily for 10 days; Acute Bacterial Exacerbations of Chronic
Bronchitis: 400 mg twice daily for 10 days; Communityacquired Pneumonia:400 mg twice daily for 14 days; Skin and
Skin Structure Infections: 200mg twice daily for 10 days
Children 12 years of age: Pharyngitis and Tonsillitis: 200 mg
twice daily for 10 days; Acute Bacterial Exacerbations of
Chronic Bronchitis: 400 mg twice daily for 10 days;Communityacquired Pneumonia: 400 mg twice daily for 14 days; Skin and
Skin Structure Infections: 200 mg twice daily for 10 days.
Cefepime
Powder for injection, 500mg, 1gm/vial, 2gm/vial
Indications:
uncomplicated
urinary
tract
infections,
uncomplicated skin and skin structure infections, moderate to
severe pneumonia, complicated intra-abdominal infections (in
combination with metronidazole ) and in children 2 months to
16 years: febrile neutropenia, uncomplicated skin/soft tissue
infections pneumonia, complicated /uncomplicated urinary tract
infections
402

8. Anti-Infectives

Cautions: pregnancy and lactation, renal impairment, may

cause antibiotic associated colitis
Drug interactions: probenecid, aminoglycosides
Contraindications: hypersensitivity to Cefepime or any other
cephalosporin group
Dose and administration: Usual Dose Range: Adults: IV 1-2
gm/kg every 6-12 hours; children: IV 50 mg/kg every 8-12
hours (above two months of age or less than 40 kg body
weight). Indication specific dosing: febrile nutropenia: 50mg/kg
every 8 hours for 7-10 days; uncomplicated skin/soft tissue
infections, pneumonia, complicated/uncomplicated UTI
50mg/kg twice daily; mild to moderate UTI IM,IV 500-1000mg
every 12 hours; peritonitis (spontaneous) IV 2 gm every 12
hours with metronidazole; otitis externa (malignant),pneumonia
IV, 2 gm every 12 hours; septic lateral/cavernous sinus
thrombosis IV 2gm every 6 hours; with metronidazole for
lateral.
Cefixime
Tablet, 200mg, 400mg
Indications: treatment of urinary tract infections, otitis media,
respiratory infections due to susceptible organisms;
uncomplicated cervical/urethral gonorrhea due to N.
gonorrhoeae.
Cautions: severe renal impairment, history of penicillin allergy.
Drug interactions: probenecid, furosemide, aminoglycosides,
warfarin.
Contraindications: cephalosporin hypersensitivity.
Side effects: diarrhea, abdominal pain, nausea, dyspepsia,
flatulence, loose stools, acute renal failure, anaphylactic
reactions, angioedema, dizziness, drug fever, headache, rash,
seizure, Stevens-Johnson syndrome.
403

8. Anti-Infectives

Dose and Administration: Oral:Adult and Child> 50kg or

>12
years:
400mg/day
divided
every
12-24
hours.Uncomplicated cervical/urethral gonorrhea due toN.
gonorrhoeae: 400mg as a single dose. Child 6 months:
8mg/kg/day divided every 12-24 hours.
Cefotaxime
Injection, as sodium, 0.5 g, 1 g in vial
Indications: susceptible infections in respiratory tract, skin,
bone and joint, urinary tract, gynecologic as well as septicemia,
and documented or suspected meningitis and other infections
due to gram-negative bacilli, gram-positive cocci and penicillinresistant pneumococci
Cautions: severe renal impairment, patients with colitis, a
history of penicillin allergy.
Drug interactions: probenecid, furosemide, aminoglycosides.
Contraindications: hypersensitivity to cefotaxime or other
cephalosporins.
Side effects: rash, pruritus, diarrhea, nausea, vomiting, colitis,
pain at injection site, anaphylaxis, arrhythmia, candidiasis,
fever, headache, interstitial nephritis, neutropenia, StevensJohnson syndrome, thrombocytopenia, urticaria, vaginitis,
agranulocytosis, aplastic anemia, cholestasis, hemolytic anemia,
hemorrhage, renal dysfunction, seizure, superinfection, toxic
nephropathy.
Dose and Administration:Adult and Child >12 years:
Uncomplicated infections:I.M, I.V: 1 g every 12 hours.
Moderate/severe infections:I.M, I.V: 1 - 2 g every 8
hours.Infections commonly needing higher doses (e.g.
septicemia): I V: 2 g every 6 - 8 hours.Gonorrhoeae and
associated infections: 500mg IM single dose.Life-threatening
infections: I.V: 2 g every 4 hours.Preop:I.M, I.V: 1 g 30 - 90
404

8. Anti-Infectives

minutes before surgery.C-section: 1 g as soon as the umbilical

cord is clamped, then 1g I.M,\
I.V at 6 and 12 hour intervals.Neonates, Infants and Children
up to 12 years:I.M, I.V: <50Kg: 50 to 180 mg/kg/day in divided
doses every 4-6 hours.
Meningitis: 200 mg/kg/day in divided doses every 6 hours.
Storage: store at a temperature not exceeding 8 oC.
Cefpodoxime
Tablet, 100mg, 200mg
Indications: treatment of susceptible acute, community
acquired pneumonia caused by S. pneumoniae or nonbetalactamase producing H.influenzae; acute uncomplicated
gonorrhea caused by N. gonorrhoeae; uncomplicated skin and
skin structure infections caused by S. aureus or S.pyogenes;
acute otitis media caused by S.pneumoniae, H.influenzae or
M.catarrhalis; pharyngitis or tonsillitis; and uncomplicated UTI
caused by E.coli, Klebsiella, and Proteus.
Cautions: renal impairment, prolonged use may result in
superinfection, use with caution in patients with a history of
penicillin allergy especially IgE-mediated reactions (eg
anaphylaxis, urticaria)
Drug interactions: probenecid, furosemide, aminoglycosides,
antacids and H2-receptor antagonists.
Contraindications: hypersensitivity to cephalosporins
Side effects: diaper rash, diarrhea in infants, headache, rash,
nausea, abdominal pain, vomiting.
Dose and Administration:Oral:Adult and Child 12 years:
Acute community-acquired pneumonia and bacterial
exacerbations of chronic bronchitis: 200 mg every 12 hours for
14 days and 10 days, respectively
405

8. Anti-Infectives

Acute maxillary sinusitis: 200mg every 12 hours for 10

days.Skin and skin structure: 400mg every 12 hours for 7-14
days. Uncomplicated gonorrhea (male and female) and rectal
gonococcal infections (female): 200mg as a single dose.
Pharyngitis/tonsillitis: 100mg every 12 hours for 5-10
days.Uncomplicated urinary tract infection: 100mg every 12
hours for 7 days.Child 2 months to 12 years: Acute otitis
media: 10mg/kg/day divided every 12 hours (400mg/day) for 5
days (maximum: 200mg/dose). Acute maxillary sinusitis:
10mg/kg/day divided every 12 hours for 10days (maximum:
200mg/dose). Pharyngitis/tonsillitis: 10mg/kg/day in 2 divided
doses for 5-10 days (maximum: 100mg/dose)
Ceftazidime
Injection, 0.5 g, 1 g, 2 g in vial
Indications: infections due to sensitive bacteria, especially
those due to pseudomonas spp. and including those resistant to
aminoglycosides.
Cautions: penicillin sensitivity, renal impairment, pregnancy
and breast-feeding, false positive urinary glucose and false
positive coombs' test.
Drug interactions: contraceptives (oral), furosemide, warfarin.
Contraindications: cephalosporin hypersensitivity; porphyria.
Side effects: diarrhea, nausea, vomiting, abdominal discomfort,
headache, rarely, antibiotic associated colitis (particularly with
higher doses), allergic reactions including rashes, pruritus,
urticaria, serum sickness like reaction, fever and arthralgia, and
anaphylaxis, erythema multiforme, toxic epidermal necrolysis,
disturbances in liver enzymes, transient hepatitis, cholestatic
jaundice eosinophilia and blood disorders (including
thrombocytopenia, leukopenia, agranulocytosis, aplastic
anaemia, and haemolytic anaemia); reversible interstitial
406

8. Anti-Infectives

nephritis, nervousness, sleep disturbances, confusion,

hypertonia, and dizziness.
Dose and Administration:Adult: IM, IV: 500mg to 2g every 812 hours. Urinary tract infections: 250-500mg every 12
hours.Neonates: 30mg/kg IV every 12 hours
Infants and Children up to 12 years: IV: 30-50mg/kg/dose
every 8 hours; maximum dose: 6g/day.
Storage: store between (-25) and (-10) oC unless otherwise
specified by manufacturer. After thawing, solutions retain their
potency for 24 hours at room temperature or for 7 days if
refrigerated.
Ceftriaxone
Injection, 0.25g, 0.5 g, 1 g, 2 g in vial
Indications: serious infections due to sensitive bacteria,
including septicaemia, pneumonia, and meningitis, surgical
prophylaxis, prophylaxis of meningococcal meningitis,
gonorrhea.
Cautions: penicillin sensitivity; renal and hepatic impairment;
premature neonates, may displace bilirubin from serum
albumin; pregnancy and breast feeding; false positive urinary
glucose and false positive coombs test.
Drug interactions: furosemide and warfarin. Do not admix
with aminoglycosides in same bottle/bag.
Contraindications: cephalosporin hypersensitivity, porphyria,
neonates with jaundice, hypoalbuminaemia, acidosis or
impaired bilirubin binding.
Side effects: diarrhea, nausea and vomiting, abdominal
discomfort, headache, antibiotic-associated colitis, allergic
reactions including rashes, pruritus, urticaria, serum sickness like reactions, fever and arthralgia, and anaphylaxis, erythema
multiforme, toxic epidermal necrolysis, disturbances in liver
407

8. Anti-Infectives

enzymes, transient hepatitis and cholestatic jaundice,

eosinophilia and blood disorders, reversible interstitial nephritis,
hyperactivity, nervousness, sleep disturbances, confusion,
hypertonia and dizziness, calcium ceftriaxone precipitates in
urine or in gall bladder - consider discontinuation if
symptomatic, rarely prolongation of prothrombin time,
pancreatitis.
Dose and Administration:Infections due to susceptible
organisms: IM, IV injection (over 3 - 4 minutes) orIV
infusion:Adult: 1 g daily; severe infections 2 - 4 g daily.
Infant and Child: 20 - 50 mg/kg daily, up to 80 mg/kg daily in
severe infections; by IV infusion (over 60 minutes).Neonate:
less than 1 week 20 - 50 mg/kg once daily, Neonates: 1-4week
and weigh 2kg or less 50mg/kg. If above 2kg, 50-75mg/kg once
daily.
Uncomplicated gonorrhea: IM: Adult: 250 mg, adolescent:
125mg as a single dose. Surgical prophylaxis:IM, IV injection
(over at least 2 to 4 minutes), 1 g as a single dose.Colorectal
surgery (with antibacterial active against anaerobes), IM or IV
(over at least 2 - 4 minutes), or by IV infusion, 2 g as a single
dose.
Storage: prior to reconstitution, store at room temperature.
Premixed solution store at -20oC; once thawed, solutions are
stable for 3 days at room temperature of 25oC or for 21 days
refrigerated at 5oC. Do not refreeze.
Imipenem and Cilastatin
Powder for Infusion, 500 mg (500mg+500mg),
250mg (250mg+250mg)
Indications: for treatment respiratory tract,urinary tract, intraabdominal, gynecologic, bone and joint, skin structure and
polymicrobic infections as well as bacterial septicemia and
408

8. Anti-Infectives

endocarditis. Antibacterial activity includes resistant gramnegative bacilli (Pseudomonas aeruginosa and Enterobacter sp),
gram-positive bacteria (methicillin-sensitive Staphyloccoccus
aureus and Streptococcus specius and anaerobes, treatment of
aerobic and anaerobic Gram-positive and Gram-negative
infections; hospital-acquired septicaemia; not indicated for CNS
infections.
Cautions: Renal impairment, pregnancy, breastfeeding,
prolonged use may result in superinfection, in patients with a
history of seizures or hypersensitivity to beta-lactions, elderly
patients, pediatric CNS infections, IV and IM preparations
cannot be interchanged.
Drug interactions: Ganciclovir, Valproate, Typhoid Vaccine
(oral),
Contraindications: Hypersensitivity to the medicine or any
component of the formulation; sensitivity to beta-lactam
antibacterials (avoid if history of immediate hypersensitivity
reaction); CNS disorders (e.g. epilepsy); severe renal
impairment, Pregnancy.
Side-effects: nausea (may reduce rate of infusion), vomiting,
diarrhoea (rarely antibiotic-associated colitis), eosinophilia, rash
(rarely toxic epidermal necrolysis and Stevens-Johnson
syndrome); less commonly hypotension, seizures, myoclonic
activity, dizziness, drowsiness, hallucinations, confusion,
leucopenia, thrombocytopenia, thrombocytosis, positive
Coombs test; rarely taste disturbances, hepatitis,
encephalopathy, anaphylactic reactions, paraesthesia, tremor,
acute renal failure, polyuria, tooth, tongue or urine
discoloration, hearing loss; very rarely, abdominal pain,
heartburn, glossitis, tachycardia, palpitation, flushing, cyanosis,
dyspnoea,
hyperventilation,
headache,
asthenia,
409

8. Anti-Infectives

haemolyticanaemia, aggravation of myasthenia gravis,

polyarthralgia, tinnitus, hypersalivation, hyperhidrosis
Dose and Administration: By intravenous infusion, in terms of
imipenem, 500 mg every 6 hours or 1 g every 8 hours; less
sensitive organisms or life-threatening infection, 1 g every 6
hours; 1 year and older, 15 mg/kg (max. 500 mg) every 6 hours;
less sensitive organisms or life-threatening infection, 25 mg/kg
(max. 1 g) every 6 hours. Children 3 months and older: IV 15
to 25 mg/kg every 6 hours for non-CNS infections. Max dose, 2
g/day for fully susceptible organisms, 4 g/day for infections
with moderately susceptible organisms. Doses up to 90
mg/kg/day have been used in older children with cystic fibrosis.
Infants 4 week to 3 month (at least 1.5 kg):IV 25 mg/kg every
6 h for non-CNS infections.
Neonates 1 to 4 wk (weighing at least 1.5 kg):IV 25 mg/kg
every 8 h for non-CNS infections. Neonates younger than 1
wk (weighing at least 1.5 kg):IV 25 mg/kg IV every 12 hours
for non-CNS infections.
Storage: Should be stored at <250c
Meropenem
Powder for injection, 500mg, 1gm
Indications:
treatment of intra-abdominal infections
(complicated appendicitis and peritonitis), bacterial meningitis
in pediatric patients, >3 months caused by S. pneumonia, H.
influenza, and N. meningitides; complicated skin and skin
infections caused by susceptible organism.
Cautions: breast feeding, renal impairment, children <3 months
of age.
Drug interactions: probenecid may increase meropenem serum
concentration; meropenem may decrease valproic acid serum
concentration.
410

8. Anti-Infectives

Contraindications: hypersensitivity to meropenem, any

component of the formulation or other carbapenems; patients
who have experienced anaphylactic reactions to other betalactams.
Side effects: headache, pain, rash, pruritus, diarrhea,
constipation, oral moniliasis (pediatric patients), injection site
reaction
Dose and Administration:IV (infusion over 15 to 30 minutes;
bolus injection over 3 to 5 minutes): Adult: Intraabdominal
Infection: 1 g IV every 8 hours for 7 to 14 days. Meningitis: 1 to
2 g IV every 8 hours for 7 to 21 days. Skin or Soft Tissue
Infection: Complicated infection: 500 mg IV every 8 hours.
Duration of therapy should generally be continued for
approximately 7 to 10 days, or for 3 days after the acute
inflammation disappears, depending on the nature and severity
of the infection. For more severe infections, such as diabetic soft
tissue infections, 14 to 21 days of therapy may be required.
Pediatric: Intraabdominal Infection: 3 months or older: 20
mg/kg IV every 8 hours; Maximum dose: 3 g/day. Children 50
kg or more: 1 g IV every 8 hours. Meningitis: 3 months or
older: 40 mg/kg IV every 8 hours, Maximum dose: 6 g/day.
Children 50 kg or more: 2 g IV every 8 hours. Skin and
Structure Infection, complicated:3 months or older: 10 mg/kg
IV every 8 hours. Maximum dose: 1.5 g/day.
Children 50 kg or more: 500 mg IV every 8 hours
Storage: store at 200c to 250c.
Gemifloxacin
Tablet, 320mg
Indications: respiratory tract infections; acute exacerbations of
chronic bronchitis, mild to moderate community acquired
pneumonia
411

8. Anti-Infectives

Cautions: hepatic and renal impairment, patients with creatinine

clearance less than 40ml/minute
Drug interactions: antacids, cimetidine, corticosteroids,
didanosine, digoxin, hormonal contraceptives, omeprazole,
probenecid, sucralfate, theophylline,warfarin, drugs that prolong
QT interval, drugs metabolized by hepatic enzimes
Contraindications: pregnancy and lactation, or adolescents
younger than 18 years of old (safety and efficacy not
established)
Dose and administration: Adults 18 years: acute
exacerbations of chronic bronchitis: 320mg once daily for 5
days; mild to moderate community acquired pneumonia: 320mg
once daily for 5-7 days.
8.1.3.Macrolides
The macrolides are bacteriostatic or bactericidal, depending on
the concentration and type of micro-organism, and are thought
to interfere with bacterial protein synthesis. Their antimicrobial
property is similar to benzylpenicillin but they are also active
against organisms such as Legionella pneumophila,
Mycoplasma pneumoniae, and some rickettsias, chlamydias,
and chlamydophilas. Macrolides have postantibiotic effect: that
is, antibacterial activity persists after concentrations have
dropped below the minimum inhibitory concentration.
Azithromycin
Capsule, 250 mg
Powder for oral suspension, 200 mg/5ml
Indications:
treatment
of
acute
otitis
media,
pharyngitis/tonsillitis, mild to moderate upper and lower
respiratory tract infections, infections of the skin, community acquired pneumonia, pelvic inflammatory disease, sexually412

8. Anti-Infectives

transmitted diseases (urethritis/cervicitis), genital ulcer, acute

bacterial exacerbations of chronic obstructive pulmonary
disease (COPD), acute bacterial sinusitis.
Cautions: hepatic and renal dysfunction, prolonged cardiac
repolarization.
Drug interactions: pimozide, phenytoin, ergot alkaloids,
alfentanil bromocriptine, carbamazepine, cyclosporine, digoxin,
disopyramide, triazolam; nelfinavir, aluminium and magnesium
containing antacids.
Contraindications: hypersensitivity to azithromycin.
Side effects: diarrhea, nausea, abdominal pain, cramping,
vomiting, acute renal failure, allergic reaction, aggressive
behaviour, anaphylaxis, angioedema, arrhythmia, cholestatic
jaundice, deafness, enteritis, erythema multiforme, headache,
hearing loss, hepatic necrosis.
Dose and Administration: Oral:Adolescents 16 years and
Adults:Respiratory tract, skin and soft tissue infections: 500 mg
on day 1 followed by 250 mg/day on days 2 5.Alternative
regimen: Bacterial exacerbation of COPD: 500 mg/day for a
total of 3 days.Bacterial sinusitis: 500 mg/day for a total of 3
days.
Urethritis/cervicitis:Due to C.trachomatis: 1 g as a single
dose;due to N.gonorrhoeae: 2 g as a single dose
Chancroid due to H-ducreyi: 1 g as a single dose. Child 6
months:Community - acquired pneumonia: 10 mg/kg on day 1
followed by 5 mg/kg/day once daily on days 2 to 5.Bacterial
Sinusitis: 10 mg/kg once daily for 3 days.Otitis media: 1 day
regimen: 30 mg/kg as a single dose; 3 days regimen: 10 mg/kg
once daily for 3 days; 5day regimen: 10 mg/kg on day 1
followed by 5 mg/kg/day once daily on days 2 to 5.Child 2
years: pharyngitis, tonsillitis: 12 mg/kg/day once daily for 5
days.
413

8. Anti-Infectives

Storage: Suspension: store dry powder below 300c; following

reconstitution, store suspension at 50c to 300c.
Clarithromycin
Tablet, 250 mg, 500 mg
Granules for oral suspension, 125 mg/5ml, 250 mg/5 ml
Powder for IV infusion, 500 mg/vial
Indications: respiratory tract infections, mild to moderate skin
and soft tissue infections, adjunct in the treatment of duodenal
ulcers by eradication of Helicobacter pylori and ycobacterium
avium infections, in combination with ethambutol.
Cautions: severe renal impairment.
Drug interactions: cisapride, pimozide, sparfloxacin,
thioridazine, benzodiazepines, calcium channel blockers,
cyclosporine, quinidine, sildenafil, midazolam, triazolam,
cisapride, ergot alkaloids, neuromuscular - blocking agents and
warfarin, amprenavir, azole antifungals, ciprofloxacin,
diclofenac, doxcycline, erythromycin, isoniazid, nefazodone,
propofol.
Contraindications: hypersensitivity to clarithromycin, or any
macrolide antibiotics, use with ergot derivatives, pimozide,
cisapride.
Side effects: headache, rash, diarrhea, vomiting, nausea,
abnormal taste, heartburn, abdominal pain, prothrombin time
increased, BUN increased.
Dose and Administration:Adult: Oral: 250-500mg twice
daily. IV infusion over 60 minutes, 500mg twice daily.M.avium
complex (MAC) infections in AIDS: 500mg twice daily plus
ethambutol.H. pylori:Oral: 500 mg twice daily (see under
omeprazole dose and admenstration). Child:Oral: 7.5-15
mg/kg/dose (maximum 500 mg) 12 hourly.
Storage: store at room temperature.
414

8. Anti-Infectives

Erythromycin
Tablet (stearate), 250mg, 500mg
Capsule, 250mg
Oral suspension, 125mg/5ml, 200mg/5ml, 250mg/5ml
Injection, 50mg/ml in 2ml ampoule
Indications: conjunctivitis in newborns, genitourinary tract
infection during pregnancy, pneumonia in infants, prophylaxis
of bacterial endocarditis, gonorrhea, legionnaires disease,
pharyngitis, sinusitis and for long term prophylaxis of rheumatic
fever, syphilis.
Cautions: pregnancy and breast-feeding, renal and hepatic
function impairment, cardiac arrhythmias (prolongation of QT
interval), porphyria, in neonates less than two weeks risk of
hypertrophic pyloric stenosis.
Drug interactions: alfentanil, carbamazepine, chloramphenicol,
itraconazole, cyclosporins, terfenadin, warfarin, xanthines such
as aminophylline, caffeine, oxtriphylline, and theophylline.
Side effects: Nausea, Vomiting, diarrhoea, abdominal, stomach
cramping and discomfort, reversible loss of hearing, recurrent
fainting, hypersensitivity (skin rash, redness or itching),
cholestatic jaundice (dark or amber urine, pale stools, stomach
pains), inflammation or phlebitis at injection site.
Dose
and
Administration:Adult:Antibacterial
(systemic):Oral: 250mg (base) every 6 hours, or 500mg every
12 hours if twice a day dosage is required. Maximum: up to 4
grams (base) daily.IV infusion: 250-500mg (base) every 6 hours.
Maximum up to 4 grams.
Endocarditis (prophylaxis): In patients with heart disease or
rheumatic or other acquired valvular heart disease who undergo
dental procedures or surgical procedure of the upper respiratory
tract, Oral, 1gm (base) one hour prior to the procedure, and
500mg 6 hours following the procedure. Genitourinary tract
415

8. Anti-Infectives

infection, including chlamydial: Oral:500mg (base) every six

hours for at least seven days. For patients unable to tolerate the
higher dosage regimen, the dosage may be halved and given for
at least fourteen days.Legionnaires disease: Oral: 500mg
(base) to 1gm(base) every six hours.Streptococcal (prophylaxis)
- continuous prophylaxis of streptococcal infections in patients
with a history of rheumatic heart disease: Oral: 250mg (base)
every twelve hours.Child:Antibacterial (systemic): oral: 7.5mg
to 12.5mg (base) per kg of body weight every 6 hours, or 17 to
25mg per kg of body weight every 12 hours. Severe infection:
15 to 25mg (base) per kg of body weight every six
hours.Antibacterial (systemic):IV infusion, 3.75 to 5mg (base)
per
kg of body weight every 6 hours.Conjunctivitis,
chlamydial:oral: 12.5mg (base) per kg of body weight every 6
hours for at least two week.Endocarditis prophylaxis:in patients
with heart disease are rheumatic or other acquired valvular
heart disease who undergo dental procedures or surgical
procedures of the upper respiratory tract: Oral: 20mg (base)
per kg of body weight one hour prior to the procedure, and
10mg per kg of body weight six hours following the procedure.
Pertusis:oral: 10 to 12.5mg (base) per kg of body weight every
6 hours for 14 days.
Pneumonia, chlamydial:oral: 12.5mg (base) per kg of body
weight every 6 hours for two weeks.
Streptococcal pharyngitis: oral: 5-12.5mg (base) per kg of body
weight every 6 hours for at least 10 days.
Neonates: oral: 7.5mg to 12.5mg (base) per kg of body weight
every 6 hours
Note: For oral dosage- continue medicine for full time of treatment

Storage: at room temperature in tight container.

416

8. Anti-Infectives

8.1.4Aminoglycosides
Aminoglycosides, such as amikacin, gentamicin, neomycin and
tobramycin have a similar antimicrobial spectrum and act by
interfering with bacterial protein synthesis by binding
irreversibly to the 30s and 50s portions of the bacterial
ribosome. They are most active against Gram-negative rods.
Aminoglycosides show enhanced activity with penicillins
against some enterococci and streptococci.
Gentamicin
Injection, 40mg/ml; 80mg/ 2ml; 20mg/2ml
Indications: biliary tract infection, bone and joint infection,
meningitis, ventriculitis, urinary tract infection, peritonitis,
bacterial septicemia.
Cautions: in premature infants and neonates, elderly, patients
with renal function impairment (check renal function test) or
dehydration, and in those with eighth-cranial nerve impairment.
Prolonged use should be avoided.
Drug interactions: avoid concurrent and/or sequential use of
two or more aminoglycosides or aminoglycosides with
capreomycin, antimysthenic, methoxyflurane or polymyxin,
cephalosporins,
ciclosporin,
cisplatin,
neostigmine,
pyridostigmine, suxamethonium, vecuronium, furosemide,
penicillines and indomethacin.
Contraindications: pregnancy, myasthenia gravis, previous
allergic reaction to one aminoglycoside.
Side effects: nephrotoxicity, increased thirst, loss of appetite,
nausea or vomiting; neurotoxicity (muscle twitching, numbness,
seizures, tingling); ototoxicity, auditory damage (loss of
hearing, ringing or buzzing a feeling of fullness in the ears),
vestibular damage (clumsiness, dizziness, nausea, vomiting,
unsteadiness)
417

8. Anti-Infectives

Dosage and Administration:Adult:Antibacterial (systemic):IM

or IV infusion: 1-1.7mg (base) per kg of body weight every
eight hours for seven to ten days or more.Urinary tract infection
(bacterial, uncomplicated):IM or IV infusion: Adults (< 60kg
body weight) - 3mg (base) per kg of body weight once a day, or
1.5mg per kg of body weight every 12 hours. Adults ( 60kg of
body weight)160mg (base) once a day, or 80mg every 12
hours.Usual adult prescribing limit - up to 7mg (base) per kg of
body weight daily in severe, life threatening infections.Child:
Antibacterial (systemic):IM or IV infusion: premature or full
term neonates up to 1 week of age: 2.5mg (base) per kg of body
weight every 12 or 24 hours for seven to ten days or
more.Older neonates and infants: 2.5mg (base) per kg of body
weight every 8 to 16 hours for 7-10 days or more.Child: 2 to
2.5mg (base) per kg of body weight every 8 hours for 7-10 days
or more.
Storage: store at room temperature and protect from freezing.
Neomycin
Tablet, 500 mg
Indications: To prepare GI tract for surgery; treatment of
diarrhea caused by E.Coli; adjunct in the treatment of hepatic
encephalopathy; bladder irrigation, ocular infections.
Cautions: renal impairment, pre-existing hearing impairment,
neuromuscular disorders.
Drug interactions: oral anticoagulants, digoxin, methotrexate.
Contraindications: hypersensitivity to neomycin or other
aminoglycosides.
Side effects: nausea, diarrhea, vomiting, irritation or soreness of
the mouth or rectal area, dyspnea, eosinophilia, nephrotoxicity,
neurotoxicity, ototoxicity.
Dose and Administration: Oral:Preoperative intestinal
antisepsis: Adult: 1 g each hour for 4 doses then 1 g every 4
418

8. Anti-Infectives

hours for 5 doses, or 1 g at 1 PM, 2 PM, and 11 PM on day

preceding surgery as an adjunct to mechanical cleansing of the
bowel and oral erythromycin; or 6g/day divided every 4 hours
for 2-3 days.Child: 90 mg/kg/day divided every 4 hours for 2
days; or 25 mg/kg at 1 PM, 2 PM and 11 PM on the day
preceding surgery as an adjunct to mechanical cleansing of the
intestine and in combination with erythromycin base.Hepatic
encephalopathy:Adult: 500-2000mg every 6-8 hours or 4 to
12g/day divided every 4-6 hours for 5 - 6 days.Child: 50 to 100
mg/kg/day in divided doses every 6 - 8 hours or 2.5 to 7
g/m2/day divided every 4 to 6 hours for 5 - 6 days not to exceed
12 g/day.
Chronic hepatic insufficiency: Adult: 4 g/day for an indefinite
period.
Storage: store in airtight containers and at room temperature.
Tobramycin
Injection, 40 mg/ml
Indications: infections caused by susceptible gram-negative
bacilli including Pseudomonas aeruginosa.
Cautions: renal impairment, pre-existing auditory or vestibular
impairment, patients with neuromuscular disorders.
Drug interactions: penicillins, neuromuscular blockers,
amphotericin B, cephalosporins, and loop diuretics.
Contraindications: hypersensitivity to tobramycin and other
aminoglycosides, pregnancy.
Side effects: confusion, disorientation, dizziness, fever,
headache, lethargy, vertigo, exfoliativ dermatitis, itching, rash,
urticaria, serum calcium, magnesium, potassium, and/or sodium
decreased, diarrhea, nausea, vomiting, anemia, easinophilia,
granulocytopenia, leukocytosis, leukopenia, thrombocytopenia,
419

8. Anti-Infectives

hearing loss, tinnitus, ototoxicity, roaring in the ears, BUN

increasd, serum creatinine increased, oliguria, proteinuria.
Dose and Administration: I.M, I.V:Adult:Severe life threatening infections:Conventional dosing: 2 to 2.5
mg/kg/dose.High dose: some clinicians suggest a daily dose of 4
- 7 mg/kg for all patients with normal renal function.Urinary
tract infection: 1.5 mg/kg /dose. Neonates: preterm <32 weeks
4- 5mg/kg every 36 hours
Preterm >32 weeks 4-5mg/kg every 24 hours.Term neonates,
Infant and Child<5 years:2- 25 mg/kg/dose every 8-12 hours.
Cystis fibrosis: 2.5 - 3.3 mg/kg every 6 - 8 hours.
Storage: store at room temperature.
8.1.5. Quinolones
Nalidixic acid and Norfloxacin are effective in uncomplicated
urinary tract infections.Ciprofloxacin is active against both
Gram-Positive and Gram Negative bacteria. It is particularly
active against Gram negative bacteria, including Salmonella,
Shigella, Campylobacter, Neisseria, and Pseudomonas,
Ciprofloxacin has only moderate activity against Gram-positive
bacteria such as streptococcus pneumoniae and Enterococcus
faecalis; it is not the drug of first choice for Pneumococcal
pneumonia.
It is active against Chlamydia and some
mycobacteria. Most anaerobic organisms are not susceptible.
Sparfloxacin is antibacterial agent similar to ciprofloxacin. It
has been reported to be more active in vitro than ciprofloxacin
against some organisms, including staphylococci and
mycobacteria, and has a much longer plasma half-life.
Cautions, Quinolones should be used with caution in patients
with a history of epilepsy or conditions predisposing to seizures;
convulsions may be induced in patients with or without a history
of convulsions; also, use with caution in G6PD deficiency,
420

8. Anti-Infectives

pregnancy or breast feeding; use in children has been associated

with an increased risk of adverse effects involving joints and
surrounding tissue structures May impair ability to perform
skilled tasks, such as operating machinery, driving Exposure to
sunlight should be avoided (discontinue if photosensitivity
occurs).
Side effects, Adverse effects of quinolones include nausea,
vomiting, dyspepsia, abdominal pain, diarrhoea, and rarely
antibiotic associated colitis; headache, dizziness, sleep
disorders, rash (rarely stevens-Johnson Syndrom and toxic
epidermal necrolysis), and pruritus; less commonly, anorexia,
transient disturbances in liver enzymes and bilirubin and
increases in blood urea and creatinine; drowsiness, restlessness,
depression, confusion, hallucinations, convulsions, paraesthesia;
photosensitivity; hypersensitivity reactions including fever,
urticaria, angioedema, arthralgia, myalgia, and anaphylaxis,
blood disorders; disturbances in vision, taste, hearing, and
smell; isolated reports of tendon inflammation and damage; if
psychiatric, neurological, or hypersensitivity reactions
occurdiscontinue the drug.
Drug interactions, Quinolones may interact with the various
compounds including analgesics, anticoagulants, ciclosporin
(increased risk of nephrotoxicity) and theophylline.
Ciprofloxacin
Tablet (as hydrochloride), 250 mg, 500mg, 1000mg
Capsule, 500mg, 1000mg
Injection Infusion (as lactate), 2 mg/ml in 50 ml and 100 ml
bottle
Indications:gastroenteritisincluding
cholera,
shigellosis,
travellers diarrhoea, campylobacter and salmonella enteritis;
typhoid; gonorrhoea; chancroid; legionnaires disease;
421

8. Anti-Infectives

meningitis (including meningococcal meningitis prophylaxis);

respiratory-tract infectionsincluding pseudomonal infections
in cystic fibrosis, but not pneumococcal pneumonia; urinarytract infections; bone and joint infections; septicaemia; anthrax;
skin infections; prophylaxis in surgery
Cautions: history of epilepsy or conditions that predispose to
seizures, G6PD deficiency, myasthenia gravis (risk of
exacerbation), pregnancy, breastfeeding, children or adolescents
(see below); avoid exposure to excessive sunlight (discontinue if
photosensitivity occurs); rarely, tendon damagediscontinue at
first sign of pain or inflammation and rest affected limb; hepatic
impairment; renal failure; avoid excessive alkalinity of urine
and ensure adequate fluid intake as risk of crystalluria
Children:Ciprofloxacin can be used in children over 1 year for
complicated urinary-tract infections, for psuedomonal lower
respiratory-tract infections in cystic fibrosis, for prophylaxis
and treatment of inhalational anthrax; and for other infections
where the benefit is considered to outweigh the potential risk.
Drug interactions: see notes above
Contraindications: Absolute- known allergy to ciprofloxacin
or other quinolones.Pregnancy and lactation, inpatients with
history of tender disorder.
Side effects: nausea, vomiting, dyspepsia, abdominal pain,
diarrhea, headache, dizziness, weakness, sleep disorders, rash,
and pruritus, increase in blood urea and creatinine; metabolic
acidosis; drowsiness, restlessness, asthenia, depression,
confusion, hallucinations, convulsions, paraesthesia, raised
intracranial pressure, cranial nerve palsy; photosensitivity,fever,
urticaria, angioedema, arthralgia, myalgia, anaphylaxis,
eosinophilia, leukopenia, thrombocytopenia, disturbances in
vision, taste, hearing smell;haemolytic anaemia, renal failure,
interstitial nephritis,hepatitis and cholestatic jaundice
422

8. Anti-Infectives

Dose and Administration: Adult: Oral:Infections due to

susceptible organisms: 250 750 mg twice daily.
Acute uncomplicated cystitis: 100 mg twice daily for 3
days.Chronic prostatitis: 500 mg twice daily for 28
days.Gonorrhea, chancroid, shigellosis, or cholera: 500 mg as a
single dose.Pseudomonal lower respiratory tract infection in
cystic fibrosis: 750 mg twice daily;
Child:5 to 17 years, up to 20 mg/kg twice daily (maximum 1.5
g daily). Most other infections: 500 to 750 mg twice daily.
Surgical prophylaxis: 750 mg 60- 90 minutes before
procedure.IV infusion (over 30 60 minutes ; 400 mg over 60
minutes), 200400 mg
twice daily pseudomonal lower
respiratory tract infection in cystic fibrosis, 400 mg twice
daily; Child 5-17 years, up to 10mg/kg 3 times daily (max. 1.2g
daily). Urinary tract infections: 100 mg twice daily.
Gonorrhoea: 100 mg as a single dose. Note: Child not
recommended (see cautions and contraindications above) but where
benefit outweighs risk, by mouth, 10 30 mg/kg daily in 2 divided
doses or by intravenous infusion, 8-16 mg/kg daily in 2 divided doses.

Storage: Tablet: store below 30oc in a well-closed

container.Injection: Store in a cool place (between 8 and 15oc)
or at controlled room temperature (between 20 and 25oc).
Protect from light and freezing.
Nalidixic acid
Tablet, 500 mg
Oral suspension 300 mg/vial
Indications: urinary tract infections; shigellosis.
Cautions: see notes above: avoid in porphyria; liver disease;
renal impairment; false positive urinary glucose (if tested for
reducing substances); monitor blood counts, renal and liver
function if treatment exceeds 2 weeks.
423

8. Anti-Infectives

Drug interactions: see notes under ciprofloxacin

Side effects: see notes above; also reported toxic psychosis,
weakness, increased intracranial pressure, cranial nerve palsy,
and metabolic acidosis.
Dose and Administration:Urinary tract infections: Oral:
Adult: 1g every 6 hours for 7 days, reduced in chronic
infections to 500 mg every 6 hours;Child over 3 months:
maximum 50 mg/kg daily in divided doses, reduced in
prolonged treatment to 30 mg/Kg daily, or 15 mg/kg twice daily
for prophylaxis.Shigellosis:Oral: Adult: 1 g every 6 hours for 5
days. Childover 3 months: 15 mg/kg every 6 hours for 5 days.
Note: Patient Advice Take on an empty stomach, preferably one
hour before a meal.

Storage: store at room temperature (up to 25oC) in a tight

container. Protect from freezing.
Norfloxacin
Table, 400 mg
Indications: uncomplicated urinary tract infections and cystitis
caused by susceptible gram-negative and gram-postive bacteria;
sexually transmitted disease (eg, uncomplicated urethral and
cervical gonorrhea) caused by N.gonorrhoeae; prostatitis due to
E. coli.
Cautions:see notes under ciprofloxacin; renal impairment.
Drug interactions: see notes under ciprofloxacin.
Side effects: see notes above, also reported euphoria, anxiety,
tinnitus, polyneuropathy, exfoliative dermatitis, pancreatitis, and
vasculitis.
Dose and Administration: Urinary-tract infections: Adult:
400 mg twice daily for 7 10 days (for 3 days in uncomplicated
lower urinary tract infections).
424

8. Anti-Infectives

Chronic relapsing urinary tract infections: 400 mg twice daily

for up to 12 weeks; may be reduced to 400 mg once daily if
adequate suppression within first 4 weeks.
Uncomplicated gonorrhea: 800 mg as a single dose.
Chronic prostatitis: 400 mg twice daily for 28 days.
Storage: at room temperature in a tight container
Sparfloxacin
Tablet, 100 mg, 200 mg
Indications:bacterial exacerbation of chronic bronchitis,
community acquired pneumonia.
Cautions: see notes above, renal impairment, cerebral
ateriosclerosis, epilepsy.
Drug interactions: medications that prolong the QTc, interval
and see notes above.
Contraindications: in patients with history of photosensitivity,
not recommended for patients with ongoing proarrhythmic
conditions; patients younger than 18 years of age, breastfeeding.
Side effects: see notes above and also phototoxicity, QTc
interval prolongation (irregular or slow heart rate; recurrent
fainting); vaginitis.
Dose and Administrations:Oral:Adult: 400 mg on the first
day, then 200 mg every twenty four hours for a total of ten days
of therapy. Child up to 18 years of age use is not
recommended in infants, children, or adolescents since
fluoroquinolones cause arthropathy in immature animals.
Note: The recommended dose for patients with renal function
impairment (creatinine clearance less than 40 ml per minute) is 400
mg on the first day, then 200 mg every forty-eight hours for a total of
nine days of therapy.

Storage: at room temperature.

425

8. Anti-Infectives

8.1.6 Tetracyclines
Tetracyclines all have a broad spectrum of activity which
includes Gram-positive and Gram-negative bacteria. Unlike the
penicillins and aminoglycosides they are usually bacteriostatic
at the concentrations achieved in the body but act similarly to
the aminoglycosides by interfering with protein synthesis in
susceptible organisms.
Doxycycline is a tetracycline and is a broad- spectrum antibiotic
effective for conditions caused by Chlamydia, rickettsia,
brucella and spirochaete, Borrelia burgdorferi (Lyme disease). It
is a preferred tetracycline since it has a more favourable
pharmacokinetic profile than tetracycline.
Doxycycline
Tablet, 100mg
Capsule, 100mg
Indications: respiratory tract infections, including pneumonia
and chronic bronchitis, urinary-tract infections, syphilis,
chlamydia,
mycoplasma,
and
rickettsia,
prostatitis,
lymphogranuloma venereum, pelvic inflammatory disease (with
metronidazole), Lyme disease; brucellosis (with rifampicin),
leptospirosis, scrub typhus and travellers' diarrhoea ,psittacosis,
cholera, melioidosis, plague, anthrax, Q fever.
Cautions: hepatic function impairment.
Drug interactions: antacids, carbamazepine, ciclosporin, oral
contraceptives, ergotamine, ferrous salts, phenobarbital,
phenytoin, rifampicin and warfarin.
Contraindications: pregnancy, and breast-feeding, in infants
and children up to 8 years of age.
Side effects: nausea, vomiting, diarrhoea, erythema, headache,
visual
disturbance,
hepatotoxicity,
pancreatitis,
426

8. Anti-Infectives

pseudomembrane colitis, discolouration of infants and

childrens teeth, photosensitivity.
Dose and Administration:Infections due to susceptible
organisms:Oral:Adult and Child over 8 years: 200 mg on first
day then 100 mg daily; in severe infections, 200 mg
daily.Syphilis:Oral: 200300 mg daily in 12 divided doses.
Uncomplicated
genital
chlamydia,
non-gonococcal
urethritis:Oral: 100 mg twice daily.
Louse and tick-borne relapsing fevers: Oral: 100 mg or 200 mg
as a single dose.Cholera:Oral:Adult: 300 mg as a single dose;
Child: over 8 years, 100 mg as a single dose.
Note: Patient Advice. Capsules should be swallowed whole with plenty of
fluid while sitting or standing to prevent oesophageal irritation. May be
given with food to counter gastric irritation

Storage: at room temperature in a tight, light-resistant

container.
Minocycline hydrochloride
Capsule, 50mg, 100mg
Indications: It is tetracycline derivative and used for treatment
of susceptible bacterial infections of both gram-negative and
gram-positive organisms; treatment of antrax (inhalational,
cutaneous, and gastrointestinal); acne; meningococcal
(asymptomatic) carrier state; Rickettsial diseases (including
rockymountain spotted fever,); nongonoccocal urethritis,
gonorrhea; acute intestinal amebiasis.
Cautions: Hepatic and renal dysfunction, It may increase
muscle weakness in patients with myasthenia gravis, and
exacerbate systemic lupus erythematosus; if treatment continued
for longer than 6 months, monitor every 3 months for
hepatotoxicity, pigmentation and for systemic lupus
erythematosusdiscontinue if these develop or if pre-existing
systemic lupus erythematosus worsens.
427

8. Anti-Infectives

Drug interactions:see under tetracycline HCI; also

coumarins,dairy products, ergotamine and methysergide, iron,
haolin, penicillins, phenindione, quinapril, retinoid, strontium
ranelate, sucralfate, sulfonylureas, zinc, typhoid vaccine(oral),
tripotassium dicitratobismuthate.
Contraindications: see under tetracycline HCI
Side-effects: see under tetracycline HCI; also dizziness and
vertigo (more common in women); rarely anorexia, tinnitus,
impaired hearing, hyperaesthesia, paraesthesia, acute renal
failure, pigmentation (sometimes irreversible), and alopecia;
very rarely systemic lupus erythematosus, discoloration of
conjunctiva, tears, and sweat.
Dose and administration: 100 mg twice daily prophylaxis of
asymptomatic meningococcal carrier state (but no longer
recommended), 100 mg twice daily for 5 days usually followed
by rifampicin
Note: Capsules should be swallowed whole with plenty of fluid while
sitting or standing

Storage: Store at 200c to 250c; protect from light and moisture

Tetracycline hydrochloride
Tablet, 250 mg, 500 mg (coated)
Capsules, 250mg, 500mg
Injection, 100 mg, 250 mg, 500 mg in vial
Indications:exacerbations of chronic bronchitis; brucellosis,
chlamydia, mycoplasma, and rickettsia; acne vulgaris, rosacea,
typhus, gonorrhea, chancroid, syphilis, and cholera.
Cautions: caution in patients with renal function impairment.
Drug interactions: aluminium and/or magnesium containing
antacids, laxatives, calcium (e.g. milk or other dairy products,
eggs) and/or iron supplements, penicillines, or streptomycin.
428

8. Anti-Infectives

Contraindications: pregnant or nursing women, infants and

children under 8 years of age (it may also depress bone growth
and cause permanent discolouration of the teeth).
Side effects: nausea, vomiting, epigastric burning and distress,
flatulence and diarrhoea occur most frequently due to gastric
irritation. Rarely photosensitivity, skin discoloration, blood
dyscrasias may occur.
Dose and Administration:Orally, given 1 hour before or 2
hours after meals with adequate amounts of fluid.
Reduce dosage in renal and hepatic function impairment.
Adult:Rickettsial infection (e.g. typhus): 1-2g daily in 2-4
divided doses for 7-10 days.Gonorrhea (uncomplicated or
disseminated) in penicillin allergies:500mg every 6 hours daily
for at least 7 days.Chancroid: 1-2g daily in 2-4 divided doses
for 7 days.
Syphilis (in penicillin allergies):Early syphilis (of not more than
2 years duration) and Late syphilis (2 years and more): 500mg
every 6 hours daily for 15 days.
Cholera: 1-2g daily in 2-4 divided doses for 48 72
hours.Child (8 years and over): usually, oral, 25 50mg/ml of
body weight daily in 2-4 divided doses.Relapsing fever:Adult:
500mg 1g every twelve hours.Child (8 years and over): 6.25
12.5mg/kg of body weight every six hours.Adult and Child:IV
or IM: administration given in two to four divided doses at dose
levels of 2.5 to 5 mg/kg/day for patients with normal renal
function depending on the severity of the infection.
Storage: at room temperature, in a tight, light-resistant
container.Note: outdated and decomposed tetracycline are toxic and
may cause nephrotoxicity and skin lesion.

429

8. Anti-Infectives

8.1.7.Chloramphenicols
Chloramphenicol was the first broad spectrum antibacterial to
be discovered; it acts by interfering with bacterial protein
synthesis and is mainly bacteriostatic. Its range of activity is
similar to that of tetracycline and includes Gram-positive and
Gram-negative bacteria, Rickettsia spp., and Chlamydiaceae.It
is associated with serious haematological adverse effects and
should be reserved for the treatment of severe infections,
particularly those caused by Haemophilus influenzae and
typhoid fever.
Chloramphenicol
Capsules, 250mg
Suspension, oral (palmitate), 125mg/5ml; 60ml.
Injection (sodium succinate), 1 g in vial
Indications: severe life-threatening infections, particularly
those caused by Haemophilus influenzae , and typhoid fever;
also, cerebral abscess, mastoiditis, relapsing fever, gangrene,
granuloma inguinale, listeriosis, severe melioidosis, plague,
psitticosis,tularaemia, Whipple disease, septicaemia, empirical
treatment of meningitis
Cautions: it should not be used for the treatment of minor and
undefined infections, or as a prophylaxis. Caution in patients
with hepatic function impairment, blood disorder, in neonates
and infants, in pregnant women, particularly those near term or
in labour, and in nursing women.
Drug interactions: phenobarbital, oral contraceptives (estrogen
containing), tolbutamide, chlorpropamide, penicillines, or
streptomycin.
Contraindications: known hypersensitivity and/or toxic
reactions to chloramphenicol.
430

8. Anti-Infectives

Side effects: nausea, vomiting diarrhoea, and bone-marrow

depression may occur.
Dose and Administration: Note: A high initial dosage should
not be given in the treatment of typhoid fever as sensitivity like
reaction occurs. Reduce dose in hepatic and/or renal
impairment.Typhoid Fever:Adult: 500mg every 6 hours daily
for 14 days. Child: 11-30kg, 250mg every 6 hours daily for 14
days. 6-10kg, 125mg every 8 hours daily for 14 days.Typhus:
Adult: 500mg every 6 hours for 10 days. Child: 50 75
mg/kg of body weight daily in divided doses every 6 hours for
10 days.
Meningitis:I.V: infants > 30 days and Child: 50 - 100
mg/kg/day divided every 6 hours.Other infections: I.V:
Adult: 50 - 100 mg/kg/day in divided doses every 6 hours;
maximum daily dose: 4 g/day.Infant > 30 days and Child: 50 75 mg/kg/day divided every 6 hours; maximum daily dose: 4
g/day.
Storage: at room temperature, in a tight container.
Thiamphenicol
Capsule, 250 mg
Tablet, 250 mg
Indications, Cautions, Drug interactions and Side effects see
under chloramphenicol.
Dose and Administration: Oral:
Adult: 1.5g daily; up to 3g daily has been given initially in
severe infections.
Child: 30-100mg/kg daily.
Gonorrhoea: oral dose ranged from 2.5g daily for 1 or 2 days
through to 2.5g on the first day followed by 2g daily on each of
4 subsequent days.
431

8. Anti-Infectives

8.1.8.Miscellaneous
Clindamycin
Capsule, 75 mg, 150 mg
Injection, 150 mg/ml in ampoule
Oral solution, 15 mg/ml
Indications: staphylococcal bone and joint infections;
peritonitis, endocarditis prophylaxis; alternate treatment for
toxoplasmosis (see section 7.4.5).
Cautions: discontinue immediately if diarrhea or colitis
develop; hepatic and renal impairment, neonates and infants;
elderly; pregnancy; breastfeeding.
Drug interactions: alcuronium, neostigmine, pyridostigmine,
vecuronium.
Contraindications: hypersensitivity to clindamycin.
Side effects: diarrhea, nausea, vomiting, abdominal discomfort,
antibiotic - associated colitis, rashes, urticaria, and rarely
anaphylaxis,
erythema
multiforme,
exfoliative
and
vesiculobullous dermtitis, jaundice and altered liver function
tests; neutropenia, eosinophilia, agranulocytosis, and
thrombocytopenia, pain, indurations, and abscess after IM
injection; thrombophlebitis after IV injection.
Dose and Administration: Osteomyelitis or peritonitis:
Oral:Adult: 150 - 300 mg every 6 hours; up to 450 mg every 6
hours in severe infections.Child: 3 - 6 mg/kg every 6 hours.IM
or IV infusion: Adult: 0.6 - 2.7 g daily in 2 - 4 divided doses,
increased up to 4.8 g daily in life-threatening infections; single
doses over 600 mg by IV infusion only; single doses by IV
infusion not to exceed 1.2 g;Neonates: 15 - 20 mg/kg
daily.Child over 1 month: 15 - 40 mg/kg daily in 3 - 4 divided
doses; severe infections, at least 300 mg daily, regardless of
weight.Endocarditis prophylaxis (for procedures under local or
no anaesthetic):Oral:Adult: 600 mg, 1 hour before
432

8. Anti-Infectives

procedure.Endocarditis prophylaxis (for procedures under

general anaesthetic): IV infusion:Adult: 300 mg over at least 10
minutes, at induction or 15 minutes before procedure, then 150
mg 6 hours later by mouth or infusion.
Storage: store at room temperature.
Metronidazole
Tablet, 250mg
Intravenous infusion, 5mg/ml in 100ml
Cream, 0.75%, 1%
Indications: treatment of anaerobic infection, bone and joint
infection, meningitis, bacterial endocarditis, prophylaxis of
perioperative infection during colorectal surgery, lower
respiratory tract infection including pneumonia, empyema and
lung abscess, bacterial septicemia, skin and soft tissue infection,
inflammatory bowel disease, antibiotic associated colitis,
Helicobacter pylori associated duodenal ulcer; see also section
1.2.
Cautions: disulfiram like reaction with alcohol; hepatic
impairment
and
hepatic encephalopathy,
pregnancy;
breastfeeding; clinical and laboratory monitoring in courses
lasting longer than 10 days; see also interactions.
Note: Avoid Alcohol use.
Drug interactions: phenytoin, cumarine or indandion derivative
anticoagulant, warfarin, disulfiram, alcohol, cimetidine,
fluorouracil, lithium, phenobarbitone.
Contraindications: chronic alcohol dependence
Side effects: nausea, vomiting, unpleasant metallic test, furred
tongue and gastrointestinal disturbances; rarely headache,
drowsiness, dizziness, ataxia, darkening of urine, erythema
multiform, pruritus, urticaria, angioedema, and anaphylaxis;
abnormal
liver
function
tests,
hepatitis,
jaundice,
thrombocytopenia, aplastic anaemia, myalgia, arthralgia,
433

8. Anti-Infectives

peripheral neuropathy, epileptiform seizures, leuxopenia, on

prolonged or high dosage regimens
Dose and Administration:Adult: Antibacterial (systemic),
anaerobic infections: Oral: 7.5mg (base) per kg of body weight
up to a maximum of 1 gm, every 6 hours for 7 days or longer;
IV-infusion, 15mg (base) per kg of body weight initially, then
7.5mg per kg of body weight up to a maximum of 1gm, every
six hours for seven days or longer; Inflammatory bowel disease:
Oral: 500mg (base) four times a day.Antibiotic associated
colitis: Oral: 500mg (base) three or four times a
day.Helicobacter - pylori associated gastritis or duodenal ulcer:
Oral: 500mg (base) three times a day with amoxicilline for one
to two weeks.Perioperative infections, colonic (prophylaxis):IV
infusion: 15mg (base) per kg of body weight one hour prior to
start of surgery and 7.5mg per kg of body weight six and twelve
hours after the initial dose.Child:Anaerobic infection: Oral:
7.5mg (base) per kg of body weight every 6 hours, or 10mg per
kg of body weight every 8 hours.Anaerobic infection - for
preterm infants: IV infusion: 15mg per kg of body weight (base)
as an initial dose, then 7.5mg per kg of body weight every 12
hours starting 48 hours after the initial dose. Term infants, IV
infusion, 15mg (base) per kg of body weight as an initial dose,
then 7.5mg per kg of body weight every 12 hours starting 24
hours after the initial dose. Infants greater than 7 days of age
and children IV infusion, 15mg (base) per kg of body weight as
an initial dose, then 7.5 mg per kg of body weight every 6 hours.
Storage: at room temperature, in a well closed, light resistant
container. Protect from freezing
Nitrofurantoin
Tablet, 50mg, 100mg
Capsule (macrocrystal), 50mg, 100mg
434

8. Anti-Infectives

Oral suspension, 0.5% W/V

Indications: prophylaxis and treatment of urinary tract
infection.
Cautions: hypersensitive to nitrofurantioin, diabetes mellitus,
electrolyte imbalance, vitamin B and folate deficiency,
pulmonary disease, hepatic impairment, peripheral neuropathy.
Drug interactions: hemolytic, neurotoxic medication,
probenecid, sulfinpyrazone.
Contraindications: impaired renal function, infants less than 3
months, pregnancy, during breastfeeding, glucose 6 phosphate
dehydrogenase (G6PD) deficiency, porphyria.
Side effects: pneumonitis (chills, chest pain, cough, fever,
troubled breathing, abdominal or stomach pain or upset,
diarrhoea, loss of appetite, nausea, vomiting), hematology
reactions, specifically granulocytopenia (sore throat and fever)
or
anemia,
neurotoxicity,
polyneuropathy,
hepatitis,
hypersensitivities rust yellow to brown discoloration of urine.
Dose and Administration: Oral:Adult: 50 to 100mg every 6
hours. Maximum up to 600 mg daily, or up to 10mg per kg of
body weight daily.
Note: Prophylaxis 50 to 100mg once a day at bedtime.

Child: infants and children 1 month of age and over, 0.75 to

1.75mg per kg of body weight every 6 hours.
Note: Prophylaxis - 1mg per kg of body weight once a day at bedtime.
Continue medicine for full time of treatment.

Storage: store at room temperature in a tight, light resistant

container.
Pentamidine Isothionate
Nebulizer solution, 300mg/vial
Indications: Treatment and prevention of pneumonia by
Pneumocystis carinii (PCP)
435

8. Anti-Infectives

Cautions: Renal and hepatic dysfunction, risk of severe

hypotension following administration (monitor blood pressure
before starting treatment, during administration, and at regular
intervals, until treatment concluded; patient should be lying
down when receiving drug parenterally); hypokalaemia,
hypomagnesaemia, coronary heart disease, bradycardia, history
of ventricular arrhythmias, concomitant use with other drugs
which prolong QT-interval; hypertension or hypotension;
hyperglycaemia
or
hypoglycaemia;
leucopenia,
thrombocytopenia, or anaemia; carry out laboratory monitoring
according to product literature; care required to protect
personnel during handling and administration.
Drug interactions: Amiodarone, amisulpride, amphotericin,
tricyclic antidepressants,droperidol,erythromycin, foscarnet,
ivabradine, moxifloxacin, phenothiazines, saquinavir.
Contraindications: Hypersensitivity to pentamidine isethionate
or any component of the formulation, pregnancy and breast
feeding.
Side effects: severe reactions, sometimes fatal, due to
hypotension, hypoglycaemia, pancreatitis, and arrhythmias; also
leucopenia,
thrombocytopenia,
acute
renal
failure,
hypocalcaemia; also reported: azotaemia, abnormal liverfunction tests, anaemia, hyperkalaemia, nausea and vomiting,
dizziness, syncope, flushing, hyperglycaemia, rash, and taste
disturbances; Stevens-Johnson syndrome reported; on
inhalation, bronchoconstriction (may be prevented by prior use
of bronchodilators), cough, and shortness of breath; discomfort,
pain, induration, abscess formation, and muscle necrosis at
injection site.
Dose and administration:Prophylaxis of Pneumocystis
jirovecii (PCP) pneumonia, by inhalation of nebulised solution
(using suitable equipment, consult product literature), 300 mg
436

8. Anti-Infectives

every 4 weeks or 150 mg every 2 weeks [unlicensed for primary

prevention].
Storage: Store intact vials at controlled room temperature and
protect from light.
Spectinomycin
Injection, 2g in vial
Indications: uncomplicated and disseminated gonorrhoea; adult
and neonatal gonococcal conjunctivitis; chancroid. Note: It is
not indicated for pharyngeal gonorrhea.
Cautions: renal impairment, pregnancy and breastfeeding.
Drug interactions: lithium, botulinum toxin.
Contraindications: hypersensitive to spectinomycin.
Side effects: hypersensitivity (chills, fever, itching or redness of
the skin), dizziness, nausea, vomiting, abdominal cramp.
Dose
and
Administration:Uncomplicated
gonococcal
infections and chancroid: deep IM injection:Adult: 2g as a
single dose (may be increased to 4g as a single dose divided
between 2 injection sites in difficult to treat cases and where
there is known antibiotic resistance)
Disseminated gonococcal infections:deep IM injection:Adult:
2g twice daily for 7 days.Neonatal gonococcal
conjunctivitis:deep IM injection: Neonate 25 mg/kg (maximum
75mg) as a single dose.
Storage: at room temperature.
Sulphamethoxazole and Trimethoprim
Tablet (pediatric), 100mg + 20mg; (adult), 400mg + 80mg,
800mg+160mg
Mixture, 200mg + 40mg in each 5ml
Injection, 400mg + 80mg in each 5ml ampoule
437

8. Anti-Infectives

Indications: prophylaxis and treatment of Pneumocystis carinii

infections, toxoplasmosis and Isospora belli diarrhea. Treatment
of
nocardiosis,
urinary
tract,
respiratory
tract,
typhoid/paratyphoid fevers and prostatic infections caused by
susceptible organisms
Cautions: elderly, renal and hepatic function impairment,
photosensitivity, Glucose-6-phosphate dehydrogenase (G6PD)
deficiency; maintain adequate fluid intake (to avoid
crystalluria); avoid in blood disorders (unless under specialist
supervision); monitor blood counts and discontinue immediately
if blood disorder develops; rash discontinue immediately;
predisposition to folate deficiency; asthma; pregnancy;
breastfeeding.
Drug interactions: cumarin or indandione derivative
anticoagulant, hydantoin, oral hypoglycemics, hemolytics,
hepatotoxic medication, methenamine, methotrexate, folate
antagonists.
Contraindications: infants up to two months of age, in patients
who are allergy to sulfonamide, furosemide, thiazide diuretics,
sulfonylureas, carbonic anhydrase inhibitors or trimethoprim.
Side effects: hypersensitivity, photosensitivity, blood disorders
unusual bleeding or bruising, unusual tiredness or weakness,
hepatitis, Stevens Johnson syndrome, aching joints and
muscles, redness, blistering, peeling, or loosening of the skin,
unusual tiredness or weakness, toxic epidermal necrosis,
dizziness, headache, GIT disturbance, loss of appetite, nausea or
vomiting.
Dose and Administration:Adult:Oral: 160mg of trimethoprim
and 800mg of sulphamethoxazole every 12 hours may be
increased to 320/1600 mg 12 hourly in severe infections.IV
infusion: 160/800 mg 12 hourly. Each 80/400mg (5ml) to be
diluted in 125ml 5% glucose or 0.9% sodium chloride solution
438

8. Anti-Infectives

or infused over 1-1.5 hours.Cerebral toxoplasmosis:

320/1600mg twice daily for 4 weeks, then 160/800 mg twice
daily for 3 months.
Isospora belli: 160/800 mg 6 hourly for 10 days.
Primary prophylaxis in HIV-infection: Oral: 160/800 mg daily.
Lower doses (80/400 mg daily or 160/800 mg 3 times a week)
have been shown to be effective for Pneumocystis pneumonia
and are better tolerated.
Child:Oral: 2 months to 5 months, 20/100mg; 6months to 5
years, 40/200 mg; 6-12 years, 80/400mg, 12 hourly.IV infusion:
6/30 mg/kg/day in 2 divided doses, increased to 9/45 mg/kg/day
in severe infections.
Pneumocystis carinii pneumonia:Treatment: Oral or IV
infusion: Adult and Child: sulphamethoxazole up to 100mg/kg
daily with trimethoprim up to 20mg/kg daily in 2-4 divided
doses for 14-21 days.
Prophylaxis: Oral: Adult and Child: sulphamethoxazole
25mg/kg with trimethoprim 5 mg/kg in 2 divided doses on
alternate days (3 times a week).
Note: For oral, continue medicine for full time of treatment, avoid too
much sun or use of sun lamp. Avoid IM administration.

Storage: at room temperature, in a tight, light-resistant

container, protect from freezing.
Trimethoprim
Injection, 20 mg/ml
Tablet, 100 mg, 200 mg
Suspension, 50 mg/ml
Indications: acute uncomplicated urinary tract infections,
respiratory tract infections and chronic prostatitis and alternative
to co-trimoxazole for Pneumocystis pneumonia, in combination
with dapsone.
439

8. Anti-Infectives

Cautions: impaired renal or hepatic function or with possible

folate deficiency.
Drug interactions: digoxin, phenytoin or phenobarbital, oral
contraceptives, zidovudine and lamivudine.
Contraindications: use in neonates.
Side effects: skin rashes, pruritus, nausea, epigastric pain and
glossitis, hyperkalaemia, bone marrow depression (with
leukopenia, thrombocytopenia and megaloblastic anaemia).
Dose and Administration:Oral:Adult: 100 mg every 12 hours
or 200 mg every 24 hours for 10 days; longer treatment periods
may be necessary for prostatitis ( i.e, 4 - 16 weeks); in the
treatment of pneumocystis carinii pneumonia; dose may be as
high as 15 - 20 mg/kg/day in 3 - 4 divided doses. Child: 4
mg/kg/day in divided doses every 12 hours.IV: Acute infection:
Adult: 200mg every 12 hours.Child under 12 years: 8mg/kg
daily in 2-3 divided doses.
Storage: store at room temperature and protect from light
Vancomycin
Injection, 500 mg in vial, 1gm
Indications: generally reserved for the treatment of infections
due to cloxacillin - resistant staphylococci and enterococci; also
as an alternative agent for prophylaxis and treatment of
endocarditis in penicillin allergic patients.
Cautions: renal impairment.
Drug interactions: ototoxic and nephrotoxic agents, e.g.
aminoglycosides.
Contraindications: hearing abnormalities.
Side effects: nephrotoxicity including renal failure and
interstitial nephritis, ototoxicity, blood disorders, nausea, chills,
fever, eosinophilia, anaphylaxis, rashes, including exfoliative
dermatitis, Stevens Johnson syndrome, and vasculitis; phlebitis;
440

8. Anti-Infectives

on rapid infusion, severe hypotension, wheezing, dyspnoea,

urticaria, pruritus, flushing of the upper body, pain and muscle
spasm of back and chest.
Dose and Administration:IV infusion:Adult: over at least 1
hour, 500 mg 6 hourly or 1 g 12 hourly.Child: over at least 1
hour, 10 mg/kg 6 hourly or 20 mg/kg 12 hourly.
Neonates: under 1 week old, initially 15 mg/kg followed by 10
mg/kg 12 hourly; 1 week - 1 month old, 15 mg/kg followed by
10 mg/kg 8 hourly.
Storage: vancomycin reconstituted IV solutions are stable for
14 days at room temperature or refrigeration.
8.1.9. Antituberculous drugs
Tuberculosis is a chronic infectious disease caused primarily by
Mycobacterium tuberculosis or sometimes M.bovis; The closely
related form M. africanum has occasionally been implicated as a
cause of human tuberculosis. Drug treatment for clinical TB Disease
always involves multi drug regimens, chosen to provide early
bactericidal activity (activity against actively dividing mycobacteria),
and sterilizing activity (activity against non-dividing/dormant, semidormant organisms), and to prevent resistance. According to the
newly revised national TBL and TB/HIV Guideline (2012),
tuberculosis cases are calassified based on anatomical site of infection
as pulmonary tuberculosis (PTB) or extrapulmenary tuberculosis
(EPTB) and type of the cases as new case, re-treatment cases
(relapsed, treatment failure, return after defult ) or MDR TB). The
complete treatment is divided in two phases as intensive (initial)
phase and continuous phase. Intensive phase consists of treatment
with combination of 4 drugs for the first 8 weeks for new cases, and
with combination of 5 drugs for the first 8 weeks followed by 4 drugs
for the next 4 weeks for re-treatment cases.Continuation phase which
follows immediately after initial phase requires treatment with a
combination of 2 drugs, to be taken for 16 weeks for new cases and
441

8. Anti-Infectives

treatment with a combination of 3 drugs for re-treatment cases for 20

weeks.
New TB case regimens consist of 8 weeks treatment with Rifampicin,
Isoniazid, Pyrazinamide and Ethambutol 2(RHZE) during the
intensive phase, followed by 16 weeks with Rifampicin and Isoniazid
4(RH).Re-treatment cases consists of 8 weeks treatment with
Streptomycin, Rifampicin, Isoniazid, Pyrazinamide and Ethambutol
2S(RHZE) followed by 4 weeks treatment with Rifampicin, Isoniazid,
Pyrazinamide and Ethambutol 1(RHZE) during the intensive phase,
followed by 5 months with Rifampicin, Isoniazid and Ethambutol
5(RH)E.

Anti TB drug Dosage for New TB cases

Patients
in Kgs
20-29
30-39
40-54
55

Treatment Phase, Regimen and Dose

Intensive Phase (2 Continuation Phase(4
Weight
months)
months)
number of (RHZE) number of
(RH)
tablets
tablets
1
1
2
2
3
3
4
4

Dosage for Previously treated cases regimen:

Patients
Treatment Phase, Regimen and Dose
Weight in Intensive Phase 3 months
Continuation Phase 5
Kgs
Dose of S & number of months Number of
RHZE tablets
RHE tablets
S*
RHZE
RH
E
20-29
(0.5 g)
1
1
11/2
30-39
(0.5 g)
2
2
11/2
40-54
(0.75g)
3
3
2
> 55
1g
4
4
3
*S in intensive phase will continue for two months only.
442

8. Anti-Infectives

The Programmatic approach to MDRTB treatment in Ethiopia is

either standardized individualized or empiric treatment
approaches.
The standardized treatment regimen for MDR TB addresses 5
patient categories:
1. Patients with MDR-TB confirmation, but no full DST results
available yet:
Regimen: E-Z-Km (Am)-Lfx-Eto-Cs
2. MDR-TB Patients susceptible to both Kanamycin and
Quinolone: Regimen is the same as above
3. MDR-TB Patients susceptible to Kanamycin, but resistant to
Quinolone:
Regimen: E-Z-Km (Am)-Mfx-Eto-Cs-PAS
4. MDR-TB Patients susceptible to Quinolone, but resistant to
Kanamycin:
Regimen: E-Z-Cm-Lfx-Eto-Cs
5. XDR-TB Cases (i.e.: MDR-TB and resistance to Quinolone
and Kanamycin)
Regimen:
E-Z-Cm-Mfx-Eto-Cs-PAS
Duration and Phases of MDR TB Treatment
Intensive phase: The injectable agent is used for minimum of 6
months and at least 4 months after culture conversion.The use of
an individualized approach which reviews the cultures, smears,
x-rays, and the patients clinical status may also aid in deciding
whether or not to continue an injectable agent longer than the
above recommendation, particularly in the case of patients for
whom the susceptibility pattern is unknown, effectiveness is
questionable for an agent(s), or extensive or bilateral pulmonary
disease is present.Continuation phase: The treatment period
following the intensive phase. The total treatment is for
minimum duration of 18 months beyond culture conversion (eg.
pediatric patients receiving second line treatment with baseline
443

8. Anti-Infectives

culture negative result). Thus if the culture is negative at

completion of first month of MDR-treatment, intensive phase
will be 6 months and continuation phase 13 months. However, if
culture conversion(two consecutive negative cultures, from
samples collected at least 30 days apart) is at completion of
second months, intensive phase will be 6 months and
continuation phase 14 months. If culture conversion is at
completion of fourth month, intensive phase will be 8 months
and continuation phase will be 14 months. Extension of therapy
to 24 months may be indicated in chronic cases with extensive
pulmonary damage.
Amikacin
Injection, (as sulphate), 50mg/ml, 250mg/ml, 500mg/ml in 2ml
vial
Indications: treatment of MDR TB in conjunction with at least
two other antituberculosis agent.
Cautions: renal impairment, drug should be discontinued if
signs of ototoxicity, nephrotoxicity, during pregnancy and
lactation.
Drug interactions:amphotericin, neuromuscular blocking
agents.
Contraindications: hypersensitivity to amikacin sulfate
Side effects: neurotoxicity, ototoxicity, nephrotoxicity, allergic
reaction, dyspnea, eosinophilia
Dose and Administration:standardized or individually adjusted
on the basis of result of sensitivity test.
Storage: stable for 24 hours at room temperature and 2 days at
refrigeration when mixed in DW, DNS, NS, LR.
Capreomycin
Powder for injection, 1 g/vial
444

8. Anti-Infectives

Indications: treatment of drug resistant tuberculosis in

conjunction with at least 2, preferably 3 (new drugs known to be
active against the resistant strain) other antituberculosis agents.
Cautions: renal insufficiency or pre-existing auditory
impairment, elderly, use with non-antituberculous drugs (i.e.,
aminoglycoside antibiotics).
Contraindications: hypersensitivity to capreomycin. Renal
function test should be monitored weekly and hepatic function
should be monitored periodically.
Drug interactions: use of other nephrotoxic and/or ototoxic
drugs including aminoglycosides (e.g., Streptomycin), colitsin,
polymyxin B, and vancomycin.
Side effects: ototoxicity, tinnitus, nephrotoxicity, eosinophilia,
acute tubular necrosis, Bartters syndrome, hypersensitivity
(urticaria,
rash,
fever),
hypokalemia,
leukocytosis,
hypocalcemia, hypomagnesemia, pain, induration, and bleeding
at injection site, vertigo.
Dose and Administration:IM, I.V: Adult: 15 mg/kg per day
(maximum dose of 1 g). The dose should be reduced for persons
greater than 59 years of age to 10 mg/kg per day (maximum 750
mg). Children: 15 to 30 mg/kg per day (maximum dose 1 g) as
a single daily dose or given twice-weekly
Storage: store at room temperature.
Cycloserine
Capsule, 250 mg
Indications: in combination with other second- line drugs for
treating tuberculosis resistant to first- line agents.
Cautions: epilepsy, depression, severe anxiety, psychosis,
severe renal insufficiency, chronic alcoholism.

445

8. Anti-Infectives

Drug interactions: alcohol, isoniazid, ethionamide and

phenytoin and dosages of anticonvalsanta should be reduced if
necessary..
Contraindications: hypersensitivity to cycloserine.
Side effects: cardiac arrhythmia, drowsiness, headache,
dizziness,
vertigo,
seizure,
confusion,
psychosis,
hyperirritability, paresthesias,, dysarthria paresis, coma, rash,
vitamin B12 deficiency, folate deficiency, liver enzymes
increased, tremor.
Dose and Administration:Oral:Adult: Initial: 250 mg every
12 hours for 14 days, then administer 500 mg to 1g/day in 2
divided doses for 18 - 24 months (maximum daily dose: 1
g).Child: 10 - 20 mg/kg/day in 2 divided doses up to 1000
mg/day for 18 - 24 months.
Note: The dosage of cycloserine in patients with renal impairment
must be adjusted according to the degree of dysfunction and blood
cyclserine concentrations.

Storage:store at room temperature

Ethambutol
Tablet, 100mg, 400mg
Indications: tuberculosis, in combination with other drugs (see
notes above)
Cautions:
visual
disturbances,ocular
examination
recommended before and during treatment; reduce dose and
monitor
plasma
concentration:
elderly;
pregnancy;
breastfeeding.
Contraindications: optic neuritis, poor vision, children under at
least 6 years of age, renal impairment
Side effects: optic neuritis, red/green colour blindness,
peripheral neuritis, rarely rash, pruritus, uriticaria, and
thrombocytopenia.
446

8. Anti-Infectives

Dose and Administration:Initial phase of combination therapy;

see notes above): Oral: 15mg/kg (15-20 mg/kg) daily,
maximum 1600mg.
Storage: at room temperature, in a well-closed container.
Protect from light, moisture, and heat.
Ethambutol + Isoniazid
Tablet, 400mg + 150mg
Indications: tuberculosis, in combination with other drugs (see
notes above)
Cautions: see ethambutol and isoniazid
Drug interactions: see ethambutol and isoniazid
Contraindications: preparation not suitable for use in children;
see ethambutol and isoniazid.
Side effects: see ethambutol and isoniazid
Dose and Administration:Tuberculosis, continuation phase of
8 months regimen: Oral: Adult: ethambutol hydrochloride
800mg and isoniazide 300 mg daily.
Storage: at room temperature, in a well closed, light resistant
container.
Ethionamide
Tablet, 250 mg
Indications: treatment of drug resistant tuberculosis in
conjunction with at least 2, preferably 3 (new drugs known to be
active against the resistant strain) other antituberculosis agents.
Cautions: depression, psychiatric illness, chronic alcoholism,
epilepsy, hypothyroidism, diabetes.
Drug interactions: isoniazide, cycloserine and terizidone.
Contraindications: hypersensitivity, severe hepatic disease.
Side effects: nausea, vomiting, anorexia, metallic taste,
abdominal discomfort, diarrhoea and weight loss, seizures,
447

8. Anti-Infectives

pellagra-like encephalopathy responsive to niacin, acute

psychosis, anxiety and depression, optic neuritis, and peripheral
neuropathy responsive to pyridoxine, hepatotoxicity.
Dose and Administration:Oral:Adult: 15 - 20 mg/kg/day as a
single dose; Maximum 1 g/day.Child: 10 -20 mg/kg/day in 2 3
divided doses after meals or 15mg/kg once daily.
Storage: store at room temperature.
Isoniazid
Tablet, 100mg, 300mg
Injection, 100mg/ml in 10ml ampoule
Oral liquid, 50mg/5ml
Indications: tuberculosis treatment, in combination with other
drugs (see notes above); tuberculosis prophylaxis
Cautions: hepatic impairment (need monitoring of liver
function); renal impairment; slow acetylator status (increased
risk of side effects); epilepsy; history of psychosis; alcohol
dependence, malnutrition, diabetes mellitus, HIV infection (risk
of peripheral neuritis); pregnancy and breast-feeding; porphyria.
Drug interactions: carbamazepine, ethosuximide, Phenytoin,
Serotonergic agents, other drugs (aluminium hydroxide:
Isoniazid should be administered at least one hour before the
antacid)
Contraindications:Hepatic impairement. Prophylaxis with
isoniazid is contraindicated for patients who have active hepatic
disease or who have had reactions to the drug. In pregnant
women, prophylaxis usually should be delayed until after
delivery.
Side effects: nausea, vomiting, constipation, dry mouth;
peripheral neuritis with high doses ( need pyridoxine
prophylaxis), optic neuritis, convulsions, psychotic episodes,
vertigo;
hypersensitivity
reactions
including
fever,
448

8. Anti-Infectives

erythemamultiforme, purpura; blood disorders including

agranulocytosis, haemolytic anaemia, aplastic anaemia; hepatitis
(especially over age of 35 years); systemic lupus erythematosuslike syndrome, pellagra, hyperreflexia, difficulty with
micturation, hyperglycaemia, and gynaecomastia reported.
Dose
and
Administration:Tuberculosis,
treatment
(combination therapy; see also notes above): Oral: 5mg/kg (4-6
mg/kg) daily (maximum, 300 mg daily)
Tuberculosis, treatment in critically ill patients unable to take
oral therapy (combination therapy): IM: Adult: 200 - 300 mg
as single daily dose; Child: 10 - 20 mg/kg daily.
Tuberculosis, prophylaxis: Oral: Adult: 300mg daily for at least
6 months; child 5mg/kg daily for at least 6 months.Note: isoniazid
should be taken on an empty stomach; if taken with food to reduce
gastrointestinal irritation, oral absorption and bioavailability may be
impaired.Pyridoxine should be coadministered in individuals susceptible to
isoniazid-induced neuropathy.

Storage: at room temperature, in a well closed, light resistant

containers.
Kanamycin
Injection, 1g/vial
Indications: in combination with other secondline drugs for
treating tuberculosis resistant to first line agents.
Cautions:renal impairment, drug should be discontinued if
signs of ototoxicity, nephrotoxicity, pregnancy and lactation.
Drug interactions:amphotericin, neuromuscular blocking
agents.
Contraindications:hypersensitivityto kanamycin sulfate.
Dose and Administration: standardized or individually
adjusted on the basis of result of sensitivity test, pretreatment
body weight and renal status.Adult and child above 15 years:
15mg/kg, daily (up to 1g) given as a single daily dose 5 to 7
449

8. Anti-Infectives

times weekly for the 2 to 4 months or until culture conversion

where dosage can then be reduced to 15mg/kg daily (up to 1 g)
2 0r 3 times weekly, in older age of more than 59 years 10
mg/kg is recommended up to 750mg daily dose recommended.
Pediatric dosage (younger than 15 years): 15 to 30mg/kg daily
(up to 1 g) given once daily or twice weekly.
Storage: at 20-250c
Levofloxacin
Tablet, 250mg, 500mg and 750mg
Infusion, 5mg/ml
Indications:in combination with other secondline drugs for
treating tuberculosis resistant to first line agents.
Cautions: not recommended in children < 18 years of age.CNS
disorders or renal dysfunction, history of prolongation QT
interval, peripheral neuropathy.
Drug interactions: warfarin, class IA and class III
antiarrhythmics, erythromycin, cisapride, antacids, oral
electrolyte supplements, quinapril, sucralfate and some
didanosine formulations, cimetidine, corticosteroids, digoxin,
(iron, multivitamins, mineral supplements: administer
levofloxacin at least two hours before or two hours after),
antidepressants and antidiabetic agents, NSAIDs, probenecid,
theophylline.
Contraindications: hypersensitivity reactions to levofloxacin
or other quinolones.
Side effects: dizziness, fever, headache, insomnia, abdominal
pain, dyspepsia, nausea, vomiting, diarrhea, constipation,
decreased vision, pharyngitis, dyspnea.
Dose and Administration: standardized or individually
adjusted on the basis of result of sensitivity test
Storage: store at room temperature.
450

8. Anti-Infectives

Moxifloxacin Hydrochloride
Tablet, 200mg, 400mg
Injection, 200mg/100ml
Indications: in combination with other second line drugs for
treating tuberculosis resistant to first line agents
Cautions: Safety and efficacy not established in children or
adlolescent younger than 18 years of age or in pregnanat or
lactating woman. CNS disorders, prolongation of QT interval,
peripheral neuropathy.
Drug interactions: class IA and class III antiarrhythmics,
antacids (at least four hours before or eight hours after antacids
that contain aluminium or magnesium), quinapril, sucralfate,
didanosine (at least four hours before or eight hours after
buffered didanosine), cimetidine, corticosteroids, (iron,
multivitamins, mineral supplements: administer moxifloxacin at
least four hours before or eight hours after this preparation
except calcium supplements), corticosteroids (increase the risk
os fevere tendon disorder).
Contraindications: known hypersensitivity to moxifloxacin or
other quinolones, or any ingredient in the formulation.
Side effects: Tendinopathy and tendon rapture, dizziness,
seizure, confussion, tremor, hallucination, clostridium diffcile
associated diarrhea (pseodu membraneous colitis).
Dose and Administration:Adult and children 15 years of age
or older receive 400 mg once daily. Intermittent regimen of
moxifloxacin 400mg once daily (5 days per week) or 400 mg 3
times weekly is also used.
Storage: follow manufacturers advice
Para-Amino Salicylic Acid (PAS)
Sachet, 4mg
451

8. Anti-Infectives

Indications:is a second-line Anti-TB agent. Its importance in

the management of pulmonary and other forms of tuberculosis
has markedly decreased since more active and better-tolerated
drugs
have
been
developed.
Side effects: Gastrointestinal problemsincluding anorexia,
nausea, epigastric pain, abdominal distress, and diarrheaare
predominant and often limit patient adherence. Patients with
peptic ulcers tolerate the drug especially poorly.
Hypersensitivity reactions to aminosalicylic acid are seen in 5%
to 10% of patients. High fever may develop abruptly, with
intermittent spiking, or it may appear gradually and be lowgrade. Generalized malaise, joint pains, and sore throat may be
present at the same time. Skin eruptions of various types appear
as isolated reactions or accompany the fever. Among the
hematological abnormalities that have been observed are
leukopenia, agranulocytosis, eosinophilia, lymphocytosis, an
atypical mononucleosis syndrome, and thrombocytopenia.
Acute hemolytic anemia may appear in some instances.
Dosage and administration: It is administered orally in a daily
Adult dose of 10 to 12 g with the daily dose being divided into 2
to 4 equal portions. Children should receive 150 to 300 mg/kg
per day in 3 to 4 divided doses. Note: it is a gastric irritant; the
drug is best administered after meals.

Protionamide
Tablet, 250 mg
Indication: Treatment of multibacillary leprosy (in combination
with dapsone and rifampicin), to prevent emergence of drug
resistance.
Cautions: Liver function tests must be performed at the start of
treatment and repeated periodically throughout.
452

8. Anti-Infectives

Contraindications: - Known hypersensitivity, Hepatic

dysfunction, Pregnancy.
Side effects: Gastrointestinal disturbanes, allergic reactions,
alopecia, convulsions, dermatitis, diplopia, dizziness, headache,
hypotension, peripheral neuropathy and rheumatic pains. Liver
dysfunction and toxic hepatitis may occur.
Dosage and administration: Adults and children: 5.0 mg/kg
daily (usual adult dose 250-375 mg).
Storage:Protionamide tablets should be kept in tightly closed
containers protected from light.
Pyrazinamide
Tablet, 400mg, 500mg, 750mg
Indication: tuberculosis, in combination with other drugs (see
notes above)
Cautions: hepatic impairment (dose related: need monitoring of
hepatic function); renal impairment; diabetes mellitus (monitor
blood glucose - may change suddenly); increased uric acid level
in urine; breast-feeding.
Note: Patients or their carers should be told how to recognize signs of
liver disorders and advised to discontinue treatment and seek
immediate medical attention if symptoms such as persistent nausea,
Vomiting, malaise or jaundice develop.

Drug interactions: uricosurics (probenecid, sulfinpyrazone)

Side effects: hepatotoxicity including fever, anorexia,
hepatomegaly, jaundice, liver failure; nausea, vomiting;
arthralgia; gout; thrombocytopenia, sideroblastic anaemia;
urticaria; skin flushing.
Contraindications: severe hepatic impairment; porphyria, acute
gout, hypersensitivity to pyrazinamide.

453

8. Anti-Infectives

Dose and Administration:Tuberculosis (initial phase of

combination therapy):Oral: 25-mg/kg (20-30mg/kg) daily,
maximum 2000mg per day
Storage: at room temperature, in a well closed container.
Rifabutin
Capsule, 150 mg
Indications: treatment of pulmonary tuberculosis in
combination with other agents. Prophylaxis of M. aviumintracellularecomplex (MAC); treatment of non-tuberculous
mycobateria
Cautions: severe hepatic or renal dysfunction.
Drug interactions: clarithromycin, azithromycin, ciprofloxacin,
fluconazole, isoniazid, protease inhibitors (PIs), non nucleoside
riverse transcriptase inhibitors (NNRTIs). Hematologic status
should be monitored periodically during therapy with this drug.
Contraindications: hypersensitivity to rifamycins, neutropenia or
other hematologic effects (thrombocytopenia).
Side effects:rash, gastrointestinal intolerance (nausea, vomiting,
anorexia, abdominal pain and diarrhea), headache, insomnia,
seiszure, parasthesia, aphasia, confusion, and hematological
effects (leucopenia, neutropenia, thrombocytopenia and
anemia), hepatotoxicity. Hypersensitivity reactions (flu-like
syndrome, chest pain, eosinophilia, bronchospasm, shock) are
reported rarely, oveitis (may be unilateral or bilateral).
Dose and Administration:Oral: Adult 15 years of age or
lder:Tuberculosis, in combination with other antituberculosis
agent: 5mg/kg (up to 300mg) given once daily or 5mg/kg 2 or 3
times weekly daily.
Pediatrics: 10-20mg/kg (up to 300mg) can be given daily or
twice weekly.Non- tuberculous mycobacteria treatment: 450 454

8. Anti-Infectives

600 mg daily.Non-tuberculous mycobacteria prophylaxis: 300

mg daily.
Storage:store at room temperature.
Rifampicin
Capsule, 150mg, 300mg, 600mg
Syrup, 20mg/5ml
Powder for injection (sodium) 300mg, 600mg in vial
Indications: tuberculosis, in combination with other drugs (see
notes above), leprosy.
Cautions: reduce dose in hepatic impairment, liver function
tests and blood counts required in liver disorders, elderly, and
on prolonged therapy; renal impairment (if dose above 600 mg
daily), pregnancy, breastfeeding ,porphyria, discolour soft
contact lenses.
Note: Advise patients on oral contraceptives to use additional
means.Resumption of rifampicin treatment after a long interval may
cause serious immonulogical reactions, resulting in renal impairment,
haemolysis, or thrombocytopenia. Discontinue permanently if serious
adverse effects occur.

Drug
Interactions:clarithromycin,
aminoslicylic
acid,
ciprofloxacin, chloramphenicol, atovaquone, clofazimine,
elalapril, PIs,
NNRTIs,
anticonvulsants,
antifungals,
.azathioprine, ciclosporin, contraceptives, dexamethasone,
fluconazole, fludrocortisone, glibenclamide, haloperidol,
hydrocortisone,, levonorgestrel, , medroxyprogesterone,
nelfinavir, nifedipine, norethisterone, phenytoin, prednisolone,
guanidine, , verapamil, warfarin
Contraindications: hypersensitivity to rifamycins, jaundice,
pregnancy, fertility and lactation.
Side effects: severe gastrointestinal disturbances including
anorexia, nausea, vomiting, diarrhea, rashes, fever, influenza455

8. Anti-Infectives

like syndrome and respiratory symptoms, collapse, shock,

haemolytic anaemia, leucopenia, acute renal failure, and
thrombocytopenic purpura-more frequent with intermittent
therapy, alterations of liver function jaundice and potentially
fatal hepatitis (dose related; do not exceed maximum dose of
600 mg daily); stains body fluid, local sensitivity and
dermatologic reactions (pruiritis, urticarial, pemphigoid
reactions, Steven Jhonson Syndrome, toxic epidermal
nucrolysis, vasculitis), adrenocortical insufficiency.
Dose and Administration:Tuberculosis (combination therapy;
see notes above):Oral: Adult and children 15 years of age or
older:10mg/kg (8 to 12mg/kg) daily (maximum dose, 600mg
daily). Pediatric: 10 to 20mg/kg (up to 600mg) daily.
Note: take dose at least 30 minutes before a meal, as absorption
is reduced when taken with food.
Storage: should be stored at a temperature of 300c (preferably
between 15-300c) or less, in a tight, light - resistant container
Rifampicin + Isoniazid
Tablet,60mg+30mg,150mg
+
100mg,
300mg
+
150mg,150mg+75mg; Capsule, 150mg + 100mg
Indications: Tuberculosis, continous phase for 4 month regimn
Cautions: preparation not suitable for use in children; see under
rifampicin, and isoniazid
Drug interactions, Contraindications, Side effects; see under
rifampicin, and isoniazid
Dose and Administration:Tuberculosis, 6-month regimen
(combination therapy: Oral: 10mg/kg (rifampicin) and 10mg/kg
(isoniazid) 3 times a week.
Rifampicin + Isoniazid + Pyrazinamide
Tablet, 60mg +30mg+150mg, 150mg + 75mg + 400mg
456

8. Anti-Infectives

Indications: tuberculosis, in combination with other drugs.

Cautions; Side effects, Drug interactions; see Rifampicin,
Isoniazid, and Pyrazinamide
Contraindications: preparations not suitable for use in
children; see rifampicin, isoniazid, and Pyrazinamide.
Dose and Administration:Tuberculosis, initial phase of 6 month treatment regimens: Oral: Adult: rifampicin 10mg/kg,
isoniazid 5mg/kg, and Pyrazinamide 25 mg/kg daily or
rifampicin 10mg/kg, isoniazid 10mg/kg and Pyrazinamide
35mg/kg 3 times a week.
Rifampicin + Isoniazid + Pyrazinamide + Ethambutol
Tablet, 150mg + 75mg + 400mg + 275mg
Indications: tuberculosis (see notes above)
Cautions, Side effects, Drug interactions, Contraindications;
see rifampicin, isoniazid,
Pyrazinamide and Ethambutol.
Dose and Administration:Tuberculosis, induction phase of 6month regimen (see notes above): Oral: rifampicin 10mg/kg,
isoniazid 5mg/kg, Pyrazinamide 25mg/kg, and Ethambutol
hydrochloride 15mg/kg daily
Streptomycin Sulphate
Powder for injection, 1g, 0.5g bases in vial
Indications: tuberculosis, in combination with other drugs (see
notes above)
Cautions: children - painful injection, avoid use if
possible,infants, and elderly (dosage adjustment), and monitor
renal, auditory, and vestibular function, and plasma
streptomycin concentrations.
457

8. Anti-Infectives

Drug interactions: alcuronium, ciclosporin, cisplatin,

furosemide, neostigmine, pyridostigmine, suxamethonium, and
vecuronium
Contraindications: hearing disorders; renal impairment,
myasthenia gravis, pregnancy
Side effects: vestibular and auditory damage; nephrotoxicity;
hypersensitivity reactions - withdraw treatment; paraesthesia of
mouth, rarely, hypomagnesaemia on prolonged therapy;
antibiotic associated colitis; also nausea, vomiting, rash; rarely,
haemolytic anaemia, aplastic anaemia, agranulocytosis,
thrombocytopenia; pain and abscess at injection site.
Dose and Administration:Tuberculosis (initial phase of
combination therapy; see notes above): deep IM injection or IV:
Adult: 15mg/kg (12-18mg/kg) daily as a single dose,maximum
1000mg (patients over 60 years may not tolerate doses above
500 to 750mg daily)
Pediatric younger than 15 years of age or weighing 40kg or less:
20-40mg/kg daily (up to 1g).
Storage: at room temperature protect from light.
Note: Reconstituted solutions os streptomycin sulphate are stable for one
week when stored at room temperature and protected from light, however
streptomycin sulfate powder for injection contains no preservatives and the
possibility of microbial contamination of reconstituted solutions must be
considered.

Terizidone
Capsule 250mg
Indication: tuberculosis both pulmonary and extra pulmonary
by resistant strains of mycobacterium TB or avium
Cautions: epilepsy, mental illness especially depression, severe
anxiety, psychosis, severe renal insufficiency, chronic
alcoholism.
458

8. Anti-Infectives

Drug interactions: alcohol, isoniazid, ethionamide and

phenytoin, fluoroquinolones, oral anticoagulants.
Contraindications: hypersensitivity to terizidone.
Side effects: Dizzness, slurred speech, convulsions, headache,
tremor, insomnia, confusion, depression and altered bebavior.
Dosage and administartion: It is available as hard gelatine
capsule of 250 mg each. The usual adult dose is 15 to 20 mg/kg
per day in three to four divided doses. Maximum recomanded
dose is 4 capsules a day i.e 1 gm daily.The maximum daily dose
is 15 to 20 mg/kg, the maximum dose being 750 mg. The daily
dose can be divided into 250 mg in the morning and 500 mg in
the evening.
8.1.10. Antileprotics
Leprosy (Hansen's disease) is a chronic disease caused by
Mycobacterium leprae; it affects the peripheral nervous system,
the skin, and some other tissues. It is transmitted from person to
person when bacilli are shed from the nose and skin lesions of
infected patients, but most individuals are naturally immune,
and symptoms are suppressed. For treatment purposes patients
may be classified as having paucibacillary (PB) or
multibacillary (MB) leprosy. The 2 forms may be distinguished
by skin smears, but facilities are not always available to process
them and their reliability is often doubtful.
Drugs recommended are dapsone, rifampicin and clofazimine.
A three drug regimen is recommended for multibacillary leprosy
and a two drug regimen for paucibacillary leprosy. Any patient
with a positive skin smear should be treated with the multidrug
therapy regimen for MB leprosy. The regimen for PB leprosy
should never be given to a patient with MB leprosy. If
diagnosis in a particular patient is not possible the multi drug
therapy regimen for MB leprosy must be used.
459

8. Anti-Infectives

Multibacillary leprosy (3 drug regimen)Rifampicin: 600mg

once-monthly, supervised (450mg for adults weighing less than
35kg).
Dapsone: 100mg daily, self administered (50mg daily or 1 - 2
mg/kg daily for adults weighing less than 35kg)
Clofazimine: 300mg once - monthly, supervised, and 50mg
daily (or 100mg on alternate days), self-administered.
Multibacillary leprosy should be treated for at least one years.
Treatment should be continued unchanged during both type I
(reversal) and type II (erythema nodosum leprosum) reactions.
During reversal reactions neuritic pain or weakness can herald
the rapid onset of permanent nerve damage. Treatment with
prednisolone (initially 40 to 60mg daily) should be instituted at
once. Mild type II reactions may respond to aspirin or
chloroquine. Severe type II reactions may require
corticosteroids; thalidomide is also useful in men and post
menopausal women who have become corticosteroid dependent,
but it would be used under specialist supervision and it should
never be used in women of child bearing potential (significant
teratogenic risk). Increase doses of clofazimine 100mg 3 times
daily for the first month with subsequent reductions, are also
useful but may take 4 - 6 weeks to attain full effect.
Paucibacillary leprosy (2 - drug regimen):
Rifampicin: 600mg once - monthly, supervised (450mg for
those weighing less than 35kg)
Dapsone: 100mg daily, self-administered (50mg daily or 1-2
mg/kg daily for adults weighing less than 35kg)
Paucibacillary leprosy should be treated for 6 months. If
treatment is interrupted the regimen should be recommended
where it was left off to complete the full courses.Neither the
multibacillary nor the paucibacillary antileprosy regimen is sufficient
to treat tuberculosis.
460

8. Anti-Infectives

Clofazimine
Capsule, 50mg, 100mg
Indications: multibacillary (MB) leprosy; type II lepra
reactions.
Cautions: pre-existing gastrointestinal symptoms (reduce dose,
increase dose interval or discontinue if symptoms develop
during treatment); liver and renal impairment; pregnancy and
breast-feeding; may discolour soft contact lenses.
Note:Patients should be warned that Clofazimine might cause a
reddish - brown discolouration of skin, conjunctiva, tears, sputum,
sweat, urine, and faces.

Side effects: reversible discoloration of skin, hair, cornea,

conjunctiva, tears, sweat, sputum; symptoms including pain,
nausea, vomiting and diarrhoea; severe mucosal and submucosal
oedema with prolonged treatment with high doses - may be
severe enough to cause sub acute small bowel obstruction.
Dose and Administration:Leprosy, see notes above
Lepromatous lepra reactions, dosage increased to 300mg daily
for maximum of 3 months.
Dapsone
Tablet, 25mg, 50mg, 100mg
Injection, 20% in 50ml ampoule
Indications: paucibacillary (PB) and multibacillary (MB)
leprosy (see notes above)
Cautions: cardiac or pulmonary disease; anaemia (treat severe
anaemia before starting); G6PD deficiency (including
breastfeeding affected infants); pregnancy; breast-feeding;
porphyria.
Note: on long term treatment patients and their carers should be told how to
recognize blood disorders and advised to seek immediate medical attention if
symptoms such as fever, sore throat, rash, mouth ulcers, purpura, bruising or
bleeding develop.

461

8. Anti-Infectives

Drug interactions:rifamycins, amprenavir, and probenecid.

Contraindications: hypersensitivity to sulfones; severe
anaemia.
Side effects: (dose-related and uncommon at doses used for
leprosy), haemolysis, methaemoglobinaemia, neuropathy,
allergic dermatitis (rarely including toxic epidermal necrolysis
and Stevens-Johnson syndrome), anorexia, nausea, vomiting,
tachycardia, headache, insomnia, psychosis, hepatitis,
agranulocytosis; dapsone syndrome (rash with fever and
eosinophilia)-discontinue immediately (may progress to
exfoliative dermatitis, hepatitis, hypoalbuminaemia, psychosis
and death)
Dose and Administration:Leprosy: 1 - 2mg/kg daily, see notes
above
Storage: at room temperature, in a well - closed, light - resistant
containers.
Rifampicin
Capsule, 150mg, 300mg, and 600mg
Indications:Paucibacillary leprosy; multibacillary leprosy;
tuberculosis (section 7.1.3)
Cautions, Drug interactions, Side effects, Contraindications;
see under section 7.1.3
Dose and Administrations: see notes above.
8.2. Antifungals
Fungal infections may be classified as superficial, affecting only
the skin, hair, nail, or mucous membranes, or systemic, affecting
the body as a whole; systemic infections tend to occur more
frequently in immunocompromised individuals such as those
with AIDS.
462

8. Anti-Infectives

Drugs used in fungal infections:Polyene antifungals: The

polyene antifungals include amphotericin and Nystatin; neither
drug is absorbed when given by mouth. They are used for oral,
oropharyngeal, and perioral infections by local application in
the mouth.Nystatin is used principally for candida albicans
infections of the skin and mucous membranes, including
esophageal and intestinal candidiasis.Amphotericin B is active
against most fungi and yeasts. It is the drug of choice for most
serious systemic mycotic infections.
Imidazole Antifungals: among the imidazole antifungal,
Ketoconazole is better absorbed by mouth than other
imidazoles. It has been associated with fatal hepatotoxicity;
prescribers should weigh the potential benefits of ketoconazole
treatment against the risk of liver damage and should carefully
monitor patients both clinically and biochemically. It should not
be used for superficial fungal infections.Miconazole is grouped
in imidazole antifungals. Miconazole can be used locally for
oral infections; it is also effective in intestinal infections.
Systemic absorption may follow use of miconazole oral gel and
may result in significant drug interactions.
Triazole Antifungals: Fluconazole is very well absorbed after
oral administration. It also achieves good penetration into the
cerebrospinal fluid to treat fungal meningitis. Itraconazole is
indicated
for
mucocutaneous
candidiasis
and
in
dermatomycoses unresponsive to conventional therapy. It is also
used in the treatment of histoplasmosis, blastomycosis and
invasive aspergillosis.
OtherAntifungals: Griseofulvin is effective for widespread or
intractable dermatophyte infections but has been superseded by
newer antifungals, particularly for nail infections. It is usually
well tolerated and is licensed for use in children. Duration of
therapy is dependent on the site of the infection and may be
463

8. Anti-Infectives

required for a number of months.Flucytosine is a synthetic

fluorinated pyrimidine with a narrow spectrum of antifungal
activity, particularly against cryptococcus and candida spp. In
susceptible fungi, it is converted to fluorouracil by cytosine
deaminase. Flucytosine is myelosuppressive and plasma
concentrations above 75mcg/ml are associated with
myelotoxicity.
Amphotericin B
Powder for injection, 10mg, 50mg in vial
Lozenges, 10mg
Indications: the drug of choice for most severe systemic
mycoses such as disseminated candidiasis, cryptococcosis,
mucormycosis, histoplasmosis, extracutaneous sporotrichosis
and blastomycosis. Also used in leishmaniasis (see section
7.4.3)
Cautions: when given parenterally, toxicity common (close
supervision necessary and test dose required); renal
impairment; hepatic and renal function test, blood counts, and
plasma electrolyte monitoring required; corticosteroids (avoid
except to control reactions); pregnancy and breast-feeding;
avoid rapid infusion (risk of arrhythmias).
Drug
interactions:
cardiac
glycosides,
ciclosporin,
corticosteroids, tacrolimus.
Contraindications: hypersensitivity to amphotericin.
Side effects: when given parenterally, anorexia, nausea and
vomiting, diarrhea, epigastric joint pain, anaemia; disturbances
in renal function (including arrhythmias), blood disorders,
neurological disorders (including hearing loss, diplopic,
convulsions, peripheral neuropathy), abnormal liver function
(discontinue treatment), rash, anaphylactoid reactions; pain and
thrombophlebitis at injection site.
464

8. Anti-Infectives

Dose and Administration: Adult:The dose and duration of

therapy depend on the infecting organism. The daily dose must
not exceed 1.5mg/kg. The following have been
suggested.Extrapulmonary cryptococcosis:IV infusion: 0.7
mg/kg/day for 4-8 weeks.Invasive candidiasis:IV infusion: 0.6
mg/kg/day; duration of therapy should be 2 weeks after
resolution of clinical features and candidaemia, but longer
courses are recommended for neutropenic patients and
endocarditis.
Candidaemia (in patients without neutropenia):IV infusion: 0.50.6mg/kg/day until at least 14 days after resolution of signs/last
positive deep-site culture.
Mucormycosis or invasive aspergillosis: IV infusion: 1 to 1.5
mg/kg/day; total dose 2.5-3g.
Lozenges: Suck 1, slowly, 4 times daily; up to 8 times daily in
severe conditions.
Clotrimazole
Powder, 1%
Mouth paint, 1%
Indications: fungal skin infections; vaginal candidiasis; otitis
externa
Cautions: Pregnancy, contact with eyes and mucous
membranes should be avoided.
Drug interactions: Benzodiazepines,calcium channel blockers,
cisapride, cyclosporine, ergot derivatives, selected HMG-CoA
reductase inhibitors, mesoridazole, mirtazapine, nateglinide,
nefazodone, pimozide, quinidine, sildenafi, tacrolimus,
thioridazine, venlafaxine,and other CYP3A4 substrates.
Contraindications: Hypersensitivity to clotrimazole or any
component of the formulation.
465

8. Anti-Infectives

Side-effects: Occasional local irritation and hypersensitivity

reactions include mild burning sensation, erythema, and itching.
Treatment should be discontinued if these are severe.
Dose and administration: Apply 23 times daily
Fluconazole
Capsule/tablet, 50mg, 100mg, and 200mg
Oral Suspension, 50mg /5ml, 200mg /5ml
Indications: vaginal and oropharyngeal candidiasis not
responding to topical therapy; oesophageal and systemic
candidiasis; cryptococcal meningitis and maintenance therapy to
prevent relapse of cryptococcal disease in patients with AIDS.
Cautions: renal or hepatic impairment.
Drug interactions: enzyme-inducing agents (e.g rifampicin),
hydrochlorthiazide, phenytoin, sulphonylureas, hypoglycemic
agents, cyclosporin, nortriptyline, and zidovudine, terfenadine,
oral anticoagulants and theophylline.
Contraindications:hypersensitivity to other azole antifungals.
Side effects: nausea, abdominal discomfort, diarrhoea,
flatulence, headache, rash (discontinue treatment or monitor
closely if infection invasive or systemic); less frequently
dyspepsia, vomiting, taste disturbance, abnormalities of liver
enzymes, angioedema, dizziness, seizures, alopecia, pruritus,
toxic epidermal necrolysis, and Stevens Johnson syndrome
reported, severe cutaneous reactions in AIDS patients also
reported.
Dose and Administration: Adult: Vaginal candidiasis:Oral:
150mg as a single dose.Oropharyngeal candidiasis:Oral: 50100mg daily for 7-14 days.
Oesophageal candidiasis:Oral: 100-200mg daily for 14-28
days.Systemic
candidiasis:Oral
or
IV:
400mg
daily.Cryptococcal meningitis:Oral or IV: 400mg daily for 8-10
466

8. Anti-Infectives

weeks, prevention of relapse in patients with AIDS, 200mg

daily.Child: Oropharyngeal candidiasis:Oral or IV: 3-6 mg/kg
on the first day, then 3 mg/kg/day.Systemic candidiasis,
cryptococcal
meningitis:Oral
or
IV:
6-12mg/kg/day
daily.Prevention of fungal infections in immunocompromised
patients following cytotoxic chemotherapy or radiotherapy; 3 to
12 mg/kg/day, depending on extent and duration of neutropenia
Storage: store tablets and powder for oral suspension below
30C. Reconstituted suspension and fluconazole injection should be
stored at 5C - 30C. Do not freeze reconstituted suspension or
intravenous infusion.

Fluconazole in Sodium Chloride

IV infusion 2mg+9mg/ml
See fluconazole above
Flucytosine
Capsule, 250mg, 500mg
IV infusion, 10 mg/ml
Solution for Injection, 2.5 g/250 ml
Indications: adjunct to amphotericin B (or fluconazole) in
cryptococcal meningitis and in systemic candidosis.
Cautions: elderly, renal impairment, pregnancy and breastfeeding.
Drug interactions: amphotericin, cytarabine.
Contraindications: hypersensitivity to flucytosine.
Side effects: rash, nausea, vomiting, diarrhea, alterations in
liver function tests; less frequently, confusion, hallucinations,
convulsions, headache, sedation, vertigo, blood disorders
including leukopenia, potentially fatal thrombocytopenia and
aplastic anemia.
467

8. Anti-Infectives

Dose and Administration:Adult and Child:Systemic

candidosis and cryptococcosis:IV infusion: (over 20 - 40
minutes), 200 mg/kg daily in 4 divided doses, for usually no
more than 7 days (at least 4 months in cryptococcal meningitis);
extremely sensitive organisms, 100 - 150 mg/kg daily in 4
divided
doses.
Systemic candidosis: initial treatment or after IV therapy, Oral:
50 - 150 mg/kg daily in 4 divided doses.
Storage: store in airtight containers and protect from light. I.V
infusion should be stored between 18oC and 25oC.
Griseofulvin
Tablet, 125mg, 250mg, 500mg
Suspension, 125mg / 5ml
Indications: dermatophyte infections of the skin, scalp, hair and
nail where topical therapy has failed or is inappropriate.
Cautions: rarely aggravation or precipitation of systemic lupus
erythematosus; breast-feeding; griseofulvin may impaired the
ability to drive or operate machinery, see also drug interaction.
Drug interactions: phenobarbitone, coumarin anticoagulants
and oral contraceptives, aspirin.
Contraindications: patients with porphyria and liver failure,
lupus erythematosus and related conditions, pregnancy (avoid
pregnancy during and for 1 month after treatment, men should
not father children with in 6 months of treatment).
Side effects: side effects are usually mild and transient and
consist of headache, skin rashes, dryness of the mouth an altered
sensation of taste, and gastro-intestinal disturbances;
angioedema, erythemamultiforme, toxic epidermal necrolysis,
proteinuria, leucopoenia and other blood dyscrasias, candidaisis,
paraesthesia, photosensitization, and severe headache have been
reported occasionally. Depression, confusion, dizziness,
468

8. Anti-Infectives

insomnia, and fatigue. Griseofulvin may precipitate or aggravate

systemic lupus erythematosus.
Dose and Administration:Adult: Oral: 500mg daily, in divided
doses or as a single dose, in severe infection dose may be
doubled reducing when response occurs;
Child: 10mg/kg daily in divided doses or as a single dose.
Storage: at room temperature, in a tight container.
Itraconazole
Capsule, 100 mg, 200 mg
Oral solution, 10 mg/ml.
Indications: vulvovaginal, oropharangeal or oesophageal
candidiasis and dermatomycoses, not responding to
conventional therapy. Useful for endemic mycoses, e.g.
histoplasmosis, and may be an effective alternative to
amphotericin B for aspergillosis.
Cautions: hepatic disease.
Drug interactions: antacids, sucralfate, H2-receptor antagonists
(cimetidine), didanosine, carbamazepine, phenytoin, rifampicin,
ciclosporin, cisapride, terfenadine, digoxin, indinavir, ritonavir,
midazolam, triazolam, warfarin.
Contraindications: hypersensitivity to any azole antifungal.
Side effects: skin rash, gastrointestinal disturbances (nausea,
diarrhea, abdominal pain, dyspepsia, vomiting, constipation,
anorexia) and headache; transient increase in liver enzymes and
rarely, hepatitis.
Dose and Administration: Oral: Adult: Vulvovaginal
candidiasis: 200 mg morning and evening for 1 day.
Oropharyngeal candidiasis: 100 mg (200 mg in AIDS or
neutropenia) daily for 15 days.
Oropharyngeal and Oesophageal candidiasis in HIV infection:
solution: 200 mg daily (given as 1 or 2 doses) for 1 to 2 weeks;
469

8. Anti-Infectives

solution held in the mouth before swallowing. Dose may be

doubled in resistant cases.
Systemic mycoses: 200 - 400 mg daily in single or 2 divided
doses.
Tinea Corporis, tinea cruris: 100 mg daily for 15 days.
Tinea pedis, tinea manuum: 100 mg daily for 30 days.
Storage: Capsule: store at room temperature; protect from light
and moisture. Oral solution: store at 25 oC; do not freeze.
Ketoconazole
Tablet, 200mg
Syrup, 20mg /5ml
Indications: in chronic mucocutaneous candidiasis, fungal
infections of the gastro intestinal tract, and dermatophyte
infections of the skin and fingernails. It is also used for the
treatment of systemic blastomycosis,
candidiasis,
coccidioidomycosis,
histoplasmosis,
&
aracoccidioidomycosis.
Cautions: during breast-feeding, in pediatrics and geriatrics,
alchlorhydria, hypochlorhydria, alcoholism, renal function
impairment
Drug interactions: antimuscarinic agents, antacids H2 receptors antagonists (note: patients should be advised to take
these medications at least 2 hours after taking ketoconazole);
rifampicin, isoniazid, phenytoin, astemizole, terfenadine,
cisapride, corticosteroids, cyclosporin, oral anticoagulants,
alcohol, oral contraceptives, tolbutamide, sucralfate, midazolam
and triazolam, didanosin, digoxin and indinavir.
Contra indications: pre-existing liver disease, pregnancy;
concurrent use of astemizole, cisapride and terfenadine with
ketoconazole is contra indicated; hypersensitivity to azole
antifungals
470

8. Anti-Infectives

Side effects: gastro intestinal disturbance, gynaecomastia,

impotence, menstural irregularities, oligospermia, azoospermia,
decreased male libido, liver toxicity, and adrenal cortex
suppression.
Dose and Administration: Oral:Adult: Candidiasis,
vulvovaginal: 200 to 400mg once a day for five days.
Carcinoma, prostatic: 400mg three times a day.
Cushings syndrome: 600 mg to 1.2 grams a day.
Paronychia: 200 to 400 mg once a day.
Pityriasis versicolor: 200 mg once a day for five to ten days.
Pneumonia,fungal or septicemia, fungal: 400 mg to 1 gram once
a day.For all other antifungal indications: 200 to 400 mg once a
day.Child: Candidiasis, vulvovaginal: Child 2 years of age and
older: 5 to 10 mg per kg of body weight once a day for five
days.Infants and Child up to 2 years of age: Dosage has not
been established.Paronychia or Penicillin marneffei infection or
pneumonia, fungal or septicemia, fungal: children 2 years of age
and older: 5 to 10 mg per kg of bodyweight once a day.Infants
and Child up to 2 years of age: Dosage has not been established.For
all antifungal indications: Child 2 years of age and older: 3.3 to
6.6 mg per kg of body weight once a day.
Note: Advise the patient to take the medication with food to increase
absorption, and to avoid alcoholic beverages.

Storage: in a wellclosed container at room temperature.

Miconazole
Tablet, 250 mg
Oral Gel, 25mg /ml
Intravenous infusion, 10 mg/ml in 20 ml
Indications: in the treatment of mucocutaneous candidiasis,
dermatophytosis, and pityriosis versicolor.

471

8. Anti-Infectives

Cautions: pregnancy and breast feeding; avoid in porphyria,

haematocrit, haemoglobin and serum electrolytes and lipids
should be monitored regularly; see also interactions.
Drug interactions: oral anticoagulants, sulphonylurea
hypoglycaemic drugs, or phenytoin (miconazole enhance the
activity of these drugs); amphotericin
Contraindications: hepatic impairment
Side effects: nausea, vomiting and diarrhea (usually on longterm treatment); rarely allergic reactions; isolated reports of
hepatitis.
Dose and Administration:Prevention and treatment of oral
and intestinal fungal infections 125 to 250 mg as tablet or 5 - 10
ml oral gel in the mouth after food 4 times daily, keep in oral
cavity near lesions before swallowing; child under 2 years,
62.5mg as tablet or 2.5ml twice daily; 2 - 6 years 125mg of
tablet or 5ml oral gel twice daily; over 6 years, 125mg of tablet
or 5ml oral gel 4 times daily.Systemic fungal infections:Adult:
IV: range from 0.2 to 1.2 g three times daily. Each dose must be
diluted in at least 200 mL of sodium chloride 0.9% or glucose
5% and infused slowly over 30 to 60 minutes. Child: IV: 20 to
40 mg/kg body-weight daily (intravenously) but not more than
15 mg/kg of miconazole should be given at each infusion.
Storage: at room temperature.
Nystatin
Tablet, 500,000IU
Oral suspension, 100,000 units/ml
Indications: prophylaxis and treatment of candidasis of skin
and mucous membranes.
Side effects: nausea, vomiting, and diarrhea; Steven Johnson
syndrome, irritation.
472

8. Anti-Infectives

Dose and Administration: Oral:Adult:intestinal candidiasis:

500, 000 unit every 6 hours, doubled in severe infections;
Child: 100,000 units 4 times daily prophylaxis, 1 million units
once daily Neonate: 100,000 units once daily.
Storage: at room temperature in a tight light resistant container.
Sertaconazole Nitrate
Skin cream, 2%
Indication: tinea pedis, tinea corporis, tinea cruris, tinea
manuum, pityriasis (tinea) versicolor.
Cautions: elderly, breast feeding, children younger than 12
years of age.
Contraindications: hypersensitivity to sertaconazole nitrate,
other imidazole derivatives, or any ingredient in the formulation
Side effects: contact dermatitis, dry skin, burning skin,
application site reaction and skin tenderness.
Dose and Administration:Apply twice daily for 4 weeks, for
topical use only.
Storage: store at room temperature
Terbinafine HCL
Tablet 125mg, 150mg, 250 mg
Indications: dermatophyte infections of the nails, ringworm
infections (including tinea pedis, cruris, and corporis) where
oral therapy appropriate (due to site, severity or extent)
Cautions: pregnancy; psoriasis (risk of exacerbation);
autoimmune disease (risk of lupus-erythematosus-like effects
Contraindications: hepatic impairment; breast feeding
Renal impairment: use half normal dose if eGFR less than
50 mL/minute/1.73 m2 and no suitable alternative available.
Side effects: abdominal discomfort, anorexia, nausea,
diarrhoea; headache; rash and urticaria occasionally with
473

8. Anti-Infectives

arthralgia
or
myalgia; less
commonlytaste
disturbance;
rarely liver toxicity (including jaundice,
cholestasis and hepatitis)discontinue treatment, angioedema,
dizziness,
malaise,
paraesthesia,
hypoaesthesia,
photosensitivity; very rarely psychiatric disturbances, blood
disorders (including leucopenia and thrombocytopenia), lupus
erythematosus-like effect, exacerbation of psoriasis, serious skin
reactions (including Stevens-Johnson syndrome and toxic
epidermal necrolysis)discontinue treatment if progressive
skin rash; also reported, pancreatitis, vasculitis, influenza-like
symptoms, rhabdomyolysis, disturbances in smell.
Dose and administration:By mouth: 250 mg daily usually for
26 weeks in tinea pedis, 24 weeks in tinea cruris, 4 weeks in
tinea corporis, 6 weeks3 months in nail infections
(occasionally longer in toenail infections); child:usually for 4
weeks, tinea capitis, over 1 year, body-weight 1020 kg,
62.5 mg once daily; body-weight 2040 kg, 125 mg once daily;
body-weight over 40 kg, 250 mg once daily
8.3. Antivirals
8.3.1. Anti-Retroviral (ARV) Agents
Currently there are six categories of ARVs. Namely, nucleoside
analogue reverse transcriptase inhibitors (NRTIs), non
nucleoside analogue reverse transcriptase inhibitors (NNRTIs),
protease inhibitors (PIs),intigerase inhibitors (IIs) , chemokine
receptor 5 (CCR5) inhibitors and fusion inhibitors (FIs).
Highly active antiretroviral therapy (HAART) is the use of a
combination of three or more antiretrovirals to achieve durable
suppression of replication.
As HIV mutates rapidly and there is a high viral turnover;
inappropriate drug prescribing may cause rapid development of
drug resistance.
474

8. Anti-Infectives

Response to therapy may be measured virologically (by serial

monitoring of viral load), immunological (by serial monitoring
of CD4 or total lymphocyte count) or clinically. Viral load
monitoring is the only way to detect the emergence of
resistance.
The Ethiopian national ARV guideline (see the latest
guideline)suggests that treatment should be commenced in a
symptomatic HIV-positive patient (WHO stage 3 or 4) or in
patients with a CD4 count of < 300 cells/mm3. It can be also
initiated in stage II when the total lymphosite count drops below
1200/mm3 in settings where there is no CD4 count.
In Ethiopia, HIV regimens are classified as first line (preferred
and alternative) and second line regimens. The first line
regimens consist of either the loose ARVs or fixed dose
combinations (FDCs) of two NRTIs and an NNRTI (either NVP
or EFV). The second line regimens are used in circumstances
when there is treatment failure which consisted use of either
loose copounds or FDCs of two or three NRTIs and a protease
inhibitor (PI).
Post Expoure prophylaxis (PEP): To be effective treatment has
to commence as soon as possible (within 1 to 2 hours, postexposure). However, the maximum delay for initiation of
treatment, which would prevent infection, is not known in
humans. Do not consider PEP beyound 72 hours post exposure.
Prophylaxis is to be given for 28 days.
Mother to Child Transmission (MTCT): ARVs prevent
transmission of HIV from mother to infant. Several
antiretroviral regimens using zidovudine, zidovudine plus
lamivudine, nevirapine, or HAART showed to reduce perinatal
transmission. There are threee circumstances for ARV drugs
during pregnancy. These include Women who become pregnant
while on ART, Pregnant women eligible for ART and Pregnant
475

8. Anti-Infectives

women not eligible for ART. The first scenario the mother
should continue the regimens unless there is a need for
substituting EVZ with NVP, incase of second scenario the
mother should put on ART according to clinical satging and in
case of the third scenario the mother should put on PMTCP
according to the national PMTCT guideline. In all the three
clinical scenarios for the use of ARVs in pregnant mothers,
ARV prophylaxis should be administered to the newborn, based
on the national PMTCT guidelines.
Nucleoside Reverse Transcriptase Inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs) are
nucleoside analogues, which act as false substrates for reverse
transcriptase and terminate the DNA chain. Currently available
NRTIs are abacavir (ABC), didanosine (ddI), lamuvidine (3TC),
zalcitabine (ddc) and zidovudine (AZT or ZDV),emticitabine
(FTC) and tenofovir (TDF).
Regimens: Dual NRTI is the conventional backbone of triple
therapy. Selection of a dual NRTI combination must avoid
cross-resistance and antagonism. According to national ARV
guideline combinations.
Start one of the following regimens in ART-naive individuals
eligible for treatment. AZT + 3TC + EFV; AZT + 3TC + NVP;
TDF + 3TC (or FTC) + EFV; TDF + 3TC (or FTC) + NVP
(Strong recommendation, moderate quality of evidence). Certain dual
NRTI backbone combinations should not be used in three-drug
therapy. These are d4T + AZT (proven antagonism), d4T + ddI
(overlapping toxicities) and 3TC + FTC (interchangeable, but
should not be used together).
Preferred first-line ART in treatment-naive adults and
adolescents:Adults and adolecents: AZT or TDF + 3TC or FTC
+ EFV or NVP. Pregnant women: AZT + 3TC + EFV or NVP.
476

8. Anti-Infectives

HIV/TB coinfection: AZT or TDF + 3TC or FTC + EFV.

HIV/HBV coinfection: TDF + 3TC or FTC + EFV or NVP.
Alternatives:TDF+3TC+NVP,d4T+3TC+EFV,
ABC+3TC+NVP, ABC+3TC+EFV and ABC+3TC+ZDV i.e
combination of two NRTI and an NNRTI;
Preferred second-line ART optionsPreferred options
Adults and adolescents (including pregnant women): If d4T or
AZTused in first-line therapy TDF + 3TC or FTC + ATV/r or
LPVr. If TDF usedin first-line therapy AZT + 3TC + ATV/r or
LPVr.
Hepatitis B coinfection: AZT + TDF + 3TC or FTC + ATV/r or
LPVr.
Abacavir (ABC)
Tablets, 60mg, 300mg (as sulphate)
Oral liquid 20mg/ml
Indications: treatment of HIV infection, in combination with
other antiretrovirals.
Cautions: hepatic and renal impairment, pregnancy,
breastfeeding.
Drug interactions: the potential for clinically significant drug
interactions is low.
Contraindications: prior hypersensitivity to the drug
Side effects: hypersensitivity reactions, nausea, vomiting,
diarrhoea, anorexia, lethargy, fatigue, fever, headache,
pancreatitis, lactic acidosis
Dose and Administration: Oral:Adult:300mg 12 hourly;Child:
3 months - 16 years, 8mg/kg twice daily
Storage: store at room temperature.
Didanosine (DDI, ddI)
Tablet, 25mg, 150mg
Chewable / dispersable tablet, 100mg,
477

8. Anti-Infectives

capsule (delayed release) 125mg,200mg, 250mg, 400mg

Indications: treatment of HIV infection, in combination with at
least two other antiretroviral drugs
Cautions: peripheral neuropathy or hyperuricaemia; renal and
hepatic impairment; pregnancy and breast-feeding; dilated
retinal examinations recommended every 6 months, or if visual
changes occur.
Drug interactions: drugs in which absorption is impaired by
increased gastric pH, e.g. fluoroquinolones, some protease
inhibitors, dapsone: take at least 2 hours before or 2 hours after
didanosine.
Contraindications: history of pancreatitis, alcholism;
conditions requiring sodium restriction.
Side effects:pancreatitis, peripheral neuropathy especially in
advanced HIV infection suspend (reduced dose may be tolerated
when symptoms resolve),lactic acidosis hyperuricaemia
(suspend treatment if significant elevation), diarrhea; nausea,
vomiting, dry mouth, asthenia, headache, hypersensitivity
reactions, retinal and optic nerve changes (especially in
children), diabetes mellitus, raised liver enzymes, liver failure.
Dose and Administration:Adult: Oral:>60 kg, 200 mg 12
hourly or 400 mg daily; < 60 kg, 125 mg 12 hourly or 250 mg
daily. Child: Oral: 240 mg/m2 daily or 120 mg/m2 12
hourly.Note: Half hour pre-meals or 1hour after meal.
Storage: store at room temperature
Emtricitabine (FTC)
Capsule, 200mg
Indications: Treatment of HIV infection in combination with at
least two other antiretroviral agents.
Cautions: lactic acidosis, severe hepatomegaly, hepatic failure,
renal impairment.
Drug interactions: concomitant use of nucleoside analogues.
478

8. Anti-Infectives

Contraindications: hypersensitivity to emitricitabine.

Side effects: headache, dizziness, insomnia, rash, diarrhea,
nausea, abdominal pain, skeletal weakness, cough, rhinitis.
Dose and Administration:Oral: Adult: 200mg once daily.
Storage: store at room temperature.
Lamivudine (3TC)
Tablet, 150mg
Oral solution, 10mg/ml
Indications: HIV infection; reduction of perinatal transmission
of HIV; post - exposure prophylaxis; only in combination with
other antiretrovirals. Chronic hepatitis B infection (off-label
use).
Cautions: renal impairment, hepatic disease, pregnancy and
breastfeeding.
Drug interactions: co-trimoxazole, trimethoprim component of
co- trimoxazole.
Contraindications:significant anaemia or neutropenia, known
hypersensitivity to the drug.
Side effects: nausea, vomiting, diarrhoea, abdominal pain,
cough; headache, insomnia, malaise, fever, rash, alopecia,
muscle disorders, nasal symptoms; peripheral neuropathy; rarely
pancreatitis
(discontinue);
neutropenia,
anaemia and
thrombocytopenia; lactic acidosis; raised liver enzymes and
serum amylase reported.
Dose and Administration: Oral: Adult: 150 mg 12 hourly; <
50 kg, 2 mg/kg 12 hourly.Chronic hepatitis B infection: 100150mg once daily. In patients with concomitant HIV infection,
use the dose for HIV treatment.Child: 3 months-12 years: 4
mg/kg (maximum 150mg) twice daily. Neonates < 30 days old:
2 mg/kg twice daily.
Storage: store at 2 - 25 oC temperature
479

8. Anti-Infectives

Stavudine (d4T)
Capsules, 15mg, 20mg, 30mg
Powder for oral solution, 1mg/mL
Indications: treatment of HIV infection, in combination with
other antiretrovirals.
Cautions: peripheral neuropathy and pancreatitis or
concomitant use with other drugs associated with pancreatits;
hepatic disease, renal impairment, pregnancy and brestfeeding.
Drug interactions: zidovudine, didanosine, zalcitabine,
dapsone, ethambutol, ethionamide and isoniazid, pentamidine,
valproate.
Side effects:Cumulative exposure to d4T has the potential to
cause disfiguring, painful and lifethreatening side-effects, such
as lipodystrophy, peripheral neuropathy and lactic acidosis.,
pancreatitis, headache, gastrointestinalintolerance (diarrhoea,
nausea, anorexia), neutropenia, thrombocytopenia, myalgia,
elevated liver enzymes.
Dose and Administration:Oral:Adult: >60kg, 40mg 12 hourly;
<60kg, 30mg 12 hourly. Renal impairment: creatinine clearance
26-50ml/min, half dose 12 hourly; creatinine clearance <25
ml/min, half dose 24 hourly.Child: > 3 months and 30kg,
1mg/kg 12 hourly; > 30 kg, as for adults.
Storage: store capsules and powder for oral solution at room
temperature. Following reconstitution, oral solution should be
stored at 2-8oC for up to 30 days.
Zalcitabine (ddC, DDC)
Tablet, 375 mcg, 750mcg
Indications: treatment of HIV infection, in combination with
other antiretrovirals.
Cautions: peripheral neuropathy, history of pancreatitis; known
hypersensitivity to the drug.
480

8. Anti-Infectives

Drug interactions: aminoglycosides, amphotericin B and

foscarnet; antacids, cimetidine, didanosine, drugs associated
with peripheral neuropathy (e.g. stavudine, chloramphenicol);
drugs
associated
with
pancreatitis
(e.g.
alcohol),
metoclopramide, probenecid.
Side effects: these tend to be dose related and may be difficult
to distinguish from the underlying disease. They tend to be
more frequent and severe in advanced disease. Dose-related
peripheral neuropathy, oral ulcers, pancreatitis, hepatitis,
arthralgia and gastrointestinal disturbances. Pharyngitis,
headache, dizziness, rash, pruritus, weight loss, fatigue, chest
pain, leucopenia, thrombocytopenia, rigors and sweating
Oesophageal ulcers, hypersensitivity reactions
Dose and Administration: Adult: Oral: 0.75mg 8 hourly.
Storage: store at room temperature.
Zidovudine / Azidothymidine (ZDV, AZT,)
Tablets, 300 mg
Capsules, 100 mg, 250 mg
Syrup, 50 mg/5ml
IV infusion, 10 mg/ml
Indications: HIV infection; reduction of perinatal transmission
of HIV; Post-exposure prophylaxis. Usually in combination
with other antiretrovirals.
Cautions: haematological toxicity; vitamin B12 deficiency
(increased risk of neutropenia); reduce dose or interrupt
treatment according to product literature if anaemia or
myelosuppression, renal impairment; hepatic impairment; risk
of lactic acidosis.
Drug interactions: ganciclovir, myelosuppressive agents,
probenecid.
Contraindications:abnormally low neutrophile counts or
haemoglobin; neonates either with hyperbilirubinaemia
481

8. Anti-Infectives

requiring treatment other than phototherapy or with raised

transaminase.
Side effects: haematological effects include anaemia and
leucopenia or neutropenia. Platelet count may rise initially after
starting therapy. Nausea, headache, myalgia, insomnia, and
rarely, myopathy, lactic acidosis, seizures, confusion, mania,
and hepatotoxicity.
Dose and Administration:Adult:Oral: 300 mg 12 hourly,
Dose may be reduced to 250 mg 12 hourly if needed.IV
infusion: over 1 hour, 1-2 mg/kg 4 hourly, in 5% glucose to
give a zidovudine concentration 2 or 4 mg/ml. The IV route is
used only until oral therapy can be given.PMTCT:
Adult: Oral: 300mg 12 hourly for at least the last 4 weeks of
pregnancy; from onset of labour to delivery, 300 mg 3 hourly.
Child:Oral: 3 months - 12years, 180 mg/m2 12 hourly;
maximum800mg/day
Neonates: for prevention of MTCT, initiated within 12 hours of
birth and given for the first 6 week of life: Oral: 2 mg/kg 6
hourly,IV: 1-5 mg/kg 8 hourly
Premature infants: Oral: 1.5 mg/kg 12 hourly for 2 weeks,
then mg/kg 6 hourly. IV, as for term infants
Storage: store at room temperature.
Tenofovir (TDF)
Tablet, 300mg
Indications:treatment of HIV infection, in combination with
other antiretrovirals.
Cautions:co-infection with hepatitis B (severe acute
exacerbation of hepatitis reported on discontinuation); renal
impairment, porphyria.

482

8. Anti-Infectives

Drug interactions: didanosine, drugs that reduce renal function

or compete for active tubular secretion (aciclovir, valaciclovir,
ganciclovir), lopinavir-ritonavir, other nephrotoxic agents.
Side effects:mild to moderate gastrointestinal effects, such as
nausea, diarrhoea, vomiting and flatulence. Tenofovir is
nephrotoxic and cause renal impairment (including acute renal
failure), proteinuria and Fanconi syndrome (renal tubular injury
with severe hypophosphataemia). Reduction in bone mineral
density may occur. Rare hypersensitivity reactions;
hyperlactataemia and hepatic steatosis.
Dose and Administration:Adult: Oral: 300 mg once
daily.Renal impairment: Increase dose interval. Creatinine
clearance 30 50 ml/min, 48 hours; 10 30 ml/min, twice
weekly; < 10 ml/min, not recommended
Non - Nucleoside Reverse Transcriptase Inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
inhibit reverse transcriptase enzyme activity directly. They
potently suppress HIV replication. High-level resistance
develops rapidly and they must always be used in combination,
usually with 2NRTIs. Cross-resistance within the class occurs.
Hypersensitivity rashes are common. Currently available
NNRTIs include nevirapine and efavirenz.
Efavirenz (EFV, EFZ)
Tablet, 50mg, 200mg, 600mg
Capsules, 50mg, 100mg, 200mg
Tablet for oral suspension, 100mg
Indications: treatment of HIV infection, in combination with
other antiretrovirals.
Cautions: hepatic and renal impairment, breast feeding, elderly;
history of mental illness or substance abuse.
483

8. Anti-Infectives

Drug interactions: efavirenz may either induce or inhibit

metabolism of other hepatically metabolised drugs. Cisapride,
midazolam, triazolam, ergot alkaloids, terfenadine, rifampicin,
phenytoin, carbamazepine, phenobarbitol, warfarin, protease
inhibitors, oral contraceptives.
Contraindications: pregnancy (teratogenic); substitute
nevirapine for efavirenz in pregnant women or women for
whom effective contraception cannot be assured.
Side effects: rash including Stevens Johnson Syndrome,
dizziness, headache, insomnia, somnolence, abnormal dreams,
fatigue, impaired concentration (administration at bed time in
the first 2 - 4 weeks reduces CNS effects); nausea; less
frequently vomiting, diarrhoea, hepatitis, depression, anxiety,
psychosis, amnesia, ataxia, stupor, vertigo; raised serum
cholesterol, elevated liver enzymes (especially if seropositive
for hepatitis B or C), pancreatitis.
Dose and Administration:Oral:Adult: 600mg once daily as a
single dose at night.Child: administered once daily, preferably
at bedtime: over 40kg, 600mg; 32.5 - 40kg, 400mg; 25-32.5kg,
350mg; 20 - 25kg, 300mg; 15-20kg, 250mg; 13-15kg,
200mg.Not recommended for children under 3 years or under 13kg.
Storage: store at room temperature.
Nevirapine (NVP)
Tablet, 200 mg
Suspension, 50 mg/5ml
Indcations: treatment of HIV infection, in combination with
other antiretrovirals; reduction of perinatal transmission of HIV
in combination with other ARVs.
Cautions: hepatic and renal impairment.
Drug interactions: oral contraceptives; rifampicin and
rifabutin; protease inhibitors.
Contraindications: hypersensitivity to the drug.
484

8. Anti-Infectives

Side effects: rash including Stevens-Johnson syndrome and

rarely, toxic epidermal necrolysis, hepatitis or jaundice reported;
nausea, vomiting, abdominal pain, diarrhoea, headache,
drowsiness, fatigue, fever; hypersensitivity reactions;
anaphylaxis, angioedema, urticaria also reported.
Dose and Administration:Oral: Adult: 200 mg daily for 14
days followed by 200 mg 12 hourly.
PMTCT: 200 mg to the mother at the onset of labour; 2 mg/kg
to the infant within 72 hours.Child: 2 months - 8 years, 4mg/kg
once daily for 2 weeks, then 7mg/kg twice daily; 8 years,
4mg/kg once daily for 2 weeks, then 4mg/kg twice daily.
Maximum 400mg/day.
Storage: store at room temperature.
Protease Inhibitors
Protease inhibitors inhibit the HIV protease enzyme. Inhibition
of this enzyme prevents cleavage of viral polyproteins, and
results in immature, non-infectious HIV viral particles.
Protease inhibitors cause potent suppression of HIV replication.
They must always be used in combination, and they are reserved
for second-line therapy if the initial treatment regimen of 2
NRTIs + 1NNRTI fails.Currently available protease inhibitors
include amprenavir, indinavir, lopinavir, nelfinavir, ritonavir
and saquinavir. There is cross- resistance between some of
these. They undergo hepatic cytochrome P450 metabolism and
some, especially ritonavir, are potent hepatic enzyme inhibitors.
This is exploited therapeutically by using subtherapeutic doses
of ritonavir to reduce metabolism of other protease inhibitors,
allowing the use of lower doses and/or increased dosing
intervals. Drug interactions are common.
Lipodystrophy and metabolic disorders
485

8. Anti-Infectives

Abnormal fat distribution, with increased abdominal girth,

dorsocervical fat deposition, breast enlargement and peripheral
fat wasting (lipo-atrophy) has been associated with HAART.
The protease inhibitors are most strongly associated with fat
accumulation.Protease inhibitors may also cause metabolic
abnormalities,
such
as
hypercholesterolaemia,
hypertriglyceridaemia and insulin resisitance. These may occur
with or without lipodystrophy.
Atazanavir
Tablet/capsule, 100mg, 150mg, 200mg, 300mg
Indications: treatment of HIV-1 infections in combination with
at least two other antiretroviral agents.
Note: In patients with prior virologic failure, coadministration with
ritonavir is recommended.

Cautions: patients with pre-existing conduction abnormalities

or with medications which prolong AV conduction; hepatic
dysfunction.
Drug interactions: cisapride, ergot derivatives, sildenafil,
antiarrhythmics, ciprofloxacin, clarithromycin, diclofenac,
doxycycline, erythromycin, isoniazid, protease inhibitors,
quinidine, verapamil.
Contraindications: do not use in children <3 months of age due
to potential for kernicterus; hypersensitivity to atazanavir.
Side effects: hyperglycemia, facial atrophy, breast enlargement,
rash, nausea, depression, dizziness, fatigue, fever, headache,
insomnia, pain, peripheral neuropathy, lipodystrophy, vomiting,
diarrhea, jaundice, myalgia.
Dose and Administration: Oral: Adult:Antiretroviral-nave
patients: 400mg once daily; administer with food
Antiretroviral-experienced patients: 300mg once daily plus
ritonavir 100mg once daily; administer with food
486

8. Anti-Infectives

Coadministration with efavirenz:Antiretroviral-nave patients: it

is recommended that atazanavir 300mg plus ritonavir 100mg be
given with efavirenz 600mg (all as asingle daily dose);
administer with food. Antiretroviral-experienced patients:
recommendations have not been established.
Indinavir (IDV)
Capsule, 200mg, 400mg
Indications: treatment of HIV infection, in combination with
twoNucleoside reverse transcriptase inhibitors and usually with
low-doseritonavir booster.
Cautions: hepatic impairment; ensure adequate hydration to
reduce risk of nephrolithiasis; diabetes mellitus; haemophilia;
pregnancy; breast feeding, metabolism of many drugs inhibited
if administered
concomitantly.
Drug interactions: carbamazepine, dexamethasone, efavirenz,
ergotamine, nelfinavir, nevirapine, Phenobarbital, phenytoin,
rifampicin,ritonavir, saquinavir.
Side effects:nephrolithiasis, unconjugated hyperbilirubinaemia,
lipodystrophy, hypercholesterolaemia, hypertriglyceridaemia
and insulin resistance. Nausea, vomiting, diarrhoea, hair loss,
dry skin and skin rashes may occur. Allergic reactions include
anaphylaxis, erythema multiforme and Stevens Johnson
syndrome. Acute haemolytic anemia and decreased neutrophil
counts have been reported.
Dose and Administration:Oral: Adult: 800 mg 8 hourly, 1
hour before or 2 hours after a meal; alternatively indinavir 800
mg plus ritonavir 100 -200 mg 12 hourly (independent of
meals).Child: 4-17 years, 500 mg/m2 (maximum 800 mg) 8
hourly.
Note. Administer 1 hour before or 2 hours after a meal; may be
administered with low-fat, light meal; when given with didanosine
487

8. Anti-Infectives

tablets, allow 1 hour between the drugs (antacids in didanosine

reduce absorption of indinavir)

Storage: store at room temperature and in a tight container.

Nelfinavir (NFV)
Tablet, 250 mg
Oral powder, 50 mg/g
Indications: HIV infection in combination with two other
antiretroviral drugs.
Cautions: hepatic and renal impairment; diabetes mellitus;
haemophilia.
Drug interactions: carbamazepin, contraceptives, ergotamine,
phenobarbital, quinidine, ritonavir, saquinavir.
Side effects: diarrhoea, nausea, vomiting, flatulence, abdominal
pain; rash, reports of elevated creatine kinase, hepatitis,
pancreatitis, neutropenia, hypersensitivity reactions including
bronchospasm, fever, pruritus and facial oedema, lipodystrophy
and metabolic effects.
Dose and Administration: Oral:Adult: 1.25g twice daily or
750mg 3 times daily.Child: under 1 year, 40 - 50mg/kg 3 times
daily or 65 - 75mg/kg twice daily; 1-13 years, 55 - 65 mg/kg
twice daily.
Note: Administer with or after food, powder may be mixed with water,
milk, formula feeds or pudding; it should not be mixed with acidic
foods or juices owing to its taste.

Storage: store at room temperature and in tight containers.

Ritonavir (RTV)
Capsule, 100 mg
Oral Solution, 80 mg/ml

488

8. Anti-Infectives

Indications: treatment of HIV infection and as a booster to

increase effect of indinavir, lopinavir or saquinavir and in
combination with two other antiretroviral drugs.
Cautions: hepatic impairment; diabetes mellitus; haemophilia.
Drug interactions: amiodarone, cisapride, clozapine, dextropropoxyphene, pethidine, pimozide, quinidine and terfenadine;
ergot alkaloids and derivatives; sedatives and hypnotics; HMG
CoA reductase inhibitors; rifabutin; anticonvulsants;
ketoconazole, macrolides; oral contraceptives; protease
inhibitors.
Contraindications: severe hepatic impairment.
Side effects: gastrointestinal intolerance (nausea, vomiting and
diarrhoea), vasodilation, orthostatic hypotension and syncope,
hypertriglyceridaemia, pancreatitis, lipodystrophy, dyspepsia,
oral ulceration, dry mouth, hyperaesthesia, hypersensitivity
reactions, including anaphylaxis.
Dose and Administration:Oral:Adult: 600 mg 12 hourly.
Gradual dose escalation may provide relief if nausea occurs or
initiation: 300mg 12 hourly for 1 day, 400mg 12 hourly for 2
days, 500mg 12 hourly for 1 day, then 600mg 12 hourly.Child:
Over 2 years, initially (to minimise nausea) 250mg/m2 12
hourly, increased gradually over a week to 350mg/m2 12 hourly
upto a maximum of 600mg 12 hourly. As a booster with other
antiretroviral drugs: Adult: 100 mg twice daily.
Child 6 months: 13 years: 57.5 mg/m2 twice daily (or 3 to 5
mg/kgtwice daily) (maximum 100 mg twice daily).
Storage: liquid-filled capsules should be stored at 2 - 8 oC but
may be stored at a temperature lower than 25 oC for up to 30
days. Store oral solution at room temperature
Saquinavir (SQV)
Tablet, 500 mg
489

8. Anti-Infectives

Capsule, 200 mg
Oral solution,80mg/ml
Indications: HIV infection in combination with two other
antiretroviral drugs and usually with low - dose ritonavir
booster.
Cautions: hepatic and renal impairment; diabetes mellitus,
haemophilia, pregnancy and breastfeeding.
Drug interactions: indinavir, nevirapine, phenobarbital,
phenytoin, rifampicin, ritonavir.
Contraindications: hypersensitivity to the drug.
Side effects: diarrhoea, buccal and mucosal ulceration,
abdominal discomfort, nausea, vomiting; headache, peripheral
neuropathy, paraesthesia, dizziness, insomnia, mood changes,
ataxia, musculoskeletal pain, asthenia; fever, pruritus, rash and
other skin eruptions, rarely Stevens - Johnson syndrome; other
rare adverse effects include thrombocytopenia and other blood
disorders, seizures, liver damage, pancreatitis and
nephrolithiasis; reports of elevated creatine kinase, raised liver
enzymes and neutropenia when used in combination therapy;
lipodystrophy and metabolic effects.
Dose and Administration: Adult: Oral: in combination with
nucleoside reverse transcriptase inhibitors and low-dose
ritonavir booster: saquinavir 1g and ritonavir 100 mg twice
daily. In combination with other antiretroviral drugs but without
ritonavir booster): 1.2g every 8 hours after a meal.Child under
16 years, safety and efficacy not established.
Note: Administer with or after food.

Storage: saquinavir liquid-filled capsules should be stored at 2 8 oC in airtight container but may be stored at a temperature
lower than 25 oC for upto 3 months. For tablets store at room
temperature
490

8. Anti-Infectives

Darunavir
Tablet (f/c), 300mg
Indications: co-administered with ritonavir, and with other
antiretroviral agents, is indicated for the treatment of HIV
infection in antiretroviral treatment-experienced adult patients,
such as those with HIV-1 strains resistant to more than one
protease inhibitor.
Cautions: sulfonamide sensitivity; monitor liver function before
and during treatment, hepatic impairment, pregnancy, breastfeeding.
Drug interactions:Abacavir,bromazepam, clarithromycin,
dantrolene, lidocaine, lopinavir, lovastatin, saquinavir,
tacrolimus, tadalafil, tamoxifen, tamsulosin, telithromycin,
temsirolimus, teniposide, tiagabine, tolterodine, topotecan,
tramadol, trazodone, trimipramine, vardenafil, venlafaxine,
verapamil, vinblastine, vincristine, voriconazole, zolpidem,
zonisamide, zopiclone.
Contraindications: Allergy to darunavir, ritonavir, sulfa
medications, or any of the ingredients in darunavir.
Side effects: haematemesis, myocardial infarction, angina, QT
interval prolongation, syncope, bradycardia, tachycardia,
palpitation, hypertension, flushing, peripheral oedema,
dyspnoea, cough, peripheral neuropathy, anxiety, confusion,
memory
impairment,
depression,
abnormal
dreams,
convulsions, increased appetite, weight changes, pyrexia,
hypothyroidism,
osteoporosis,
gynaecomastia,
erectile
dysfunction, reduced libido, dysuria, polyuria, nephrolithiasis,
renal failure, arthralgia, visual disturbances, dry eyes,
conjunctival hyperaemia, rhinorrheoa, throat irritation, dry
mouth, stomatisis, nail discoloration, acne, seborrhoeic
dermatitis, eczema, increased sweating, alopecia
491

8. Anti-Infectives

Dose and Administration: With low-dose ritonavir, adult and

child over 6 years, body-weight over 40 kg, previously treated
with antiretroviral therapy, 600 mg twice daily; child over 6
years, previously treated with antiretroviral therapy, bodyweight 2030 kg, 375 mg twice daily; body-weight 3040 kg,
450 mg twice daily
With low-dose ritonavir, adult over 18 years not previously
treated with antiretroviral therapy, 800 mg once daily. Missed
dose: If a dose is more than 6 hours late on the twice daily regimen
(or more than 12 hours late on the once daily regimen), the missed
dose should not be taken and the next dose should be taken at the
normal time

Storage: store at room temperature and in a tight container.

Integrase Inhibitor
Raltegravir
Tablet, 400mg
Indications: in combination with other antiretroviral drugs for
HIV infection resistant to multiple antiretrovirals
Cautions: risk factors for myopathy or rhabdomyolysis; chronic
hepatitis B or C (greater risk of hepatic side effects); hepatic
impairment; pregnancy;
Drug Interactions: histamine H antagonists, proton pump
inhibitors, rifampicin
Contraindications: breast-feeding
Side effects: abdominal pain, flatulence, constipation,
lipodystrophy; dizziness, asthenia; arthralgia; pruritus,
hyperhidrosis; less commonly vomiting, gastritis, hepatitis,
myocardial infarction, hypertriglyceridaemia, allodynia,
headache, renal failure, anaemia, neutropenia, and muscle
spasm
492

8. Anti-Infectives

Dose and administration: adult and child over 16 years, 400

mg twice daily
Combination ARVs:
Lamuvidine + Nevirapine +Stavudine
Tablet, 150mg +200mg + 30mg; 30mg+50mg+6mg;
60mg+100mg+12mg
Indications: for the treatment of HIV infection, once patients
have been stabilized on the maintenance regimen of nevirapine
200 mg bid, and have demonstrated adequate tolerability to
nevirapine.
Cautions: it should not be administered to patients who have
just initiated therapy with nevirapine. This is because an initial
lead-in dosing of 200 mg nevirapine once daily for 2 weeks is
recommended. Following this lead-in dose, a dose escalation
(maintenance dose) to 200 mg nevirapine bid may be carried out
in the absence of any hypersensitivity reactions.
Dose and Administration: Adult:200mg+150mg+30mg:1
tablet twice daily for patients weighing <60 kg; 200mg + 150mg
+ 40mg: 1 tablet twice daily for patients weighing >60 kg
Lamivudine +Zidovudine + Nevirapine
Tablet, 150mg +300mg +200mg; 30mg +60mg +50mg
Indications: treatment of HIV infection, once patients have
been stabilized on the maintenance regimen of nevirapine
200mg bid, and have demonstrated adequate tolerability to
nevirapine.
Cautions, Drug Interactions, Contraindications and side
effects: see under Lamivudine, Zidovudine and Nevirapine
Dose and Administration: Adult: Tablet, 150mg +300mg
+200mg (one tablet twice daily)
Note:Lamivudine +Zidovudine + Nevirapine Tablets, 150mg
+300mg +200mg should not be administered to patients who have
493

8. Anti-Infectives

just initiated therapy with nevirapine. This is because an initial leadin dosing of 200mg nevirapine once daily for 2 weeks, along with the
standard doses of lamivudine + zidovudine twice daily is
recommended. Following this lead-in dose, a dose escalation
(maintenance dose) to Lamivudine +Zidovudine + Nevirapine
Tablets, 150mg +300mg +200mg twice daily may be carried out in
the absence of any hypersensitivity reactions.Patients who interrupt
nevirapine dosing for more than 7 days should restart the
recommended dosing, using one 200mg nevirapine tablet daily for the
first 14 days (lead-in) in combination with the other lamivudine +
zidovudine, followed by Lamivudine +Zidovudine + Nevirapine
Tablets, 150mg +300mg +200mg twice daily in the absence of any
signs of hypersensitivity.

Abacavir sulphate + Lamivudine +Zidovudine

Tablet, 60mg+30mg+60mg
Indications: It is indicated in combination with other
antiretrovirals or alone for the treatment of HIV-1 infection.
Contraindications:Previously hypersensitivity to abacavir or
any other component of the product.
Dose and Administration:Children 6 weeks of age and above:
Children weighing 25 kg or more, adolescents and adults: For
these patient groups other fixed-dose formulations with higher
amounts of the active substances are available.
Number of tablets by weight to be taken twice daily (12 hourly)

3-5.9 kg
1

6-9.9 kg
1.5

10-13.9 kg
2

14-19.9 kg 20-24.9 kg
*
3
2.5

This dose can be delivered as one and a half tablets twice daily, or
*
by giving 2 tablets in the morning and one tablet in the evening. This
dose can be delivered as two and a half tablets twice daily, or by
giving 3 tablets in the morning and 2 tablets in the evening.
494

8. Anti-Infectives

Tenofovir +Lamivudine
Tablet, 300mg +300mg
Indications: in combination with other antiretrovirals for the
treatment of HIV-1 infection,
Cautions, Drug Interactions, Contraindications and side
effects: see under Tenofovir and Lamivudine
Dose and Administration: one tablet once daily taken orally
with or without food.
Storage: Store in cool dry place
Lamivudine+ Zidovudine (Combivir)
Tablets, 150mg+ 300mg, 30mg+60mg
Cautions, contraindications and side effects: see indivisual
drugs
Dose and Administration:Adult and Child >12 years: Oral:
one tablet twice daily.
Lamivudine +Stavudine
Tablet, 150mg +30mg
Indications: treatment of HIV infection as a component of
combination antiretroviral therapy.
Cautions, Drug Interactions, Contraindications and side
effects: see under lamivudine and stavudine
Dose and Administration: Adult: 1 tablet two times a day
Efavirenz +Emitricitabine + Tenofovir
Tablet, 600mg +200mg +300mg
Indications: alone as a complete regimen or in combination
with other antiretroviral agents for the treatment of HIV-1
infection in adults.
Cautions, Drug Interactions, Contraindications and side
effects: see under Efavirenz, Emitricitabine and Tenofovir
495

8. Anti-Infectives

Dose and Administration: Ault: one tablet on an empty

stomach, preferably at bed time
Emtricitabine + Tenofovir
Tablet, 200mg + 300mg
Indications: Treatment of HIV infection in combination with
other antiretroviral agents.
Cautions, contraindications and side effects see indivisual
drugs
Dose and Administration:Oral: Adult: one tablet
(emtricitabine 200mg and tenofovir 300mg) once daily.
Abacavir sulphate +Lamivudine
Tablet, 600mg+300mg,
Indications: Treatment of HIV infection in combination with
other antiretroviral agents.
Caution: pregnancy
Contraindications: because dosage of abacavir and lamivudine
cannot be adjusted individually, the fixed-combination
preparation should not be used in pediatric patients.
Dose and Administration:Oral: 600mg/300mg once daily
Storage: store at room temperature.
Lopinavir +Ritonavir
Capsule, 133.33mg +33.33mg
Oral suspension, 80mg +20mg/ml
Tablet, 200mg +50mg; 100mg +25mg
Indications: treatment of HIV-1 infection in combination with
other antiretroviral agents.
Cautions, Drug Interactions, Contraindications and side
effects: see under lopinavir and ritonavir.
496

8. Anti-Infectives

Dose and Administration: Adult: two 200/50 mg tablets twice

daily taken with or without food or 800mg + 200mg once daily.
Note: once daily dosing is recommended only for treatment-naive adults.
Lopinavir/ritonavir should not be administered once-daily in regimens that
include efavirenz, nevirapine, amprenavir, fosamprenavir, or nelfinavir
Age or
Oral Solution
Tablets
Weight
(80 mg lopinavir/
(100mg lopinavir/25mg ritonavir)
20 mg ritonavir
per ml)
Age 14 days 16/4 mg/kg BID, or Use oral solution
to 6 months
300/75 mg/m2 BID
Age 6 months to 18 years
7-15 kg
(12/3 mg/kg BID)
7 to 10 kg
1.25 ml BID
Tablets are not recommended; use
oral solution
>10 to <15 1.75 ml BID
Tablets are not recommended; use
kg
oral solution
15-40 kg
(10/2.5 mg/kg BID)
15 to 20 kg
2.25 mL BID
2 tablets BID (100/25 mg
formulation) or1 tablet BID (200/50
mg formulation)
>20 to 25 kg 2.75 mL BID
2 tablets BID or 1 tablet BID
(200/50 mg formulation)
>25 to 30 kg 3.5 mL BID
3 tablets BID
(100/25 mg formulation)
>30 to 35 kg 4 mL BID
3 tablets BID
(100/25 mg formulation)
>35 to 40 kg

4.75 mL BID

>40 kg

400/100 mg BID
(same as adult
dosage)
5 ml BID

>40kg

4 tablets BID (100/25 mg

formulation)orn2 tablets BID
(200/50 mg formulation)

4 tablets BID (100/25 mg

formulation) or 2 tablets BID
(200/50 mg formulation)

497

8. Anti-Infectives

8.3.2 Anti-Hepatitis
Adefovir dipivoxil
Tablet, 10mg
Indications:
chronic
hepatitis
B
infection
with either compensated liver disease with evidence of viral
replication, and histologically documented active liver
inflammation and fibrosis or decompensated liver disease
Cautions: monitor liver function tests every 3 months, and viral
markers for hepatitis B every 36 months during treatment
(continue monitoring for at least 1 year after discontinuation
recurrent hepatitis may occur on discontinuation); monitor renal
function before treatment then every 3 months, more frequently
in renal impairment or in patients receiving nephrotoxic drugs;
elderly; discontinue if deterioration in liver function, hepatic
steatosis, progressive hepatomegaly or unexplained lactic
acidosis Renal impairment:10 mg every 48 hours if eGFR 30
50 mL/minute/1.73 m2; 10 mg every 72 hours if eGFR 10
30 mL/minute/1.73 m2; no information available if eGFR less
than 10 mL/minute/1.73 m2; see also Cautions above
Side-effects: nausea, vomiting, dyspepsia, abdominal pain,
flatulence, diarrhoea; asthenia, headache; renal failure;
hypophosphataemia; rash and pruritus; also reported pancreatitis
Dose and administration: adult over 18 years, 10 mg once
daily
Entacavir
Tablet, 0.5mg, 1mg
Oral solution, 0.05mg/ml
Indications: chronic hepatitis B infection either with
compensated liver disease (with evidence of viral replication,
498

8. Anti-Infectives

and histologically documented active liver inflammation or

fibrosis) or decompensated liver disease
Cautions: monitor liver function tests every 3 months, and viral
markers for hepatitis B every 36 months during treatment
(continue monitoring for at least 1 year after discontinuation
recurrent hepatitis may occur on discontinuation); HIV
infectionrisk of HIV resistance in patients not receiving
highly active antiretroviral therapy; lamivudine-resistant
chronic hepatitis Brisk of entecavir resistance; discontinue if
deterioration in liver function, hepatic steatosis, progressive
hepatomegaly or unexplained lactic acidosis
Renal impairment: reduce dose if eGFR less than
50 mL/minute/1.73 m2; consult product literature
Pregnancy: toxicity in animal studiesmanufacturer advises
use only if potential benefit outweighs risk; effective
contraception required during treatment.
Breast-feeding: manufacturer advises avoidpresent in milk
in animal studies.
Side-effects: nausea, vomiting, dyspepsia, diarrhoea, raised
serum amylase and lipase, headache, fatigue, dizziness, sleep
disturbances; lesscommonlythrombocytopenia, rash, alopecia
Dose and administration: Compensated liver disease not
previously treated with nucleoside analogues, adult over 18
years, 500 micrograms once daily. Compensated liver disease
with lamivudine-resistant chronic hepatitis B adult over 18
years, 1 mg once daily; consider other treatment if inadequate
response after 6 months. Decompensated liver disease,
adult over 18 years, 1 mg once daily.
Note: To be taken at least 2 hours before or 2 hours after food

Ribavirin
Tablet, 200mg
499

8. Anti-Infectives

Inications: severe respiratory syncytial virus bronchiolitis in

infants and children; in combination with peginterferon alfa
or interferon alfa for chronic hepatitis C in patients without liver
decompensation
Cautions: Exclude pregnancy before treatment, cardiac disease,
gout, eye examination recommended before treatment, thyroid
function test recommended before treatment
Interactions: Abacavir,Azathioprine,Didanosine,Stavudine,Zid
ovudine
Contraindications:
Pregnancy,
breast-feeding,
renal
impairment, severe cardiac disease, including unstable or
uncontrolled cardiac disease in previous 6 months;
haemoglobinopathies, severe debilitating medical conditions;
autoimmune disease, uncontrolled severe psychiatic condition;
history of severe psychiatric condition in children
Side-effects: Haemolytic anaemia, nausea, vomiting, dyspepsia,
abdominal pain, flatulence, constipation, diarrhoea, colitis, chest
pain, palpitation, tachycardia, peripheral oedema, changes in
blood pressure, syncope, flushing, cough, dyspnoea, headache,
dizziness, asthenia, impaired concentration and memory, sleep
disturbances, abnormal dreams, anxiety, depression, suicidal
ideation, psychoses, dysphagia, weight loss, dysphonia,
paraesthesia, hypoaesthesia, ataxia, hypertonia, influenza-like
symptoms, thyroid disorders, hyperglycaemia, menstrual
disturbances, breast pain, prostatitis, sexual dysfunction,
micturition disorders,dehydration, hypocalcaemia, myalgia,
arthralgia, hyperuricaemia, visual disturbances, eye pain, dry
eyes, hearing impairment, tinnitus, earache, dry mouth, taste
disturbances, mouth ulcers, stomatitis, glossitis, tooth disorder,
gingivitis, alopecia, pruritus, dry skin, rash, increased sweating,
psoriasis, photosensitivity, and acne;
500

8. Anti-Infectives

Dose and administration: Oral:Adult: Chronic hepatitis C,

genotype 1,4 (in combination with peginterferon alfa2a):<75kg: 1000mg/day in 2 divided doses for 48 weeks;
75kg: 1200 mg/day in 2 divided doses for 48 weeks. Chronic
hepatitis C, genotype 2,3 (in combination with peginterferon
alfa-2a): 800mg/day in 2 divided doses for 24 weeks.
Note: Tablet: Should be administered with food.

Telbivudine
Tablet, 600mg
Indications: chronic hepatitis B infection with compensated
liver disease, evidence of viral replication, and histologically
documented active liver inflammation or fibrosis
Cautions: pregnancy, breast feeding, hepatic impairment, renal
impairment
Interactions: Interferon Alfa
Counselling: Patients should be advised to promptly report
unexplained muscle pain, tenderness, or weakness, or numbness,
tingling or burning sensations

Side effects: nausea, diarrhoea, abdominal pain, raised serum

amylase and lipase; cough; dizziness, headache, fatigue;
rash; less commonly; taste disturbance, arthralgia, myalgia,
myopathy (discontinue treatment), and peripheral neuropathy;
also reported, lactic acidosis and rhabdomyolysis
Dose and Administration: Adult and child over 16 years,
600 mg once daily
8.3.3. Other Antivirals
Acyclovir
Tablet, 200mg, 400mg
Powder for injection, 250mg, 500mg in vial
Cream, 5% 2mg
501

8. Anti-Infectives

Ointment,5%
Indications: treatment of primary genital herpes; disseminated
varicella-zoster (chickenpox) in immunocompromised patients;
herpes simplex encephalitis and herpes zoster.
Cautions: renal impairment, maintain adequate hydration;
pregnancy and breast-feeding.
Drug interactions: probenecid, any nephrotoxic drugs.
Contraindications: hypersensitivity to acyclovir.
Side effects: nausea, vomiting, abdominal pain, diarrhea,
headache, fatigue, rash urticaria, pruritus, photosensitivity;
rarely hepatitis, jaundice, dyspnoea, angioedema, anaphylaxis,
neurological reactions (including dizziness, confusion,
hallucinations and drowsiness); acute renal failure, decreases in
hematological indices; on intravenous infusion, severe local
inflammation (sometimes leading to ulceration), fever, and
rarely agitation, tremors, psychosis and convulsions.
Dose and Administration:Adult: Treatment of primary genital
herpes:Oral: 200mg 5 times daily for 7-10 days or 400 mg 3
times daily for 7-10 days.
Prevention of recurrence of genital herpes:Oral: 400 mg twice
daily.
Disseminated
varicella-zoster
(chickenpox) in
immunocompromised patients: IVinfusion: 10 mg/kg 3 times
daily for 7 days.Herpes simplex encephalitis:IV infusion: 10
mg/kg 3 times daily for 10 days.Herpes zoster: 800mg every 4
hours (5 times/day) for 7-10 days.Child: For up to 12 years, IV
infusion (over at least 1 hour), 250 mg/m2 8 hourly for 5-7 days.
This may be doubled in herpes encephalitis and in varicellazoster in immunocompromised patients.
Varicella (chickenpox): 20mg/kg (maximum 800mg/dose) 4
times daily for 5 days, initiated within 24 hours of appearance of
the rash.
Storage: store at controlled room temperature.
502

8. Anti-Infectives

Adenine Arabinoside
Injection, 500 mg in vial
Vidarabine was formerly used intravenously in the treatment of
severe and disseminated herpes simplex infections and
herpeszoster but aciclovir is preferred.
Amantadine hydrochloride
Capsule, 100mg.
Syrup, 50mg/5ml
Indications: Parkinsons disease (not for drug induced
parkinson - like syndromes) (See section 4.5); influenza
prohylaxis.
Cautions: epilepsy, serious mental disorders, a hisory of
eczematoid rashes, congestive heart failure and/ or peripheral
oedema, or orthostatic hypotension.
Drug interactions: agents with anticholinergic effects, alcohol,
CNS stimulants, hydrochlorothiazide and triamterene, levodopa.
Contraindications: hypersensitivity to amantadine.
Side effects: livedo reticularis (skin discolouration) mainly of
the legs; oedema of the legs. CNS reactions like psychotic
episodes, convulsions and nausea. Headache, constipation,
insomnia and nervousness, urinary retention, dry mouth, blurred
vision as well as neutropenia and skin rashes have occurred.
Dose and Administration:Oral: Adult: Influenza A viral
infection: 100mg twice daily; initiate within 24-48 hours after
onset of symptoms; discontinue as soon as possible based on
clinical response (generally within 3-5 days or within 24-48
hours after symptoms disappear).
Influenza A prophylaxis: 100mg twice daily.
Parkinson's disease: 100mg twice daily as sole therapy; may
increase to 400mg/day if needed with close monitoring.Child:
503

8. Anti-Infectives

Influenza A treatment: 1-9 years: 5mg/kg/day in 2 divided

doses. 10 years and < 40kg: 5mg/kg/day; maximum dose: 150
mg/day. 10-12 years and 40kg: 100 mg twice daily
Storage: store at 15-30 oC; protect from freezing.
Famciclovir
Tablet, 125mg, 250mg, 500mg
Indications: treatment of herpes zoster, acute genital herpes
simplex and suppression of recurrent genital herpes.
Cautions: renal impairment; pregnancy and breastfeeding.
Drug interactions: see under acyclovir
Side effects: nausea, vomiting, headache, rarely dizziness,
confusion, hallucinations, rash, abdominal pain and fever have
been reported in immunocompromised patients.
Dose and Administration: Adult: Oral: herpes zoster: 250mg
3 times daily for 7 days or 750mg once daily for 7 days (in
immunocompromised, 500mg 3 times daily for 10 days).Genital
herpes, first episode, 250mg 3 times daily for 5 days; recurrent
infection,
125mg
twice
daily for
5
days
(in
immunocompromised, all episodes, 500mg twice daily for 7
days). Genital herpes, suppression, 250mg twice daily (in HIV
patients, 500mg twice daily) interrupted every 6-12
months.Child: not recommended.
Foscarnet
IV, 24 mg/ml
Indications: treatment of cytomegalovirus retinitis in AIDS
patients when ganciclovir fails or is contraindicated, also for
aciclovir resistant herpes simplex virus infection.
Cautions: renal impairment.
Drug interactions: ciprofloxacin, cyclosporin, amphotericin B,
I.V pentamidine, aminoglycosides, ritonavir, and saquinavir.
504

8. Anti-Infectives

Contraindications: hypersensitivity to foscarnet.

Side effects: fever, headache, seizure, nausea, diarrhea,
vomiting, anemia, nephrotoxicity, fatigue, dizziness, depression,
confusion, rash, anorexia, granulocytopenia, leukopenia, vision
abnormalities, coughing, dyspnea.
Dose and Administration: Adult: CMV retinitis: I.V:
Induction treatment: 60 mg/kg/dose every 8 hours or 100 mg/kg
every 12 hours for 14-21 days.Maintenance therapy: 90-120
mg/kg/day as a single infusion.
Acyclovir-resistant HSV induction treatment: I.V: 40
mg/kg/dose every 8-12 hours for 14-21 days.
Storage: store injection at room temperature.
Ganciclovir
Capsules, 250mg, 500mg
Powder for IV infusion, 500 mg/vial
Indications: treatment of slight or life threatening
cytomegalovirus (CMV) infections in immuno-compromised
patients, and for the prevention of CMV disease in transplant
recipients.
Cautions: thrombocytopenia, impaired renal function.
Drug interactions: zidovudine; agents that inhibit renal tubular
secretion; antineoplastic agents, co-trimoxazole.
Contraindications: hypersensitivity to ganciclovir.
Side effects: myelosuppression, neutropenia, thrombocytopenia,
CNS effects, fever, skin rash, GI disturbances; liver function
abnormalities; phlebitis. Fertility may be impaired.
Dose and Administration:Adult:CMV retinitis:
IV infusion: initially 5mg/kg 12 hourly infused at a constant rate
over 1 hour (10mg/kg/day) for 14 - 21 days.Maintenance: IV
infusion 6mg/kg/day for 5 days /week; or 5mg/kg/day for 7
days/week.Oral: maintenance therapy (in HIV - infected
505

8. Anti-Infectives

patients, when retinitis is stable): 1g 3 times daily, or 500mg 6

times daily, with food.
Storage: store intact vials at room temperature and capsules at
5-25oC.
Oseltamivir Phosphate
Capsule, 30mg, 45mg
Powder to reconstitute as suspension, 12mg/ml
Indications: treatment of uncomplicated acute illness due to
influenza (A or B) infection in children 1 year of age and
adults who have been symptomatic for no more than 2 days;
prophylaxis against influenza (A or B) infection in children
year of age and adults.
Cautions: Renal impairment, primary or concomitant bacterial
infections, pregenancy, breastfeeding, oseltamivir is not a
substitute for the influenza virus vaccine.Safety and efficacy for
use in hepatic impairment, treatment or prophylaxis in
immunocompromised patients, patients with chronic cardiac
and/or respiratory disease and in children <1 year of age have
not been established
Contraindications: Hypersensitivity to oseltamivir or any
component of the formulation.
Side effects: nausea, vomiting, abdominal pain, diarrhoea;
headache; conjunctivitis; less commonly eczema; also reported
hepatitis,
gastro-intestinal
bleeding,
arrhythmias,
neuropsychiatric disorders (more frequent in children and
adolescents), visual disturbances, Stevens-Johnson syndrome,
and toxic epidermal necrolysis.
Dose and Administration:Dosage: OralTreatment: Initiate
treatment within 2 days of onset of symptoms; duration of
treatment: 5 days:Children: 1-12 years:
15kg: 30mg twice daily
506

8. Anti-Infectives

>15kg to 23kg: 45mg twice daily

>23 kg to 40kg: 60kg twice daily
>40kg: 75mg twice daily
Adolescents 13 years and Adults: 75mg twice daily
Prophylaxis: Initiate treatment within 2 days of contact with an
infected individual; duration of treatment: 10 days, Children: 112 years
15kg: 30mg twice daily
>15kg to 23kg: 45mg twice daily
>23 kg to 40kg: 60kg twice daily
>40kg: 75mg twice daily
Adolescents 13 years and Adults: 75mg once daily. During
community outbreaks, dosing is 75mg once daily. May be used
for up to 6 weeks; duration of protection lasts for length of
dosing period.
Dosage adjustment in renal impairment: Adults: CIcr 10-30
mL/minute:
Treatment: Reduce dose to 75mg once daily for 5 days
Prophylaxis: 75mg mg every other day or 30mg once daiy
Storage: Capsules: Store at 250c.Oral suspension: Store at 250c
and reconstitute with water. Once reconstituted, store
suspension under refrigeration at 20c to 80c; do not freeze. Use
within 10days of preparation.
Ribavirin
Tablet, 200mg
Indications: in combination with peginterferon alfa-2a injection
for the treatment of chronic hepatitis C in patients with
compensated liver disease that were previously untreated with
alpha interferons.

507

8. Anti-Infectives

Cautions: monitor for anemia 1-2 weeks after initiation;

cardiac, pulmonary, and elderly patients; paediatric patients < 3
years of age.
Drug interactions: nucleoside analogues (didanosine,
lamivudine, stavudine, zidovudine).
Contraindications: hypersensitivity to ribavirin; women of
childbearing age who will not use contraception reliably;
pregnancy;
male
partners
of
pregnant
women;
hemoglobinopathies; as monotherapy for treatment of chronic
hepatitis C; patients with autoimmune hepatitis; anemia, severe
heart disease.
Side effects: dizziness, headache, fatigue, fever, insomnia,
irritability,
depression,
emotional
lability,
impaired
concentration, alopecia, rash, pruritus, nausea, anorexia,
vomiting, dyspepsia, decreased hemoglobin, myalgia, dyspnea,
flu-like syndrome.
Dose and Administration:Oral: Adult: Chronic hepatitis C,
genotype 1, 4 (in combination with peginterferon alfa2a):<75kg: 1000mg/day in 2 divided doses for 48 weeks;
75kg: 1200 mg/day in 2 divided doses for 48 weeks. Chronic
hepatitis C, genotype 2,3 (in combination with peginterferon
alfa-2a): 800mg/day in 2 divided doses for 24 weeks.Tablet:
Should be administered with food.
Storage: store at room temperature.
Valaciclovir
Tablet, 500mg
Indications: treatment of herpes zoster and of herpes simplex
infections of the skin and mucous membranes including initial
and recurrent genital herpes.
Cautions: maintain adequate hydration; renal impairment;
pregnancy and breast-feeding.
508

8. Anti-Infectives

Drug interactions: see acyclovir.

Side effects: as a prodrug of acyclovir it is anticipated that side
effects will be comparable; nausea and headache reported.
Dose and Administration:herpes zoster: 1g 3 times daily for 7
days. Herpes simplex, first episode, 500mg twice daily for 5
days (up to 10 days if severe); recurrent infection, 500mg twice
daily for 5 days.Child: not recommended.
8.4. Antiprotozoals
8.4.1 Antimalarials
Malaria is one of the most serious protozoal infections,
which is transmitted by anopheline mosquitoes and rarely by
congenital transmission, transfusion of infected blood or use of
contaminated syringes among drug addicts. It is caused by
infection by any of four species of plasmodium. Plasmodium
vivax is the most extensively distributed and cause much
debilitating disease. P falciparum is also widespread, and
causes the most severe infections, which are responsible for
nearly all malarial - related deaths. P. Ovale is mainly confined
to Africa and is less prevalent, while P.malariae, which causes
the least severe but most persistent infections also occur widely.
Certain tissue forms of P. vivax and P. ovale which
persist in the liver for many months and even years are
responsible for the relapses characteristic of malaria such latent
forms are not generated by P. falciparum or P. malaria.
Recrudescence of these infections results from persistent blood
forms in inadequately treated or untreated patients.
Treatment of Malaria
Blood Schizontocides are the mainstay of the treatment of acute
malaria and some are used for prophylaxis. They include the 4aminoquinolines (chloroquine), the related arylaminoalcohols
509

8. Anti-Infectives

(quinine and mefloquine), and artemisinin and its derivatives

(artemether, artemether + lumefantrene (AL) and artesunate).
They suppress malaria by destroying the asexual blood forms of
the parasites but, because they are not active against intrahepatic
forms, they do not eliminate infections by P.vivax and P.ovale.
Chloroquine, a rapidly acting schizontocide, is well
tolerated, safe and inexpensive. It should be used to treat
malaria wherever the parasites remain susceptible. P.malaria
and P.ovale remain fully sensitive to chloroquine where as wide
spread chloroquine resistance strains of P. falciparum have been
reported in many countries. Resistance in P. vivax has also
become established in several parts of the world. Infections
acquired in areas of known or unknown chloroquine resistance
are treated now with quinine followed. Parenteral administration
of chloroquine may be used when there is no expectation of
resistance in cases of severe and complicated malaria, when the
patient is unable to take oral medication and when neither
quinine nor quinidine is available.
If subsequent relapse occurs in P.ovale and P.vivax
infections primaquine should be administered, after a second
course of chloroquine, to eliminate the intrahepatic infection.
Because sulfonamides can induce hypersensitivity in pregnant
women and possible kernicterus in the newborn; AL should be
used whenever possible to treat chloroquine resistant malaria
except during the 1st trimester of pregnancy during which
quinine should be used. If AL is not available oral Quinine is
used.
Quinine, given orally, should be reserved for p falciparum infections likely to be unresponsive to other drugs. It
is used as the first-line treatment for pregnant women during the
first trimester and for children of less than 5 kg.
510

8. Anti-Infectives

Rectal Artesunate or intramuscular [IM] artemether are

used as pre-referral treatment for severe malaria cases (Patients
arriving at a health post with severe malaria are given rectal
artesunate (or intramuscular artemether when rectal artesunate is
unavailable).

Intravenous) artesunate infusion or IM injection (or,

alternatively, quinine IV infusion when artesunate is not
available) is the first-line anti-malarial drug for management of
severe malaria and should be replaced by a full dose of AL for
artesunate infusion or IM injection and quinine oral for quinine
infusion or IM injection once the patient is able to swallow.
First Line Treatment for Severe Malaria
IV or IM artesunate (preferred) or, IM artemether or IV quinine
infusion (artesunate not available) or IM quinine (artesunate not
available) can be used for severe malaria case mangmnet due to
P. falciparum.
The recommended treatment for severe malaria in all patients
including pregnant women is artesunate infusion, or
alternatively quinine infusion or alternatively artemether IM if
both of these are unavailable. Pre-referral therapy for severe
malaria in pregnant women is with rectal artesunate, or rectal
artemether or alternatively IM quinine if both of these are
unavailable. Special precaution should be taken to prevent
hypoglycaemia in pregnancy. Primaquine and mefloquine are
contraindicated during pregnancy. Intermittent preventive
treatment with sulfadoxine-pyrimethamine (SP) is not
recommended in Ethiopia.
Mefloquine remains effective except in certain areas of
resistance.No parenteral preparations are currently available,
and is thus suitable only for patients who can take drugs by
mouth. It is generally well tolerated, although, some adverse
effects have been reported. However, because of the danger of
511

8. Anti-Infectives

the emergence of mefloquine-resistant strains of P. falciparum

and because of its potential toxicity, it should be used only
following either microscopic or careful clinical diagnosis of P.
falciparum infections that are known or strongly suspected to be
resistant to chloroquine.Mefloquine and atovaquone-proguanil
are the recommended chemoprophylactic anti-malaria drugs in
Ethiopia.
In multi-drug resistant malaria, preparations of
artemisinin or its derivatives (artemether or artesunate) offer the
only prospect of cure. They should not be used in the first
trimester of pregnancy. For the treatment of multiresistant
falciparum malaria oral artesunate may be an effective
antimalarial.
A fixed-dose of oral formulation of artemether with
lumefantrine is recommended for the treatment of
uncomplicated falciparum malaria. The combination is not for
use in first trimester pregnancy. AL is used for mixed infections
due to both P.falciparium and P.vivax.
Primaquine is recommended as a radical cure for 14 days for
patients who are not living in malaria endemic areas. In the
otherhand Primaquine is not currently recommended at the
health post level, because the prevalence of glucose-phosphatedehydrogenase (G6PD) deficiency is not known in Ethiopia. As
a result, it is difficult to detect and manage complications of
primaquine at this level.
Pregnancy: malaria is especially dangerous during
pregnancy and the seriousness of the disease usually outweighs
any potential risk from treatment.
For falciparum malaria, the adult treatment doses of oral and
intravenous quinine can safely be given to pregnant women.
In the case of P.vivax or P.ovale, however, the radical
cure with primaquine should be postponed until the pregnancy
512

8. Anti-Infectives

is over; instead chloroquine should be continued at a dose of

600mg each week during the pregnancy.
AL is not recommended for infants under 5 kg and
pregnant women in first trimester with uncomplicated malaria.
Use oral quinine in such cases.
First line of treatment of uncomplicated malariaP. falciparum
positive by multispecies RDT: AL is the recommended firstline drug for treatment of uncomplicated P. falciparum malaria.
AL tablets are given according to body weight in six doses over
three days.
Second line treatment of uncomplicated malaria
AL may be used to treat P. vivax infection when chloroquine is
unavailable. If AL is not available for P. falciparum or mixed
malaria infections, use oral quinine. If both chloroquine and AL
are not available for P. vivax infection, use quinine.
Prophylaxis against malaria
No drug regimen gives assured protection to everybody,
and indiscriminate use of existing antimalarials increases the
risk of inducing resistance.
Mefloquine may be used for prophylaxis in areas of high
risk. Where possible prophylaxis should be started 2-3 weeks
before travel to enable any adverse reactions to be identified
before exposure (over three-quarters of adverse reactions occur
by the third dose) and should be continued for 4 weeks after the
second and third trimesters. It should be used in early pregnancy
only if alternative drugs are either not available or unlikely to be
effective and when it is impracticable for the woman to leave
the endemic area.
Proguanil, a predominantly tissue schizontocide with
little blood schizontocidal activity, is a causal prophylactic
agent since it is active against pre-erythrocytic intrahepatic
forms, particularly of P.falciparum. The latent persistent liver
513

8. Anti-Infectives

forms of P.ovale and P.vivax are unresponsive. However, there

is evidence that it may be effective against P.vivax only
immediately after the initial infection. P.falciparum resistance
to proguanil and related compounds may occur in malaria
endemic areas and particularly where it has been employed in
mass prophylaxis. Proguanil is used for prophylaxis with
chloroquine in areas where there is resistance to chloroquine but
a low risk of infection as it may give some protection against
P.falciparum and may alleviate symptoms if an attack
occurs.Pregnancy:travel to malarious areas should be avoided
during pregnancy; if travel is unavoidable, effective prophylaxis
must be used. Chloroquine and proguanil may be given in usual
doses in areas where P.falciparum strains are sensitive; in the
case of proguanil, folic acid 5mg daily should be given.
Alpha, Beta Arteether
Injection, 150mg/2ml
Indications: Chloroquine resistant malaria, complicated
falciparam malaria and cerebral malaria.
Cautions: Pregnancy, breastfeeding.
Contraindications: Contraindicated in patients with
hypersensitive to artemisinin derivatives.
Dose and Administration:Alpha, Beta arteether is for
intramuscular use only. Adult: 150mg/ml once daily for 3
consecutive days. Children: 3mg/Kg per day administered by
intramuscular injection over a 3-day period.
Storage: Store in cool dark room.
Artemether
Injection, 80 mg/ml, 40 mg /ml, 20 mg/ml
Suppository, 40 mg
Oral suspension, 40 mg/0.5ml, 80mg/ml
514

8. Anti-Infectives

Indications: is an alternative treatment for malaria pre-referral

therapy or alternate severe malaria treatment.
Contraindications: first trimester of pregnancy. IM Artemether
should only be used during the first trimester of pregnancy when
IV/IM artesunate (preferred) and IV/IM quinine are both
unavailable.
Side effects: headache, nausea, vomiting, abdominal pain,
diarrhoea; dizziness, tinnitus, neutropenia, elevated liver
enzyme values; cardiotoxicity; neurotoxicity in animal studies.
Dose and Administration:Adult and Child over 6 months: IM:
loading dose of 3.2 mg/kg, then 1.6 mg/kg daily until patient
can tolerate oral medication or to maximum of 7 days.
Artemether seems to be as effective as IV quinine when given
rectally to infants in coma from cerebral malaria. The initial
dose for babies weighing less than 9 kg was 40 mg (one
suppository). For those weighing more than this it was 80 mg.
All then received a 40 mg suppository once a day for 6 days.
Artesunate
Tablet, 100mg, 200mg, injection, 60mg/ml, Suppository 50mg,
100mg.
Indications: Rectal artesunate treatment for emergency prereferral therapy for severe malaria and treatment of severe
malaria due to P. falciparum.
Cautions: risk of recurrence if used alone in non-immune
patients.
Contraindications: first trimester of pregnancy.
Side effects: headache, nausea, vomiting, abdominal pain,
diarrhoea, dizziness, tinnitus, neutropenia, elevated liver
enzyme values; ECG abnormalities, including prolongation of
QT interval; temporary suppression of reticulocyte response and
induction of blackwater fever, reported.
515

8. Anti-Infectives

Dose and Administration: Rectal artesunate treatment for

emergency pre-referral therapy for severe malaria dosed at
10mg/kg body weight. Once able to tolerate oral medicines,
complete Artemether-lumefantrine (AL) treatment.
Artemether + Lumfantrine
Tablet (dispersible), 20mg + 120mg
Indications:treatment of uncomplicated malaria due to
P.falciparum and mixed infections. AL may be used to treat P.
vivax infection when chloroquine is unavailable.
Cautions:electrolyte disturbances, concomitant administration
of drugs that prolong QT interval; severe renal or hepatic
impairment.
Drug interactions:amiloride, amitriptyline, azithromycin,
chloroquine, chlorpromazine, ciprofloxacin, clomipramine,
erythromycin, fluconazole, fluphenazine, furosemide, grapefruit
juice, hydrochlorothiazide, mefloquine, naldixic acid, ofloxacin,
procainamide,
pyrimethamine,
quinidine,
quinine,
spironolactone, sulfadoxine + pyrimethamine.
Contraindications: pregnancy (first trimester) and infants less
than 5 kg, breastfeeding, history of arrhythmias, of clinically
relevant bradycardia, and congestive heart failure accompanied
by reduced left ventricular ejection fraction.
Side effects: abdominal pain, anorexia, diarrhoea, nausea and
vomiting; headache, dizziness, sleep disorders; palpitations;
arthralgia, myalgia; cough; asthenia; fatigue; pruritus, rash.
Dose and Administration:Oral:Adult: 35-65kg, 4 tablets as a
single dose repeated after 8 hours, then twice daily on the
following 2 days (i.e. 3-day course of 6 doses). Over 65 kg, as
for 35-65 kg, but with closer monitoring for treatment failure /
recrudescence
516

8. Anti-Infectives

Child: 5 - < 15kg, 1 tablet; 15 - < 25kg, 2 tablets; 25 - < 35kg, 3

tablets;
35 65 kg, 4 tablets, repeated after 8 hours,
then twice daily on the following 2 days (i.e. a 3-day course of 6
doses).
Storage: At room temperature.
Chloroquine Phosphate
Tablets, 250mg, 500mg (equivalent to 150mg, 300mg
chloroquine base)
Syrup, 50mg/5ml
Injection, 50mg/ml;(equivalent to 40 mg chloroquine base)
Indications: treatment of P. vivaxmalaria.
Cautions:patients should avoid alcoholic beverages while
taking chloroquine.
Side effects: gastro-intestinal disturbances, headache, also
convulsions, visual disturbances, depigmentation or loss of hair,
skin reactions (rashes, pruritus); rarely, bone-marrow
suppression; other side effects (not usually associated with
malaria prophylaxis or treatment).
Drug interactions: carbamazepine, ciclosporin, digoxin,
ethosuximide, mefloquine, phenytoin and valproic acid.
Dose and administration: Orally with meals or milk and
intramuscularly. Where chloroquine syrup is not available the
tablets can be given to children by crushing and mixing with
sweetened milk on spoon.

517

8. Anti-Infectives

Oral treatment of cases with chloroquine dose table for 150mg

base/tablet or 50mg base/5ml syrup:
Age group in
year

Chloroquine Dosage
(Expressed in mg base and in tablets)

Under 1 year

75mg tab
40 mg tab
75mg tab
75mg tab
150mg 1 tab
75mg tab
75mg tab
75mg tab
300mg 2 tab
150mg 1 tab
150mg 1 tab
150mg 1 tab

STAT
6 hours later
2nd. Day
3rd. day
STAT
6 hours later
2nd. Day
3rd. day
STAT
6 hours later
2nd. Day
3rd. day

450mg 3 tab
225 mg 1 tab
225 mg 1 tab
225 mg 1 tab
600mg 4 tab
300 mg 2 tab
300 mg 2 tab
300 mg 2 tab

STAT
6 hours later
2nd. Day
3rd. day
STAT
6 hours later
2nd Day
3rd day

1 -5 years

6 9 years

10 -15 years

ADULT
(16 years and
over)

Storage: at room temperature.

Dihydroartemisinin
Tablet, 60mg
Dihydroartemisinin appears to offer no advantage over
artesunate or artemether for the treatment of uncomplicated or
severe malaria. However, it may be used in the absence of
micro-scopic diagnosis if the compound is the recommended
first-line treatment.
518

8. Anti-Infectives

Dose and Administration: 4 mg/kg in divided loading dose on

the first day followed by 2 mg/kg daily for 6 days.
Mefloquine hydrochloride
Tablet, 250mg
Indications:prophylaxis of malaria for travelers to areas where
high risk of malaria
Cautions:pregnancy, cardiac conduction disorders; avoid for
prophylaxis in severe hepatic impairment and in epilepsy;
breastfeeding, infants under 3 months.
Drug interactions: artemether + lumfantrine, atenolol,
carbamazepine, chloroquine, digoxin, ethosuximide, nifedipine,
phenytoin, propranolol, quinidine, quinine, timolol, valproic
acid, verapamil.
Contraindications:neuropsychiatric
disorders
including
depression or convulsions; hypersensitivity to quinine.
Side effects: nausea, vomiting, diarrhoea, abdominal pain,
anorexia, headache, dizziness, loss of balance, somnolence,
insomnia and abnormal dreams; neurological and psychiatric
disturbances including sensory and motor neuropathies, tremor,
ataxia, visual disturbances, tinnitus, vestibular disorders;
convulsions, anxiety, depression, confusion, hallucinations,
panic attacks, emotional instability, aggression, agitation and
psychoses; circulatory disorders, tachycardia, bradycardia,
cardiac conduction disorders; muscle weakness, myalgia,
arthralgia; rash, urticaria, pruritus, alopecia; disturbances in
liver function tests, leukopenia, leucocytosis, thrombocytopenia;
rarely, Stevens-Johnson syndrome, atrioventricular block and
encephalopathy.
Dose and Administration: prophylaxis should start 1-3 weeks
departure and continue for 4 weeks after last exposure, 5 mg /kg
mefloquine salt once weekly
519

8. Anti-Infectives

Weight (Kg)

Age (approx.)

<9
9 19
20 30
31 45
36 50+

< 3 months
3 23 months
2 7 year
8 10 year
11 14+

Number of tablets per

week
Not Recommended

Atovaquone-proguanil
Tablet 250mg atovaquone and 100mg proguanil hydrochloride
Indication:Prophylaxis of Plasmodium falciparum malaria
Dosage and administration: Start prophylaxis 1 or 2 days
before entering a malaria-endemic area and continue during the
stay and for 7 days after return.
Contraindication: Prophylaxis of P. falciparum in patients with
severe renal function impairment (Ccr less than 30 mL/min);
hypersensitivity to any component of the product. Weight and
dosage schedule:
Weight Atovaquone/Proguanil HCl
Dosage Regimen
(kg)
Total Daily Dose
11-20
62.5 mg/25 mg
1 Pediatric Tablet daily
21-30
125 mg/50 mg
2 Pediatric Tablets as a single
dose daily
31-40
187.5 mg/75 mg
3 Pediatric Tablets as a single
dose daily
>40
250 mg/100 mg
1 Tablet (adult strength) as a
single dose daily

Primaquine phosphate
Tablet, 7.5mg base, 15mg base
Indications: For the prevention of relapses (radical cure) of
malaria caused by Plasmodium vivax and Plasmodium ovale.
520

8. Anti-Infectives

Cautions: G6PD deficiency, history of acute hemolytic anemia,

systemic disease associated with agranulocytopenia (e.g.
rheumatoid arthritis), and in those patients who are
hypersensitive to Primaquine. Caution is also required during
breast-feeding.
Drug interactions: bone marrow depressants, and other drugs
that cause hemolysis (e.g dapsone).
Contraindications: during pregnancy and in patients with
Glucose 6 phosphate dehydrogenase (G6PD) deficiency.
Side effects: haemolytic anemia especially in G6PD deficiency,
leucopenia, abdominal pain or cramps, nausea, vomiting,
methemoglobinemia (cyanosis - bluish fingernails, lips, or skin,
dizziness or light headedness, difficult breathing, unusual
tiredness or weakness).
Dose and Administration:Adult: : Oral: 26.3mg (15mg base)
once a day for 14 days or 45 mg base once weekly for 8 weeks.
Child:Oral: 0.68mg (0.39mg base) per kg of body weight once a
day for 14 days.
Storage: at room temperature in a well closed, light-resistant
container.
Quinine Dihydrochloride
Tablet, (Dihydrochloride or sulphate), 300mg, 600mg
Injection, 300mg/ml in 1ml ampoule
Indications: quinine is indicated an alternate drug for the
treatment of severe and complicated malaria, and may be used
when the preferred drug, intravenous artesunate, and the
alternate drug IM artemether, is unavailable. Oral quinine is
used as the first-line treatment of uncomplicated p. falciparum
malaria for pregnant women during the first trimester and for
children of less than 5 kg.
521

8. Anti-Infectives

Cautions: during pregnancy and breast feeding, in patients with

atrial fibrillation, conduction defects, heart block and glucose 6
phosphate dehydrogenase (G6DP) deficiency.
Drug interactions: mefloquine, quinidine, cimetidine,
halofantrine, digoxin, antacids, other hemolytics.
Contraindications: haemoglobinuria, optic neuritis and in
patients hypersensitive to quinine or quinidine.
Side effects: cinchonism (blurred vision or change in colour
vision, severe headache, nausea or vomiting, ringing or buzzing
in ears or transient loss of hearing), GIT disturbances
(abdominal or stomach cramps or pain, nausea, vomiting,
diarrhoea), confusion, hypersensitivity reaction (fever,
angioedema, blood disorder including thrombocytopenia and
intravascular coagulation), acute renal failure, hypoglycemia.
ResistantPlasmodium falciparum malaria:
Dose and Administration: Oral:Adult: 600 mg (quinine
sulfate) every 8 hours for 3, 7, or 10 days;Child: 10 mg/kg
(quinine sulfate) every 8 hours for 3, 7, or 10 days; duration of
treatment depends on local susceptibility of P. falciparum and
whether or not additional antimalarials also used.Note: Patient
Advice: If all or part of a dose is vomited within one hour, the same
amount must be readministered immediately.Treatment of multiple-

drug resistant Plasmodium falciparum malaria (in patients

unable to take quinine by mouth): Slow IV infusion (over 4
hours):Adult: 20 mg/kg (quinine dihydrochloride) followed by
10 mg/kg (quinine dihdrochloride) every 8 hours;Child: 20
mg/kg (quinine dihydrochloride) followed by 10 mg/kg (quinine
dihydrochloride) every 12 hours;Initial dose should be halved in
patients who have received quinine, quinidine or mefloquine
during the previous 12 24 hours.
Storage: at room temperature in a well closed container (for
tablet).
522

8. Anti-Infectives

8.4.2. Amoebicides and Antigiardial Agents

Metronidazole is a 5-nitroimidazole derivative with activity
against protozoa and anaerobic bacteria. In amoebiasis,
metronidazole acts as an amoebicide at all sites of infection with
Entamoeba histolytica. Because of its rapid absorption it is
probably less effective against parasites in the bowel lumen and
is therefore used in conjunction with a luminal amoebicide such
as diloxanide furoate or di-iodohydroxyquinoline in the
treatment of amoebic dysentery and in extra-interstinal
amoebiasis, including hepatic amoebiasis.Tinidazole has the
antimicrobial actions of metronidazole and usually administered
as a single dose by mouth with or without food.
Dehydroemetine, a synthetic derivative of emetine, is a tissue
amoebicide with similar actions and uses, although probably of
lower toxicity.
Chloroquine Phosphate
Tablet, 150mg base
Syrup, 50mg base /5ml
Injection, 150mg base in 5ml ampoule
Indications: treatment of extraintestinal amebiasis, usually in
combination with an effective intestinal ameobicide. However,
it is not considered a primary drug. See also under section
7.4.1.
Cautions: pregnancy and breast-feeding, severe blood
disorders, hepatic function impairment; sever neurological
disorders, retinal or visual field changes. See also under section
7.4.1.
Drug interactions: mefloquine, antiepileptics, cardiac
glycosides, and cyclosporin.
Side effects: see under section 7.4.1.
Dose and Administration:Extraintestinal amebiasis:
523

8. Anti-Infectives

Adult: 1g/day (600mg base) for 2 days followed by 500 mg/day

(300 mg base) for at least 2 3 weeks
Child: 10 mg/kg (base) once daily for 2 3 weeks (up to 300
mg base/day)
Storage: Store in a well-closed container and at room
temperature.
Dehydroemetine
Injection, 30 mg/ml in 1 and 2 ml ampoules
Indications: treatment of intestinal amoebiasis.
Cautions:breast-feeding, pregnancy, severe disease of any
organ.
Contraindications:cardiac, renal, or neuromuscular disease.
Side effects:nausea, vomiting, diarrhoea, weakness, low blood
pressure, irregular heartbeats, pain at the injection site
Dose and Administration:Adult: IM: 1mg/kg daily (maximum
daily dose of 60 mg), generally for up to 4 6 day, but no more
than 5 days in children. Elderly or severely ill patients, 0.5
mg/kg
Storage: store at room temperature.
Diloxanide Furoate
Tablet, 500mg
Indications: chronic amoebiasis, intestinal amoebiasis. It is a
drug of choice for asymptomatic patients with E.histolytica
cysts in the faces.
Side effects: flatulence, vomiting, urticaria, pruritus
Dose and Administration:Oral:Adult: 500mg 3 times daily for
10 days. Child over 25 kg, 20mg/kg daily in 3 divided doses for
10 days; course may be repeated if necessary.
Metronidazole
Table/Capsule, 250mg
524

8. Anti-Infectives

Syrup 4% w/v, 250mg/5ml,200mg/5ml,250mg/5ml

Suspension (oral), 125mg/5ml
Intravenous infusion, 5mg / ml in 100ml
Suppositories, 500mg
Indications: invasive amoebiasis and giardiasis, trichomoniasis,
tissue nematode infections, bacterial infections (section 7.1.2);
Helicobacter pylori eradication.
Cautions, Drug interactions, Contraindications, Side effects
-see section 7.1.2 under metronidazole.
Dose and Administration:Invasive amoebiasis: Oral: Adult
and Child: 30mg/kg daily in 3 divided doses for 8 - 10 days;
subsequent course of luminal amoebicide.
Invasive amoebiasis (if oral administration not possible): IV
infusion: Adult and Child: 30 mg/kg daily in 3 divided doses
(until patient able to complete course with oral drugs),
subsequent course of luminal amoebicide.
Giardiasis: Oral: Adult: 2g once daily for 3 days,
Child: 15mg/kg daily in divided doses for 5 - 10 days.
Urogenital trichomoniasis: Oral: Adult: 2g as a single dose or
400 500 mg twice daily for 7 days; sexual partners should be
treated concomitantly.
Note 1: In amoebiasis and giardiasis, various dosage regimens are
used and definitive recommendations should be based on local
experience.
Note 2: Patient Advice: Metronidazole tablets should be swallowed
whole with water, during or after a meal; metronidazole suspension
should be taken ne hour before a meal.

Storage: at room temperature, in a well closed, light resistant

container.
Tinidazole
Tablet, 250mg, 500mg
525

8. Anti-Infectives

Indications: in the treatment of susceptible protozoal infections

and in the treatment and prophylaxis of anaerobic bacterial
infections.
Cautions: see under metronidazole; avoid porphyria
Drug interactions: alcohol
Side effects: see under metronidazole
Dose and Administration:Intestinal amoebiasis, 2gm daily for
2 - 3 days; Child: 50 - 60 mg/kg daily for 3 days.Amoebic
involvement of liver, 1.5 - 2gm daily for 3 - 6 days, Child: 50 60mg/kg daily for 5 days.
Urogenital trichomoniasis and giardiasis, single 2gm dose
(repeated once if necessary); Child: single dose of 50 - 75
mg/kg.
Ornidazole
Tablet, 500mg
Indication: treatment of susceptible protozoal infections
(amoebiasis, giardiasis, and trichomoniasis) and also in
treatment and prophylaxis of anaerobic bacterial infections
Cautions: use of ornidazole should be avoided during
pregnancy and breast feeding mothers, do not take alcohol while
taking ornidazole
Contraindications: contraindicated in patients who are
hypersensitive to the ornidazole
Side effects: dose related side effects such as gastrointestinal
disturbances, nausea and vomiting, weakness, dissiness,
drowsiness, insomnia, changes in mood and peripheral
neuropathy
Drug interactions: alcohol, disulfiram
Dose and administration: adults oral: amoebiasis 500 mg
twice daily for 5 to 10 days, for amoebic dysentery or amoebic
liver abscess 1.5 g as a single dose for 3 days
526

8. Anti-Infectives

Children: 25 mg per kg body weight as a single dose for 5 to 10

days, amoebic dysentery 40 mg per kg as a single dose for 3
days. Trichomoniasis: adults: a single dose of 1.5 g or a 5 day
course of 500 mg twice daily, children: 25 mg per kg as a single
dose
8.4.3. Leshmaniacides
Leishmaniasis is caused by the protozoa leishmania. It can be
categorized as visceral, cutaneous or mucocutaneous. It may be
a self-limiting localized skin lesion but may range from this to
disseminated progressive disease. In endemic areas there is
usually a reservoir of disease in a mammalian host and the usual
vectors are sand flies.
Sodium Stibogluconate, an organic pentavalent
antimony compound, is the treatment of choice for visceral
leishmaniasis. The dose is 20mg/kg daily (max. 850 mg) for at
least 20 days by intramuscular or intravenous injection; the
dosage varies with different geographical regions and expert
advice should be obtained. Skin lesions are treated for 10 days.
Amphotericin is used with or after an antimony
compound for visceral leishmaniasis unresponsive to the
antimonial alone; side effects may be reduced by using
liposomal amphotericin at a dose of 1-3mg/kg daily for 10 - 21
days to a cumulative dose of 21- 30mg/kg.
Pentamidine Isethionate has been used in antimony
resistant visceral leishmaniasis, but although the initial response
is often good, the relapse rate is high; it is associated with
serious side effects.
Amphotericin B
Powder for injection, 50mg / vial
Liposomal injection, 10mg, 50mg / vial,
527

8. Anti-Infectives

Logenzegs, 10mg
Oral suspension,100mg/ml
Indications:leishmaniasis
Cautions, Drug interactions, and Side effects (see section
7.2).
Dose and Administration: Adult: IV infusion: 0.25 mg/kg/day,
increased gradually to 0.5-1mg/kg/day; total dose 13g.Liposomal
injection:treatment
of
visceral
leishmaniasis:Immunocompetent patients: 3 mg/kg/day on days
1-5, and 3 mg/kg/day on days 14 and 21; a repeat course may be
given in patients who do not achieve parasitic
clearance.Immunocompromised patients: 4 mg/kg/day on days
1-5, and 4 mg/kg/day on days 10, 17, 24, 31, and 38.
Paramomycine
Injection 375mg/ml
Indication: Paromomycin sulfate is indicated for intestinal
amebiasisacute and chronic (Note- It is not effective in
extraintestinal amebiasis); management of hepatic comaas
adjunctive therapy.
Note: this medicine is aminoglycoside antibiotic, prescribed for
certain types of intestinal infections such as amebiasis,
cryptosporidiosis and leishmaniasis.

Cautions: in patients with history of hearing problems, ulcer,

myasthenia gravis, Parkinson disease or kidney problems,
dehydration, any allergy, who are taking other medications,
elderly, children, during pregnancy and breastfeeding.
Contra indications:Hypersensitivity to the medicine or any
component of the formulation. It is also contraindicated in
intestinal obstruction.
Side-effects: Nausea, vomiting, abdominal cramps and diarrhea.
528

8. Anti-Infectives

Dose and Administration:Intestinal amebiasis: Adults and

Pediatric Patients: Usual dose25 to 35 mg/kg body weight
daily, administered in three doses with meals, for five to ten
days. Management of hepatic coma: Adults: Usual dose4 g
daily in divided doses, given at regular intervals for five to six
days.
Storage:Store it at controlled room temperature (20-25C) and
in an airtight container.
Pentamidine Isethionate
Powder for injection, 200mg, 300mg/ vial
Indications: pentamidine is used parenterally in the treatment
of early African Trypanosomiasis, of various forms of
leishmaniasis, and of pneumonia due to pneumocystis carinii.
Cautions: avoid rapid intravenous administration of
pentamidine. Patients should remain supine during
administration and their blood pressure should be monitored.
Pentamidine should be used under close supervision and great
care. Caution should be taken during pregnancy, breastfeeding
(breast-feeding is not recommended during pentamidine therapy
because of the potential risks to the new born), and in geriatric
patients. Patients should be instructed in proper oral hygiene
during treatment, including caution in use of regular
toothbrushes, dental floss, and toothpicks. Pentamidine
Isethionate should be used with caution when the following
medical problems exist: bleeding disorder; bone marrow
depression, cardiac disease or arrhythmias, dehydration, renal
function impairment, diabetes mellitus, hypoglycemia, &
hypotension.
Drug interactions: bone marrow depressants, radiation therapy,
and didanosine, foscarnet, nephrotoxic medications.
Contraindications: previous allergic reaction to pentamidine.
529

8. Anti-Infectives

Side
effects:
nephrotoxicity,
leucopenia,
anaemia,
thrombocytopenia, raised liver enzyme, hypoglycaemia
followed by hyperglycaemia and insulin dependent diabetes
mellitus, hypotension, the IM administration often causes pain,
swelling, sterile abscess formation, and muscle necrosis at the
site of injection.
Dose and Administrations:Note:Pentamidine is toxic when given
by injection and can affect the kidney, liver, blood and pancreas but
systemic effects are rare following inhalation.Adult:Leishmaniasis

visceral:Intravenous infusion, 2 to 4 mg per Kg of body weight,

administered over one to two hours, once a day for up to fifteen
days. Administration may be repeated in one to two weeks if
required.Leishmaniasis, cutaneous: Intravenous infusion, 2 to 4
mg per kg of body weight, administered over one to two hours,
once or twice a week until the lesions heal.Trypanosomiasis,
African (without CNS involvement): Intravenous infusion, 4 mg
per Kg of body weight, administered over one to two hours,
once a day for ten days.Pneumonia, Pneumocystis
carinii:Intravenous infusion, 4 mg per Kg of body weight,
administered over one to two hours. Once a day for fourteen to
twenty-one days, depending on clinical response.Usual adult
prescribing limits:Trypanosomiasis, African 3 to 5 mg per Kg
of body weight a day. Child: See adult dose
Storage: Prior to reconstitution, store between 2oc and 8oc (36oF
and 80oF), unless other wise specified by manufacturer. Protect
dry powder and reconstituted solution from light.
Sodium Stibogluconate
Injection, 100mg/ml
Indications: a primary agent in the treatment of Leishmaniasis.
It is treatment of choice for visceral leishmaniasis.
530

8. Anti-Infectives

Cautions: hepatic impairment, pregnancy, IV injection must be

given slowly over 5 minutes (to reduce risk of local thrombosis)
and stopped if coughing and substernal pain, mucocutaneous
disease, heart-disease occur. Treat intercurrent infections (e.g.
Pneumonia)
Contraindications: significant renal impairment, breastfeeding.
Side effects:anorexia, nausea, vomiting, abdominal pain,
headache, lethargy, myalgia, raised liver enzyme, coughing and
substernal pain, rarely anaphylaxis, fever, sweating, flushing,
vertigo, bleeding from nose and gum, jaundice, rash, pain and
thrombosis on IV administration, IM injections is also painful.
Dose and Administration: See notes above.
8.4.4. Trypanocides
African trypansomiasis, or sleeping sickness, is a protozoan
infection transmitted by Glossina Spp. (tsetse flies). Two
subspecies of Trypanosoma brucei- T. brucei gambiense and
T.brucei rhodesiense - produce distinctive clinical forms of the
diseases.The early stage of African Trypanosomiasis results
from infection of the blood stream and lymph nodes. The late
meningoencephalitic stage results from infection of the central
nervous system.
The drugs used for treatment are pentamidine, suramin
and melarsoprol.Treatment of early-stage infections of
T.b.rhodesiense with suramin sodium and T.b. gambiense with
Pentamidine Isethionate can be curative if started before the
central nervous system has become involved. In areas where
pentamidine resistance occurs, suramin sodium may be used for
T.b.gambiense infection. Melarsoprol is used for confirmed
cases of T.b.rhodesiense and T.b. gambiense with
meningoencephalitic involvement.
531

8. Anti-Infectives

Melarsoprol
Powder for injection, 36 mg/ml
Indications: treatment of meningoencephalitic stage of T.b.
gambiense or T.b. rhodesiense infections.
Cautions: episodes of reactive encephalopathy, pneumonia and
malaria, malnutrition; G6PD deficiency, leprosy.
Contraindications: pregnancy, influenza epidemics.
Side effects: fatal reactive encephalopathy characterized by
headache, tremer, slurred speech, convulsions and ultimately
coma, myocardial damage, albuminuria, hypertension,
hypersensitivity reactions, agranulocytosis, dose-related renal
and hepatic impairment, hyperthermia, urticaria, headache,
diarrhoea and vomiting - in late stage of treatment.
Dose and Administration: Adult and Child:Slow IV injection:
gradually increased from 1.2 mg/kg to maximum of 3.6 mg/kg
daily in courses of 3 - 4 days with intervals of 7 - 10 days
between courses or 2.2 mg/kg daily for 10 days.
Storage: store at room temperature.
Melarsonyl potassium
Powder for injection, 200mg
Melarsonyl potassium is a water-soluble derivative of
melarsoprol which was formerly used as an alternative to
melarsoprol but was probably more toxic and less effective.
Pentamidine Isethionate
Powder for injection , 200mg, 300mg/ vial
Indications, Cautions, Drug interactions, Contraindications,
Side effects, see under leshmaniacides (section 7.4.3)
Dose and Administration:Treatment of haemolymphatic stage
of T.b gambiense infection: IM injection: Adult and Child: 4
mg/kg daily or on alternative days for a total of 7 - 10 doses.
532

8. Anti-Infectives

Treatment of meningoencephalitic stage of T.b.gambiense (prior

to melarsoprol): IM injection: Adult and Child: 4mg/kg daily
on days one and two. Note: Reconstitution and Administration.
According to manufacturer's directions, Pentamidine Isethionate is
toxic; care is required to protect personnel during handling and
administration.

Suramin Sodium
Powder
for injection 1gm / vial
Indications: Suramin is a trypanocide used in the treatment of
the early stages of African trypanosomeasis.
Cautions, Contraindications,Side effects; see under suramin
sodium, section 7.5.1
Dose and Administration: Suramin is not used as a sole
therapy for late stage infection with central nervous
involvement. Because of the danger of sever reaction, a test
dose of 100 - 200mg should be given before initial treatment.
Adult: IV if test dose tolerated - 20mg per kg of body weight of
suramin up to maximum of 1gm in adults given every 5 or 7
days, usually to a total of 5 injections and not exceeding of
injections.
8.4.5. Medicines for Toxoplasmosis
Toxoplasmosis is caused by infection with the protozoan
parasite
Toxoplasma
gondii.
Toxoplasmosis
in
immunocompetent individuals is usually asymptomatic.
Patients with impaired immunity may develop serious
complications such as encephalitis, myocarditis, and
pneumonitis.
The treatment of choice is a combination of
pyrimethamine and sulfadiazine. Calcium folinate should also
be given every third day during treatment to counteract
533

8. Anti-Infectives

megaloblastic anaemia. Treatment is ideally continued for

several weeks after clinical cure. Prolonged even life long,
maintenance therapy should be considered for AIDS patients
since the tissue cyst forms of T.gondii will not have been
affected by the initial treatment.
Congenital toxoplasmosis is not a problem in women
who have toxoplasma antibody before conception but primary
toxoplasmosis during early pregnancy is serious because of the
risk of transplacental transmission, which may result in foetal
death or congenital toxoplasmosis.
Clindamycin has some antiprotozoal actions, and has
been used, usually with other antiprotozoals, in various
infections including toxoplasmosis. Clindamycin with
pyrimethamine has been used for treatment of toxoplasmosis
instead of the more usual treatment with pyrimethamine plus
sulfadiazine, in patients unable to tolerate sulfonamides.
Clindamycin
Capsule, 75 mg, 150 mg
Injection, 150 mg/ml in ampoule
Oral solution, 15 mg/ml
Indications: treatment for toxoplasmosis.
Cautions, Drug interactions, Contraindications, Side effects
and Storage see section 7.1.2.
Dose and Administrations:patients with AIDS and toxoplasmic
encephalitis: Oral: Clindamycin 600mg every 6 hours for at
least 3 weeks, maintenance, 1200mg daily; patients also
received pyrimethamine or Clindamycin 600mg four times daily
together with pyrimethamine 75mg daily for 6 weeks.Acute
therapy with pyrimethamine and clindamycin 600mg four times
daily by mouth or 1200mg every 6 hours intravenously.
534

8. Anti-Infectives

Primaquine Phosphatesee above

Tablet, 15 mg
Pyrimethamine
Tablet, 25mg
Indications: in combination with sulfapyrimedine - type
sulfonamide in the treatment of toxoplasmosis.
Cautions: pregnancy and breast-feeding, hepatic function
impairment and in those patients hypersensitive to
pyrimethamine.
Drug interactions:bone marrow depressants, folate antagonists.
Contraindications: pregnancy (14 or 16 weeks),
hypersensitivity, history of seizures disorders, anaemia and bone
marrow depression.
Side effects: Atrophic glossitis (pain, burning, or inflammation
of the tongue, change in or loss of taste), blood dyscrasias,
specifically agranulocytosis (fever, sore throat), megaloblastic
anaemia (unusual tiredness, or weakness), or thrombocytopenia
(unusual bleeding or bruising), GIT disturbance (anorexia,
Nausea, vomiting, diarrhoea), Hypersensitivity (skin rash).
Dose and Administration:Toxoplasmosis (in second and third
trimesters of pregnancy): Oral: Adult: 25mg daily for 3-4
weeks.Toxoplasmosis in neonates: Oral: 1 mg/kg daily; duration
of treatment depends on whether neonate has overt diseasecontinue for 6 months, or is without overt disease but, born to
mother infected during pregnancy-treat for 4 weeks, followed
by further courses if infection confirmed.Toxoplasmosis in
immunodeficiency: Oral: Adult: 200mg in divided doses on first
day, then 75-100mg daily for at least 6 weeks, followed by a
suppressive dose of 25-50mg daily.

535

8. Anti-Infectives

Chorioretinitis: Oral: Adult: 75mg daily for 3 days then 25mg

daily for 4 weeks; in unresponsive patients, 50 mg daily for a
further 4 weeks.
Note: for the treatment of toxoplasmosis, pyrimethamine must always
be taken with sulfadiazine. Take with meals and continue medicine
with full time of treatment.

Storage:at room temperature in a tight, light-resistant container.

Spiramycin
Tablet, 3 mega unit
Indications: for treatment of toxoplasmosis.
Caution, Drug interactions and Side effects see erythromycin
(section 7.1.2).
Dose and Administration:Oral: Adult: 6-9 million units daily,
in 2 or 3 divided doses. Doses of up to 15 million units have
been given daily in divided doses for severe infections.
Storage: store at room temperature.
Sulfadiazine
Tablet, 500mg
Indications: toxoplasmosis (with pyrimethamine); rheumatic
fever
Cautions: hepatic and renal impairment; maintain adequate
fluid intake (to avoid crystalluria); avoid in blood disorders
(unless under specialist supervision); monitor blood counts and
discontinue immediately if blood disorder develops; rashes discontinue immediately; elderly; asthma, G6PD deficiency;
pregnancy - avoid in first trimester, but may be given thereafter
if danger of congenital transmission; breast feeding; see also
interactions.
Drug interactions: ciclosporin, glibenclamide, pyrimethamine
& co-trimoxazole (increased risk of antifolate effect), Warfarin
536

8. Anti-Infectives

Contraindications: hypersensitivity to sulfonamides, severe

renal failure or severe hepatic impairment, porphyria.
Side effects: nausea, vomiting, diarrhea, headache,
hypersensitivity reactions
including
rashes,
pruritus,
photosensitivity reactions, exfoliative dermatitis, and erthema
nodosum; rarely, erythemamultiforme and toxic epidermal
necrolysis; crystalluria resulting in haematuria, oliguria, anuria,
blood disorders including granulocytopenia, agranulocytosis,
aplastic anaemia, purpura - discontinue immediately, liver
damage, pancreatitis, antibiotic - associated colitis, eosinophilia,
cough and shortness of breath, pulmonary infiltrates, aseptic
meningitis, depression, convulsions, ataxia, tinnitus, and
electrolyte disturbances .
Dose and Administrations:Toxoplasmosis (in second and third
trimesters of pregnancy): Oral: Adult: 3g daily in 4 divided
doses.Toxoplasmosis in neonates: Oral: 85mg/kg daily in 2
divided doses; duration of treatment depends on whether the
neonate has overt disease continue for 6 months, or is without
overt disease but born to mother infected during pregnancy treat for 4 weeks, followed by further courses, if infection
confirmed.Toxoplasmosis in immunodeficiency: Oral: Adult: 4
- 6g daily in 4 divided doses for at least 6 weeks, followed by a
suppressive dose of 2 - 4g daily.
Note: For the treatment of toxoplasmosis, Sulfadiazine must always
be taken with pyrimethamine.

Storage: below 30oc in a tight container, protect from light.

Sulfadoxine +Pyrimethamine
Tablet, 500mg +25mg
Injection, 500mg +25mg in2.5ml ampoule
Indication: Toxoplasmosis
537

8. Anti-Infectives

Contraindications: should not be given to pregnant women

whose gestational age is less than 16 weeks (4 months)
Dose and Administration: two tablets (1000mg+ 50mg) twice
daily for two days then two tablets daily for six weeks.
8.5. Anthelmintics
8.5.1. Filaricides
Filarial nematode infections are endemic in large areas of the
tropics and produce considerable morbidity. These are loiasis
(arises from infections with loa loa), lymphatic filariasis (by
wuchereria bancorofti, brugia malayi, or B.timori),
onchocerciasis (river blindness, is caused by infection with the
filarial nematode onchocerca volculus), mansonella infections.
Diethylcarbamazine is effective against microfilariae
and adults of loa loa, Wuchereria bancrofti, and Brugia malayi.
To minimise reactions, treatment is commenced with a dose of
diethylcarbamazine citrate 1 mg/kg on the first day and
increased gradually over 3 days to 6mg/kg daily in divided
doses; this dosage is maintained for 21 days and usually gives a
radical cure for these infections. Close medical supervision is
necessary particularly in the early phase of treatment. In heavy
infections there may be a febrile reaction, and in heavy loa loa
infection there is a small risk of encephalopathy. In such cases
treatment must be given under careful in-patient supervision and
stopped at the first sigh of cerebral involvement. (And specialist
advice sought).
Ivermectin is very effective in onchocerciasis and it is
now the drug of choice. A single dose of 150 micrograms/kg by
mouth produces a prolonged reduction in microfilarial levels.
Retreatment at intervals of 6 to 12 months depending on
symptoms must be given until the adult worms die out.
538

8. Anti-Infectives

Reactions are usually slight and most commonly take the form
of temporally aggravation of itching and rash.
Suramin is the only macrofilaricide that is currently
available for use against Onchocera volvulus. Administered
intravenously over a period of several weeks suramin also kills
microfilariae.It is, however, one of the most toxic substances
used in clinical medicine and should always be given under
medical supervision in a hospital. A careful assessment must
always be made of the patient's capacity to withstand the effects
of suramin treatment both before and during administration.
Diethyl Carbamazine Citrate
Tablet, 50 mg
Indications: in the treatment of lymphatic filariasis due to
Wuchereria bancrofti (bancroftian filariasis), Brugia malayi, or
B. timori. It is also used in loiasis due to Loa loa and also for
toxocariasis.
Cautions: treatment with diethyl carbamazine should be closely
supervised since hypersensitivity reactions are common and
may be severe, especially in patients with onchocerciasis or
loiasis.Avoid mass treatment schedules for infants, pregnant
women, the elderly and debilitated patients, especially those
with cardiac or renal disease. Caution if dizziness, loss of
vision, night blindness, or tunnel vision occurs. Diethyl
carbamazine should be administered with caution (eg. Gradually
increasing doses) to prevent or minimize allergic reactions.
Side effects: itching and sweating of face, especially eyes;
fever, lymphadenopathy; skin rash and visual disturbances;
nausea; vomiting; headache; dizziness, drowsiness.
Dose
and
Administration:Oral:Lymphatic
filariasis
(bancroftian):Adult and Child over 10 years: 6mg/kg daily,
preferably in divided doses after meals, for 21 days; Child under
539

8. Anti-Infectives

10 years, half the adult dose; mass treatment program, Adult and
Child over 10 years, 6mg/kg in divided doses over 24 hours,
once a year; Child under 10 years, half the adult dose.Lymphatic
filariasis (brugian): Adult and Child over 10 years, 3-6mg/kg,
preferably in divided doses after meals, for 6-12 days; Child
under 10 years, half the adult dose; mass treatment control
program, Adult and Child over 10 years, 3-6mg/kg in divided
doses over 24 hours, 6 times at weekly or monthly intervals;
Child under 10 years, half the adult dose. Occult filariasis:
Adult: 8mg/kg daily for 14 days, repeated as necessary if
symptoms return.
Loiasis, treatment: Adult: 1mg/kg as a single dose on the first
day, doubled on two successive days, then adjusted to 2-3mg/kg
3 times daily for a further 18 days. Loiasis, prophylaxis: Adult:
300mg weekly for as long as exposure occurs
Note: Diethyl Carbamazine should be taken immediately after meals.

Storage: in airtight containers at room temperature.

Ivermectin
Tablet, 3mg, 6mg (scored)
Indications: suppressive treatment of onchocerciasis; as a
secondary agent in the treatment of bancroftian filariasis caused
by wucheria bancrofti.
Cautions: breast-feeding (avoid treating mother until infant is 1
week old).
Contraindications: pregnancy (delay treatment until after
delivery), hypersensitivity to ivermectin.
Side effects: Mazotti like reaction, specifically arthralgia or
myalgia (joint or muscle pain), dizziness, fever, headache,
lymphadenopathy (painful and tender nodes in necks, armpits,
or groin), skin rash or itching - due to death of microflaria in
540

8. Anti-Infectives

skin; or unusual tiredness or weakness; postural hypotension

(light headedness while standing).
Dose and Administration:Bancroftian filariasis: Oral: Adult:
200mcg (0.2mg) per kg of body weight as a single dose.
Suppression of microfilariae: Oral: Adult and Child over 5 years
(and weighing over 15kg), 150mcg/kg as a single dose once a
year.
Note: avoid food or alcohol for at least 2 hours before and after a
dose.

Storage: at room temperature in a well-closed container.

Primaquine see baove
Tablet, 15 mg
Suramin Sodium
Powder for injection, 1gm in vial
Indications:
curative
treatment
of
onchocerciasis;
trypanosomiasis (sec. 7.4.4)
Cautions: administer only under close medical supervision in
hospital and with general condition of patient improved as far as
possible before treatment (see notes above); first dose - possible
loss of consciousness (see under dosage, below); maintain
satisfactory food and fluid intake during treatment; urine tests
before and weekly during treatment - reduce dose if moderate
albuminuria, discontinue immediately if severe albuminuria or
casts in urine.
Contraindications:previous anaphylaxis or suramin sensitivity,
pregnancy (delay treatment until after delivery); severe liver or
renal function impairment; elderly or debilitated; total blindness
(unless required for relief from intensely itchy lesions).
Side effects: nausea, vomiting, shock, loss of consciousness
reaction such as urticaria and pruritis, and later paraesthesia,
541

8. Anti-Infectives

hyperaesthesia of the palms and soles, skin eruptions, fever,

photophobia and lachrymation, albuminuria, haematuria.
Dose
and
Administration:Curative
treatment
of
onchocerciasis: slow IV injection: Adult 3.3mg/kg as a single
dose (see first (test) dose administration, below), followed at
weekly intervals by incremental doses of 6.7 mg/kg, 10.0mg/kg,
13.3 mg/kg, 16.7 mg/kg, and 16.7mg/kg on weeks 2 to 6
respectively (total dose 66.7 mg/kg over 6 weeks). Reconstitute
in water for injections to produce a final concentration of
10%.First (test) dose: Administer first dose with particular
caution; wait at least 1 minute after injecting the first few
microlitres; inject the next 0.5ml over 30 seconds and wait 1
minute; inject the remainder over several minutes.
8.5.2. Schistosomicides
Schistosomiasis, a waterborne parasitic infection, is caused by
several species of trematode worms (blood flukes).
Intestinal schistosomiasis is caused principally by Schistosoma
mansoni as well as S.japonicum, S.mekongi, and S.intercalatum.
Urinary schistosomiasis is caused by S.haematobium. The latter
is an important predisposing cause of squamous cell cancer of
the bladder.
Praziquantel is used for the treatment of chronic schistosomiasis
and is effective against all species of schistosomes.
Metrifonate and oxamniquine are also used but are only
effective against S.haematobium and S.mansoni respectively.
Antischistosomal drugs may cause clinical deterioration if used
during the acute phase of infection; treatment is either delayed
or given in conjunction with a corticosteroid.
Metrifonate
Tablet, 100mg
542

8. Anti-Infectives

Indications: urinary schistosomiasis due to S.haematobium.

Cautions: avoid for those recently exposed to insecticides or
other agricultural chemicals with anticholinesterase activity;
pregnancy.
Drug interactions: depolarizing muscle relaxants such as
suxamethonium (avoid for at least 48 hours), organophosphorus
insecticides.
Side effects: cholinergic side effects, nausea, vomiting,
abdominal pain, diarrhea, headache, dizziness, and weakness.
Dose and Administration:Oral: 7.5mg/kg in three doses at
intervals of 2 weeks.
Storage:Store at a temperature not exceeding 25oc.
Oxamniquine
Capsule, 250mg
Suspension, 250ml/5ml
Indications: intestinal schistosomiasis due to Schistosoma
mansoni (acute stage and chronic hepatosplenic disease)
Cautions: epilepsy, pregnancy, breast-feeding. May impair
ability to perform skilled tasks, for example operating
machinery, driving.
Side effects: dizziness and drowsiness, headache, vomiting,
diarrhea, intense reddish discoloration of urine occur
commonly; rarely, urticaria, hallucinations, epileptiform
convulsions; raised liver enzyme values; transient fever,
eosinophilia.
Dose and Administration:Intestinal Schistosomiasis due to
S.mansoni (East and central Africa, Arabian peninsula):Oral:
Adult and Child 30mg/kg in 2 divided doses.
Storage: at room temperature in a tight container.
Praziquantel
Tablet, 600mg
543

8. Anti-Infectives

Indication: treatment of schistosomiasis; intestinal tapeworm

infections (T. solium, T. saginata, D. latum and H. nana);
cysticercosis caused by T. solium.
Cautions: moderate to severe liver disease and in those
hypersensitive to praziquantel; pregnancy and breast-feeding,
nursing mothers (discontinue breast-feeding on the day of
therapy and for 72 hours thereafter). The drug causes
drowsiness that patients are to be advised not to drive vehicles
or operate machineries.
Side effects:CNS effects (dizziness, drowsiness, headache,
malaise), fever, GIT effects (abdominal cramps or pain, loss of
appetite, nausea or vomiting, bloody diarrhoea), increased
sweating, skin rash, hives or itching.
Dose and Administration:Oral: Adult and Child (above 4):S.
haematobium, S.mansoni:Oral: 20mg per kg of body weight
two times a day for 1 day. S.Japonium, S. mekongi:Oral: 20mg
per kg of body weight 3 times a day for 1 day.T. solium, T.
saginata, infections: 5-10mg/kg as a single dose.H. nana
infection: 15-25 mg/kg as a single dose. D. latum infection: 1025mg/kg as a single dose. Cysticercosis: 50mg/kg daily in 3
divided doses for 14 days with prednisolone (or similar
corticosteroid) given 2-3 days before and throughout treatment
period.
Storage: store below 30oc
8.5.3. Other Anthelmintics
Albendazole
Tablet, 200mg, 400mg
Oral Suspension, 100mg/5ml
Indications: for the treatment of single or mixed intestinal
nematode infection such as ascariasis, enterbiasis, hookworm
544

8. Anti-Infectives

infection, or trichuriasis and strongyloidiasis. Also for treatment

of hydatid disease caused by Echinococcus glanulosus
Cautions: breast-feeding. Exclude pregnancy before starting
treatment.
Contraindications: pregnancy.
Side effects: GIT disturbances, headache, dizziness, changes in
liver enzyme, rarely reversible alopecia (loss of hair), rash,
fever, blood disorders, including leucopenia and pancytopenia.
Dose and Administration:Adult and Child over 2 years:
Oral:Single or mixed intestinal parasites:Oral: 400 mg as a
single dose (given for 3 days in heavy mixed infestations
involving Trichuris or Taenia spp.). Repeated after 3 weeks if
required.
Strongyloidiasis: 400mg given once or twice daily for 3
consecutive days. May be repeated after 3 weeks.
Giardiasis: 400 mg once daily for 5 days
Hydatid:<60 kg: 15mg/kg/day in 2 divided doses (maximum:
800mg/day); 60 kg body weight: 400mg twice daily.
Administer dose for three 28-day cycles with a 14-day drug-free
interval in between.
Storage: at room temperature.
Levamisole
Tablet, 40mg
Indications: treatment of ascariasis, hookworm and mixed
ascariasis with hookworm infections; with fluorouracil for the
treatment of colorectal carcinoma after complete resection of
primary tumour.
Cautions: sensitive to levamisole
Drug interactions: anticoagulants (cumarine and indandione),
bone marrow depressants.
545

8. Anti-Infectives

Contraindications: advanced liver or kidney disease, preexisting blood disorders.

Side effects: nausea, vomiting, abdominal pain, dizziness and
headache.
Dose and Administration:Oral:Adult: 120mg (3 tablets) as a
single dose. Child: 3mg per kg of body weight as a single dose.
Mebendazole
Tablets, 100mg, 500mg
Oral suspension, 100mg/5ml
Indications: For the treatment of whipworm (trichuris
trichuria), pinworm (Enterobius Vermicularis), roundworm
(Ascaris Lumbricoids), hookworm (Ancylostoma duodenale,
Nectar americanus), and capillariasis in single or mixed
infections.
Cautions: ulcerative colitis, liver diseases, hypersensitivity,
treatment of intestinal worm is recommended in children over 1
year of age, there is limited data to assess the risk-benefit in
those under one year. During pregnancy and in nursing women.
In hookworm and whipworm infections iron supplements may
be required as anemia may occur.To prevent reinfection all
other infected member of the family should be treated. Personal
hygiene and sanitation should be observed and all bedding and
nightclothes washed after treatment, especially in pinworm
infection.
Side effects:transient abdominal pain or upset, nausea,
vomiting, diarrhoea, dizziness, headache, skin rash and itching
may occur occasionally in cases of massive infection and
expulsion of worms.
Dose and Administration:Oral: Adult and Child over 1 year:
Ascariasis: 500mg as a single dose or 100mg twice daily for 3
days.
546

8. Anti-Infectives

Hookworm infections, trichuriasis: 100mg twice daily for 3

days; if eggs persist in the faeces, second course after 3-4
weeks; alternatively 500mg as a single dose.
Adult and Child over 2 years:Enterobiasis: 100mg as a single
dose, repeated after interval of 2-3 weeks; all household
members over 2 years should be treated at the same
time.Capillariasis: 200mg daily for 20-30 days; for mass
treatment control programmes, 500mg as a single dose 4 times a
year.Roundworm, Whipworm, Hookworm mixed infection:
100mg twice daily, morning and evening, for 3 consecutive
days. May be repeated in 2- 3 weeks if required.Tapeworm
(Taenia spp.): 100 mg twice daily for 6 days. There are reports
of high success rates with higher doses for shorter periods
(200mg twice daily for 4 days or 300mg twice daily for 3 days).
Repeat after 3 weeks if necessary.
Storage: at room temperature, in well-closed containers.
Niclosamide
Tablet (chewable), 500mg.
Indications: eradication of tapeworm and H.nana.
Cautions:caution in patients with hypersensitivity to
niclosamide, in children under 2 years and during pregnancy.
Side effects:nausea or vomiting, stomach pain, bad taste in
mouth, dizziness, drowsiness, skin rash and itching may rarely
occur.
Dose and Administration: Oral: preferably after a light meal
or breakfast. Tablets should be crushed or chewed thoroughly
and washed down with a small amount of water.
For small children tablets should be grounded as finely as
possible and mixed with small amount of water.
In those with chronic constipation a mild laxative may be given
before or after administering the drug.
547

8. Anti-Infectives

A second course of niclosamide may be given if proglotides and

/or ova persist for 7 14 days after treatment.Adult: tapeworm:
2g H.nana: 2 g on the first day, followed by 1 g for the
following 6 days.
Child: 1 5 years: 500mg; 6-12 years: 1g
Note: The dose may be given once as a single dose or half the dose
first and the other half 1 hour later.

Storage: At room temperature, in a tight container, away from

heat and direct light.
Piperazine
Tablet (Adipate), 300mg
Elixir (Citrate), 500mg/5ml, 622.5mg/5ml, 750mg/5ml,
706mg/5ml, 937.5mg/5ml, 1gm/5ml
Indications: for the treatment of round worm (Ascaris
Lumbricoids) and pinworm (Enterobius) infections.
Cautions: caution in patients with epilepsy, impaired renal or
hepatic function, and hypersensitivity. Supportive therapy
should be given for anemic, dehydrated or malnourished
patients prior to administration of the drug. Treat other members
of the family paying attention to personal hygiene.
Drug interactions: chlorpromazine.
Side effects:nausea, vomiting, mild diarrhoea, abdominal
cramps, headache, and dizziness may occur occasionally.
Dose and Administration:Oral: in constipated patients a
purgative should be given to ease expulsion of the worm. A
single dose is usually enough to treat roundworms. However,
the dose may be repeated in 2 days if a patient has large number
of roundworms.
Roundworm infection (Ascariasis):Adult: 3- 4g (30 40ml) or
75mg/kg of body weight as a single dose.
548

8. Anti-Infectives

Child: 75mg/kg of body weight as a single dose. Or, 1 5 years,

1g (10ml) as a single dose.6 12 years 2g (20ml) as a single
dose.Pinworm Infection (Enterobiasis, oxyuriasis):Adult: 2g
(20ml) or 65mg/kg of body weight every 12 hours daily for 7
days.
Child: 65 mg/kg of body weight as a single dose for 7 days.
Or,1 5 years 750 mg (7.5ml) once daily for 7days.6 12 years
1 g (15ml) once daily for 7days. Maximum 2.5 g once
daily.
Storage:at room temperature, insight containers, protected from
light.
Pyrantel Pamoate
Tablet, 125mg base
Oral suspension, 250mg base /5ml
Indications: treatment of Ascariasis, enterobiasis (pinworm
infection), helminth infection (multiple), hookworm infection
Cautions: pre-existing liver dysfunction, severe malnutrition or
anaemia.
Drug interactions: piperazine
Contraindications: hypersensitivity to the drug
Side effects: nausea, vomiting, tenesmus, anorexia, diarrhoea
drowsiness, headache, trouble in sleeping, hypersensitivity (skin
rash)
Dose and Administration:Adult:Ascariasis:Oral: 11mg (base)
per kg of body weight as a single dose may be repeated in 2 or 3
weeks if required.
Entrobiasis:Oral: 11mg (base) per kg of body weight as a single
dose. Repeat in 2 or 3 weeks.
Hookworm (infection):Oral: 11mg (base) per kg of body weight
once a day for three days.
549

8. Anti-Infectives

Trichostrongliasis:Oral: 11mg (base) per kg of body weight as

a single dose. Maximum - up to 1 gm (base)
Child 2 years and over same as adults
Storage: at room temperature in a tight, light resistant
container.
Thiabendazole
Tablet, 500mg
Oral suspension, 500mg/ml
Indications: for treatment of strongyloidiasis, cutaneous and
visceral larva migrans, dracontiasis, symptoms of trichinosis. It
is also used as secondary treatment for threadworm when mixed
with above infestations, adjunct in hookworm, whipworm or
roundworm (but not suitable for mixed infection involving
round worms due to risk of migration). It is not used for
prophylactic purpose
Cautions: hepatic and renal function impairment, in elderly.
Discontinue if hypersensitivity reaction occur, correct anemia,
dehydration or malnutrition preferably before treatment.
Drug interactions: theophylline.
Contraindications: pregnancy, breast-feeding.
Side effects: anorexia, nausea, vomiting, diarrhoea, dizziness,
headache, pruritus, drowsiness, hypersensitivity reaction (fever,
chills, angioedema, rashes), visual disorder.
Dose and Administration:Adult: Oral:Cutaneous Larva
migrans: 25mg per kg of body weight two times a day for two
days. May be repeated two days after completion of treatment if
active lesions are still present.
Visceral Larva migrans: 25mg per kg of body weight 2 times a
day for 5-7 days may be repeated in 4 weeks if required.
Strongyloidiasis:Uncomplicated infection: 25mg per kg of body
weight 2 times a day for two days. Hyper infection syndrome:
550

8. Anti-Infectives

25mg per kg of body weight 2 times a day for 5-7 days may be
repeated if required.
Trichinosis: 25mg per kg of body weight two times a day for 24 days based on patient response. Maximum - up to 3 grams
daily.Child: (children 13.6kg of body weight and above) - same
as adults dose.
Note: Continue medicines for full time of treatment and take after
meals.

Storage:at room temperature in a tight container.

551

9. Medicines Used In Endocrine Disorders And Contraceptives

9. MEDICINES for ENDOCRINE DISORDERS and

CONTRACEPTIVES
9.1. Pituitary Hormone Preparations
Vasopressin, also known as antidiuretic hormone, is used in the
treatment of pituitary diabetes insipidus, chiefly as
desmopressin. It has documented efficacy in the short-term
management of bleeding oesophageal varices and colonic
diventricular bleeding.
Desmopressin, a synthetic analogue of vasopressin, differs from
vasopressin in being longer-acting and in evoking minimal
vasoconstrictor effects. It is used for diagnosis and treatment of
diabetes insipidus. Intravenous injection may be used when
intranasal or oral administration is considered unsuitable.
Desmopressin Acetate
Tablet, 100 mcg, 200 mcg
Injection, 4 mcg/ml
Nasal spray, 100 mcg/ml, 10 mcg/metred spray
Indications: diagnosis and treatment of diabetes insipidus;
management of mild to moderate haemophilia.
Cautions: renal failure and hypertension; elderly; cystic
fibrosis.
Contraindications: cardiac insufficiency and other conditions
treated with diuretics.
Side effects: fluid retention and hyponatraemia; abdominal
pain, haedache, nausea, vomiting, epistaxis.
Dose and Administration:Adult: Diabetes insipidus: Oral:
initially 0.1 mg 3 times daily, adjusted to a maximum of 1.2
mg/day in 3 divided doses.Intranasal: 10- 20 mcg (0.1- 0.2 ml)
1 - 2 times daily.IV: 1 - 4 mcg (0.25 - 1 ml) 1 - 2 times
daily.Enuresis:Oral: under 65 years, 0.2 mg at bedtime; may be
552

9. Medicines Used In Endocrine Disorders And Contraceptives

increased to 0.4 mg if necessary.Child: Diabetes insipidus:

Oral: initially 0.1 mg 3 times a day, adjusted to a maximum of
1.2mg/day in 3 divided doses.
Intranasal: 5-10 mcg (0.05-0.1ml) 1-2 times daily.I.V: over 1
year, 0.4 - 1mcg 1-2 times daily; under 1year, 0.2 - 0.4mcg 1-2
times daily.Enuresis: Intranasal: over 5 years, 10-40mcg (0.10.4ml) given before sleep.Oral: over 5 years, initially 0.2mg at
bedtime; may be increased to 0.4 mg if necessary.
Storage: store tablets at room temperature; Injection at 2 80c.Nasal solution of desmopressin acetate preserved with
benzalkonium chloride should be stored at 20 - 25 oC, nasal
solutions preserved with chlorobutanol should be refrigerated at
2-8oC.
Vasopressin
Injection, 20 units/ml in 1 ml ampoule
Indications: treatment of diabetes insipidus, prevention and
treatment of postoperative abdominal distention.
Cautions: chronic nephritis, asthma, epilepsy, migraine, heart
failure, or other conditions which might be aggravated by water
retention.
Drug interactions:cimetidine, chlorpropamide, clofibrate,
carbamazepine,
fludrocortisone,
urea,
or
tricyclic
antidepressants, lithium, heparin, demeclocycline, noradrenaline
and alcohol.
Side effects: large parenteral doses cause headache, sweating,
tremor, nausea, vomiting, diarrhoea, cramp. In women, cause
uterine cramps of a menstrual character. Hyponatraemia with
water retention.Hypersensitivity reactions (urticaria and
bronchial constriction). Cardiovascular effects (hypertension,
arrythmias).
553

9. Medicines Used In Endocrine Disorders And Contraceptives

Dose and Administration:Diabetes insipidus:SC or I.M: Adult:

5-10 units 2-4 times/day as needed.Child: 2.5-10 units 2-4
times/day as needed.Abdominal distention: Adult: I.M: 5 units
stat, 10 units every 3-4 hours.
Storage: store in airtight containers at 2o to 8oC.
9.2. Corticosteroidal Preparations
The corticosteroids are used in physiological (low) doses for
replacement
therapy
in
adrenal
insufficiency.
In
pharmacological (high) doses, glucocorticoids decrease
inflammation, suppress the immune response, stimulate
erythroid cells of the bone marrow, promote protein catabolism,
reduce intestinal absorption, increase blood glucose, and elevate
blood pressure, increase renal excretion of calcium and promote
redistribution of fat and development of cushingoid features.
Systemic administration of corticosteroids is contraindicated in
patients with peptic ulcer, osteoporosis, psychoses, or severe
psychoneuroses, and they should be used only with great
caution in the presence of congestive heart failure or
hypertension, in patients with diabetes mellitus, epilepsy,
glaucoma, infectious diseases, chicken pox and severe
herpeszoster, ocular herpes simplex, chronic renal failure and
uremia in elderly persons. Patients with active or doubtfully
quiescent tuberculosis should not be given corticosteroids
except, very rarely, as adjuncts to treatment with tubercular
drugs. Corticosteroids are usually contraindicated in the
presence of acute infections, because of the interference with
inflammatory and immunological response during long courses
of corticosteroid therapy. Patients should be examined regularly
and in particular, checked for hypertension, glucosuria,
hypocalcaemia, gastric discomfort, and mental changes.
Sodium intake may need to be reduced and potassium
554

9. Medicines Used In Endocrine Disorders And Contraceptives

supplements may be necessary. Monitoring of the fluid intake

and output, and daily weight records may give early warning of
fluid retention.
Corticosteroids should not be administered concurrently with
barbiturates, carbamazepine, phenytoin, primidone, or
rifampicin; potassium depleting diuretics such as thiazide,
anticoagulants, antidiabetics antihypertensives, salicylates,
antimuscarinics, somatotropin, somatrem & vaccines, live virus,
or other immunizations.
Signs of potential side effects upon using of corticosteroid are
diabetes mellitus; burning, numbness, pain, or tingling at or near
injections site; congestive heart failure (in susceptible
individuals); generalized allergic reaction; local allergic reaction
or infection at injection site; psychic disturbances; sudden
blindness generalized anaphylaxis; cardiac arrhythmias;
flushing of face or cheeks; seizures, acne; adrenal suppression; a
vascular necrosis; cataracts, posterior subcapsular; Cushing's
syndrome effects; cutaneous or subcutaneous tissue atrophy;
ecchymosis; fluid and sodium retention; glaucoma with possible
damage of optic nerves; growth suppression (in children);
hypokalemic syndrome; impaired wound healing; increased
intracranial pressure; secondary fungal or viral ocular infection;
osteoporosis or bone fractures; pancreatitis; peptic ulceration or
intestinal perforation; scaring at injection site; steroid
myopathy; tendon rupture; and thin fragile skin.
Note: The risk of adverse effects with pharmacologic doses of
corticosteroids generally increases with the duration of therapy
and frequency of administration and to a lesser extent, with
dosage.
Withdrawal of systemic corticosteroids:Gradual withdrawal
should be considered in those whose disease is unlikely to
relapse and who have:Recently received repeated courses with
555

9. Medicines Used In Endocrine Disorders And Contraceptives

in 1 year of stopping long-term therapy; Other possible causes

of adrenal suppression; Received more than 40mg daily
prednisolone (or equivalent); Been given repeat doses in the
evening;Received more than 3 weeks' treatment.
Abrupt withdrawal may be considered in those whose disease is
unlikely to relapse and who have received treatment for 3 weeks
or less and are not included in the patient groups described
above.
During corticosteroid withdrawal the dose may be reduced
rapidly down to the physiological dosage (equivalent to 7.5mg
prednisolone daily) and then reduced more slowly. Assessment
of the disease may be needed during withdrawal to ensure that
relapse does not occur.
Corticosteroids cover during stress. Patients who are unable to
take the dose by mouth should receive parenteral corticosteroid
cover.
For patients requiring surgery, parenteral hydrocortisone should
be
administered
as
follows:200mg
hydrocortisone
intramuscularly with premeditation; 100mg hydrocortisone by
intravenous infusion in 5000ml 0.9% sodium chloride during
surgery; 100mg hydrocortisone intramuscularly every 6 hours
for 72 hours after surgery. For patients requiring minor surgical
procedures; 100mg by hydrocortisone intramuscularly shortly
before and after intervention.
Betamethasone
Tablet, 0.5mg
Indications: inflammatory dermatoses such as seborrheic or
atopic dermatitis, neurodermatitis, anogenital pruritus, psoriasis,
and inflammatory phase of xerosis.
Cautions,Drug interactions, Contraindications and Side
effects: see notes above
556

9. Medicines Used In Endocrine Disorders And Contraceptives

Dose and Administration:Adult: Oral: 2.4 - 4.8 mg/day in 2-4

doses; range: 0.6-7.2 mg/day.Child: Oral: 0.0175-0.25
mg/kg/day divided every 6-8 hours or 0.5-7.5 mg/m2/day
divided every 6-8 hours.
Storage:store at 2-30 oC.
Betamethasone Sodium Phosphate + Betamethasone
Dipropionate
Injection, 2mg + 5mg/2ml
Indications: Allergic States: Control of various incapacitating
allergic conditions intractable to conventional treatment, in
serum sickness and allergic reactions to drugs or insect bites.
Contraindications: Systemic fungal infections, hypersensitivity
reactions to Betamethasone or other corticosteroids.
Drug interactions: phenobarbital, rifampin, phenytoin,
ephedrine,
estrogen,
amphotericin
B,
coumarin-type
anticoagulants, nonsteroidal anti-inflammatory drugs or alcohol,
salicylate concentrations, somatotropin.
Side effects: The same as for other corticosteroids:
Abdominal distention, nausea, vomiting, increased appetite,
weight gain, pancreatitis, ulcerative esophagitis or peptic
ulcer.Impaired wound healing, erythema, hirsutism, increased
sweating, suppression of skin test reactions, hyper-pigmentation
or hypo-pigmentation, subcutaneous and cutaneous atrophy or
sterile abscess in site of injection. Increased intracranial
pressure with papilledema, posterior subcapsular cataract,
increased intraocular pressure (glaucoma), vertigo or headache.
Euphoria, insomnia, mood swings from severe depression to
frank psychotic manifestations, personality changes or
convulsions.Menstrual irregularities, development of cushingoid
state, suppression of fetal intrauterine or childhood growth,
secondary adrenocortical and pituitary unresponsiveness
557

9. Medicines Used In Endocrine Disorders And Contraceptives

particularly in times of stress (e.g. trauma, surgery or illness)

and negative nitrogen balance due to protein catabolism.
Decreased
carbohydrate
tolerance,
hyperglycemia,
manifestations of latent diabetes mellitus, and increased
requirements of insulin or oral hypoglycemic agents in
diabetics.
Rare instances of blindness associated with intra-lesional
therapy around the head. Joint instability may result from
repeated intra-articular injections.
Dose and Administration: Systemic Administration:Treatment
is initiated with 1-2ml, injected deeply intramuscular in the
gluteal region, and repeated as necessary. In severe illness 2ml
might be required initially. A wide variety of dermatologic
conditions respond to an I.M. injection of 1ml Suspension, to be
repeated as necessary.In respiratory tract disorders, effective
control of symptoms is obtained in bronchial asthma, hay fever,
allergic bronchitis and allergic rhinitis with a dose of 1-2ml I.M.
In the treatment of acute or chronic bursitis, 1-2ml I.M.
injection. Dose
can
be
repeated
as
necessary.
Local Administration:In acute subdeltoid, subacromial,
olecranon and prepatellar bursitis an intra-bursal injection of 12ml of suspension may relieve pain and restore full range of
movement within few hours.Chronic bursitis may be treated
with reduced dosage once acute symptoms are controlled.In
acute tenosynovitis, tendinitis and peritendinitis, one injection
of suspension should alleviate the condition.In chronic forms of
these conditions, it may be necessary to repeat the injection as
the patient's condition requires.Recommended dose for intraarticular injection varies according to the size of the joint: Large
joints
(such
as
knee,
hip
and
shoulder):1-2ml.
Medium joints (such as elbow, wrist and ankle): 0.5-1ml.
Small joints (such as foot, hand joints): 0.25-0.5
558

9. Medicines Used In Endocrine Disorders And Contraceptives

ml.Recommended doses at intervals of one week in bursitis

under calccaneal spur is 0.5ml. In synovial cyst is 0.250.5ml. In tenosynovitis, periosteitis of cuboid is 0.5ml and in
acute
gouty
arthritis
is
0.5-1ml.
After favorable response is obtained the proper maintenance
dosage should be determined by decreasing the initial dose in
small decrements at appropriate time intervals until the lowest
dose which will maintain an adequate clinical response is
determined.
Storage: between 2 and 25C. Protect from freezing.
Dexamethasone
Tablet, 0.5mg, 0.75mg, 1mg, 2mg,4mg
Injection, 4mg/ml, 25mg/ml, 50mg/ml
Indications:suppression of inflammatory and allergic disorders;
shock; diagnosis of Cushing's disease, congenital adrenal
hyperplasia; cerebral oedema; nausea and vomiting with
chemotherapy; rheumatic disease; see also notes above.
Cautions, Contraindications, Drug interactions and Side
effects; see notes above
Side effects: see notes above; perineal irritation may follow
intravenous administration of the phosphate ester.
Dose and Administration: Oral: usual range 0.5-10mg daily.
IM injection or slow IV injection or infusion (as dexamethasone
phosphate), initially 0.5-20mg; Child 200-500 micrograms/kg
daily.Cerebral oedema (as dexamethasone phosphate),
intravenous injection, 10mg initially, then 4mg by intramuscular
injection every 6 hours as required for 2-10 days.Shock (as
dexamethasone phosphate), intravenous injection or infusion, 26mg/kg, repeated in necessary after 2-6 hours.Note:

Dexamethasone 1mg dexamethasone

dexamethasone sodium phosphate 1.3 mg
559

phosphate

1.2mg

9. Medicines Used In Endocrine Disorders And Contraceptives

Storage:at room temperature.

Fludrocortisone Acetate
Tablet, 0.1mg, 0.3 mg
Indications: partial replacement therapy for primary and
secondary adrenocortical insufficiency in Addisons disease;
treatment of salt-losing adrenogenital syndrome.
Cautions, Contraindications, Drug interactions and Side
effects; see notes above.
Dose and Administration: Oral:Adult: 0.1-0.2 mg/day with
ranges of 0.1 mg 3 times/week to 0.2 mg/day.Addisons disease:
initial: 0.1mg/day; if transient hypertension develops, reduce the
dose to 0.05 mg/day. Preferred administration with cortisone
(10-37.5 mg/day) or hydrocortisone (10-30mg/day).Infant and
Child: 0.05-0.1mg/day
Storage:store in well-closed container and at room temperature.
Fluticasone Furoate
Nasal Spray, 27.5mcg
Indications: prophylaxis and treatment of allergic rhinitis and
perennial rhinitis; nasal polyps
Cautions: Corticosteroid nasal preparations should be avoided
in the presence of untreated nasal infections, and also after nasal
surgery (until healing has occurred); they should also be
avoided in pulmonary tuberculosis. Patients transferred from
systemic corticosteroids may experience exacerbation of some
symptoms. Systemic absorption may follow nasal
administration particularly if high doses are used or if treatment
is prolonged. The height of children receiving prolonged
treatment with nasal corticosteroids should be monitored; if
growth is slowed, referral to a paediatrician should be
considered.
560

9. Medicines Used In Endocrine Disorders And Contraceptives

Contraindication:intolerance to corticosteroids, glaucoma,

infections (fungal, bacterial or parasitic or systemic viral), nasal
septic ulcers, nasal trauma, nasal surgery
Drug interactions:Nelfinavir,Ritonavir
Side effects: Local side-effects include dryness, irritation of
nose and throat, nasal ulceration and epistaxis. Raised intraocular pressure or glaucoma may occur rarely. Headache, smell
and taste disturbances may also occur. Hypersensitivity
reactions, including bronchospasm, have been reported.
Dose and Administration: Rhinitis: 100 micrograms (2 sprays)
into each nostril once daily, preferably in the morning, increased
to maximum twice daily if required; when control achieved
reduce to 50 micrograms (1 spray) into each nostril once daily;
child 411 years, 50 micrograms (1 spray) into each nostril once
daily, preferably in the morning, increased to maximum twice
daily if required. Nasal polyps:Adult and Adolescent over 16
years, 200 micrograms (approx. 6 drops) into each nostril once
or twice daily; consider alternative treatment if no improvement
after 46 weeks.
Hydrocortisone
Tablet (Acetate), 5mg, 10 mg
Injection (sodium succinate), 50mg/ml in 2ml ampoule,
125mg/ml
Powder for injection, 25mg/amp, 500mg in vial
Indications: adrenocortical insufficiency; hypersensitivity
reactions including anaphylactic shock inflammatory bowel
disease.
Cautions,Drug interactions, Contraindications and Side
effects; see notes above
Dose
and
Administration:Replacement
therapy
in
adrenocortical insufficiency: Oral: Adult: 20 - 30mg daily in
561

9. Medicines Used In Endocrine Disorders And Contraceptives

divided doses (usually 20 mg in the morning and 10 mg in early

evening), Child, 10 - 30mg.
Acute adrenocortical insufficiency: Slow IV injection or IV
infusion: Adult: 100 500 mg, 3 - 4 times in 24 hours or as
required; Slow IV injection, Child up to 1 year 25mg, 1-5 years
50mg, 6 - 12 years 100mg.
Reconstitution and Administration: According to manufacturer's
directions.
Storage: At room temperature, in a tight, light resistant
container, protect from freezing.Note: Reconstituted solutions
should be used only if it is clear and should be discarded after 3
days.After reconstitution, protect the solution from light.

Methylprednisolone Acetate
Injection (aqueous suspension), 40 mg/ml, 80mg/ml in 1 and
2ml ampoules
Indications: treatment of rheumatoid arthritis, osteoarthritis,
bursitis and other non-infectious inflammatory conditions. Antiinflammatory effects may be evident within 12-24 hours and
usually last 3-4 weeks.
Cautions, Contraindications, Drug interactions and Side
effects; see notes above.
Dose and Administration: Intra-articular, large joints (knees,
ankles, shoulders) 20-80mg; medium joints (elbows, wrists) 1040mg; small joints (metacarpophalangeal, interphalangeal,
sternoclavicular, acromioclavicular) 4-10 mg. Soft-tissue
injection, up to 60 mg, depending on the amount of inflamed
tissue.
Storage: store at room temperature.
Prednisolone
Tablet, 1mg, 3.5mg, 5mg, 10mg
562

9. Medicines Used In Endocrine Disorders And Contraceptives

Injection (Sodium Phosphate), 10mg/ml, 25mg/ml in 2ml

ampoule
Indications: suppression of inflammatory and allergic
disorders; inflammatory bowel disease, asthma, and rheumatic
disease, for the treatment of adrenocortical insufficiency and as
immune suppression.
Cautions, Contraindications, and Drug interactions and Side
effects; see notes above.
Intra articular injection of prednisolone is contraindicated in
patients with arthroplasty of joint; blood clotting disorders, intra
articular fracture, current or history of periarticular infection,
osteoporosis & unstable joint.Note: owing to its less pronounced
mineralocorticoids activity prednisolone is less likely than
hydrocortisone to cause sodium retention, electrolyte imbalance, and
oedema.

Dose and Administration:Suppression of inflammatory and

allergic disorders: Oral: Adult: initially up to 10 - 20mg daily
(severe disease, up to 60mg daily), preferably taken in the
morning after breakfast: dose can often be reduced within a few
days, but may need to be continued for several weeks or
months: maintenance, 2.5 - 15mg daily or higher; cushingoid
features are increasingly likely with doses above 7.5mg daily;
Child: fractions of adult dose may be used (for example, at 1
year 25% of adult dose, at 7 years 50%, and at 12 years 75%)
but clinical factors must be given due weight.
Storage: store in a tight container at room temperature. Protect
from freezing and light.
Triamicinolone Acetonide
Tablet, 4mg
Injection, 10mg/ml, 40mg/ml in 1ml vial
563

9. Medicines Used In Endocrine Disorders And Contraceptives

Indications:suppression of inflammatory and allergic disorders;

rheumatic disease.
Cautions, Drug interactions, Contraindications, Side effects
see notes above. Anorexia, weight loss, flushing, depression,
and muscle wasting are reported to have been particularly
associated with Triamicinolone.
Dose and Administration:Oral: 4 - 48mg daily although daily
doses over 32mg is seldom indicated.
Deep intramuscular injection, into gluteal muscle, 40mg of
Acetonide for depot effect, repeated at intervals according to the
patient's response, maximum single dose 100mg.
Storage: at room temperature. Protect from freezing and light.
9.3. Thyroid Hormones and Antithyroid Agents
Thyroid agents are natural or synthetic agents containing
levothyroxine (thyroxine) or liothyronine (tri-iodothyronine).
The principal effect is to increase the metabolic rate. They also
exert a cardio stimulatory effect which may be the result of a
direct action on the heart. The main agent for thyroid
replacement and described in this section is thyroxin. It is used
in hypothyroidism (myxoedema) and also in diffuse non-toxic
goiter, Hashimoto thyroiditis (lymphadenoid goiter) and thyroid
carcinoma. Neonatal hypothyroidism requires prompt treatment
for normal development.
Thyroxin Sodium (Levothyroxine Sodium) is the
treatment of choice for maintenance therapy. It is almost
completely absorbed from the gastrointestinal tract but the full
effects are not seen for up to 1 to 3 weeks after beginning
therapy; there is a slow response to dose change and effects may
persist for several weeks after withdrawal. Dosage of thyroxin
sodium in infants and children for congenital hypothyroidism
and juvenile myxoedema should be titrated according to clinical
564

9. Medicines Used In Endocrine Disorders And Contraceptives

response, growth assessment and measurement of plasma

thyroxin and thyroid stimulating hormone.
Antithyroid drugs are used for hyperthyroidism either to prepare
patients for thyroidectomy or for long-term management.
Antithyroid agents are used to achieve euthyroidism in
patients with thyrotoxicosis. Propylthiouracil and carbimazole,
interfere with thyroxine synthesis in the thyroid gland and are
used mainly to prepare patients for surgery or irradiation, or in
the long-term management of hyperthyroidism associated with
Graves disease.
Antithyroid drugs do not block the release of stored
thyroid hormones and it is only when the performed hormones
are depleted and concentrations of circulating hormones decline
that clinical effects become apparent. An additional action of
propylthiouracil is inhibition of the peripheral deiodination of
thyroxine to tri-iodothyronine.
Propylthiouracil is given in a dose of 200 to 400mg daily
in adults and this dose is maintained until the patient becomes
euthyroid; the dose may then be gradually reduced to a
maintenance dose of 50 to 150mg daily.
Antithyroid drugs only need to be given once daily because of
their prolonged effect on the thyroid. Over-treatment with the
rapid development of hypothyroidism is not uncommon and
should be avoided particularly during pregnancy because it can
cause fetal goiter.
Pregnancy and breastfeeding:Propylthiouracil cross the
placenta and in high doses may cause fetal goiter and
hypothyroidism- the lowest dose that will control the
hyperthyroid state should be used (requirements in Graves
disease tend to fall during pregnancy).Propylthiouracil appears
in breast milk but this does not preclude breastfeeding as long as
565

9. Medicines Used In Endocrine Disorders And Contraceptives

neonatal development is closely monitored and the lowest

effective dose is used.
Iodine has been used as an adjunct to antithyroid drugs
for 10 to 14 days before partial thyroidectomy; however, there is
little evidence of a beneficial effect. Iodine should not be used
for long-term treatment because its antithyroid action tends to
diminish. In patients in whom drug therapy fails to achieve
long-term remissions definitive treatment with surgery or
(increasingly) radioactive iodine is preferable.
Propranolol is useful for rapid relief of thyrotoxic
symptoms and may be used in conjunction with antithyroid
drugs or as an adjunct to radioactive iodine. Beta-blockers are
also useful in neonatal thyrotoxicosis and in supraventricular
arrhythmias due to hyperthyroidism. Propranolol has been used
in conjunction with iodine to prepare mildly thyrotoxic patients
for surgery but it is preferable to make the patient euthyroid
with carbimazole. Laboratory tests of thyroid function are not
altered by beta-blockers.
Most experience is treating
thyrotoxicosis has been gained with propanolol but nadolol is
also used.
Iodine + Potassium Iodide (Aqueous Iodine oral solution or
Lugol's solution)
Solution, 5% + 10%
Indications: thyrotoxicosis (pre-operative).
Cautions: pregnancy, children; not for long-term treatment.
Contraindications: breastfeeding.
Side effects: hypersensitivity reactions including Coryza - like
symptoms, headache, lacrimation, conjunctivitis, pain in
salivary glands, laryngitis, bronchitis, rashes; on prolonged
treatment depression, insomnia, impotence; goiter in infants of
mothers taking iodides.
566

9. Medicines Used In Endocrine Disorders And Contraceptives

Dose and Administration: 0.3ml 3 times daily well diluted with

milk or water.
Carbimazole
Tablet, 5 mg
Indications: hyperthyroidism.
Cautions: impaired liver function, tracheal obstruction.
Drug interactions: oral anticoagulants and heparin.
Contraindications: hypersensitivity to carbimazole.
Side effects: pruritus, skin rashes, non-specific gastrointestinal
disturbances, headache, mild arthralgia, urticaria, alopecia,
drug-induced agranulocytosis, cholestatic hepatitis with
jaundice, blood dyscrasias and "drug-fever" reactions.
Dose and Administration: Oral:Adult: Initially 20 - 60 mg
daily until there is euthyroidism.
Maintenance: 5 - 15 mg
as a single daily dose.
Child: the usual initial daily dose is 15mg per day.
Storage: do not store above 25C; Store in the original
container.
Propranolol
Tablet, 10mg, 40mg
Injection, 1mg/ml in 1ml ampoule
See notes above and section 3.3 under propranolol
Propylthiouracil
Tablet, 25mg, 50mg, 100mg
Indications: hyperthyroidism
Cautions: liver disorders, pregnancy, breast-feeding, reduce
dose in renal impairment.
Side effects: nausea, mild gastrointestinal disturbances
headache, rashes and pruritus, arthralgia; rarely alopecia, bone
567

9. Medicines Used In Endocrine Disorders And Contraceptives

marrow suppression, urticaria, leucopoenia; rarely coetaneous

viscosities, thrombocytopenia, aplastic anaemia, hepatitis, lupus
erythematous - like syndromes.
Dose and Administrations:see notes above
Storage: at room temperature.
Thyroxin Sodium
Tablet, 0.05mg, 0.1mg
Indications: hypothyroidism
Cautions: cardiovascular disorders (myocardial insufficiency or
ECG evidence of myocardial infarction); hypopituitarism or
predisposition to adrenal insufficiency (must be corrected by
corticosteroid prior to initial levothyroxine); elderly, longstanding hypothyroidism, diabetes insipidus, diabetes mellitus
(may need to increase dose of insulin or oral antidiabetic drug);
pregnancy; breast feeding.
Drug interactions: warfarin.
Contraindications:thyrotoxicosis, cholestyramine or colestipol,
sympathomimetics.
Side effects: (usually with excessive dose) anginal pain,
arrhythmias, palpitations, tachycardia, skeletal muscle cramps,
diarrhea, vomiting, tremors, restlessness, excitability, insomnia,
headache, flushing, sweating, excessive loss of weight and
muscular weakness.
Dose and Administration:Hypothyroidism: Oral: Adult:
initially 50 - 100micrograms daily (25-50 micrograms for: those
over 50 years) before breakfast, increased by 25 - 50
micrograms every 3 - 4 weeks until normal metabolism
maintained (usual maintenance dose, 100 200 micrograms
daily); where there is cardiac disease, initially 25 micrograms
daily or 50 micrograms on alternate days, adjusted in steps of 25
micrograms every 4 weeks.Congenital hypothyroidism and
568

9. Medicines Used In Endocrine Disorders And Contraceptives

juvenile myxoedema: Oral: Child: up to 1 month, initially 5 - 10

micrograms/kg daily, adjusted in steps of 25 micrograms every
2 - 4 weeks, until mild toxic symptoms appear, then reduce dose
slightly.
Storage: at room temperature store in a tight light resistant
container.
9.4. Insulin and oral antidiabetic agents
Diabetes mellitus is a disorder of carbohydrate
metabolism in which the action of insulin is diminished or
absent through altered secretion, decreased insulin activity, or a
combination of both factors. There are two principal classes of
diabetes (and many sub types not listed here):
Type I diabetes: Type I diabetes, also referred to as
insulin dependent diabetes mellitus (IDDM), is due to a
deficiency of insulin following autoimmune destruction of
pancreatic beta cells. Patients with type I diabetes require
administration of insulin.
Type II diabetes: Type II diabetes, also referred to as noninsulin dependent diabetes (NIDDM), is due to reduced
secretion of insulin or to peripheral resistance to the action of
insulin. Although patients may be controlled on diet alone,
many require administration of oral antidiabetic drugs or insulin
to maintain satisfactory control.
The aim of treatment is to achieve the best possible
control of plasma glucose concentration and prevent or
minimize complications including microvascular complications
(retinopathy, albuminuria, neuropathy).
Diabetes mellitus is a strong risk factor for
cardiovascular disease. Other risk factors such as smoking,
hypertension, obesity and hyperlipidaemia should also be
addressed.
569

9. Medicines Used In Endocrine Disorders And Contraceptives

Management of diabetes mellitus

Insulin: Insulin plays a great role in the regulation of
carbohydrate, fat and protein metabolism. It is a polypeptide
hormone of complex structure. There are differences in the
amino acid sequence of animal insulin's, human insulin's and the
human insulin analogues.Insulin may be of beef or pork origin
or it may be human insulin produced by gene technology or by
modification of porcine insulin.
All insulin preparations are to a greater or lesser extent
immunogenic in man but immunological resistance to insulin
action is uncommon. Human and Porcine insulin are less
immunogenic than bovine insulin and where possible most
newly diagnosed IDDM patients are now given human insulin.
Insulin of whatever origin is formulated to provide a range of
preparations offering:
Short duration which have a relatively rapid onset of action,
namely soluble insulin, insulin lispro and insulin aspart.
Intermediate action, e.g isophane insulin and insulin zinc
suspension; and
Long action which have a relatively slower in onset, e.g.
Crystalline insulin Zinc suspension
For those who require administration of insulin, appropriate
combinations of insulin therapy will have to be worked out for
the individual patient. In pregnancy insulin requirements should
be monitored frequently.
Examples of recommended insulin regimens
Short - acting insulin mixed with intermediate - acting
insulin: twice daily (before meals)
Short - acting insulin mixed with intermediate acting insulin
before breakfast: Short-acting insulin before evening meal;
and Intermediate-acting insulin: at bed time
570

9. Medicines Used In Endocrine Disorders And Contraceptives

Short-acting insulin: three times daily (before breakfast,

midday and evening meal)
Intermediate - acting insulin at bedtime
Intermediate-acting insulin with or without short-acting
insulin once daily either before breakfast or at bedtime
suffices for some patients with type II diabetes who need
insulin, sometimes in combination with oral hypoglycemic
drugs.
Insulin is inactivated by gastro-intestinal enzymes, and must
therefore be given by injection; the subcutaneous route is ideal
in most circumstances. It is usually injected in to the upper
arms, thighs, buttocks, or abdomen; there may be increased
absorption from a limb site if the limb is used in strenuous
exercise following the injection. Generally subcutaneous
insulin injections cause few problems; fat hypertrophy does
however occur but can be minimized by rotating the injection
site. Local allergic reactions are now rare. The various types of
insulin may also be given intramuscularly when the onset of
action is faster than with the subcutaneous route. An even faster
onset may be achieved with intravenous administration, but this
route is only suitable for fast-acting or soluble insulin.
Hypoglycemia: The most frequent complications of
insulin therapy is hypoglycemia and patients taking insulin
should be educated about its cause, symptoms, and treatment.
Most patients can recognize the early warning signs of
hypoglycemia and by taking sugar immediately they can prevent
more serious symptoms developing. Comatose patients should
be given intravenous glucose or, if this is not practicable,
subcutaneous or intramuscular glucagons.
Hypoglycemia can also develop in patients taking oral
hypoglycemic, notably the sulphonylureas. Some patients may
no longer be able to recognize the warning signs of
571

9. Medicines Used In Endocrine Disorders And Contraceptives

hypoglycemia after transferring from animal to human insulin

and these patients, if appropriate, should be transferred back to
porcine insulin.
Car drivers need to be particularly careful to avoid
hypoglycemia.
They should check their blood glucose
concentrations before driving and, on long journeys, at intervals
of approximately two hours; they should ensure that a supply of
sugar is always readily available. If hypoglycemia occurs the
driver should switch off the ignition until recovery is complete
(may be 15 minutes or longer). Driving is not permitted when
hypoglycemic awareness has been lost. For sporadic physical
activity departing from the patients usual daily routine extra
carbohydrate may need to be taken to avert hypoglycemia.
Blood glucose should be monitored before, during and after
exercise.
Diabetic Ketoacidosis: Diabetic ketoacidosis results
from a lack of insulin due to a number of factors and the onset
may be over hours or days.
It is characterized by
hyperglycemia, hyperketonaemia, and acidaemia and is a
medical emergency which should be treated promptly with fluid
and electrolyte replacement and insulin.
However, over
vigorous fluid replacement without severe dehydration carries
the risk of precipitating cerebral oedema.
Surgery: Insulin dependent diabetics who require
surgery should be managed with a continuous intravenous
insulin infusion. Insulin is given as normal the night before
operation, and switched to either a variable rate infusion via a
syringe pump, together with a 10% glucose drip, or to a
combined insulin-glucose infusion, on the day of operation.
Subsequent conversion back to subcutaneous insulin should be
undertaken before breakfast, giving the first subcutaneous dose
30 minutes before stopping continuous infusion. Non - insulin
572

9. Medicines Used In Endocrine Disorders And Contraceptives

dependent patients should have any oral treatment omitted on

the day of operation, and may be given insulin by a similar
regimen if control is poor or deteriorates as can happen with
major surgery.
Soluble insulin is a short - acting form of insulin. When
injected subcutaneouly it has a rapid onset of action (after 30 60 minutes), a peak action between 2 and 4 hours, and duration
of action up to 8 hours when injected intravenously, soluble
insulin has a very short half - life of only about 5 minutes.
When administered subcutaneous, intermediate-acting
insulin's have an onset of action of approximately 1 - 2 hours, a
maximal effect at 4 - 12 hours and duration of action of 16 - 24
hours. They can be given twice daily together with short - acting
insulin or once daily, particularly in elderly patients. They can
be mixed with soluble insulin in the syringe, essentially
retaining properties of each component.
The duration of action of different insulin preparations
varies considerably from one patient to another and this needs to
be assessed for every individual. The type of insulin used and its
dose and frequency of administration depend on the needs of
each patient. For patients with acute onset diabetes mellitus,
treatment should be started with soluble insulin given 3 times
daily with medium acting insulin at bedtime. For those less
seriously ill, treatment is usually started with a mixture of
premixed short and medium acting insulin given twice daily.
The proportions of soluble insulin can be increased in patients
with excessive post-prandial hyperglycaemia. Patients should
remain on the same insulin throughout treatment. Regimens
should be developed by each country.
Acarbose
Tablet, 50mg, 100mg
573

9. Medicines Used In Endocrine Disorders And Contraceptives

Indications: diabetes mellitus inadequately controlled by diet or

by diet with oral antidiabetic drugs
Cautions: monitor liver function; may enhance hypoglycaemic
effects of insulin and sulfonylureas (hypoglycaemic episodes
may
be
treated
with
oralglucose but
not
with
sucrose); interactions: Appendix 1 (antidiabetics)
Contraindications: inflammatory bowel disease, predisposition
to partial intestinal obstruction; hernia, previous abdominal
surgery. Hepatic impairment: avoid. Renal impairment: avoid if
eGFR less than 25 mL/minute/1.73 m2. Pregnancy and Breastfeeding: avoid
Side-effects: flatulence, soft stools, diarrhoea (may need to
reduce dose or withdraw), abdominal distention and
pain; rarely, nausea, abnormal liver function tests and skin
reactions; very rarely ileus, oedema, jaundice, and hepatitis
Note: Antacids unlikely to be beneficial for treating side-effects

Dose and adminstration: adults over 18 years, initially 50 mg

daily increased to 50 mg 3 times daily, then increased if
necessary after 68 weeks to 100 mg 3 times daily; max.
200 mg 3 times daily
Counselling: Tablets should be chewed with first mouthful of food or
swallowed whole with a little liquid immediately before food. To
counteract possible hypoglycaemia, patients receiving insulin or a
sulfonylurea as well as acarbose need to carry glucose (not sucrose
acarbose interferes with sucrose absorption).

Biphasic Insulin (BP)

Injection (highly purified), 100 units/ml in 10ml vial
Indications: diabetes mellitus (intermediate acting)
Cautions, Drug interactions, Side effects: see notes above and
under soluble insulin; Protamine may cause allergic reactions

BP stands for Bovine and porcine

574

9. Medicines Used In Endocrine Disorders And Contraceptives

Dose and Administrations:By subcutaneous injection,

according to requirements
Storage: store at 20C to 80C. Do not allow freezing protect from
light.
Note: It should be gently shaken before use.

Biphasic Isophane Insulin (soluble/Isophane Mixture)

Injection, 50/50, 30/70, 100 units/ml in 10ml vial
Indications: diabetes mellitus (intermediate acting)
Cautions, Drug interactions, Side effects; see notes above and
under soluble insulin; protamine may cause allergic reactions.
Dose and Administration:By subcutaneous injection,
according to requirements
Storage: Store at 20C to 80C. Do not allow freezing protect from
light.
Note: It should be gently shaken before use.

Insulin soluble /Neutral (HPB)

Injection 100 units/ml
Indications: diabetes mellitus; diabetic emergencies and at
surgery; diabetic ketoacidosis or coma.
Cautions: see notes above; reduce dose in renal impairment;
occasionally insulin resistance necessitating large doses;
pregnancy and breastfeeding; see also interactions.
Drug interactions: analgesics, antibacterials, antifungals,
uricosurics.
Side effects: hypoglycaemia in overdose; localized and rarely
generalized, allergic reactions; lipoatrophy at injection site;
insulin resistance.

HPB stands for Human, porcine, and Bovine

575

9. Medicines Used In Endocrine Disorders And Contraceptives

Dose and Administration:Diabetes mellitus: SC, IM, IV

injection or infusion: Adult and Child according to individual
requirements
Storage: store at 20C to 80C. Do not allow to freeze protect from
light.
Insulin Zinc suspension/Insulin Lente (HPB)
Injection 100 units/ml
Indications: diabetes mellitus (long acting)
Cautions, Drug interactions, Side effects: see notes above and
under soluble insulin.
Dose and Administrations: By subcutaneous injection,
according to requirements
Storage: store between 20C and 80C protect from freezing.
Isophane/NPH insulin (HPB)
Injection, 100units/ml
Indications: diabetes mellitus Cautions, Drug interactions,
Side effects; see notes above and under soluble insulin;
Protamine may cause allergic reactions.
Dose and Administrations: By subcutaneous injection,
according
to
requirements.Intravenous
injection
is
contraindicated.
Storage: unopened vials of insulin should be stored at 20C to
80C and should not be subjected to freezing. The vial in use may
be stored at room temperature; exposure to extremes in
temperature or direct sunlight should be avoided.

576

9. Medicines Used In Endocrine Disorders And Contraceptives

Oral antidiabetic drugs

If patients with NIDDM have not achieved suitable control after
about 3 months old dietary modification and increased physical
activity, then oral hypoglycemic may be tried. The two major
classes of oral hypoglycemic agents are the sulphonylureas and
the biguanides. Sulphonylureas act mainly by increasing
endogenous insulin secretion, whilst biguanides act chiefly by
decreasing hepatic gluconeogenesis and increasing peripheral
utilization of glucose. Both types of agents only function in the
presence of some endogenous insulin production.
Oral treatment of NIDDM is usually begun with a
sulphonylureas. Chlorpropamide has more adverse effects than
the other sulphonylureas. It has a long half life and hence is
considered to have an increased tendency to cause
hypoglycaemia, although a recent large study reported that
hypoglycaemic
episodes
were
less
frequent
with
chlorpropamide than Glibenclamide. Use of chlorpropamide is
therefore inadvisable in the elderly; Glibenclamide is also best
avoided for the same reason.
A sulphonylurea with a short half-life, such as tolbutamide,
should be used instead in such patients.
Unfortunately
sulphonylureas can cause weight gain so severely obese patients
may be treated with the biguanide metformin rather than a
sulphonylurea. Metformin is as effective as the sulphonylurea
in terms of blood glucose control but has a rare tendency to
cause lactic acidosis in patients with renal failure and should
therefore be avoided in patients at risk. Patients with NIDDM
who cannot be controlled adequately by oral therapy and diet
need to be given insulin either in addition to or in place of the
oral therapy.
Contraindications: sulphonylureas should be avoided where
possible in severe hepatic and renal impairment and in
577

9. Medicines Used In Endocrine Disorders And Contraceptives

porphyria. They should not be used while breast feeding and

insulin therapy should be substituted during pregnancy.Insulin
therapy should also be instituted temporarily during intercurrent
illness (such as myocardial infarction, coma, infection, and
trauma). Oral antidiabetic drugs should be omitted on the
morning of surgery; insulin is often required because of the
ensuing
hyperglycaemia
in
these
circumstances.
Sulphonylureas are contraindicated in the presence of
ketoacidosis.
Side effects: side effects of sulphonylureas are generally mild
and infrequent and include gastro-intestinal disturbances such as
nausea, vomiting, diarrhoea and constipation.They can
occasionally cause a disturbance in liver function, which may
rarely lead to cholestatic jaundice, hepatitis and hepatic failure.
Hypersensitivity reactions can occur, usually in the first 6 - 8
weeks of therapy; they consist mainly of allergic skin reactions
which progress rarely to erythema multiforme and exfoilative
dermatitis, fever and jaundice; photosensitivity has rarely been
reported with chlorpropamide. Blood disorders are also rare but
may include leucopenia, thrombocytopenia, agranulocytosis,
pancytopenia, haemolytic anaemia, and aplastic anaemia.
Chlorpropamide has appreciably more side effects, mainly
because of its very prolonged duration of action and the
consequent hazard of hypoglycaemia and it should generally no
longer be used. It may also cause facial flushing after drinking
alcohol; this effect does not normally occur with other
sulphonylureas. Chlorpropamide may also enhance antidiuretic
hormone secretion and very rarely cause hyponatraemia.
Biguanides: The biguanides are agents of first choice in the
management of obese type 2 diabetics, but the small risk of
lactic acidosis demands that they may be used with caution.
Risk factors for lactic acidosis include: impaired renal or hepatic
578

9. Medicines Used In Endocrine Disorders And Contraceptives

function, cardiopulmonary insufficiency, presence of infections,

excessive alcohol intake, and certain systemic illnesses, e.g.
leukaemia.
Metformin is useful in management of obese diabetics because
it induces a mild anorexia and so helps to control weight gain.
The biguanides include metformin.
Glimepiride
Tablet, 3mg
Indications: treatment of type II diabetes mellitus
Cautions: pregnancy, hypoglycemia may be produced during
use.
Drug interactions: CYP2C8/9 inhibitors (e.g ketoconazole,
NSAIDs, pioglitazone), beta blockers, chloramphenicol,
cimetidine, fluconazole, salicylates, sulfonamides, tricyclic
antidepressants may increase effect of Glimepiride. Glimepiride
may increase effects of cyclosporines, CYP2C8/9 inducers may
decrease effects of Glimepiride (e.g carbamazepine,
Phenobarbital,
phenytoin,
rifampine,
estrogens,
oral
contraceptives, thiazides and other diuretics, NSAIDs,
isoniazide)
Contraindications: hypersensitivity to glimepiride, other
sulfonyl ureas or sulfonamides or to any of the excipients, breast
feeding, insulin dependent diabetes, ketoacidosis (with or
without coma), severe renal or hepatic function disorders. In
case of severe renal or hepatic function disorders, a changeover
to insulin is required.
Side effects: dizziness, headache, hypoglycemia, nausea,
weakness, anorexia, heartburn, vomiting
Dose and Administration: oral:Adult:Starting dose: 1 mg
glimepiride per day. If good control is achieved this dosage
should be used for maintenance therapy.If control is
579

9. Medicines Used In Endocrine Disorders And Contraceptives

unsatisfactory the dosage should be increased, based on the

glycaemic control, in a stepwise manner with an interval of
about 1 to 2 weeks between each step, to 2, 3 or 4 mg
glimepiride per day.A dosage of more than 4 mg glimepiride per
day gives better results only in exceptional cases. The maximum
recommended dose is 6 mg glimepiride per day.
Storage: at room temperature.
Metformin
Tablet, 500mg, 850mg
Indications: type 2 diabetes mellitus.
Cautions: substitute insulin during severe infection, trauma,
surgery; breastfeeding.
Drug interactions: alcohol, cimetidine & other cationic
medication excreted by renal tubular transport (such as:
amiloride, nifedipine, digoxin, morphine, procainamide,
quinidine, quinine, ranitidine, triamterene, trimethoprim,
vancomycin); Furosemide; vitamin B12.
Contraindications: renal impairment (withdraw if renal
impairment suspected; hepatic impairment; heart failure; severe
infections or trauma; dehydration; alcohol dependence;
pregnancy.
Side effects: anorexia, nausea and vomiting, diarrhoea patients
with renal failure (discontinue); decreased vitamin B12
absorption.
Dose and Administrations:Oral: Adult: 500mg every 8 hours
or 850mg every 12 hours with or after food (maximum 2g daily
in divided doses).
Storage: Store at room temperature in a light resistant
container, unless otherwise specified by manufacturer.

580

9. Medicines Used In Endocrine Disorders And Contraceptives

Sulphonamides, Urea Derivatives

Sulphonylureas act mainly by stimulating the release of
endogenous insulin. Some pancreatic beta-cell responsiveness
should remain intact for these agents to be effective. They may
provide good control of blood glucose and have been shown to
reduce the microvascular complications of diabetes. They are
used in the management of type 2 diabetes not controlled by diet
alone, and may be given together with a biguanide if necesary to
achieve control. The sulphonylureas in common use include
glibenclamide, glimepiride, glipizide, chlorpropamide and
tolbutamide.
Chlorpropamide
Tablet, 100mg, 250mg
Indications: type II diabetes mellitus.
Cautions, Contraindications, Side effects; see notes above.
Drug interactions: see under Glibenclamide.
Dose and Administrations: Initially 250mg daily with
breakfast (Elderly 100 - 125 mg but avoid - see notes above),
adjusted according to response; maximum 500 mg daily.
Storage: Store in a well-closed container at room temperature
Glibenclamide
Tablet, 5mg
Indications: type II diabetes mellitus
Cautions, Side effects, Contraindications: see notes above
Drug interactions: analgesics (azapropazone, phenylbutazone
and possibly other NSAIDs enhance effect of sulphonylureas),
antibacterial, antifungals, uricosurics.
Dose and Administrations: Initially 5mg daily with or
immediately after break fast (Elderly 2.5mg, but avoid - see
581

9. Medicines Used In Endocrine Disorders And Contraceptives

notes above), adjusted according to response, maximum 15mg

daily.
Glimepiride
Tablet, 1mg, 2mg, 4mg
Indications: management of type 2 diabetes mellitus (NIDDM).
Cautions, Contraindications and Side effects: see notes
above.
Drug interactions: see under Glibenclamide.
Dose and Administration: Adult: Oral: initially 1 mg once
daily, before breakfast. If necessary the dose may be increased
by 1 mg at weekly intervals up to 6 mg daily, according to blood
glucose levels; maximum 8 mg daily.
Glipizide
Tablet, 2.5 mg, 5 mg, 10 mg
Indications: management of type 2 diabetes mellitus (NIDDM).
Cautions, Contraindications and Side effects: see notes
above.
Drug interactions: see under Glibenclamide.
Dose and Administration: Adult: Oral: initially, 2.5 - 5 mg
daily, 15 - 30 minutes before breakfast (2.5 mg in the elderly
and in liver impairment), gradually increased, if necessary, to a
maximum of 40 mg/day. Amounts exceeding 15 mg/day should
be given in divided doses.
Storage: store at controlled room temperature.
Pioglitazone
Tablet, 15mg, 30mg, 45mg
Indications:Type 2 diabetes mellitus (NIDDM), monotherapy:
Adjunct to diet and exercise, to improve glycemic control. Type
2 diabetes mellitus (NIDDM), combination therapy with
582

9. Medicines Used In Endocrine Disorders And Contraceptives

sulfonyl urea, metformin, or insulin: when diet, exercise, and a

single agent alone does not result in adequate glycemic control.
Cautions: should not be used in diabetic ketoacidosis; use in
type 1 diabetes is not recommended; anemia; not for use in
children < 18 years of age.
Drug interactions: delavirdine, fluconazole, gemfibrozil,
ketoconazole, nicardipine, NSAIDs, sulfonamides, amiodarone,
fluoxetin, glimepride, glipizide, phenytoin, sertraline, warfarin.
Contraindications: hypersensitivity reaction, active liver
disease, patients who have experienced jaundice during therapy.
Side effects: serum triglycerides decreased, HDL-cholesterol
increased, weight gain, upper respiratory tract infection, edema,
headache, fatigue, hypoglycemia, anemia, myalgia, sinusitis,
pharyngitis.
Dose and Administration: Oral: Adult:Monotherapy: Initial:
15-30 mg once daily; if response is inadequate, the dosage may
be increased in increments up to 45mg once daily; maximum
recommended dose: 45mg once daily.Combination therapy:
Maximum recommended dose: 45mg/day
With sulphonylureas: Initial: 15-30 mg once daily;
With metformin: Initial: 15-30mg once daily
With insulin: Initial: 15-30mg once daily
Rosiglitazone maleate
Tablet, 1mg, 2mg, 4mg, 8mg
Indications: type 2 diabetes mellitus (noninsulin dependent,
NIDDM):Monotherapy: improve glcemic control as an adjunct
to diet and exercise; combination therapy: in combination with a
sulfonylurea, metformin, or insulin when diet, exercise, and a
single agent do not result in adequate glcemic control.

583

9. Medicines Used In Endocrine Disorders And Contraceptives

Cautions: diabetic ketoacidosis; use in type 1 diabetes;

premenopausal, anovulatory women; anemia or depressed
leukocyte count; edema.
Drug interactions: delavirdine, fluconazole, gemfibrozil,
ketoconazole, nicardipine, NSAIDs, sulfonamides, amiodarone,
fluoxetin, glimepride, glipizide, phenytoin, sertraline, warfarin.
Contraindications: active liver disease, patients who
previously experienced jaundice during troglitazone therapy.
Side effects: weight gain, increase in total cholesterol, increased
LDL-cholesterol, increased HDL-cholesterol, edema, headache,
fatigue, hyperglcemia, hypoglycemia, diarrhea, anemia, back
pain.
Dose and Administration: Oral: Adult:Monotherapy: Initial: 4
mg daily as a single daily dose or in divided doses twice daily.
If response is inadequate after 12 weeks of treatment, the dosage
may be increased to 8 mg daily as a single daily dose or in
divided doses twice daily.Combination therapy: With
sulfonylureas: initial: 4 mg daily as a single daily dose or in
divided doses twice daily; doses of sulfonylurea should be
reduced if the patient reports hypoglycemia.
With metformin: initial: 4 mg daily as a single daily dose or in
divided doses twice daily. If response is inadequate after 12
weeks of treatment, the dosage may be increased to 8 mg daily
as a single daily dose or in divided doses twice daily.With
insulin: initial: 4 mg daily as a single daily dose or in divided
doses twice daily. Doses of insulin should be reduced by 10% to
25% if the patient reports hypoglycemia or if the plasma glucose
falls to < 100 mg/dl.
Saxagliptin+ Metformine
Tablet, 5mg+500mg, 5mg+1000mg, 2.5mg+1000mg
Indications: type II diabetes mellitus
584

9. Medicines Used In Endocrine Disorders And Contraceptives

Cautions: elderly; determine renal function before treatment

and periodically thereafter; Hepatic impairment; Renal
impairment
Contraindication: Pregnancy, Breast-feeding
Drug Interactions: Alcohol,Anabolic Steroids, Beta-blockers,
Corticosteroids, Diazoxide, Diuretics, Loop, Diuretics, Thiazide
and related, MAOIs, Oestrogens,Progestogens, Testosterone
Side-effects: vomiting, dyspepsia, gastritis; peripheral oedema;
headache, dizziness, fatigue; upper respiratory tract infection,
urinary tract infection, gastroenteritis, sinusitis, nasopharyngitis;
hypoglycaemia, myalgia; less commonly dyslipidaemia,
hypertriglyceridaemia, erectile dysfunction, arthralgia; also
reported rash.
Dose: Adult over 18 years, 5 mg once daily
Thiazolidinediones
The thiazolidinediones, such as pioglitazone and rosiglitazone,
improve glycaemic control by reducing cellular insulin
resistance.
Tolbutamide
Tablet, 500mg
Indications: type II diabetes mellitus
Cautions, Contraindications; see notes above.
Side effects: see notes above, also headache, and tinnitus.
Drug interactions: see under Glibenclamide.
Dose and Administrations:0.5 to 1.5g (maximum 2g) daily in
divided doses; with or immediately after breakfast
Storage: store in a well-closed container at room temperature.
Gliclazide
Tablate (sustained release) 30 mg, 40 mg, 80mg
585

9. Medicines Used In Endocrine Disorders And Contraceptives

Indications: type 2 diabetes mellitus

Cautions:
may encourage weight gain and should be
prescribed only if poor control and symptoms persist despite
adequate attempts at dieting
Contraindications: renal and heopatic imperment, pregnancy
and breats feeding, should be avoided where possible in acute
porphyria. It is contraindicated in the presence of ketoacidosis.
Side-effects: gastro-intestinal disturbances such as nausea,
vomiting, diarrhoea, and constipation
Dose and Administration:Initially, 4080 mg daily, adjusted
according to response; up to 160 mg as a single dose, with
breakfast; higher doses divided; max. 320 mg daily
9.5. Female Sex hormones and Combination preparations
Therapeutically, oestrogens, progestogens and their derivatives
are used alone or in combination:
In oral contraceptives to suppress ovulation.
To control abnormalities in ovarian hormone secreation in
the treatment of dysfunctional uterine bleeding and primary
dysmenorrhoea.
Peri and postmenopausally to relieve symptoms and to
prevent and possibly treat the long-term sequelae of the
menopause.
To induce normal pubertal development in Turner's
syndrome and other hypo-oestrogenic states. Patients with
delayed puberty should be managed by a specialist as
injudicious use of oestrogen can cause abnormal breast
development.
They are also used in high doses in the palliative treatment of
advanced prostatic carcinoma.

586

9. Medicines Used In Endocrine Disorders And Contraceptives

Chorionic Gonadotrophin
Powder for injection, 1500 IU, 5000 IU
Indications: induces ovulation and pregnancy in anovulatory,
infertile
females;
treatment
of
hypogonadotrophic
hypogonadism, prepubertal cryptorchidism; spermatogenesis
induction with follitropin alfa or follitropin beta.
Cautions: asthma, epilepsy, migraine, or cardiovascular
disorders, including hypertension, or renal disorders.
Contraindications: hypersensitivity to the drug; prostatic
carcinoma, precocious puberty.
Side effects: headache, tiredness, changes in mood, depression,
restlessness, edema, (especially in males), and pain on injection,
gynaecomastia, ovarian hyperstimulation with marked ovarian
enlargement or cyst formation, acute abdominal pain, ascites,
pleural effusion, hypovolaemia, shock, and thrombo-embolic
disorders in severe cases.
Dose and Administration: Adult: I.M:Induction of ovulation:
5000-10,000 units given to mimic the midcycle peak of
luteinising hormone. Up to 3 repeat injections of up to 5000
units each may be given within the following 9 days to prevent
insufficiency of the corpus luteum.Prepubertal cryptorchidism
(males): IM: 500-4000 units three times weekly.Delayed
puberty associated with hypogonadism in males: IM: 500-1500
units twice weekly.
Storage: store at 2o to 15 oC in airtight containers; protect from
light.
Conjugated estrogens (equine)
Vaginal cream, 0.625 mg/g base
Tablet,0.3mg,0.45 mg,0.625 mg, 0.9 mg, 1.25 mg, 2.5 mg
Indications: for replacement therapy in naturally occurring or
surgically induced estrogen deficiency state associated with
587

9. Medicines Used In Endocrine Disorders And Contraceptives

menopausal and postmenopausal symptoms; e.g. hot flushes,

sleep disturbances and atrophic vaginitis; prostatic cancer,
breast cancer, abnormal uterine bleeding.
Cautions: postmenopausal women, endometriosis, asthma,
epilepsy, migraine, coronary heart disease, diabetes or renal
disorders; gallbladder disease, cholestatic jaundice.
Drug
interactions:
hydrocortisone,
anticoagulants,
aminoglutethimide, carbamazepine, phenobarbital, rifampin,
nafcillin, nevirapine, phenytoin, ethanol, rifamycins.
Contraindications: hepatic dysfunction; a history of ostrogen
dependent neoplasia such as breast or endometrial cancer,
endometrial hyperplasia, undiagnosed vaginal bleeding,
cerebrovascular accident; thrombosis or thromboembolic
disorders; active thrombophlebitis, ophthalmic vascular disease;
known or suspected pregnancy.
Side effects: there may be sodium and water retention with
oedema, weight gain, tenderness and enlargement of the breasts,
changes in libido, menstrual disorders and withdrawal bleeding,
alterations in liver function, jaundice, gallstones, depression,
headache, migraine, dizziness, a decrease in glucose tolerance,
and decrease in tolerance of contact lenses. Nausea and
vomiting and other gastro-intestinal disturbances. Skin
reactions, cardiovascular effects (risk in blood pressure).
Dose and Administration:Adult:Atrophic vaginitis:
Vaginal cream: PV or Topicaly: 1-2 g daily, on a cyclical basis;
maximum 4 g/day.Oral: initial: 0.3 mg/day; the lowest dose that
will control symptoms should be used. May be given cyclically
or daily, depending on medical assessment of patient.In
menopausal and postmenopausal symptoms: Oral: 0.3 to 1.25
mg daily is given in conjunction with a progestogen in women
with a uterus.Primary ovarian failure: Oral: 1.25 mg daily.
Female hypogonadism: Oral: 2.5 to 7.5 mg daily administered
588

9. Medicines Used In Endocrine Disorders And Contraceptives

on a cyclical basis.Palliative treatment of prostatic carcinoma:

Oral: 1.25 to 2.5 mg three times daily.Abnormal uterine
bleeding: Oral: 1.25 mg, may repeat every 4 hours for 24 hours,
followed by 1.25 mg once daily for 7-10 days.
Storage: store in airtight containers and at room temperature.
Conjugated estrogens (equine) (initial phase) + Conjugated
estrogens (equine) and Medroxyprogesterone acetate
(second phase)
Biphasic tablet conjugated estrogens 0.625mg and conjugated
estrogens 0.625mg / medroxyprogesterone acetate 5mg.
Indications: women with an intact uterus; treatment of
moderate to severe vasomotor symptoms associated with
menopause; treatment of atrophic vaginitis; osteoporosis
(prophylaxis).
Contraindications: pregnancy.
Dose and Administration: Oral:Adult:One maroon conjugated
estrogen 0.625mg tablet daily on days 1 through 14 and one
light blue conjugated estrogen 0.625mg / MPA 5mg tablet daily
on days 15 through 28.
Conjugated estrogens and Medroxyprogesterone acetate
Monophasic tablet, 0.3+1.5mg, 0.45+1.5mg, 0.625+2.5mg,
0.625+5mg
Dose and Administration: Oral:Adult:
One conjugated estrogen 0.3mg / MPA 1.5mg tablet daily; dose
may be increased to one conjugated estrogen 0.625mg /
MPA5mg tablet daily.
Diensterol
Vaginal Cream 0.1%
589

9. Medicines Used In Endocrine Disorders And Contraceptives

Indications: treatment of atrophic vaginitis or other vaginal

disturbancesassociated with hypoestrogenic conditions.
Cautions and Contraindications: abnormal vaginal bleeding,
breast cancer, active/recent stroke or heart attack, asthma,
diabetes, seizures, migraine headaches, liver disease, heart
disease (e.g., high blood pressure, heart attacks, congestive heart
failure), kidney disease, low thyroid hormone (hypothyroidism),
abnormal calcium level in the blood, depression, high blood
pressure during pregnancy (toxemia), cholestatic jaundice,
uterine fibroids, endometriosis, cholesterol or lipid problems,
gallbladder disease, excessive weight gain, certain blood
disorder (porphyria), any allergies (especially peanut allergy).
Side effects: vaginal irritation, dizziness, lightheadedness,
headache,stomach upset, bloating, nausea, weight changes,
increased/decreased interest in sex, and breast tenderness,
mental/mood changes (e.g., severe depression, memory loss),
calf pain/swelling, sudden severe headache, chest pain, trouble
breathing, one-sided weakness, slurred speech, vision changes,
breast lumps, swelling of hands or feet, changes in vaginal
bleeding, unusual vaginal discharge/itching/odor, yellowing of
the eyes or skin, rash, itching, swelling, severe dizziness,
trouble breathing.
Dose and Administration: the usual dosage range is one or two
applicatorful per day for one or two weeks, then gradually
reduced to one half initial dosages for a similar period. A
maintenance dosage of one applicatorful, one to three times a
week, may be used after restoration of the vaginal mucosa has
been achieved.
Storage: store at room temperature and away from light and
moisture.

590

9. Medicines Used In Endocrine Disorders And Contraceptives

Estradiol Valerate
Tablets, 1 mg, 2 mg
Indications: treatment and prophylaxis of menopausal and
postmenopausal disorders, and in menstrual symptoms arising
from estrogen deficiency.
Cautions, Contraindications and Side effects: as for the
estrogens in general.
Dose and Administration: Adult:Oral: 1 - 2 mg daily,
according to severity of symptoms and clinical response.
Storage: store at room temperature.
Estradiol + Estriol +Estrone
Monophasic tablet, 600mcg + 270mcg + 1.4 mg
Dose and Administration:
Menopausal symptoms and Osteoporosis prophylaxis:1 to 2
tablets daily, with cyclical progestogen for 12 - 14 days of each
cycle in women with intact uterus.
Estraiol
Tablet, 2mg
Intravaginal cream, 0.01 %
Pessary, 500 mcg
Indications: actions and uses similar to those described for the
oestrogens in general.
Cautions, Contraindications and Side effects; similar to
estrogens.
Dose and Administration:
Adult: Oral: initially 2-8 mg daily for 5-7 days; maintenance 24 mg daily, cyclically or continuously.
Atrophic vaginitis:PV, 1 applicator (0.5g) daily for 2-3 weeks,
maintenance 1 application twice weekly.
Storage: stores in airtight containers.
591

9. Medicines Used In Endocrine Disorders And Contraceptives

Ethinyl estradiol
Tablet, 1 mg, 2mg
Indications: hormone replacement for menopausal symptoms,
osteoporosis prophylaxis; palliation in breast cancer in men and
postmenopausal women; contraception in combination with a
progestogen.
Cautions: progestogen may need to be added to regimen to
reduce risk of endometrial cancer due to unopposed estrogen;
migraine; history of breast nodules of fibrocystic disease;
uterine fibroids may increase in size; symptoms of
endometriosis may be exacerbated; predisposition to
thromboembolism; presence of antiphospholipid antibodies;
increased risk of gall bladder disease; porphyria.
Drug interactions: rifampicin, ritonavir, warfarin, doxycycline,
nevirapine, phenytoin.
Contraindications: pregnancy; estrogen - dependent cancer;
active thrombophlebitis or thromboembolic disorders;
undiagnosed vaginal bleeding; breastfeeding; liver disease,
Dubin Johnson and Rotot syndromes.
Side effects: nausea and vomiting, abdominal cramps and
bloating; weight increase; breast enlargement and tenderness;
premenstrual - like syndrome; sodium and fluid retention;
changes in liver function; cholestatic jaundice; rashes and
chloasma, changes in libido; depression, headache, migraine,
dizziness, leg cramps; contact lenses may irritate.
Dose and Administration: Oral: Adult:Hormone replacement
(female): 10 - 20 mcg daily.Palliation in breast cancer in
postmenopausal women: 0.1- 1 mg 3 times daily.
Storage: store at room temperature
Etonogestrol+ Ethinyl estradiol
Vaginal ring, 11.7mg+2.7mg
592

9. Medicines Used In Endocrine Disorders And Contraceptives

The ring should be placed in the vagina and left in place for 3
weeks. After 3 weeks, it is removed for a 1-week break; then a
new ring is inserted. The directions on the label should be
followed carefully. More than one contraceptive ring at a time
should never be used. The contraceptive ring should be inserted
and removed on the same day of the week and at about the same
time of day.
Hydroxyprogesterone Caproate
Injection, 250 mg/ml in 1 ml ampoule
Indications: used for recurrent miscarriage and various
menstrual disorders.
Dose and Administration: Recurrent miscarriage associated
with proven progesterone deficiency: IM: 250-500mg weekly
given during the first half of pregnancy.
Norethisterone (Norethindrone)
Tablet, 5 mg
Indications:
endometriosis;
menorrhagia;
severe
dysmenorrhoea; contraception (section - 8.4.1); hormone
replacement therapy (HRT).
Cautions: epilepsy; migraine; diabetes mellitus; hypertension;
cardiac or renal disease and those susceptible to
thromboembolism; depression; breast-feeding.
Drug
interactions:
carbamazepine,
ciclosporine,
dexamethasone, fludrocortisone, glibenclamide, griseofulvin,
hydrocortisone, insulins, metformin, nevirapine, phenobarbital,
phenytoin, prednisolone, rifampicin, warfarin.
Contraindications: pregnancy, undiagnosed vaginal bleeding;
hepatic impairment or active liver disease; severe arterial
disease, breast or genital tract cancer, porphyria; history in
593

9. Medicines Used In Endocrine Disorders And Contraceptives

pregnancy of idiopathic jaundice, severe pruritus or pemphigoid

gestations.
Side effects: acne, urticaria, fluid retention, weight increase,
gastrointestinal disturbances, changes in libido, breast
discomfort, premenstrual symptoms, irregular menstrual cycles,
depression, insomnia, somnolence, alopecia, hirsutism,
anaphylactoid - like reactions; exacerbation of epilepsy and
migraine; rarely jaundice.
Dose and Administration: Adult:Oral:Endometriosis: 10 mg
daily starting on fifth day of cycle (increased if spotting occurs
to 20 - 25 mg daily, reduced once bleeding has stopped).
Menorrhagia: 5 mg three times daily for 10 days to stop
bleeding; to prevent bleeding 5 mg twice daily from day 19 to
26 of cycle.Dysmenorrhoea: 5 mg 2 - 3 times daily from day 5
to 24 for 3 to 4 cycles.
Storage: protect from light.
9.6. Male sex hormone Preparations and its antagonists
Mesterolone
Tablet, 25 mg
Indications: replacement therapy for adult on set hypogonadism
or following parenteral therapy after secondary sexual
characteristics have developed
Cautions, Contraindications, Drug interactions and Side
effects; see under testosterone.
Dose and Administration:Adult:Oral: initially 25 mg 3 times
daily; maintenance 25 mg once or twice daily, depending on
individual response.
Storage: protect from light.

594

9. Medicines Used In Endocrine Disorders And Contraceptives

Testosterone
Indications: hypogonadism; palliative treatment of advanced
breast cancer in women.
Cautions: cardiac, renal or hepatic impairment; elderly,
ischaemic heart disease, hypertension, epilepsy, skeletal
metastases (risk of hypercalcaemia); regular examination of
prostate during treatment; prepubertal boys.
Drug interactions: glibenclamide, insulins, metformin,
warfarin.
Contraindications: breast cancer in men, prostate cancer,
hypercalcaemia, pregnancy, breastfeeding, nephrosis, and
history of primary liver tumours.
Side effects: prostate abnormalities and prostate cancer,
headache, depression, gastrointestinal bleeding, nausea,
cholestatic jaundice, changes in libido, gynaecomastia, anxiety,
asthenia generalized paraesthesia, electrolyte disturbances
including sodium retention with oedema and hypercalcaemia;
increased bone growth; andrognic effects such as hirsutism,
male pattern baldness, seborrhoea, acne, priapism, precocious
sexual development and premature closure of epiphyses in prepubertal males, virilism in females, and suppression of
spermatogenesis in men.
Storage: protect from light and store at room temperature.
Preparations include:
Testosterone propionate
Injection, 10mg/ml, 100 mg/ml, 250 mg/ml in 1 ml ampoule
Dose and Administration: IM: 50mg two or three times
weekly.

595

9. Medicines Used In Endocrine Disorders And Contraceptives

Testosterone propionte + Testosterone phenyl propionate

+Testosterone isocaproate + Testosterone decanoate
Injection, 30 mg + 60 mg + 60 mg + 100 mg
Dose and Administration: IM: usually 1ml every 4 weeks.
9.7. Contraceptives
Hormonal Contraceptives
Hormonal contraceptives are only generally available for
women although preparations for men are being evaluated. Oral
contraceptives are divided in to 2 main types: combined
(containing an oestrogen and a progestogen) and progestogen only:
They produce a contraceptive effect mainly by
suppressing the hypothalamic pituitary system resulting in
prevention of ovulation.
In addition changes in the
endometrium make it unreceptive to implantation and changes
in the cervical mucus may prevent sperm penetration.
Combined Oral Contraceptives: Oral contraceptives
containing an oestrogen and a progestogen are the most
effective preparations for general use. Advantages of combined
oral contraceptives include:
Reliable and reversible.
Reduced dysmenorrhoea and menorrhagia;
Reduced incidence of premenstrual tension.
Less symptomatic fibroids and functional ovarian cysts;
Less benign breast disease
Reduced risk of ovarian and endometrial cancer
Reduced risk pelvic inflammatory disease, which may be a
risk with intra uterine devices.
An association between the amount of estrogen and
progestogen in oral contraceptives and an increased risk of
adverse cardiovascular effects has been observed.
596

9. Medicines Used In Endocrine Disorders And Contraceptives

The oestrogen content ranges from 20 to 50 micrograms and

generally a preparation with the lowest oestrogen and
progestogen content which gives good cycle control and
minimal side - effects in the individual woman is chosen.
The risk of hypertension increases with increasing
duration of oral contraceptive use and they should be
discontinued if the woman becomes hypertensive during use.
Combined oral contraceptives are associated with an increased
risk of thromboembolic and thrombotic disorders and an
increase in risk of cerebrovascular disorders including stroke
and subarachnoid hemorrhage.
Risk factors for venous Thromboembolism or Arterial disease:
Risk factors for venous thromboembolism include family
history of venous thromboembolism in first degree relative age
less than 45 years, obesity, long-term immobilization and
varicose veins.
Risk factors for arterial disease: Risk factors for arterial disease
include family history of arterial disease in first - degree relative
age under 45 years, diabetes mellitus, hypertension, smoking,
age over 35 years, obesity and migraine.
If 2 or more factors for either venous thromboembolism
or arterial disease are present, combined oral contraceptives
should be avoided.
Combined oral contraceptives are
contraindicated if there is severe or focal migraine
Estrogen containing oral contraceptives should be
discontinued four weeks prior to major elective surgery and all
surgery to the legs. When discontinuation is not possible
consideration, should be given to the prophylactic use of
subcutaneous heparin.
Reasons to Stop Combined Oral Contraceptives
Immediately: Combined estrogen-containing oral contraceptives
597

9. Medicines Used In Endocrine Disorders And Contraceptives

should be stopped immediately if any of the following

symptoms occur.
Sudden severe chest pain (even if not radiating to left arm):
Sudden breathlessness (or cough with blood stained sputum)
Severe pain in calf of one leg
Severe stomach pain
Serious neurological effects including unusual, severe,
prolonged headache especially if first time or getting
progressively worse or sudden partial or complete loss of
vision or sudden disturbance of hearing or other perceptual
disorders or dysphagia or bad fainting attach or collapse or
first unexplained epileptic seizure or weekness, motor
disturbances, very marked numbness suddenly affecting one
side or one part of body:
Hepatitis, jaundice, liver enlargement;
Severe depression
Blood pressure above systolic 160mmHg and diastolic
100mmHg;
Detection of a risk factor.
Diarrhea and vomiting: Diarrhea and vomiting up to 3 hours
after taking an oral contraceptive or very severe diarrhea can
interfere with its absorption. Additional precautions should
therefore be used during and for 7 days after recovery. If the
vomiting and diarrhoea occurs during the last 7 tablets, the next
pill - free intervals should be omitted (in the case of every day
tablets the inactive ones should be omitted).
Interactions: The effectiveness of both combined and
progestogen only oral contraceptives may be considerably
reduced by interaction with drugs that induce hepatic enzyme
activity (e.g carbamazepine, griseofulvin, modafinil, nelfinavir,
nevirapine, oxcarbazepine, phenytoin, phenobarbital, primidone,
ritonavir, topiramate, and above all, rifabutin and rifampicin);
598

9. Medicines Used In Endocrine Disorders And Contraceptives

advice on the possibility of interaction with newer antiretroviral

drugs should be sought from HIV specialists: some broadspectrum antibiotics (eg. Ampicillin, doxycycline) may reduce
the efficacy of combined oral contraceptives by impairing the
bacterial flora responsible for recycling of ethinylestradiol from
the large bowel.
Effectiveness of oral progestogen only preparations is not
affected by broad-spectrum antibiotics but is reduces by enzyme
inducing drugs.
Progestogen-only
contraceptives:
Progestogen
only
contraceptives, such as oral levonorgestrel may offer a suitable
alternative when estrogens are contraindicated but the oral
progestogen only preparations do not prevent ovulation in all
cycles and have a higher failure rather than combined estrogen
containing preparations. Progestogen - only contraceptives carry
less risk of thromboembolic and cardiovascular disease than
combined oral contraceptives and are preferable for women over
35 years, for heavy smokers, and for those with hypertension,
valvular heart disease, diabetes mellitus, and migraine, they can
be used as an alternative to estrogen containing combined
preparations prior to major surgery. Menstrual irregularities
(oligomenorrhoea, menorrhagia, and amenorrhoea) are
common. Injectable preparations of Medroxy progesterone
acetate or norethisterone enantate may be given intramuscularly.
They have prolonged action and should only be given with full
counseling and manufacturer's information leaflet.
One tablet daily, on a continuous basis, starting on day 1 of
cycle and taken at the same time each day (if delayed by longer
than 3 hours contraceptive protection may be lost). Additional
contraceptive precautions are not necessary when initiating
treatment.
599

9. Medicines Used In Endocrine Disorders And Contraceptives

Changing from a combined oral contraceptive: start on the

day following completion of the combined oral contraceptive
course without a break (or in the case of every day tablets
omitting the inactive ones).
After childbirth: start any time after 3 weeks postpartum
(increased risk of breakthrough bleeding if started earlier) lactation is not affected.
Emergency contraception: Emergency contraception can be
obtained using levonorgestrel, one tablet of 750 micrograms
should be taken as soon as possible (within 72 hours) after
unprotected intercourse followed 12 hours later by another one
tablet. Under those circumstances it prevents about 86% of
pregnancies that would have occurred if no treatment had been
given. Adverse effects include nausea, vomiting, headache,
dizziness, breast discomfort, and menstrual irregularities. If
vomiting occurs within 2-3 hours of taking the tablets,
replacement tablets can be given orally with an antiemetic.It
should be explained to the woman that her next period may be
early or late; that she needs to use a barrier contraceptive
method until her next period, and that she should return
promptly if she has any lower abdominal pain or if the
subsequent menstrual bleed is abnormally light, heavy, brief or
absent. There is no evidence of harmful effects to the fetus if
pregnancy should occur.
9.7.1. Combined Oral Contraceptives
Drospirenone+Ethinyl Estradiol
Tablet (film coated), 3mg+0.03mg,3mg+0.02mg
Indications:oral contraceptive
Contraindications: hypersensitivity to ethinyl estradiol;
drospirenone or any components of the formulation; sever
hypertension history of or current thrombophlebitis or venous
600

9. Medicines Used In Endocrine Disorders And Contraceptives

thromboebolic disorder cerebral vascular disease; coronary

artery disease.
Side effects: nausea; withdrawal bleeding may occur. Dose
and Administration:oral:1 tablet daily for 28 consecutive
days. Dose should be taken at the same time each day either
after the evening meal or at bed time.
Storage: store at 250 c
Levonorgestrel (D-Norgestrel) +Ethinylestradiol and Iron
tablets Tablet, (0.15mg + 0.03mg, 0.25mg + 0.05mg, 0.5mg +
0.05mg; 0.3mg + 0.03mg), 0.05mg+0.03mg (6tablets),
0.075mg+0.05 (5tablets), 0.125mg+0.03mg (10 tablets)
Norethindrone (Norethisterone) + Ethinylestradiol
Tablet, 0.5mg + 0.035m
Norethindrone (Norethisterone) + Mestranol and iron
tablets Tablet, 1mg + 0.05mg)
Indications:
contraception,
menstrual
symptoms,
endometriosis.
Cautions: risk factor for venous thromboembolism and arterial
disease (see notes above); migraine; hyperprolactinaemia (seek
specialist advice); some types of hyperlipidaemia; gallbladder
disease; depression; long-term immobilization, sickle-cell
disease; inflammatory bowel disease including crohn disease;
see also interactions
Drug interactions: see notes above

Each iron Tablet contains: Ferrous fumarate 75 mg

601

9. Medicines Used In Endocrine Disorders And Contraceptives

Contraindications: pregnancy; twenty-one days postpartum;

breastfeeding until weaning or for first 6 months postpartum;
personal history of venous or arterial thrombosis, heart disease
associated with pulmonary hypertension or risk of embolism;
migraine; history of sub-acute bacterial endocarditis; ischaemic
cerebrovascular disease; liver disease, including disorders of
hepatic secretion such as Dubin - Johnson or Rotor syndromes,
infections hepatitis (until liver function normal); porphyria;
systemic lupus erythematosus; liver adenoma; history of
cholestasis; gall stones: estrogen - dependent neoplasms;
neoplasms of breast or genital tract; undiagnosed vaginal
bleeding; history during pregnancy of pruritus, chorea, herpes,
deteriorating otosclerosis; cholestatic jaundice; pemphigoid
gestationis; diabetes mellitus (if either retinopathy, neuropathy
or if more than 20 years duration); after evacuation of
hydatidiform mole (until return to normal of urine and plasma
gonadotrophin values)
Side effects: nausea, vomiting, headache, breast tenderness,
increase in body weight, thrombosis, changes in libido,
depression, chorea, skin reaction, chloasma, hypertension,
impairment of liver function, 'spotting' in early cycles, absence
of withdrawal bleeding, irritation of contact lenses; rarely,
photosensitivity and hepatic tumours; breast cancer (small
increase in risk of breast cancer during use which reduces
during the 10 years after stopping; risk factor seems related to
age at which contraceptive is stopped rather than total duration
of use; small increase in risk of breast cancer should be weighed
against the protective effect of the ovary and endometrium)
Dose and Administrations: Contraception (21 - day combined
(monophasic) preparations), by mouth, Adult (female), 1 tablet
('pill') daily for 21 days; subsequent courses repeated after 7 day pill - free interval (during which withdrawal bleeding
602

9. Medicines Used In Endocrine Disorders And Contraceptives

occurs). Administration each tablet (pill') should be taken at

approximately the same time each day; if delayed by longer than
24 hours contraceptive protection may be lost. It is important to
bear in mind that the critical time for loss of protection is when
a pill is omitted at the beginning or end of a cycle (which
lengthens the pill - free interval).
Note: The following advice is recommended. If you forget a pill, take
it as soon as you remember, and the next one at the normal time. If
you are 12 or more hours late, the pill may not work; as soon as you
remember, continue normal pill - taking, but for 7 days an additional
method of contraception such as the sheath will be required. If the 7
days run beyond the end of your packet, start the next packet when
you have finished the present one - do not have a gap between
packets.

Storage: at room temperature, in a well - closed container.

9.7.2 Progestogen - only contraceptives
Indications: contraception
Cautions: heart disease, sex-steroid dependent functional
ovarian cysts, active liver disease, recurrent cholestatic jaundice,
history of jaundice in pregnancy; see also interactions
Drug interactions: see notes above under interaction and
progestogen only contraceptives notes.
Contraindications: pregnancy, undiagnosed vaginal bleeding;
severe arterial disease; liver adenoma, porphyria; after
evacuation of hydatidiform mole (until return to normal of urine
and plasma gonadotrophin values); see notes above
Side effects: menstrual irregularities (see also notes above);
nausea, vomiting, headache dizziness, breast discomfort,
depression, skin disorders, disturbance of appetite, weight
changes, changes in libido.
Breast cancer: There is a small increase in the risk of having
breast cancer diagnosed in women using or who have recently
603

9. Medicines Used In Endocrine Disorders And Contraceptives

used, a progestogen - only contraceptive pill; this relative risk

may wholly or partly be due to an earlier diagnosis. The most
important risk factor appears to be the age at which the
contraceptive is stopped rather than the duration of use; the risk
disappears gradually during the 10 years after stopping and
there is no excess risk by 10 years.
Dose and Administrations: See under preparation
Oral Preparations
Norethindrone (Norethisterone)
Tablet, 0.35mg
Dose and Administration: 1 tablet daily at same time each
days starting on day 1 of cycle then continuously; if
administration delayed for 3 hours or more it should be regarded
as a 'missed pill'.
Parentral preparations
Medroxyprogesterone Acetate,
Injection (aqueous suspension), 150mg/ml in l ml vial
Dose and Administration: by deep intramuscular injection,
150mg within first 5 days of cycle or within first 5 days after
parturition (delay until 6 weeks after parturition if breastfeeding); for long-term contraception, repeated every 12 weeks
(if interval greater than 12 weeks and 5 days, exclude pregnancy
before next injection and advise patient to use additional
contraceptive measures (e.g barrier) for 14 days after the
injection).
Norethindrone (Norethisterone) Enanthate
Injection (oily), 200mg/ml in 1 ml ampoule
604

9. Medicines Used In Endocrine Disorders And Contraceptives

Dose and Administration: by deep intramuscular injection

given very slowly into gluteal muscle, short-term contraception,
200mg with in first 5 days of cycle or immediately after
parturition (duration 8 weeks); may be repeated once after 8
weeks (withhold breast-feeding for neonates with severe or
persistent jaundice requiring medical treatment).
Implants
Etonogestrel
Implant (subdermal) 68 mg/capsule, pack of 1 capsule.
Dose and Administration:by subdermal implantation, no
previous hormonal contraceptive, 1 implant inserted during first
5 days of cycle; parturition or abortion in second trimester, 1
implant inserted between days 21 - 28 after delivery or abortion
(if inserted after 28 days additional precautions necessary for
next 7 days); abortion in first trimester, 1 implant inserted
immediately; changing from an oral contraceptive, consult
product literature; remove within 3 years of insertion.
Levonorgestrel (D-Norgestrel)
Tablet, 0.03mg, 0.075mg
Implant capsule (subdermal); 108mg/capsule pack of 2
capsules; 75mg/capsule pack of 2 capsules.
Intra uterine device, 52mg
Dose and Administration: Implant capsule -by subdermal
implantation, set of 6 implant capsules inserted within first 5
days of cycle (preferably on 1st day after 1st day additional
precautions necessary for following 7 days) or 21st day after
parturition (after this any additional, precautions necessary for
following 7 days), remove within 5years of insertion.
Intra uterine device: To be inserted into uterine cavity; should
be inserted within 7 days of onset of menstruation or
immediately after 1st trimester abortion; release 20mcg
605

9. Medicines Used In Endocrine Disorders And Contraceptives

lovonorgestrel/day over 5 years. May be removed and replaced

with a new unit at anytime during menstrual cycle; do not leave
any one system in place for 5years.
Note: Inserted in the uterine cavity, to a depth of 6-9cm, with the provider
insertion device; should not be forced into the uterus.

9.7.3. Contraceptive Devices, Barriers, and Spermicides

Condoms (male and female)
Indications: as a primary method of contraception to prevent
pregnancy at times when oral contraceptives or intrauterine
devices may not be effective or are contraindicated or as an
adjuvant to the periodic abstinence (rhythm) method of
contraception.Also for prevention (prophylactic) of Sexually
transmitted diseases (STDs)
Cautions: in medical or psychosocial conditions where a critical
need exists for highly effective contraception. Persons must be
sufficiently counseled regarding the need for consistent and
correct use of condoms if they are to be effective in preventing
pregnancy.
Contraindication: sensitivity to latex condom
Side effect: burning, stinging, warmth, itching, other irritation
of the Skin, penis, rectum, or vagina, vaginal dryness or
malodor, allergic vaginitis, contact dermatitis.
Note: Condoms should be completely unrolled into the penis before
any genital contact occurs and remain intact throughout intercourse

Copper T 380 A
Indications: Copper T 380 A is an intra-uterine device used for
prevention of pregnancy, most suitable in parous women but
should be a last-resort contraceptive for young nulliparous
women because of the increased risk of pelvic inflammatory
disease and infertility.
Cautions: caution should be taken in those with anaemia, heavy
menses, history of pelvic inflammatory disease, diabetes,
606

9. Medicines Used In Endocrine Disorders And Contraceptives

valvular heart disease (antibiotic cover needed) - avoid if

prosthetic valve or past attack of infective endocarditis;
epilepsy, increased risk of expulsion if inserted before uterine
involution; there should be gynaecological examination before
insertion, 6 weeks after (or sooner if there is a problem), then
after 6 months, then yearly. The IUD should be removed if
pregnancy occurs.
Contraindications: Pregnancy, severe anaemia, known HIV
infectionvery heavy menses, history of ectopic pregnancy or
tubal surgery, distorted or small uterine cavity, genital
malignancy, pelvic inflammatory disease, immunosuppressive
therapy, copper allergy, Wilson's disease, medical diathermy.
Side effects: Uterine or cervical perforation, displacement,
pelvic infection may be exacerbated, heavy menses,
dysmenorrhoea, allergy, some pain on insertion (pain helped by
giving NSAIDs half an hour before insertion) bleeding,
occasionally, epileptic seizures, vasovagal attack.Note: Copper T
380A should be fitted into uterine cavity after the end of menstruation and
before the calculated time of implantation.An intrauterine device should not
be removed in mid cycle unless an additional contraceptive was used for the
previous 7 days.

Diaphragm with spermicides

Indications: Diaphragm is a mechanical barrier method of
contraception designed to hold spermicides near the cervical os,
which is particularly important in the event that the diaphragm
is dislodged or does not form a complete seal around the cervix.
Cautions: Caution is required in cases where there was recent
abortion or parturition, in chronic allergic conditions, in genital
contact dermatitis.
Drug interactions: Avoid use of diaphragm (with spermicides)
with vaginal or topical medications, and vaginal douch products.
607

9. Medicines Used In Endocrine Disorders And Contraceptives

Contraindications: Allergy to spermicides (Nonoxinol,

octoxinol), menstruation, toxic-shock syndrome.
Side effects: Vulvovaginal candidiasis (thick, white or curd like
vaginal discharge), toxic shock syndrome (dizziness, fever,
lightheadedness, chills, sunburn-like rash followed by peeling of
the skin, muscle aches, hypotension, unusual redness of the
mucous membrane inside of the mouth, nose, throat, vagina or
conjunctiva; confusion)
Dose and Administration:Nonoxinol 9 vaginal cream with
diaphragm:
Intravaginal,
Initially
1
applicatorful
(approximately 1 teaspoonful of 0.5% cream placed into cup
(diaphragm) and additional spermicides spread along the rim of
diaphragm just before insertion of diaphragm and not longer
than six hours prior to intercourse. An additional applicatorful
should be inserted into the vagina just prior to each repeat act of
intercourse or if intercourse occurs later than six hours after
initial diaphragm placement.Nonoxinol 9 vaginal foam with
diaphragm: Intravaginal, initially 1 applicatorful placed into
vagina and additional spermicide spread along the rim of
diaphragm just before insertion of diaphragm and not longer
than one hour prior to intercourse. An additional applicatorful
should be inserted into vagina just prior to, and not longer than
one hour before, each repeat of intercourse.
Nonoxinol 9 vaginal gel with diaphragm: Intravaginal, initially
2 teaspoonful of a 2% gel placed into cup and additional
spermicide spread along the rim of diaphragm just before
insertion of diaphragm and not longer than six hours prior to
intercourse. An additional applicatorful should be inserted into
vagina, just prior to each repeat act of intercourse or if
intercourse takes place later than six hours after initial
diaphragm placement.Octoxinol 9 vaginal cream with
diaphragm: Intravaginal, initially 2 teaspoonful placed into cup
608

9. Medicines Used In Endocrine Disorders And Contraceptives

and additional spermicide spread along the rim of diaphragm

just before insertion of diaphragm and not longer than six hours
prior to intercourse. An additional applicatorful should be
inserted into vaginal just prior to each repeat act of intercourse
or if intercourse occurs later than six hours after initial
diaphragm placement.
Octoxinol 9 vaginal jelly with diaphragm: Intravaginal, initially
1 applicatorful placed into cup and additional spermicide spread
along the rim of diaphragm just before insertion of diaphragm
and not longer than six hours prior to intercourse. An additional
applicatorful should be inserted into vagina just prior to each
repeat act of intercourse or if intercourse occurs later than six
hours after initial diaphragm placement.
Storage: at room temperature.
Nonoxinol, octoxinol,
Creams, Foams, Gels
Indications: Vaginal spermicides are used as chemical barrier
contraceptive for prevention of pregnancy.
Also used for prevention of sexually transmitted diseases when
used in combination with latex condoms.
Cautions: Caution is required in chronic allergy (local), genital
contact dermatitis, in medical or psychosocial conditions where
a critical need exists for highly effective contraception. Caution
should also be taken in recent parturition or abortion.
Drug interactions: vaginal or topical medication, especially
those containing aluminium, citrate, cotton dressing, hydrogen
peroxide, iodide, lanolin, nitrates, permanganates, salicylates,
silver salts, sulfonamides. Avoid also use of spermicides with
vaginal douche products or other vaginal or local cleansing
products.
609

9. Medicines Used In Endocrine Disorders And Contraceptives

Contraindications: allergy to octoxinol, nonoxinol, and

benealleonium chloride, menstruation, history of toxic-shock
syndrome, Genital ulcer, vaginal epithelial irritation.
Side effects: burning, stinging, warmth, itching, or other
irritation of the skin, penis, rectum, or vagina, vaginal discharge
(transient), vaginal dryness or odor, Allergic vaginitis
(persistent vaginal redness, irritation, rash, dryness, or whitish
discharge), contact dermatitis (persistent skin rash, redness,
irritation or itching), urinary tract infection (female) - due to
change in vaginal flora.
Dose and Administration:Nonoxinol 9 vaginal cream Intravaginal, 1 applicatorful of 5% cream inserted just prior to
intercourse. An additional applicatorful should be inserted into
vagina just prior to each repeat act of intercourse.Nonoxinol 9
vaginal Foam - Intravaginal, 1 applicatorful of inserted just
prior to and not longer than one hour prior to each act of
intercourse.Nonoxinol 9 vaginal Gel - Intravaginal, 1
applicatorful of a 4% gel inserted just prior to and not longer
than one hour prior to intercourse.
Storage: at room temperature, in a well-closed container (cream
and gel), protect from freezing.
Nonoxynol
Pessaries, 5%
Indication: Prevention of pregnancy
Dose and Administration: Insert 1 pessary vaginally at least 10
minutes prior to intercourse; effective for 1 hour.
9.8. Medicines affecting Gonadotrophins
Danazole
Capsules, 100 mg, 200 mg
610

9. Medicines Used In Endocrine Disorders And Contraceptives

Indications: in the management of endometriosis, benign breast

disorders such as fibrocystic disease, gynaecomastia and prepubertal breast hypertrophy; hereditary angioedema.
Cautions: seizure, migraine, or conditions influenced by edema.
Drug interactions: carbamazepine, cyclosporine, and warfarin.
Contraindications: undiagnosed genital bleeding; pregnancy;
breast-feeding; porphyria; markedly impaired hepatic, renal, or
cardiac function.
Side effects: greasy skin, acne, voice changes and possibly
signs of virilisation (when therapy should be stopped
immediately).
Dose and Administration:Adult: Oral:Endometriosis: 200 800 mg daily in divided doses, adjusted according to response,
usually for 3 - 6 months (maximum 9 months).Cyclical breast
pain and nodularity: 100 mg twice daily for a maximum of 3
months.
Storage: store at room temperature.
9.9. Medicines used for impotence
The phosphodiesterase type 5 (PDE5) inhibitors, sildenafil,
tadalafil are equally effective in mild to moderate erectile
dysfunction. The choice of drug depends on the patients
requirements and the side-effect profile of the drug. Tadalafil is
the longest lasting with efficacy up to 36 hours. Tadalafil can be
taken with food and alcohol, whilst sildenafil has delayed and
reduced absorption when taken with a high fat meal. Failure
with one drug does not imply that the others will be ineffective
as well. These drugs are strongly contraindicated in patients
taking vasodilator nitrates.
Sildenafil is a phosphodiesterase type 5 inhibitor. The
neurotransmitter produced in the penis as the result of erotic
stimulation is nitric oxide, which promotes the production of
611

9. Medicines Used In Endocrine Disorders And Contraceptives

cGMP causing vasodilation. By blocking the action of PDE5

(which breaks down cGMP), sildenafil allows the concentration
of cGMP to build up during erotic stimulation. Sildenafil reacts
to a lesser degree with other isoenzymes of PDE, whichaccounts
for some of the side effects.
Sildenafil Citrate
Tablet, 25 mg, 50 mg, 100 mg
Indications: male erectile dysfunction.
Cautions: predisposition to priapism (e.g. sickle cell disease,
leukaemia); hepatic or severe renal impairment, elderly.
Drug interactions: nitrates; agents that inhibit cytochrome
P450 (eg. itraconazole, ketoconazole, erythromycin and
cimetidine); other agents for erectile dysfunction.
Contraindications: concurrent use with nitrates or nitric oxide
donors (combination can be fatal); severe ischaemic heart
disease; retinitis pigmentosa (possible disorders of retinal PDE).
Side effects: cardiovascular effects related to vasodilation
(headache, flushing, dizziness and hypotension); dyspepsia;
mild and transient abnormal vision and sensitivity to light
priapism has been reported.
Dose and Administration: Adult:Oral:Initially 50 mg taken 1
hour before anticipated sexual activity; titrate upwards to 100
mg if effect is inadequate or downwards to 25 mg if severe sideeffects occur. The maximum dosing frequent is once per day
and maximum dose is 100mg.Hepatic or renal impairment, the
elderly, and concomitant use with agents known to inhibit
cytochrome P450: Initially 25 mg.
Storage: store at room temperature.
Tadalafil
Tablet, 5mg ,10mg,20mg
612

9. Medicines Used In Endocrine Disorders And Contraceptives

Indications, Cautions,Drug interactions, Contraindications

and Side effects; See under sildenafil and notes above.
Dose and Administration: Adult:Oral: 20mg from 16 minutes
to 36 hours before sexual activity. Maximum 20 mg once in 24
hours.Mild to moderate hepatic impairment (avoid if severe):
Maximum 10mg once daily.
Vardenafil
Tablet, 5 g, 10mg, 20mg
Indications: erectile dysfunction
Cautions: hepatic impairment, renal impairment; bleeding
disorders or active peptic ulceration; susceptibility to
prolongation of QT interval (including concomitant use of drugs
which prolong QT interval), should be used with caution in
cardiovascular disease, left ventricular outflow obstruction,
anatomical deformation of the penis (e.g. angulation, cavernosal
fibrosis, Peyronies disease), and in those with a predisposition
to priapism (e.g. in sickle-cell disease, multiple myeloma, or
leukaemia). Concomitant treatment with a phosphodiesterase type-5
inhibitor and an alpha-blocker can increase the risk of postural
hypotension: initiate treatment with a phosphodiesterase type-5
inhibitor (at a low dose) only once the patient is stable on the alphablocker

Drug interactions: alpha blockers, calcium channel blockers,

ketoconazole, itraconazole, nifidipine,indinavir erythromycin,
nitrates, ritonavir saquinavir, and grape juice.
Contra-indications: ontra-indicated in patients receiving
nitrates, in patients in whom vasodilation or sexual activity are
inadvisable, or in patients with a previous history of nonarteritic anterior ischaemic optic neuropathy. In the absence of
information, manufacturers contra-indicate this drug in
hypotension (avoid if systolic blood pressure below 90 mmHg),
613

9. Medicines Used In Endocrine Disorders And Contraceptives

recent stroke, unstable angina, and myocardial infarction. Also

hereditary degenerative retinal disorders
Side-effects: dyspepsia, nausea, vomiting, headache (including
migraine), flushing, dizziness, myalgia, back pain, visual
disturbances (non-arteritic anterior ischaemic optic neuropathy
has been reportedstop drug if sudden visual impairment
occurs), and nasal congestion. Less common side-effects
include painful red eyes, palpitation, tachycardia, hypotension,
hypertension, and epistaxis. Other rarely side-effects include
syncope, hypersensitivity reactions (including rash, facial
oedema, and Stevens-Johnson syndrome), and priapism. Serious
cardiovascular events (including arrhythmia, unstable angina,
and myocardial infarction), seizures, sudden hearing loss
(discontinue drug and seek medical advice), and retinal vascular
occlusion. Less commonly drowsiness, dyspnoea, increased
lacrimation, photosensitivity; rarely anxiety, seizures, transient
amnesia, hypertonia, and raised intra-ocular pressure
Dose and administration: adults over 18 years, initially 10 mg
(elderly and patients on alpha-blocker therapy 5 mg) approx.
25 60 minutes before sexual activity, subsequent doses
adjusted according to response up to maximum 20 mg as a
single dose; maximum 1 dose in24 hours. Note: Onset of effect may
be delayed if taken with high-fat meal.

614

10. Obstetric And Gynaecological Medications

10. OBSTETRIC and GYNAECOLOGICAL MEDICINES

Medicines used in obstetrics: medicines may be used to
modify uterine contractions. These include oxytocic medicines
to stimulate uterine contractions both in induction of labour and
to control postpartum haemorrhage and beta2-adrenoceptor
agonists used to relax the uterus and prevent premature labour.
Postpartum haemorrhage: Ergometrine and oxytocin
differ in their actions on the uterus. In moderate doses oxytocin
produces slow generalized contractions with full relaxation in
between;
ergometrine
produces
faster
contractions
superimposed on a tonic contraction. High doses of both
substances produce sustained tonic contractions. Oxytocin is
now recommended for routine use in postpartum and post abortion haemorrhage since it is more stable than ergometrine.
However, ergometrine may be used if oxytocin is not available
or in emergency situations.
Premature labour: Salbutamol is a beta2-adrenoceptor
agonist which relaxes the uterus and can be used to prevent
premature labour in uncomplicated cases between 23 and 24
weeks of gestation. Its main purpose is to permit a delay in
delivery of at least 48 hours. The greatest benefit is obtained by
using this delay to administer corticosteroid therapy or to
implement other measures known to improve perinatal health.
Prolonged therapy should be avoided since the risk to the
mother increase after 48 hours and the response of the
myometrium is reduced.
Treatment of vaginal and vulval conditions: Antiinfective drugs: Candidal vulvitis can be treated locally with
cream but is almost invariably associated with vaginal infection
which should also be treated. Vaginal candidiasis is treated
primarily with antifungal pessaries or cream inserted high into
615

10. Obstetric And Gynaecological Medications

the vagina (including during menstruation) local irritation may

occur on application of vaginal antifungal products.
Imidazole drugs (clotrimazole, miconazole) are effective
in short courses of 3 to 14 days according to the preparation
used; single dose preparations after an advantage when
compliance is a problem. Vaginal applications may be
supplemented with antifungal cream for vulvitis and to treat
other superficial sites of infection.
Nystatin is a well established treatment (but stain
clothing yellow). One or two pessaries are inserted for 14 to 28
nights; they may be supplemented with cream for vulvitis and
to treat other superficial sites of infection.
Trichomonal infections: Commonly involve the lower
urinary tract as well as the genital system and need systemic
treatment with metronidazole or tinidazole. Bacterial infections
with Gram - negative organisms are particularly common in
association with gynaecological operations and trauma.
Metronidazole is effective against certain Gram - negative
organisms, especially Bacteroides spp. and may be used
prophylactically in gynaecological surgery. Metronidazole is
also indicated for bacterial vaginosis.
Aminocaproic Acid
Injection, 100 mg/ml in 1 ml ampoule.
Indications: treatment of excessive bleeding from fibrinolysis.
Cautions: cardiac, renal or hepatic disease.
Drug interactions: oral contraceptives, estrogens.
Contraindications: hypersensitivity to aminocaproic acid;
disseminated intravascular coagulation (without heparin);
evidence of an intravascular clotting process.
Side effects: arrhythmia, bradycardia, hypotension, peripheral
ischemia,
syncope,
confusion,
thrombosis,
fatigue,
616

10. Obstetric And Gynaecological Medications

hallucinations, headache, rash, pruritus, abdominal pain,

anorexia, cramps, GI irritation, nausea, dry ejaculation,
agranulocytosis, bleeding time increased, watery eyes, vision
decreased, tinnitus, failure, myoglobinuria, dyspnea, nasal
congestion, pulmonary embolism.
Dose and Administration:Adult: IV: 4 - 5 g during the first
hour, followed by 1 g/hour for 8 hours or until bleeding
controlled (maximum daily dose: 30 g).
Storage: store at room temperature.
Bromocriptine Mesylate
Tablet, 2.5 mg
Indications: galactorrhoea, amenorrhoea and infertility
associated with hyperprolactinaemia, and certain cases of
acromegaly (adjunctive therapy). It is used to suppress
lactation after stillbirth or abortion, or when breast - feeding is
contraindicated.
Cautions: psychotic disorders, parkinsonism with dementia,
compromised cerebral circulation, ischaemic heart disease, liver
disease, peptic ulcers.
Drug
interactions:
metoclopramide,
domperidone,
antipsychotic agents, tricyclic antidepressants, methyldopa,
reserpine, antihypertensive agents, alcohol.
Contraindications: hypersensitivity to ergot alkaloids,
toxaemia of pregnancy, uncontrolled hypertension or severe
cardiovascular disease.
Side effects: nausea, postural hypotension, drowsiness and
dizziness, especially early in therapy. Hypertension, myocardial
infarction, seizures and stroke, dyskinesia, hallucinations,
confusion and behavioral disturbances, urticaria, skin rashes,
peptic ulceration, nasal stuffiness, visual disturbance,
617

10. Obstetric And Gynaecological Medications

impotence and urinary retention, retroperitoneal fibrosis, pleural

thickening and effusions, and digital vasospasm.
Dose and Administration:Oral: Adult:Suppression of
lactation: 2.5 mg twice daily for 2 weeks, starting not before 4
hours after parturition, and provided that viral signs have
established. If lactation recurs 2 - 3 days after treatment is
stopped, it may be reinstituted and continued for another
week.Hypogonadism
or
amenorrhoeal,
galactorrhoea
syndromes: initially 1.25 mg once daily at bedtime; gradually
increases to an average of 2.5mg 2- 3 times daily.
Storage: store at a temperature less than 25oC.
Bupivacaine Hydrochloride
Injection, 0.5% in 10ml vial
Indication: long-acting local anaesthetic agent. Particularly
useful for producing prolonged analgesia during labour and
caesarean section, where the interval between doses is usually
2-3 hours.
Cautions, Contraindications, Drug interactions, Side effects
and Dose and Administration; see section 5.4 (local
anaesthetic).
Clomiphene Citrate
Tablet, 50 mg
Indications: management of anovulatory or oligo - ovulatory
infertility in women with an intact hypothalamic - pituitary ovarian axis.
Cautions: ectopic pregnancy, breast-feeding.
Contraindications: hepatic dysfunction, ovarian cysts,
undiagnosed abnormal uterine bleeding, pregnancy.
Side effects: reversible ovarian enlargement and cyst formation
(withdraw therapy); hot flushes, abdominal discomfort and
618

10. Obstetric And Gynaecological Medications

pain, nausea and vomiting, breast discomfort, abnormal uterine

bleeding, headache, skin rashes, weight gain; CNS effects such
as dizziness, nervousness, depression, fatigue, insomnia, visual
disturbances (blurring of vision, diplopia and photophobia),
reversible hair loss, hepatotoxicity.
Dose and Administration:Oral:
Adult: initially 50 mg daily for 5 days, starting on day 3 to 5 of
the menstrual cycle or after an induced bleed. If ovulation is
confirmed but conception fails, the same dose may be repeated
during
the
next
cycle.
If ovulation fails, the dose may be increased to 100 mg daily (as
a single dose) for 5 days.
Storage: store at room temperature.
Clotrimazole
Cream (vaginal), 1%
Tablet (vaginal), 100mg, 500mg
Indications: in the local treatment of vulvovaginal candidiasis
caused by Candida albicans and other species of candida in
pregnant (second and third trimester only) and non-pregnant
women.
Note:It is not effective in the treatment of vulvovaginitis caused by
other common pathogens such as Trichomonas vaginitis.

Cautions: pregnancy and labour and in those patients who are

allergic to clotrimazole and its family. Use hygienic measures
to cure infection and prevent reinfection by wearing cotton
panties instead of synthetic underclothes and wearing only
freshly washed under clothes. Sex partners should be advised to
use condom.
Contraindications: hypersensitivity to clotrimazole
Side effects: vaginal burning, itching, discharge, or other
irritation not present before therapy, abdominal or stomach
619

10. Obstetric And Gynaecological Medications

cramps or pain, burning or irritation of penis of sexual partner;

headache.
Dose and Administration:cream:Intravaginal, 50mg (1
applicatorful of 1% vaginal cream), once a day, preferably at
bed time, for six to fourteen consecutive days.Tablets: Nonpregnant patients: Intravaginal, 500mg as a single dose,
preferably at bedtime or 100mg once a day preferably at
bedtime, for six or seven consecutive days.Pregnant patients:
Intravaginal (100mg once a day), preferably at bedtime, for
seven consecutive days.
Storage: vaginal cream - store between 2 and 300c in a
collapsible tube or in a tight container. Vaginal tablet - at room
temperature in a well-closed container
Dienogest
Tablet, 2mg
Indications:Management of pelvic pain associated with
endometriosis
Cautions: bleeding, breast cancer, carbohydrate intolerance,
chloasma, Cholestatic jaundice, Hepatic tumors, ovarian cysts,
pruritus, retinal vascular lesions, venous thromboembolism
(VTE).
Drug interactions: CYP3A4 inducers, CYP3A4 inhibitors,
barbiturates, benzodiazepines, phenytoin, rifamycin derivatives.
Contraindications: hypersensitivity to dienogest or any
component of the formulation; undiagnosed abnormal vaginal
bleeding; active venous thromboembolic disorder; history of or
current arterial and cardiovascular disease (eg, MI, CVA);
diabetes mellitus with vascular involvement; history of or
current severe hepatic disease where liver function tests remain
abnormal; history of or current hepatic neoplasia (benign or
malignant); known or suspected sex-hormone-dependent
620

10. Obstetric And Gynaecological Medications

malignancy; ocular lesions due to ophthalmic vascular disease,

such as partial or complete vision loss or defect in visual fields;
current or history of migraine with focal aura; breast-feeding;
known or suspected pregnancy.
Side effects: headache, depression, sleep disturbance,
irritability, migraine, nervousness, acne, alopecia, breast
discomfort, ovarian cyst, libido decreased, nausea, weight gain,
abdominal pain, vaginal bleeding, weakness.
Dose and administration: Adult: Endometriosis: Oral: 2 mg
once daily. Administer without regard to meals. If a dose is not
absorbed due to vomiting and/or diarrhea within 3-4 hours of
administration, repeat dose.
Storage: Store in original packaging at 15C to 30C
Dinoprostone (prostaglandin E2)
Tablet (vaginal), 3 mg
Suppository (vaginal), 20mg
Indications: Suppositories: Terminate pregnancy from 12th
through 28th week of gestation; evacuate uterus in cases of
missed abortion or intrauterine fetal death.
Vaginal insert: Initiation and/or cervical ripening in patients at
or near term in whom there is a medical or obstetrical indication
for the induction of labor.
Cautions: cervicitis, infected endocervical lesions, acute
vaginitis, compromised (scarred) uterus or history of asthma,
hypertension or hypotension, epilepsy, diabetes mellitus,
anemia, jaundice, cardiovascular, renal, or hepatic disease.
Drug interactions:oxytocin may augment the activity of
oxytocic agents and their concomitant use is not recommended.
A dosing interval of at least 30 minutes is recommended for the
sequential use of oxytocin following the removal of the
dinoprostone vaginal insert. A 6 hours interval is needed
621

10. Obstetric And Gynaecological Medications

between the insertion of dinoprostone and initiation of oxytocin

infusion.
Contraindications: hypersensitivity to prostaglandins, fetal
distress, unexplained vaginal bleeding during this pregnancy,
acute pelvic inflammatory disease, uterine fibroids, and cervical
stenosis.
Side effects: headache, vomiting, diarrhea, nausea, bradycardia,
fever, back pain, bronchospasm, cardiac arrhythmia, chills,
cough, dizziness, dyspnea, flushing, hot flushes, hypotension,
pain, shivering, syncope, tightness of the chest, vasomotor and
vasovagal reactions, wheezing.
Dose and Administration: Abortifacient: Insert 1 suppository
high in vagina, repeat at 3- 5 hour intervals until abortion
occurs up to 240 mg (maximum dose); continued
administration for longer than 2 days is not advisable.Cervical
ripening:Suppositories: Intracervical: 2 - 3 mg. Vaginal Tablet:
induction of labour, inserted high in to posterior formix, 3 mg,
followed after 6-8 hours by 3 mg if labour is not established;
maximum 6 mg.
Storage: store suppositories at a temperature not exceeding 20 oC.
Ergometrine maleate
Injection, 0.25 mg/ml, 0.5mg/ml
Tablet, 0.25mg, 0.5mg
Indications: prevention and treatment of postpartum and
postabortion hemorrhage in emergency situations. Oxytocin and
ergometrine combined are more effective in early pregnancy
than either drug alone.
Cautions: cardiovascular diseases, hypertension, renal and
hepatic function impairment, multiple pregnancy, sepsis, or
hypersensitivity.
622

10. Obstetric And Gynaecological Medications

Drug interactions: adrenaline. Tobacco smoking should also

be avoided.
Contraindications: induction of labour, first and second stages
of labour, coronary artery disease, eclampsia or preeclampsia or
pregnancy.
Side effects: dizziness, mild and transient headache, ringing in
the ears and hypertension may occur rarely. Abdominal pain,
nausea, vomiting and uterine cramping may also occur,
especially after intravenous injection.
Dose and Administration:Adult: Prevention and treatment of
postpartum haemorrhage, when oxytocin is not available:IM
injection: 200 mcg when the anterior shoulder is delivered or
immediately after birth
Excessive uterine bleeding: Slow IV injection: 250-500 mcg
when the anterior shoulder is delivered or immediately after
birth.Secondary postpartum haemorrhage:Oral: 0.2-0.4 mg 2-4
times daily, usually for 48 hours.
Storage: Injection: 2-80C, or as specified by manufacturer.
Protect from light and freezing. Tablets: Store at room
temperature, in tight container and protect it from light.
Note: Discoloured solution or solutions containing visible particles
should not be used.

Estradiol Valerate
Injection, 10mg/ml in 1ml ampoule
Indications: Treatment of moderate to severe vasomotor
symptoms associated with menopause, treatment of vulvar and
vaginal atrophy, abnormal uterine bleeding due to hormonal
imbalance.
Cautions: cardiovascular disease, hypertension, familial
defects of lipoprotein metabolism, breast feeding mother.
623

10. Obstetric And Gynaecological Medications

Contraindications: Hypersensitivity to estradiol or any

component of the formulation, undiagnosed abnormal vaginal
bleeding, history of or current thrombophlebitis or venous
thromboembolic disease (eg, stroke), carcinoma of the breast,
estrogen-dependent tumor, hepatic dysfunction and pregnancy.
Side effects: as for the estrogens in general.
Dose and Administration: Moderate to severe vasomotor
symptoms associated with menopause and female
hypoestrogenism (due to hypogonadism): 10-20mg every 4
weeks
Storage: store at room temperature.
Isoconazole
Vaginal tablet, 300mg, 600mg
Cream, 1%, 2%
Indications: treatment of vaginal mycoses, particularly due to
Candida spp.
Cautions: pregnancy.
Side effects: local reactions including burning or itching may
occur following the application of isoconazole.
Dose and Administration: Pessaries: 600mg or 300mg daily
for 3 days.
Storage: protect from light.
Magnesium Sulfate
Injection, 2%, 5%, 10 %, 20 %, 50 % in 20 ml
Indications: prevention of recurrent seizures in eclampsia.
Cautions: hepatic impairment, renal failure.
Drug interactions:alcuronium, nifedipine, suxamethonium,
vecuronium.
Contraindications: hypersensitivity to magnesium sulfate.
624

10. Obstetric And Gynaecological Medications

Side effects: generally associated with hypermagnesaemia,

nausea, vomiting, thirst, flushing of skin, hypotension,
arrhythmias, coma, respiratory depression, drowsiness,
confusion, loss of tendon reflexes, muscle weakness.
Dose and Administration: Adult: IV injection: initially 4 g
over 5 - 10 minutes followed by IV infusion at a rate of 1 g
every hour for at least 24 hours after the last seizure; recurrence
of seizures may require additional IV bolus of 2g.
Storage: store at room temperature.
Methylergometrine Maleate
Injection, 0.2mg/ml
Tablet, 0.12mg
Indications: prevention and treatment of postpartum or
postabortal uterine bleeding due to uterine atony or
subinvolution. Its use is not recommended prior to delivery of
the placenta since placental entrapment may occur. It is also
used to lessen expulsion of uterine contents in cases of
incomplete abortion.It is not indicated for induction or
augmentation of labor, to induce abortion, or in cases of
threatened spontaneous abortion because of its propensity to
produce non-physiologic, tetanic contractions and its long
duration of action.
Cautions: hepatic and renal function impairment,
hypocalcaemia, mitral valve stenosis, venoatrial shunts and in
those patients tha are allergic to methylergometrine or ergot
alkaloids.
Drug interactions: general anaesthetic especially halothane,
bromocriptine, other ergot alkaloids, nicotine, tobacco smoking,
nitroglycerine, vasoconstrictors and vasopressors.
Contraindications: pregnancy, labour and delivery, unstable
anginal pectoris, recent myocardial infarction, history of
625

10. Obstetric And Gynaecological Medications

cerebrovascular accident, history of transient ischemic attack,

cardiovascular disease, coronary artery disease, eclampsia or
preeclampsia, (history of) severe hypertension, occlusive
peripheral vascular disease, severe raynauds phenomenon.
Side effects: nausea, vomiting, abdominal pain, diarrhoea,
uterine cramping dizziness, sweating, tinnitus (ringing in the
ears)
Dose and Administration:Adult:uterine stimulant: Oral: 0.2
to 0.4mg two or four times a day until the danger of uterine
atony and hemorrhage has passed.
IV or IM: 0.2mg repeated in two or four hours if necessary, up
to five doses.
Storage: at room temperature in a tight container (tablets),
protect from light and from freezing.
Metronidazole
Intravenous infusion, 5mg/ml in 100ml
Syrup, 4% w/v, 250mg/5ml
Tablet, 250mg
Tablet (vaginal), 500mg
Indications: used for the treatment of bacterial vaginosis
(formerly called, Haemophilus vaginitis, Gardnerella vaginitis,
non-specific vaginitis, Carynebacterium vaginitis, or anaerobic
vaginosis) which is a non-inflammatory vaginal syndrome
characterized by replacement of the normal vaginal flora
(predominantly hydrogen producing lactobacillus) with a mixed
flora including Gardnerella vaginalis.It is also used in the
treatment of female pelvic infections, including endometritis,
endomyometritis, tube-ovarian abscess, and liver abscess
caused by bacteriodes species, including the B. fragilis group,
clostridiumspecies,
petpococcus
species,
and
626

10. Obstetric And Gynaecological Medications

peptostreptococcus species. See also section 7.1.2 & 7.4.2 for

other uses.
Cautions: abnormal neurologic symptoms, history of blood
dyscrasias. Reduce dosage in patients with hepatic impairment.
Use the drug during pregnancy with caution when it is clearly
needed. Breast feeding should be interrupted in nursing
mothers.
Drug interactions: alcohol, anticoagulants (cumarin - or
indandione - derivatives), cimetidine, disulfiram, phenobarbital,
phenytoin.
Contraindications: history of hypersensitivity to the drug or
other nitroimidazole derivatives.
Side effects: nausea, vomiting, diarrhoea, loss of appetite, dry
mouth, sharp unpleasant metallic taste, constipation, abdominal
discomfort, numbness, tingling, pain, or weakness in hands or
feet, seizures, leucopenia, thrombocytopenia, vaginal
candidiasis (any vaginal irritation, discharge, or dryness not
present before therapy).
Dose and Administration: Adult:Vaginosis (bacteria):Oral: 2
g as a single dose or 500 mg twice daily for 7 days.
Intravaginal: 500mg placed high into the vagina every night for
ten or twenty consecutive days. IV-infusion, 15mg (base) per kg
of body weight initially, then 7.5mg per kg of body weight up
to a maximum of 1gm, every six hours for seven days or longer.
Pelvic inflammatory disease: Oral: 500mg of metronidazole
twice daily with ofloxacin given orally in a dosage of 400mg
twice daily. Therapy should be continued for 14
days.Note:Metronidazole may cause dizziness. Patients should be
advised to avoid alcoholic beverages and to comply with full time of
treatment.

Storage: at room temperature in a well-closed, light-resistant

container.
627

10. Obstetric And Gynaecological Medications

Metronidazole + Miconazole
Vaginal pessary, 750mg +200mg
Indications:vaginal candidiasis due to Candida albicans,
bacterial vaginitis due to anaerobic bacteria and Gardnerella
vaginalis, trichomonal vaginitis due to Trichomonas vaginalis
and in mixed vaginal infections.
Cautions:alcohol, vaginal contraceptives (diaphragms or
condoms), renal failure, liver failures, hepatic encephalopathy,
pregnancy and lactation.
Contraindications: hypersensitive to the drug, first trimester of
pregnancy, porphyria, epilepsy and serious liver function
disorders; Children.
Side effects:Hypersensitivity reactions (skin rash). Miconazole
nitrate can cause vaginal irritation (burning, itching) as all other
imidazole derivative antifungal drugs applied intravaginally (26%). If there is severe irritation, treatment should be
discontinued. Side effects due to systemic use of metronidazole
are hypersensitivity reactions (rare), leukopenia, ataxia, mental
changes, peripheral neuropathy at overdose and after long
period of usage, convulsion, diarrhea (seldom), constipation,
dizziness, headache, lack of appetite, vomiting, nausea,
abdominal pain or cramp, taste changes (seldom), dry mouth,
metallic or bad taste, tiredness. These side effects occur very
rarely, because of low blood levels of metronidazole after
intravaginal
application.
Drug Interactions:Alcohol, oral anticoagulants, phenytoin,
phenobarbital, disulfiram, cimetidine, lithium, astemizole,
terfenadine, theophylline and procainamide.
Dose and Administration: one pessary should be inserted high
into the vagina at night for 7 days.In recurrent cases, or when
the vaginitis has been resistant to other treatments, application
628

10. Obstetric And Gynaecological Medications

of one pessary at night for 14 days is recommended.

Storage: store at room temperature
Miconazole Nitrate
Tablet (vaginal), 200mg, 400mg
Cream (vaginal), 2%
Indications: treatment of Vulvovaginal candidiasis caused by
Candida albicans and other species of candida in pregnant
(second and third trimesters only) and non-pregnant women.
Cautions, Contraindications, Side effects: Same as
clotrimazole
Dose and Administration:Adult:Vaginal cream: Intravaginal,
one applicatorful once a day at bed time for seven or fourteen
days. It may be repeated if needed.Vaginal tablets:
Intravaginal, 100mg once a day at bed time for seven days. It
may be repeated for seven days if needed or 200mg or 400mg
once a day at bedtime for three days. It may be repeated if
needed.
Storage: at room temperature in a tight container
Mifepristone
Tablet, 200 mg
Indications: medical termination of intrauterine pregnancy,
through day 49 of pregnancy. Patients may need treatment with
misoprostol and possibly surgery to complete therapy.
Cautions: severe anemia.
Drug interactions: substrate of CYP3A4, progestin.
Contraindications:
hypersensitivity
to
mifepristone,
misoprostol, other prostaglandins, chronic adrenal failure,
porphyrias, hemorrhagic disorder or concurrent anticoagulant
therapy, pregnancy termination greater than 49 days, IUD in
place, ectopic pregnancy or undiagnosed adnexal mass,
629

10. Obstetric And Gynaecological Medications

concurrent long term corticosteroid therapy, inadequate or lack

of access to emergency medical services, inability to understand
effects and/or comply with treatment.
Side effects: vaginal bleeding and uterine cramping, bleeding
or spotting occurs in most women for a period of 9-16 days,
headache, dizziness, abdominal pain, nausea, vomiting, and
diarrhea.
Dose and Administration:Oral:Adult:Termination of
pregnancy: treatment consists of three visits by the patient; the
patient must read medication guide and sign patient agreement
prior to treatment:
Day 1: 600 mg (three 200 mg tablets) taken as a single dose
under physician supervision.
Day 3: patient must return to the healthcare provider 2 days
following administration of mifepristone; if termination of
pregnancy cannot be confirmed using ultrasound or clinical
examination, 400 mcg (two 200 mcg tablets) of misoprostol can
be given. Patient may need treatment for cramps or
gastrointestinal symptoms at this time.Day 14: patient must
return to the healthcare provider in approximately 14 days after
administration of mifepristone to confirm complete termination
of pregnancy by ultrasound or clinical examination. Surgical
termination is recommended to manage treatment failures.
Storage: store at room temperature.
Misoprostol
Tablet, 100mcg, 200mcg, 400mcg, 800mcg
Tablet (vaginal), 25mcg
Indication: It is used to induce abortion; intravaginal use ripens
the cervix before surgical abortion
Cautions, Drug interactions, Contraindications, Side effects
and Storage see section 1.2 under misoprostol.
630

10. Obstetric And Gynaecological Medications

Dose and administration

For gestation up to 9 weeks, mifepristone 200 mg by mouth
followed 13 days later by misoprostol 800 micrograms
vaginally; in women at more than 7 weeks gestation (4963
days), if the abortion has not occurred 4 hours after misoprostol,
a further dose of misoprostol 400 micrograms may be given
vaginally or by mouth.For gestation between 9 and 13 weeks,
mifepristone 200 mg by mouth followed 3648 hours later by
misoprostol 800 micrograms vaginally followed if necessary by
a maximum of 4 further doses at 3-hourly intervals of
misoprostol 400 micrograms vaginally or by mouth. For
gestation between 13 and 24 weeks, mifepristone 200 mg by
mouth followed 3648 hours later by misoprostol
800 micrograms vaginally then a maximum of 4 further doses at
3-hourly intervals of misoprostol 400 micrograms by mouth.
Neomycin + Polymixin B + Nystatin
Tablet (vaginal), 35000IU +35000IU +100000IU
Indications: Topical treatment of vaginal infections
Cautions: pregnancy, renal failure
Drug interactions: spermicidal products and condoms
Contraindications: breast-feeding, allergy to one of its
ingredients or another substance of the same family, use of
latex diaphragms or condoms
Side effects: Possibility of contact allergic eczema or away
from the site of application in case of prolonged use.
Dose and Administration:vaginal:Adult: Place one tablet
deep in the vagina for 12 days. Do not stop treatment during
menstrual periods.
Storage: Store below 25C.
Nystatin
631

10. Obstetric And Gynaecological Medications

Cream (vaginal), 100,000 units

Pessary (ovules), 100,000 units
Indications: local treatment of vulvovaginal candidiasis caused
by Candida (monilia) albicans and other candida species.
Note: It is not effective against Trichomonas Vaginalis or
Gardnerella vaginalis (Haemophilus Vaginalis).

Cautions: discontinue treatment with nystatin therapy if

irritation or sensitization occurs. They are also advised against
interrupting or discontinuing vaginal nystatin therapy during a
prescribed regimen even during menstruation or if symptomatic
relief occurs after only a few days of therapy unless otherwise
instructed by their physician.
Contraindications: sensitivity to nystatin
Side effects: vaginal irritation not present before therapy
Dose and Administration:Adult:Nystatin vaginal cream:
Intravaginal, insert 1-2 applicatorfuls at night for at least 14
nights.Nystatin vaginal pessary: Intravaginally, insert 1-2
pessaries at night for at least 14 nights.
Storage: at room temperature in a tight, light-resistant
container.
Oxytocin
Injection, 1unit/ml, 5units/ml, 10units/ml
Indications: for nonselective induction of labour for medical
reasons and for stimulation or reinforcement of labour in
patients with dysfunctional inertia. Parenteral oxytocin is also
indicated for management of incomplete or therapeutic
abortion, as well as to produce uterine contractions during the
third stage of labour. Oxytocin is also indicated to control
postpartum bleeding or hemorrhage.
Cautions: particular caution needed when given for induction
or enhancement of labour in presence of borderline
632

10. Obstetric And Gynaecological Medications

cephalopelvic disproportion (avoid if significant), mild or

moderate pregnancy-induced hypertension or cardiac disease,
women over 35 years or with history of lower-uterine segment
caesarean section, fetal death in utero or meconium-stained
amniotic fluid, avoid tumultuous labour (may cause amniotic
fluid embolism). Avoid large infusion volumes and restrict
fluide intake by mouth (risk of water intoxication and
hyponatraemia),
effects
enhanced
by
concomitant
administration of prostaglandins (very careful monitoring of
utrine activity), caudal block anaesthesia (may enhance
hypertensive effects of sympathomimetic vasopressors). See
also interaction.
Drug interactions: hydrocarbon, inhalation anesthetics such as
enflurane, halothane, isoflurane, and with vasopressors, other
oxytocics.
Contraindications: significant cephalopelvic disproportion,
cord presentation, total placenta previa, vasa previa, where
vaginal delivery is contraindicated, fetal distress, hypertonic
uterine patterns, obstetrical emergencies requiring surgical
intervention, uterine inertia or severe toxemia on prolonged use.
Side effects: fast or irregular heartbeat, nausea or vomiting
Dose and Administration:Adult:Induction or stimulation of
labour:IV infusion: initially at an initial rate 0.5 to 4 milliunits
(0.0005 to 0.004 unit) per minute, and then increased gradually
at intervals every 20-60 minutes in increments of 1 to 2
milliunits (0.001-0.002 unit) per minute until a contraction
pattern similar to that of normal labour is obtained. The rate of
up to 6 milliunits per minute is reported to produce plasma
oxytocin concentrations comparable to those in natural labour
but doses of up to 20 milliunits (0.02 units) or more per minute
may be required. The rate may be reduced gradually once
labour is induced.Incomplete or therapeutic abortion: IV
633

10. Obstetric And Gynaecological Medications

infusion: 10 units at a rate of 20 to 40 milliunits (0.02 to 0.04

units) per minute.Control of postpartum uterine bleeding:IV
infusion: 10 units at a rate of 20 to 40 milliunits per minute
following delivery of the infant(s) and preferably placenta(s).
A rate of 20-100 milliunits per minute may be used following
abortion.
Storage: store oxytocin at 2 to 8oC, protect from freezing.
10units/ml (1ml) may also be stored at 15 to 25oC for up to 30
days.
Oxytocin + Ergometrine Maleate
Injection, 5 units + 500mcg in each ml
See notes under ergometrine maleate
Dose: IM injection: 1ml; IV injection, no longer recommended
Ritodrine Hydrochloride
Injection, 10mg/ml in 5ml ampoule
Indications:prevention of premature labour and abortion.
Cautions:mild-to-moderate preeclampsia, hypertension, or
diabetes.
Drug interactions: atropine, beta-adrenergic blockers,
corticosteroids, magnesium sulfate, diazoxide, meperidine,
general anesthetics, sympathomimetics.
Contraindications: before 20th week of pregnancy and when
continuation of pregnancy is hazardous to mother or fetus,
hypersensitivity, pre-existing maternal conditions that would be
seriously affected by pharmacologic properties of beta-mimetic
agent.
Side effects: palpitations, chest pain or tightness;, heart
murmur, angina pectoris, myocardial ischemia, alterations in
BP, pulmonary edema, sinus bradycardia upon drug
withdrawal, arrhythmias, drowsiness, weakness, mild
634

10. Obstetric And Gynaecological Medications

tachycardia, tremor, headache (including migraines),

nervousness, restlessness, emotional upset, anxiety, malaise,
hyperventilation, erythema, rash, nausea, constipation, diarrhea,
vomiting, epigastric distress, ileus, bloating, leucopenia,
agranulocytosis, hemolytic icterus, impaired liver function,
lactic acidosis, glycosuria, dyspnea, sweating, chills,
hypokalemia, hyperglycemia.
Dose and Administration: IM: 10 mg every 3 to 8 hours and
continued for 12 to 48 hours after the contractions have
stopped.
Storage: store at room temperature and protect from excessive
heat.
Salbutamol
Injection, 0.5mg/ml in 1ml ampoule
Indications: arrest uncomplicated premature labour between
24-33 weeks gestation; see also section 2.2.
Cautions:
suspected
cardiac
disease,
hypertension,
hyperthyroidism, hypokalaemia, diabetes mellitus, mild to
moderate pre-eclampsia. The patient's state of hydration and
heart rate should be monitored carefully.
Drug interactions: corticosteroids, diuretics, theophylline.
Side effects: nausea, vomiting, flushing, sweating, tremor,
hypokalemia, tachycardia, muscle cramps, palpitation and
hypotension, increased tendency to uterine bleeding, pulmonary
oedema, chest pain or tightness, arrhythmias, headache.
Contraindications: cardiac disease, eclampsia and severe preeclampsia, intra-uterine infection, antepartum haemorrhage
(requires immediate delivery), placenta praevia, cord
compression, not used in first or second trimesters.
Dose
and
Administration:
Premature
labour:
Adult:intravenous infusion: 10 micrograms/minute gradually
635

10. Obstetric And Gynaecological Medications

increased to maximum of 45 micrograms/minute until

contractions have ceased, then gradually reduced; or by
intravenous or intramuscular injection, 100 250 micrograms
repeated according to patients response; subsequentlyby mouth
4 mg every 6 8 hours:
Storage: Store at room temperature. Protect from light.

636

11. Antineoplastic And Adjuvants

11. ANTINEOPLASTICS and ADJUVANTS

The treatment of cancer with medicines, radiotherapy and
surgery is complex and should only be undertaken by an
oncologist. For this reason the following information is
provided merely as a guide. Chemotherapy may be given as a
curativeor palliative intent of treatment. Where the condition
can no longer be managed with cytotoxic therapy, alternative
palliative treatment should be considered.For some tumours,
single drug chemotherapy may be adequate, but for many
malignancies a combination of medicinesprovides the best
response. Examples of combination therapy include:
'CHOP' is the acronym for a chemotherapy regimen used in
the treatment of non-Hodgkin lymphoma. CHOP consists of
(Cyclophosphamide,Hydroxydaunorubicin (also called
doxorubicin or Adriamycin),Oncovin (Vincristine),
Prednisone or Prednisolone).
'ABVD'is a chemotherapy regimen used in the first-line
treatment of Hodgkin lymphoma, supplanting the older
MOPP protocol. It consists of concurrent treatment with the
chemotherapy
drugs:
Adriamycin
(doxorubicin/hydroxydaunorubicin),
Bleomycin,
Vinblastine, Dacarbazine (similar to procarbazine).
'MOPP'(Mustargen (Chlormethine), Oncovin (Vincristine),
Procarbazine, Prednisolone) for Hodgkins disease.
Cytotoxic medicines are often combined with other classes of
medicines in the treatment of malignant conditions. Such
medicines include hormone agonists and antagonists,
corticosteroids and immunostimulant medicines. Combinations
are, however, more toxic than single medicines.The following
information covers medicines that have specific anti-tumor
activity. However, they are toxic medicines which should be
used with great care and monitoring.
637

11. Antineoplastic And Adjuvants

Precautions and Contraindications: treatment with cytotoxic

medicines should be initiated only after baseline tests of liver
and kidney function have been performed and baseline blood
counts established. It may be necessary to modify (adjust
doses) or delay treatment cycle by one week in certain
circumstances. The patient should also be monitored regulary
during chemotherapy and cytotoxic medicines should be
withheld if there is significant deterioration in bone marrow,
liver or kidney function.
Cytotoxic medicines should be administered with care to avoid
undue toxicity to the patient or exposure during handling by the
health care provider.
Many cytotoxic medicines are teratogenic and should not be
administered during pregnancy especially in the first trimester.
Contraceptive measures are required during therapy and
possibly for a period after therapy has ended.
General adverse effects: Antineoplastic agents exert their
effect on rapidly dividing cells (malignant cells, bone marrow,
mucous membranes, hair follicles) and therefore have common
toxicities, despite different modes of action. Toxicities depend
on dose, schedule and route of administration as well as
predisposing factors in the patient. Potential benefit of
particular regimen needs to be weighed against toxicity for each
individual patient.
The acute effects of antineoplastic medication frequently
include nausea and vomiting, which may be severe.
Bone Marrow suppression: Malignant tumours may develop as
a long term complication of cytotoxic therapy. These include
acute myeloid leukaemia, solid tumours, Hodgkin's disease,
ovarian cancer and gastric cancer.
Reproductive toxicity: Most cytotoxic medicines are
teratogenic. In most men receiving chemotherapy the sperm
638

11. Antineoplastic And Adjuvants

count will return to normal within 2 years of of subsequent

recovery of spermatogenesis.
Hyperuricaemia may complicate treatment of conditions such
as non-Hodgkin lymphomas and leukaemia. Renal damage may
result from the formation of uric acid crystals. Patients should
be adequqtely hydrated and hyperuricaemia may be managed
with allopurinol initiated 24 hours before cytotoxic treatment
and continued for 7 to 10 days afterwards.
Alopecia is common.
11.1.Alkylating Agents
Alkylating medicines are among the most widely used
medicines in cancer chemotherapy. They act by damaging
DNA and therefore interfering with cell replication. However,
there are two complications.
1. They affect gametogenesis and may cause permanent male
sterility; in women, the reproductive span may be shortened by
the onset of a premature menopause.
2. A marked increase in the incidence of acute nonlymphocytic leukaemia, in particular when combined with
extensive radiation therapy.
Alkylating
agents
include;
busulfan,
chlorambucil,
cyclophosphamide, mechlorethamine hydrochloride, melphalan
and thiotepa.
Busulfan
Tablets, 0.5 mg, 2 mg
Indications: chronic myeloid leukaemia, conditioning regimens
for bone marrow transplantation.
Cautions: seizures, patients recently given other
myelosuppressive drugs or radiation treatment.
639

11. Antineoplastic And Adjuvants

Drug interactions: azole antifungals, ciprofloxacin,

clarithromycin, diclofenac, doxycycline, erythromycin,
isoniazide, nicardipine, propofol, protease inhibitors, quinidine,
verapamil, aminoglutethimide, carbamazepine, naficillin,
nevirapine, phenobarbitol, phenytoin, rifamycins.
Contraindications: pregnancy, hypersensitivity to busulfan.
Side effects: sterility, ovarian suppression, amenorrhea,
testicular
atrophy,
malignant
tumors,
leukopenia,
thrombocytopenia, anemia, nausea, vomiting, diarrhea,
alopecia, amenorrhea, hyperpigmentation, bone marrow
suppression.
Dose and Administration: (refer to individual protocols)
Oral:For remission induction of CML:
Adult: 4 - 8 mg/day (may be as high as 12 mg/day).
Child: 0.06 - 0.12 mg/kg/day or 1.8 - 4.6 mg/m2/day;
Bone Marroe Transplant ablative conditioning regimen:
Adult and Child: 1mg/kg/dose every 6 hours for 16 doses.
Storage: store in a well-closed container at room temperature.
Chlorambucil
Tablet, 2 mg, 5 mg
Indications: chronic lymphocytic leukaemia; Hodgkin and low
grade non-Hodgkins lymphomas; breast, ovarian and testicular
carcinoma, thrombocythemia.
Cautions: seizure and bonemarrow suppression.
Drug interactions: live vaccines, ethanol.
Contraindications: pregnancy.
Side effects: myelosuppression (leukopenia, thrombocytopenia,
anemia) skin rash, hyperuricemia, menstrual changes, nausea,
vomiting, diarrhea, oral ulceration, agitation, ataxia, confusion,
fever.
Dose and Administration: (refer to individual protocols):
Oral:Adult: 0.1- 0.2 mg/kg/day or 3 - 6 mg/m2/day for 3-6
640

11. Antineoplastic And Adjuvants

weeks, then adjust dose on basis of blood counts or 0.4 mg/kg

and increased by 0.1mg/kg biweekly or monthly or 14
mg/m2/day for 5 days, repeated every 21-28 days.Child:
general short courses: 0.1- 0.2 mg/kg/day or 4.5 mg/m2/day for
3 - 6 weeks for remission induction (usual: 4-10mg/day);
maintenance therapy: 0.03 - 0.1mg/kg/day.Chronic lymphocytic
leukaemia (CLL):Biweekly regimen: Initial: 0.4 mg/kg/dose
every 2 weeks; increase doses by 0.1mg/kg every 2 weeks until
a response occurs and/or myelosuppresion occurs.Monthly
regimen: Initial: 0.4 mg/kg, increase dose by 0.2 mg/kg every 4
weeks until a response occurs and /or myelosuppression occurs.
Malignant
lymphomas:
Non-Hodgkins
lymphoma:
0.1mg/kg/day.Hodgkins lymphoma: 0.2mg/kg/day.
Storage: store in refrigerator at 2-8oC; protect from light.
Cyclophosphamide
Powder for injection, 200 mg, 500 mg, 1000mg in vial
Tablet, 50 mg
Indications: malignant lymphomas including non-Hodgkins
lymphoma, lymphocytic lymphoma; multiple myeloma;
leukaemias,
mycosis,
fungoides;
neuroblastoma;
adenocarcinoma of the ovary, retinoblastoma; breast cancer;
severe rheumatoid arthritis.
Cautions: hepatic, renal, or bone marrow damage.
Drug interactions: allopurinol, succinyl choline, halothane,
chloramphenicol, carbamazepine, nevirapine, phenytoin,
suxamethonium, phenobarbitol, thiazide, digoxine, azole
antifungals,
ciprofloxacin,
clarithromycin,
diclofenac,
doxycycline, erythromycin, isoniazide, protease inhibitors,
quinidine, verapamil, aminoglutethimide, phenobarbitol.
Contraindications: pregnancy and breast feeding
641

11. Antineoplastic And Adjuvants

Side
effects:
sterility,
amenorrhea,
leukopenia,
thrombocytopenia, anemia, nausea, vomiting, aneroxia,
mucositis, acute hemorrhagic cystitis, renal tubular necrosis,
headache, skin rash, nasal congestion, diarrhea, alopecia,
amenorrhea.
Dose and Administration:Adult and Child:Oral: 50-100
mg/m2/day as continuous therapy or 400-1000 mg/m2 in
divided doses over 4-5 days as intermittent therapy.IV: single
dose: 400-1800 mg/m2 (30-50 mg/kg) per treatment course (1-5
days) which can be repeated at 2-4 week intervals.Continuous
daily doses: 60-120 mg/m2 (1-2.5mg/kg) per day.
Storage: store at a temperature not exceeding 25oc.
Mechlorethamine Hydrochloride(Nitrogen Mustard)
Powder for injection, 10 mg in vial
Indications: Hodgkin's disease, non-Hodgkin's lymphoma,
malignant effusions.
Cautions:Local reactions to extravasation of into the
subcutaneous tissue result in a severe, brawny, tender
induration that may persist for a long time.
Drug interactions: vaccines, ethanol.
Contraindications:pre-existing profound myelosuppression or
infection, pregnancy, breast feeding.
Side effects: delayed menses, oligomenorrhea, amenorrhea,
impaired spermatogenesis, nausea, vomiting, myelosuppressive,
fever, vertigo, alopecia, hyperuricemia, diarrhea, anorexia,
metallic taste, ototoxicity, precipitation of herpes zoster.
Dose
and
Administration:
(refer
to
individual
protocols):Adult: IV: 0.4 mg/kg or 12-16 mg/m2 for one dose
or divided into 0.1 mg/kg/day for 4 days, repeated at 4-6 week
intervals.Adult and Child: I.V: 6 mg/m2 on days 1 and 8 of a
28 day cycle (MOPP regimen)
Storage: store intact vials at room temperature.
642

11. Antineoplastic And Adjuvants

Melphalan
Tablet, 2 mg, 5 mg
Indications: multiple myeloma, ovarian carcinomas and
malignant melanoma.
Cautions: impaired renal function, elderly.
Drug interactions: cimetidine, cyclosporine, ethanol.
Contraindications: pregnancy, severe bone marrow
suppression.
Side effects: leukopenia, thrombocytopenia, anemia, rash,
nausea, vomiting, diarrhea, vasculites, alopecia, pruritus,
sterility, amenorrhea, bladder irritation, hemorrhagic cystitis,
agranulocytosis, hemolytic anemia, hepatitis, jaundice,
pulmonary fibrosis.
Dose
and
Administration:
(refer
to
individual
protocols)Adult: Multiple myeloma:Oral 6 mg/day initially
adjusted as indicated or 0.15 mg/kg/day for 7 days or 0.25
mg/kg/day for 4 days; repeat at 4-6 week intervals.Ovarian
carcinoma:Oral:0.2 mg/kg/day for 5 days, repeat every 4-5
weeks.
Storage: store in refrigerator at 2-8oC; protect from light.
Temozolomide
Capsule:5mg, 20mg, 100mg, 140mg, 180mg, 250mg
Indications:first line for glioblastoma multiforme in adults in
combination with radiotherapy and subsequently as
monotherapy; adult patients with refractory (first relapse)
anaplastic astrocytoma who have experienced disease
progression on nitrosourea and procarbazine. ;. It is also
licensed for second-line treatment of malignant glioma in adults
and children over 3 years.
Cautions: Hepatic and renal impairment
Drug-interaction: Valproate, clozapine, food
643

11. Antineoplastic And Adjuvants

Contraindications: Hypersensitivity to temozolomide and

Dacarbazine or any component of the formulation; pregnancy
and breast-feeding.
Side effect: Oral mucositis, tumour lysis syndrome,
Hypericaemia, nausea and vomiting, alopecia, bone marrow
suppression, fatigue, headache, convulsions, anorexia,
constipation, rash, abdominal pain, stomatitis.
Dose
and
administration:
(refer
to
individual
protocols):Anaplastic astrocytoma (refractory): Intial dose:
150mg/m2/day for 5 days; repeat every 28 days. Subsequent
doses of 100-200mg/m2/day; based upon hematologic tolerance.
This monthly-cycle regimen may be preceded by a 6 to 7 week
regimen of 75mg/m2/day.
glioblastoma multiforme (high-grade glioma):
Concomitant phase: 75mg/m2/day for 42 days with
radiotherapy. ANC 1500/mm3, platelet count 100,000/mm3,
and common toxicity criteria (CTC) nonhematological toxicity
grade 1 (excludes alopecia, nausea/vomiting):75mg/m2/day may
be continued throughout the 42-day concomitant period up to 49
days.
Maintenance phase (consist of 6 treatment cycles): Begin 4
weeks after concomitant phase completion. Note: Each
subsequent cycle is 28 days (consisting of 5 days of drug
treatment followed by 23 days without treatment).
Cycle1:150mg/m2/day for 5 days
Elderly: Patients 70 years of age had a higher incidence of
grade 4 neutropenia and thrombocytopenia in the first cycle of
therapy than patients < 70 years of age.
Storage: Store capsules at room temperature (15-25oC)
Thiotepa
Powder for injection, 15 mg/vial
644

11. Antineoplastic And Adjuvants

Indications: superficial tumors of the bladder; palliative

treatment of breast and ovarian carcinomas and malignant
lymphomas.
Cautions: hepatic, renal, or bone marrow damage.
Drug interactions: other alkylating agents, succinylcholine and
other neuromuscular agents.
Contraindications: pregnancy, breast feeding, severe
myelosuppression.
Side effects: myelosuppression (anaemia, pancytopenia)
dizziness, fever, rash, pruritus, headache, hyperpigmentation,
hyperuricemia, anorexia, nausea, vomiting, hemorrhagic
cystitis, pain at injection site, hematuria.
Dose
and
Administration:
(refer
to
individual
protocols):Adult:Bladder tumors: Intra vesically 30-60 mg
instilled (in 60 ml of sterile water) once weekly for four weeks
or 12mg/m2 IV bolus every three weeks:I.M, I.V, SC: 3060mg/m2 once weekly. Breast and ovarian carcinoma I.V:
0.3-0.4 mg/kg by rapid IV administration every 1-4 weeks or
0.2 mg/kg or 6-8 mg/m2/day for 4-5 days every 2-4 weeks.
Child:Sarcomas: I.V: 25-65 mg/m2 as a single dose every 21
days.
Storage: store intact vials under refrigeration (2-8oC) and
protect from light.
11.2. Cytotoxic antibiotics
Medicines used in this group are widely used. Many cytotoxic
antibiotics act as radiomimetics and simultaneous use of
radiotherapy should be avoided as it may result in markedly
enhanced toxicity.
Daunorubicin Hydrochloride, Doxorubicin hydrochloride
(Adriamycin), Epirubicin are anthracycline antibiotics. Other
cytotoxic antibiotics include actinomycin-D and bleomycin.
645

11. Antineoplastic And Adjuvants

The anthracyclines can cause acute cardiotoxicity (arrhythmias)

and long-term dose-related cardiomyopathy, which is often
reversible. Assessment of adequate left ventricular function and
careful monitoring for cardiac symptoms and signs is required
during the following treatment. The anthracyclines are
contraindicated in patients with pre-existing cardiac disease or
severe hepatic or renal impairment. The elderly are at special
risk of developing cardiac complications with this group of
drugs.
Actinomycin-D (Dactinomycin)
Foramulations: Powder for injection, 0.5 mg in vial
Indications: trophoblastic tumours, wilm tumour, Ewing
sarcoma, rhabdomycosarcoma.
Cautions: hepatobiliary dysfunction.
Drug interactions: Live vaccines, radiation therapy.
Contraindications: infants <6 months of age, herpeszoster.
Side effects: fatigue, malaise, fever, lethargy, alopecia, skin
eruptions, acne, increased pigmentation, hypocalcemia, severe
nausea, vomiting, anorexia, myelosuppression, anemia,
mucositis, stomatitis, diarrhea, abdominal pain, hepatitis.
Dose and Administration: (refer to individual protocols): Adult:
I.V. 2.5 mg/m2 in divided doses over 1 week, repeated every 2
weeks or 0.75-2 mg/m2 every 1-4 weeks or 400-600
mcg/m2/day for 5 days, repeated every 3-6 weeks.Child (> 6
months): IV 15 mcg/kg/day or 400-600 mcg/m2/day for 5 days
every 3-6 weeks.
Storage: protect from light and humidity and store at room
temperature (15-25oC).
Bleomycin
Formulations: Powder for injection (lyo-philised), 15 unit in
vial.
646

11. Antineoplastic And Adjuvants

Indications: adjunct to surgery and radiotherapy in palliative

treatment of Hodgkins and non-Hodgkins lymphomas;
reticulum cell sarcoma and lymphoma; carcinomas of the head,
neck, larynx, cervix, penis, skin, vulva, testicles including
embryonal
cell
carcinoma,
choriocarcinoma
and
teratoma,malignant effusions, germ cell tumors of the ovary,
kaposis sarcoma.
Cautions: pulmonary diseases.
Drug interactions: lomustine, cisplatin, digoxin, phenytoin,
oxygen, live vaccines.
Contraindications: pregnancy and breast feeding.
Side effects: Raynaud's phenomenon, pain at the tumor site,
phlebitis,
peeling
of
the
skin,
hyperkeratosis,
hyperpigmentation, alopecia, stomatitis, mucositis, anorexia,
weigt loss, tachypnea, pulmonary fibrosis, hypoxia, rash,
anaphylactoid reactions.
Dosage and Administration: (refer to individual
protocols):Adult and Child: Single agent therapy: I.M, I.V,
and SC:Squamous cell carcinoma, lymphoma, testicular
carcinoma: 0.25-0.5 units/kg (10-20 units/m2) 1-2
times/week.Combination agent therapy: I.M, I.V: 3-4 Units/m2.
I.V: (ABVD): 10 units/m2 on days 1 and 15
Pleural sclerosing: 60-240 units as a single infusion
*1unit = 1mg
Storage: store at 2 - 8oc Refregration.
Daunorubicin Hydrochloride
Powder for injection, 20 mg in vial
Indications: acute leukaemias
Cautions: impaired hepatic, renal, or biliary function.
Drug interactions: Live vaccines
647

11. Antineoplastic And Adjuvants

Contraindications: congestive heart failure or arrhythmias;

bone marrow suppression, pregnancy.
Side effects: alopecia, mild nausea or vomiting, discolouration
of urine, darkening or redness of skin, hyperuricemia, diarrhea,
GI ulceration, myelosuppressive.
Dosage and Administration: (refer to individual protocols)
Adult and Child: I.V: 30-60 mg/m2/day for 3-5 days, repeat
dose in 3-4 weeks.
Storage: store at room temperature.
Doxorubicin hydrochloride (Adriamycin)
Powder for injection, 10 mg, 50 mg in vial.
Indications: acute leukaemias; carcinomas of the breast,
bladder, ovary and thyroid; neuroblastoma; wilm tumour, NonHodgkins and Hodgkins lymphomas; soft tissue sarcomas,
osteosarcoma.
Cautions: hepatic impairment.
Drug interactions: cyclosporin, phenytoin, stavudine, live
vaccines,allopurinol,
cyclophosphamide,
mercaptopurine,verapamil, promethazine, azole antifungals,
chlorpromazine, erythromycin, ciprofloxacin.
Contraindications: pregnancy and breast feeding; bone
marrow suppression.
Side effects: cardiovascular diseases, alopecia, nausea,
vomiting, mucositis, ulceration, anorexia, diarrhea, esophagitis,
discolouration of urine (red), myelosuppression, leukopenia,
arrythmias, heart block, facial flushing, hyperpigmentation of
nail beds, hyperuricemia.
Dosage and Administration: (refer to individual protocols)
Adult:As a single therapy I.V. I.: 50-75 mg/m2 repeat every 21
days or 20-30 mg/m2/days for 2-3 days, repeat in 4 weeks or
20 mg/m2 once weekly.
648

11. Antineoplastic And Adjuvants

In Combination therapy: I.V. I. 40-60 mg/m2 every 21-28

days.Multiple Myeloma: Combination therapy: I.V.I 9mg/m2
/day on days 1-4 (in VAD regimen)
Child: As a single therapy: I.V.I. 35-75 mg/m2 as a single
dose, repeat every 21 days or 20-30 mg/m2 once weekly or 6090 mg/m2 given as a continuous infusion over 96 hours every
3-4 weeks. In Combination therapy: I.V. I. 40-60 mg/m2 every
21-28 days.
Storage: store at room temperature (15-25oC).
Doxorubicin (Liposomal)
Injection, 10mg, 50mg in vial
Indications: Treatment of AIDS-related Kaposis sarcoma,
breast cancer, ovarian cancer, solid tumors
Cautions: In patient with high cumulative doses of
anthracyclines, anthracenediones, and cyclophosphamide;
patients with previous thoracic radiation or who have preexisting cardiac disease.
Drug
interactions:
Cylosporine,
allopurinol,
cyclophosphamide, mercaptopurine, streptozocin, verapamil,
paclitaxel, progesterone, bupropion, promethazine, propofol,
selegiline, sertraline, and other CYP2B6 substrates, azol
antifungals, chlorpromazine, clarithromycin, diclofenac,
doxycycline, erythromycin, isoniazid, quinine, ritonavir,
aminoglutethimide,
carbamazepine,
nafcillin,
nevirapine,Phenobarbital, phenytoin, rifamycinsand other
CYP3A4 inducers, digoxin, zidovudine, live vaccines.
Contraindications: Hypersensitivity to doxorubicin, other
anthracyclines, or any component of the formulation; breastfeeding, pregnancy.
Side effects: Peripheral edema, fever, headache, pain, alopecia,
palmar-plantar, erythrodysesthesia/hand-foot syndrome, rash,
649

11. Antineoplastic And Adjuvants

stomatitis,
vomiting,
nausea,
constipation,
anorexia,
neutropenia, leucopenia, cytopenia, anemia, weakness,
agitation, confusion, acne, dry skin
Dosage and Administration:AIDS-related Kaposis sarcoma:
IV: 20 mg/m2/dose once every 3 weeks
Breast cancer: IV: 20-80mg/m2/dose every 8 weeks
Ovarian cancer: IV: 50 mg/m2/dose every 4 weeks
Solid tumors: IV: 50-60 mg/m2/dose every 3-4 weeks
Epirubicin
Powder for injection, 50 mg in vial, Injection, 2mg/ml
Indications: adjuvant therapy for primary breast cancer,
Hodkins diseases, Non-Hodkins lymphoma, carcinoma of
esophagus, ovarian carcinoma.
Cautions: hepatic impairment, renal dysfunction, cardiac
disease.
Drug interactions: cimetidine, ethanol.
Contraindications: severe myocardial insufficiency, severe
arrythmias, pregnancy, lactation.
Side effects: lethargy, alopecia, amenorrhea, nausea, vomiting,
mucositis, diarrhea, leucopenia, hot flashes, anemia,
thrombocytopenia, conjunctivitis, infection, fever, rash, skin
changes, anorexia.
Dosage and Administration: Adult: I.V: 100-120 mg/m2 once
weekly every 3-4 weeks or 50-60 mg/m2 days 1 and 8 every 3-4
weeks
Storage: store in refrigerator (2-8oC).

650

11. Antineoplastic And Adjuvants

11.3. Antimetabolites
Antimetabolites are incorporated into new nuclear material or
combine irreversibly with vital cellular enzymes, preventing
normal cellular division.Antimetabolites include: capecitabine,
cytarabine, fluorouracil, mercaptopurine and methotrexate.
Capecitabine
Tablet, 150mg, 500mg
Injection, 26mg/ml
Indications: treatment of metastatic colorectal cancer,
metastatic breast cancer, gall balder cancer, colangio carcinoma
Cautions: bone marrow suppression, poor nutritional status, on
warfarin therapy, 80 years of age, or renal or hepatic
dysfunction.
Drug interactions: warfarin.
Side effects: edema, fatigue, fever, dermatitis, diarrhea, mild to
moderate nausea, vomiting, stomatitis, decreased appetite,
anorexia, abdominal pain, constipation, anemia, lymphopenia,
thrombocytopenia, dyspnea.
Dose
and
Administration:
(refer
to
individual
protocols):Adult: Oral: 2500 mg/m2/day in 2 divided doses (~
12 hours apart) at the end of a meal for 14 days followed by a 1
or 2 week rest period.
Storage: store at room temperature (15-25oC).
Cytosine Arabinoside (Cytarabine)
Formulations: Powder for injection, 20 mg in vial
Indications: acute lymphoblastic leukaemia; chronic myeloid
leukaemia; meningeal leukaemia; erythroleukemia; nonHodgkins lymphoma, CNS lymphoma.
Cautions: hepatic impairment.
Drug interactions: alkylating agents, methotrexate,
gentamicin, flucytosin, digoxin.
651

11. Antineoplastic And Adjuvants

Contraindications: hypersensitivity to cytarabine.

Side
effects:
Myelo
suppression
(leukopenia,
thrombocytopenia,anemia), cerebral toxicity, conjunctivities,
corneal keratitis, pulmonary edema, pericarditis, seizures,
oral/anal ulceration, rash, nausea, vomiting, anorexia,
stomatitis, bleeding, hepatic dysfunction, mild jaundice,
dizziness, headache, confusion, itching, hyperuricemia,
diarrhea, urinary retention, hepatotoxicity, megaloblastic
thrombophlebitis, myalgia, peripheral neuropathy.
Dosage and Administration: (refer to individual
protocols):Adult and Child:Remission induction: IV: 100-200
mg/m2/day for 5-10 days; a second course, beginning 2-4
weeks after the initial therapy.Remission maintenance:IV: 70200 mg/m2/day for 2-5 days at monthly intervals.IM, SC: 1-2.5
mg/kg single dose for maintenance at 1-4 week intervals.I.T.:
(meningeal leukaemia, CNS lymphoma): 5-75 mg/ m2 every
two weeks.
Storage: store at room temperature (15-25oC).
Fluorouracil
Injection, 250 mg/5ml, 500mg/10ml ampoule
Indications: carcinomas of the colorectum, breast, stomach,
pancreas, cervix, prostate, ovary and endometrium; liver
tumours; head and neck tumours actinic keratoses.
Cautions: impaired kidney and liver function.
Drug interactions: cimetidine, warfarin, metronidazole,
phenytoin, live vaccines.
Contraindications: depressed bone marrow function,
thrombocytopenia,
potentially
serious
infections,
dihydropyrimidine dehydrogenase (DPD) enzyme deficiency,
pregnancy.
652

11. Antineoplastic And Adjuvants

Side effects: rash, alopecia, nausea, vomiting, anorexia,

diarrhea, stomatitis, esophagitis, leukopenia, dry skin, GI
ulceration, peripheral neuropathy
Dosage and Administration: (refer to individual protocols):
Adult:IV bolus: 500-600 mg/m2 every 3-4 weeks or 425 mg/m2
on days 1-5 every 4 weeks. Continuous IV infusion: 1000
mg/m2/day for 4-5 days every 3-4 weeks or 2300-2600 mg/m2
on day 1 every week or 300-400 mg/m2/day or 225 mg/m2/day
for 5-8 weeks (with radiation therapy).
Storage: store at room temperature (15-25oC).
Mercaptopurine
Tablet- 50 mg
Indications: acute leukaemias.
Cautions: hepatic impairment, elderly.
Drug
interactions:
allopurinol,
phenytoin,
sulfamethoxazole+trimethoprime,live vaccines, doxorubicin,
warfarin, sulfasalazine.
Contraindications: severe bone marrow suppression,
pregnancy, breast feeding.
Dose and Administration: (refer to individual protocols):
Adult: Oral:Induction: 2.5 - 5 mg/kg/day (100-200mg).
Maintenance: 1.5 - 2.5 mg/kg/day or 80 100 mg/m2/day given
once daily
Child:Oral:Induction: 2.5 5 mg/kg/day or 70 100
mg/m2/day given once daily. Maintenance: 1.5 - 2.5 mg/kg/day
or 50 75 mg/m2/day given once daily
Storage: store at room temperature (15-25oC).
Methotrexate
Powder for injection, 5 mg, 50mg in vial
Injection, 2mg/ml, 4mg/ml, 8mg/ml
653

11. Antineoplastic And Adjuvants

Tablets, 2.5 mg, 10mg

Indications: carcinoma of the breast, head and neck, and lung,
trophoblastic tumours; acute lymphoblastic leukaemia,
meningeal leukaemia, non-Hodgkins lymphomas; advanced
cases of mycosis fungoides; non-metastatic osteosarcoma;
psoriasis, severe rheumatoid arthritis.
Cautions: renal and hepatic impairment.
Drug interactions: acetyl salicylicacid, amoxicillin, ampicillin,
benzyl penicillin, cyclosporin, dexamethasone, fludrocortisone,
hydrocortisone, ibuprofen, phenoxymethylpenicillin, phenytoin,
prednisolone, pyrimethamine, sulfadiazine, sulfadoxine +
pyrimethamine, sulfamethoxazole + trimethoprim.
Contraindications: breast feeding, pregnancy,sexually active
males avoid emprignating females during and for a minimum of
three months after therapy.
Side effects: headache, vomiting, fever, seizure, reddening of
skin, hyperuricemia, defective oogenesis or spermatogenesis,
ulcerative stomatitis, glossitis, nausea, vomiting, diarrhea,
anorexia, mucositis, renal failure, nephropathy, pharyngitis,
vasculitis, dizziness, malaise, encephalopathy, fever, chills,
rash, diabetes, cystitis, hemorrhage, myelosuppressive,
cirrhosis, blurred vision, renal dysfunction, pneumonitis.
Dosage and Administration: (refer to individual protocols):
Adult:Trophoblastic tumours: Oral, I.M: 15-30 mg/day for 5
days; repeat in 7 days for 3-5 courses.I.V: 11 mg/m2 days 1
through 5 every 3 weeks.
Head and neck cancer: Oral, IM, IV: 25-50 mg/m2 once
weekly.Mycosis fungoides: Oral, IM: initial (early stage): 550 mg once weekly or 5-37.5 mg twice weekly.Bladder
cancer: IV: 30 mg/m2 day 1 and 8 every 3 weeks or 30mg/m2
day 1, 15, and 22 every 4 weeks.Breast cancer: IV: 3060mg/m2 days 1 and 8 every 3-4 weeks.Gastric cancer: IV:
654

11. Antineoplastic And Adjuvants

1500mg/m2 every 4 weeks.Non-Hodgkins lymphomas: IV:

30mg/m2 days 3 and 10 every 3 weeks or 120mg/m2 day 8 and
15 every 3-4 weeks.Sarcoma: IV: 8-12g/m2 weekly for 2-4
weeks.Severe Rheumatoid arthritis: Oral: 7.5mg once weekly
or 2.5 mg every 12 hours for 3 doses perweek, not to exceed
20mg/week.
Psoriasis: Oral: 2.5-5mg/dose every 12 hours for 3 doses given
weekly or Oral, IM: 10-25mg/dose given once weekly.
Storage: store in well-closed containers at 15 - 30oc.
Note: Calcium Folinate (folinic acid) is used as an antidote for
toxicity and side effects of methotrexate (see below and section 12.4
about folinic acid for details)

Calcium Folinate (Leucovorin Calcium)

Powder for injection, Folinic Acid (Calcium salt),15mg
Injection, 15mg, 50mg/vial
Tablet, 15mg
Indications: high-dose methotrexate therapy (folate rescue,
inadvertent overdose of methotrexate);used to counteract the
folate-antagonist action of methotrexate and thus speed
recovery
from
methotrexate-induced
mucositis
or
myelosuppression (folinic acid escue); with fluoruracil in the
palliative treatment of advanced colorectal cancer for better
response.
Cautions: pernicious anemia or other megaloblastic anemias
due to vitamin B12 deficiency; pregnancy; breastfeeding.
Drug interactions: phenobarbital, phenytoin, and cotrimoxazole.
Contraindications: hypersensitivity to leucovorin.
Side effects: allergic reactions; pyrexia after parentral
administration.
655

11. Antineoplastic And Adjuvants

Dose and Administration: (refer to individual protocols):

Adult and Child: IM or IV injection or infusion: Antidote to
methotrexate (usually started 24 hour after methotrexate), up to
120 mg in divided doses over 12 to 24 hours, then 12 to 15 mg
by IM every 6 hours for 48 - 72 hoursor 15mg by mouth every
6 hours for 48-72 hours. Methotrexate overdosage (started as
soon as possible, preferably within 1 hour of methotrexate), by
IV injection or infusion, Adult and Child, dose equal to or
higher than that of methotrexate, at rate not exceeding
160mg/minute.With fluorouracil in colorectal cancer, consult
specialist literature.
Storage: store at room temperature (15-25oC) and protect from
light.
Vinca Alkaloids and Etoposide
The vinca alkaloids vinblastine and vincristine are used to treat
acute leukaemia, lymphomas, and breast and lung cancer.
Reversible dose-limiting neurotoxicity is found: peripheral
neuropathy with paraesthesiae, cranial nerve palsies, muscle
weakness, loss of deep tendon reflexes, paralytic ileus, and
grandmal seizures. Pre-existing neurological disease may
predispose to severe neuropathy.Etoposide is useful in small
cell carcinoma of the bronchus, testicular cancer and
lymphomas. It has been used in Kaposi's sarcoma.
Etoposide (Phosphate)
Capsules, 50 mg, 100 mg
Concentrate for infusion, 20 mg/ml.
Powder for injection, 100 mg/vial
Indications: testicular tumours; lung cancer.
Cautions: hepatic or renal impairment; elderly.
Drug interactions: Live vaccines.
656

11. Antineoplastic And Adjuvants

Contraindications: intrathecal administration, pregnancy,

breast feeding.
Side effects: alopecia, diarrhea, nausea, vomiting, anorexia,
anemia, leukopenia, mucositis, hypotension, unusual fatigue,
stomatitis, hepatic dysfunction.
Dosage and Administration: (refer to individual protocols):
Adult:Lung cancer:IV: 35 mg/m2/day for 4 days or 50
mg/m2/day for 5 days every 3-4 weeks total dose 400
mg/day. Oral: Twice the IV dose rounded to the nearest 50 mg
given once daily if total dose 400 mg or in divided doses if >
400 mg. Testicular cancer: IV: 100 mg/m2 every other day for
3 doses repeated every 3-4 weeks
Storage: store intact vials of injection at room temperature (1525oC) and oral capsules in refrigeration (2-8oC).
Vinblastine (Sulphate)
Powder for injection, 10 mg, in vial
Indications: treatment of Hodgkins and non-Hodgkins
lymphoma; advanced testicular carcinoma, breast carcinoma;
palliative treatment of Kaposis sarcoma, trophoblastic tumours.
Cautions: hepatic impairment
Drug interactions: Live vaccines , azole antifungals,
ciprofloxacin, clarithromycin, diclofenac, doxycycline,
erythromycin, isoniazide, propofol, protease inhibitors,
quinidine, and verapamil, aminoglutethimide, carbamazepine,
nafcillin, nevirapine, phenobarbital, phenytoin and rifamycins.
Contraindications: pregnancy and breastfeeding.
Side effects: alopecia, diarrhea, stomatitis, anorexia, metallic
taste, severe bone marrow suppression, granulocytopenia,
thrombocytopenia, hypertension, Raynaud's phenomenon,
depression, malaise, headache,
657

11. Antineoplastic And Adjuvants

seizure, rash, dermatitis, hyperuricemia, abdominal pain,

nausea, vomiting, urinary retention, bronchospasm.
Dose and Administration: (refer to individual protocols):
Adult and Child: IV: 4-20 mg/m2 (0.1-0.5mg/kg) every 7-10
days or 5 day continuous infusion of 1.5 to 2 mg/m2/day or
0.1-0.5 mg/kg/week.
Storage: store at in refrigrators (2 - 8oc).
Vincristine Sulfate
Powder for injection, 1mg, 5mg in vial
Indications: acute lymphoblastic leukaemia; neuroblastoma,
wilm tumour, Hodgkin and non-Hodgkin lymphomas;
rhabdomyosarcoma, Ewing sarcoma; mycosis fungoides.
Cautions: hepatic impairment.
Drug interactions: phenytoin, live vaccines.
Contraindications: pregnancy and breastfeeding.
Side effects: alopecia, orthostatic hypotension or hypertension,
seizure, headache, CNS depression, fever, rash, hyperuricemia,
constipation, anorexia, nausea, vomiting, weightloss, diarrhea,
bladder atony, photophobia
Dose and Administration: Adult: 0.4-1.4 mg/m2, may repeat
every week or 0.4-0.5 mg/day continuous infusion for 4 days
every 4 weeks or 0.25-0.5 mg/m2/day for 5 days every week.
Storage: store at 2 - 8oc.
Hormones and Antihormones
Anastrazole
Tablet, 1mg (film coated)
Indications: treatment of locally-advanced or metastatic breast
cancer (ER-positive or hormone receptor unknown) in
postmenopausal women; treatment of advanced breast cancer in
postmenopausal women with disease progression following
658

11. Antineoplastic And Adjuvants

tamoxifen therapy; adjuvant treatment of early ER-positive

breast cancer in postmenopausal women.
Caution: hyperlipidemias.
Drug interactions: estrogen, tamoxifen.
Contraindications: pregnancy (risk factor D), hypersensitivity
reaction.
Side effects: vasodilation, headache, depression, hot flashes,
arthritis, arthralgia, back pain, cough increased, pharyngitis,
peripheral edema, hypertension, insomnia, dizziness, anxiety,
rash, vomiting ,constipation, diarrhea, anorexia, anemia,
dyspnea.
Dose and Administration:Breast cancer:Adult: Oral (refer to
individual protocols): 1 mg once daily.
Storage: store at room temperature.
Bicalutamide
Tablet, 50mg, 150mg
Indications: locally advanced prostate cancer at high risk of
disease progression, either alone or as adjuvant treatment to
prostatectomy or radiotherapy; locally advanced, non-metastatic
prostate cancer when surgical castration or other medical
intervention inappropriate; advanced prostate cancer in
combination with gonadorelin analogue or surgical castration
Cautions: hepatic impairment, also consider periodic liver
function tests
Drug interactions:Coumarins
Side effects : nausea, diarrhoea, cholestasis, jaundice; asthenia,
weight gain; gynaecomastia, breast tenderness, hot flushes,
impotence, decreased libido; anaemia; alopecia, dry skin,
hirsutism, pruritus; less commonly vomiting, abdominal pain,
dyspepsia, interstitial lung disease, pulmonary fibrosis,
depression, haematuria, thrombocytopenia, hypersensitivity
659

11. Antineoplastic And Adjuvants

reactions including angioneurotic oedema and urticaria; rarely

cardiovascular disorders (including angina, heart failure, and
arrhythmias), and hepatic failure
Dose and administration: Locally advanced prostate cancer at
high risk of disease progression: 150 mg once daily. Locally
advanced, non-metastatic prostate cancer when surgical
castration or other medical intervention inappropriate: 150 mg
once daily. Advanced prostate cancer: in combination with
goserelin analogue or surgical castration, 50 mg once daily
(started at the same time as surgical castration or at least 3 days
before goserelin therapy)
Tamoxifen Citrate
Tablet, 10 mg, 20mg
Indications: adjuvant treatment of estrogen - receptor-positive
breast cancer; metastatic breast cancer; reduce the incidence of
breast cancer in women at high risk.
Cautions: leukopenia, thrombocytopenia, or hyperlipidemias.
Drug interactions: warfarin, allopurinol, cyclosporine,
delavirdine, fluconazole, gemfibrozil, ketoconazole, NSAIDs,
sulfonamides,
chlorpromazine,
miconazole,
fluoxetine,
quinidine, quinine, ritonavir, erythromycin, ciprofloxacin,
diclofenac, doxycycline, isoniazid, verapamil, carbamazepine,
phenobarbital, phenytoin, rifampin, nevirapine.
Contraindications: pregnancy; breast-feeding.
Side effects: hot flushes; endometrial changes (symptoms such
as vaginal bleeding and other menstrual irregularities, vaginal
discharge, pelvic pain); increased pain and hypercalcaemia with
bony metastases; tumour flare; nausea and vomiting; liver
enzyme changes; thromboembolic events; decreased platelet
count; oedema; alopecia; rash; headache; visual disturbances;
rarely hypersensitivity reactions.
660

11. Antineoplastic And Adjuvants

Dosage and Administration:Adult:Breast cancer: Metastatic:

20 mg/day; Prevention (high-risk females): 20mg/day for 5
years.
Storage: store in well closed containers at controlled room
temperature.
Testosterone Propionate
Tablet (buccal), 10 mg
Indications: used for replacement therapy
Cautions: cardiac impairment, elderly, ischaemic heart disease,
hypertension, epilepsy, migraine, diabetes mellitus, skeletal
metastases (risk of hypercalcaemia), undertake regular
examination of the prostate and breast during treatment; monitor
full blood count, lipid profile and liver function. Women:
Regularly assess for androgenic side-effects; women should be
advised to report any signs of virilisation e.g. deepening of the
voice or hirsutism.
Drug Interactions: Antidiabetics, coumarins, phenindione.
Contra indications: breast cancer in men, prostate cancer,
history of primary liver tumours, hypercalcaemia, nephrotic
syndrome, Hepatic impairment and avoid if possiblefluid
retention and dose-related toxicity, renal impairment,
Pregnancy; Breast-feeding; child and adolescentsunder 18
years.
Side effects: prostate abnormalities and prostate cancer,
headache, depression, gastro-intestinal bleeding, nausea,
vomiting,
cholestatic
jaundice,
changes
in
libido,
gynaecomastia,
polycythaemia,
anxiety,
irritability,
nervousness, asthenia, paraesthesia, hypertension, electrolyte
disturbances including sodium retention with oedema and
hypercalcaemia, weight gain; increased bone growth, muscle
cramps, arthralgia; androgenic effects such as hirsutism, male661

11. Antineoplastic And Adjuvants

pattern baldness, seborrhoea, acne, pruritus, excessive frequency

and duration of penile erection, precocious sexual development
and premature closure of epiphyses in pre-pubertal males,
suppression of spermatogenesis in men and virilism in women;
rarely liver tumours; sleep apnoea also reported; with patches,
buccal tablets,andgel, local irritation and allergic reactions
(including burn-like lesions with patches), and taste
disturbances
Dose and Administration: hypogonadism, 30 mg every 12
hours.Note: Place rounded side of tablet on gum above front teeth and hold
lip firmly over the gum for 30 seconds. If tablet detaches within 4 hours of
next dose, replace with new tablet which is considered the second dose for
the day.

Raloxifene Hydrochloride
Tablet, 30mg
Indication: Prevention and treatment of osteoporosis in
postmenopausal women, prophylaxis of invasive breast cancer
in post menopausal women at high risk
Cautions: History of venous thromboembolism/ pulmonary
embolism; patients with cardiovascular disease; history of
cervical/uterine
carcinoma;
renal/hepatic
insufficiency;
concurrent use of estrogens; women with a history of elevated
triglycerides in response to treatment with oral estrogens.
Contraindications: Hypersensitivity to the medicine or any
component of the formulation; active thromboembolic disorder;
pregnancy, breast feeding.
Drug Interactions: Highly proteinbound medicines, warfarin,
clofibrate, indomethacin, naproxen, ibuprofen, diazepam,
phenytoin, tamoxifen, ampicillin, cholestryramine.
Side effects: Hot flashes, arthralgia, sinusitis, infection, chest
pain, fever, migraine, depression, insomnia, rash, peripheral
edema, nausea, dyspepsia, vomiting, GI disorder
662

11. Antineoplastic And Adjuvants

Dosage and Administration: Adults: Female; Oral: 60mg per

day which may be administrered any time of the day without
regard to meals
Monoclonal Antibodies
Bevacizumab
Injection, 25 mg/ml, 25mg/ vial
Indications: metastatic colorectal cancer as a component of
multidrug therapy, breast cancer and lung cancer
Cautions: cardiovascular disease.
Drug interactions: it may potentiate the cardiotoxic effects of
anthracyclines.
Contraindications: hypersensitivity reactions.
Side effects: hypertension, hypotension, thromboembolism,
headache, dizziness, alopecia, weight loss, hypokalemia,
abdominal pain, vomiting, diarrhea, anorexia, constipation,
stomatitis, dyspepsia, flatulence, leukopenia, epistaxis,
gastrointestinal hemorrhage, neutropenia, myalgia, dyspnea.
Dosage and Administration:IV:Adult:Colorectal cancer: 5-10
mg/kg every 2 weeks
Storage: store vials at 2 - 8 oC. Protect from light; do not freeze
or shake.
Rituximab
Injection, 100 mg/10ml
Indications: relapsed or refractory CD20 positive, B-cell nonHodgkin's lymphoma, chronic lymphoid leukemia
Cautions: cardiac or pulmonary disease and hypersensitivity
reactions.
Side effects: abdominal pain, anemia, dyspnea, hypotension,
and neutropenia are more common in patients with bulky
disease. Central nervous system (fever, chills, headache, pain),
663

11. Antineoplastic And Adjuvants

rash, pruritus, angioedema, nausea, abdominal pain,

lymphopenia, cough, rhinitis.
Dosage and Administration:Adult: I.V infusionManufacturer's
labeling: 375 mg/m2 once weekly for 4 - 8 weeks. or 100 mg/m2
IV day 1, then 375 mg/m2 3 times/week for 11 doses has also
been reported (cycles may be repeated in patients with
refractory or relapsed disease).Retreatment following disease
progression: 375 mg/m2 once weekly for 4 doses.
Storage: store vials under refrigeration (2 - 8 oC).
11.4. Cytotoxic immunosuppressants
Azathioprine
Tablet, 50 mg
Indications: organ transplantation, in combination with
steroids and/or other immunosuppressants; auto immune
diseases such as systemic lupus erythematosus, refractory
rheumatoid arthritis, idiopathic thrombocytopenia purpura,
autoimmune haemolytic anemia and chronic active hepatitis.
Cautions: liver and renal impairment, monitor hematologic
function closely.
Drug interactions: allopurinol, sulfasalazine, warfarin.
Contraindications: pregnancy.
Side
effects:
myelosuppression
with
occasional
thrombocytopenia
and
anaemia;
severe
red
cell
megaloblastosis, hepatotoxicity, hypersensitivity reactions,
including anaphylaxis, may occur.
Dose
and
Administration:Adult
and
Child:Renal
transplantation:Oral: 2-5 mg/kg/day to start, then 1-3 mg / kg /
day maintenance.Adult: Rheumatoid arthritis: Oral: 1
mg/kg/day for 6-8 weeks; increase by 0.5 mg/kg every 4 weeks
until response or up to 2.5 mg/kg/day.
Storage: store at room temperature.
664

11. Antineoplastic And Adjuvants

11.5. Other Antineoplastics

Cisplatin
Powder for injection, 10 mg, 50 mg/ vial
Injection, 10mg, 50mg/vial
Indications: treatment of head and neck, breast, testicular and
ovarian cancer; Hodgkins and non-Hodgkins lymphoma;
neuroblastoma, sarcomas, bladder, gastric, lung, esophageal,
cervical, and prostate cancer; myeloma, melanoma,
mesothelioma, small cell lung cancer, and osteosarcoma.
Cautions: renal impairment, myelosuppression, hearing
impairment.
Drug interactions: acetazolamide, amiloride, furosemide,
gentamicin, hydrochlorothiazide, phenytoin, spironolactone,
streptomycin, vancomycin, vaccine (live).
Contraindications: pregnancy.
Side effects: peripheral neuropathy, mild alopecia, nausea and
vomiting, myelosuppressive, elevation of liver enzymes,
nephrotoxicity, ototoxicity, arrhythmias, blurred vision,
bradycardia, cerebral blindness, hemolytic anemia, electrolyte
imbalance.
Dosage and Administration: (refer to individual protocols)
I.V. in not less than 4 hours and it needs prehydration.Adult:
Advanced bladder cancer: 50-70 mg/m2 every 3-4 weeks.Head
and neck cancer: 100-120 mg/m2 every 3-4 weeks.Metastatic
ovarian cancer: 75-100 mg/m2 every 3 weeks.Testicular cancer:
10-20 mg/m2/day for 5 days repeated every 3-4 weeks.
Storage: store at room temperature and protect from light.
Dacarbazine
Powder for injection, 100mg, 200mg, 500mg, 600mg,
1000mg/vial
665

11. Antineoplastic And Adjuvants

Indications: treatment of malignant melanoma, hodgkins

disease, soft-tissue sarcomas, medullary carcinoma of the
thyroid,and neuroblastoma.
Dose and Administration:(refer to individual protocols)
I.V:Hodgkins disease, ABVD: 375mg/m2 days 1 and 15 every
4 weeks or 100 mg/m2/day for 5 days.Metastatic melanoma
(alone or in combination with other agents): 150-250mg/m2
days 1-5 every 3-4 weeks. Metastatic melanoma: 850mg/m2
every 3 weeks
Storage: store intact vials under refrigeration (2-8oC) and
protect from light.
Hydroxycarbamide (hydroxyurea)
Capsule, 500 mg
Indications: treatment of metastatic disease, chronic myeloid
leukaemia, haemoglobinopathies including sickle cell disease
and tumours of the head and neck, an adjunct to nucleoside
reverse transcriptase inhibitor in the treatment of HIV disease.
Cautions: renal impairment, bone marrow suppression,
erythrocytic abnormalities, and elderly.
Drug interactions: zidovudine, zalcitabine, didanosine,
fluorouracil, cytarabine, and stavudine.
Contraindications: severe anemia, pregnancy.
Side effects: edema, drowsiness, hallucinations, headache,
dizziness, disorientation, seizure, fever, chills, erythema of
hands and face, rash, pruritus, hyperpigmentation, dry skin, skin
cancer, hyperuricemia, nausea, vomiting, stomatitis, anorexia,
diarrhea, constipation, pancreatitis, dysuria, myelosuppression,
hepatotoxicity, peripheral neuropathy, dyspnea, pulmonary
fibrosis.

666

11. Antineoplastic And Adjuvants

Dose and Administration: (refer to individual protocols):

Oral:Adult:Solid tumors: Intermittent therapy: 80 mg/kg as a
single dose every third day.
Continuous therapy: 20-30 mg/kg/day given as a single
dose/day. Concomitant therapy with irradiation: 80 mg/kg as a
single dose every third day starting at least 7 days before
initiation of irradiation.Resistant chronic myelocytic leukemia:
Continuous therapy: 20-30 mg/kg as a single daily dose. HIV
(in combination with ARV agents): 1000-1500 mg daily in a
single dose or divided doses.Sickle cell anemia: initial: 15
mg/kg/day, increased by 5 mg/kg every 12 weeks if blood
counts are in an acceptable range until the maximum tolerated
dose of 35 mg/kg/day is achieved.
Storage: store at room temperature.
Procarbazine
Capsule, (as hydrochloride) 50 mg
Indications: treatment of Hodgkin's disease.
Cautions: renal and hepatic impairment.
Drug interactions: foods containing high amounts of tyramine,
epinephrine,
amphetamine,
antidepressants,
narcotics,
phenothiazines, and other CNS depressants.
Contraindications: pre-existing bone marrow aplasia; ethanol
ingestion; pregnancy.
Side effects: mental depression, manic reactions, hallucinations,
dizziness, headache, nervousness, insomnia, nightmares, ataxia,
confusion, CNS stimulation, amenorrrhea, nausea, vomiting,
anorexia, abdominal pain, stomatitis, dysphagia, diarrhea,
constipation,
thrombocytopenia,
hemolytic
anemia,
myelosuppressive, paresthesia, neuropathies, nystagmus,
pleural effusion, cough, hepatotoxicity, peripheral neuropathy,
alopecia, hyperpigmentation.
667

11. Antineoplastic And Adjuvants

Dose and Administration: (refer to individual protocols):

Oral:Adult: Initial: 2-4 mg/kg/day in single or divided doses
for 7 days then increase dose to 4-6 mg/kg/day until response is
obtained.Child:BMT aplastic anemia conditioning regimen:
12.5 mg/kg/dose every other day for 4 doses.Hodgkin's disease:
MOPP/IC-MOPP regimens: 100 mg/m2/day for 14 days and
repeated every 4 weeks. Neuroblastoma and medulloblastoma:
dose as high as 100-200 mg/m2/day once daily have been used.
Storage: store in tight, light - resistant containers and at room
temperature.
Miscellaneous
Filgrastin
Injection, 300 mcg/ml, 300 mcg/0.5ml syringe, 480 mcg/1.6ml,
480 mcg /0.8 ml syringe, 30mu/0.5ml
Indications: stimulation of granulocyte production in patients
with malignancies, including myeloid malignancies; receiving
myelosuppressive therapy associated with a significant risk of
neutropenia; severe chronic neutropenia (SCN); receiving bone
marrow transplantation (BMT); undergoing peripheral blood
progenitor cell (PBPC) collection.
Cautions: complete blood count and platelet count should be
obtained prior to chemotherapy.
Drug interactions: medicines which may potentiate the release
of neutrophils (e.g. lithium)
Contraindications:
concurrent
myelosuppressive
chemotherapy orradiation therapy, pregnancy, breast feeding
Side effects: neutropenic fever, alopecia, nausea, vomiting,
diarrhea, mucositis, chest pain, fluid retention, headache,
anorexia.
Dosage and Administration: Refer to individual protocols: IV
or SC:Myelosuppressive therapy: 5 mcg/kg/day doses may be
668

11. Antineoplastic And Adjuvants

increased by 5 mcg/kg according to the duration and severity of

the neutropenia.BMT: 5 to 10 mcg/kg/day doses may be
increased by 5 mcg/kg according to the duration and severity of
neutropenia.PBPC: 10 mcg/kg/day or 5 to 8 mcg/kg twice daily
in donors. Severe chronic neutropenia: Congenital: 6mcg/kg
twice daily
Idiopathic/Cyclic:5 mcg/kg/day
Storage: store in refrigerator at 2 8 oC.
Granisetrone Hydrochloride
Tablet, 1mg, 2 mg
Injection, 1mg, 3mg in ampoule
Indications: prophylaxis of chemotherapy - related emesis;
prophylaxis of nausea and vomiting associated with radiation
therapy, including total body irradiation and fractionated
abdominal radiation; prophylaxis of postoperative nausea and
vomiting (PONV).
Cautions: chemotherapy -related emesis; liver diseas or in
pregnancy.
Drug interactions: substrate of CYP3A4.
Contraindications: hypersensitivity reactions.
Side effects: headache, constipation, hypertension, dizziness,
insomnia, anxiety somnolence, fever, abdominal pain, diarrhea,
dyspepsia, elevated liver enzymes.
Dose and Administration: Oral: Adult:Prophylaxis of
chemotherapy-related emesis: 2 mg once daily up to 1 hour
before chemotherapy or 1 mg twice daily; the first 1 mg dose
should be given up to 1 hour before chemotherapy.Prophylaxis
of radiation therapy-associated emesis: 2 mg once daily given 1
hour before radiation therapy.
Storage: store at room temperature and protect from light.
669

11. Antineoplastic And Adjuvants

Ondansetron
Tablet, 4mg, 8mg
Syrup, 4mg/5ml
Injection, 2mg/ml, 4mg/ml, 8mg/ml
Suppository, 16mg
Indications: management of nausea and vomiting induced by
chemotherapeutic agents and radiotherapy; prevention and
treatment of post-operative nausea and vomiting.
Cautions: previous hypersensitivity to other selective 5HT3receptor antagonists; hepatic impairment; subacute intestinal
obstruction; porphyria; pregnancy; lactation.
Contraindications: known hypersensitivity to the product.
Side effects: headache, flushing, hiccups, constipation,
transient, asymptomatic increase in aminotransferases.
Hypersensitivity reactions (anaphylaxis, bronchospasm,
hypotension, shock, angioedema, urticaria).transient visual
disturbances and dizziness with rapid IV administration; pain,
redness at injection site.
Dosage and Administration: Adult: Highly emetogenic
chemotherapy (e.g. cisplatin):Slow IV or IM, 8mg immediately
before treatment, followed by 2 further IV or IM doses of 8mg
2-4 hours apart (or by a continuous IV infusion of 1mg/hour for
up to 24 hours). Alternatively, a single dose of 32mg diluted in
50-100ml 0.9% sodium chloride solution and infused over not
less than 15 minutes immediately before chemotherapy. To
protect against delayed or prolonged emesis after the first
24hours, continue with oral, 8mg 12hourly for up to 5 days.Less
emetogenic chemotherapy: Oral: 8mg 1-2 hours beore
treatment (or slow IV or IM, 8mg immediately before
treatment), followed by oral, 8mg 12 hourly for up to 5
days.Post-operative nausea and vomiting: immediately before
670

11. Antineoplastic And Adjuvants

induction of anaesthesia or postoperatively, 4mg IM or IV over

2-5 minutes. Alternatively, 16mg orally 1 hour before
induction. Repeat dosing has not been studied.Moderate to
severe hepatic impairment: total daily dose of 8mg should not
be exceeded.Child: Emetogenic chemotherapy: >4 years, IV,
5mg/m2 given over 15 minutes, immediately before treatment,
followed by oral, 4mg 12 hourly for up to 5 days. Postoperative nausea and vomiting: 2 years, slow IV, 0.1mg/kg
up to a maximum of 4 mg, prior to, at, or after, induction of
anaesthesia.
Ibandronate
Tablet, 50mg, 150mg
Indications: Hypercalcemia of malignancy, reduce bone pain
and skeletal complications from metastatic bone disease.
Cautions, Drug interactions,Contraindications, Side effects
and Dose and Administration:See under bone modulating
medicine underIbandronate
Zoledronic acid
4mg/5ml injection
Indication: for treatment of hypercalcemia associated with
malignant neaplasms and adjunct to antineoplastic therapy for
the treatment of bone metastases of solid tumors and osteolytic
lesions of multiple myeloma.
Cautions: renal impairment, serum concentration of calcium,
phosphate, magnesium, potassium, and other electrolytes, and
also hematocrit and hemoglobin should be monitored carefully.
Asprin-sensitive asthmatic patients, breastfeeding, children and
elderly.
Contraindication: known hypersensitivity to zoledronic acid,
other bisphophonates, or any ingredient in the formulation.
671

11. Antineoplastic And Adjuvants

Side effects: fever, nausea, constipation, anemia, dyspnea,

diarrhea, progression of cancer, abdominal pain, insomnia,
vomiting, urinary tract infection, anxiety, hypophosphatemia,
confusion, agitation, hypokalemia, skeletal pain, cough,
hypotension. Hypomagnesemia.
Drug interaction: loop diuretics, aminoglycosides, nephrotoxic
agents, thalidomide.

672

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

12. BLOOD PRODUCTS and MEDICINES

AFFECTING the BLOOD
12.1. Anticoagulants
Anticoagulants are used to prevent thrombus formation or
extension of an existing thrombus in the slower-moving venous
side of the circulation, where the thrombus consists of a fibrin
web enmeshed with platelets and red cells. They are therefore
used widely in the prevention and treatment of deep-vein
thrombosis in the legs, prophylaxis of emobilization in
rheumatic heart disease and atrial fibrillation and to prevent
thrombi forming on prosthetic heart valves.
Dalteparin
Injection, (Antifactor Xa), 5,000U; 10,000U; 25,000U;
75,000U
Prefilled syringe, 5000U, 7500U, 10,000U
Indications: Prevention of deep vein thrombosis (DVT) which
may lead to pulmonary embolism, in patients requiring
abdominal surgery who are at risk for thromboembolism
complications (eg, patients >40 years of age, obesity, patients
with malignancy, history of DVT or pulmonary embolism, and
surgical procedures requiring general anesthesia and lasting >30
minutes); prevention of DVT in patients undergoing hipreplacement surgery; patients immobile during an acute illness;
prevention of ischemic complications in patients with unstable
angina or non-Q-wave myocardial infarction on concurrent
aspirin therapy; in patients with cancer, extended treatment (6
months) of acute symptomatic venous thromboembolism (DVT
and/or PE) to reduce the recurrence of venous
thromboembolism
Cautions and Side effects; see under heparin.
673

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Dosage and Administration: Note: Each 2500 units of anti-Xa

activity is equal to 16 mg of dalteparin.
Adult: SC: DVT prophylaxis: Note: In morbidly obese patients
(BMI 40 kg/m2), increasing the prophylactic dose by 30%
may be appropriate (Nutescu, 2009):
Abdominal surgery:Low-to-moderate DVT risk: SC: 2500
units 1-2 hours prior to surgery, then once daily for 5-10 days
postoperatively.High DVT risk: SC: 5000 units the evening
prior to surgery and then once daily for 5-10 days
postoperatively. Alternatively in patients with malignancy:
2500 units 1-2 hours prior to surgery, 2500 units 12 hours later,
then
5000
units
once
daily
for
5-10
days
postoperatively.General surgery with risk factors for VTE: 2500
units 1-2 hours preoperatively followed by 2500-5000 int.units
every morning (may administer 2500 units no sooner than 4
hours after surgery and 8 hours after previous dose provided
hemostasis has been achieved) or if other risk factors are
present (eg, malignancy, heart failure), then may administer
5000 units the evening prior to surgery followed by 5000 units
every evening postoperatively; continue treatment until patient
is mobilized (approximately 5-7 days).
Total hip replacement surgery: SC: Note: Three treatment options
are currently available. Dose is given for 5-10 days, although up to
14 days of treatment have been tolerated in clinical trials. The
American College of Chest Physicians (ACCP) recommends a
minimum duration of at least 10-14 days; extended duration of up to
35 days is suggested.

Postoperative regimen:Initial: 2500 units 4-8 hours after

surgery (or later if hemostasis not achieved). The ACCP
recommends initiation 12 hours after surgery if postoperative
regimen chosen.Maintenance: 5000 int. units once daily; allow
at least 6 hours to elapse after initial postsurgical dose (adjust
674

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

administration time accordingly).Preoperative regimen

(starting day of surgery):Initial: 2500 int. units within 2 hours
before surgery. The ACCP recommends initiation 12 hours
before surgery if preoperative regimen chosen. At 4-8 hours
after surgery (or later if hemostasis not achieved), administer
2500 int. units.Maintenance: 5000 units once daily; allow at
least 6 hours to elpase after initial postsurgical dose (adjust
administration time accordingly)
Preoperative regimen (starting evening prior to
surgery):Initial: 5000 int. units 10-14 hours before surgery.
The ACCP recommends initiation 12 hours before surgery if
preoperative regimen chosen. At 4-8 hours after surgery (or
later if hemostasis not achieved), administer 5000 int.
units.Maintenance: 5000 int. units once daily, allowing 24
hours between doses.Immobility during acute illness: 5000
units once daily.
Unstable angina or non-Q-wave myocardial infarction: SC: 120
units/kg body weight (maximum dose: 10,000 units) every 12
hours for up to 5-8 days with concurrent aspirin therapy.
Discontinue dalteparin once patient is clinically stable.Obesity:
Use actual body weight to calculate dose; dose capping at
10,000 units recommended.
Venous thromboembolism, extended treatment in cancer
patients: SC:Initial (month 1): 200 units/kg (maximum dose:
18,000 units) once daily for 30 days.Maintenance (months 2-6):
~150 units/kg (maximum dose: 18,000 units) once daily. If
platelet count between 50,000-100,000/mm3, reduce dose by
2,500 units until platelet count recovers to 100,000/mm3. If
platelet count <50,000/mm3, discontinue dalteparin until
platelet count recover to >50,000/mm3.

675

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Note: If increased bleeding risk, may give 100 units/kg SC twice

daily. Concomitant treatment with a vitamin-K antagonist is usually
initiated immediately.

Storage: Store at temperatures of 20C to 25C. Multidose

vials may be stored for up to 2 weeks at room temperature after
entering.
Enoxaparin
Injection, 20mg/0.2ml, 40mg/0.4ml, 60mg/0.6ml, 80mg/0.8ml,
100mg/ml
Indications: Acute coronary syndromes: Unstable angina
(UA), non-ST-elevation (NSTEMI), and ST-elevation
myocardial infarction (STEMI).DVT prophylaxis: Following
hip or knee replacement surgery, abdominal surgery, or in
medical patients with severely-restricted mobility during acute
illness who are at risk for thromboembolic complications. DVT
treatment (acute): Inpatient treatment (patients with and without
pulmonary embolism) and outpatient treatment (patients
without pulmonary embolism).
Note: High-risk patients include those with one or more of the
following risk factors: >40 years of age, obesity, general anesthesia
lasting >30 minutes, malignancy, history of deep vein thrombosis or
pulmonary embolism

Cautions and Side effects:see under heparin.

Dose and Administration: One mg of enoxaparin is equal to
100 units of anti-Xa activity (World Health Organization First
International Low Molecular Weight Heparin Reference
Standard).Adult:DVT prophylaxis: Note: In morbidly obese
patients (BMI 40 kg/m2), increasing the prophylactic dose by
30% may be appropriate for some indications or bariatric
surgery, dose increases may be >30% based on clinical trial
data. SubQ:Hip replacement surgery: Twice-daily dosing: 30
mg every 12 hours, with initial dose within 12-24 hours after
676

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

surgery, and every 12 hours for at least 10 days or until risk of

DVT has diminished or the patient is adequately anticoagulated
on warfarin. The American College of Chest Physicians
recommends initiation 12 hours preoperatively or 12 hours
postoperatively; extended duration of up to 35 days
suggested.Once-daily dosing: 40 mg once daily, with initial
dose within 9-15 hours before surgery, and daily for at least 10
days (or up to 35 days postoperatively) or until risk of DVT has
diminished or the patient is adequately anticoagulated on
warfarin. The American College of Chest Physicians
recommends initiation 12 hours preoperatively or 12 hours
postoperatively; extended duration of up to 35 days suggested
(Guyatt, 2012).Knee replacement surgery: 30 mg every 12
hours, with initial dose within 12-24 hours after surgery, and
every 12 hours for at least 10 days or until risk of DVT has
diminished or the patient is adequately anticoagulated on
warfarin. The American College of Chest Physicians
recommends initiation 12 hours preoperatively or 12 hours
postoperatively; extended duration of up to 35 days suggested.
Abdominal surgery: 40 mg once daily, with initial dose given
2 hours prior to surgery; continue until risk of DVT has
diminished (usually 7-10 days).
Heparin
Injection (solution for injection) 1000U/ml, 5000 U/ml,
10,000U/ml, 12,500 U/ml, 25,000U/ml
Injection, 1000IU in 500ml Normal Saline.
Indications: Prophylaxis and treatment of thromboembolic
disorders; as an anticoagulant for extracorporeal and dialysis
procedures.
Cautions: hepatic impairment and renal failure; spinal or
epidural anaesthesia risk of spinal haematoma; pregnancy;
677

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

diabetes mellitus, acidosis, concomitant potassium-sparing

drugs increased risk of hyperkalaemia.
Drug interactions: acetylsalicylic acid, captopril and
ibuprofen, nitroglycerin, omega-3 fatty acids
Contraindications: Hypersensitivity to heparin or any
component of the formulation (unless a life-threatening
situation necessitates use and use of an alternative anticoagulant
is not possible); severe thrombocytopenia; uncontrolled active
bleeding except when due to disseminated intravascular
coagulation (DIC); not for use when appropriate blood
coagulation tests cannot be obtained at appropriate intervals
(applies to full-dose heparin only)
Note: Some products contain benzyl alcohol as a preservative; their
use in neonates, infants, or pregnant or nursing mothers is
contraindicated by some manufacturers.

Side effects: immune-mediated thrombocytopenia usually

developing 6 to 10 days after commencement of therapy;
haemorrhage, skin necrosis, hypersensitivity reactions including
urticaria, angioedema and anaphylaxis, osteoporosis after
prolonged use and rarely alopecia.
Dosage and Administration: Many concentrations of heparin
are available ranging from 1 unit/mL to 20,000 units/ml.
Carefully examine each prefilled syringe or vial prior to use
ensuring that the correct concentration is chosen. Heparin lock
flush solution is intended only to maintain patency of I.V.
devices and is not to be used for anticoagulant therapy.Acute
coronary syndromes: I.V. infusion (weight-based dosing per
institutional nomogram recommended):STEMI: Adjunct to
fibrinolysis (full-dose alteplase, reteplase, or tenecteplase)
(Antman, 2008): Initial bolus of 60 units/kg (maximum: 4000
units), then 12 units/kg/hour (maximum: 1000 units/hour) as
continuous infusion. Check aPTT every 4-6 hours; adjust to
678

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

target of 1.5-2 times the upper limit of control (50-70 seconds).

Duration of heparin therapy depends on concurrent therapy and
the specific patient risks for systemic or venous
thromboembolism.Unstable angina (UA)/non-ST-elevation
myocardial infarction (NSTEMI) (Anderson, 2007): Initial
bolus of 60 units/kg (maximum: 4000 units), followed by an
initial infusion of 12 units/kg/hour (maximum: 1000
units/hour). Check aPTT every 4-6 hours; adjust to target of
1.5-2 times the upper limit of control (50-70 seconds). Continue
for 48 hours in low risk patients managed with a conservative
strategy (ie, no diagnostic angiography or PCI) (Jneid,
2012).Percutaneous
coronary
intervention:No
prior
anticoagulant therapy:If no GPIIb/IIIa inhibitor use planned:
Initial bolus of 70-100 units/kgorIf planning GPIIb/IIIa
inhibitor use: Initial bolus of 50-70 units/kg.
Prior anticoagulant therapy:If no GPIIb/IIIa inhibitor use
planned: Additional heparin as needed (eg, 2000-5000 units)
orIf planning GPIIb/IIIa inhibitor use: Additional heparin as
needed (eg, 2000-5000 units) (target ACT 200-250 seconds
regardless of device). Thromboprophylaxis (low-dose
heparin): SubQ: 5000 units every 8-12 hours. Note: The
American College of Chest Physicians recommends a minimum
of 10-14 days for patients undergoing total hip arthroplasty,
total knee arthroplasty, or hip fracture surgery.Treatment of
venous thromboembolism: Note: Start warfarin on the first or
second treatment day and continue heparin until INR is 2 for
at least 24 hours (usually 5-7 days). Intermittent I.V.
Anticoagulation: Intermittent I.V.: Initial: 10,000 units, then
50-70 units/kg (5000-10,000 units) every 4-6 hours.
Maintenance of line patency (line flushing): When using daily
flushes of heparin to maintain patency of single and double
lumen central catheters, 10 units/mL is commonly used for
679

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

younger infants (eg, <10 kg) while 100 units/mL is used for
older infants, children, and adults. Capped PVC catheters and
peripheral heparin locks require flushing more frequently (eg,
every 6-8 hours). Volume of heparin flush is usually similar to
volume of catheter (or slightly greater). Additional flushes
should be given when stagnant blood is observed in catheter,
after catheter is used for drug or blood administration, and after
blood withdrawal from catheter.
Storage: store at room temperature.
Warfarin Sodium
Tablets, 2 mg, 5 mg, 10mg
Indications: prophylaxis of emboilization in rheumatic heart
disease and atrial fibrillation; prophylaxis after insertion of
prosthetic heart valve; prophylaxis and treatment of venous
thrombosis and pulmonary embolism; transient ischaemic
attacks.
Cautions: hepatic or renal failure, recent surgery,
breastfeeding.
Drug interactions: acetylsalicylic acid, alcohol, allopurinol,
amoxicillin,
ampicillin,
azathioprine,
carbamazepine,
ceftazidime,
ceftriaxone,
chloramphenicol,
cimetidine,
ciprofloxacin, contraceptives, dexamethasone, doxycycline,
erythromycin, fluconazole, fludrocortisone, glibenclamide,
griseofulvin, hydrocortisone, ibuprofen, levonorgestrol,
levothyroxine, medroxy progesterone, metronidazole, naldixic
acid, norethisterone, ofloxacin, phenobarbital, phenytoin,
phytomenadione,
prednisolone,
proguanil,
quinidine,
rifampicin, ritonavir, sulfadiazine, tamoxifen, testosterone.
Contraindications: Hypersensitivity to warfarin or any
component of the formulation; hemorrhagic tendencies (eg,
patients bleeding from the GI, respiratory, or GU tract; cerebral
680

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

aneurysm; cerebrovascular hemorrhage; dissecting aortic

aneurysm; spinal puncture and other diagnostic or therapeutic
procedures with potential for significant bleeding; history of
bleeding diathesis); recent or potential surgery of the eye or
CNS; major regional lumbar block anesthesia or traumatic
surgery resulting in large, open surfaces; blood dyscrasias;
severe uncontrolled or malignant hypertension; pericarditis or
pericardial effusion; bacterial endocarditis; unsupervised
patients with conditions associated with a high potential for
noncompliance; eclampsia/pre-eclampsia, threatened abortion,
pregnancy (except in women with mechanical heart valves at
high risk for thromboembolism)
Side effects: haemorrhage, hypersensitivity, rash, alopecia,
diarrhea, unexplained drop in haematocrit, 'purple toes', skin
necrosis, jaundice, hepatic dysfunction, nausea, vomiting and
pancreatitis.
Dose and Administration:Oral:Adult: initially 5 - 10 mg
daily for 2 - 5 days or until, the desired prothrombin activity is
reached. Maintenance is determined by individual response and
is usually 2 - 10 mg daily (taken at the sametime each day).
Infants and Child: 0.05-0.34mg/kg/day; infants < 12 months
of age may require doses at or near the high end of this range;
consistent anticoagulation may be difficult to maintain in
children < 5 years of age.
Storage: protect from light and store at room temperature.
12.2. Antiplatelates
Antiplatelet agents are medications that block the formation of blood
clots by preventing the clumping of platelets. This antiplatelet effect
is used to prevent blood clot formation inside arteries, particularly in
individuals who have atherosclerosis (narrowing of the blood vessels)
of their arteries, or are otherwise prone to develop blood clots in their
arteries.
681

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Acetylsalicylic Acid
Tablet, 75mg, 81mg, 100mg (enteric coated)
Indications: It is used for prophylaxis of platelet aggregation
and prevention of thrombosis.That is, it interferes with the
clotting process by inhibiting the action of an enzyme that is
involved in the production of a chemical that causes platelets to
clump together.
Cautions, Drug interactions, Contraindications, Side effects
and storage: see section 4.1 under acetylsalicylic acid.
Dose and Administration: For most cardiovascular uses,
typical maintenance dosing of aspirin is 81 mg once daily.
Acute coronary syndrome (ST-segment elevation myocardial
infarction [STEMI], unstable angina (UA)/non-ST-segment
elevation myocardial infarction [NSTEMI]): Oral: Initial: 162325 mg given on presentation (patient should chew nonentericcoated aspirin especially if not taking before presentation); for
patients unable to take oral, may use rectal suppository (300
mg). Maintenance (secondary prevention): 75-162 mg once
daily indefinitely.
Note: When aspirin is used with ticagrelor, the recommended
maintenance dose of aspirin is 81 mg/day.

UA/NSTEMI: Concomitant antiplatelet therapy:If invasive

strategy chosen: Aspirin is recommended in combination with
either clopidogrel, ticagrelor, (or prasugrel if at the time of PCI)
or an I.V. GP IIb/IIIa inhibitor (if given before PCI, eptifibatide
and tirofiban are preferred agents).If noninvasive strategy
chosen: Aspirin is recommended in combination with
clopidogrel or ticagrelor.Analgesic and antipyretic:Oral: 325650 mg every 4-6 hours up to 4 g/day; Rectal: 300-600 mg
every 4-6 hours up to 4 g/day. Anti-inflammatory: Oral:
Initial: 2.4-3.6 g/day in divided doses; usual maintenance: 3.6682

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

5.4 g/day; monitor serum concentrations.Aortic

repair(unlabeled use): Oral: 50-100 mg once daily.

valve

Clopidogrel
Tablet, 75mg
Indications: Reduces rate of atherothrombotic events
(myocardial infarction, stroke, vascular deaths) in patients with
recent MI or stroke, or established peripheral arterial disease;
reduces rate of atherothrombotic events in patients with
unstable angina (UA) or non-ST-segment elevation MI
(NSTEMI) managed medically or with percutaneous coronary
intervention (PCI) (with or without stent) or CABG; reduces
rate of death and atherothrombotic events in patients with STsegment elevation MI (STEMI) managed medically.
Dose and Administration: Oral: 75mg daily. A loading dose of
300mg is conventionally prescribed for patients with acute
coronary syndromes or those having a stent placed. Some
authorities advise a loading dose of 600mg.Recent MI, recent
stroke, or established peripheral arterial disease
(PAD): Oral: 75 mg once daily. Note: The ACCF/AHA guidelines
for PAD recommend clopidogrel as an alternative to
aspirin.Coronary artery disease (CAD), established: Oral: 75
mg once daily. Note: Established CAD defined as patients 1-year
post ACS, with prior revascularization, coronary stenosis >50% by
angiogram, and/or evidence for cardiac ischemia on diagnostic
testing.

Secondary prevention of cardioembolic stroke (patient not

candidate for oral anticoagulation): Oral: 75 mg once daily (in
combination with aspirin).
Acute coronary syndrome (ACS): Oral:Unstable angina, nonST-segment
elevation
myocardial
infarction
(UA/NSTEMI): Initial: 300 mg loading dose, followed by 75
683

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

mg once daily for up to 12 months (in combination with aspirin

indefinitely) (Jneid, 2012). The American College of Chest
Physicians recommends combination aspirin dose of 75-100 mg.
ST-segment elevation myocardial infarction (STEMI): 75 mg
once daily (in combination with aspirin 162-325 mg initially
followed by 81-162 mg/day or 75-100 mg/day).
Percutaneous coronary intervention (PCI) for acute coronary
syndrome (eg, UA/NSTEMI or STEMI): Loading dose: 600 mg
given as early as possible before or at the time of PCI, followed
by 75 mg once daily (in combination with aspirin 81 mg/day).
12.3. Hemostatic Agents
Absorbable Gelatin Sponge
Indication: as a haemostatic agent by providing a physical
meshwork within which clotting can occur.
Side effects: increase incidence of infection, compression of
surrounding tissue due to fluid absorption, granuloma
formation, and fibrosis. Generally, gelatin sponges cause little
tissue reaction and can be applied to bone, dura, and pleural
tissue.
Dose and Administrations: gelatin sponge can be applied dry
or soaked in saline or thrombin solutions when applied to skin
wounds the gelatin liquifies within 2 to 5 days; when implanted
into tissues it is absorbed with in 4 to 6 weeks.
Aminocaproic Acid
Injection, 250 mg/ml in 20ml ampoule
For full profile; see section 9 under aminocaproic acid.
Fibrinogen
Powder, 1g in vial
Indications: for the control of bleeding and prophylactic
treatment of patients deficient in fibrinogen or for treatment of
684

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

haemorrhage
in
afibrinogenaemia.

congenital

hypofibrinogenaemia

or

Note: Fibrinogen is prepared from human plasma

Cautions: risk of thrombosis, Pregnancy, Breast-feeding

Side-effects: Rarely fever, allergic reactions; very rarely
thromboembolic events (including myocardial infarction and
pulmonary embolism)
Phytomenadione (vitamin K1)
Injection, 1mg/0.5ml, 10mg/ml in 1 ml ampoule.
Indications: for the treatment of hemorrhage due to Vitamin k
deficiency.
Cautions: severe liver diseases.
Drug interactions: antacids (aluminium hydroxide), wide
spectrum antibiotics, quinidine, quinine, high doses of
salicylates, antibacterials like sulfonamides, cumarine or
indandione - derivative anticoagulants (such as dicumarol), and
other hemolytics.
Side effects: flushing of face, redness, pain, or swelling at place
of injection, unusual taste.
Dose and Administration:Subcutaneously or intramuscularly.
It should not be given repeatedly to patient with severe liver
diseases, once the response to the initial dose is
unsatisfactory.Adult:I.M. or S.C., 2.5 to 10mg (up to 25mg),
may be repeated after 6-8 hours if necessary. Child:Infants IM or SC, 1-2 mg; ChildIM or SC, 5-10mg.
Storage: at room temperature. Protect from light and freezing.
12.4. Antianemic Agents
Iron-deficiency anaemia: Anaemia is usually understood to
mean a lowering of haemoglobin concentration, red cell count,
or packed cell volume to below 'normal' values but the criteria
685

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

for normality are somewhat arbitrary and difficult to establish.

Before initiating treatment for anaemia it is essential to
determine which type is present. Iron salt may be harmful and
result in iron over load if given alone to patients with anemias
other than those due to iron deficiency.
Treatment is only justified in the presence of a
demonstrable iron - deficiency state. Before starting treatment,
it is important to exclude any serious underlining cause of the
anaemia (e.g gastric erosion, colonic carcinoma). Prophylaxis is
justifiable in pregnancy only for women who have additional
risk factors for iron deficiency (e.g poor diet), menorrhagia,
after subtotal or total gastrectomy, and in the management of
low birth - weight infants such as premature babies, twins, and
in infants delivered by caesarean section.
Ferrous salt: many iron compounds have been used for
this purpose, but do not offer any real advantage over the
simple ferrous fumarate, gluconate, or sulphate salts.
The usual adult dose is sufficient of these salts to supply
about 100 to 200mg of elemental iron daily. The approximate
elemental iron content of various ferrous salts is ferrous
fumarate 200mg (65mg iron), ferrous gluconate 300mg
(35mgiron), ferrous succinate 100mg (35mg iron), ferrous
sulfate 300mg (60mg iron), and dried ferrous sulfate 200mg
(65mg iron)
Iron intake in the evening has been reported to improve
its absorption.
Iron intake with meals may reduce
bioavailability but improve tolerability and adherence.
If adverse effects arise with one salt, dosage can be
reduced or a change made to an alternative iron salt.
The hemoglobin concentration should rise by about 100 200mg/100ml per day. After the haemoglobin has risen to
normal, treatment should be continued for a further three
686

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

months in an attempt to replenish the iron stores.

Gastrointestinal irritation may occur. Nausea and epigastric
pain are dose related. Oral iron may exacerbate diarrhoea in
patients with inflammatory bowel disease but care is also
needed in patients with intestinal strictures and diverticulae.
Iron as iron dextran or iron sorbitol should be given parenterally
only if the patient has severe gastrointestinal adverse effects
with oral preparations, continuing severe blood loss or
malabsorption. Parenteral iron may cause more harm than
benefit. Provided that the oral iron preparation is taken reliably
and is absorbed then the haemoglobin response is not
significantly faster with the parenteral route than the oral route.
Megaloblastic anaemias; these are due to lack of either
vitamin B12 (hydroxycobalamin) or folate or both. The clinical
features of folate deficient megaloblastic anaemia are similar to
those of vitamin B12 deficiency except the accompanying severe
neuropathy does not occur; it is essential to determine which
deficiency is present and underlying cause is established in
every case.
Preparations containing ferrous salt and folic acid are
used for the prevention of megaloblastic anaemia in pregnancy.
The low doses of folic acid in these preparations are inadequate
for the treatment of megaloblastic anaemias.
Calcium Folinate (Leucovorin calcium)
Injection, 3 mg/ml, 7.5mg/ml, 10mg/ml
Tablet, 15mgasFolinic acid
Indications: treatment of megaloblastic anemias when folate is
deficient as in infancy, sprue, pregnancy, and nutritional
deficiency when oral folate therapy is not possible.

687

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Cautions, Contraindications, Drug interactions, Side effects

and Storage; see section 11; under calcium folinate and folinic
acid.
Dose and Administration:Adult and Child: Folate-deficient
megaloblastic anemia: IM: 1 mg/day
Megaloblastic anemia secondary to congenital deficiency of
dihydrofolate reductase: IM: 3-6 mg/day.
Cyanocobalamin (Vitamin B12)
Injection, 100 mcg/ml, 1000 mcg/ml in 1 ml ampoule.
Indications: Treatment of pernicious anemia; vitamin
B12 deficiency due to dietary deficiencies or malabsorption
diseases, inadequate secretion of intrinsic factor, and inadequate
utilization of B12 (eg, during neoplastic treatment); increased
B12requirements due to pregnancy, thyrotoxicosis, hemorrhage,
malignancy, liver or kidney disease
Cautions: I.M route used to treat pernicious anemia; Vitamin
B12 deficiency for > 3 months results in irreversible
degenerative CNS lesions.
Drug interactions: ethanol, chloramphenicol, cholestyramine,
cimetidine, colchicine, neomycin, potassium.
Contraindications:Hypersensitivity to cyanocobalamin, cobalt,
or any component of the formulation.
Side effects: headache, anxiety, dizziness, pain, nervousness,
hypoesthesia, itching, sore throat, nausea, vomiting, dyspepsia,
diarrhea, weakness, back pain, arthritis, myalgia, paresthesia,
abnormal gait, dyspnea, rhinitis.
Dose and Administration:Anemias: IM or deep SC:
Pernicious anemia, congenital:Adult: 100 mcg/day for 6 - 7
days; if improvement, administer same dose on alternate days
for 7 doses; then every 3 - 4 days for 2 - 3 weeks; once
hematologic values have returned to normal, maintenance
688

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

dosage: 100 mcg/month.Child: 30 - 50 mcg/day for 2 or more

weeks (to a total dose of 1000 - 5000 mcg), Then follow with
100 mcg/month as maintenance dosage.Vitamin B12
deficiency:Adult: Initial: 30 mcg/day for 5 - 10 days;
maintenance: 100 - 200 mcg/month.Child:Neurologic signs:
100 mcg/day for 10 - 15 days (total dose of 1-1.5 mg), then
once or twice weekly for several months.Hematologic signs: 10
- 50 mcg/day for 5 - 10 days, followed by 100 - 250 mcg/dose
every 2 - 4 weeks.
Storage: store at room temperature, protect from light.
Epoetin alfa and beta
Injection, epoetin alfa, 2000 units/ml
Epoetin alfa prefilled syringe, 1000 units/ml, 2000 units/ml,
3000 units/ml, 4000 units/ml, 10,000 units/ml.
Epoetin beta powder for injection, 500 units/vial; 1000
units/vial; 2000 units/vial; 3000 units/vial; 4000 units/vial,
5000 units/vial; 6000 units/vial, 10,000 units/vial.
Epoetin beta powder for injection (multi dose injection), 50,000
units/vial, 100, 000 units/vial
Indications: Treatment of anemia due to concurrent
myelosuppressive chemotherapy in patients with cancer
(nonmyeloid malignancies) receiving chemotherapy (palliative
intent) for a planned minimum of 2 additional months of
chemotherapy; treatment of anemia due to chronic kidney
disease (including patients on dialysis and not on dialysis) to
decrease the need for RBC transfusion; treatment of anemia
associated with HIV (zidovudine) therapy when endogenous
erythropoietin levels 500 mUnits/mL; reduction of allogeneic
RBC transfusion for elective, noncardiac, nonvascular surgery
when perioperative hemoglobin is >10 to 13 g/dL and there is
a high risk for blood loss
689

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Cautions: hypertension, ischaemie vascular disease, seizures,

myeloid malignancy, untreated iron deficiency.
Contraindications: Hypersensitivity to epoetin or any
component of the formulation; uncontrolled hypertension; pure
red cell aplasia (due to epoetin or other epoetin protein drugs);
multidose vials contain benzyl alcohol and are contraindicated
in neonates, infants, pregnant women, and nursing women
Side effects: clotting of vascular access and dialysers;
hypertension, headache, seizures, flu-like symptoms and skin
rash.
Dose and Administration: Anemia associated with chronic
kidney disease: Individualize dosing and use the lowest dose
necessary to reduce the need for RBC transfusions.Chronic
kidney disease patients ON dialysis (I.V. route is preferred for
hemodialysis patients; initiate treatment when hemoglobin is
<10 g/dL; reduce dose or interrupt treatment if hemoglobin
approaches or exceeds 11 g/dL): I.V., SubQ: Initial dose: 50100 units/kg 3 times/week.Chronic kidney disease
patients NOT on dialysis (consider initiating treatment when
hemoglobin is <10 g/dL; use only if rate of hemoglobin decline
would likely result in RBC transfusion and desire is to reduce
risk of alloimmunization or other RBC transfusion-related risks;
reduce dose or interrupt treatment if hemoglobin exceeds 10
g/dL): I.V., SubQ: Initial dose: 50-100 units/kg 3 times/week.
Dosage adjustments for chronic kidney disease patients (either
on dialysis or not on dialysis):If hemoglobin does not increase
by >1 g/dL after 4 weeks: Increase dose by 25%; do not
increase the dose more frequently than once every 4 weeks.
If hemoglobin increases >1 g/dL in any 2-week period: Reduce
dose by 25%; dose reductions can occur more frequently than
once every 4 weeks; avoid frequent dosage adjustments.
690

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Inadequate or lack of response over a 12-week escalation

period: Further increases are unlikely to improve response and
may increase risks; use the minimum effective dose that will
maintain a Hgb level sufficient to avoid RBC transfusions and
evaluate patient for other causes of anemia. Discontinue therapy
if responsiveness does not improve.
Anemia due to chemotherapy in cancer patients: Initiate
treatment only if hemoglobin <10 g/dL and anticipated duration
of myelosuppressive chemotherapy is 2 months. Titrate
dosage to use the minimum effective dose that will maintain a
hemoglobin level sufficient to avoid red blood cell transfusions.
Discontinue erythropoietin
following completion
of
chemotherapy. SubQ: Initial dose: 150 units/kg 3 times/week or
40,000 units once weekly until completion of chemotherapy.
Dosage adjustments:If hemoglobin does not increase by >1
g/dL and remains below 10 g/dL after initial 4 weeks: Increase
to 300 units/kg 3 times/week or 60,000 units weekly;
discontinue after 8 weeks of treatment if RBC transfusions are
still required or there is no hemoglobin response.
If hemoglobin exceeds a level needed to avoid red blood cell
transfusion: Withhold dose; resume treatment with a 25% dose
reduction when hemoglobin approaches a level where
transfusions may be required.
If hemoglobin increases >1 g/dL in any 2-week
period or hemoglobin reaches a level sufficient to avoid red
blood cell transfusion: Reduce dose by 25%.
Anemia due to zidovudine in HIV-infected patients: Titrate
dosage to use the minimum effective dose that will maintain a
hemoglobin level sufficient to avoid red blood cell transfusions.
Hemoglobin levels should not exceed 12 g/dL.
Serum erythropoietin levels 500 mUnits/mL and zidovudine
doses 4200 mg/week): I.V., SubQ: Initial: 100 units/kg 3
691

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

times/week; if hemoglobin does not increase after 8 weeks,

increase dose by ~50-100 units/kg at 4-8 week intervals until
hemoglobin reaches a level sufficient to avoid RBC transfusion;
maximum dose: 300 units/kg. Withhold dose if hemoglobin
exceeds 12 g/dL, may resume treatment with a 25% dose
reduction once hemoglobin <11 g/dL. Discontinue if
hemoglobin increase is not achieved with 300 units/kg for 8
weeks.
Surgery patients (perioperative hemoglobin should be >10
g/dL and 13 g/dL; DVT prophylactic anticoagulation is
recommended): SubQ: Initial dose:
300 units/kg/day beginning 10 days before surgery, on the day
of surgery, and for 4 days after surgery or
600 units/kg once weekly for 4 doses, given 21-, 14-, and 7
days before surgery, and on the day of surgery
Symptomatic anemia associated with myelodysplastic
syndrome (unlabeled use): SubQ: 40,000-60,000 units 1-3
times/week (NCCN MDS guidelines v.2.2011)
Storage: store in refrigerator and should not be frozen.
Ferrous Salt
Capsule
Drop
Tablet (enteric coated)
Indications: Prevention and treatment of iron-deficiency
anemias
Cautions: hepatitis or hepatic function impairment, kidney
diseases, intestinal tract inflammatory conditions (e.g. peptic
ulcer, or colitis), or alcoholism. Caution patients about toxic
effects of accidental overdose. Especially in children.
Drug interactions: acetohydroxamic acid, dimercaprol,
etidronate (avoid using iron supplements with in two hours of
692

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

etidronate), fluoroquinolones (it should be taken at least two

hours before or two hours after iron supplements), tetracycline,
chloramphenicol, antacids, calcium (carbonate or phosphate).
Side effects: abdominal discomfort, vomiting, diarrhoea or dark
stools may occur commonly, large doses may have irritant and
corrosive effects of the gastrointestinal mucosa and necrosis
and perforation may occur. Iron drops may temporarily stain the
teeth.
Dose and Administration: Orally. Iron drops may be placed
well back on the tongue followed with water. It is best given on
an empty stomach but may be given with or after meals to
lessen gastrointestinal irritation. Treatment may be continued
for 3-6months, and not longer except in patients with continued
bleeding, or repeated pregnancies.Prophylactic: Adult: 300mg
once daily.Child: 5mg/kg of body weight once daily or, 150
300mg once daily.
Treatment:Adult: 300mg every 12 hours, gradually increased
up to 300mg every 6-8 hours daily as needed and
tolerated.Child: 10mg/kg of body weight every 8 hours daily.
Or 6-12 years 300mg every 12 hours daily.1-5 years -120mg
every 8 hours daily. Under 1year 60mg every 8 hours daily.
Storage: At room temperature, in a tight container. Protect
from light and freezing.
Ferrous salt + Folic Acid*
Capsule
Tablet
Indications: Prevention of iron and folic acid deficiencies in
pregnancy.

*Any Ferrous salt containing elemental Iron of accepted therapeutic value

693

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Cautions: low doses of folic acid in the combination

preparations above are inadequate for treatment of
megaloblastic anaemia;
Side effects: see ferrous salts
Dose and Administration:Prevention of iron and folic acid
deficiencies in pregnancy: Oral:Adult the equivalent of about
100mg elemental iron with 350 - 400 micrograms folic acid
daily throughout pregnancy.
Fluoxymesterone
Tablet, 2mg, 10mg
Indications: Replacement of endogenous testicular hormone;
in females, palliative treatment of breast cancer.
Caution: liver disease, heart disease, kidney disease, allergies,
enlarged prostate. Stimulation of erythropoiesis, angioneurotic
edema.
Contraindications: Males with carcinoma of the breast or the
prostate (known or suspected); women who are or may become
pregnant. Pregnancy or breast-feeding.
Side effects:headache, indigestion, oily skin, acne, anxiety, and
sleeplessness. Males may experience breast tenderness, change
in sex drive, impotence or problems with erections. Females
may experience deepening of the voice, change in sex drive,
irregular menstruation or enlargement of the clitoris. Vomiting,
swelling of the ankles or feet, unusual weight gains, yellowing
of the eyes/skin.
Dose and Administration: Hypogonadism (Males): Oral: 5-20
mg/day. Delayed puberty (Males): Oral: 2.5-20 mg/day for 4-6
months. Inoperable breast carcinoma (Females): Oral: 10-40
mg/day in divided doses for 1-3 months
Storage: store at room temperature
694

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Folinic acid, see calcium folinate too

Tablet, 15 mg
Indications:
1. Folinic acid is used to counteract the folate-antagonist action
of methotrexate and thus speed recovery from methotrexateinduced mucositis or myelosuppression (folinic acid
rescue).
2. Folinic acid is also used in the management of methotrexate
overdose, together with other measures to maintain fluid and
electrolyte balance, and to manage possible renal failure.
3. Treatment of megaloblastic anemia when folic acid
deficiency is present (this mainly occurs in infants, during
pregnancy, in malabsorption syndromes, liver diseases,
sprue and malnutrition). When treating megaloblastic
anaemias, the results are comparable to those obtained with
folic acid. Following an overdose of folic acid antagonists,
Calcium folinate performs considerably better than folic
acid because the folic acid antagonists inhibit the
metabolism of folic acid into folinic acid, but have no effect
on the folinic acid.
4. Adjunct to fluorouracil in colorectal cancer. When folinic
acid and fluorouracil are used together in metastatic
colorectal cancer the response-rate improves compared to
that with fluorouracil alone. In combination with fluoruracil
to treat cancers such as; colon and rectal, head and neck,
esophageal, and other cancers of the gastrointestinal tract.
5. Folinic acid does not counteract the antibacterial activity of
folate antagonists such as trimethoprim.where folates
provides differential rescue of the host but not the parasite.
Caution:avoid simultaneous administration with methotrexate;
not indicated for pernicious anaemia or other megaloblastic
anaemias caused by vitamin B12 deficiency. Haematological
695

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

remissions may occur, while the neurological manifestations

remain progressive. Simultaneous therapy with a folic acid
antagonist and Calcium Leucovorin is not recommended
because the effect of the folic acid antagonist is either reduced
or completely inhibited
Contraindications:it is improper therapy for pernicious
anaemia and other megaloblastic anaemias secondary to the lack
of Vitamin B12. If used in these conditions, haematological
remission may occur, but neurological manifestations are likely
to progress.Intrathecal injection; not known to be harmful
during pregancy, benefit outweighs risk; breast-feeding:
presence in breast milk during breast feeding unknown but
benefit outweighs risk.
Drug Interactions:Folic acid in large amounts may folates
possibly reduce plasma concentration of andcounteract the
antiepileptic effect of phenobarbital, phenytoin and primidone,
and increase the frequency of seizures. High oral, intravenous
or intramuscular doses may reduce the efficacy of intrathecally
administered methotrexate. Calcium folinate may enhance the
toxicity of fluorouracil.Raltitrexed (is chemically similar to
folic acid and is in the class of chemotherapy drugs called
folate antimetabolites) avoidance concomitant administration
with folates advised.
Side effects:rarely pyrexia after parenteral use; insomnia,
agitation, and depression after high doses. Allergic
sensitisation, including anaphylactoid reactions and urticarial.
Nausea and vomiting with very high. Seizures and/or syncope
have been reported rarely in cancer patients.
Dose and Administration:Calcium folinate may be given
orally or parenterally by intravenous infusion or by
intramuscular injection but should not be administered
696

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

intrathecally.Suspected methotrexate overdosage (Rescue

therapy following methotrexate over dose), by intravenous
injection or by intravenous infusion (at a maximum rate of 160
mg/minute), initial dose equal to or exceeding dose of
methotrexate.It is given orally or parenterally to overcome the
toxic effects of methotrexate or other DHF reductase
inhibitors.Prevention of methotrexate-induced adverse effects,
usually started 12 to 24 hours after start of methotrexate
infusion; by intramuscular injection or by intravenous injection
or by intravenous infusion, 15 mg, repeated every 6 hours for 24
hours (may be continued by mouth).Metabolic disorders leading
to folate deficiency, by mouth or by intravenous infusion: Child
up to 18 years 15 mg once daily; larger doses may be required
in older children. Prevention of megaloblastic anaemia
associated with pyrimethamine and sulfadiazine treatment of
congenital toxoplasmosis, by mouth: Neonate 5 mg 3 times a
week (increased up to 20 mg 3 times a week if neutropenic);
Child 1 month to 1 year 10 mg 3 times a week. Treatment of
Folate Deficiency(Megaloblastic anaemia), by mouth: Child up
to 12 years 250 microgram/kg once daily; Child 1218 years 5
to 15 mg once daily. The length of time therapy must be
continued depends on the underlying disease. It is customary to
continue therapy for about 4 months, when all folate-deficient
red cells will have been eliminated and replaced by new folatereplete populations. Adjunct to fluorouracil incolorectal cancer,
consult product literature.
Note: Before large doses of folic acid are given, cobalamin deficiency
must be excluded and, if present, corrected, otherwise cobalamin
neuropathy may develop, despite a response of the anemia of
cobalamin deficiency to folate therapy.
Note 2: Particular care should be taken when treating elderly or
debilitated colorectal cancer patients with Calcium Leucovorin/5697

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

fluorouracil, as these patients may be at increased risk of severe

toxicity, particularly severe gastrointestinal toxicity.
Note 3: Excessive amounts of calcium folinate may nullify the
chemotherapeutic effect of folic acid antagonists.

Storage: room temperature, 15-25oC

Iron Complex
Injection, 50mg/ml in 2ml ampoule (Dextran, Sorbitol) Iron
dextran injection is a sterile colloidal solution of ferric
hydroxide and dextrans of weight average molecular weight
between 5000 and 7000 or a complex of ferric hydroxide with
dextran containing 5% (50 mg/mL) of iron.Iron sorbitol
injection is a sterile Colloidal solution of a complex of iron,
Sorbitol and citric acid, stabilized with dextrin and Sorbitol.
Indications: used for iron-deficiency anaemia
Cautions: oral iron not to be given until 5 days after last
injection. Anaphylactic reactions can occur with parenteral iron
and a test dose is recommended before each dose; the patient
should be carefully observed for 60 minutes after the first test
dose and for 15 minutes after subsequent test doses (subsequent
test doses not necessary for intramuscular administration).
Facilities for cardiopulmonary resuscitation must be available;
risk of allergic reactions increased in immune or inflammatory
conditions.
Contraindications: history of allergic disorders including
asthma, and eczema; infection; active rheumatoid arthritis,
Hepatic impairment (avoid in severe impairment), Renal
impairment (avoid in acute renal failure), Pregnancy (avoid in
first trimester); child under 14 years
Side effects:less commonly nausea, vomiting, abdominal pain,
flushing, dyspnoea, anaphylactic reactions (see Anaphylaxis
above), numbness, cramps, blurred vision, pruritus, and rash;
rarely diarrhoea, chest pain, hypotension, angioedema,
698

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

arrhythmias, tachycardia, dizziness, restlessness, fatigue,

seizures, tremor, impaired consciousness, myalgia, arthralgia,
sweating, and injection-site reactions; very rarely hypertension,
palpitation, headache, paraesthesia, haemolysis, and transient
deafness
Dose and Administration: By deep intramuscular injection
into the gluteal muscle or by slow intravenous injection or by
intravenous infusion, calculated according to body-weight and
iron deficit, consult product literature and.
Iron gluconate + Manganese gluconate + copper gluconate
Oral solution, 5mg+1.33mg+0.77mg
Indications: For treatment of anemia related to pregnancy
during the post partum period or lactation and in association
with parasitic infection.
Iron sucrose
Injection, 100mg/5ml
Indication: Treatment of iron-deficiency anemia in chronic
kidney disease (CKD), including nondialysis-dependent and
dialysis-dependent patients
Contraindication: Hypersensitivity to iron sucrose or any
component of the formulation
Dose and Administration:Iron-deficiency anemia in
CKD:I.V.:Hemodialysis-dependent
patient:
100
mg
administered during consecutive dialysis sessions to a
cumulative total dose of 1000 mg (10 doses); may repeat
treatment if clinically indicated.Peritoneal dialysis-dependent
patient: Two infusions of 300 mg administered 14 days apart,
followed by a single 400 mg infusion 14 days later (total
cumulative dose of 1000 mg in 3 divided doses); may repeat
treatment if clinically indicated.Nondialysis-dependent patient:
200 mg administered on 5 different occasions within a 14-day
699

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

period (total cumulative dose: 1000 mg in 14-day period); may

repeat treatment if clinically indicated. Note: Dosage has also
been administered as 2 infusions of 500 mg on day 1and day 14.
Cancer-/chemotherapy-associated anemia (unlabeled use):I.V.:
200 mg I.V. infusion (maximum: 300 mg/infusion) over 1 hour
every 2-3 weeks or 200 mg slow I.V. injection over 2-5 minutes
every 1-4 weeks. Total cumulative dose: 1000 mg. Test doses
(25 mg slow I.V. push) are recommended in patients with a
history of hypersensitivity to any I.V. iron preparation (eg,
dextran) or those with other drug allergies.
Storage: Store intact vials at controlled room temperature of
20C to 25C. Do not freeze. Iron sucrose is stable for 7 days at
room temperature or under refrigeration when undiluted in a
plastic syringe or following dilution in normal saline in a plastic
syringe (2-10 mg/mL) or I.V. bag (1-2 mg/mL).
Oxymetholone
Tablet, 2.5mg, 5mg, and 10mg
Indication: Treatment of anemias caused by deficient red cell
production.
Caution: liver impairment.
Contraindication: Hypersensitivity to oxymetholone or any
component of the formulation; breast cancer in men; breast
cancer in women with hypercalcemia; prostate cancer; severe
hepatic dysfunction; nephrosis or nephrotic phase of nephritis;
pregnancy or use in women who may become pregnant
Side effects: liver disturbances and jaundice.
Dose and Administration: Oral: 1-5 mg/kg/day once daily;
usual effective dose: 1-2 mg/kg/day; give for a minimum trial of
3-6 months because response may be delayed
Storage: store at room temperature.
700

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

12.5. Blood Substitutes and Plasma Expanders

Dextrans (Dextran 70 and Dextran 40) and polygeline
are m acromolecular substances which are metabolized slowly;
they may be used at the outset to expand and maintain blood
volume in shock arising from conditions such as burns or
septicemia. Plasma substitutes may be used as an immediate
short - term measure to treat haemorrhage until blood is
available.
They are rarely needed when shock is due to sodium and
water depletion because, in these circumstances, the shock
responds to water and electrolyte repletion.
Plasma substitutes should not be used to maintain
plasma volume in conditions such as burns or peritonitis where
there is loss of plasma protein, water and electrolytes over
periods of several days or weeks. In these situations, plasma or
plasma protein fractions containing large amounts of albumin
should be given.
Dextran 70 by intravenous infusion is used
predominantly for volume expansion. Dextran 40 intravenous
infusion is used in an attempt to improve peripheral blood flow
in ischaemic disease of the limbs. Dextrans 40 and 70 have
also been used in the prophylaxis of thromboembolism but are
now rarely used for this purpose.
Dextrans may interfere with blood group cross-matching or
biochemical measurements and these should be carried out
before infusion is begun.
Cautions: plasma substitutes should be used with caution in
patients with cardiac disease or renal impairment; urine output
should be monitored. Care should be taken to avoid haematocrit
concentration from falling below 25 - 30% and the patient
should be monitored for hypersensitivity reactions.
701

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Side effects: Hypersensitivity reactions may occur including,

rarely, severe anaphylactic reaction. Transient increase in
bleeding time may occur.
Albumin, Salt-free
Solution, 20 % in 100 ml
Indications: Plasma volume expansion and maintenance of
cardiac output in the treatment of certain types of shock or
impending shock; may be useful for burn patients, ARDS, and
cardiopulmonary bypass; other uses considered by some
investigators (but not proven) are retroperitoneal surgery,
peritonitis, and ascites; unless the condition responsible for
hypoproteinemia can be corrected, albumin can provide only
symptomatic relief or supportive treatment
Cautions: hepatic or renal failure.
Drug interactions: ACE inhibitors.
Contraindications: Hypersensitivity to albumin or any
component of the formulation; patients with severe anemia or
cardiac failure.
Side effects: edema, hyper/hypotension, hypervolemia,
tachycardia, chills, fever, headache, pruritus, rash, urticaria,
nausea, vomiting, bronchospasm, pulmonary edema,
anaphylaxis.
Dose and Administration: IV:Adult: Note: Use 5% solution in
hypovolemic patients or intravascularly-depleted patients.
Use 25% solution in patients in whom fluid and sodium intake is
restricted. Usual dose: 25 g; initial dose may be repeated in 15-30
minutes if response is inadequate; no more than 250 g should be
administered within 48 hours.Hypovolemia: 5% albumin: 0.5-1

g/kg/dose; repeat as needed. Note: May be considered after

inadequate response to crystalloid therapy and when nonprotein
colloids are contraindicated. The volume administered and the
speed of infusion should be adapted to individual response.
702

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Large-volume paracentesis (>5 L) (unlabeled use): 25%

albumin: 5-8 g for every liter removed (Garcia-Compen, 1993;
Moore, 2003) or50 g total for paracentesis >5 L (ATS,
2004). Note: Administer soon after the procedure to avoid
postprocedural complications (eg, hypovolemia, hyponatremia,
renal impairment).
Spontaneous bacterial peritonitis (SBP) in patients with
cirrhosis (unlabeled use): 25% albumin: Initial: 1.5 g/kg,
followed by 1 g/kg on day 3 (in conjunction with appropriate
antimicrobial therapy) (ATS, 2004; Sort, 1999). Note: Clinical
trial employed albumin 20%; however, the difference in
concentration compared with 25% albumin is deemed to be
clinically inconsequential.
Child:Hypovolemia: I.V.: 0.5-1 g/kg/dose (10-20 mL/kg/dose
of albumin 5%); maximum dose: 6 g/kg/day.
Storage: store at a temperature 30oC; do not freeze.
Dextran (MW 40, 000)
Solution, 10% w/v in 5% Dextrose; 500ml
Indications: Blood volume expander used in treatment of
shock or impending shock when blood or blood products are
not available; also used as a priming fluid in pump oxygenators
during cardiopulmonary bypass and for prophylaxis of venous
thrombosis and pulmonary embolism in surgical procedures
associated with a high risk of thromboembolic complications
Cautions: see notes above; can interfere with some laboratory
tests (see also above); correct dehydration beforehand, give
adequate fluids during therapy and, where possible, monitor
central venous pressure; pregnancy.
Contraindications: Hypersensitivity to dextran or any
component of the formulation; marked hemostatic defects (eg,
thrombocytopenia, hypofibrinogenemia) of all types including
703

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

those caused by medications (eg, heparin, warfarin); marked

cardiac decompensation; renal disease with severe oliguria or
anuria
Side effects: see notes above
Dose and Administrations:Volume expansion/shock: I.V.:
Dextran 40: Infuse 500-1000 mL (~10 mL/kg) as rapidly as
possible (maximum: 20 mL/kg/day for first 24 hours; 10
mL/kg/day thereafter); therapy should not be continued beyond
5 days.
Pump prime: Dextran40: varies with the volume of the pump
oxygenator; generally, the solution is added in a dose of 10-20
mL/kg (or 1-2 g/kg); usual maximum total dose: 20 mL/kg (or 2
g/kg).
Postoperative prophylaxis of venous thrombosis/pulmonary
embolism (Dextran 40): Begin during surgical procedure and
give 500-1000 mL (~10 mL/kg); an additional 50 g (500 mL)
should be administered every 2-3 days during the period of risk
(up to 2 weeks postoperatively); usual maximum infusion rate
for nonemergency use: 4 mL/minute
Dextran (MW 70,000)
Solution, 6% w/v in 5% dextrose; 500ml
Indications: Blood volume expander used in treatment of
shock or impending shock when blood or blood products are
not available; also used as a priming fluid in pump oxygenators
during cardiopulmonary bypass and for prophylaxis of venous
thrombosis and pulmonary embolism in surgical procedures
associated with a high risk of thromboembolic complications
Cautions: see notes above; can interfere with some laboratory
tests (see also above); where possible, monitor central venous
pressure; pregnancy.
704

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Contraindication: Hypersensitivity to dextran or any

component of the formulation; marked hemostatic defects (eg,
thrombocytopenia, hypofibrinogenemia) of all types including
those caused by medications (eg, heparin, warfarin); marked
cardiac decompensation; renal disease with severe oliguria or
anuria
Side effects: see notes above
Dose and Administrations: IV infusion: after moderate to
severe haemorrhage or in the shock phase of burn injury
(initially 48 hours), 500 - 1000ml rapidly initially followed by
500ml later if necessary (see also notes above); total dosage
should not exceed 20ml/kg during initial 24 hours: C total
dosage should be not exceed 20ml/kg.
Hydroxyethyl Starch
Large Volume Parenteral, 6%w/v of, 500ml
Indications: lood volume expander used in treatment of
hypovolemia; adjunct in leukapheresis to improve harvesting
and increase the yield of granulocytes by centrifugation.
Cautions: caution in patients with severe bleeding disorders,
cardiac disease, liver disease, or renal impairment; urine output
should be monitored. Care should be taken to avoid haematocrit
concentration from falling below 2530% and the patient
should be monitored for hypersensitivity reactions.
Contraindications: Hypersensitivity to hydroxyethyl starch or
any component of the formulation; renal failure with oliguria or
anuria (not related to hypovolemia); any fluid overload
condition (eg, pulmonary edema, congestive heart failure); preexisting coagulation or bleeding disorders
Side-effects: Hypersensitivity reactions may occur including,
rarely, severe anaphylactic reactions. Transient increase in
bleeding time may occur.
705

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Dose and Administration: intravenous infusion only; total

volume and rate of infusion are dependent on the clinical
situation and the individual patient; should be individualized
according to the duration and extent of hypovolemia &
administered in accordance with accepted clinical practices for
fluid and electrolyte management.The initial 10 - 20 ml is to be
infused slowly, keeping the patient under close observation
(due to possible anaphylactoid reactions).Intravenous infusion,
hetastarch (weight average molecular weight 450 000) 6% in
sodium chloride intravenous infusion 0.9%; Dose by
intravenous infusion, 5001000 mL; usual daily max. 1500 mL
(see notes above)
Children: The dosage in children should be adapted to the
individual patient colloid needs, taking into account the disease
state, as well as the hemodynamic and hydration status.
Storage: do not freeze
Isoplasma
Solution, 500 ml.
Indications: Used for plasma volume expansion in the
treatment of certain types of shock, including shock resulting
from burns, crushing injuries, abdominal emergencies, or any
other cause where there is a predominant loss of plasma fluids
and not RBCs.
Cautions and Sideeffects: See note above
Plasma Antihaemophillic (Human)
Solution, 50 ml, 100 ml, 250 ml
Indications: management of hemophilia A for patients in
whom a deficiency in factor VIII has been demonstrated;
treatment of spontaneous bleeding in patients with severe von
Willebrand disease and in mild and moderate von Willebrand
706

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

disease where desmopressin is known or suspected to be

inadequate.
Cautions: hypersensitivity to any component of the
formulation.
Side effects: acute hemolytic anemia, allergic reactions, blurred
vision, chest tightness, chills, edema, fever, headache,
hyperfibrinogenemia, increased bleeding tendency, itching,
lethargy, nausea, tachycardia.
Dose and Administration: Adult and Child: I.V:individualize
dosage based on coagulation studies performed prior to
treatment and at regular intervals during treatment: 1AHF unit
is the activity present in 1 ml of normal pooled human plasma;
dosage shouldbe adjusted to actual vial size currently stocked in
the pharmacy.
Storage: store under refrigeration, and avoid freezing
Polygeline + Na+ + K+ + Ca++ + ClSolution, 35g + 145 mmol + 5.1 mmol + 6.25 mmol +
145mmol/1000ml
Indications: correction of low blood volume
Cautions: blood samples for cross-matching should be taken
before infusion; haemorrhagic diasthesis; congestive heart
failure, renal impairment, hypertension, oesophageal varices.
Contraindications: severe congestive heart failure; renal
failure.
Side effects: urticarial and other hypersensitivity reactions rarely severe anaphylactoid reactions.
Dose and Administrations:Correction of low blood volume:IV
infusion: initially 500 - 1000ml of a 3.5% solution.

707

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

13. MEDICINES for CORRECTING WATER,

ELECTROLYTE and ACID-BASEDISTU RBANCES
Electrolytes are used to correct disturbances in fluid and
electrolyte homoeostasis or acid-base balance and to reestablish osmotic equilibrium of specific ions.
13.1. Oral Electrolytes
Ammonium Chloride
Tablet, 500mg
Indications: Ammonium chloride may be used as a systemic
acidifying agent for the treatment of metabolic alkalosis or to
acidify the urine. Ammonium salts are no longer used as
diuretics, but are sometimes used to maintain an acid pH of
urine. This may be useful as an adjunct in treating urinary tract
infections or for increasing urinary excretion of drugs after an
overdose.
Other conditions that have been treated with ammonium
chloride include hypochloremia with severe metabolic
alkalosis, Meniere's disease, and premenstrual syndrome.
Cautions: Ammonia toxicity may occur; observe constantly for
signs and symptoms of toxicity (pallor, sweating, retching,
irregular breathing, bradycardia, cardiac arrhythmias, local and
general twitching, tonic convulsions and coma)
Side effects: ammonium salts are irritant to the gastric mucosa
and may produce nausea and vomiting.
Dose and Administration: The usual dose is one gram three
times daily for up to 6 days. To maintain an acidic pH of the
urine, ammonium chloride 1 to 2 grams is administered every 4
to 6 hours for no longer than six days. For forced acid diuresis
to aid in the excretion of basic drugs, such as amphetamines, 4
grams every two hours may be given.
708

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Storage: store in airtight containers.

Calcium
Tablet (ionizable), 500 mg, 1g (eff.).
Indications: used as calcium supplementation in pregnant and
lactating women and in growing children, latent tetany, rickets
and osteomalacia (additional to specific therapy). Prevention of
pre-and postmenopausal bone demineralisation, osteoporosis, as
supportive treatment in allergic conditions
Cautions: calcium salts should be used cautiously if at all, in
patients with sarcoidosis, renal or cardiac disease, and in
patients receiving cardiac glycosides.
Check urinary calcium excretion in patients with mild
hypercalciuria impaired renal function or a history of urinary
concrements; reduce dosage or discontinue therapy if necessary.
Avoid high doses of Vitamin D.
Drug interactions: oral tetracycline or fluoride (avoid
concomitant use within 3 hours); cardiac glycosides; calcium
channel blockers; phenytoin; gallium nitrate; Etidronate,
cellulose sodium phosphate, thiazide.
Contraindications:
hypersensitivity
to
the
drug,
hypercalcaemia, severe hypercalcium, severe renal failure,
sarcoidosis, and renal calculi.
Side effects: hypotension (dizziness), flushing and /or sensation
of warmth or heat, irregular heart beat. Nausea or vomiting,
gastrointestinal irritation & constipations, skin redness, rash,
pain, or burning at injection site, sweating.
Dose and Administration:Hypocalcaemia (prophylaxis):
Oral: amount based on normal daily-recommended intakes:

709

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Persons
Adolescent and adult males/females
Pregnant females and Breast-feeding
Birth to 3 years of age
4 to 10 years of age

Milligram
800 - 1200
1200
400 800
800

Hypocalcaemia (treatment):Treatment dose is individualized by

prescriber based on severity of deficiency.
Storage: store at room temperature in a tight container or
original foil packaging.
Calcium Folinate
Tablet, 5mg, 15mg, 25mg
Indications: Antidote for folic acid antagonists (methotrexate,
trimethoprim, pyrimethamine) and rescue therapy following
high-dose methotrexate; in combination with fluorouracil in the
treatment of colon cancer; treatment of megaloblastic anemias
when folate is deficient as in infancy, sprue, pregnancy, and
nutritional deficiency when oral folate therapy is not
possible.Adjunctive cofactor therapy in methanol toxicity;
prevention of pyrimethamine hematologic toxicity in HIVpositive patients.
Cautions, Contraindications, Drug interactions, Side effects
and Storage; see section 10.under calcium folinate.
Dose and Administration:Adult: Treatment of weak folic acid
antagonist overdosage (eg, trimethoprim, pyrimethamine): Oral:
5-15 mg/day. High-dose methotrexate-rescue dose: Initial: Oral,
I.M., I.V.: 15 mg (~10 mg/m2); start 24 hours after beginning
methotrexate infusion; continue every 6 hours for 10 doses,
until methotrexate level is <0.05 micromole/L. Adjust dose as
follows:Normal methotrexate elimination: Oral, I.M., I.V.: 15
mg every 6 hours.
710

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Delayed early methotrexate elimination: I.V.: 150 mg every 3

hours until methotrexate level is <1 micromole/L, then 15 mg
every 3 hours until methotrexate level is <0.05 micromole/L
Calcium Glubionate + Calcium Galacto gluconate
Syrup, 28.75 g+ 5.9 g/100ml
Indications, Cautions, Drug interactions, Contraindications;
see under calcium gluconate.
Calcium Gluconate
Syrup, 4gm/15ml
Tablet, 500mg
Indications: as a source of calcium ion for treating calcium
depletion occurring in conditions such as chronic
hypoparathyroidism, pseudo-hypoparathyroidism, osteomalcia,
rickets, chronic renal failure, and hypocalcaemia secondary to
the administration of anticonvulsant medications.It is also used
as a dietary supplemental therapy for persons who may not get
enough calcium in their regular diet.
Cautions: dehydration or electrolyte imbalance, diarrhoea,
chronic gastrointestinal malabsorption, history of renal
calciculi, chronic renal function impairment.
Drug interactions: calcitonin, calcium channel blocking agents
such as verapamil, calcium or magnesium containing
medications, estrogens, milk and milk products phenytoin, oral
tetracyclines, vitamin D.
Contraindications: Primary or secondary hypercalcemia,
hypercalciuria or calcium renal calculi, sarcoidosis.
Side effects: acute hypercalcemic syndrome (drowsiness,
continuing nausea, and vomiting, weakness), calcific renal
calculi.
711

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Dose and Administration:Adult: Antihypocalcemic or

Nutritional supplement:Oral: 8.8 - 16.5gm (800 - 1500 mg of
calcium ion) a day, in divided doses.Child: Antihypocalcemic:
Oral: 500-720mg (45-65mg of calcium ion) per kg of body
weight a day, in divided doses.
Storage: at room temperature in a well-closed container.
Calcium Lactate
Tablet, 300mg
Indications: as a source of calcium ion for treating calcium
depletion.
Cautions, Contraindication, Drug Interaction, Side effects;
see under calcium gluconate.
Dose and Administration:Adult:Adults, Females/Males:
recommended dietary allowance (RDA):19-50 years: 1000
mg/day 51 years, females: 1200 mg/day. 51-70 years, males:
1000 mg/day. Females: Pregnancy/Lactating: Requirements are
the same as in nonpregnant or nonlactating females
Child: 1-6 months: Adequate intake: 200 mg/day; 7-12 months:
Adequate intake: 260 mg/day; 1-3 years: RDA: 700 mg/day; 48 years: RDA: 1000 mg/day; 9-18 years: RDA: 1300 mg/day.
Note: Drink a full glass of water.

Storage: at room temperature in a tight container.

Magnesium Chloride
Tablet, 400mg, 800mg
Injection, 50ml/vial
Indications:correction and prevention of hypomagnesemia
Dose and Administration:Adult: 54-483 mg/day in divided
doses; refer to product labeling. The RDA of magnesium is
4.5mg/kg which is a total daily allowance of 350-400mg for
adult men and 280-300mg for adult women. During pregnancy
712

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

the RDA is 300mg and during lactation the RDA is 355mg.

Injection: I.V:Adult: 8-24mEq/day; Children: 2-10 mEq/day.
The usual recommended pediatric maintenance intake of
magnesium ranges from 0.2-0.6 mEq/kg/day. The dose of
magnesium may also be based on the caloric intake; on that
basis, 3-10mEq/day of magnesium is needed; maximum
maintainance dose: 8-16 mEq/day
Oral Rehydration Salts (ORS)
Powder, each sachet for 1litre contains, see table below
Indications: For the prevention and treatment of mild to
moderate dehydration, particularly dehydration from acute
diarrhea of any cause, in all age group.
Cautions andSide effects: See notes on section 1.6.
Note: Severe dehydration should be treated with intravenous fluids
(Lactated ringers injection).
Electroyte

Sodium chloride
Glucose
Anhydrous
Potassim Chloride
Trisodium Citrate
Dehydrate

Gram/Liter

2.6
13.5

Electrolyte
Sodium
GlucoseAnhydrous

mmol/l
75
75

1.5
2.9

Potassium
Citrate

20
10

Chloride
Total osmolality

65
245

Dose and Administration: Orally (by cup and spoon in young

children):To be dissolved in sufficient water to produce 1 litre.
Do not boil the prepared solution. Discard any remaining
solution after 24 hours.
Prevention of dehydration:In diarrhoea without signs of
dehydration, after each loose stool give Less than 2 years, 50 100ml; 2 - 10 year, 100 - 200ml.
713

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Treatment of diarrhea:In diarrhoea with moderate

dehydration:75ml of ORS solution per Kg of body weight in
46 hours. Repeat if dehydration persists.
See table below.
Note: The Table beloe shows the approximate amount of ORS solution to be
given. Use the patients age only when the weight is not known. During
rehydration therapy, continue breast-feeding the infants. In Infants under 6
months of age who are not breastfeed, also give 100 200ml of clean water.
In dehydrated children with pneumonia, without concurrent diarrhoea, give
half the amounts of ORS shown in the Table below.

Oral Rehydration Salt dose by Age and weight:

Age
Weight
(Kg.)
Amou
nt (ml)

<4
month

4 -11
month

12-23
month

2-4
year

514
year

15 year
or older

<5

5-7.9

8 -10.9

1115.9

16-29.9

30+

200-400

400-600

600-800 800-1200 1200-2200 2200-4000

Note: puffy eyelids indicate excess. It should be discontinued until it

disappears.

Storage: at room temperature. In a dry place out of direct

sunlight. In high humidity, the ORS may lump or become hard.
If the powder is white, even if it is hard, the ORS has
deteriorated and it should not be used.
Potassium chloride
Tablet, 300mg, 500mg, 600mg, 750mg, and 1gm
Indications: for treatment of potassium depletion
Cautions: in elderly, mild to moderate renal impairment (close
monitoring required), intestinal stricture, and history of peptic
ulcer; see also interactions.
Drug interactions: special hazard if given with drugs liable to
raise plasma potassium concentration such as potassium-sparing
714

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

diuretics, angiotension converting enzyme inhibitors, or

cyclosporins.
Contraindications: severe renal impairment, plasma potassium
concentrations above 5 m mol/liter.
Side effects: nausea, vomiting (severe symptoms may indicate
obstruction), oesphageal or small bowel ulceration.
Dose
and
Administration:Adult:for
prevention
of
hypokalaemia: Oral: 2-4gm daily by mouth in patients taking
normal diet. Smaller doses must be used if there is renal
insufficiency (common in the elderly) otherwise there is danger
of hyperkalaemia.
Storage: at room temperature.
Sodium Bicarbonate
Tablet, 500 mg
Indications: Management of metabolic acidosis; gastric
hyperacidity; as an alkalinization agent for the urine; treatment
of hyperkalemia; management of overdose of certain drugs,
including tricyclic antidepressants and aspirin
Cautions: the drug should be administered with extreme
caution to patients with heart failure, oedema, renal impairment,
hypertension, or aldosteronism and elderly, avoid prolonged
use. Sodium bicarbonate should be used during pregnancy only
when clearly needed.
Contraindications: metabolic or respiratory alkalosis, in
patients with hypocalcemia in whom alkalosis may induce
tetany, in patients with excessive chloride loss from vomiting or
continuous GI suctioning, and in patients at risk of developing
diureticinduced hypochloremic alkalosis. The drug should not
be used orally as an antidote in the treatment of acute ingestion
of strong mineral acids.
715

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Side effects: stomach cramps, belching, and flatulence,

alkalosis on prolonged use.
Dose and Administration: 3 g in water every 2 hours until
urinary PH exceeds 7; maintenance of alkaline urine 5-10 g
daily.
Storage: in tightly closed containers at room temperature.
Sodium Chloride
Tablet, 650 mg, 1 g
Indications: used for the treatment of extracellular volume
depletion and in the prevention or treatment of deficiencies of
sodium and chloride ions and in the prevention of muscle
cramps and heat prostration resulting from excessive
perspiration during exposure to high temperature.
Cautions: hypertension, heart failure, peripheral or pulmonary
oedema, impaired renal function or pre-eclampsia; in patients
receiving corticosteroids or corticotropin, particular caution is
necessary in geriatric or post operative patients.
Contraindications: in patients with conditions in which
administration of sodium and chloride is detrimental.
Side effects: administration of large doses may give rise to
sodium accumulation and oedema, nausea, vomiting, diarrhoea,
abdominal cramps, thirst, reduced salivation and lachrymation,
sweating, fever, tachycardia, hypertension, renal failure.
Dose and Administration:A suggested oral replacement dose
of sodium chloride is about 1 to 2 g (approximately 17 to 34
mmol of sodium) three times daily depending on individual
needs either with food or as a solution; doses of up to 12 g daily
may be necessary in severe cases.

716

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

13.2. Parenteral Electrolyte

Solutions of electrolytes are given intravenously, to meet
normal fluid and electrolyte
requirements or to replenish
substantial deficits or continuing losses, when the patient is
nauseated or vomiting and is unable to take adequate amounts
by mouth.Sodium, potassium, chloride, magnesium, phosphate,
and water depletion can occur singly and in combination with
or without disturbances of acid - base balance.
Calcium Chloride
Injection, 10% (100mg/ml),
13.6mEq Calcium in 10ml, 5mmol of calcium in 10ml, 5mmol of
calcium &Ions in 5ml
Indications: Cardiac resuscitation when epinephrine fails to
improve myocardial contractions, cardiac disturbances of
hyperkalemia, hypocalcemia, or calcium channel blocking
agent toxicity; emergent treatment of hypocalcemic tetany,
treatment of hypermagnesemia.
Contraindications: In ventricular fibrillation during cardiac
resuscitation, hypercalcemia, and in patients with risk of
digitalis toxicity, renal or cardiac disease; not recommended in
treatment of asystole and electromechanical dissociation;
patients with suspected digoxin toxicity.
Cautions: Digitalized patients, respiratory failure, or acidosis
Drug interactions: Thiazide diuretics, digoxin, calcium
channel blockers (eg. verapamil)
Side effects: Bradycardia, cardiac calcemia, hypercalciuria,
hypotension, lethargy, mania, muscle weakness, syncope, tissue
necrosis, vasodilation, ventricular fibrillation.
Dose and Administration:Calcium chloride has 3 times more
elemental calcium than calcium gluconate. One gram of
calcium chloride is equal to 270mg of elemental calcium; one
717

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

gram of calcium gluconate is equal to 90mg of elemental

calcium. Dosages are expressed in terms of the Calcium
chloride salt based on a solution concentration of
100mg/ml(10%) containing 1.4mEq (27.3mg/ml) elemental
calcium.Cardiac arrest in the presence of hyperkalemia,
magnesium toxicity, or calcium antagonist toxicity: IV: Infant
and children: 20mg/kg; may repeat in 10 minutes if necessary.
Adolescents and adults: 2-4mg/kg, repeat in 10 minutes if
necessary.Hypocalcemia: IV:Children: 2.7-5mg/kg/dose every
4-6 hours.Alternative pediatric dosing: Infants and Children:
10-20mg/kg/dose, repeat every 4-6 hours if needed. Adults:
500mg to 1g/dose repeated every 4-6 hours if needed.
Hypocalcemic tetany: IV:Neonates: Divided doses totaling
approximately 170mg/kg/24 hours. Infants and children:
10mg/kg over 5-10 minutes; may repeat after 6-8 hours or
follow with an infusion with a maximum dose of
200mg/kg/day; alternatively, higher doses of 35-50mg/kg/dose
repeated every 6-8 hours have been used.Adults: 1g over 10-30
minutes; may repeat after 6 hours.Hypocalcemia secondary to
citrated blood transfusion: IV:Neonates, Infant and children:
Give 32mg (0.45mEq elemental calcium) for each 100ml
citrated blood infused.Adult: 200-500mg per 500ml of citrated
blood (infused into another vein).
Calcium gluconate (levulinate)
Injection, 10% in 10ml ampoule
Indications: in the treatment of hypocalcaemia in conditions
that require a rapid increase in serum calcium - ion
concentration, such as neonatal hypocalcaemia tetany; tetany
due to parathyroid deficiency.
It is also indicated to decrease or reverse the cardiac depressant
effect of hyperkalemia on electrocardiographic (ECG) function,
718

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

and as an aid in the treatment of CNS depression due to over

dosage of magnesium sulfate.
Cautions: cardiac function impairment, ventricular fibrillation
during cardiac resuscitation, renal function impairment,
diarrhoea.
Drug interactions: calcitonin, verapamil, calcium and
magnesium containing medications, digitalis glycoside,
magnesium sulfate, milk and milk products, phenytoin, oral
tetracyclines, vitamin D.
Contraindications: digitalis toxicity, primary or secondary
hypercalcemia, hypercalciuria, calcium renal calculi,
sarcoidosis.
Side effects: hypotension (dizziness), flushing and/or sensation
of warmth or heat, irregular heartbeat; nausea or vomiting, skin
redness, rash, pain, or burning at injection site, sweating,
tingling sensation.
Dose and Administration:Adult:Antihypocalcemic or
Electrolyte replenisher: IV: 970mg (94.7mg of calcium ion),
administered slowly at a rate not to exceed 5ml (47.5mg of
calcium ion) a minute. The dosage may be repeated, if
necessary, until tetany is controlled.Antihyperkalemic:IV: 1 to 2
grams (94.7 to 189 mg of calcium ion), administered slowly at a
rate not to exceed 5ml a minute, the dosage being titrated and
adjusted by constant monitoring of ECG changes during
administration.Antihypermagnesemic:IV:
1
to
2gms,
administered at a rate not to exceed 5ml a
minute.Child:Antihypocalcemic: IV: 200-500mg (19.5-48.8mg
of calcium ion) as a single dose, administered slowly at a rate
not to exceed 5ml (47.5mg of calcium ion) a minute, repeated if
necessary until tetany is controlled.
Storage: at room temperature, protect from freezing.
719

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Dextrose
Injection, 5% in 500ml, 1000ml; 10% in 500ml, 1000ml; 40%
in 20ml, 50% in 50ml
Indications: for the treatment of hypoglycemia due to insulin
excess or other causes.
Cautions: caution in patients with diabetes mellitus or with
carbohydrate intolerance for any reason.
Contraindication: anuria.
Side effects: rapid administration may cause local pain;
hyperglycemia and glycosuria, which if undetected and
untreated can lead to dehydration, coma, and death.
Dose and Administration: The clear solution is given slowly
by intravenous route. For the treatment of hypoglycemia: Adult
and child: 20 to 40ml Dextrose 40%; may be repeated in
severe cases.
Storage: at room temperature.
Dextrose in Normal Saline
Injection, 5% in 500ml, 1000ml; 10% in 500ml, 1000ml
Indications: In states of sodium depletion like vomiting and
diarrhoea due to gastroenteritis, Diabetic keto acidosis,
Paralytic ileus, salt losing bowel disease, Renal salt wasting
diseases.
Cautions: In volume overload states.
Dose and Administration: Depending on the volume of fluid
lost and clinical parameters. Monitor the patient during
administration to prevent volume overload.
Hdroxyethyl starch
Large Volume Parenteral, 6% w/v of 500ml
A starch composed of more than 90% of amylopectin that has
been etherified with hydroxyethyl groups; the terms tetrastarch,
pentastarch, and hetastarch reflect the degree of etherification
720

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Indications: low blood volume

Cautions, Contraindications, Side effects, Dose and
administrations and Storagessee section 11.4 under
Hdroxyethyl starch
Lactated potassium saline injection (Darrow's solution)
Injection solution, each 1000 ml contains K+ 35mEq + Na+ 121
mEq+CI- 103 mEq+ lactate 53 mEq in 500 ml, 1000 ml
Injection solution (half strength) each 1000 ml contains; K+
17.5 meq+ Na+ 60.5 mEq+CI- 51.5 meq + Lactate 26.5 mEq in
500 ml, 1000 ml
Indications: It is a mixture of potassium chloride, sodium
chloride and sodium lactate; used in fluid therapy to repair a
potassium deficit.
Lactated Ringer's injection (Hartmann's solution)
Injectable solution, each 1000ml contains;K+ 5.4meq +
Na+130.7meq+ Ca++3.6meq+Cl-111.5meq+Lactate 28.2meq in
500ml, 1000ml
Indications: for replacement of electrolytes and water losses in
severe dehydration.
Contraindications: severe liver and renal damage.
Dose and administration: slow intravenous: Adult and Older
Child: 100ml/kg of body weight within 4 hours, immediately
until radial pulse is easily felt. Infant: 30ml/kg of body weight
within 1 hour followed by 40ml/kg of body weight within the
next 2 hours; followed by Oral ORS 40ml/kg of body weight
within the next 3 hours.
Note: If condition worsens, the rate of administration and the amount
of fluid may need to be increased. After the first 6 hours, begin
breast-feeding, or for nonbreastfeed infants give 100 200ml clean
water before continuing ORS therapy. After rehydration is complete,
feeding should start immediately.
721

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Storage: at room temperature.

Peritoneal dialysis fluid No 1
Injectable solution, each 1000ml contains;
Na+ 130.0-140mmol + Ca++ 1.5-2.0mmol +Mg++ 0.50.75mmol +HCO3- (as acetate/lactate) 35-45mmol +Cl- 90.0102mmol +Dextrose 15g in 1000ml, 2000ml
Indications: It is indicated for a single daily exchange for the
long (8 to 16 hour) for the management of End-Stage Renal
Disease or indicated for patients in acute or chronic renal failure
when nondialystic medical therapy is judged to be inadequate.
It may also be indicated in the treatment of certain fluid and
electrolyte disturbances, and for patients intoxicated with
certain poisons and drugs. However, for many substances other
methods of detoxification have been reported to be more
effective than peritoneal dialysis.
Cautions: in patients with a number of abdominal conditions
including disruption of the peritoneal membrane or diaphragm
by surgery or trauma, extensive adhesions, bowel distention,
undiagnosed abdominal disease, abdominal wall infection,
hernias or burns, fecal fistula or colostomy, tense ascites,
obesity, and large polycystic kidneys, recent aortic graft
replacement and severe pulmonary disease.
Side effects: Fluid imbalances, hypovolemia, hypervolemia,
hypertension, hypotension, disequilibrium syndrome and
muscle cramping.
Dose and Administration:To avoid the risk of severe
dehydration and hypovolemia and to minimize the loss of
protein, it is advisable to select the peritoneal dialysis solution
with the lowest level of osmolarity consistent with the fluid
removal requirements for that exchange.
722

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

Peritoneal dialysis fluid No. 2

Injectable solution, each 100ml contains;
Na+ 130.0-140mmol + Ca++ 1.5-2.0mmol + Mg++ 0.50.75mmol +HCO3- (as acetate/lactate) 35 - 45mmol +Cl- 90.0
- 102mmol +Dextrose 45g in 1000ml, 2000ml
See under peritoneal dialysis fluid No 1
Potassium chloride
Injection, 150mg/ml in 10ml ampoule
Indications: treatment of potassium depletion or hypokalaemia,
with or without metabolic alkalosis, in chronic digitalis
intoxication, and in patients with hypokalaemia familiar
periodic paralysis; see also oral potassium supplements, section 11.1.
Cautions: for intravenous infusion the concentration of
solution should not usually exceed 3.2g (43mmol)/litre;
specialist advice and ECG monitoring in difficult cases.
Drug interactions: potassium sparing diuretics, angiotension
converting enzyme inhibitors cyclosporins, digitalis glycoside,
parenteral calcium salts, laxatives.
Contraindications: hyperkalemia.
Side effects: rapid infusion toxic to heart; see section 11.1
Dose and Administration: IV infusion Note:Injectable
potassium chloride products, in strengths of 1.5mEq and 2mEq
per ml must be diluted prior to IV administration. Direct patient
injection of potassium concentrate may be instantaneously
fatal. However, injectable potassium chloride products in
strengths of 0.1 and 0.4mEq per ml are intended for use with a
calibrated infusion device and do not require dilution.
Adult:Antihypokalemic or electrolyte replenisher:IV infusion:
the dose and rate of infusion to be determined by the individual
requirements of each patient, up to 400mEq of potassium a day
(usually not more than 3mEq per kg of body weight). The
723

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

response of the patient, as determined by the measurement of

serum potassium concentration and the electrocardiogram
following the initial 40 to 60mEq infusion, should indicate the
subsequent infusion rate required.
Child:Antihypokalemic or Electrolyte replenisher:IV infusion:
up to 3mEq of potassium per kg of body weight or 40mEq per
square meter of body surface area a day. Volume of
administered fluids must be adjusted to body size.
Storage: at room temperature, protect from freezing.
Ringer's injection
Injectable solution, each 1000ml contains:
Na+ 147mEq + K+ 4mEq + Ca++ 45mEq + Cl
300ml, 500ml,1000ml

155.5mEq in

Sodium Bicarbonate
Injection (concentrated), 7.5 % (40 meq/50ml) in 50 ml
ampoule; 8.4% (50meq/50ml)
Indications: for the treatment of acute metabolic acidosis, and
relief of discomfort in mild urinary tract infections.
Cautions: in acute metabolic acidosis the manufacturers warn
that avoid excessive IV administration or avoid rapid injection
(10 ml /minute) of hypertonic sodium bicarbonate solutions in
neonates and children younger than 2 years of age; and see also
notes under sodium bicarbonate (oral).
Contraindications:see under sodium bicarbonate (oral).
Side effects: chemical cellulitis because of their alkalinity,
subsequently resulting in tissue necrosis, ulceration, and/or
sloughing at the site of injection; and see also notes under
sodium bicarbonate (oral)
Note: The above side effect is caused due to inadvertent extravasation of
hypertonic solutions of sodium bicarbonate and this can be treated by

724

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

elevating the affected area, applying warm compresses to the site, and
locally injecting lidocaine or hyaluronidase.

Dose and Administration:By slow intravenous injection, a

strong solution (up to 8.4 %), or by continuous intravenous
infusion, a weaker solution (usually 1.26 %), an amount
appropriate to the body base deficit.
Storage: at room temperature & freezing should be avoided.
Sodium chloride
Injection, 235mg/ml, 0.9% (Normal saline) in 10ml, 20ml,
500ml, 1000ml; 3% in 500ml
Injection, 30%-30mg in 10ml
Indications: used for extracellular fluid replacement and in the
management of metabolic alkalosis in the presence of fluid loss
and mild sodium depletion. Hypertonic (3%, 5%) sodium
chloride injection is used in the management of severe sodium
chloride depletion when rapid electrolyte restoration is
essential.
Cautions: see section 11.1
Contraindications: in patients with conditions in which
administration of sodium and chloride is detrimental. Sodium
chloride 3% and 5% injections are also contraindicated in the
presence of increased, normal, or only slightly decreased serum
electrolyte concentrations.
Side effects: venous thrombosis or phlebitis, extravasation,
hypervolemia, hypernatremia (on excessive administration); see
also section 11.1
Dose and Administration:Adult:IV infusion - 1 liter of 0.9%
sodium chloride injection daily or 1-2 L of 0.45% sodium
chloride injection daily. The usual initial IV dose of 3 or 5%
sodium chloride injection is 100ml given over a 1-hour period,
725

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

before additional amounts are administered. It should not

exceed 100ml/hour.
Storage: at room temperature, protect from freezing.
Sodium lactate
Injection Na+ 16.7mlEq + Lactate 16.7mlEq in 100ml
Indications: It is primarily indicated, after dilution, as a source
of bicarbonate for prevention or control of mild to moderate
metabolic acidosis in patients with restricted oral intake whose
oxidative processes are not seriously impaired. It is neither
intended nor effective for correcting severe acidosis states
which require immediate restoration of plasma bicarbonate
levels. Sodium lactate has no advantage over sodium
bicarbonate and may be detrimental in the management of lactic
acidosis. It should not be used in conditions in which lactate
levels are increased (e.g., shock, congestive heart failure,
respiratory alkalosis) or in which utilization of lactate is
diminished (e.g., anoxia, beriberi). Therefore, it is not use for
the treatment of lactic acidosis.
Contraindications: It is contraindicated in patients suffering
from hypernatremia or fluid retention.
Cautions: Congestive heart failure, sodium-retaining states,
other edematous, over hydration, pulmonary edema, severe
renal insufficiency, in patients with oliguria or anuria. Caution
must be exercised in the administration of parenteral fluids,
especially those containing sodium ions, to patients receiving
corticosteroids or corticotrophin, Pregnancy and breast feeding
mother.
Dose and Administration:Sodium Lactate Injection is
administered intravenously only after addition to a larger
volume of fluid. The amount of sodium ion and lactate ion to be
added to larger volume intravenous fluids should be determined
726

13. Medicines For Correcting Water Electrolyte And Acid-Base Disturbances

in accordance with the electrolyte requirements of each

individual patient.
13.3. Enteral Nutrition
Enteral nutrition includes feeding by mouth, by nasogastric or
nasoenteric tube, or directly into a gastrostomy or other
enterostomy. It may be supplemental, if normal food intake is
possible but inadequate, or total. Individual patients vary in
their requirements according to age, size, and metabolic state,
but a diet supplying 2000 to 3000 kcal of energy and 10-15g of
nitrogen (as 60 to 90 g of protein) in 2 to 3 litres of fluid is
fairly typical; because absorption from the gastrointestinal tract
is incomplete requirements are higher than by parenteral route.
Preparations containing whole protein (often derived from milk
or soya) are generally preferred. Although preferred to
parenteral nutrition, enteral feeding is not without
complications. Patients may be at risk of oesophagitis,
aspiration, and regurgitation as a result of the tube insertion;
other potential problems include diarrhea, nausea and vomiting,
gastric retention, hyperglycaemia, fluid and electrolyte
disturbances, and microbial contamination of the feed regimen.
1.
Calcium Caseinate
2.
Soya-based non-milk preparations

727

14.Vitamins

14. VITAMINS
Vitamins are used for the prevention and treatment of
specific deficiency states or when the diet is known to be
inadequate. Large doses of vitamins (megavitamin therapy)
have been proposed for a variety of disorders, but adequate
evidence of their value is lacking. Excessive intakes of most
water - soluble vitamins have little effects due to their rapid
excretion in urine, but excessive intakes of fat - soluble
vitamins accumulate in the body and are potentially dangerous.
Vitamin A (Retinol) is a fat - soluble substance stored in body
organs, principally the liver.
Deficiency of Vitamin A (Retinol) is associated with
occular defects (particularly xerophthalmia) and an increased
susceptibility to infections particularly measles and diarrhoea.
Despite initial epidemiological evidence suggesting that vitamin
A or carotene may have a protective effect against some
epithelial cancers, the claims have not been substantiated.
Massive overdose can cause rough skin, dry hair, an enlarged
liver, and a raised erythrocyte sedimentation rate and raised
serum calcium and serum alkaline phosphatase concentrations.
In view of evidence suggesting that high levels of
vitamin A may cause birth defects women who are (or may
become) pregnant are advised not to take vitamin A
supplements (including tablets and fish liver oil drops), except
on the advice of a doctor or an antenatal clinic; nor should they
eat liver or products such as liver pate or liver sausage.
Vitamin B is composed of widely differing substances
which are, for convenience, classed as 'vitamin B complex'.
Thiamine (Vitamin B1) is used orally for deficiency due to
inadequate dietary intake, severe deficiency may result in 'beriberi'. Thiamine is given by intravenous injection in doses of up
728

14.Vitamins

to 300mg daily (parenteral preparations may contain several B

group vitamins) as initial treatment in severe deficiency states.
Potentially severe allergic reactions may occur after parenteral
administration; facilities for resuscitation should be
immediately available. Pyridoxine (Vitamin B6) deficiency is
rare as the vitamin is widely distributed in foods, but deficiency
may occur during isoniazid therapy and is characterized by
peripheral neuritis. High dose are given in some metabolic
disorders, such as hyperoxaluria.
Nicotinic acid inhibits the synthesis of cholesterol and
triglyceride and is used in some hyperlipidaemias.
Nicotinic acid and nicotinamide are used to prevent and treat
nicotinic acid deficiency (pellagra). Nicotinamide is generally
preferred as it does not cause vasodilation.
Folic acid is essential for the synthesis of DNA and
certain proteins. Deficiency of folic acid or vitamin B12 is
associated with megaloblastic anaemia. Folic acid should not
be used in undiagnosed megaloblastic anaemia unless Vitamin
B12 is administered concurrently, otherwise neuropathy may be
precipitated.
Supplementation with folic acid 400 micrograms daily is
recommended for women of child - bearing potential in order to
reduce the risk of serious neural tube defects in their offspring.
Ascorbic acid (Vitamin c) is used for the prevention and
treatment of scurvy. Claims that ascorbic acid is of value in the
treatment of common colds are unsubstantiated.
The term Vitamin D covers a range of compounds
including ergocalciferol (Vitamin D2) and colecalciferol
(Vitamin D3). These two compounds are equipotent and either
can be used to prevent and treat rickets.

729

14.Vitamins

Simple deficiency of Vitamin D occurs in those who

have an inadequate dietary intake or who fail to produce enough
colecalciferol (Vitamin D3) in their skin from the precursor 7 dehydrocholesterol in response to ultraviolet light.
Children with dark skin must continue vitamin D
prophylaxis for up to 24 months because of their inability to
produce enough vitamin D3 in their skin. Dark skin with a high
melanin content must be exposed to daylight longer than light
skin in order to obtain the same synthesis of vitamin D3.
Vitamin D is also used in deficiency states caused by intestinal
malabsorption or chronic liver disease and for the
hypocalcaemia of hypoparathyroidism.
Vitamin K is necessary for the production of blood clotting
factors (see sec. 10.1)
14.1. Vitamins, single
Alfacalcidol (1ahydroxycholecalciferol)
Capsule, 0.25mcg
Capsule(s/g), 1mcg
Vitamin D requires hydroxylation by the kidney to its active
form, therefore the hydroxylated derivatives alfacalcidol or
calcitriol should be prescribed if patients with severe renal
impairment require vitamin D therapy.
Indications: see notes above.
Cautions: monitor plasma-calcium concentration in patients
receiving high doses and in renal impairment; pregnancy;
breast-feeding; nephrolithiasis
Contra indications: hypercalcaemia; metastatic calcification
Side effects: symptoms of overdosage include anorexia,
lassitude, nausea and vomiting, diarrhoea, constipation, weight
loss, polyuria, sweating, headache, thirst, vertigo, and raised

730

14.Vitamins

concentrations of calcium and phosphate in plasma and urine;

also rarely nephrocalcinosis, pruritus, rash, and urticaria
Dose and Administration:Oral: Adult and Child over 20 kg,
initially 1 microgram daily (elderly 500 nanograms), adjusted to
avoid hypercalcaemia; maintenance, usually 0.251 microgram
daily; Neonate and Preterm Neonate: initially 50100
nanograms/kg daily,child under 20 kg initially 50
nanograms/kg daily
Ascorbic Acid (Vitamin C)
Drops, 200mg/ml
Injection, 50mg/ml in 2ml ampoule, 100mg/ml in 5ml ampoule,
200mg/ml
Tablet, 100mg, 500mg, 1gm
Indications: for prophylaxis and treatment of vitamin C
(ascorbic acid) deficiency states which lead to scurvey.
Cautions: caution should be necessary not to take large amount
during pregnancy. Importance of not taking more than the RDA
should also be considered. Caution is required in those with
sensitivity to ascorbic acid.
Drug interactions: cellulose sodium phosphate, deferoxamine,
disulfiram and vitamin B12 (with large doses of vitamin C).
Side effect: dizziness or faintness, kidney stones (oxalate)
Dose and Administration: Adult:Dietary supplement: Oral:
50 to 100mg a day. Treatment of deficiency: Oral, IV or IM:
100 to 250mg one or three times a day. Child: Dietary
supplement: Infants and Children up to 4 years of age: Oral: 20
to 50mg a day.Treatment of deficiency:Oral, IV or IM: 100 to
300mg a day in divided doses.
Storage: at room temperature in a tight, light resistant
container.

731

14.Vitamins

Calciferol (Ergocalciferol/Vitamin D2)

Injection, 300,000-units/ml in 2 ml ampoule
Oral solution, 20,000-units/ ml, 400,000 units/ml
Tablet (strong), 1.25 mg (50,000units)
Indications: used in the treatment of chronic hypocalcemia,
hypophosphatemia, rickets and osteodystrophy associated with
various medical conditions including chronic renal failure,
familial hypophosphatemia, and hypoparathyroidism (post
surgical or idiopathic or pseudohypoparathyroidism); for
prevention and treatment of vitamin D deficiency states; and to
treat anticonvulsant induced rickets & osteomalacia.
Note: Ergocalciferol may not be the preferred agent in the treatment
of familial hypophosphatemia or hypoparathyroidism because the
large doses needed are associated with a risk of overdose and
hypercalcemia, and ergocalciferol not usually preferred in patients
with renal failure since these patients have impaired ability to
synthesize calcitriol from colecalciferol and ergocalciferol.

Cautions: ergocalciferol should be administered with extreme

caution, if at all, to patients with impaired renal function and
with extreme caution in patients with heart disease, renal
stones, or arteriosclerosis; large doses of VitaminD analogs
should not be administered to nursing women; take care to
ensure correct dose in infants and pregnant.
Drug interactions: antacids (magnesium containing), in high
doses of calcium containing preparations and diuretics
(thiazide), vitamin D analogs.
Contraindications: hypercalcemia, hypervitaminosis D, Renal
Osteodystrophy
with
hyperphosphatemia,
metastatic
calcification, hypersensitivity to effects of Vitamin D.
Side effects: symptoms of over dosage include anorexia,
lassitude, nausea and vomiting, diarrhoea, weight loss, polyuria,
sweating, headache, thirst, vertigo, and raised concentrations of
calcium and phosphate in plasma and urine.
732

14.Vitamins

Dose and Administrations:Ergocalciferol injection

Adult:Deficiency (prophylaxis or treatment):Intravenous
infusion, as part of total parenteral nutrition solutions, the
specific amount determined by individual patient
need.Malabsorption: IM: 10,000 units per day. Child: see adult
dose. Ergocalciferol oral solution Adult: Deficiency
(prophylaxis): Oral: amount based on normal dailyrecommended intakes:
Person
Microgram
Adolescent and adult
5-10
Pregnant and breast feeding 10

Units
200 400
400

Deficiency (treatment): Treatment dose is individualized by

prescriber based on severity or deficiency: Vitamin D
resistant rickets:Oral: 12,000 to 500,000 units per day.
Vitamin D dependent rickets:Oral: 10,000 to 60,000 units per
day (up to 500,000 units/day). Osteomalacia due to prolonged
use of anticonvulsants:Oral: 1000 to 4000 units per day.
Familial hypo phosphatemia: Oral: 50,000 to 100,000 units per
dayHypoparathyroidism: Oral: 50,000 to 150,000 units per
day. Child:Deficiency (prophylaxis):Oral amount based on
normal daily-recommended intakes.
Persons
Birth to 3 years of age
4 to 10 years of age

Microgram Units
7.5 10
300 - 400
10
400

Deficiency (treatment):Treatment dose is individualized by

prescriber based on severity of deficiency. Vitamin Ddependent rickets:Oral: 3000 to 10,000 units per day (up to
50,000 units/day).Osteomalacia due to prolonged use of
anticonvulsants: Oral: 1000 units per day.
733

14.Vitamins

Hypoparathyroidism:Oral: 50,000 to 200,000 units per

day.Ergocalciferol tablets:Adult: see Ergocalciferol oral
solution; Child: see Ergocalciferol oral solution
Storage: in tight, light - resistant containers at a room
temperature.
Cholecalciferol (Vitamin D3)
Capsule, 250mcg
Injection (oily), 300,000 IU/ml
Indications, Cautions, Side effects, Drug interactions, Dose
and Administration; see under ergocalciferol.
Cyanocobalamine (vitamin B12)
Injection, 100mcg/ml, 1000mcg/ml in 1ml ampoule
See section 11.3 under Cyanocobalamine (vitamin B12)
Folic Acid
Injection, 5 mg/ml in 1 ml ampoule
Tablet, 200 mcg, 1 mg, 5 mg
Indications: for prevention and treatment of folic acid
deficiency states, including megaloblastic anemia and in
anemias of nutritional origin, pregnancy, infancy, or childhood;
folic acid is being used in the diagnosis of folate deficiency
Cautions: women receiving antiepileptic therapy need
counseling before starting folic acid.
Drug interactions: cyanocobalamin; agents causing folic acid
deficiency with long term use (phenytoin, oral contraceptives,
isoniazid, NSAIDs in high doses and glucocorticosteroids);
antifolate
agents
(trimethoprim,
pyrimethamine
and
methotrexate)
Contraindications: should never be given without vitamin B12
in undiagnosed megalolblastic anaemia or other vitamin B12
734

14.Vitamins

deficiency states because risk of precipitating subacute

combined degeneration of the spinal cord; folate-dependent
malignant disease, folic acid injection that contains benzyl
alcohol as a preservative should not be used in new born and
immature infants.
Side effects: allergic reaction, specifically; bronchospasm;
erythema; fever; general malaise; skin rash; or itching.
Dose and Administrations: Folic acid Injection: Adult:
Deficiency (prophylaxis): IV infusion, as part of total parenteral
nutrition solutions, the specific amount determined by
individual patients need.Deficiency (treatment): IM, IV, or deep
SC: 250 mcg (0.25 mg) to 1 mg a day until a hematologic
response occurs.Diagnostic aid (folate deficiency):IM: 100 to
200 mcg (0.1 to 0.2 mg) a day for ten days plus low dietary
folic acid and Vitamin B12.Child: See usual adult dose.
Folic acid Tablets:Deficiency (prophylaxis): Oral: amount
based on normal daily-Recommended intakes:
Persons
Adult males
Adult females
Pregnant females
Breast feeding females
Birth to 3 years of age
4 to 6 years of age
7 to 10 years of age

Microgram
150 400
150 400
400 - 800
260 800
25
75 400
100 400

Diagnostic aid (folate deficiency):Oral: 100 to 200 mcg (0.1 to

0.2 mg) a day for ten days plus low dietary folic acid and
vitamin B12.Deficiency (treatment): treatment dose is
individualized by prescriber based on severity of deficiency.
Storage: at room temperature in a well-closed container.
735

14.Vitamins

Mecobalamine
Tablet, 500mcg
Indications: management of peripheral neuropathies such as
diabetic neuropathies which are associated with damaged nerve
fibers leading to symptoms like tingling, numbness and pain.
Contraindications: Hypersensitivity to mecobalamin.
Cautions: should not be used for more than one month unless it
is effective.
The prolonged use of larger doses of mecobalamin is not
recommended for patients whose occupation requires the
handling of mercury or mercury compounds.
Side effects: anorexia, nausea, vomiting and diarrhea, rash.
Dose and Administration: Adult: Oral: 3 tablets (1500mcg)
daily divided into three doses. The doses may be adjusted
depending on the patients age and symptoms
Storage: store at a temperature below 25OC, protect from light
and moisture
Menadiol Sodium Diphosphate
Injection, 10mg /ml
Tablet, 10 mg
Indications: in the prevention and treatment of
hypoprothrombinemia secondary to factors limiting absorption
or synthesis of Vitamin K.
Cautions: the drug should not be used in neonates; in patients
with hepatic function impairment, G6PD deficiency and
vitamin E deficiency.
Drug interactions: anticoagulants (coumarin or indandione
derivative), hemolytics
Contraindications: neonates and infants, late pregnancy
Side effects: anaphylaxis, cyanosis, dizziness, hypotension,
profuse sweating, rapid and weak pulse, and in newborns,
736

14.Vitamins

hemolytic anemia and liver toxicity, which may progress to

kernicterus.
Dose and Administration: Oral dosage formsAdult:
Hypoprothrombinemia secondary to obstructive jaundice and
biliary fistulas: Oral: 5 mg/day.Hypoprothrombinemia anemia
secondary to the administration of antibacterials or salicylate:
Oral: 5 to 10 mg per day.Child:Vitamin (prothrombogenic); or
Antidote (to drug- induced hypoprothrombinemia): Oral: 5 to
10 mg per day,parenteral dosage forms.
Adult:Nutritional supplement (Vitamin), prothrombogenic; or
Antidote (to drug induced hypoprothrombinemia): IM or SC: 5
to 15 mg one or two times a day.
Storage: in a light resistant container at room temperature;
especially menadiol sodium bicarbonate injection should be
protected from freezing.
Nicotinamide
Injection, 5 mg/ml, 100 mg/ml in 1 ml ampoule
Tablet, 100 mg
Indications: nicotinamide and nicotinic acid (niacin) are used
to prevent niacin deficiency and to treat pellagra. Niacin (but
not nicotinamide) is also indicated in the treatment of
hyperlipidemia.
Cautions: blood glucose concentration should be monitored
periodically and also liver function should be determined
periodically in patients receiving long-term niacin or
nicotinamide therapy. Large doses of niacin or nicotinamide
should be administered with caution to patients with gallbladder
disease or a history of jaundice or liver disease, diabetes
mellitus, gout, peptic ulcer, or allergy, in women who are or
may become pregnant unless the possible benefits out weight
the potential risks to the fetus.
737

14.Vitamins

Drug interactions: niacin reportedly potentiates the

hypotensive effect of ganglionic blocking drugs.
Contraindications:
niacin
and
nicotinamide
are
contraindicated in patients with, active peptic ulcer, or
hypersensitivity to the drugs. Niacin is also contraindicated in
patients with arterial hemorrhaging or severe hypotension
Side effects: anaphylactic reaction with injection only,
hepatotoxicity or cholestasis with high doses of extended
release niacin.
Dose and Administration: Oral:Deficiency (prophylaxis):
Oral: amount based on normal daily- Recommended intakes:
Persons
Adolescent and adult males
Adolescent and adult females
Pregnant females
Breast feeding females
Birth to 3 years of age
4 to 6 years of age
7 to 10 years of age

Milligram
15 20
13 15
17
20
5-9
12
13

Deficiency (treatment): Treatment dose is individualized by

prescriber based on severity of deficiency.
Parenteral:Deficiency (prophylaxis):IV infusion: as part of total
parenteral nutrition solutions, the specific amount determined
by individual patient need. Deficiency (treatment):Adult:IM:
50 to 100 mg five to more times a day; IV (slow): 25 to 100 mg
2 or more times a day.Child:IV (slow): up to 300 mg a day
Storage: at room temperature in a tight container.
Nicotinic Acid
Injection, 50 mg/ml in 1 ml ampoule
738

14.Vitamins

Tablet, 50 mg
Indications, Cautions, Side effects, Drug interactions,
Contraindications, see notes under nicotinamide
Dose and Administrations: Oral: Adult: Antihyperlipidemic:
Initial: Oral: 1 gram three times a day, the dosage being
increased in increments of 500 mg a day every two to four
weeks as needed.Maintenance: Oral: 1 to 2 grams three times a
day.Parentral: see under nicotinamide
Storage: at room temperature in a well closed container.
Protect from freezing.
Phytomenadione (Vitamin K1)
Injection, 1mg/0.5ml 10mg/ml in 1ml ampoule.
Indications: prothrombogenic nutritional supplement, it is also
used for treatment and prevention of various coagulation
disorders including hypoprothrombinemia, or as an antidote to
drug induced hypoprothrombinemia; see also section 10.1
Cautions, Drug interactions, Side effect; see section 10.1
under phytomenadione
Dose and Administration:SC or IM, it should not be given
repeatedly to patients with severe liver disease, once the
response to the initial dose is unsatisfactory.
Adult:Nutritional supplement (Vitamins), prothrombogenic or
Antidote (to drug-induced hypoprothrombinemia): 2.5 to 10mg
(up to 25mg), may be repeated after 6-8 hours if necessary.
Child: Nutritional supplement (vitamin), prothrombogenic or
Antidote (to drug-induced hypoprothrombinemia),Treatment of
hypoprothrombinemia: Infants:IM or Sc: 1-2 mg.Child:IM or
Sc: 5-10mg.
Storage: at room temperature, protect from light and freezing.
Pyridoxine Hydrochloride (Vitamin B6)
Injection, 50mg/ml in 2ml ampoule, 150mg/ml
739

14.Vitamins

Tablet, 40mg, 50mg, 100mg, 300mg.

Indications: for prevention and treatment of pyridoxine
deficiency states that may occur as a result of inadequate
nutrition or intestinal malabsorption.
It is also used as antidote in cyclosporin poisoning and to
terminate seizures and prevent neuropathy associated with
isoniazid poisoning.
Cautions: sensitive to pyridoxine.
Drug interactions: levodopa, cycloserine, isoniazid,
penicillamines, hydralazine.
Side effects: sensory neuropathy in prolonged use
Dose and Administration:Adult:Deficiency states: Oral: 2050mg up to 3 times daily isoniazid neuropathy, prophylaxis
10mg daily, therapeutic - 50mg three times daily.Idiopathic
sideroblastic anaemia:Oral: 100-400mg daily in divided
doses.Nutritional supplement - Dietary supplement:Oral: 1020mg per day for three weeks followed by 2 to 5mg per day (in
a multivitamin preparation) for several weeks.Drug Induced
deficiency:Prevention: Oral: 10-50mg per day for
penicillamine or 100-300mg per day for cycloserine,
hydralazine, or isoniazid. Treatment: Oral: 50 to 100mg per
day as needed to prevent relapse; IM or IV, 50 to 200mg per
day for three weeks, followed by 25 to 100mg per day as
needed.Child:Dietary supplement: Oral: 2.5 to 10mg per day
for three weeks, followed by 2 to 5mg per day (in a
multivitamin preparation) for several weeks.
Storage: at room temperature, protect from light and from
freezing.
Thiamine Hydrochloride (Vitamin B1)
Injection, 50mg/ml in 2ml ampoule
Tablet, 5mg, 10mg, 100mg, 300mg

740

14.Vitamins

Indications: for prevention and treatment of thiamine

deficiency states that may occur as a result of inadequate
nutrition or intestinal malabsorption.It is used for temporary
metabolic correction of genetic enzyme deficiency diseases
such as subacute nercotizing encephalomyelopathy (SNE,
Leighs disease), maple syrup urine disease (branched-chain
aminoacidopathy), and lactic acidosis associated with pyruvate
carboxylase deficiency and hyperalaninemia.
Cautions: patients sensitive to thiamine and in those with
Wernicke's encephalopathy.
Side effects: anaphylactic reaction (coughing, difficulty in
swallowing; hives; itching of the skin, swelling of face, lips or
eyelids, or wheezing or difficulty in breathing).
Dose and Administration:Adult:Nutritional supplement
(Vitamin)Beriberi (initial in mild or maintenance following
severe): Oral: 5 to 10mg three times a day (in a multivitamin
preparation).
Beriberi (critical illness):IM or slow IV, 5-100mg three times a
day followed by maintenance oral administration.Treatment of
deficiency: Oral: 1-10mg three times a day until improvement
occurs,
followed
by
recommended
dietary
allowance.Child:Nutritional supplement (Vitamin)Beriberi
(mild): Infants:Oral: 10mg per day.Beriberi (critical illness): IM
or slow IV: 10-25mg per day.Treatment of deficiency: Oral: 10
to
50mg
per
day
in
divided
doses.
Dietary
supplement:Infants:Oral: 300 to 500mcg (0.3-0.5mg) per
day.Child:Oral: 500mcg (0.5mg) to 1mg per day.
Storage: at room temperature in a tight, light-resistant
container. Protect from light and freezing.
Vitamin A
Capsule, 25,000 IU, 50,000 IU, 100,000 IU
Oral solution, 150,000 IU/ml (concentrated), 50,000 IU/ml
741

14.Vitamins

Tablet, 50,000 IU, 100,000 IU 200,000 IU

Injection, under 200,000 IU/ml
Indications: for prevention or treatment of vitamin A
deficiency states, causing keratomalacia, xerophthalmia and
nyctalopia (night blindness). This may occur as a result of
inadequate nutrition or intestinal malabsorption.
Note: Vitamin A is not useful for treatment of dry or wrinkled skin,
eye problems, or prevention or treatment of infections not related to
vitamin A deficiency.

Cautions: high doses exceeding 6000 units are not

recommended during pregnancy, caution is recommended in
young children taking high doses of vitamin A; long-term
vitamin A use in the elderly may increase the risk of vitamin A
overload; in patients with chronic renal failure, chronic
alcoholism, cirrhosis, hepatic disease and viral hepatitis.
Drug interactions: calcium supplements, isotretinoin,
tetracycline, vitamin E, cholestyramine, colestipol, mineral oil,
oral neomycin.
Contraindications: hypervitaminosis A
Side effects: symptoms of acute overdose - bleeding from gums
or sore mouth; bulging soft spot on head-in babies, confusion or
unusual excitement; diarrhoea, dizziness, or drowsiness, double
vision, severe headache, severe irritability, peeling of skin,
especially on lips and palms; severe vomiting
Dose and Administration:Adult:Deficiency:Oral: 30,000 RE
(100,000units) a day for 3 days followed by 7500 to 15,000 RE
(25,000 to 50,000 unit) a day for 14 days. With xerophthalamia:
Oral: 7500 to15, 000 RE (25,000 to 50,000 units) a day.
Note: RE=Retinol Equivalent; one RE = one mcg of Retinol =
3.33 units of vitamin A.

742

14.Vitamins

IM, Intravenous infusion, as a part of total parenteral

nutrition solution, the specific amount determined by
individual patient need.
IM 15,000 to 30,000 RE (50,000-100,000 units) a day for
three days, followed by 15,000 RE (50,000 units) a day for
two weeks.
Child: DeficiencyInfants less than 1year: Oral: 3000 RE
(10,000 units) per kg per day for 5 days followed by 2250 4500 RE (7500 to 15,000 units) per day for 10 days; IM, 1500 3000 RE (500-10,000 units) a day for ten days; in severe
deficiency - IM, 2250 to 4500 RE (7500 to 15,000 units) a day
for ten days.
Children 1-8 years of age: Oral: 3000 RE (10,000 units) per kg
per day for 5 days followed by 5100 to 10,500 RE (17,000
to35,000 units) a day for 10 days.
With xerophthalamia: Oral: 1500 RE (5000 units) per kg of
body weight for five days, then in combination with
intramuscular Vitamin A (7500 RE or 25,000 units per kg of
body weight a day) until recovery occurs.
IM: 1500-4500 RE (5000-15,000 units) a day for ten days; in
severe deficiency IM: 5250 to 10,500RE (17,500-35,000
units) a day for ten days.
Storage: at room temperature in a tight, light-resistant
container. Protect from light and freezing.
Vitamin E (Tocopherol)
Injection, 50mg/ml in 20ml ampoule
Tablet, 100mg; 100mg (Chewable)
Capsule, 200mg, 400mg
Soft gelatin capsule, 400mg
Indications: Dietary supplement

743

14.Vitamins

Cautions: predisposition to thrombosis; increased risk of

necrotising enterocolitis in neonate weighing less than 1.5 kg.
Interactions: warfarine, tipranavir
Contraindications: hypersensitivity to Vitamin E or any
component of the formulation.
Side effects: diarrhoea and abdominal pain with doses more
than 1 g daily
Dose and Administration: Recommended daily allowance
(RDA):Premature infants 3months: 17mg
Infants (adequate intake; RDA not established): 6months:
4mg; 7 12 months: 6mg; Children: 1-3 years: 6mg; upper
limit of intake should not exceed 200mg/day; 4-8 years: 7mg;
upper limit of intake should not exceed 300 mg/day; 9-13 years:
11mg; upper limit of intake should not exceed 600 mg/day; 1418 years: 15mg; upper limit of intake should not exceed 800
mg/day; Adult: 15mg; upper limit of intake should not exceed
1000 mg/day; Vitamine E deficiency: Child (with
malabsorption syndrome): 1 unit/kg/day of water miscible
vitamin E (to raise plasma tocopherol concentrations to the
normal range within 2 months and to maintain normal plasma
concentrations); Adult: 60-75 units/day; Prevention of Vitamin
E deficiency: Adult: 30 units/day
Storage: protect from light
14.2. Vitamins, Combinations
Vitamin A + D
Capsule, 4,000 IU + 400IU; see notes above
14.2.1. Vitamin B complex preparations*
The most important B group vitamins appear to be thiamine
(vitamin B1), riboflavin (vitamin B2), pyridoxine (vitamin B6),
Pantothenic acid (vitamin B5), nicotinic acid/nicotinamide
744

14.Vitamins

(niacin, vitamin B3, niacinamide), cyanocobalamin (vitamin

B12) and folic acid/folate.
Indications: supplement for use in the wasting syndrome in
chronic renal failure, uremia, impaired metabolic functions of
the kidney, dialysis; labeled for OTC use as a dietary
supplement.
Dose and Administration: Oral:Adult:Dietary supplement:
One tablet daily. Renal patients: One tablet or capsule daily
between meals; takes after treatment if on dialysis.
14.2.2. Multivitamin preparations*
14.2.3. Multivitamin with minerals and/or extracts*
* Any combinations proven to be therapeutically effective can
be acceptable

745

15. Antihistamines And Antiallergics

15. ANTIHISTAMINES and ANTIALLERGICS

15.1. Antihistamines
Antihistamines diminish or abolish the main actions of
histamine in the body by competitive, reversible blockade of
histamine receptor sites on tissues; they do not inactivate
histamine or prevent its synthesis or release. Histamine H1
receptors are responsible for vasodilatation, increased capillary
permeability, flare and itch reactions in the skin, and to some
extent for contractions of smooth muscle in the bronchi and
gastro-intestinal tract.
Antihistamines are used for the symptomatic relief of
hypersensitivity reactions including urticaria and angioedema,
rhinitis, and conjunctivitis.
Antihistamines are generally
considered to be ineffective in asthma. They should not be used
to control transfusion reactions caused by ABO incompatibility.
Antihistamines are widely used, often with a
decongestant, in compound preparations for the symptomatic
treatment of coughs and the common cold.
Antihistamines are also used to control the pruritus associated
with skin disorders such as atopic eczema. Some antihistamines,
including promethazine, are used for their sedative effects;
antihistamines such as cyproheptadine may be of value in the
prophylaxis of migraine, particularly in children.
Side effects: The most common side effects of the older
antihistamines is sedation, varying from slight drowsiness to
deep sleep, and including lassitude, dizziness, and in
coordination, sedative effects, when they occur, may diminish
after a few days of treatment.
Paradoxical CNS stimulation may occur especially in
children, with insomnia, nervousness, euphoria, irritability,
tremors and rarely nightmares, hallucinations, and convulsions.
In high doses CNS stimulation may be attributed to
746

15. Antihistamines And Antiallergics

antimuscarinic activity. Extrapyramidal symptoms may develop

with phenothiazine derivatives and have been reported with
some other antihistamines.
Older antihistamines possess antimuscarinic properties
and may produce similar adverse effects to atropine. In addition
headache, psychomotor impairment, gastro intestinal
disturbances such as nausea, vomiting, diarrhoea, or epigastric
pain have occurred with antihistamines.
Other side effects of antihistamines include palpitations
and arrhythmias, hypotension, hypersensitivity reactions
(including bronchospasm, angioedema, and anaphylaxis, rashes
and photosensitivity reactions), extrapyramidal effects,
dizziness, confusion, depression, sleep disturbances, tremor,
convulsions, blood disorders, and liver dysfunction.
Caution and Contraindications: Antihistamines should not be
given to premature infants or neonates: this group of patients
has an increased susceptibility to antimuscarinic effects.
Phenothiazine antihistamines should be avoided in young
children because of the potential risk of central and obstructive
apnoea and reduced arousal. Recommendations range from
avoidance in children under 1 year of age to children under 2
years. Elderly patients are also more susceptible to many
adverse effects of antihistamines, including antimuscarinic
effects, sedation, and hypotension.Sedating antihistamines have
significant antimuscarinic activity and they should therefore be
used with caution in prostatic hypertrophy, urinary retention,
susceptibility to angle-closure glaucoma, and pyloroduodenal
obstruction. Caution may be required in epilepsy. Children and
the elderly are more susceptible to side-effects. Many
antihistamines should be avoided in acute porphyria but some
are thought to be safe.
747

15. Antihistamines And Antiallergics

Hepatic impairment: Sedating antihistamines should be avoided

in severe liver diseaseincreased risk of coma.Pregnancy:
Most manufacturers of antihistamines advise avoiding their use
during pregnancy; however, there is no evidence of
teratogenicity except for hydroxyzine where toxicity has been
reported with high doses in animal studies. The use of sedating
antihistamines in the latter part of the third trimester may cause
adverse effects in neonates such as irritability, paradoxical
excitability, and tremor.
Breast-feeding:Most antihistamines are present in breast milk
in varying amounts; although not known to be harmful; most
manufacturers advise avoiding their use in mothers who are
breast-feeding.
Many antihistamines may cause drowsiness; so patients should
not drive or operate machinery. Because of their antimuscarinic
properties antihistamines should be used with care in conditions
such as closed angle glaucoma, urinary retention prostatic
hyperplasia, or pyloroduodenal obstruction. Other adverse
effects of antihistamines suggest caution in patients with
epilepsy, severe cardiovascular disorders, or, for phenothiazines,
in those with liver disorders.
Drug interactions: Antihistamines may enhance the sedative
effects of central nervous system depressants including alcohol,
barbiturates, hypnotics, opioid analgesias, anxiolytic sedatives,
and neuroleptics. MAOIs may enhance the antimuscarinic
effects of antihistamines, and antihistamines have an additive
antimuscarinic action with other antimuscarinic drugs, such as
atropine and tricyclic antidepressants. Antihistamines could
mask the warning signs of damage caused by ototoxic drugs
such as aminoglycoside antibiotics.

748

15. Antihistamines And Antiallergics

Budesonide
Nasal Spray, 32mcg, 64mcg
Indications: management of symptoms of seasonal or perennial
rhinitis.
Contraindications: hypersensitivity to Budesonide or any
componenet of the formulation.
Dose and Administration: Nasal inhalation: Childern 6 years
and Adults: 64mcg/day as a single 32mcg spary in each nostril.
Some patients who do not achieve adequate control may benefit
from increased dosage. A reduced dosge may be effective after
initial control is achieved. Maximum dose: Children 12 years:
128mcg/day; Adult: 256mcg/day.
Storage: store with valve up at 20oc to 25oc and protect from
light.
Cetirizine
Oral solution, 1mg/ml
Tablet, 5mg, 10mg
Indications: symptomatic relief of hypersensitivity reactions
including rhinitis and chronic urticaria.
Cautions and Drug interactions; see notes above
Contraindications: see notes above; also pregnancy and breastfeeding
Side effects: see notes above, incidence of sedation and
antimuscarinic effect is low
Dose and Administration: Oral:Adult and Child over 6 years:
10mg daily or 5mg twice daily; Child 2 - 6 years: hay fever,
5mg daily or 2.5mg twice daily.
Storage: store in a well - closed container at room temperature.
Chlorpheniramine Maleate
Syrup, 2mg/5ml
Tablet, 2mg, 4mg, 6mg
749

15. Antihistamines And Antiallergics

Indications: symptomatic relief of allergy such as hay fever,

urticaria, emergency treatment of anaphylactic reactions.
Cautions: see notes above; also pregnancy and breast-feeding.
Drug interactions, Contraindications: see notes above.
Side effects: see notes above; also exfoliative dermatitis and
tinnitus reported; injections may cause transienthypotension or
CNS stimulation and may be irritant.
Dose and Administration: Oral:Adult: 4 mg every 4-6 hours,
maximum 24 mg daily; Child: Less than 1 year old not
recommended. 1-2 years 1mg twice daily; 2-5 years 1mg every
4-6 hours, maximum 6 mg daily; 6-12 years 2 mg every 4-6
hours, maximum 12 mg daily.
Storage: at room temperature in a tight, light-resistant
container.
Cyproheptadine Hydrochloride
Syrup, 2mg/5ml
Tablet, 4mg, 10mg
Indications: symptomatic relief of allergy such as hay fever,
urticaria migraine.
Cautions, Drug interactions and Side effects; see notes above
Contraindications: see notes above; also breast-feeding
Dose and Administration: Oral:Allergy: Adult: 4 mg 3-4 times
daily; usual range 4 - 20mg daily, max, 32 mg daily; Child
under 2 years not recommended, 2-6 years, 2mg 2-3 times daily,
maximum 16 mg daily.Migraine: 4 mg with a further 4 mg after
30 minutes if necessary; maintenance, 4 mg every 4 - 6 hours.
Desloratadine
Tablet, 5mg
Syrup, 0.5mg/ml

750

15. Antihistamines And Antiallergics

Indications: relief of nasal and non-nasal symptoms of seasonal

allergic rhinitis (SAR) and perennial allergic rhinitis (PAR);
treatment of chronic idiopathic urticaria (CIU)
Contraindications: hypersensitivity to desloratadine, loratadine
or any componenetof the formulation.
Cautions: pregnancy, breastfeeding
Side effects: headache, fatigue, somnolence, dizziness,
xerostomia, nausea, dyspepsia, myalgia, pharyngitis.
Drug interactions: erythromycin, ketoconazole
Dose and Administration: Child 6-11 months: 1 mg once daily;
12 months to 5 years: 1.25mg once daily; 6-11 years: 2.5mg
once daily; Children 12 years and adult: 5mg once daily.
Storage: store at room temperature.
Dexchlorpheniramine Maleate
Tablet, 2mg, 4mg, 6mg
Indications: Treatment of perennial and seasonal allergic
rhinitis; vasomotor rhinitis; allergic conjunctivitis due to
inhalant allergens and foods; mild, uncomplicated allergic skin
manifestations of urticaria and angioedema; amelioration of
allergic reactions to blood or plasma; dermographism;
adjunctive anaphylactic therapy.
Cautions: Use in the children and elderly (approximately 60
years and above), narrow angle glaucoma, stenosing peptic
ulcer, pyloroduodenal obstruction, symptomatic prostatic
hypertrophy, Bladder neck obstruction, History of bronchial
asthma, increased intraocular pressure, hyperthyroidism,
cardiovascular disease, hypertension.
Drug interactions: Alcohol, CNS depressants (hypnotics,
sedatives, tranquilizers, etc.), MAOIs.
Contraindications: Treatment of lower respiratory tract
symptoms; MAO inhibitor therapy; any component of the
product or other antihistamines of similar chemical structure.
751

15. Antihistamines And Antiallergics

Antihistamines also are contraindicated in newborn or

premature infants, and breast-feeding mothers.
Side effects: Urticaria, drug rash, anaphylactic shock,
photosensitivity, excessive perspiration, chills, dryness of
mouth, nose and the throat, hemolytic anemia,
thrombocytopenia,
agranulocytosis,
hemolytic
anemia,
thrombocytopenia, agranulocytosis, sedation, sleepiness,
dizziness, disturbed coordination, fatigue, confusion,
restlessness, excitation, nervousness, tremor, irritability,
insomnia, euphoria, paresthesias, blurred vision, diplopia,
vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis,
convulsions, epigastric distress, anorexia, nausea, vomiting,
diarrhea, constipation, urinary frequency, difficult urination,
urinary retention, early menses, thickening of bronchial
secretions, tightness of chest and wheezing, nasal stuffiness.
Dose and Administration:Adults and Children 12 yearof age
and older: Oral tablets: 4 or 6 mg at bedtime orevery 8 to 10
hours.Children 6 to 12 yr of age: oraltablets: 4 mg/ day,
preferably at bedtime.Children 2 to 5 yr of age: oralsyrup: 0.5
mg ( teaspoonful) every 4 to 6 hours.Note: Advice patient to
swallow tablets whole and not to crush, chew, or break the tablet.

Dexchlorpheniramine Maleate+ Betamethasone

Tablet, 2mg+0.25mg
Indications: It is recommended in the treatment of difficult
cases of respiratory, dermatologic and ocular allergies, as well
as ocular inflammatory disorders, where adjunctive systemic
corticosteroid therapy is indicated.
Cautions, Drug interactions and Side effects: See individual
medicine
Contraindications: It is contraindicated in patients with
systemic fungal infections, newborn and premature infants, and
752

15. Antihistamines And Antiallergics

patients receiving MAO inhibitor therapy and in those who have

shown hypersensitivity to any component of the products or
medicines of similar chemical structures.
Dose and Administration: The recommended initial dose for
adults and children over 12 years is 1 to 2 tablets two times
daily, after meals and at bedtime. Thedose is not to exceed 8
tablets per day. In younger children dosage should be adjusted
according to the severity of the condition and the response of the
patient, rather than by age or body weight.Children 6 to 12 years

the recommended dose are 1 tablet twice a day. If an additional

daily dose is required, it should be taken preferable at bedtime.
The dose is not to exceed 4 tablets a day.
Diphenhydramine Hydrochloride
Capsule, 25mg, 50mg
Elixir, 12.5mg/5ml
Injection, 50ml in 1ml ampoule
Indications: symptomatic relief of hypersensitivity reactions
including urticaria and angioedema, rhinitis and conjunctivitis
and in pruritic skin disorders; other indications also for motion
sickness and in control of parkinsonism and drug induced
extrapyramidal disorders; short term management of insomnia.
Cautions, Drug interaction, Contraindications, Side effects;
see notes above.
Does and Administration: Oral:Adult: 25 to 50 mg every four
to six hours as needed. Child: Up to 6 years of age, 6.25 to 12.5
mg every four to six hours; 6 to 12 years of age, 12.5 to 25 mg
every four to six hours, not to exceed 150mg per day.
Parenteral dosage form:Adult: IM or IV: 10 to 50 mg.Child:
IM: 1.25 mg per kg of body weight or 37.5 mg per square meter
of body surface four times a day not to exceed 300 mg per day.
Note:premature and full-term neonates use is notrecommended.

753

15. Antihistamines And Antiallergics

Storage: at room temperature, in tight and light-resistant

containers. Protect from freezing.
Fexofenadine
Tablet: 120mg, 180mg
Indications: management of allergic rhinitis and chronic
idiopathic urticaria.
Cautions: sleep disorder, insomnia or paroniria, nausea,
dyspepsia, back pain, throat irritation
Contraindications: other antihistamines or decongestants fruits
(grape, orange, apple) juice.
Drug interaction: Antacids containing aluminum and
magnesium
Storage: store at room temperature
Levocetrizine
Tablet, 5mg
Indications, Cautions, Drug interactions, Side effects and
storage; see under cetrizine.
Dose and Administration:Adult: Allergic rhinitis and
Urticaria:Oral: 5mg once daily (at night). Child: over 12 years,
as for adults. Safety and efficacy not established in children
under 12 years.
Loratadine
Syrup, 5mg/5ml
Tablet, 10mg
Indications: symptomatic relief of allergy such as hay fever,
urticaria.
Cautions, Drug interactions: see notes above
Contraindications: see notes above, also pregnancy and breastfeeding
754

15. Antihistamines And Antiallergics

Side effects: see notes above; incidence of sedation and

antimuscarinic effect is low.
Dose and Administrations:Oral: Adult and Child over 6 years:
10mg daily; Child 2 - 5 years: 5mg daily.
Storage: store in airtight containers, protect from light.
Loratadine+ Pseudoephedrine
Tablet, 5mg+120mg
Indications:temporarily relieves these symptoms due to hay
fever or other upper respiratory allergies (runnynose, sneezing,
itchy, watery eyes, itching of the nose or throat).Temporarily
relieves nasal congestion due to the common cold, hay fever or
other respiratory allergies. Reduces swelling of nasal
passages.Temporarily relieves sinus congestion and pressure.
Temporarily restores freer breathing through the nose
Cautions: heart disease, thyroid disease, high blood pressure,
diabetes, trouble urinating due to an enlarged prostate gland,
liver or kidney disease.
Drug interactions: Bromocriptine, ergot alkaloids,MAOIs,
medicines for allergies, colds, breathing difficulties,
procarbazine, stimulant medicines for attention disorders,
weight loss, or to stay awake, digoxin, efavirenz, linezolid,
medicines for depression like amitriptyline, nortriptyline,
medicines for heart disease or blood pressure like atenolol,
clonidine, doxazosin, mecamylamine, methyldopa, reserpine, St.
John's wort, theophylline, tizanidine, yohimbine.
Contraindications: if you have ever had an allergic reaction to
this product or any of its ingredients. If you are now taking a
prescription monoamine oxidase inhibitor (MAOI) (certain
drugs for depression, psychiatric, or emotional conditions, or
Parkinsons disease), or for 2 weeks after stopping the MAOI
drug.
755

15. Antihistamines And Antiallergics

Side effects: Cough, dry mouth, headache, loss of appetite,

nausea
Dose and Administration:Adults and children 12 years and
over: 1 tablet daily with a full glass of water; not more than 1
tablet in 24 hours.
Note: do not divide, crush, chew or dissolve the tablet

Storage: Store at room temperature between and protect from

moisture and light.
Pheniramine Aminosalicylate
Tablet, 50mg, 75mg
Indications: symptomatic relief of hypersensitivity reactions
including urticaria and angioedema, rhinitis and conjunctivitis,
and in pruritic skin disorders; prevention and control of motion
sickness.
Cautions, Drug interactions, Contraindications and Side
effects; see notes above.
Dose and Administration:Oral: 25 to 50 mg two or three times
a day
Storage: Protect from light.
Promethazine Hydrochloride
Elixir, 5 mg/5ml
Injection, 25 mg/ml in 1 ml and 2 ml ampoules
Suppository, 25 mg, 50 mg
Tablet, 10 mg, 25 mg
Indications: symptomatic relief of allergy such as hay fever,
urticaria, premedication; emergency treatment of anaphylactic
reactions; sedation; motion sickness
Cautions: see notes above; also pregnancy and breast-feeding.
Contraindications, Drug interactions; see notes above
756

15. Antihistamines And Antiallergics

Side effects: see notes above; intramuscular injection may be

painful.
Dose and Administration: Adult:Oral: 5-12.5 mg three times a
day before meals and at bed time, or 25 mg at bed time as
needed.IM or IV: 25mg; may be repeated within two hour if
necessary. Rectal: 25mg; may be repeated in two hours if
necessary.Child (Children 2 years of age and over):Oral:
125mcg per kg of body weight every four to six hours, or 500
mcg (0.5mg) at bed time as needed, or 5 to 12.5mg three times a
day or 25mg at bed time as needed.IM: 125mcg (0.125mg) per
kg of body weight every four to six hours or 500 mcg (0.5mg)
per kg of body weight at bed time as needed, or 6.25-12.5mg
three times a day or 25mg at bed time as needed.
Storage: Tablet and Injectables - store at room temperature in a
tight and light resistant container. Suppository - store between
2oc and 80c in a tight, light resistant container.
Terfenadine
Syrup, 30 mg/5ml
Tablet, 60 mg
Indications: symptomatic relief of allergy such as allergic
rhinitis, urticaria
Cautions: see notes above; also pregnancy and breast-feeding
Contraindications: see notes above; avoid grapefruit juice
(may inhibit metabolism of terfenadine)
Drug interactions: see notes above
Side effects: see notes above; incidence of sedation and
antimuscarinic effects low; erythema multiform and
galactorrhoea reported; ventricular arrhythmias (including
torsades de pointes) have followed excessive dosage.
Dose and Administration:Allergic rhinitis and conjunctivitis:
Adult and child over 50 kg: Oral: 60 mg daily increased if
757

15. Antihistamines And Antiallergics

necessary to 120 mg daily in single or 2 divided doses. Allergic

skin disorders: Adult and Child over 50 kg: Oral: 120 mg daily
in single or 2 divided doses.
Triprolidine Hydrochlorides
Elixir, 2mg/5ml
Tablet, 2.5 mg, 10 mg
Indications: symptomatic relief of hypersensitivity reactions
including urticaria, rhinitis and conjunctivitis and in pruritic
skin disorders
Cautions, Drug interactions, Contraindications, Side effects;
see notes above
Dose and Administration:Adult: 2.5 to 5 mg three times daily
Storage: in airtight containers, protect from light.
15.2. Medicines used in Allergic Emergencies
Anaphylactic shock and conditions such as angioedema
are medical emergencies that can result in cardiovascular
collapse and/or death. They require prompt treatment of
possible laryngeal edema, bronchospasm or hypertension.
Atopic individuals are particularly susceptible. Insect bites and
certain foods including eggs, fish, peanuts and nuts are also a
risk for sensitized persons. Therapeutic substances particularly
associated with anaphylaxis include blood products, vaccines,
hyposensitizing (allergen) preparations, antibiotics (especially
penicillins), iron injections, heparin, and neuromuscular
blocking medicines. Acetyl salicylic acid and other NSAIDs
may cause bronchoconstriction in leukotriene-sensitive patients.
In the case of medicine allergy, anaphylaxis is more likely to
occur after parenteral administration. Resuscitation facilities
should always be available when injecting a medicine associated
with a risk of anaphylactic reactions.
758

15. Antihistamines And Antiallergics

First line treatment of a severe allergic reaction includes

administering epinephrine (adrenaline), keeping the airway open
(with assisted respiration if necessary) and restoring blood
pressure. Epinephrine (adrenaline) should immediately be given
by intramuscular injection to produce vasoconstriction and
bronchodilation and injections should be repeated every 10
minutes until blood pressure and pulse have stabilized. If there
is cardiovascular shock with inadequate circulation, epinephrine
(adrenaline) must be given cautiously by slow intravenous
injection of a dilute solution. An intravenous corticosteroid e.g.
hydrocortisone (as sodium succinate) in a dose of 100 - 300 mg
is of secondary value in the initial management of anaphylactic
shock because the onset of action is delayed for several hours,
but should be given to prevent further deterioration in severely
affected patients.
Adrenaline (Epinephrine)
Injection, 0.1 % in 1 ml ampoule
Indications: emergency treatment of acute anaphylaxis;
angioedema; cardiopulmonary resuscitation; see also section 2.5
and 3.2 for other uses of Adrenaline
Cautions: hyperthyroidism, diabetes mellitus, heart disease,
hypertension, arrhythmias, cerebro-vascular disease, angleclosure glaucoma, second stage of labor, elderly patients.
Side effects: anxiety, tremor, tachycardia, arrhythmias,
headache, cold extremities; also hypertension (risk of cerebral
hemorrhage) and pulmonary edema (on excessive dosage or
extreme sensitivity) nausea, vomiting, sweating, weakness,
dizziness, and hyperglycemia also reported
Dose and Administrations:Caution: Different dilutions of
epinephrine injection are used for different routes of
administration. IM or SC injections use 1:1000 epinephrine
759

15. Antihistamines And Antiallergics

injection.Slow IV injection use 1:10 000 epinephrine

injection.This route should be reserved for severely ill patients
when there is doubt about the adequacy of circulation and
absorption from the intramuscular site.
Hydrocortisone
Injection (sodium succinate), 50 mg/ml
Indications: used for life-threatening shock only after less toxic
therapies have proven ineffective.
Cautions: pregnancy and in children; in patients with
hypothyroidism or cirrhosis, psychosis, hypertension,
congestive heart failure, diverticulitis, HIV, herpes simplex, oral
herpetic lesions, renal function impairment or disease,
tuberculosis, diabetes mellitus.
Drug interactions: alcohol, acetaminophen, non-steroidal antiinflammatory drugs, parenteral amphoterecin B, atropine, oral
antidiabetic agents or insulin, digitalis glycoside, diuretics,
isoniazid.
Contraindications: known hypersensitivity to any of
corticosteroids, recent surgery, osteoporosis, scleroderma,
Cushing's syndrome.
Side effects: immunosuppression, muscle pain or weakness,
delayed wound healing, edema, hypertension, cataract, diabetes
mellitus, nausea, vomiting, anorexia, headache, vertigo,
insomnia, restlessness, acne, impaired wound healing, increased
sweating, hirustism.
Dose and Administration:Adult: for life threatening shock:
IV-massive dose 50 mg/kg initially and repeated in 4 hours
and/or every 24 hours if needed, or 0.5-2g IV initially and
repeated at 2 to 6 hours intervals as required.
Storage: at room temperature.
760

15. Antihistamines And Antiallergics

Promethazine Hydrochloride
Injection, 0.1% in 1ml ampoule,
1:1000 1mg/ml
Indications: Symptomatic relief of allergy such as hay fever
and urticaria; emergency treatment of anaphylactic reactions.
Cautions: see section 1.4 under promethazine HCI; also avoid
extravasation with IV injection; severe coronary artery disease,
hepatic and renal dysfunction.
Contra-indications: see section 1.4 under promethazine HCI
Drugs interaction and Side-effects: See section1.4 under
promethazine HCI
Dose and administration:By deep intramuscularinjection, 25
50 mg; max. 100 mg; child 510 years6.2512.5 mg.By slow
intravenous injection inemergencies, 2550 mg as a solution
containing 2.5 mg/ml in water for injections; maximum 100 mg.
Storage: prior to dilution, store at room temperature; protect
from light. Solutions in NS or D5W are stable for 24 hours at
room temperature.

761

16. Ophthalmic Agents

16.
OPHTHALMIC AGENTS
16.1. Antiglaucoma
16.1.1. Beta -adrenergic Antagonists
Topical application of a beta-blocker to the eye reduces intraocular pressure effectively in chronic simple glaucoma,
probably by reducing the rate of production of aqueous humour.
Administration by mouth also reduces intra-ocular pressure but
this route is not used since side effects may be troublesome.
Betaxolol
Solution (eye drop), 0.5 %
Indications: treatment of chronic open-angle glaucoma and
ocular hypertension.
Dose and Administration: Adult: Instill one drop twice daily.
Cautions: concurrent use of beta-blockers
Drug interactions: amiodarone, ciprofloxacin, ketoconazole,
norfloxacin, chlorpromazine, fluoxetin, quinine, ritonavir,
phenobarbital.
Contraindications: hypersensitivity to the drug, sinus
bradycardia, overt cardiac failure, caradiogenic shock,
pregnancy (2nd and 3rd trimester).
Side effects: bradycardia, breast abscess, cataracts, cystitis,
diabetes melitus, gout, heart block,
hypertension,
hypothyroidism.
Storage: store at room temperature
Levobunolol
Solution (eye drop), 0.5%
Indications: treatment of chronic open-angle glaucoma or
ocular hypertension
Dose and Administration: Adult: Instill one drop in the
affected eye(s)
1-2times/day.
762

16. Ophthalmic Agents

Storage: store at room temperature

Timolol Maleate
Solution (eye drop), 0.25%, 0.5 %
Indications: ocular hypertension; chronic open-angle
glaucoma, aphakic glaucoma, some secondary glaucoma.
Cautions: older people; angle-closure glaucoma.
Drug interactions: acetazolamide, alcohol, epinephrine,
lidocaine, nifedipine, prazosin, procainamide, quinidine,
verapamil, thiopental, reserpine, metformin, hydralazine.
Contraindications: uncontrolled heart failure, bradycardia,
heart block; asthma, obstructive airways disease.
Side effects: stinging, burning, pain, itching, erythema,
transient dryness, allergic blepharitis, transient conjunctivitis,
keratitis, decreased corneal sensitivity, diplopia, ptosis;
systemic effects, particularly on the pulmonary, cardiovascular
and central nervous systems, may follow absorption.
Dose and Administration: by instillation into the eye, 1 drop
twice daily.
Storage: store at room temperature.
16.1.2. Adrenergic Agents
Most adrenergic agonists reduce the pressure in the eyes by
reducing how much fluid (aqueous humor) the eyes produce.
They also increase the amount of fluid that drains out of the
eyes.
Apraclonidine HCL
Eye drops, 0.5%, 1%
Indications:prevention and treatment of post surgical
intraocular pressure (IOP) elevation; short-term, adjunctive
therapy in patients who require additional reduction of IOP.
763

16. Ophthalmic Agents

Cautions: history of angina, severe coronary insufficiency,

recent myocardial infarction, heart failure, cerebrovascular
disease, vasovagal attack, chronic renal failure; depression;
pregnancy and breast-feeding
Contraindications: history of severe or unstable and
uncontrolled cardiovascular disease
Dose and Administration: 1%; control or prevention of
postoperative elevation of intraocular pressure after anterior
segment laser surgery, apply 1 drop 1 hour before laser
procedure then 1 drop immediately after completion of
procedure; CHILD not recommended
0.5%; short-term adjunctive treatment of chronic glaucoma in
patients not adequately controlled by another drug (see note
below), apply 1 drop 3 times daily usually for max. 1 month,
CHILD not recommended
Side effects: dry mouth, taste disturbance; hyperaemia, ocular
pruritus, discomfort and lacrimation (withdraw if ocular
intolerance including oedema of lids and conjunctiva);
headache, asthenia, dry nose; lid retraction, conjunctival
blanching and mydriasis reported after peri-operative use; since
absorption may follow topical application systemic effects (see
Clonidine Hydrochloride, section 2.5) may occur.Note: May not
provide additional benefit if patient already using two drugs that
suppress the production of aqueous humour.

Brimonidine
Eye drop, 0.2%
Indications: lowering of intraocular pressure (IOP) in patients
with open-angle glaucoma or ocular hypertension.
Cautions:severe cardiovascular disease; cerebral or coronary
insufficiency, Raynauds syndrome, postural hypotension,
depression, hepatic or renal impairment; pregnancy, breastfeeding; Driving
764

16. Ophthalmic Agents

Dose and Administration:Children 2 years of age and

Adults: Glaucoma: Instill 1 drop in affected eye (s) 3 times/day
(approximately every 8 hours)
Side effects: ocular reactions including conjunctival
hyperaemia, stinging, pruritus, allergy, and conjunctival
folliculosis, visual disturbances, blepharitis, epiphora, corneal
erosion, superficial punctuate keratitis, eye pain, discharge,
dryness, and irritation, eyelid inflammation, oedema, pruritus
conjunctivitis, photophobia; also, hypertension, headache,
depression, dry mouth, fatigue, drowsiness; less commonly,
taste disturbances, palpitation, dizziness, syncope, rhinitis, nasal
dryness.
16.1.3. Parasympathomimetics (miotics)
They act by opening up the inefficient drainage channels in the
trabecular meshwork resulting from contraction or spasm of the
ciliary muscle.
Pilocarpine hydrochloride
Solution (eye drop), 1-4%
Eye ointment, 1-4%
Indications:
chronic
open-angle
glaucoma;
ocular
hypertension; emergency treatment of acute angle-closure
glaucoma; to antagonize effects of mydriasis and cycloplegia
following surgery or ophthalmoscopic examination.
Cautions: retinal disease, conjunctival or corneal damage;
monitor intra-ocular pressure in chronic open-angle glaucoma
and in long term treatment; cardiac disease, hypertension,
asthma, peptic ulceration, urinary - tract obstruction, Parkinson
disease, stop treatment if symptoms of systemic toxicity
develop.
765

16. Ophthalmic Agents

Do not carry out skilled tasks, for example operating machinery

or driving until vision is clear.
Drug interactions: beta-blockers, anticholinergic drugs
(atropin).
Contraindications: acute iritis, acute uveitis, anterior uveitis,
some forms of secondary glaucoma; acute inflammation of
anterior segment; not advisable after angle closure surgery.
Side effects: eye pain, blurred vision, ciliary spasm,
lacrimation, myopia, browache; conjunctival vascular
congestion, superficial keratitis, vitreous hemorrhage and
increased pupillary block have been reported; lens opacities
have occurred following prolonged use; rarely systemic effects
including hypertension, tachycardia, bronchial spasm,
pulmonary oedema, salivation, sweating, nausea, vomiting, and
diarrhea.
Dose and Administration:
Chronic open-angle glaucoma: instill into the eye, 1 drop 4
times daily.Acute angle-closure glaucoma before surgery: by
instillation intothe eye, 1 drop every 10 minutes for 30-60
minutes, then 1 drop every 1-3 hours until intra-ocular pressure
subsides.
Storage: store at room temperature.
16.1.4. Carbonic Anhydrase Inhibitors
The carbonic anhydrase inhibitors, acetazolamide and
dorzolamide, reduce intra-ocular pressure by reducing aqueous
humour production. Systemic use also produces weak diuresis.
Acetazolamide
Tablet/capsule, 250 mg
Powder for injection, 125 mg, 500 mg in vial

766

16. Ophthalmic Agents

Indications: reduction of intra-ocular pressure in open-angle

glaucoma, secondary glaucoma, and preoperatively in angleclosure glaucoma
Cautions: elderly; pregnancy; breastfeeding; diabetes;
pulmonary obstruction; monitor blood count and electrolytes if
used for long periods.
May impair ability to perform skilled tasks, for example
operating machinery, driving.
Drug interactions: quinidine, procainamide, mexiletine and
TCAs, lithium, diuretics and potassium-depleting agents.
Contraindications: hypersensitivity to sulfonamides; chronic
angle-closure glaucoma, hypokalaemia, hyponatraemia,
hyperchloraemic acidosis; renal and hepatic impairment.
Side effects: nausea, vomiting, diarrhea, taste disturbance; loss
of appetite, paraesthesia, flushing, headache, dizziness, fatigue,
irritability, depression; thirst, polyuria.
Dose and Administration: Adult: Primary open-angle: Oral:
250 mg 1 - 4 times daily or 500 mg sustained release capsule
twice daily.Secondary, acute (closed angle):IV: initially 250 500 mg repeated if necessary in 2 - 4 hours to a maximum of
1g/day.
Child:Oral: 8 - 30 mg/kg/day in 3 - 4 divided doses. IV: 20-40
mg/kg/24 hours divided every 6 hours, not to exceed 1g/day.
Storage: store at room temperature.
Brinzolamide
Eye Drops, 1 %, 2%
Indications:adjunct to beta-blockers or used alone in raised
intra-ocular pressure; in ocular hypertension and in open-angle
glaucoma.
Cautions: pregnancy, breast-feeding; closed angle glaucoma,
Glaucoma caused by accumulation of pigment particles in the
drainage channels of the eye (pigmentary glaucoma), Glaucoma
767

16. Ophthalmic Agents

caused as a result of a disorder of part of the eyeball called the

ciliary body (pseudoexfoliative glaucoma), Diabetes; Contact
lens wearers; dry eyes; People with conditions that may affect
the front layer of the eye (cornea).
Drug interactions: oral carbonic anhydrase inhibitors (e.g.
Acetazolamide), other eye medications, clotrimazole,
itraconazole, ketoconazol, eritonavir,high dose salicylates
Contra-indications: Known hypersensitivity to brinzolamide
or any ingredient in the formulation; Allergy to medicines from
the sulphonamide group; renal impairment; hyperchloraemic
acidosis; Children under 18 years old.
Side-effects: Inflammation of the eyelids (blepharitis), dry eyes,
Eye itching, blurred vision, eye stinging or burning, sensation of
something being in the eye, discharge from the eye, headache,
abnormal taste, dry mouth. Uncommon side effects: keratitis,
conjunctivitis, eyelid swelling, redness or itching, corneal
erosion, photophobia, bradycardia, atrial fibrillation, anaemia,
sleepiness, diarrhoea, nausea, upper abdominal pain, flatulence,
urticaria, Nasal inflammation or dryness, feeling weak or
fatigued
Dose and administration: Adult:ophthalmic: For glaucoma or
ocular hypertension, instill 1 drop of a 1% suspension in the
affected eye(s) 3 times daily.
Dorzolamide
Drops, 2 %
Indications: topical treatment of ocular hypertension and open
angle glaucoma
Cautions and Side effects: see acetazolamide
In dorzolamide, local effects include bitter taste, burning,
stinging or itching of the eye, blurred vision, tearing,
conjunctivitis, eyelid inflammation.
768

16. Ophthalmic Agents

Dose and Administration: Adult:Monotherapy: Instill 1 drop 3

times daily. Adjunctive therapy with a topical beta-blocker:
Instill 1 drop twice daily
Storage: store in light- resistant containers at room temperature
Methazolamide
Tablet, 25 mg, 50 mg, 100 mg
Indications: Adjunctive treatment of open-angle or secondary
glaucoma; short-term therapy of narrow-angle glaucoma when
delay of surgery is desired
Cautions, Drug interactions, Contraindications and Side
effects: see under acetazolamide
Dose and Administration: Adult: Oral: 50-100mg 2-3
times/day.
16.1.5. Prostaglandins analogue
They reduce intra-ocular pressure in ocular hypertension or in
open-angle glaucoma by increase uveoscleral outflow.
Bimatoprost
Eye drops, 0.003%
Indications: raised intra-ocular pressure in open-angle
glaucoma; ocular hypertension
Cautions: Hepatic impairment, renal impairment
Contraindication: Hypersensitivity to bimatoprost or any
component of the formulation
Dose and administration: Open-angle glaucoma or ocular
hypertension: Instill 1 drop into affected eye(s) once daily in the
evening; do not exceed once-daily dosing (may decrease IOPlowering effect.)If used with other topical ophthalmic agents,
separate administration by at least 5 minutes.
Side-effects: brown pigmentation particularly in those with
mixed-color irides, blepharitis, ocular irritation and pain,
conjunctival hyperaemia, transient punctuate epithelial erosion,
769

16. Ophthalmic Agents

skin rash, dry eyes, headache, and photophobia; they may also
cause, darkening, thickening and lengthening of eye lashes.
Storage: between2 to 250c
Latanoprost
Eye drops, 0.005%
Indications: reduction of elevated intraocular pressure in
glaucoma and ocular hypertension in patients intolerant or
unresponsive to other agents.
Dose and Administration: Adult: Instill 1 drop once daily.
Cautions,Side effects & Contraindication as Bimatoprost
Storage: store at room temperature.
Travoprost
Eye drops, 0.004%
Indications: for the reduction of elevated intraocular pressure
in patients with open angle glaucoma or ocular hypertension.
Cautions: See underbimatoprost
Contraindication: Hypersensitivity to travoprost or any
component of the formulation; pregnancy
Dose and Administration: one drop in the affected eye(s) once
daily in the evening.
Storage: between2 to 250c
16.1.6. Hyperosmotic agents
Hyperosmotic agents lower intraocular pressure by creating an
osmotic gradient between the blood and the ocular fluids.
Glycerol Mannitol and Isosorbide are useful short - term ocular
hypotensive drugs, used in the pre-operative treatment of acute
closed - angle glaucoma.
Glycerol
Oral solution, 50%, 70%
770

16. Ophthalmic Agents

Indications: used for short-term reduction of vitreous volume

and intraocular pressure before and after ophthalmic surgery,
and as an adjunct in the management of acute glaucoma.
Cautions: caution in applying glycerol to the cornea.
Side effects: headache, nausea, vomiting, diarrhoea, thirst,
dizziness, and mental confusion may occur less frequently.
Cardiac arrhythmias have been reported.
Dose and Administration: Adult and Child: Oral: 1 to 1.8
g/kg given as a 50 % solution.
Storage: store in airtight container.
Isosorbide
Oral solution, 40% - 50%
Indications: short-term reduction of intraocular pressure, used
prior to and after intraocular surgery, interrupt an acute attack of
glaucoma.
Cautions: when giving repetitive doses particularly in patients
with diseases associated with salt retention; breast feeding.
Contraindications:
Well-established
anuria,
severe
dehydration, frank or impending acute pulmonary edema,
severe cardiac decompensation, hypersensitivity to any
component of this preparation
Side effects: nausea, vomiting, headache, confusion, and
disorientation may occur. Occurrences of syncope, gastric
discomfort, lethargy, vertigo, thirst, dizziness, hiccups,
hypernatremia, hyperosmolarity, irritability, rash and lightheadedness have been reported.
Dose and Administration: initial dose of is 1.5 gm/kg body
weight (equivalent to 1.5 mL /lb. of body weight). The onset of
action is usually within 30 minutes while the maximum effect is
expected at 1 to 1 1/2 hours. The useful dose range is 1 to 3
gm/kg body weight and the drug effect will persist up to 5 to 6
hours. Use two to four times a day as indicated.
771

16. Ophthalmic Agents

Storage: Store at 15-30C

Mannitol
Injection, 20%, 25%
Indications: reduction of increased intraocular pressure.
Cautions:extravasation
causes
inflammation
and
thrombophlebitis.
Dose and Administration: Adult: IV: 1.5-2 g/kg administered
as a 20 % or 25% solution over a period of 30-60 minutes.
16.1.7. Combinations
Dorzolamide HCL and timolol maleate in a fixed combination
ophthalmic solution is used topically to reduce elevated IOP in
patients with open angle glaucoma or ocular hypertension who
have not responded adequately to a topical Beta-adrenergic
blocking agent. Timolol may be used alone or in conjunction.
When used in conjunction with these agents, timolol may have
an additive IOP-lowering effect. If timolol is used to reduce IOP
in patients with angle closure glaucoma, the drug should not be
used alone but in combination with mitotic since timolol has
little or no effect on pupil size.
Timolol + Bimatoprost
Eye drops, 0.5% + 0.003%
Indications: see note above
Cautions: Decreased kidney function, Decreased liver function,
Closed angle glaucoma, neovascular glaucoma, inflammatory
glaucoma, congenital glaucoma, Inflammatory conditions of the
eye, disorders of the back of the eye (cornea), dry eyes, People
with an artificial lens in (pseudophakia), People with no lens in
the eye (aphakia), Closed or blocked retinal vein,diabetic
retinopathy, hypoglycaemia, history of severe heart disease,
Heart failure, A severe form of angina pectoris, not caused by
772

16. Ophthalmic Agents

exertion (Prinzmetal's angina), Severe disorders of blood

circulation,hypotension, hyperthyroidism, Psoriasis, Abnormal
muscle weakness (myaesthenia gravis).
Drug Interactions: beta-blockers, eg atenolol; calcium channel
blockers, e.g. nifedipine, verapamil, diltiazem, digoxin,
medicines for abnormal heart rhythms (antiarrhythmics), e.g.
amiodarone.
Contraindications: Hypersensitivity to the active substances or
to any of the excipients, asthma or history of asthma,
Severe chronic obstructive pulmonary disease (COPD), sinus
bradycardia, Serious defect in the heart's electrical message
pathways resulting in decreased function of the heart (2nd or
3rd degree heart block), Uncontrolled heart failure, cardiogenic
shock, Pregnancy, Breastfeeding, children and adolescents
under 18 years of age
Dose and Administration: The recommended dose is one drop
in the affected eye(s) once daily, administered in the morning.If
more than one topical ophthalmic product is to be used, the
different products should be instilled at least 5 minutes apart.
Side effects: Red eye(s), Growth and darkening of eyelashes,
Eye irritation including stinging, burning and itching, Sensation
of something in the eye(s), Dry eye(s), Eye pain, photophobia,
Corneal erosion, Redness, itching or swelling of the eyelid(s),
Darkening of the eyelid(s) or skin around the eye(s),
Inflammation of the eyelid(s), inflammation of the iris , Eye
discharge, Headache, rhinitis, change in colour of the iris,
cataracts, Dizziness, slowed or irregular heart rate, changes in
blood pressure, shortness of breath, macular oedema
Storage: Store below 25C. Do not use more than 30 days after
opening. Keep bottle tightly closed when not in use.

773

16. Ophthalmic Agents

Timolol + Brimonidine
Eye drops, 0.5% + 2%
Indications: see note above
Cautions, contraindications and side effects: see under Timolol
+ Bimatoprost
Drug interaction: monoamine oxidase inhibitor (MAOIs), eg
the
antidepressants
phenelzine,
tranylcypromine
or
isocarboxacid (these eye drops should not be started until 14
days after stopping treatment with an MAOI)tricyclic
antidepressants,
eg
amitriptyline,
imipraminerelated
antidepressants, eg mianserin, medicines for high blood
pressure, see also under Timolol + Bimatoprost
Dose and Administration: instill one drop twice a day (12
hours apart) into the affected eye(s)
Timolol + Brinzolamide
Eye drops, 0.5% + 1%, 2%
Indicactions: see notes above
Timolol + Dorzolamide
Eye drops, 0.5% + 2%
Indications: inhibitor of human carbonic anhydrase II.
Cautions: pregnancy; lactation
Contraindications: bronchial asthma; history of bronchial
asthma; severe chronic obstructive pulmonary disease; sinus
bradycardia; second or third degree atrioventricular block; overt
cardiac failure; cardiogenic shock; hypersensitivity to any
components of the product.
Side effects: burning; stinging; redness of the eye(s); blurred
vision; tearing or itching; bitter taste sensation after instillation;
shortness of breath; upset stomach
Dose and Administration: instill one drop into the affected eye
(s) 2 times daily
774

16. Ophthalmic Agents

Storage: store between 15-25 0c. Discard after 30 days of

opening.
Timolol + Latanoprost
Eye drops, 0.5% + 0.005%
Indications: reduction of intraocular pressure (IOP) in patients
with open angle glaucoma and ocular hypertension who are
insufficiently responsive to topical beta-blockers or
prostaglandin analogues.
Contraindications: lactation; also see under Timolol +
Dorlzolamide
Side effects: eye irritation; eye pain; increased iris pigmentation
which may be permanent; bradycardia; arrhythmia; congestive
heart failure; bronchospasm and allergic reactions
Dose and Administration:instill one drop into the affected eye
(s) once daily.
Storage: store between 2-8 0c. Protect from light, once opened
container may be stored at room temperature below 250c
Timolol + Pilocarpine
Eye drops, 0.5% + 2% - 4%
Indications: see notes above
Timolol + Travoprost
Eye drops, 0.5% + 0.004%
Indications: treatment of open angle glaucoma and raised
pressure in the eye (ocular hypertension)
Caution:Closed angle glaucoma; neovascular glaucoma;
pigmentary glaucoma; pseudoexfoliative glaucoma; congenital
glaucoma; Thyroid eye disease; conjunctivitis; pseudophakia;
aphakia; People with a closed or blocked retinal vein;
Diabetes; diabetic retinopathy; hypoglycaemia ; History of
severe heart disease; Heart failure; A severe form of angina
775

16. Ophthalmic Agents

pectoris, not caused by exertion (Prinzmetal's angina); People

with poor blood circulation in the arteries of the extremities, eg
hands and feet ; hypotension; hyperthyroidism ; History
of allergies; Psoriasis; myaesthenia gravis.
Contraindications: Allergy to other beta-blocker medicines;
asthma or history of asthma; severe COPD; allergic rhinitis;
People with other breathing problems; sinus bradycardia; 2nd or
3rd degree heart block; Uncontrolled heart failure; cardiogenic
shock; corneal dystrophy; Pregnancy; Breastfeeding; allergic to
one or any of its ingredients
Side effects: see under Timolol + Latanoprost
Dose and Administration: Adults: instill one drop into the
affected eye (s) once daily.
16.2. Mydriatics / Cycloplegics
Both dilation of the pupil (mydriasis) and paralysis of
accommodation (cycloplegia) are produced by anticholinergic
agents applied topically. These agents are not only used as aids
in the examination of the eye and other ophthalmic procedures
but also in the management of inflammatory conditions of the
eye to treat or prevent the formation of adhesions between the
lens and the iris. Atropine is useful in inflammatory conditions
involving the iris and uveal tract, and for refraction in children
up to about 6 years of age.
Cyclopentolate has a more rapid onset and shorter duration of
action than atropine. Systemic toxicity is possible, especially in
infants.
Homatropine has weaker effets than atropin; action is more
rapid and less prolonged. It may be preferred to atropin for
diagnostic purposes but is considered an inadequate cycloplegic
in children.
776

16. Ophthalmic Agents

Tropicamide displays action similar to atropine but with more

rapid onset and shorter duration. It is considered an inadequate
cycloplegic in children.
Hyoscine onset of action is more rapid, duration shorter and it is
more toxic than atropine.
Phenylephrine is mainly a direct acting alpha-adrenoceptor
stimulant. 2.5-10% solutions produce mydriasis with
insignificant effect on accommodation. 10% solutions may have
profound effects on the cardiovascular system and should be
used with caution. It is mainly indicated for dilatation of the
pupil for funduscopy, sometimes in combination with
cyclopentolate or tropicamide.
Atropine Sulphate
Solution (eye drops), 0.5 %, 1 %
Eye ointment, 1%
Indication: iritis, uveitis; cycloplegic refraction procedures.
Cautions: may precipitate acute attack of angle-closure
glaucoma, particularly in the elderly or long-sighted; risk of
systemic effects with eye drops in infants under 3 months - eye
ointment preferred. May cause sensitivity to light and blurred
vision. Do not carry out skilled tasks, for example operating
machinery or driving, until vision is clear.
Contraindication: angle-closure glaucoma.
Side effects: transient stinging and raised intra-ocular pressure;
on prolonged administration, local irritation, hyperaemia,
edema, conjunctivitis, contact dermatitis; systemic toxicity may
occur in the very young and the elderly.
Dose and Administration: by instillation into the eye:
Cycloplegic refraction: Adult: 1 drop (1%) twice daily for 1-2
days before procedure or a single application of 1 drop (1%) 1
hour before procedure.Child: under 3 months (see cautions), 3
777

16. Ophthalmic Agents

months-1 year (0.1%), 1-5 years (0.1-0.5%), over 5 years (0.51%), 1 drop twice daily for 1-3 days before procedure with a
further dose given 1 hour before procedure. Iritis,
Uveitis:Adult: instill 1 drop (0.5 or 1%) up to 4 times
daily.Child: instill 1 drop (0.5 or 1%) up to 3 times daily.
Storage: store at room temperature.
Cyclopentolate Hydrochloride
Solution (eye drops), 0.5 %, 1 %, 2 %
Indications: diagnostic procedures requiring mydriasis and
cycloplegia.
Cautions, Contraindications and Side effects; see under
atropine sulphate.
Dose and Administration: Instill 1 drop followed by another
drop in 5 minutes.
Storage:store at a temperature not exceeding 8oC in airtight
containers.
Homatropine Hydrobromide
Solutions (eye drop), 1%, 2%
Indications: mydriasis and cycloplegia; uveitis.
Cautions: see notes above.
Contraindications: angle closure glaucoma.
Side effects: transient stinging and raised intraocular pressure,
on prolonged administration, local irritation, hyperaemia,
oedema and conjunctivitis may occur: contact dermatitis;
systemic toxicity may occur in the very young and the elderly.
Dose and Administration:For refraction: instill one drop,
repeated if necessary 5 or 10 minutes later.Uveitis (treatment):
one or two drops may be installed up to every 3 to 4 hours.
Storage: store in airtight containers. Protect from light.

778

16. Ophthalmic Agents

Hyoscine (scopolamine) Hydrobromide

Solution (eye drop), 0.25 %
Indications: produce cycloplegia and mydriasis; treatment of
iridocyclitis.Cautions, Drug interactions, Contraindications,
Side effects and Storage,
Dose and Administration:Refraction:Adult: Instill 1-drop 1
hour before procedure.Child: Instill 1 drop twice daily for 2
days before procedure.Iridocyclitis:Adult: Instill 1 drop up to 4
times /day.Child: Instill 1 drop of 0.25 % to eye(s) up to 3
times/day.
Storage: store at room temperature
Phenylephrine
Solution (eye drop), 1 %, 2 %, 2.5 %, 5 %, 10 %.
Indications:mydriasis, diagnostic aid and ophthalmic
decongestion
Cautions: The 10% solution should be used with caution in
patients with diabetes, hypertension, cardiac disease, severe
arteriosclerotic changes or thyrotoxicosis. (A dramatic increase
in blood pressure may be produced). It should be avoided in the
elderly and neonates.
Drug interactions: beta-blockers and other antihypertensive
(reserpine), TCA, MAO inhibitors.
Contraindications: hypersensitivity, hypertension, and
ventricular tachycardia.
Side
effects:
systemic
effects
includehypertension,
subarachnoid haemorrhage, ventricular arrhythmias and
myocardial infarction; also trembling, headache, agitation and
sweating. Blood pressure changes are most pronounced in the
elderly, neonates and patients with orthostatic hypotension.
Hypersensitivity reactions such as allergic conjunctivitis or
dermatitis may occur. Pigment granules may be released from
779

16. Ophthalmic Agents

the iris into the aqueous; they disappear within 12-24 hours.
Rebound miosis the day after administration and subsequent
decreased sensitivity to the mydriatic effect may occur in the
elderly.
Dose and Administration:Adult: 1 drop of a 10 % solution as
required.
Storage: store at controlled room temperature; protect from
light and excessive heat.
Tropicamide
Solution (eye drop), 0.5 %, 1 %
Indications: dilatation of the pupil to examine the fundus.
Cautions: patients aged over 60 years and hypermetropic (longsighted) may precipitate acute angle-closure glaucoma; darkly
pigmented iris, more resistant to papillary dilatation exercise
caution to avoid overdosage.
Avoid operating machinery or driving for 1 to 2 hours after
mydriasis
Side effects: transient stinging and raised intraocular pressure;
on prolonged administration - local irritation, hyperaemia,
oedema and conjunctivitis.
Dose and Administration:Adult and Child:Ocular
instillation: 1 or 2 drops of 0.5%; 15 - 20 minutes before
examination of eye.
Storage: store at room temperature.
Tropicamid + Phenylephrine
Solution (eye drop), 0.5 % + 1 %
Indication: can be used both for diagnostic and therapeutic
purpose:Therapeutic purpose: Inflammatory conditions of the
uveal tract. Diagnostic purpose: Retinal photography,
780

16. Ophthalmic Agents

Refractive errors, Fundus examination/photography, Slit lamp

examination
Pre-operative use: In order to undergo surgical procedure that
requires the visualization of structures behind the iris, such as
cataract extraction, vitrectomy and retinal detachment surgery,
the pupil must be adequately dilated before surgery.
Cautions: Pregnancy, breast-feeding mother, children
Drug Interaction: MAO inhibitors, tricyclic antidepressants
Contraindications: Hypersensitivity to the medicine and any
components of the formulation; narrow angles or narrow angles
glaucoma.
Side effects: May cause elevated Intra ocular pressure, stinging
on application, dryness of the mouth, blurred vision,
tachycardia, photophobia with or without corneal staining,
headache, parasympathetic stimulation and allergic reactions.
Dose and administration:Therapeutic purpose: 1-2 drops bidqid or as required.Diagnostic /Pre-operative purpose: 1-2 drops
in the eye(s) 15-30 minutes prior to the procedure.
Storage: Store in a cool dry place Protect from light.
16.3. Anti-infectives, Ophthalmic
16.3.1. Antibacterials
Acute bacterial infection of the external eye, including
acute bacterial conjunctivitis, corneal ulceration, blepharitis,
dacryocystitis, and discharging sockets are caused by the
pathogens Staphylococcus aureus, Streptococcus pneumoniae,
and Haemophilus influenza. Bacterial infections are generally
treated topically with eye drops and eye ointments. Systemic
administration is sometimes appropriate in blepharitis. Intraoccular infection, a variety of routes (intra corneal, intra vitreal
and systemic) may be used.
781

16. Ophthalmic Agents

Chloramphenicol has a broad spectrum of activity and is

the drug of choice for superficial eye infections.
Gentamicin
is
a
broad-spectrum
bactericidal
aminoglycoside antibiotic with particular activity against
Pseudomonas aeruginosa, Neisseria gonorrhoea and other
bacteria that may be implicated in blepharitis or conjunctivitis.
Tetracycline is a broad spectrum antibiotic with activity
against many Gram- positive and Gram-negative bacteria
including N. gonorrhoea. Ophthalmic tetracycline is used in
blepharitis, conjunctivitis, and keratitis produced by susceptible
bacteria.Many antibacterial preparations also incorporate a
corticosteroid but such mixtures should not be used unless a
patient is under close specialist supervision. In particular they
should not be prescribed for undiagnosed red eye which is
sometimes caused by the herpes simplex virus and may be
difficult to diagnose.
Administration: Frequency of application depends on the
severity of the infection and the potential for irreversible ocular
damage; antibacterial eye preparations are usually administered
as follows: Eye drops, apply 1 drop at least every 2 hours then
reduce frequency as infection is controlled and continue for 48
hours after healing; Eye ointment, apply either at night (if eye
drops used during the day) or 34 times daily (if eye ointment
used alone).
Chloramphenicol
Eye ointment, 1 %, 5 %
Solution (eye drop), 0.4 %, 0.5 %, 1 %, 5 %
Indications: topical treatment of superficial ocular infections
involving the conjunctiva and/or cornea caused by susceptible
organisms.
782

16. Ophthalmic Agents

Contraindications: previous allergy or toxic reaction to

chloramphenicol
Side effects: hypersensitivity
Dose and Administration:Ointment topical:a thin strip
(approximately 1cm) to the conjunctiva every three hours; Eye
drops, 1 drop every one to four hours
Storage: at room temperature in a tight container, protect from
freezing.
Ciprofloxacin
Eye ointment, 0.3 %
Solution (eye drop), 0.3%
Indication: superficial bacterial infections, see notes above;
corneal ulcers and prophylaxis during otic surgeries such as
mastoid surgery
Cautions: ifirritation persists or increases, discontinue. Do not
touch the dropper, since this may contaminate solution.
Contraindications: Hypersensitivity to quinolone group of
antibacterial or any of the Components of the formulation
Dose and administration:Superficial bacterial infection:Adult
and Child apply eye drops 4 times daily; in severe infection
apply every 2 hours during waking hours for 2 days, then 4
times daily; maximum duration of treatment 21 days. Adult and
Childover 1 year, apply 1.25 cm eye ointment 3 times daily for
2 days, then twice daily for 5 days. Corneal ulcer:Adult and
Childapply eye drops throughout day and night, day 1 apply
every 15 minutes for 6 hours then every 30 minutes, day 2 apply
every hour, days 314 apply every 4 hours; maximum duration
of treatment 21 days. Adult and Child over 1 year, apply eye
ointment throughout day and night; apply 1.25 cm ointment
every 12 hours for 2 days, then every 4 hours for next 12 days.
Side effects: local burning and itching; lid margin crusting;
hyperaemia; taste disturbances; corneal staining, keratitis, lid
783

16. Ophthalmic Agents

oedema, lacrimation, photophobia, corneal infiltrates; nausea

and visual disturbances.
Storage: Store at room temperature
Erythromycin
Eye ointment, 0.5 %
Solution (eye drop), 1%
Indications: topical prophylaxis of neonatal conjunctivitis
caused by Chlamydia trachomatis.Topical treatment of
superficial ocular infections of the conjunctiva and/or cornea
caused by susceptible organisms.
Cautions: intolerance to erythromycin.
Side effects: eye irritation.
Dose and Administration:ointment, a thin strip (approximately
1cm six times a day. Neonatal conjunctivitis/Ophthalmia
neonatorum: topical: to each conjunctiva, a thin strip
(approximately 0.5 to 1 cm) of ointment as a single dose
following cesarean or vaginal delivery.
Storage: at room temperature. Protect from freezing.
Gentamicin
Solution (eye drop), 0.3 %
Indications: blepharitis; bacterial conjunctivitis; systemic
infections.
Cautions: discontinue if purulent discharge; inflammation or
exacerbation of pain.
Contraindications: hypersensitivity to aminoglycoside group
of antibiotics
Side effects: burning, stinging, itching, dermatitis.
Dose and Administration:Mild to moderate infection:by
instillation into the eye: Adult and Child: 1 drop every 2 hours,
reducing frequency as infection is controlled, then continue for
48 hours after healing is complete.Severe infection: by
784

16. Ophthalmic Agents

installation in to the eye: Adult and Child: 1 drop every hour,

reducing frequency as infection is controlled, then continue for
48 hours after healing is complete.
Moxifloxacin
Solution (eye drop), 0.3%, 5ml
Indication: bacterial conjunctivitis.
Side effects: conjunctivitis, dry eye, ocular discomfort, ocular
hyperemia, ocular pain, ocular pruritus, subconjunctival
hemorrhage, tearing, visual acuity decreased.
Dose and Administration: Children 1 year and Adult: Instill
1 drop into affected eye (s) 3 times per day for 7 days.
Storage: store at room temperature
Neomycin Sulphate
Eye ointment 0.5 %, 2 %
Indications: treatment of superficial ocular infections, caused
by susceptible organisms
Cautions: sensitive to neomycin.
Side effects: burning or stinging, blurred vision hypersensitivity
to neomycin
Dose and Administration: a thin strip (approximately 1cm)
every eight to twenty-four hours.
Storage: at room temperature, protect from freezing
Ofloxacin
Solution (eye drop), 0.3%, 5ml
Indications: to treat bacterial infections of the eye
Cautions: pregnancy; breast-feeding
Drug interactions: see quinolone under section 7.1.2
Contraindications: History of hypersensitivity to Ofloxacin, to
other quinolone, or to any of the components in this medication
785

16. Ophthalmic Agents

Side effects: dizziness; nausea; blurred vision; burning;

discomfort in the eye , edema, eye pain; redness; stinging;
tearing. Systemic effects
Dose and administration:Adults and children>1 year:
conjunctivitis: instill 1-2 drops in affected eye(s) every 2-4
hours for the first 2 days, then use 4 times/day for additionsl 5
days.
Corneal ulcer: 1-2 drops every 30 minutes while awake and
every 4-6 hours after retiring for the first 2 days; beginning on
day 3, instill 1-2 drops every hour while awake for 4-6
additional days; thereafter, 1-2 drops 4times/day until clinical
cure
Storage: store at room temperature
Oxytetracycline Hydrochloride
Eye ointment, 0.5 %
Indications: superficial infections of the eye caused by
susceptible bacteria.
Cautions: sensitive to tetracyclines.
Side effect: burning, stinging, increased lacrimation, foreign
body sensation.
Dose and Administration:Adult:topical, in the lower
conjunctival sac of the infected eye: a thin amount of
ophthalmic ointment every 6-12 hours daily.
Storage: at room temperature in a collapsible ophthalmic
ointment tube, protect from freezing.
Polymyxin B + Bacitracin
Eye ointment, polymyxin B 100, 000 units and Bacitracin
500,000 units
Indications: treatment of superficial infections caused by
susceptible organisms.
786

16. Ophthalmic Agents

Dose and Administration: Adult and Child:Instil ribbon in

the affected eye(s) every 3 - 4 hours for acute infections or 2 -3
times/day for mild to moderate infections for 7 - 10 days.
Rifamycin
Solution (eye drop), 1%
Rifamycin is an antibacterial that has been used in the treatment
of infections caused by susceptible organisms such as
staphylococci. It is given by local instillation and topical
application.
Tetracycline
Eye ointment, 1 %
Solution (eye drop), 1 %
Indications: for the treatment of superficial bacterial infections
of the eye (Purulent conjunctivitis), trachoma, and for the
prophylaxis of gonococcal and nongonococcal ophthalmia
neonatorum.
Dose and Administration: Topical, to the conjunctiva.
Purulent Conjunctivitis: Adult and Child: Apply a thin strip
(approximately 1cm) of ointment onto the infected eye every 6
hours daily for 5 days.Trachoma:Adult and Child: Apply a
thin strip of ointment onto each eye twice daily for a minimum
of 6 weeks.Prophylaxis of gonococcal and nongonococcal
ophthalmia neonatorum: Apply a thin strip of ointment onto
each of neonates shortly (no later than 1 hour) after delivery.
Storage: at room temperature.
Tobramycin
Solution (eye drop), 0.3 %
Indications: topically used to treat superficial ophthalmic
infections caused by susceptible bacteria.
787

16. Ophthalmic Agents

Cautions, Contraindications and Drug interactions; see

under section7.1.2.
Side effects: conjunctival erythema, lid itching, lid swelling.
Dose and Administration: Adult and Child 2 months:
Instill 1 to 2 drops of solution every 4 hours; for severe
infections instill 2 drops every 30 - 60 minutes initially, then
reduce to less frequent intervals.
Storage: store at 2-30oC.
16.3.2. Antivirals
Herpes simplex virus may cause serious sight-threatening eye
infections. Ophthalmologists should treat these conditions.
Acyclovir is the drug of choice for all herpes simplex eye
infections. It is highly active in vitro against herpes simplex
(HSV) types II and I. Penetration through the cornea is
sufficient to provide antiviral concentrations in the aqueous
humour. With usual doses, clinically significant amounts are not
absorbed systemically.
Acyclovir
Eye ointment, 3 %
Indications: used for herpes simplex keratitis.
Side effects: transient stinging which occasionally may follow
immediately after application. Acyclovir has caused superficial
punctuate keratopathy, but this has healed without apparent
sequelae.
Dose and Administration:The ointment should be placed
inside the lower conjunctival sac 5 times a day, at about 4
hourly intervals. Treatment should be continued for 14 days, or
at least 3 days after healing is complete, whichever is shorter.
Storage: store at room temperature
788

16. Ophthalmic Agents

Gancyclovir
Injection, 500mg in ampoule
Indications: sight-threatening cytomegalovirus infections in
immunocompromised
patients
only;
prevention
of
cytomegalovirus disease during immunosuppressive therapy
following organ transplantation; local treatment of CMV
retinitis
Cautions: Close monitoring of full blood count (severe
deterioration may require correction and possibly treatment
interruption); history of cytopenia; potential carcinogen and
teratogen; radiotherapy; ensure adequate hydration during
intravenous administration; vesicantinfuse into vein with
adequate flow preferably using plastic cannula; children
(possible risk of long-term carcinogenic or reproductive
toxicity);
Drug interactions: didanosine, mycophenolate, probenecid,
zidovudine.
Contra indications: Hypersensitivity to ganciclovir,
ganciclovir, aciclovir, or valaciclovir; abnormally low
haemoglobin, neutrophil, or platelet counts, pregnancy, preastfeeding,renal impairment
Dose and Administration: Adult: By intravenous infusion,
initially (induction) 5 mg/kg every 12 hours for 1421 days for
treatment or for 714 days for prevention; maintenance (for
patients at risk of relapse of retinitis) 6 mg/kg daily on 5 days
per week or 5 mg/kg daily until adequate recovery of immunity;
if retinitis progresses initial induction treatment may be
repeated;
Child 1month- 18 years :initially (induction) 5mg/kg every 12
hours for 14-25 days, for treatment or for 7-14 days for
prevention; maintainance (for patients at risk of relapse of
retinitis), 6mg/kg daily on 5 days per week or 5mg/kg daily
789

16. Ophthalmic Agents

until adequate recovery of immunity; if retinitis progresses

initial induction treatment may be repeated.
Side effects:GI upset, taste disturbance, hepatic dysfunction;
dyspnoea, chest pain, cough; headache, insomnia, convulsions,
dizziness, peripheral neuropathy, depression, anxiety,
confusion, abnormal thinking, fatigue, weight loss, anorexia;
infection, pyrexia, night sweats; anaemia, leucopenia,
thrombocytopenia, pancytopenia, renal impairment; myalgia,
arthralgia; macular oedema, retinal detachment, vitreous
floaters, eye pain; ear pain; dermatitis, pruritus; injection-site
reactions;
Idoxuridine
Solution (eye drop), 0.1 %
Eye ointment, 0.5 %
Indications: keratitis or keratoconjunctivities caused by herpes
simplex.
Cautions: do not exceed frequency or duration of treatment,
discontinue if no relief within 7 days; concurrent use of a
corticosteroid.
Contraindications: pregnancy; concurrent use of an eye
preparation containing boric acid.
Side effects: burning, itching, irritation, pain, conjunctivities,
oedema, inflammation, photophobia, pruritus, and rarely
allergic reactions.
Dose and Administration:Herpes simplex keratitis: by
instillation into the eye, 1 drop every hour during daytime and
every 2 hours at night-time, reducing frequency as infection is
controlled to 1 drop every 2 hours during daytime and every 4
hours at night-time, then continue for 3 - 5 days after healing is
complete; maximum length of treatment 21 days; alternatively,
by application to the eye, 1 application of ointment every 4
790

16. Ophthalmic Agents

hours during daytime and once at night time (5 applications),

then continue for 3 - 5 days after healing is complete; maximum
length of treatment 21 days.
Storage: store at room temperature.
Trifluridine
Solution (eye drop), 1 %
Indications: treatment of herpetic keratitis and infections with
stromal involvement.
Cautions: hypersensitivity to trifluridine.
Side effects: transient irritation, itching and oedema; allergic
reactions.
Dose and Administration: Instill 1 drop 2 hourly upto a
maximum of 9 times daily, until complete reepithelialisation has
occured; then reduce to 4 hourly, continued for a few days.
Storage: store between 2 oC and 8oC.
Vidarabine
Eye ointment, 3%
Solution (eye drop), 3 %, 5ml
Indications: treatment of herpes simplex keratitis and
keratoconjunctivitis.
Side effects: irritation and pain of the eye; superficial punctate
keratitis, photophobia, lacrimation, and occlusion of the
lachrymal duct.
Dose and Administration: applied 5 times daily every 3 hours
until corneal re-epithelialisation has occurred, then twice daily
for a further 7 days to prevent recurrence.
Storage: store in airtight containers.

791

16. Ophthalmic Agents

16.3.3. Antifungals
Fungal infections of the cornea can cause serious sightthreatening disease. Fungal ulcers are often associated with
excessive and prolonged topical corticosteroid use or eye
injuries involving vegetative material. The ulcers are indolent
and require specialist management.Topical preparations may
need to be made by a pharmacist, e.g. miconazole, amphotericin
B. Natamycin is topical ophthalmic preparation. Effective
concentrations are produced within the corneal stroma, but not
in intraocular fluid. Systemic absorption is not expected.
Econazole
Solution (eye drop), 1 %
It has a broad spectrum of activity against Cryptococcus,
Aspergillus,Curvularia, Candida,Microsporum,Paecilomyces,
and Trichophyton. For topical use, a 1% solution in arachis oil
or a 10 mg/mL commercial solution (Monistat IV) is well
tolerated. Topical use of miconazole may cause surface toxicity
after prolonged use
Natamycin
Solution (eye drop), 5 %
Indications: conjunctivities and fungal blepharitis, fungal
keratitis.
Cautions: concurrent application of natamycin and a topical
corticosteroid. Contraindications: hypersensitivity to the drug.
Side effects: eye irritation, redness, or swelling.
Dose and Administration: Adult:Fungal keratitis: Instill 1 drop
1 - 2 hourly, reduced to 6 - 8 times daily after 3 - 4 days, and
generally continued for 14 - 21 days.Fungal blepharitis and
Conjunctivities: Instillation 4 - 6 times daily may be sufficient.
Note: shake well before use.
792

16. Ophthalmic Agents

Storage: store at room temperature.

16.4. Anti-inflammatories
Non steroidal anti-inflammatory drugs
NSAIDs inhibit prostaglandin synthesis, thereby reducing
prostaglandin-mediated intraocular inflammation.NSAIDs eye
drops use for the treatment of seasonal allergic conjunctivitis,
cystoid and other types of macular oedema and for prophylaxis
and treatment of inflammation of the eye following surgery or
laser treatment.
Bromofenac
Solution (eye drop), 1 %
Indications: treatment of postoperative inflammation
Cautions: should be used with caution in patients with
underlying bleeding tendencies or in those receiving drugs
known to prolong bleeding time.
Drug interactions: topical corticosteroids
Contraindications: known hypersensitivity to bromfenac
sodium or any ingredient in the formulation
Side effects transient burning or stinging, punctate corneal
epithelial erosion
Dose and administration: Adults: instill 1 drop twice daily
beginning 24hrs after surgery and continuing for 2 weeks
postoperatively.
Storage: store at room temperature
Cyclosporine
Solution (eye drop), 0.05%, 0.2%, 1%, 2%
Indications: Cyclosporine ophthalmic is used to increase tear
production in people with dry eye disease.
Contraindications: known hypersensitivity to Cyclosporine
793

16. Ophthalmic Agents

Side effects: burning, itching, stinging, redness, overflow of

tears, red eyes, and eye discharge
Dose and administration: instill 1 drop twice a day.
Storage: Store at room temperature
Diclofenac sodium
Eye drop, 0.1%
Indications: for postoperative prophylaxis and treatment of
ocular inflammation; for temporary relief of pain and
photophobia in corneal refractive surgery; to prevent and treat
cystoid macular oedema
Cautions: pregnancy
Contraindications: known hypersensitivity to any components
of the product
Side effects: burning and stinging; corneal deposits; corneal
edema; lacrimation
Dose and administration: Cataract Surgery: apply One drop
six hourly beginning 24 hours after surgery for the first 2 weeks
of the postoperative period. Corneal Refractive Surgery:apply
one drop an hour prior to corneal refractive surgery then 15
minutes after the surgery, and then apply one drop 6 hourly for
3 days.
Storage: Store between 15C to 25C
Flurbiprofen
Solution (eye drop), 0.03%
Indications: is used primarily to control intra operative miosis
during anterior segment surgery, cystoid macular edema,
photophobia.
Cautions: epithelial herpes simplex keratitis, hemophilia or
other bleeding problems.
794

16. Ophthalmic Agents

Drug interactions: acetylcholine chloride; anticoagulant,

coumarin or heparin; epinephrine (ophthalmic).
Contraindications: allergic reaction to Flurbiprofen or other
systemic or ophthalmic NSAIDs.
Side effects: keratitis, elevated intraocular pressure, corneal
edema, chemosis, bleeding in eye; redness in eye.
Dose and Administration:Miosis inhibition1drop every thirty
minutes, beginning two hours prior to surgery. For
postoperative treatment of ocular inflammation: 1 drop every
four hours for 1-3 weeks
Storage: store at room temperature.
Ketorolac
Solution (eye drop), 0.4%, 0.5%
Indications: prophylaxis and treatment of inflammation
following ocular surgery; mild-moderate allergic conjunctivitis
Contraindications: hypersensitivity to ketrolac or other
systemic or ophthalmic NSAIDs
Cautions: Patients with known bleeding tendencies or those
receiving anticoagulants; pediatric patients <3 years of age
Side effects: transient burning/stinging, headache, conjunctival
hyperemia, corneal infiltrates, iritis, ocular edema,superficial
keratitis.
Dose and Administration: Child 3 years and Adults:Allergic
conjunctivitis (0.5%): Instill 1 drop six hourly. Inflammation
following cataract extraction (0.5%): Instill 1 drop six hourly
for 2 weeks; beginning 24 hours after surgery. Pain following
corneal refractive surgery (0.4%):Instill 1 drop six hourly up to
4 days.
Storage: store at room temperature
Suprofen
Solution (eye drop), 1%
795

16. Ophthalmic Agents

Indications: inhibition of intraoperative miosis.

Cautions:Patients with known bleeding tendencies
Contraindication: epithelial herpes simplex keratitis (dendritic
keratitis) and hypersensitive to any component of the
medication.
Side effects: burning and stinging,itching and redness; iritis,
pain, chemosis, photophobia, irritation, and punctuate epithelial
staining.
Dose and Administration: instill 1 drop at 3, 2 and 1 hour(s)
prior to surgery to prevent intra operative miosis; or Instill 1
drop every 4 hours since the day before surgery.
Storage: Store at room temperature
Anti-histamines
Drugs under this category attach to histamine receptors, preventing
the chemical histamine from triggering symptoms of an allergic
reaction.

Ketotifen
Solution (eye drop), 0.025%
Indications:seasonal allergic conjunctivitis in adults and
children aged three years and older
Cautions: pregnancy
Contraindications: Children under three years of age; known
sensitivity or allergy to any ingredient in the formulation
Side effects: Pain and irritation of the eyes; punctate corneal
epithelial erosion; dry eyes; photophobia; eyelid disorders;
Dose and Administration: instill one drop, every 8 to 12 hours
Levocabastine
Solution (eye drop), 0.05%
Indications: treatment of mild-moderate allergic conjunctivitis
Caution: pregnancy
796

16. Ophthalmic Agents

Side effect headache, Bad taste, blurred vision, burning or

stinging, corneal infiltrates, dry eye, rhinitis, and sinusitis
Dose and Administration: children 12 years and Adults: instill
one drop six hourly for 2 weeks.
Antihistamine and Vasoconstrictor
The body produces antibodies to "fight" specific antigens.
Antibodies attach to mast cells to release histamine thereby
allergic reaction will trigger. Ocular decongestants constrict the
superficial conjunctival vessels and somewhat reduce
congestion and redness. The transient stinging of the drop may
relieve some of the itching. Ocular decongestant/ antihistamine
combinations work better than the vasoconstrictors.
Unfortunately, these drops do not provide relief for all allergy
sufferers with ocular symptoms because not every allergic
response is due to histamine.
Antazoline + Naphazoline
Solution (eye drop), 0.025% + 0.5%
Indications: treatment of temporary relief of the signs and
symptoms of allergic conjunctivitis
Cautions: pregnancy; breast-feeding
Side effects: eye pain, headache, redness/itching/swelling in or
around the eyes
Dose and Administration:instill 1 drop every 3-4 hourly
Storage: store at room temperature
Oxymetazoline Hydrochloride
Solution (eye drop), 0.025%, 0.05%
Oxymetazoline
Hydrochloride
is
a
direct-acting
sympathomimetic agent, which has a vasoconstrictor effect on
mucosal blood vessels when applied topically.
797

16. Ophthalmic Agents

Indications: treatment of Short-term relief for mild allergic

symptoms.
Cautions: avoid Prolonged or excessive use that may cause
rebound congestion and drug-induced rhinitis.
Side effects: occasionally cause local stinging or burning,
sneezing, and dryness of the mouth and throat.
Dose and Administrationinstill 1 drop every 4-6 hourly
Tetrahydrozoline Hydrochloride
Solution (eye drop), 0.05 %
Tetrahydrozoline is a sympathomimetic agent with alphaadrenergic activity.
Indications: treatment of Short-term relief for mild allergic
symptoms
Cautions: avoid Prolonged or excessive use
Side effects: occasionally cause local stinging or burning,
sneezing, and dryness of the mouth and throat.
Dose and Administrationinstill 1 drop every 4-6 hourly
Mast cell Stabilisers
Mast-cell stabilizers prevent calcium influx across mast-cell
membranes, thereby preventing mast-cell degranulation and
mediator release. They take days to weeks to reach their peak
efficacy. They do not provide immediate relief from allergic
symptoms.Cromolyn sodium (Crolom) inhibits neutrophil,
eosinophil, and monocyte activation in vitro. Traditional mastcell stabilizers such as cromolyn sodium, lodoxamide
(Alomide), and pemirolast (Alamast) prevent mast-cell
degranulation but They are used for allergic, vernal, and atopic
conjunctivitis.
Lodoxamide Tromethamine
Solution (eye drop), 0.1%
798

16. Ophthalmic Agents

Indications: for the treatment of vernal keratoconjunctivities,

vernal conjunctivitis, and vernal keratitis
Contraindications: hypersensitivity to any component of the
formulation
Side effects burning, stinging, and discomfort upon instillation
Dose and Administration: instill 1 drop six hourly for up to 3
months.
Storage: store at room temperature
Nedocromil Sodium
Solution (eye drop), 2%
It has a mast-cell stabilizing effect as well as H1-antagonism
Indications: for thetreatment of Allergic Conjunctivitis, vernal
conjunctivitis, vernal keratitis and vernal keratoconjunctivities,
Cautions: breast-feeding
Contraindications: hypersensitivity to any component of the
formulation,Children >3 years
Side effects: stinging or burning of the eyes; blurred vision;
increased eye redness or itching; Odd taste in the mouth; nasal
congestion
Dose and Administration: instill one drop twice daily.
Storage: store at room temperature
Sodium cromoglycate
Solution (eye drop), 2% and 4%
Indications:for thetreatment of allergic, vernal, and atopic
conjonctivitis
Cautions: breast-feeding
Contraindications: hypersensitivity to any component of the
formulation
Side effects: transient burning and stinging; dryness around the
eye; edema; watery eyes; dyspnea
799

16. Ophthalmic Agents

Dose and Administration: children > 4 years and Adults:

instill one drop six hourly for up to 3 months
Storage store at room temperature
Pemirolast potassium
Solution (eye drop), 0.1%
Indications:for thetreatment of allergic, vernal, and atopic
conjonctivitis
Cautions: pregnancy
Contraindications: hypersensitivity to any component of the
formulation
Side effects: transient burning and stinging; dryness around the
eye; watery eyes; dyspnea
Dose and Administration: children > 3 years and Adults:
apply one drop four times/ day for up to 3 months
Storage store at room temperature
Combined Antihistamine and mast cell stabilizer
These agents distinguish by their ability to block as well as to
stabilize activated mast cells and prevent the release of
cytokines
Olopatadine
Solution (eye drop), 0.1%
Indications: for thetreatment of allergic, vernal, and atopic
conjonctivitis
Cautions: pregnancy; children <3 years of age; do not wear
contact lenses if eyes are red
Contraindications:
hypersensitivity
to
Olopatadine
hydrochloride or any component of the formulation
Side effects: headache; cold syndrome; nausea; taste
perversion; weakness; blurred vision; burning; stinging; dry
800

16. Ophthalmic Agents

eye; foreign body sensation; hyperemia; keratitis; eyelid edema;

rhinitis; sinusitis; pharyngitis
Dose and Administration: Adults and children 3 years:instill
1 drops twice daily
Storage: store at room temperature
Steroids: Corticosteroids
Corticosteroids are very effective at treating ocular allergies and
many ocular disorders but they have a more dangerous sideeffect profile. They are also prone for abuse. Complications of
corticosteroid therapy can be seen with any mode of
administration. Therefore, these agents should be used only
when the benefits of therapy outweigh the risks of the
medications themselves. The dose and duration of therapy must
individualize. It is generally preferable to begin therapy with a
high dose of corticosteroids (topical or systemic) and taper the
dose as the inflammation subsides. If corticosteroid therapy
needs for longer than 23 weeks, the dosage should taper before
discontinuation.
Indications: for thetreatment of corticosteroid-responsive
allergic conjonctivitis, active inflammation of conjunctiva,
cornea, and anterior segment of the globe, prevention or
treatment of complications such as treat cystoid macular
oedema, therapy for corneal allograft rejection, explosive onset
of severe noninfectious posterior uveitis, panuveitis or optic
neuritis
Cautions: Long-term use of corticosteroid need close follow-up
for glaucoma (open-angle glaucoma) and for other major
complications. Corticosteroid therapies,longer than 23 weeks,
should be tapered before discontinuation. All corticosteroids
may exacerbate bacterial, viral, mycobacterial and fungal
801

16. Ophthalmic Agents

diseases of the eye and should be used with caution in these

settings.
Contraindications : Patients with ocular fungal diseases ;
herpes simplex keratitis; tuberculosis; viral disease; cataracts,
open angle glaucoma; diabetes mellitus; hypertension; peptic
ulcer or gastro esophageal reflux disease; patients who are
immunocompromised (from acquired or congenital causes) and
patients with psychiatric conditions are at high risk for
corticosteroid-induced exacerbations of their systemic
conditions. In these patients, Corticosteroids treatment should
be avoid or the last choice.
Side effects: Glaucoma; cataract formation; secondary ocular
infections or exacerbations of ocular infections are the most
serious ocular side effects. Other ocular side effects include
decreased vision, lacrimation, burning, stinging, redness; optic
nerve damage, eye pain and ptosis.
Retardation of skeletal maturation and growth, osteoporosis and
bone fractures, cushingoid appearance, diabetes, peptic ulcers,
myopathy, hypertension, altered mental status, pseudotumor
cerebri, and increased mortality from infection Addisonian
crisis on withdrowal are more on systemic corticosteroid use.
Dose and Administration: Choice of available corticosteroid
agents and dosage regimens remains somewhat empirical.
Steroids can be used topically (iritis), intravenously (optic
neuritis), intravitreally (endophthalmitis), or in a periocular
fashion (uveitis). Topical corticosteroid drops are effective for
allergic conjonctivitis, active inflammation of conjunctiva,
cornea, and anterior uveitis, beneficial effects on vitritis or
macular edema. Systemic corticosteroids use for the treatment
of vision-threatening chronic uveitis when topical
corticosteroids are insufficient, explosive onset of severe
noninfectious posterior uveitis or panuveitis optic neuritis.
802

16. Ophthalmic Agents

Dexamethasone
Solution (eye drop), 0.1%
Indications; contraindications; drug interactions and side
effects: see notes above
Dose and Administration : in severe inflammatory conditions
instill one drop every hour during day, every 2 hours at night
until favorable response is obtained, then taper to 1 drop every 4
hours ;
For mild to moderate inflammation, instill one drop 2-4 times
/day.
Storage: store at room temperature
Flurometholone
Solution (eye drop),1%
Eye ointment, 0.1%
Indications; contraindications; drug interactions and side
effects: see notes above
Dose and Administration: ointment: apply thin strip ointment
one to three times a day.Eye drop: In severe inflammation,
instill 1 drop every hour during day, every 2 hours at night until
favorable response is obtained, then taper to 1 drop every 4
hours.
For mild to moderate inflammation, instill one drop 2-4 times
/day.
Storage: store at room temperature
Loteprednol
Solution (eye drop), 0.1%, 0.2%, 0.5%
Indications; contraindications; drug interactions and side
effects: see notes above
Dose and Administration: In severe inflammation, instill 1
drop every hour during day, every 2 hours at night until
803

16. Ophthalmic Agents

favorable response is obtained, then taper to 1 drop every 4

hours;
For mild to moderate inflammation, instill one drop 2-4 times
/day.
Storage: store at room temperature
Methylprednisolone
Injection, 40mg/ml in 1ml ampoule
Indications:vision-threatening, explosive onset of severe
noninfectious posterior uveitis, panuveitis or optic neuritis
Contraindications; drug interactions and side effects: see
notes above.
Dose and Administration: methylprednisolone (1 gm/day
infused over 1 hour) therapy may be administered for 3 days,
followed by oral prednisone starting at 12 mg/kg/day, which
is tapered in a gradual fashion every 1 to 2 weeks until the
disease is quiescent. The lowest possible dose that will control
the ocular inflammation and minimize side effects is desired.
This dose should be 510 mg or less per day.
Prednisolone
Eye drop: 0.25%, 1%
Indications, Contraindications; drug interactions and side
effects: see notes above
Dose and Administration:For mild to moderate inflammation,
instill one drop 2-4 times /day.Therapy for corneal allograft
rejection: 1% eye drops every 15 minutes to two hours, which is
tapered based on the clinical responses
Storage: store at room temperature
16.5. Anti-infective/Anti-inflammatory combination.
Many antibacterial preparations also incorporate a corticosteroid
but such mixtures should not be used unless a patient is under
804

16. Ophthalmic Agents

close specialist supervision. In particular, they should not be

prescribed for undiagnosed 'red eye, which is sometimes
caused by the herpes simplex virus and may be difficult to
diagnose.
Chloramphenicol + Dexamethasone
Solution (eye drop), 0.5% + 0.1%
Indications: treatment of mild to moderate bacterial
conjunctivitis and eyelids associated with inflammation; pre and
post-operatively for prevention of infection and scarification
Cautions: pregnancy, breast feeding
Drug interactions:see in the individual drug above
Contraindications:see in the individual drug above.
Side effects: see in the individual drug above
Dose and Administration: install one to two drops in the
affected eye four times daily.
Storage: at room temperature
Flucortolone Pivalante + Chloramphenicol
Solution (eye drop), 0.5% +0.2%
Indications: treatment of mild to moderate bacterial
conjunctivitis and eyelids associated with inflammation; pre and
post-operatively for prevention of infection and scarification
Drug interactions:see in the individual drug above
Contraindications:see in the individual drug above.
Side effects: see in the individual drug above
Dose and Administration: install one two to four times daily.
Storage: at room temperature
Gentamycine +Betamethasone
Solution (eye drop), 3mg +1mg/ml

805

16. Ophthalmic Agents

Indications: treatment of mild to moderate bacterial

conjunctivitis and eyelids associated with inflammation; pre and
post-operatively for prevention of infection and scarification
Drug interactions:see in the individual drug above
Contraindications:see in the individual drug above.
Side effects: see in the individual drug above
Dose and Administration: install one to two drops in the
affected eye four times daily.
Storage: at room temperature
Gentamycine +Dexamethasone
Solution (eye drop), 0.3% +0.1%
Indications: treatment of mild to moderate bacterial
conjunctivitis and eyelids associated with inflammation; pre and
post-operatively for prevention of infection and scarification
Cautions: pregnancy, breast feeding
Drug interactions:see in the individual drug above
Contraindications:see in the individual drug above.
Side effects: see in the individual drug above
Dose and Administration: install one to two drops in the
affected eye four times daily.
Storage: at room temperature
Neomycin + Dexamethasone phosphate
Solution (eye drop), 0.5% + 0.05%; 0.5% + 0.1%
Indications: treatment of mild to moderate bacterial
conjunctivitis and eyelids associated with inflammation;
Drug interactions:see in the individual drug above
Contraindications:see in the individual drug above.
Side effects: see in the individual drug above
Dose and Administration:instill 1-2 drops up to six times a day
Storage: store at room temperature
806

16. Ophthalmic Agents

Neomycin + Hydrocortisone + Polymixin B Sulphate

Suspension (eye drop), 3.5mg (base) + 10mg +10,000 units
(base) in each ml
Indications: steroid-responsive inflammatory condition and
bacterial infection or a risk of bacterial infection exists.
Drug interactions:see in the individual drug above
Contraindications:see in the individual drug above.
Side effects: see in the individual drug above
Dose and Administration: instill 1-2 drops every 4 to 6 hours
Storage: store at room temperature
Neomycin Sulphate + Polymixin B Sulphate +
Dexamethasone
Solution (eye drop), 3.5mg +6000 IU +0.1%
Indications: steroid-responsive inflammatory condition and
bacterial infection or a risk of bacterial infection exists.
Drug interactions:see in the individual drug above
Cautions: pregnancy, breast feeding
Contraindications:see in the individual drug above.
Side effects: see in the individual drug above
Dose and Administration: instill 1-2 drops in eye(s) every 4 to
6 hours
Storage: store at room temperature
OxytetracyclineHydrochloride+ Hydrocortisone Acetate +
Polymixin B sulphate
Solution (eye drop), 5 mg + 15 mg + 10,000 units in each ml.
Indications:steroid-responsive inflammatory condition and
bacterial infection or a risk of bacterial infection exists.
Drug interactions:see in the individual drug above
Contraindications:see in the individual drug above.
Side effects: see in the individual drug above
807

16. Ophthalmic Agents

Dose and Administration: instill 1-2 drops in every 4 to 6

hours
Storage: store at room temperature
Tobramycin + Dexamethason
Solution (eye drop), 0.3% +0.1%
Indications: steroid-responsive inflammatory condition and
bacterial infection or a risk of bacterial infection exists.
Drug interactions:see in the individual drug above
Contraindications:see in the individual drug above.
Side effects: see in the individual drug above
Dose and Administration:instill 1-2 drops in every 4 to 6 hours
Storage: store at room temperature.
16.6. Anesthetics, Local
Indications: Topical preparations yield corneal and
conjunctival anesthesia for comfortable performance of
examination techniques, removal of superficial foreign bodies,
corneal scraping for bacteriologic studies, for use of contact
lenses associated with fundus examination and laser procedures.
Local retrobulbar and eyelid blocks yield excellent anesthesia
and akinesia for intraocular and orbital surgery.
Cautions: Because topical anesthetics can become drugs of
abuse that can eventually lead to chronic pain syndromes and
vision loss, they should not be dispensed to patients.
Drug interactions: anti-arrhythmic drugs,MAOIs, clozapine,
indometacin, phenelzine
Contraindications: local anesthetics are contraindicated in
patients with known hypersensitivity to these drugs,
cardiovascular disease, epilepsy, hypertensive crisis, liver
disease, renal failure, avoid in the 3rd trimester of pregnancy, If
treatment is essential during breast feeding alternative methods
of feeding the infant should be considered.
808

16. Ophthalmic Agents

Side effects: Reactions following the administration of local

anesthetics are usually toxic and only rarely allergic. A true
allergic reaction to a -caine medication includes wheezing,
urticaria, and respiratory distress. A history of sweating,
tachycardia, headache, or hypertension suggests intravascular
injection of epinephrine. The toxic manifestations of local
anesthetics are generally related to dose. Toxic reactions cause
overstimulation of the CNS, which may lead to excitement,
restlessness, apprehension, disorientation, tremors, and
convulsions (cerebral cortex effects), as well as nausea and
vomiting (medulla effects). Cardiac effects initially include
tachycardia and hypertension. Ultimately, however, depression
of the CNS and the cardiovascular system occurs, which may
result in sleepiness and coma (cerebral cortex effects) as well as
in irregular respirations, sighing, dyspnea, and respiratory arrest
(medulla effects). Cardiac effects of CNS depression are
bradycardia and hypotension. Central nervous system
stimulation can be counteracted by IV diazepam; respiratory
depression calls for ventilatory support.
Benoxinate hydrochloride
Solution (eye drop), 0.4 % topical use
Indications; Drug interactions; Contraindications and Side
effects: see note above
Storage: store at room temperature
Bupivacaine Hydrochloride
Injection, 0.5 %, 0.75 % in 10 ml ampoule
Indications; Drug interactions; Contraindications and Side
effects: see note above
Storage: store at room temperature

809

16. Ophthalmic Agents

Cocaine Hydrochloride topical use

Solution (eye drop), 1%, 2%
Indications: Corneal anesthesia
Drug interactions; Contraindications and Side effects: see note
above
Storage: store at room temperature
Lidocaine Hydrochloride
Lidocaine (Xylocaine) is an amide local anesthetic used in
strengths of 1%, and 2% (with or without epinephrine) for
injection. It yields a rapid (5-minute) retrobulbar or eyelid block
that lasts 12 hours. The topical solution, applied to the
conjunctiva with a cotton swab for 12 minutes, reduces the
discomfort of subconjunctival injections.
Indications; Drug interactions; Contraindications and Side
effects: see note above
Dose and administration: the maximum safe dose of the 2%
solution for local injection is 15 mL in adults
Storage: store at room temperature
Lidocaine Hydrochloride + Adrenaline
Injection, 1%, 2% +1: 1000 IU
Indications; Drug interactions; Contraindications and Side
effects: see note above
Dose and administration: the maximum safe dose of the 2%
solution for local injection is 15 mL in adults
Storage: store at room temperature
Marcaine Hydrochloride
Injection, 0.5%
Indications; Drug interactions; Contraindications and Side
effects: see note above
Storage: store at room temperature
810

16. Ophthalmic Agents

Procaine Hydrochloride
Injection 2 % in 2 ml vial
Indications; Drug interactions; Contraindications and Side
effects: see note above
Storage: store at room temperature
Propanocaine Hydrochloride
Solution (eye drop), 0.5 %
Injection, 2 %
Indications; Drug interactions; Contraindications and Side
effects: see note above
Storage: store at room temperature
Tetracaine Hydrochloride
Solution (eye drop), 0.5 %
Indications: short-acting local anesthesia of cornea and
conjunctiva.
Drug interactions; Contraindications and Side effects: see
note above
Storage: store at room temperature.
16.7. Diagnostics and Miscellaneous Agents
Artificial tear (Carboxyl methyl Cellulose + Hydroxypropyl
Methyl Cellulose)
Ointment, Drops
Acetylcholine Chloride
Powder for injection (intra-ocular), 100 mg
Indications: produces complete miosis in cataract surgery,
keratoplasty, iridectomy and other anterior segment surgery
where rapid miosis is required.
811

16. Ophthalmic Agents

Cautions: If miosis is to be obtained quickly anatomical

hindrances to miosis, such as anterior or posterior synechiae,
must be released, prior to administration. During cataract
surgery, use only after delivery of the lens.Aqueous solutions of
acetylcholine chloride are unstable. Prepare solution
immediately before use. Do not use solution, which is not clear
and colorless. Discard any solution that has not been used.
Drug interactions: tacrine, flubiprofen and suprofen
Contraindications: hypersensitivity to acetylcholine chloride,
acute iritis and acute inflammatory disease of the anterior
chamber
Side effect Infrequent cases of corneal edema, corneal
clouding, and corneal decompensation have been reported with
the use of intraocular acetylcholine. Adverse reactions have
been reported rarely, which are indicative of systemic
absorption. These include bradycardia, hypotension, flushing,
breathing difficulties and sweating.
Dose and Administration: Adult: Intraocular: 0.5 - 2 ml of 1 %
injection (5 to 220 mg) instilled into anterior chamber before or
after securing one or more sutures.
Storage: store at room temperature.
Acetylcysteine + Hypermellose
Eye drop, 5% + 0.35%
Indications: relief of severe dry eye symptoms associated with
syndromes related to excess mucous production
Ahmed Valve
Indications: drainage device commonly used in the treatment of
recalcitrant glaucoma
Complications: can include shallow anterior chamber,
hypotony, suprachoroidal hemorrhage, and blockage of the tube
by blood, fibrin, or iris Long-term complications include tube
812

16. Ophthalmic Agents

erosion through the conjunctiva, valve migration, corneal

decompensation, tubecornea touch, and retinal detachment
Alphachymotrypsin
Powder for injection, 300 units
Indications: intra-capsular cataract extraction, to have
Chemical dissolution of the zonular fibers to reduced the
number and severity of complications. Proteolytic enzyme that
has been used in ophthalmology for the dissection of the zonule
of the lens, thus facilitating and reducing trauma of the eye. For
this purpose a solution of chymotrypsin in a sterile diluent such
as sodium chloride 0.9% has been injected to irrigate the
posterior chamber.
Baerveldts Valve
Indication: Glaucoma drainage devices (Baerveldts Valve) are
used for patients with refractory glaucoma or complicated
glaucoma, such as uveitic glaucoma, neovascular glaucoma, and
pediatric and developmental glaucoma. It is designed to divert
aqueous humor from the anterior chamber to an external
reservoir.
Bevacizumab
Injection, 4mg/ml vial
Indications: to reduce Macular oedema occurs in diabetes
mellitus; retinal vein occlusion or other macular diseases. It has
valuable effect in various neovascular and edematous retinal
conditions
Cautions: Do not mix with dextrose-containing solutions. Heart
disease, stork, or bleeding disorder,
Drug interaction: Anthracyclines, any drugs or supplements
that interfere with blood clotting can raise the risk of bleeding
during treatment with Bevacizumab. These include vitamin E;
813

16. Ophthalmic Agents

NSAIDs such as aspirin, ibuprofen and naproxen and many

others; warfarin; clopidogrel
Contra indications: hypersensitive to Bevacizumab, murine
products, or any component of the formulation and pregnancy
and breast-feeding.
Side effects: cataract formation, glaucoma, bleeding, hypotony,
damage to the retina or cornea, endophthalmitis
Dose and administration: Under direct visualization in indirect
ophthalmoscopy, through the parsplana at 3.75 mm posterior to
the limbus, inject 1.25mg Bevacizumab into the mid-vitreous
cavity as slowly as possible. After the injection, you have to
check patients intraocular pressure, the retina status or for
vitreous hemorrhage.
Storage: store vials at 2oc to 8oc. Protect from light; do not
freeze.
Biological Glue Tubes
Indications: Tissue adhesive is one of the alternatives to
conventional suturing and has some added advantages. Use of
the Biological glue is simple, safe, cost and effective.
Contraindications: Jagged or stellate lacerations; Bites,
punctures or crush wounds; contaminated wounds; mucosal
surfacesor high-moisture areas
Side effects:anaphylaxis, interference with tissue repair,
bleeding diathesis.
Dose and Administration: After cleansing, approximate edges
of the wound manually and evenly. Squeeze the glue gently on
its applicator to apply the edges of the wound at least three
layers should be applied to ensure optimal strength to the wound
closure. The wound should not be touched until the adhesive
dries completely. Fanning or blowing on the wound will not
814

16. Ophthalmic Agents

speed up polymerization. Excess adhesive can simply be wiped

away with dry gauze if done immediately.
C3F8 Gas Injection
100ml, 500ml, 1lit, 2lit, 5lit. Bottle
Indications: for the treatment of sub macular hemorrhage due
to age-related macular degeneration; to close macular holes; for
Vitrectomy (retinal disorder surgery) and useful for flattening a
detached retina and keeping it attached while healing occurs
Cautions: It is unsafe to fly in a plane while gas remains in the
eye.
Contraindications:Gas injection is also used It is frequently
necessary to maintain a certain head position following surgery
when gas is used.
Complications: include progression of cataracts and elevated
eye pressure (glaucoma). Vision in a gas-filled eye is usually
rather poor until at least 50% of the gas is absorbed.
Express Tube
Glaucoma Filtration tube
Indication: use in glaucoma patients to reduce intraocular
pressure where medical and conventional surgical treatments
have failed
Caution: it should not be used if sterility or performance is
compromised.
Contraindications: Presence of ocular disease such as uveitis,
ocular infection, severe dry eye, severe blepharitis.
Fluorescein sodium
Solution (eye drop), 0.25%, 0.4%
Eye paper (sterile strip)
Injection (IV), 0.5%, 2.5%, 5 %, 10% in 10 ml ampoule
815

16. Ophthalmic Agents

Indications: demonstrates defects of corneal epithelium,

diagnostic aid in ophthalmic angiography.
Cautions: transient blurring of vision - advice patient not to
operate machinery or drive until vision is clear. Care must be
taken to avoid extravasations during injection as the high pH of
fluorescein solution can result in severe local tissue damage.
Contraindications: avoid use with soft contact lenses; in
known patient with hypersensitivity to fluorescein sodium or
any other ingredients in this product.
Side effects: Irritating to eyes May cause skin and respiratory
tract irritation. Prior to use the injection form, perform
intradermal skin test; have epinephrine 1:1000, an
antihistamine, and oxygen available
Dose and Administration:Strips: moisten strip with sterile
water. Place moistened strip at the fornix into the lower cul-desac close to the punctum. For best results, patient should close
lid tightly over strip until desired amount of staining is obtained.
Patient should blink several times after application.
Injection:Adult: 500 - 750 mg injected rapidly into antecubital
vein.Child: 3.5 mg/lb (7.5 mg/kg) injected rapidly into
antecubital vein.
Storage: Store at 2- 25C; Donot Freeze
5-Flurouracil
Injection, 50mg/ml, 250mg, 500mg vial
Hydroxypropyl Methyl Cellulose (Hypromellose)
Solution (eye drop), 0.3%, 0.5%, 1%, 2.5%
Injection, 2% vial
Indications: it is used as a surgical aid in certain eye surgeries,
such as cataract removal and lens implantation procedures. It
helps maintain the shape of the eye during surgery as well as
protect the tissues of the eye from damage due to surgical
816

16. Ophthalmic Agents

instruments and as a vehicle for eye drops and as artificial tears

and contact lens solution
Side effects: Blurred vision, decreased vision, Pain in the eye,
redness of the white part of the eye or inside of the eyelid,
sensitivity of the eye to light, lacrimation or throbbing eye pain
Lisseman Green
Solution (eye drop), 1%
Indications: Evaluation of tear deficiency states and detection
of various epithelial lesions.
Mitomycin C
Powder for injection, 2mg vial
Indications: antimetabolite used during the initial stages of a
trabeculectomy to prevent excessive postoperative scarring.
Molteno Valve
Indication:It is Glaucoma Drainage Devices for surgical
Implants for the treatment of Glaucoma
Perfluorocarbon liquids
Injection, 5ml, 10ml vial
Indications: facilitate surgery in conditions like proliferative
vitreoretinopathy, giant retinal tears, and drainage of
suprachoroidal hemorrhages, diabetic traction, retinal
detachments with a rhegmatogenous component, dislocated
crystalline or intraocular lenses, and retinal detachment
associated with choroidal coloboma.
Polyvinyl Chloride
Solution (eye drop), 0.1%, 0.5%, 1%
Indication: For use as a lubricant to prevent further Irritation or
to relieve dryness of the eye(s)
817

16. Ophthalmic Agents

Cautions:Stop use and ask a doctor if you experience eye pain,

changes in vision, continued redness or irritation of the eye, or
if the condition worsens or persists for more than 72 hours.
Dose and Administration: Instill 1 or 2 drops in the affected
eye(s) as needed
Store: at 200 to 25C; away from heat; Protect from freezing.
Keep tightly closed.
Povidone Iodine Solution
Eye drop, 1%, 5%, 10% bottle
Povidone-iodine is readily available worldwide, either as a
powder or as a 10% solution. Depending on the type of
application, for ophthalmic use, the solution must be diluted to
the appropriate strength. The diluents may be a balanced salt
solution or other appropriate diluents. In the appropriate
concentration, it is not toxic to the eye as are other iodine
bearing compounds
Indication: disinfect the eyes and surrounding skin before
ophthalmic surgery and intraocular injections.
Cautions: pregnancy, breast feeding, pediatric patients, patients
with thyroid disorders, renal dysfunction
Contraindications: Hypersensitivity to iodine or to any of the
excipients
Side effects: the medication the eye turns brown for a few
minutes proving that it has been applied
Ranibizumab
Injection, 10mg/ml vial
Indications: treatment of neovascular (wet) age-related macular
degeneration (AMD), visual impairment due to diabetic macular
oedema (DME),visual impairment due to macular oedema
818

16. Ophthalmic Agents

secondary to retinal vein occlusion (branch RVO or central

RVO).
Cautions: monitor intra-ocular pressure, the perfusion of the
optic nerve head and for signs of ocular infection, pregnancy
Drug interactions: anti-VEGF (vascular endothelial growth
factor) agents (systemic or ocular).
Contraindications: Hypersensitivity to the active substance or
to any of the excipients, active or suspected ocular or periocular
infections, active severe intraocular inflammation
Side effects: Dry eye; eye discomfort; feeling of something in
the eye; eye or eyelid swelling; eye pain, pressure, redness,
bleeding, or discharge, headache; increased tears; nausea; nose
or throat irritation; seeing floaters or spots, allergic reactions
(rash; hives; itching; difficulty breathing; tightness in the chest;
swelling of the mouth, face, lips, or tongue); chest, jaw, or left
arm pain
Dose and Administration:intravitrealAdult: Initially 0.5 mg
once a month for 3months into the affected eye, There after
monitor visual acuity once a month; if Necessary subsequent
doses may be given at least 1 Month apart. Antimicrobial eye
drops should be administered into the affected eye for 3 days
before and 3 days after each injection.
Storage: Store in the refrigerator between 2-80c, Protect from
Sunlight.
Rose benegal
Solution (eye drops), 1%
Indication: For use as a diagnostic agent when superficial
corneal or conjunctival tissue change is suspected, especially in
dry eyes. Unlike fluorescein, which stains epithelial defects,
rose bengal will stain damaged cells and give a clearer
indication of the extent of damage. It is irritating to the eyes.
819

16. Ophthalmic Agents

Storage: Store at room temperature

Silicon oil
Injection, 1000CSK, 5000CSK vials
Indications: Used in eye operations, retinal surgery for
substituting the vitreous fluid.
Side effects: Silicone oil injection may induce multiple
complications, including cataract, glaucoma, and keratopathy,
raised intraocular pressure, band keratopathy
Sodium Hyaluronate
Solution (eye drop), 0.1%
Injection, 1%, 1.3%, 1.4%, 2%, 3% vials
Indications: assist in the extraction of cataracts, the
implantation of intraocular lenses, corneal transplants, glaucoma
filtration, retinal attachment and in the treatment of dry eyes
Cautions: Monitor intraocular pressure, Pregnancy
Side effects: Transient rise in intraocular pressure
Synthetic Tissue Graft Pericardium, Cornea, Sclera
Trypan Blue
Injection, 0.01%, 0.25%, 0.5%
Indications: as an aid in ophthalmic surgery by staining the
anterior capsule of the lens.
Storage: Store between 15-25C. Protect from direct sunlight.

820

17. Ear, Nose And Throat Preparations

17. EAR, NOSE and THROAT PREPARATIONS

17.1. Nasal and Oropharyngeal, Preparations
Symptoms of nasal congestion associated with vasomotor
rhinitis and the common cold can be relieved by the short-term
use (usually not longer than 7 days) of decongestant nasal drops
and sprays. These all contain sympathomimetic drugs which
exert their effect by vasoconstriction of the mucosal blood
vessels which in turn reduces oedema of the nasal mucosa.
They are of limited value because they can give rise to rebound
congestion (rhinitis medicamentosa) on withdrawal, due to a
secondary vasodilatation with a subsequent temporary increase
in nasal congestion.
Ephedrine nasal drop is the safest sympathomimetic
preparation and can give relief for several hours. The more
potent
sympathomimetic
drugs
xylometazoline
and
oxymetazoline are more likely to cause a rebound effect. All of
these preparations may cause a hypertensive crisis if used
during treatment with a monoamine oxidase inhibitor.
Mild cases of allergic rhinitis are controlled by topical nasal
corticosteroids or oral antihistamines; systemic nasal
decongestants are of doubtful value. Antazoline is often used
with a vasoconstrictor such as naphazoline for the treatment of
rhinitis.
Inhalations of warm moist air are useful in the treatment of
symptoms of acute infective conditions, and the use of
compounds containing volatile substances such as menthol and
eucalyptus may encourage their use.
Mouthwashes have a mechanical cleansing action and freshen
the mouth. Providone - Iodine mouthwash is useful for mucosal
infections but does not inhibit plague accumulation. It should
821

17. Ear, Nose And Throat Preparations

not be used for periods longer than 14 days because a significant

amount of iodine is absorbed.
There is no convincing evidence that antiseptic lozenges and
sprays have a beneficial action and they sometimes irritate and
cause sore tongue and sore lips. Some of these preparations also
contain local anesthetics which relieve pain but may cause
sensitization. The throat lozenges are Amyl-metacresol +
Dichlorbenzyl Alcohol and Dequalinium Chloride.
The most common cause of a sore throat is a viral infection
which does not benefit from anti-infective treatment. Fungal
mouth infections such as candida albicans which are sometimes
associated with the use of broad-spectrum antibiotics or of
cytotoxics; withdrawing the causative drug may lead to rapid
resolution. Otherwise, an antifungal drug may be effective. Of
the antifungal drugs used for mouth infections, miconazole and
nystatin are not absorbed from the gastro-intestinal tract and are
used by local application in the mouth. Miconazole occupies an
intermediate position since it is used by local application in the
mouth but is also absorbed to the extent that potential
interactions need to be considered.
Acyclovir Cream
Cream, 5% 2gm
Indications: to treat cold sores (fever blisters; blisters that are
caused by herpes simplex virus) on the face or lips
Cautions:indiscriminate use of topical acyclovir may result in
the emergence of resistance. Do not apply acyclovir cream to
any unaffected skin, or to genital herpes sores.
Contraindications:allergy to one or any of the ingredients;
allergy to valaciclovir; herpes simplex virus infections of the
eye.
822

17. Ear, Nose And Throat Preparations

Dose and Administration: topical: Adult: 5 times per day for

4 days. Therapy should be initiated as early as possible
following onset of signs and symptoms (i.e. during the
prodrome or when lesions appear).
Side effects:burning or stinging, dry or cracked lips, flakiness
or dryness of skin, itching, difficulty to breathe, tightness in the
chest, dizziness.
Storage:store at room temperature
Adrenaline
Inhalation, 1mg/2.5cc normal saline solution
Indications:acute breathing problems; to open breathing
passages and make breathing easier.
Cautions: heart disease, heart rhythm problems, chest pain
(angina), diabetes, high blood pressure, thyroid disease, a
history of strokes, seizures, drug allergies, pregnancy
Drug interactions: anti-hypertensives, beta-blockers (e.g.,
propranolol), anti- diabetics, anti- depressants
Contraindications:allergy to adrenaline, cardiac arrhythmias,
angle closure glaucoma
Dose and Administration:inhaled into the lungs using special
breathing equipment
Side effects:Tremor, nervousness, shakiness, headache, nausea,
heartburn, lightheadedness, sleeping difficulty, unusual taste in
mouth, hoarseness or dry throat may occur the first several days;
rash, rapid heartbeats, chest pain, dizziness, coughing, breathing
trouble
Storage:Store in a cool area protected from light.
Amyl Meta-cresol + Dichlorobenzyl Alcohol
Lozenges, 0.6 mg + 1.2 mg
See notes above
823

17. Ear, Nose And Throat Preparations

Antazoline + Naphazoline
Solution (nose drop), 0.5 % + 0.025 %
Indication: allergic rhinitis
See notes above
Beclomethasone Dipropionate
Nasal spray (aerosol), 50 mcg/dose
Indications: prophylaxis and treatment of seasonal
(intermittent) and non-seasonal (persistent) allergic rhinitis.
Sometimes useful in non-allergic (vasomotor) rhinitis.
Cautions: systemic infections or ocular herpes simplex
Contraindications: status asthmaticus
Side effects: agitation, depression, dizziness, angioedema, rash,
urticaria, burning, sneezing, nasal stuffiness, nose bleedings,
cough, wheezing.
Dose and Administration: Adult: 100 mcg (2 sprays) into each
nostril twice daily, or 50 mcg into each nostril 3-4 times daily.
Storage: store at room temperature. Do not store near heat or
open flame.
Chlorhexidine Gluconate
Oral Solution, 0.12%
Indications: used along with regular tooth brushing/flossing to
treat gingivitis.
Caution: do not swallow the medicine and instruct not to eat for
2-3 hours after treatment
Contraindications: allergy to chlorhexidine gluconate or other
formula ingredients
Side effects: Tooth/tongue staining, increased tartar,
mouth/throat irritation, and change in taste of food/drinks; Oral
irritation and local allergy-type symptoms.
824

17. Ear, Nose And Throat Preparations

Dose and Administration: Adult:Treatment of gingivitis: oral

prophylaxis: floss and brush teeth, completely rinse toothpaste
from mouth. Wash with 15ml chlorhexidine undiluted for 30
seconds and expectorate. Repeat twice daily (morning and
evening)
Storage: Store at room temperature away from light and
moisture.Note: Chlorhexidine gluconate may be incompatible with
some ingredients in toothpaste; leave an interval of at least 30
minutes between using mouthwash and toothpaste

Clotrimazole
Troches, 10mg ;Drops, 100ml ;Spray, 100ml;Mouth paint, 1%

Indications: treatment and prophylaxis of oropharyngeal

candidiasis in immunocompromised patients that may be
induced by chemotherapy, radiotherapy, or steroid therapy.
Cautions: pregnancy, lactation, liver disease; children less than
3 years of age (for clotrimazole troches), avoid contact with eye.
Drug interactions: polyene antimycotics like Amphotericin B,
nystatin, and natamycin.
Contraindications: known hypersensitivity to the drug or any
of the ingredients.
Side effects: Nausea, vomiting, unpleasant mouth sensations
and pruritus
Dose and Administration: Adult and children > 3
years:Troches: Prophylaxis: 10 mg troches dissolved 3
times/day for the duration of chemotherapy or until steroids are
reduced to maintenance level. Treatment: Slowly dissolve in the
mouth (15-30 minutes), one troche five times a day for fourteen
consecutive days. Mouth paint: 10-20 drops gently applied to
mouth, preferably with cotton bud, 3-4 times a day. All lesions
in the mouth must be covered.
Storage: Store in a cool, dry place
825

17. Ear, Nose And Throat Preparations

Dequalinium chloride
Lozenge, 0.25 mlSee notes above
Ephedrine Sulphate
Solution (Nose drop), 1 %
Indication: nasal congestion
Cautions: avoid excessive or prolonged use, caution in infants
less than 3 months (no good evidence of value - if irritation
occurs might narrow nasal passage)
Drug interactions: anesthetics, antibacterial, antidepressants,
antihypertensives, Beta-blockers, dopaminergics.
Side effects: local irritation, nausea, headache; after excessive
use tolerance with diminished effect; rebound congestion;
cardiovascular effects also reported.
Dose and Administration:Instill 1 - 2 drops into each nostril up
to 3 or 4 times daily.
Fluticasone Furoate
Nasal Spray, 27.5mcg
Indications:treatment of symptoms of seasonal and perennial
allergic rhinitis in adults and children 2 years. Cautions:
pregnancy, breast feeding; Epistaxis, nasal ulceration, Candida
albicans infection, nasal septal perforation, impaired wound
healing. Monitor patients periodically for signs of adverse
effects on the nasal mucosa.
Drug interactions:Potent inhibitors of cytochrome P450 3A4
(CYP 3A4), Co-administration of ritonavir
Contraindications:patients with recent nasal ulcers, nasal
surgery, or nasal trauma; hypersensitivity to the medicines and
any component of the formulation.
Side effect: headache, epistaxis, pharyngolaryngeal pain, nasal
ulceration, back pain, pyrexia, and cough.
826

17. Ear, Nose And Throat Preparations

Dose and administration: intranasal use only. Usual starting

dosages: Adults and adolescents 12 years: is 110 mcg once
daily administered as 2 sprays (27.5 14 mcg/spray) in each
nostril. Children 2-11 years: 55 mcg once daily administered as
1 spray (27.5mcg/spray) in each nostril.
Gentian Violet
Solution, 1 %
Indications: candidal infections of the mouth and throat
(thrush).
Cautions: avoid swallowing of the solution. Infants should be
turned face downward after application to minimize the amount
of drug ingested.
Side effects:Irritaion or sensitivity reactions or ulceration of
mucosal membranes may occur. Esophagitis, laryngitis, or
trachitis may result from swallowing the solution.
Dose and Administration:Topical, to the oral mucous
membranes. It should be painted only on individual lesions with
cotton.Adult and Child: every 8 12 hours daily for 3 years.
Storage: at room temperature, in tight containers
Hexetidine
Solution, 0.1 %
Indications: for local infection and/or hygiene
Side effects: allergic contact dermatitis and alterations in taste
and smell local irritation
Dose and Administration: Rinse with 15-30ml, undiluted, for
30 seconds twice daily.
Hexidine
Oral Solution, 0.1gm/100ml, 0.2%

Any mouth wash and antiseptic preparations are also acceptable

827

17. Ear, Nose And Throat Preparations

Indications: Prevention of plaque in absence of brushing,

prevention and treatment of gingivitis, treatment of oral thrush
and oral ulcers, aid in treatment of mouth and throat infections.
Dose and Administration: Rinse with 15-30ml, undiluted, for
30 seconds twice daily.
Hydrogen peroxide
Solution, 1.5%,3%
Indications: antiseptic and deodorant mouthwash. By its
effervescence, it may liberate debris from inaccessible cavities
and aid in proper cleansing of the buccal cavity.
Dose and Administration: dilute 3% to 1.5% before use as a
mouthwash. (Some 3% hydrogen peroxide with an equal
amount of water added will give 1.5% hydrogen peroxide)
Menthol + Eucalyptus oil + Light Magnesium carbonate
Inhalation, 2 % + 10 % + 7 %
Indications: for relief of nasal obstruction in acute rhinitis or
sinusitis and to promote warm moist air inspiration in
bronchitis.
Cautions: boiling water should not be used for the preparation.
Dose and Administration: add one teaspoonful to a pint of hot,
not boiling, water and inhale the vapour.
Miconazole
Oral Gel, 25 mg/ml
Indications: oral fungal infections
Cautions: pregnancy, avoid in porphyria
Drug interactions: anticoagulants, sulphonylureas, phenytoin,
cisapride, and cyclosporin.
Side effects: mild gastrointestinal disturbances
Dose and Administration:Adult: Place 5 10 ml in the mouth
after food and retain near lesions 4 times daily.
828

17. Ear, Nose And Throat Preparations

child under 2 years: 2.5 ml twice daily, 2 6 years 5 ml twice

daily, over 6 years : 5 ml 4 times daily.
* Localized lesions smear small amounts of gel on affected area with
clean finger

Storage: Store at room temperature protected from light

Mometasone furoate
Intranasal spray, 0.05%
Indications: treatment of nasal symptoms of seasonal and
perennial allergic rhinitis in adults and children 2 years of age;
prevention of nasal symptoms associated with seasonal allergic
rhinitis 12 years of age and adults; treatment of nasal polyps in
adults.
Cautions: should be avoided in the presence of untreated nasal
infections, and also after nasal surgery (until healing has
occurred); also be avoided in pulmonary tuberculosis. Systemic
absorption may follow nasal administration particularly if high
doses are used or if treatment is prolonged. The height of
children receiving prolonged treatment should be monitored; if
growth is slowed, referral to a paediatrician should be
considered.
Side effects: nasal dryness, irritation of nose and throat,
epistaxis, nasal ulceration, headache, smell and taste
disturbances,hyperactivity,
sleep
disturbances,
anxiety,
depression, and aggression particularly in children,
hypersensitivity reactions, including bronchospasm.
Dose and Administration: Nasal spray: Allergic rhinitis: Adult
and Child 12 years: 2 sprays in each nostril daily; when used
for the prevention of allergic rhinitis, treatment should begin 2-4
weeks prior to pollen season.Child 2-11 years: 1 spray in each
nostril daily.
829

17. Ear, Nose And Throat Preparations

Nasal polyps: Adult: 2 sprays in each nostril twice daily; 2

sprays once daily may be effective in some patients.
Storage: store at room temperature and protect from light.
Nystatin
Pastilles, 100,000 units
Suspension, 100,000 units/ml
Oral gel, 1000,000 IU/gm, tube- 50gm
Cream, 100,000 IU/gm, Tube- 50gm
Indications: oral and perioral fungal infections
Contraindications: hypersensitiviu7ty to the drug or any
ingredient in the respective formulation.
Side effects: nausea, vomiting, and diarrhoea, oral irritation and
sensitization reported
Dose and Administration:100,000 units 4 time daily after
food. Usually for 7 days (continued for 48 hours after lesions
have resolved). Nystatin 100,000 units up to four times daily
may be given to neonates. Immuno suppressed patients may require
higher doses (e.g 500,000 units 4 times daily). The formulation should
be kept in contact with the affected area for as long as possible and
patients should avoid taking food or drink earlier than one hour after
a dose.

Storage: nystatin deteriorates on exposure to heart light,

moisture, or air. Nystatin oral suspension should be stored in
tight, light resistant containers at room temperature; freezing of
the oral suspension should be avoided.
Oxymetazoline Hydrochloride
Nasal solution 0.05 %
Indications:nasal congestion associated with acute or chronic
rhinitis, common cold, upper respiratory allergies, and otitic
barotraumas
830

17. Ear, Nose And Throat Preparations

Cautions, contraindications, side effects see under section OP.

404 Vasoconstrictors, Oxymetazoline Hydrochloride
Dose and Administration: adults and children greater than 6
years of age:2-3 drops ever12 hours usually in the morning or
evening.
Phenylephrine
Solution (Nose drops), 0.25%, 0.5%, 1%
Indications: symptomatic relief of nasal and Eustachian tube
congestion
Cautions: breast-feeding women and children
Side effects: prolonged use will cause increase in running nose
with chronic nasal mucosa swelling. Burning, dryness, or
stinging of nasal mucosa may occur rarely.
Dose and Administration:Intranasal, Avoid prolonged use, and
avoid using more medications than the amount recommended.
Rinse dropper with hot water and dry with clean tissue after
using.Adult and Child over 12 year: 1-2 drops every four hours
of 0.25% to 0.5% solution as needed. 2 or 3 drops of the 1%
solution into each nostril every 3-4 hours as necessary.Child 612 years: 2-3 drops or 0.25% solution into each nostril every 3-4
hours as necessary.
Storage: at room temperature. In a tight and lightresistant
container.
Povidone - Iodine
Solution, 1 %
Indications: for oral hygiene
Cautions: caution should be taken during pregnancy and breast
feeding
Contraindications: avoid regular use in patients with thyroid
disorders and receiving lithium therapy.
831

17. Ear, Nose And Throat Preparations

Side
effects:
idiosyncratic
mucosal
irritation
and
hypersensitivity reactions may interfere with thyroid function
tests and with tests for occult blood.
Dose and Administration: Mouth wash or gargle.
Adult and Child over 6 years, up to 10ml undiluted or diluted
with an equal quantity of warm water for 30 seconds up to 4
times daily for 14 days.
Pseudoephedrine Hydrochloride
Syrup, 30 mg/ml
Indications: symptomatic relief or nasal congestion
Cautions, Side effects, Drug interactions; see under ephedrine
sulphate
Dose and Administrations:Orally: Adult: 60mg, 3 - 4 times
daily, children 2 to 5 years, 15 mg 3 times daily; 6 to 12 years,
30 mg 3 times daily.
Pseudoephedrine + Loratadine
Tablet, 120 mg + 5 mg
Indications: temporary relief of symptoms of seasonal allergic
rhinitis, other upper respiratory allergies, or the common cold
Cautions, Side effects, Drug interactions: see individual drugs
Dose and Administration: 1 tablet every 12 hours.
Saline Solution
Solution, 0.09%
A saline solution is a salt-water solution. The sterile solution is
typically used for nasal irrigation, flush wounds and skin
abrasions. It will not burn or sting when applied.
Sodium Chromoglycate
Aqueous Nasal Spray, 4% (5.2mg/spray)
Nasal Spray, 2%
Nasal drop, 2%
832

17. Ear, Nose And Throat Preparations

Indications: prophylaxis and treatment of allergic rhinitis

Drug interactions: Methacholine
Contraindications: Hypersensitivity to the medicines and any
component of the formulation.
Dosage and administration: Adult and children: 4%, 1 spray
into each nostril 24 times daily
2%, 1 spray into each nostril 46 times daily
Side-effects: local irritation; rarely transient bronchospasm
Storage: Store below 30oc, in the original container, in dry
place
Triamicinolone Acetonide
Oral paste, 0.1 %
Indications: adjunctive treatment and temporary relief of
symptoms associated with oral inflammatory lesions and
ulcerative lesions resulting from trauma.
Cautions: hypothyroidism, cirrhosis, nonspecific ulcerative
colitis and patients at increased risk for peptic ulcer disease,
hepatic impairment, diabetes, hypertension, osteoporosis,
glaucoma, cataracts or tuberculosis.
Drug interactions: NSAIDs, barbiturates and phenytoin,
rifampin, vaccine
Contraindications: fungal, viral, or bacterial infections of the
mouth or throat
Side effects: hypertension, convulsions, fever, atrophy of oral
mucosa, burning, and irritation
Dose and Administration: Oral topical: press a small dab
(about inch) to the lesion until a thin film develops. A larger
quantity may be required for coverage of some lesions. For
optimal results use only enough to coat the lesion with a thin
film; do not rub in.
Storage: store at room temperature
833

17. Ear, Nose And Throat Preparations

Xylometazoline Hydrochloride
Spray, 0.025%, 0.05%
Solution (Nasal drop), 0.05 %, 0.1 %
Indications: nasal congestion
Cautions:
pregnancy,
heart
disease,
hypertension,
hyperthyroidism, Diabetes
Contraindications:monoamine
oxidase
inhibitors
antidepressant (eg phenelzine, isocarboxazid, tranylcypromine
or moclobemide)
Side effects: see under ephedrine sulfate
Dose and Administration:Adult: drops: instil 2 - 3 drops of 0.1
% solution into each nostril 2 - 3 times daily when required;
maximum duration 7 days; not recommended for children under
12 years.Child: over 3 months instil 1 - 2 drops of 0.05 %
solution into each nostril 1 - 2 times daily when required (not
recommended for infants under 3 months of age, doctor's advice
only under 2 years); maximum duration 7 days. Adults and
children 12 years of age and over: spray; 2 or 3 sprays (0.05%)
in each nostril not more often than every 8 to 10 hours.
17.2. Otic Agents
Otitis externa: Otitis externa or inflammation of the skin of the
external auditory canal may be due to infections with bacteria,
viruses, or fungi or secondary to skin disorders such as eczema,
although more than one factor is often responsible for chronic
otitis externa. The treatment includes thorough cleansing and
the use of appropriate antibiotic eardrops, often containing a
corticosteroid as well, even though some have doubted the value
of topical antibiotics. Eardrops containing aminoglycosides,
such as gentamicin, neomycin, or polymixins should not be used
when the eardrum is perforated because of the risk of
ototoxicity.
834

17. Ear, Nose And Throat Preparations

A solution of acetic acid 2 % acts as an antifungal and

antibacterial in the external ear canal. It may be used to treat
mild otitis externa but in severe cases an anti-inflammatory
preparation with or without an anti-infective drug is required.
Solutions containing an anti-infective and a corticosteroid are
used for treating cases where infection is present with
inflammation and eczema.
Otitis media or inflammation of the middle ear can be acute or
chronic, serous (with effusion; secretary) or supportive local
treatment of acute otitis media is ineffective and there is no
place for drops containing a local anaesthetic. Many attacks are
viral in origin and need only treatment with a simple analgesic
such as paracetamol for pain. Sever bacterial infection should
be treated with systemic antibiotics.The organisms recovered
from patients with chronic otitis media are often opportunists
living in the debris, keratin, and necrotic bone present in the
middle ear and mastoid. Thorough cleansing with an aural suction
tube may completely resolve infection of many years duration.Acute
exacerbations of chronic infection may require systemic antibiotics.

Acetic Acid
Solution (ear drop), 2 %See notes above
Betamethasone
Solution (ear drop), 0.1 %
Indications: management of non-infected inflammatory
conditions of the external ear.
Cautions: it should be avoided in the presence of infection, and
excessive use also avoided.
Dose and Administration: Instill 2 or 3 drops into the ear every
2 - 3 hours until inflammation is controlled, after which the
frequency may be reduced.
835

17. Ear, Nose And Throat Preparations

Chloramphenicol
Solution (ear drop), 1 %, 2 %, 5 %
Indications: used in the treatment of bacterial infection in otitis
externa.
Cautions: over growth with non-susceptible organisms, Avoid
prolonged use
Side effects: high incidence of sensitivity reactions to vehicle,
optic and peripheral neuritis
Drug interactions: alfentanil, chlorpropamide, phenytoin,
tolbutamide, rifampicin, warfarin, vitamin B12, folic acid
Contraindications: hypersensitive to the drug or any
ingredients in the formulations; perforated tympanic membrane.
Mothers receiving otic chloramphenicol should not breast-feed
their infants.
Dose and Administration:Apply 2 3 drops into the ear 2 3
times daily
Storage: Store below 300C in a tight container protected from
freezing
Ciprofloxacin
Ear drops, 0.3%, 5ml
Indications: treatment of Otitis externa, acute otitis media,
chronic suppurative otitis media & prophylaxis during otic
surgeries such as mastoid surgery
Cautions: If irritation persists or increases, discontinue. Do not
touch the dropper, since this may contaminate solution.
Contraindications: Hypersensitivity to quinolone group of
antibacterials or any of the Components of the formulation
Dosage and administration: 2-3 drops every 2-3 hours
Side effect: Discomfort, pain, or itching in the ear; headache
Storage: Store at room temperature
836

17. Ear, Nose And Throat Preparations

Clioquinol +Flumethasone Pivalate

Solution (ear drops), 1% +0.02%
Indications: treatment of external ear infections caused by
bacterial and fungal organisms
Cautions: pregnancy
Contraindications: Viral infections of the skin (e.g.,
chickenpox, skin eruptions following vaccination, herpes
simplex, herpes zoster), tuberculosis of the skin, syphilis,
rosacea, acne vulgaris, perioral dermatitis, iodine, application to
ulcerated areas; application to the eye; children under 2 years of
age
Side effects: signs of irritation such as burning sensation,
itching or skin rash at the site of application; hypersensitivity
reactions.
Dose and Administration: children > 2 years and Adults:
Instill 2 - 3 drops into the affected ear twice daily general limit
duration to 10 days.
Storage: store between 15-30 0c
Clotrimazole
Solution (ear drop), 1 %
Indications: fungal infection in otitis externa
Side effects: occasional local irritation or sensitivity
Dose and Administration: Ear, apply 2 - 3 times daily
continuing for at least 14 days after disappearance of infection
Cocain Hydrochloride
Topical Solution, 4% (40mg/ml), 10% (100mg/ml)
Indications: local (topical) anesthesia of accessible mucous
membranes of the oral, laryngeal and nasal cavities.
Cautions: Pregnancy, breast feeding and severely traumatized
mucosa and sepsis.
837

17. Ear, Nose And Throat Preparations

Contraindications: patients with a known history of

hypersensitivity to the drug or to the components of the topical
solution
Dosage and administration: the dosage varies and depends
upon the area to be anesthetized, vascularity of the tissues,
individual tolerance, and the technique of anesthesia. The lowest
dose needed to provide effective anesthesia should be
administered. Dose should be reduced for children and for
elderly and debilitated patients. It can be administered by means
of cotton applicators or packs, instilled into a cavity, or as a
spray
Side effects: nausea, nervousness, unusual feelings of wellbeing, or restlessness
Storage: Store at room temperature
Dichlorobenzene + Chlorobutol + Turpentine oil
Solution (ear drop), 2 % + 5 % + 10 %
Dose and Administration: Instill 5 drops into the ear 10 to 30
minutes before syringing.
Gentamicin
Solution (ear drop), 0.3 %
Indications: bacterial infection in otitis externa
Cautions: avoid prolonged use.
Contraindications: perforated tympanic membrane
Side effects: local sensitivity
Dose and Administration:Ear, apply 3 - 4 drops 3 - 4 times
daily; reduce frequency when relief obtained.
Hydrogen peroxide
Solution, 3 %
Hydrogen peroxide has antimicrobial properties, which are
reduced in the presence of organic matter. Their frothing action
838

17. Ear, Nose And Throat Preparations

makes them useful to loosen and aid removal of debris in the ear
canal.
Storage: at room temperature in airtight container Solutions
should not be stored for long periods. Those not containing a
stabilizer should be stored at a temperature not exceeding 15 0C.
Protect from light.
Neomycin Sulphate + Hydrocortisone + Polymixin B
Sulphate
Ear drops, 3.5 mg + 10 mg + 10,000 units in each ml,
34,000units +1% +10,000units/ml
Indications: see section 15.5 (anti infective).
Cautions: pregnancy
Contraindications: hypersensitivity to any of its components;
if the external auditory canal disorder is suspected or known to
be due to cutaneous viral infection (for example, herpes simplex
virus or varicella zoster virus).
Dose and Administration:Adult: instill 4 drops 3-4 times per
day. Child: instill 3 drops into affected ear 3-4 times per day.
Ofloxacin
Ear drops, 0.3%
Indications:treatment ofOtitis Externa, chronic suppurative
otitis Media with perforated tympanic membranes and
acuteotitis media in the presence of tympanostomy tubes in
children
Cautions: pregnancy; breast feeding; do not touch the dropper,
since this may contaminate solution.
Contraindications: History of hypersensitivity to ofloxacin, to
other quinolones, or to any of the components in this
medication.
Dosage and administration:otitis externa: Adults: 10 drop
twice daily. Children (under 12): 5 drops twice daily. Chronic
839

17. Ear, Nose And Throat Preparations

suppurative otitis media with perforated tympanic membranes:

Adults: 10 drops twice daily for 14 days. Acute otitis media in
the presence of tympanostomy tubes:children: Apply 5 drops
twice daily for 14 days. Note: Ofloxacin ear drops should be
instilled into the ear canal of the infected ear, while the patient lies
with the ear upwards. The position should be maintained for at least 5
minutes after administration.

Side effects: Pruritus, ear ache, dizziness, headache, vertigo,

nausea, seborrhea
Storage: Store at room temperature
Oxytetracycline
Ear drop, 0.5%
Indications: treatment of infections caused by a variety of
Gram positive and Gram negative microorganisms
including Mycoplasma
pneumoniae,
Pasteurella pestis,
Escherichia
coli,
Haemophilus
influenzae (respiratory
infections), and Diplococcus pneumoniae.
Contraindications: pregnancy, breast feeding hypersensitivity
to tetracycline or any component of the formulation
Oxytetracycline Hydrochloride + Hydrocortisone Acetate +
Polymyxin B sulphate
Ear drop, 5 mg +15 mg + 10,000 units in each ml.
Indications: bacterial infection with eczematous inflammation
in otitis external (see also notes above)
Caution: avoid prolonged use
Contraindications: perforated tympanic membrane
Side effects: local sensitivity reactions

840

18. Dermatological Agents

18. DERMATOLOGICAL AGENTS

18.1. Anti-infective, Topical
Antifungals
Ringworm: infection can affect the scalp (tinea capitis), body
(tinea corporis), groin (tinea cruris), hand (tinea manuum), foot
(tinea pedis, athletes foot) or nail (tinea unguium). Scalp and
nail infection requires systemic treatment; additional topical
application of antifungal may reduce the risk of
transmission.Most other local ringworm infections can be
treated adequately with topical antifungal preparations. Benzoic
acid and methylrosanilinium chloride (genetian violet)
solution are inexpensive and effective fungistatic compounds
for the treatment of ringworm infections. Minor skin lesions
due to ringworm can be cleared with repeated applications of
compound benzoic acid ointment (Whitfield ointment), which
combines the fungistatic action of benzoic acid with the
keratolytic action of salicylic acid. However, the most effective
topical treatment for dermatophyte infections is a cream
containing an imidazole such as clotrimazole, ketoconazole
and miconazole, which are effective for long established lesions
but is more expensive than compound benzoic acid ointment.
Candidiasis: Candida can infect the oral cavity, the vagina or
the skin. The most sever infections of candida are now seen in
patients with HIV infection. Candidal skin infections may be
treated with topical imidazole antifungals, clotrimazole,
ketoconazole, miconazole. Topical application of nystatin is
also effective for candidiasis but it is ineffective against
dermatophytosis. Refractory candidiasis requires systemic
treatment.
Pityriasis versicolor: Pityriasis (tinea) versicolor is caused by
commensal yeast. It may be treated topically with a course of
841

18. Dermatological Agents

selenium sulphide repeated after one month. Topical imidazole

antifungals and topical terbinafine are alternatives but large
quantities may be required. If topical therapy fails or if the
infection is widespread, pityriasis versicolor is treated
systemically with an azole antifungal. Relapse is common,
especially in immunocompromised patients.
Choice of Antifungal formulation
Both vehicles and active ingredients are important in the
treatment of skin conditions; the vehicle alone may have more
than a placebo effect. The vehicle affects the degree of
hydration of the skin, has mild anti-inflammatory effects, and
aids the penetration of the active drug.
Lotions or sprays are suitable for application to large and hairy
areas. Ointments are generally used on dry areas; they are best
avoided on moist skin. Creams are cosmetically more
acceptable than ointments and they are best suitable for moist
areas.
Paints and solutions for application to the nail are occasionally
effective for early dystrophy in onychomycosis. Dusting
powders are of little therapeutic value in the treatment of fungal
skin infections and may cause skin irritation; they may have
some role in preventing re-infection.
Cautions: Contact with eyes and mucous membranes should be
avoided.
Side effects:Occasional local irritation and hypersensitivity
reactions include mild burning sensation, erythema, and itching.
Treatment should be discontinued if these are severe.
Benzoic Acid + Salicylic Acid (Whitfields Ointment)
Ointment, 6 %+ 3 %, 12 % + 6 %
Indications: fungal infections of the skin (mild dermatophyte
infections, particularly tinea pedis and tinea corporis).
842

18. Dermatological Agents

Cautions: it should not be applied to broken or inflamed skin.

Side effects: skin irritation, dryness may occur and mild
inflammatory reaction.
Dose and Administration: Topical, to the skin for several
weeks until the infected stratum is shed usually at least 4 weeks.
Prolonged use should be avoided and irritation of the skin
occurs.Apply sparingly to the affected area every 8-12 hours
daily.
Storage: at room temperature, in a tight container.
Castellani's paint (Magenta + Boric Acid + Phenol +
Resorcinol + Alcohol 90 % + Acetone)
Solution each 100 ml contains: 400 mg + 800mg + 4g+ 8g +
8.5 ml + 4 ml (water q.s. 100 ml).
Indications: castellanis paint is applied topically in the
treatment of superficial fungal infections of the skin including
tinea pedis and ringworm infections.
Cautions: the drug is poisonous when ingested. The drug
should not be applied to eroded skin or over extensive areas.
Dose and Administration:Castellanis paint is applied topically
by means of an applicator or swab. The skin should be cleansed
with soap and water and thoroughly dried prior to application.It
is usually applied once or twice daily; however, application of
the drug 3 times daily may be necessary in chronic or stub born
infections. The solution should be applied no more often than
once daily in infantile eczema. In dry, scaling dermatophytoses,
application of the solution may be alternated with ointments
containing other antifungal agents or keratolytics.
Storage: the solution should be stored in a tight, light resistant
container at room temperature(300); freezing should be avoided
and protect from humidity.
843

18. Dermatological Agents

Clotrimazole
Cream 1 %
Solution 1 %
Topical powder, 1%
Mouth paint, 1%
Indications.Treatment of susceptible fungal infection and
topical clotrimazole is indicated in the treatment of cutaneous
candidiasis (moniliasis) caused by Candida albicans.It is also
indicated for treatment of tinea corporis (ring worm of the
body), tinea cruris (ringworm of the groin, jock itch), and tinea
pedis (ringworm of the foot; athletes foot).It is also used in the
treatment of tinea versicolor (pityriasis versicolor, sun
fungus), and in the treatment of paronychia, tinea barbae, and
tinea capitis.
Cautions: sensitive to clotrimazole or any componont of the
formulation
Side effects: hypersensitivity (skin rash, hives, blistering,
burning, itching peeling, redness, stinging, swelling and other
sign of skin irritation not present before therapy).
Dose and Administration:Adult and Child: topical, to the skin
and surrounding area, two times a day, morning and evening.
Storage: at room temperature in a tight container, protect from
freezing.
Methylrosanilinium chloride (Genitian Violet)
Solution, 0.5 %, 1 %
Indications: for the treatment of skin infections caused by
candida and bacteria, and genital candidiasis.
Contraindications: It should not be applied on ulcerative
lesions of the facea and if hypersensitivity to the gentian violet.
Side effects: skin or genital irritation may occur. It also stains
skin and clothing.
844

18. Dermatological Agents

Dose and Administration: Topical, to the skin. Do not cover

the affected area with dressings after application.
Apply every 8 12 hours daily for about 3 days.
Storage: at room temperature, in tight containers.
Isoconazole
Cream, 1%, 2%
Indications: cutaneous mycotic infections.
Cautions, Side effects: see notes above
Dose and Administration: apply twice daily.
Itraconazole
Capsule, 100mg
Injection, 100mg/10ml
Indications, cautions, drug interactions, contraindications,
and side effects, dose and administration and storage:see
section 7.2.
Ketoconazole
Cream, 2 %
Ointment
Shampoo, 2 %
IndicationsCream: Tinea infections: Rub gently into the
affected area once daily. Duration of treatment: Tinea corporis,
cruris: 2 weeks; tinea pedis: 6 weeks. Skin fungal infections if
use cream and if we use Shampoo (ketoconazole 2%): Tinea
versicolor: Apply to damp skin, lather, leave on 5 minutes, and
rinse (one application should be sufficient)
Cautions: patients should be advised to avoid contact of
ketoconazole shampoo with the eyes since irritation may occur.
Ketoconazole 2 % cream or shampoo should be used with
caution in nursing women, during pregnancy and pediatrics if
and hypersensitivity reactions occured.
845

18. Dermatological Agents

Side effects: itching, stinging, or irritation not present before

therapy for cream and shampoo; contact dermatitis for
cream.Note: Ketoconazole 2 % cream is intended for topical
application to the skin only and should not be applied to the eye nor
administered intravaginally.

Dose and Administration:Ketoconazole creamAdult: Topical

to the affected skin and surrounding area.Tinea corporis or
Tinea cruris, Tinea pedis or Pityriasis versicolor: once a
day.Candidiasis, cutaneous: once a day. More resistant cases
may require twice a day treatment.Seborrheic dermatitis: two
times a day.
Paronychia or Tinea barbae or Tinea capitis: two or three times
a day.Note: Safety and efficacy have not been established for
pediatric use.

Ketoconazole shampoo: Adult:Dermatitis, seborrheic: Topical,

twice a week for 2 to 4 weeks. Leave in place for 3 to 5 minutes
before rinsing. Prophylaxis: once a week every 1 or 2 weeks.
Pityriasis versicolor: Topical, to the affected skin and
surrounding area(s), as a single application. Leave in place for
5 minutes before rinsing.Child: safety and efficacy have not
been established.
Storage: at room temperature. Protect from freezing.
Ketoconazole + Zinc Pyrithione
Shampoo, 2% + 1% w/w
Indications: seborrheic dermatitis and dandruff.
Cautions: allergic to ketoconazole and pyrithione zinc.
Dose and Administration: Wash hair and scalp daily or at least
2 times per week.
Miconazole Nitrate
Cream, 2 %
Lotion, 2 %
846

18. Dermatological Agents

Tincture, 2 %
Indications: fungal skin infections
Cautions, Side effects: see notes above
Dose and Administration:Apply twice daily continuing for 10
days after lesions have healed; nail infections, apply 1 2 times
daily.
Contraindications:Hypersensitivity to miconazole or any
component of the formulation
Storage: at room temperature in a fight container
Nystatin
Cream, 100,000 IU/g
Ointment, 100,000 IU/g
Powder 100,000 IU/g
Indications: skin infections due to Candida Spp. (see also notes
above)
Cautions: see notes above
Dose and Administration: Apply 2 4 times daily
Storage:Cream Store at room temperature; avoid excessive heat
(40C/104F).Topical powder: Store at 20C to 25C (68F to
77F); avoid excessive heat (40C/104F).
Salicylic Acid
Ointment, 2 %, 5 %, 10 %
Indications: treatment of acne vulgaris, seborrheic dermatitis,
psoriasis, and common wart (excluding on the face).
Cautions: avoid contact with eyes, mouth, and mucous
membranes; avoid application to large areas. Significant
peripheral neuropathy, patients with diabetes risk neuropathic
ulcers.
Contraindications: broken or inflamed skin; children under 2
years.
847

18. Dermatological Agents

Side effects: stinging, local irritation, and salicylism may occur

when large areas are treated particularly in children.
Dose and Administration: Topical to the skin:Apply to
affected area every 12-24 hours daily starting with the 2%
progressively increasing the concentration up to 5% for acne
vulgaris and up to 10% for seborrheic dermatitis, psoriasis and
common wart. Apply until it gets better.
Storage: at room temperature, in tight containers.
Selenium Sulphide
Suspension, 2.5 %
Indications: seborrhoeic dermatitis; treatment of itching and
flaking of the scalp associated with dandruff, tocontrol scalp
seborrheic dermatitis.Treatment of tinea versicolor.
Cautions: do not apply to damaged skin (risk of systemic
toxicity); avoid contact with eyes; do not use with in 48 hours of
applying any type of hair coloring or permanent waving
preparation.
Contraindications: children under 5 years. For external use
only; avoid contact with eyes and genital areas. Due to the risk
of systemic toxicity, do not use on damaged skin or mucous
membranes.
Side effects: local irritation, hair discoloration or loss;
absorption may result in systemic toxicity including tremors,
weakness, lethargy, pain in lower abdomen, occasional vomiting
(symptoms usually resolve with in 10 days).
Dose and Administration:Seborrhoeic dermatitis: massage 5
10 mg of suspension in to wet hair and leave for 2 3 minutes
before rinsing thoroughly; repeat twice weekly for 2 weeks, then
once weekly for 2 weeks, and then only when needed.Note: To
minimize absorption, rinse hair thoroughly after use and remove all
traces from skin (including nails). Tinea versicolor: apply the 2.5%
848

18. Dermatological Agents

lotion to affected area and lather with small amount of water;

leave on skin for 10 minutes, then rinse thoroughly; apply every
day for 7 days.
Storage: at room temperature. Freezing should be avoided.
Nystatin
Cream, 1%
Indications: indicated for dermatophyte and yeast infections of
the skin and appendages, including tinea versicolor.
Dose and Administration: clean and dry affected area before
application. Apply 1-2 times daily until infection is clear
(usually 1-2 weeks).
Tolnaftate
Solution, 1%
Indications: tolnaftate is an antifungal agent used topically in
the treatment or prophylaxis of various forms of tinea and of
pityriasis versicolor.
Note Tolnaftate is not considered suitable for deep infections
in nail beds or hair follicles but it may be used concomitantly
with a systemic agent.
Contraindications: hypersensitivity to tolnaftate or any
component of the formulation; nail and scalp infections
Cautions: if irritation or hypersensitivity occurs, or if the
patients skin disease does not improve with in 10 days or
becomes worse during self medication with tolnaftate, treatment
should be discontinued and the patient should consult a
physician or pediatrist. Tolnaftate preparations should not come
in contact with the eyes.
Side effects: irritation, contact dermatitis.
Dose and Administration: Tolnaftate is applied twice daily for
2 to 6 weeks. Repeat treatment may be required.
849

18. Dermatological Agents

Storage: It should be stored in tight container at room

temperature. Freezing of the solution should be avoided.
Zinc undecenoate + Undecenoic Acid
Ointment, 20 % + 5 %
Powder, 20 % + 2 %
Powder (aerosol), 20 %+ 2 %
Indications: for the treatment of athlete's foot (tinea pedis), jock
itch (tinea cruris), and other skin infections caused by
dermatophytic fungi (ring worm)
Dose and Administration:Athletes foot ringworm:topically:
twice daily after cleansing the affected area, for 4 weeks.Jock
itch: topically, twice daily after cleansing the affected area, for
two weeks.
Note: The ointment or cream should be used at night and the powder
may be used during the day.

Antibacterial preparations
Staphylococcal infections of the skin such as impetigo,
folliculitis, and furunculi and streptococcal infections such as
cellulitis and erysipelas are very common where the climate is
hot and humid, where standards of hygiene are compromised,
and in immunodeficient patients.
Skin infections such as erysipelas and cellulitis systemic
antibacterial treatment is more appropriate because the infection
is too deeply seated for adequate penetration of topical
preparations.
An ointment containing 2% mupirocin, which is active
against Gram-positive bacteria, is of value, particularly in
impetigo.
Mupirocin is not related to any other antibacterial in use; it is
effective for skin infections, particularly those due Grampositive organisms but it is not indicated for pseudomonal
850

18. Dermatological Agents

infection. Although Staphylococcus aureus strains with lowlevel resistance to mupirocin are emerging, it is generally useful
in infections resistant to other antibacterials. To avoid the
development of resistance mupirocin should not be used for
longer than 10 days and its use in hospital should be avoided if
possible.
Infected burns should be treated with silver sulfadiazine
which is bactericidal against both Gram-positive and Gramnegative organisms.
Topical preparations containing
neomycinand bacitracin are also widely used but these carry a
risk of sensitization particularly with continued or repeated use.
Topical use of preparations containing antimicrobials which
are widely used systemically should be avoided. These include
penicillins, sulfonamides, streptomycin and gentamicin which
should be reserved for the systemic treatment of infections
because of the possibility of including sensitivity and favouring
the emergence of resistant organisms.
Clindamycin Phosphate
Solution 1%
Indications: treatment of severe acne.
Dose and Administration: apply a thin film twice daily.
Contraindications:
Hypersensitivity
to
clindamycin,
lincomycin, or any component of the formulation.
Side effects: Dryness, burning, itching, scaliness, erythema, or
peeling of skin (lotion, solution); oiliness (gel, lotion)
Dose and Administration: Apply a thin film twice daily.
Clioquinol
Cream, 3%
Ointment, 3%
851

18. Dermatological Agents

Indications: topically for treating primary skin infections such

as impetigo, or skin conditions complicated by infection.
Side effects: allergic or irritant reactions of the skin occur
occasionally; staining of fomites and hair can occur.
Dose and Administration: Apply 2- 3 times daily to affected
areas.
Cautions clioquinol generally appears to be well tolerated
following topical application to the skin. Local irritation, rash,
and sensitivity reactions have been reported occasionally.
Storage: store at a temperature less than 30oC; freezing should
be avoided.
Erythromycin
Cream, 2%
Ointment, 1%
Solution, 2%
Indications: treatment of acne vulgaris.
Dose and Administration: Apply over the affected area twice
daily after the skin has been thoroughly washed and patted dry
Contraindications: hypersensitivity to erythromycin, any
macrolides antibiotics, or any component of the formulation.
Storage: store solution at 15-30 oC, and ointment at a
temperature less than 27oC.
Fusidic Acid
Cream, 2%
Indications: for staphylococcal infections and treatment of
primary and secondary skin infections caused by susceptible
organisms.
Cautions: should be used for acute skin infections (5 days) and
not for prolonged periods. Prolonged use may result in
superinfection (including fungal infections). Discontinue use if
superinfection occurs; evaluate and treat.
852

18. Dermatological Agents

Side effect: prolonged use may result in superinfection

(including fungal infections). Discontinue use if superinfection
occurs; evaluate and treat appropriately and local
hypersensitivity reactions.
Dose and Administration: Apply 3 - 4 times daily.
Storage: Store at 15C to 25C.
Gentamicin
Cream, 0.1%
Ointment, 0.3%
Indications: treatment of superficial infections of the skin
caused by susceptible bacteria.
Cautions: hypersensitivity to the drug.
Dose and Administration: Apply 3 - 4 times per day to
affected area.
Storage:store at 2-300C. But refrigeration is not recommended.
Metronidazole
Cream, 0.75%, 1%
Gel, 1%
Lotion, 1%
Indications: treatment of inflammatory lesions and erythema of
rosacea.
Cautions and Contraindications: A history of hypersensitivity
reactions to any of the components. Use with caution in those
with blood dyscrasias. Avoid contact with the eyes.
Side effects: tearing of the eyes, transient erythema, dryness,
burning and skin irritation.
Dose and Administration:Acne rosacea: Topical:
0.75%: Apply and rub thin film twice daily, morning and
evening, to entire affected areas after washing. Significant
therapeutic results should be noticed within 3 weeks.1%: Apply
thin film to affected area once daily.
853

18. Dermatological Agents

Mupirocin
Ointment, 2%
Indications: bacterial skin infection (see also notes above)
Contraindications:mupirocin is contraindicated in patients
with a history of hypersensitivity to the drug or any ingredient
in the formulation.
Cautions: renal impairment; may sting
Dose and Administration: Skin infection: apply up to 3 times
daily for up to 10 days.Note: contains macrogol and
manufacturer advises caution in renal impairment
Storage: at room temperature
Neomycin + Bacitracin
Ointment, 4 mg + 500,000 IU
Powder, 0.25 % + 9.5 %
Indications: superficial bacterial infections of the skin due to
staphylococci and streptococci
Cautions: avoid application to substantial areas of skin or to
broken skin (risk of significant systemic absorption), over
growth of resistant organisms on prolonged use.
Side effects: sensitization, especially to neomycin, causing
reddening and scaling, anaphylaxis reported rarely; systemic
absorption leading to irreversible ototoxicity, particularly in
renal impairment.
Dose Administration: Apply thin layer 3 times daily.
Storage: at room temperature.
Nitrofurazone
Gauze Dressing
Indications: as an adjunctive therapy for second and third
degree burns when resistance to other agents is a real or
potential problem; in skin grafting when bacterial contamination
854

18. Dermatological Agents

may cause graft rejection or donor site infection, especially in

hospitals with a history of resistant bacteria.
Cautions: if over growth of nonsusceptible organisms occur, or
if irritation, sensitization, or superinfection develops, treatment
should be discontinued. Caution should be taken in patient with
renal function impairment.
Side effects: contact dermatitis
Dose and Administration:Adult:Burns or Skin infections:
Topical directly to lesion or place on gauze depending on the
usual dressing technique
Child: safety and efficacy have not been established
Storage: at room temperature in a well-closed container. Protect
from freezing.
Silver Sulphadiazine
Cream, 1 %
Indications: prophylaxis and treatment of infection in burns.
Cautions: renal or hepatic impairment; G6PD deficiency;
breastfeeding.
Contraindications:
hypersensitivity
to
sulfonamides;
pregnancy; neonates.
Side effects: allergic reactions include rashes, burning and
itching; argyria and sulfonamide induced systemic toxicity,
including blood disorders following application to large areas or
prolonged use; transient leucopoenia reported.
Dose and Administration:Apply using aseptic technique daily
(more frequently if volume of exudate is large) whilst there is a
possibility of infection, or until healing is complete. Therapy is
usually continued until healing is progressing well or until the
site is ready for grafting
Storage: At room temperature. Discard, if the cream changes
its colour (dark) up on storage.
855

18. Dermatological Agents

Sodium Fusidate
Ointment, 2 %
Indications: staphylococcal skin infections and treatment of
primary and secondary skin infections caused by susceptible
organisms
Cautions: avoid contact with eyes and treatment of primary and
secondary skin infections caused by susceptible organisms.
Contraindications:
hypersensitive
to
fusidates
andhypersensitivity to fusidic acid or any component of the
formulation.
Side effects: rarely hypersensitivity reactions
Dose and Administrations: Apply 3 4 times daily,
Storage: store in airtight containers at a temperature of 2oC to
8oC. Protect from light.
Tetracycline
Ointment, 3 %
Indications: bacterial skin infections
Cautions: sensitivity to tetracyclines; over growth with nonsusceptible organisms; stains clothing
Side effects: rarely local hypersensitivity reaction
Dose and Administration:Adult: Antibacterial (topical):
Topical, to the skin, one or two times a day.
Child: see adult dose.
Storage: store at room temperature in a well-closed container.
Protect from freezing.
Scabies and Pediculicides
Permethrine are used for Scabies (Sarcoptes scabiei). Aqueous
preparations are preferable to alcoholic lotion, which are not
recommended owing to irritation of excoriated skin and the
genitalia. Older preparations include benzyl benzoate, which is an irritant
and should be avoided in children; it is less effective than Permethrine.

856

18. Dermatological Agents

The itch of scabies persists for some weeks after the

infestation has been eliminated and antipruritic treatment may
be required. Application of crotamiton can be used to control
itching after treatment with more effective acaricides, but
caution is necessary if the skin is excoriated.
Head and body lice are readily treated with permethrin;
malathionis effective against pubic lice. Benzyl benzoate may
be used for all lice infections.
Benzyl Benzoate
Lotion, 25 %,
Indications: scabies; head, body and pubic lice.
Cautions: avoid contact with face, eyes, mucous membranes
and urethral meatus. Do not apply to inflamed skin or weeping
surfaces; not recommended for children; breastfeeding
(withhold during treatment).
Side effects: slight local irritation, transient burning sensation,
occasionally rashes. Frequent use causes contact dermatitis.
Dose and Administration: Scabies:Adult: apply from neck
down at night for 2 nights; on each occasion wash off after at
least 24 hours.A single treatment is usually effective but, if
necessary, may be repeated after 1 week.
Dilute with an equal amount of water for children (12.5%), and
1 part with 3 parts of water for infants (6%).Pediculosis: Adult:
apply to affected area and wash off 24 hours later; further
applications possibly needed after 7 and 14 days.
Storage: At room temperature, in airtight, light resistant
containers. Protect from heat.
Crotamiton
Cream, 10 %
Lotion, 10 %
Indications: topical treatment of scabies and pruritus.
857

18. Dermatological Agents

Cautions: crotamiton should not be applied to acutely inflamed

skin or raw, weeping surfaces and If primary irritation or
hypersensitivity occurs, treatmen. The drug is for topical use
only and should not be administered orally or intravaginally. It
should be discontinued and the drug should be removed with
soap and water. Crotamiton should be used during pregnancy
only when clearly needed. Contact with the face, eyes, mucous
membranes and urethral meatus should be avoided.
Contraindications: a history of sensitivity or allergy to the
drug and in those who exhibit a primary irritation response to
topically applied medications. Acute exudative dermatoses
Side effects: slight local irritation, allergic skin sensitivity may
occur with prolonged use
Dose and Administration:Crotamiton, in the form of a 10 %
cream or lotion is applied topically. The drug should not be
administered orally.A thin layer of the 10 % cream or lotion
should be applied uniformly and massaged gently into all skin
surfaces from the neck to the toes. A second coat of the cream
should be applied after 24 hours.In adults, 30 g of the cream for
one application; a proportionately smaller amount is used in
children. Treatment may be repeated after 7 10 days if mites
appear or new lesions develop. The patient should bath 48
hours after the last application to remove the drug.Note: Before
applying crotamiton, advice the patient to bath with soap and water,
taking cares to scrub and remove scaling or crusted detritus, then
towel dry.

Storage: It should be stored in tight, light resistant containers at

a room temperature.
Gamabenzene Hexachloride (Lindane)
Cream, 1 %
858

18. Dermatological Agents

Indications: for treatment of pediculosis (lice) infestation

caused by Pediculus humanus var. capitis (head louse) and
phthirus pubis (public or crab louse) and their ova.It is also
indicated for the treatment of scabies infestation caused by
Sarcoptes scabies.
Cautions: caution is required in children and infants. It is not
recommended for use in premature neonates. Caution should be
taken in patients with convulsive disorders, in those who are
sensitive to lindane and in patients with skin rash or raw or
broken skin.
Side effects: skin irritation not present before therapy (if it is
applied in correctly and repeatedly), itching of skin, CNS
toxicity (if absorbed systemically) - convulsions, dizziness,
clumsiness, or unsteadiness, fast heartbeat, muscle cramp,
nervousness, restlessness, or irritability, vomiting.
Dose and Administration: pediculicide, scabicide-Topical, to
the skin, as a 1% cream for one application.
Storage: at room temperature in a tight container.
Malathion
Shampoo, 1%,
Indications: scabies, head lice and crab lice
Cautions: avoid contact with eyes; do not use on broken or
secondarily infected skin; children under 6 months, medical
supervision required
Contraindications: use in neonates and/or infants;
hypersensitivity to Malathion.
Side effects: skin irritation and hypersensitivity reactions;
chemical burns also reported
Dose and Administration: Head lice: rub 0.5% preparation
into dry hair and scalp, allow todry naturally, and remove by
washing after 12 hours repeat application after 7 days. Crab
859

18. Dermatological Agents

lice: apply 0.5% aqueous preparation over whole body, allow

todry naturally, wash off after 12 hours or overnight; repeat
application after 7 days.
Storge: Read the manufacturer life information
Permethrine
Cream, 5 %
Lotion, 1%, 5%
Indication: scabies, head and body lice
Cautions: do not use on inflamed or broken skin: avoid contact
with eyes; breast feeding (with hold during treatment). That
means the drug is for external use only and should not be
administered orally.
Side effects: local irritation; rarely rashes and oedema
Dose and Administration:Scabies and body lice: apply cream
over whose body and wash of after 8 12 hours.
Note: for external use only.

Storage: store between15 to 25oc. Protect from freezing.

Sulphur
Ointment, 5 %, 10 %
Indications: for the treatment of seborrheic dermatitis, scabies
especially infants under 2 months of age and in pregnant and
nursing women. It is also indicated as an aid in the treatment of
acne vulgaris.
Cautions: sensitivity to sulfur.
Drug interactions: medicated soaps, acne preparations or
preparations containing a peeling agent, such as benzoyl
peroxide, resorcinol, salicylic acid, tretinoin, after shave lotions,
astringents, perfumed toiletries, shaving creams or lotions,
cosmetics, isotretinoin, medicated cosmetics or cover-ups,
topical mercury compounds.
860

18. Dermatological Agents

Side effect: skin irritation not present before therapy, redness

and peeling of skin.
Dose and Administration:Adult and Child (>2 years)
Antiacne agent: topical, to the skin, as a 0.5% ointment as
needed.Antiseborrheic or keratolytic: topical, to the skin, as to
10% ointment once or two times a day.
Scabicides: Topical, to the entire body from the neck down, as
6% sulfur in petrolatum at bedtime for 3 nights, patients may
bath before each application and should bath after 24 hours
following the last application to remove the drug.
Storage: at room temperature, protect from freezing
Antiviral
Acyclovir
Ointment, 5%
Indications: treatment of mucocutaneous herpes simplex
infections, herpes labialis, for serious skin and mucosal
(including genital) herpetic infections.
Cautions: indiscriminate use of topical aciclovir may result in
the emergence of resistance. It has no role in the treatment of
herpes zoster.
Side effects: mild pain, burning or stinging often occurs when
applied to ulcerated lesions. Erythema, itch, mild dryness and
skin hypersensitivity rashes occur.
Dose and Administration: topical:Adult: 1.3cm ribbon of
ointment for a 10cm square surface area every 3 hours (6
times/day) for 7 days.
Storage: store at room temperature.
Others
Fluorouracil
Cream, 2%, 4%
861

18. Dermatological Agents

Indications: management of actinic or solar keratoses and

superficial basal cell carcinomas.
Contraindications.hypersensitivity to fluorouracil or any
component
of
the
formulation;
dihydropyrimidine
dehydrogenase (DPD) enzyme deficiency; pregnancy.
Dose and Administration: apply 10 minutes after washing,
rinsing, and drying the affected area. Apply using fingertip
(wash hands immediately after application) or nonmetal
application. Avoid eyes, nostrils, and mouth. Do not cover area
with an occlusive dressing.
Storage: store at controlled room temperature.
18.2. Anti-Inflammatories, Topical
Topical corticosteroids often produces dramatic suppression of
skin diseases, such as eczema, infantile eczema, atopic
dermatitis, dermatitis herpetiformis, contact dermatitis,
seborrhoeic dermatitis, neurodermatitis, some forms of
psoriasis, and intertrigo, in which inflammation is a prominent
feature. However, the disease may return or be exacerbated
when corticosteroids are withdrawn.
Application of the corticosteroids to the skin has lead to loss of skin
collagen, subcutaneous atrophy local hypopigmentation of deeply
pigmented skins. Topical corticosteroids should not be applied with
an occlusive dressing to large areas of the body because of the risk of
systemic absorption. Also they should not be used for the treatment of
rosacea and should not be used indiscriminately for pruritus.
Corticosteroids should not be applied to ulcers of the leg and long
term topical use is best avoided, especially in children. Patients
should be advised that topical corticosteroids should be applied
sparingly in thin layers, by smoothing gently into the skin preferably
after a bath and that no benefit is gained from more frequent than
twice daily application or by vigorous rubbing. Treatment should be
discontinued as soon as a positive result is obtained.
862

18. Dermatological Agents

Cautions: Avoid prolonged use of topical corticosteroids in the

face (keep away from eyes). In children avoid prolonged use
and use potent or very potent corticosteroids under special
supervision; extremely caution is required in dermatoses of
infancy including naapy rash-treatment should be limited to 5-7
days. The use of potent and very potent corticosteroids in
psoriasis can result in rebound relapse, development of
generalized postural psoriasis and local and systemic toxicity.
Contraindications: these drugs are contraindicated in untreated
bacterial, fungal and viral skin lesions, in acne rosacea and
perioral dermatitis; potent cortecosteroids are contraindicated in
wide spread plaque psoriasis.
Dose Administration:see above.Topical corticosteroids are
spread thinly on the skin; the length of cream or ointment
expelled from a tube may be used to specify the quantity to be
applied to a given area of skin. This length can be measured
interms of a fingertip unit. One fingertip unit (approximately
500 mg) is sufficient to cover an area that is twice of the flat
adult palm.
Suitable quantities of corticosteroid preparations to be prescribed
for specific areas of the bodies
Creams and Ointments
Face and nack
15 to 30 g
Both hands
15 to 30 g
Scalp
15 to 30 g
Both arms
30 to 60 g
Both legs
100 g
Trunk
100 g
Groins and genitalis
15 to 30 g
These amounts are usually suitable for an adult for a single daily
application for two weeks

Topical corticosteroid preparation potencies are a result of the

formulation as well as the corticosteroid.
863

18. Dermatological Agents

Betamethasone
Betamethasone Dipropionate, Cream, 0.025%, 0.05%
Betamethasone Valerate, Cream, 0.1%; Ointment, 0.1%;
Scalpapplication, 0.1%
Indications: inflammatory dermatoses such as seborrheic or
atopic dermatitis, neurodermatitis, anogenital pruritus, psoriasis,
inflammatory phase of xerosis.
Cautions; Side effects, Contrindications: see under
hydrocortisone and notes above.
Dose and Administration: apply thin film 2-4 times per day.
Therapy should be discontinued when control is achieved; if no
improvement is seen, reassessment of diagnosis may be
necessary.
Clobetasol Propionate
Cream, 0.05% w/w
Ointment, 0.05% w/w
Scalp Application, 0.1%
Indications: short term relief of inflammation of moderate to
severe corticosteroid-responsive dermatoses (very high-potency
topical corticosteroid).
Cautions; Side effects, Contrindications: see under
hydrocortisone and notes above.
Dose and Administration: discontinue when control is
achieved; if improvement not seen within 2 weeks, reassessment
of diagnosis may be necessary.
Adult and Child 12 years: Steroid responsive dermatoses:
apply twice daily for up to 2 weeks (maximum dose: 50
g/week).
Desoximethasone
Cream, 0.05% 0.25%
864

18. Dermatological Agents

Gel, 0.05%
Lotion, 0.25%
Ointment, 0.25%
Indications: relieves inflammation and pruritic symptoms of
corticosteroid-responsive dermatoses (intermediate-to highpotency topical corticosteroid).
Cautions; Side effects, Contrindications: see under
hydrocortisone and notes above.
Dose and Administration: apply a thin film to affected area
twice daily.Ointment: Child 10 years and Adult: apply a thin
film to affected area twice daily.
Dexamethasone sodium Phosphate
Cream, 0.1%
Indications: systemically and locally for chronic swelling;
allergic diseases.
Cautions; Side effects, Contrindications: see under
hydrocortisone and notes above.
Dose and Administration: apply 1-4 times /day.
Flucinolone Acetonide
Cream, 0.025%
Ointment, 0.025%
Indication: Inflammatory skin disorders such as eczema,
psoriasis
Caution and contraindications: see notes above
Dose and administration: Apply thinly 2-4 times daily,
reducing strength as condition responds.
Hydrocortisone Acetate
Cream 1%
Ointment 1%
865

18. Dermatological Agents

Indications: contact dermatitis, atopic dermatitis (eczema),

lichen planus; intractable pruritus and phototoxic reactions,
including polymorphic light eruptions and actinic prurigo; shortterm treatment of psoriasis of the face and flexures.
Cautions: children (avoid prolongrd use); occlusive dressings
increase penetration into keratinized lesions (use occlusive
dressing only at night and for no longer than 2 days; avoid use
on weeping lesions); secondary infection requires treatment
with an appropriate antimicrobial.
Contraindications: untreated skin infections or broken skin;
rosacea, acne, perioral dermatitis.
Side effect: exacerbation of local infection; atrophic changes
less likely with mild corticosteroids, but infants and children
particularly susceptible. Contact dermatitis (burning and itching
of skin, apparent chronic therapeutic failure), folliculitis,
furunculosis, pustules, pyoderma, or vesiculation (painful, red
or itchy, pus containing blisters in hair follicles), hyperaesthesia
(increased skin sensitivity). Burning, dryness, irritation, itching,
or redness of skin, mild and transient increased redness or
scaling of skin lesions, minor and transient skin rash.
Dose and Administration:Adult: topical, to the skin, as a 0.1 1% cream or 0.5 - 2.5% ointment one to four times a day.Child
2 years of age and older: topical, to the skin, as 0.5% cream one
to four times a day or as a 1% ointment one or two times a day.
Note:Advise patient not to use it in or around the eye.
Storage: at room temperature in a well closed container, protect
from freezing.
Mometasone furoate
Cream, Lotion, Ointment 0.1 %
Indications: see under hydrocortisone and notes above
866

18. Dermatological Agents

Cautions; Side effects, Contrindications: see under

hydrocortisone and notes above.
Dose and Administration: Adult:Topical, to the site, once a
day. Child: dosage has not been established.
Storage: Store between 2 oC to 30oC in a well-closed container.
Note: For external use only. Do not use in or around the eye

Nimesulide
Gel (transdermal), 1%
Indication: Symptomatic relief of pain associated with sprains
and acute traumatic tendinitis.
Cautions: Pregnancy, breast feeding mother and children under
12 years, should not be applied to skin wounds or open injuries.
Simultaneous use with other topical creams.
Contraindications:Known hypersensitivity to nimesulide or to
any other excipients in the gel; use in patients in whom aspirin,
or other medicinal products inhibiting prostaglandin synthesis,
induced allergic reactions such as rhinitis, urticaria or
bronchospasm.
Dosage and administration: Adults: It should be applied in a
thin layer to the affected area 3-4 times daily and massaged until
it is completely absorbed. However it may vary depending on
the size of the affected area and response. Therapy should be
reviewed after 4 weeks.
Children under 12 years: It has not been studied in children.
Therefore, safety and efficacy have not been established and the
product should not be used in children.
Side-effects: mild or moderate local irritation, erythema, rash,
desquamation, pruritus and related local reactions at the
application site. Mild, but transient skin discoloration and
staining of clothing have been noted.
Storage: Do not store above 30C.
867

18. Dermatological Agents

Pimecrolimus
Cream, 1%
Indications: short-term and intermittent long-term treatment of
mild to moderate atopic dermatitis in patients not responsive to
conventional therapy or when conventional therapy is not
appropriate.
Cautions: do not apply to areas of active cutaneous viral
infection. Minimize or avoid natural/artificial sunlight exposure.
Not recommended in children < 2 years of age.

Drug interactions: CYP3A inhibitors.

Contraindications: hypersensitivity reactions.
Side effects: headache, pyrexia, burning at application site,
nasopharyngitis, cough, bronchitis.
Dose and Administration: Adult and Child 2
years:Topical: Apply thin layer to affected area twice daily; rub
in gently and completely.
Note: Continue as long as signs and symptoms persist; discontinue if
resolution occurs; re-evaluate if symptoms persist > 6 weeks.

Storage: store at room temperature. Do not freeze.

Triamicinolone
Ointment, 0.1%
Indications: inflammatory dermatoses responsive to steroids.
Cautions; Side effects, Contrindications: see under
hydrocortisone and notes above.
Dose and Administration: apply thin film to affected areas 2-4
times/day.
18.3. Anti-infective/Anti-inflammatory Combinations
Combination of an imidazole and a mild corticosteroid (such as
hydrocortisone 1%) may be of value in the treatment of
eczematous intertrigo and in the first few days only of a
severely inflamed patch of ringworm.
868

18. Dermatological Agents

Such combinations should only be used under supervision

because of the risk that signs of resistant infection may be
suppressed.
Clioquinol+ Hydrocortisone
Cream, 3 % + 0.5 or 1 %
Ointment, 3% + 0.5% or 1%
Indications: see notes above, and under hydrocortisone
Cautions: see notes above and under section. 16.2
Dose and Administration: Topical, Apply thinly1 2 times
daily
Clotrimazole + Hydrocortisone
Cream, Ointment, 1% + 1%
Indications: athletes foot and fungal infection of skin folds
with associated inflammation; see notes above and under
hydrocortisone
Cautions, Side effects, Contraindications; see notes above and
section 16.2 and clotrimazole (sec. 16.1)
Dose and Administration: Topical, apply thinly 1 2 times
daily
Storage: protect from light.
Dexamethasone Acetate + Clotrimazole
Cream, 0.4mg +100mg
Indication: Inflammation and infection of skin involving fungi.
Dosage and administration: Apply twice daily
Fluocinolone Acetonide + Neomycin
Cream, 0.025% w/w+0.5% w/w
Indications: Indicated for the treatment of corticosteroidresponsive dermatoses with secondary infection. (Topical
corticosteroids share anti-inflammatory, anti-pruritic and
vasoconstrictive actions.)
869

18. Dermatological Agents

Cautions: Systemic absorption of topical corticosteroids has

produced reversible hypothalamic-pituitary-adrenal (HPA) axis
suppression,
manifestations
of
Cushing's
syndrome,
hyperglycemia, and glucosuria in some patients. Conditions
which augment systemic absorption include the application of
the more potent steroids, Avoid contact with the eyes, The
treated skin area should not be bandaged or otherwise covered
or wrapped as to be occlusive unless directed by the physician,
Because of the concern of nephrotoxicity and ototoxicity
associated with neomycin, this combination product should not
be used over a wide area or for extended periods of time.
Contraindications:Topical corticosteroids are contraindicated
in those patients with a history of hypersensitivity to any of the
components of the preparation. This product should not be used
in the external auditory canal if the eardrum is perforated.
Side effects: Burning; Itching; Irritation; Dryness; Folliculitis;
Hypertrichosis; Acneiform eruptions; Hypopigmentation;
Perioral dermatitis; Allergic contact dermatitis; Maceration of
the skin; Secondary infection; Skin atrophy; Striae; Miliaria;
Ototoxicity; Nephrotoxicity.
Dose and administration: Generally applied to the affected
area as a thin film from two to four times daily depending on the
severity of the condition.
Storage: Store at room temperature; avoid freezing and
excessive heat, above 40C
Fusidic Acid/ Sodium Fusidate + Bethamethasone
Cream, 2% +0.064%,
Ointment, 2% +0.064%, 2% +1%
Indications:
Inflammatory dermatoses where bacterial
infection is present or likely to occur eg, atopic eczema, discoid
eczema, stasis eczema, seborrhoeic dermatitis, contact
870

18. Dermatological Agents

dermatitis, lichen simplex chronicus, psoriasis, discoid lupus

erythematosus.
Caution: Children, Atrophic striae likely to occur on prolonged
application (>4 weeks). Systemic absorption resulting in adrenal
suppression may occur especially under occlusion with weekly
doses of >30 g. Avoid prolonged use on flexures and
intertriginous areas.
Contraindication: Hypersensitive to the medicine, or any
component of the formulation.Viral disease of the skin, perioral
dermatitis, acne rosacea, fungal skin infections and ulcerative
conditions.
Side effect: Skin irritation, eg itching, burning, stinging; Rash;
Worsening of eczema; Skin thinning; thread veins or stretch
marks (prolonged use only); Groupings of fine blood vessels
becoming prominent under the skin (telangiectasia);
Inflammation of hair follicles (folliculitis); Decreased skin
pigmentation at application area, Puffiness of skin on the face.
Dose and administration: Uncovered lesions: Apply 2 - 3
times a day. Covered lesions: Less frequent applications may be
adequate.
Note:Atrophic striae likely to occur on prolonged application (>4
weeks). Systemic absorption resulting in adrenal suppression may
occur especially under occlusion with weekly doses of >30 g. Avoid
prolonged use on flexures and intertriginous areas.

Mupirocin+BetamethasoneDipropionate
Ointment, 2% +0.05% w/w
Indication: For the treatment of primary and secondary skin
infections, such as: Impetigo, Hypoderma, Cellulitis, Balanitis,
Folliculitis, Furunculosis, Styme, Abrasions, Infected burnings,
infected psoriases, infected ulcers

871

18. Dermatological Agents

18.4. Keratolytics/Caustics and Antiacne Agents

Benzoyl peroxide is a keratolytic drug with bacteriostatic
activity against propionibacterium acnes and staphylococcus
epidermidis. It is used mainly in the treatment of acne usually
in topical preparations containing 2.5 to 10 %. Adverse effects
include initial stinging effect & contact sensitization. Caution is
required when applying it near the eyes, the mouth and other
mucous membranes, and to sensitive areas of the neck.
Salicylic acid may be used in all hyperkeratotic and scaling
conditions to enhance the rate of loss of surface scale. Coal tar
is more active than salicylic acid and has anti-inflammatory and
antiscaling properties.
Some preparations contain both
preparations of Glutaraldehyde, and combination of salicylic
acid, lactic acid and polidocanol are available. They are
suitable for the removal of warts on hands and feet.
The topical retinoids, which include tretinoin and isotretinoin,
are effective in treating acne vulgaris in which comedones,
papules and pustules predominate, but are usually inadequate in
eradicating severe pustular or deep nodular cystic lesions. They
act by normalizing keratinisation, but their exact mechanism of
action remains to be fully elucidated. Comedone formation is
inhibited and they thus provide prophylactic treatment for acne.
The antimicrobial effect on Propionibacterium acnes and its
influence on follicular hyperkeratosis make azelaic acid a
suitable topical agent for moderate acne vulgaris.
Podophyllum resin is a mixture of resins, strongly irritant to
normal skin and mucous membranes. It has an antimitotic action
and is used as paint in the topical treatment of soft veneral
warts, or as an ointment (with salicylic acid) for plantar and non
mucosal warts. The main active component of podophyllin is
podophyllotoxin. Purified podophyllotoxin is being used in
872

18. Dermatological Agents

newer preparations at low concentration with good effect. It is

also useful for the treatment of molluscum contagiosum.
Adapalene
Gel, 0.1%
Indication: It helps the skin renew itself. Adapalene topical is
used to treat severe acne in people who are at least 12 years old.
Contraindication: Allergic to adapalene, products that contain
alpha hydroxy or glycolic acid
Caution: Sunburned, windburned, dry, chapped, irritated, or
broken skin.
Dose and Administration: Applied once daily in the evening.
Apply the medication in a thin layer to the entire face or other
affected skin areas.
Storage: At room temperature away from moisture and heat.
Azelaic Acid
Cream, 20%
Indications: topical treatment of mild to moderate
inflammatory acne vulgaris and rosacea.
Cautions: about 2% of applied azelaic acid is systemically
absorbed and excreted unchanged in urine; a daily application of
10 g cream (2 g azelaic acid) should not be exceeded; avoid
contact with the eyes; safety and efficacy have not been proven
for use for more than 6 months.
Contraindications: hypersensitivity to propylene glycol or
azelaic acid.
Side effects: local skin irritation (redness, itching, scaling,
burning) may occur initially, but usually regresses. If persistent,
reduce frequency of application.
Hypersensitivity and photosensitivity reactions have been
reported.
873

18. Dermatological Agents

Dose and Administration: apply to clean skin twice daily;

maximum 10 g/day (2 g azelaic acid).Sensitive skin: start with
daily applications and gradually increase to twice daily.
Improvement occurs after 4 weeks.
Storage: store at room temperature.
Benzoyl peroxide
Gel, 2.5 %, 5 %, 10 %
Solutions, 2.5 %, 5 %, 10 %
Indications: mild to moderate acne and as an adjunct to oral
therapy in more severe cases.
Cautions: avoid contact with eyes, mouth, and mucous
membranes; avoid use of occlusive dressings; avoid excessive
exposure to sunlight.
Side effects: initial irritation common but subsides with
continued use; rarely, contact sensitivity occurs, occasionally
even 1 application can cause severe irritation; may bleach
fabrics, hair and skin.
Dose and Administration:Apply 1 2 times daily preferably
after washing with soap and water, start treatment with lower
strength preparations
Storage: at 2 to 8oc in a container that has been treated to reduce
static charges and that has a device for the release of excess
pressure.Note:caution, Benzoyl percussion on heat.

Coal Tar + Salicylic Acid

Ointment, 2 % + 5 % or 2 % + 10 %
Indications: hyperkeratotic skin disorders associated with
psoriasis and occasionally chronic atopic eczema.
Cautions: avoid eyes, mucous, genital or rectal areas and
broken or inflamed skin. Use suitable chemical protection
gloves for extemporaneous preparation.Salicylate toxicity. If
874

18. Dermatological Agents

large areas of skin are treated; salicylate toxicity may be a

hazard.
Side effects: skin irritation and acne-like eruptions,
photosensitivity: stains skin, hair and fabric, excessive drying.
Dose and Administration: Apply 1 2 times daily.
Glutaraldehyde
Solution, 10 %
Indications: warts, particularly planar warts (see also notes above)
Cautions: protect surrounding skin, not for application to face,
mucosa, or anogenital areas.
Side effects: rashes, skin irritation (discontinue if severe), stains
skin brown.
Dose and Administrations: Apply twice daily.
Storage: store at a temperature not exceeding 15oC.
Podophyllin Paint
Solution, 25%
Indications: topical treatment of benign growths including
external genital and perianal warts, papillomas, fibroids.
Cautions: avoid application to healthy tissues; do not use for
treating facial or oral mucosal warts; use of large amounts of
drug should be avoided; should not be applied to or near
mucous membranes.
Contraindications: pregnancy, diabetic patient.
Side effects: pruritus, nausea, vomiting, abdominal pain, and
diarrhea.
Dose and Administration: 10% to 25% solution in compound
benzoin tincture; apply drug to dry surface, use 1 drop at a time
allowing drying between drops until area is covered; total
volume should be limited to < 0.5 ml per treatment session.
Storage: store at room temperature.
875

18. Dermatological Agents

Retinoic Acid (Tretinoin)

Cream, 0.025%
Gel, 0.01%, 0.025%
Lotion, 0.025%, 0.05%
Ointment, 0.05%
Indications: treatment of acne vulgaris, photodamaged skin;
palliation of fine wrinkles, mottled hyperpigmentation, and
tactile roughness of facial skin as part of a comprehensive skin
care and sun avoidance program.
Caution: eczema.
Drug interactions: topical application of sulphur, benzoyl
peroxide, salicyclic acid, resorcinol, photosensitizing
medications
(thiazides,
tetracyclines,
fluoroquinolones,
phenothiazines, sulfonamides).
Contraindications: hypersensitivity to retinoic acid.
Side effects: most likely to occur with incorrect use. Transient
burning, excessive redness, dryness, oedema or blistering,
heightened susceptibility to sunlight and temporary hyper and
hypopigmentation, apparent exacerbation of inflammatory
lesions.
Dose and Administration: applyto dry skin, after thorough
cleansing, before bedtime. Frequency of application should be
individualized.
Storage: store at 25 oC; gel is flammable, keep away from heat
and flame.
Salicylic Acid
Ointment, 2%, 5%, 10%
Indications: treatment of acne vulgaris, seborrheic dermatitis,
psoriasis, and common wart (excluding on the face).
Cautions: avoid contact with eyes, mouth, and mucous
membranes; avoid application to large areas.
876

18. Dermatological Agents

Contraindications: broken or inflamed skin; children under 2

years.
Side effects: stinging, local irritation, and salicylism may occur
when large areas are treated particularly in children.
Dose and Administration: Topical to the skin:Apply to
affected area every 12-24 hours daily starting with the 2%
progressively increasing the concentration up to 5% for acne
vulgaris and up to 10% for seborrheic dermatitis, psoriasis and
common wart. Apply until it gets better.
Storage: at room temperature, in tight containers.
Salicylic Acid +Betamethasone Dipropionate
Ointment/Lotion, 2% +0.06%
Indications: Subacute and chronic hyperkeratotic and dry
dermatoses.Betamethasone Dipropionate is a synthetic
fluorinated corticosteroid. In combination with salicylic acid it
is indicated for the treatment of chronic lichenified eczema,
lichen planus, lichen simplex and non bullous ichthyosiform
erythroderma. It is also effective in the less responsive
conditions such as psoriasis of the scalp and chronic plaque
psoriasis of the hands and feet but excluding widespread plaque
psoriasis. Topical salicylic acid softens keratin, loosens
cornified epithelium and desquamates the epidermis.
Cautions: Pregnancy and beast feeding mother. Not to be used
in or near the eyes. Avoid contact with mucous membranes.
Prolonged topical corticosteroid treatment may result in
systemic corticosteroid effects; may also lead to formation of
striae or atrophy of the skin or subcutaneous tissue. Absorption
of corticosteroid through the skin is increased when used with
occlusive dressings. Caution when used in patients with stasis
dermatitis or other skin diseases with impaired blood
circulation.
877

18. Dermatological Agents

Contraindications: Rosacea, acne, perioral dermatitis, perianal

and genital pruritus. Hypersensitivity to any of the ingredients
of the preparations contra-indicates their use as does
tuberculosis and most viral lesions of the skin, particularly
herpes simplex, vacinia, varicella. It should not be used in
napkin eruptions, fungal or bacterial skin infections without
suitable concomitant anti-infective therapy.
Side effects: Pruritus, irritation, folliculitis, maceration of skin,
skin atrophy, hypertrichosis, acneiform eruptions, secondary
infection, hypopigmentation, perioral dermatitis, allergic contact
dermatitis, striae and miliaria.
Dose and administration: Adults: In most cases a few drops
should be applied to the affected areas once or twice daily and
massaged gently and thoroughly into the skin. For some patients
adequate maintenance therapy may be achieved with less
frequent application.
It is recommended that preparations are prescribed for two
weeks. The maximum weekly dose should not exceed
60g.Children: Dosage in children should be limited to 5 days.
Storage: Do not store above 25C.
Silver Nitrate + Potassium Nitrate
Toughened, 95% + 5%
Indications: cauterization of wounds and sluggish ulcers,
removal of granulation tissue and warts; aseptic prophylaxis of
burns.
Cautions: do not use application sticks on the eyes; prolonged
use may result in skin discoloration.
Contraindications: not for use on broken skin, cuts, or wounds
Side effects: burning and skin irritation, staining of the skin,
hyponatremia, methemoglobinemia.
878

18. Dermatological Agents

Dose and Administration: Sticks: Apply to mucous

membranes and other moist skin surfaces only on area to be
treated 2 - 3 times/ week for 2- 3 weeks.
Storage: store in a tight, light- resistant container and in dry
place.
18.5. Medicines for Psoriasis and Eczema
Zinc oxide is mildly astringent and is used topically as a
soothing and protective application in eczema and slight
excoriations and for hemorrhoids. It is usually mixed with
purified talc, which is used in massage to allay irritation and
prevent chafing. Zinc oxide reflects UV radiation and is used as
sunscreens.
Ichthammol is usually used in chronic lichenified forms of
eczema or to control pruritus.
Dithranol is an effective, but difficult-to-administer, topical
treatment for psoriasis. When used optimally, responsive
plaques should clear with approximately 3 weeks of treatment.
Dithranol needs to be incorporated into a suitable base to
minimize side-effects. The presence of salicylic acid is
necessary to prevent its inactivation. It is most commonly used
in a stiff paste.
Vitamine D has both keratinocyte differentiation and
inflammatory modifying effects. The synthetic analogue of 1,
25-dihydroxyvitamin D3, calcipotriol, is less calcaemic than the
parent compound. It has been shown to be effective in plaque
psoriasis.
Calcipotriol
Cream, Ointment, Scalp application, 0.005%
Indication: treatment of moderate plaque psoriasis.
Cautions: hypercalcaemia.
Contraindication: hypersensitivity to calcipotriol.
879

18. Dermatological Agents

Side effects: skin irritation and allergic rashes, facial dermatitis

with applications to the face; indiscriminate use of calcipotriol
can cause hypercalcaemia.
Dose and Administration: Apply twice daily to affected areas
to a maximum of 100 g/week. Wash off immediately if face
becomes contaminated.
Dithranol
Paste, 1%
Scalp application, 0.25%, 0.5%
Indications: treatment of psoriasis
Cautions and Contraindications: dithranol is an irritant; avoid
contact with the eyes and tender parts of the body. Its use on
the face should be limited to carefully supervised inpatient
management only. It should not be used on acute eruptions or
excessively inflamed areas.
Side effects: irritation of normal and psoriatic skin. Fever,
rigors, flu-like symptoms and lymphadenopathy. It stains skin,
hair, nails, fabrics and fomites a reddish brown color.
Dose and Administration:Skin application: Apply sparingly
only to psoriatic lesions and rub gently and carefully into the
skin until absorbed. Avoid applying an excessive quantity,
which may cause unnecessary soiling and staining of the
clothing or bed linen.Scalp application: comb hair to remove
scalar debris, wet hair and after suitably parting, rub cream well
into the lesions, taking care to prevent the cream from spreading
on to the forehead.Remove by washing or showering; optimal period of
contact will vary according to the strength used and the patients response to
treatment. Continue treatment until the skin is entirely clear (i.e. when there
is nothing to feel with the fingers and the texture is normal).

Storage: store at a temperature of 8-15 oC in airtight containers.

880

18. Dermatological Agents

Ichthammol
Ointment, 10 %
Indications: for treatment of chronic lichenified eczema.
Side effect: skin irritation.
Dose and Administration: topically, apply to the skin 1-3
times daily.
Zinc Oxide
Ointment 15 %
Lotion 15 %
Indication:protective coating for mild skin irritations and
abrasions, smoothing and protective to promotre healing of
chapped skin, diper rash.
Contra indications: Hypersensitivity to zinc oxide or any
component of the formulation
Side effects: Skin sensitivity, irritation
Dose and administration:Adult, Child, Protectant: Topical:
Apply as required to affected areas several times daily
Zinc oxide + Talc
Paste, 15 % + 25 %
Indications: treats and prevents diaper rash, protects minor skin
irritation.
Cautions: avoid contact with eyes and face, do not use on
broken skin.
Storage: store at a temperature of 15-25oC.
18.6. Antiprurities
Pruritus (itching) is a common symptom of many skin disorders
as well as of several systemic diseases and may be extremely
distressing.
However, contact with certain substances,
conditions that dry the skin, stress, and extremes of temperature
may also be a cause. Thus, an important part of treatment is to
eliminate or minimize the reason for the irritation.Preparations
881

18. Dermatological Agents

containing crotamiton are used as an antipruritic agent. One

application may be effective for 6 to 10 hour.
Preparations containing calamine are often ineffective.
Calamine
Lotion (oily), 5 %
Indications: mild pruritus
Dose and Administrations: Topically: Apply liberally 3 to 4
time daily
Calamine + Zinc Oxide
Cream, 4 % + 3 %
Lotion, 15 % + 5 %
Indications: mild pruritus
Dose and Administrations: Topically: Apply liberally 3 to 4
times daily
Crotamiton
Cream, 10%
Lotion, 10 %
Indications: treatment of scabies and symptomatic treatment of
pruritus.
Cautions: crotamiton should not be applied to acutely inflamed
skin or raw, weeping surfaces. If primary irritation or
hypersensitivity occurs, treatment should be discontinued and
the drug should be removed with soap and water. Crotamiton
should be used during pregnancy only when clearly needed.
Contact with the face, eyes, mucous membranes and urethral
meatus should be avoided, use on physicians advice for
children under 3 years.
Contraindications: a history of sensitivity or allergy to the
drug and in those who exhibit a primary irritation response to
topically applied medications. Acute exudative dermatoses
882

18. Dermatological Agents

Side effects: slight local irritation, allergic skin sensitivity may

occur with prolonged use
Dose and Administration:Adult and Child: Scabicide: Wassh
thoroughly and scrub away loose scales, then towel dry; apply a
thin layer and massage drug onto skin of the entire body from
the neck to the toes (with special attention to skin folds, creases,
and interdigital spaces). Repeat application in 24 hours. Take a
cleansing bath 48 hours after the final application. Treatment
may be repeated after 7-10 days if live mites are still present.
Pruritus: Massage into affected areas until medication is
completely absorbed; repeat as necessary.
18.7. Depigmenting Agents
Hydroquinone
Solution, 2%, 4%
Skin cream: 4%
Indications: gradual bleaching of hyperpigmented skin
conditions.
Cautions: pregnancy, limit application to area no larger than
face and neck or hands and arms.
Contraindiactions: hypersensitivity to hydroquinone, sunburn,
depilatory usage.
Side effects: dermatitis, dryness, erythema, stinging,
inflammatory reaction, sensitization, irritation.
Dose and Administration: Adult and Child 12 years:
topical: apply thin layer and rub in twice daily.
18.8. Pigmenting Agents
Psoralens (furocoumarins) occur in nature and are found
primarily
in
plants.
They
are
photosensitisers.
Photochemotherapy
using
8-methoxypsoralen,
5883

18. Dermatological Agents

methoxypsoralen or 4,5,8-trimethoxypsoralen with ultraviolet

light (usually UVA) is an effective method of treating several
dermatological conditions including psoriasis, vitiligo, mycosis
fungoides and atopic eczema. Because specialized facilities and
expertise are required, it is recommended that this therapy be
limited to hospitals and specialist practices.Psoralens applied
topically (lotion, cream) are useful for localized disease or when
oral administration is contraindicated or not tolerated.
Methoxsalen(8-Methoxypsoralen)
Solution, 1 %
Capsule, 10 mg, 20 mg
Tablet, 10 mg, 20 mg
Indications: symptomatic control of severe, recalcitrant
disabling psoriasis; repigmentation of idiopathic vitiligo;
palliative treatment of cutaneous T-cell lymphoma (CTCL).
Cautions: albinism, erythropoietic protoporphyria, lupus
erythematosus,
porphyria
cutanea
tarda,
xeroderma
pigmentosum, aphakia, cataracts.
Drug interactions: anthracin, certain organic dyes (methylene
blue, methylene orange), coal tar or coal tar derivatives,
diuretics, griseofulvin, bacteriostatic soaps, naldixic acid,
phnothiazines, sulfonamides, tetracyclines.
Contraindictions: cataract, melanoma, and pregnancy.
Side effects: Immidiate nausea, vomiting, headache,pruritus,
oedema and CNS disturbances (dizziness,nervousness,
insomnia, depression and excitation).Delayed- actinic damage
(accelerated
ageing,carcinomas,
cataracts,
pigmented
naevi);immunosuppression;
precipitation
of
lupus
erythematosus and herpes simplex.
Dose and Administration:Adult:Psoriasis:Oral: 10-70mg 1.52 hours before exposure to UVA light; dose may be repeated 2884

18. Dermatological Agents

3 times per week, based on UVA exposure; doses must be given

at least 48 hours apart; dosage is based upon patients body
weight and skin type: <30kg: 10mg; 30-50kg: 20mg; 51-65kg:
30mg; 66-80kg: 40mg; 81-90 kg: 50mg; 91-115kg: 60mg;
>115kg: 70mg.Vitiligo:Oral: 20mg 2-4 hours before exposure
to UVA light; dose may be repeated based on erythema and
tenderness of skin; do not give on 2 consecutive days.
Adult and Child>12 years:Vitiligo:Topical Apply up to 1%
solution 2 hours before exposure to UVA light, treatment is
repeated usually once weekly.
Psoriasis: apply approximately 0.15% solution 15 minutes
before UVA exposure.
Storage: store at room temperature and protect from light.
18.9. Dermatological, systemic
Acitretin
Capsule, 10 mg, 25 mg, 50 mg
Indications: severe psoriasis not responsive to make
conventional therapy; pustular psoriasis; severe extensive
disorders of keratinisation resistant to conventional treatments,
such as congenital ichthyosis, Darrier's disease and pityriasis
rubra pilaris.
Cautions: hepatic and renal impairment; hypervitaminosis A;
hyperlipidaemias; known hypersensitivity.
Drug interactions: agents causing intracranial pressure (e.g.
tetracyclines), hepatotoxic agents (e.g. methotrexate), protein
bound drugs (e.g. phenytoin), vitamin A.
Contraindications: pregnancy or breast-feeding, patients under
18 years of age.
Side effects: hypervitaminosis A, e.g. dryness of mucosae (dry
mouth, nose and eyes, chelitis, keratitis, stomatitis, epistaxis);
885

18. Dermatological Agents

reversible hair loss; nail dystrophies and paronychia; thin fragile

skin, exfoliation especially of palms and soles.
Skin rashes; reversible impairment of dark adaptation; raised
intracranial pressure; musculoskeletal pains with hyperostosis
and extra skeletal soft-tissue calcification, osteoporosis;
premature epiphyseal closure; gastrointestinal irritation;
hepatitis and transient reversible elevations of liver enzymes;
elevation of serum lipids; disturbance in glucose metabolism,
malaise; sweating; drowsiness.
Dose and Administration: Adult: Individually adjusted to
limit side effects and to maximize therapeutic response. Oral:
Initially, 25 - 30 mg once daily with a meal for 2 - 4 weeks,
increasing to 50 mg/day for a further 6-8 weeks; maximum 75
mg/day.
Maintenance: 50 mg/day or less, based on therapeutic results
and tolerability.
Storage: store at room temperature.
Cyproterone acetate and Ethinyl estradiol
Tablet, 2mg + 35mcg
Indications: indicated for resistant and severe acne, severe
signs of androgenisation in women (e.g. hirsutism), male sexual
deviation, and inoperable prostatic carcinoma.
Cautions: cyproterone should be administered only after full
endocrine assessment.
Contraindications: pregnancy, cardiac disease, diabetes
mellitus, liver disease.
Side effects: abnormal vision, allergic reaction, anemia,
cerebrovascular accident, liver failure, depression, in women
weight gain, decreased libido and dry vagina.
Dose and Administration: Cyproterone acetate 2mg and
ethinylestradiol 0.035 mg daily from day 1 of cycle.
886

18. Dermatological Agents

Storage: store at room temperature.

Etretinate
Capsule, 10mg, 25mg
Indications: treatment of severe, extensive psoriasis that has not
responded to other treatment, especially generalized and palmoplantar pustular psoriasis.
Cautions, Contraindications, Drug interactions and Side
effects see isotretinoin.
Dose and Administration: Oral: 0.75 to 1mg/kg daily in
divided doses. A maximum dose of 1.5 mg/kg daily.
Erythrodermic psoriasis:250 mcg/kg daily, increased at weekly
intervals by 250 mcg/kg daily until optimal response
occurs.Following the initial response, generally after 8-16
weeks of therapy, maintenance doses of 500 to 750 mcg/kg
daily have been given.
Finasteride
Tablet, 1mg
Indications: androgenetic alopecia in men
Cautions: obstructive uropathy
Side effects: testicular pain, hypersensitivity
(including lip and face swelling, pruritus and rash)
Dose and Administration: Oral: 1 mg daily

reactions

Hydroxychloroquine
Tablet, 200mg
Indications: Active rheumatoid arthritis (including juvenile
idiopathic arthritis), systemic and discoid lupus erythematosus;
dermatological conditions caused or aggravated by sunlight.
Cautions: Hepatic impairment, renal impairment, pregnancy
and
Breast-feeding.Manufacturers
recommend
regular
887

18. Dermatological Agents

ophthalmological examination but the evidence of practical

value is unsatisfactory. It should be used with caution in
neurological disorders (especially in those with a history of
epilepsy), in severe gastro-intestinal disorders, in G6PD
deficiency, in acute porphyria, and in the elderly. It may
exacerbate psoriasis and aggravate myasthenia gravis.
Concurrent use of hepatotoxic drugs should be avoided.
Drug interactions: Agalsidase (Alfa and Beta), Amiodarone,
antacids,
antiepileptics,
ciclosporin
cimetidine,digoxin,
droperidol,kaolin,
laronidase,mefloquine,moxifloxacin,
neostigmine, pyridostigmine,artemether with lumefantrine and
histamine.
Side effects: gastro-intestinal disturbances, headache and skin
reactions (rashes, pruritus); those occurring less frequently
include ECG changes, convulsions, visual changes, retinal
damage, keratopathy, ototoxicity, hair depigmentation, hair loss,
and discoloration of skin, nails, and mucous membranes. Sideeffects that occur rarely include blood disorders (including
thrombocytopenia, agranulocytosis, and aplastic anaemia),
mental changes (including emotional disturbances and
psychosis), myopathy (including cardiomyopathy and
neuromyopathy), acute generalised exanthematous pustulosis,
exfoliative
dermatitis,
Stevens-Johnson
syndrome,
photosensitivity, and hepatic damage; angioedema has also been
reported. Important: very toxic in overdosageimmediate
advice from poisons centres essential
Dose and administration: Administered on expert advice, 200
400 mg daily (but not exceeding 6.5 mg/kg daily based on ideal
body-weight, see also recommendations above). Child 1 month
18 years: based on ideal body-weight, 56.5 mg/kg (max.
400 mg) once daily.
888

18. Dermatological Agents

Isotretinoin
Capsules, 10 mg, 20 mg
Indications: mainly for the management of intractable acne, but
may also be effective in controlling keratinisation disorders such
as the ichthyoses and keratosis follicularis.
Cautions: history of depression.
Drug interactions:tetracyclines, acitretin, tretinoion, vitamin A.
Contraindications: pregnancy, hypervitaminosis A; hepatic and
renal insufficiency; hyperlipidaemia's; known hypersensitivity.
Side effects: dryness of mucosa; reversible hair loss, nail
dystrophies and paronychia, thin fragile skin, exfoliation
especially of palms and soles.Skin rashes; reversible impairment
of dark adaptation; raised intracranial pressure; musculoskeletal
pains with hyperostosis and extraskeletal soft-tissue
calcification, osteoporosis; premature epiphyiseal closure;
gastrointestinal irritation; hepatitis and transient reversible
elevations of liver enzymes; elevation of serum lipids;
disturbance in glucose metabolism; malaise; sweating;
drowsiness,
haematological
abnormalities.
Depression,
psychosis, behavioral disorders, and seizures have been
reported.
Dose and Administration:Adult: Oral:Initially: 0.5 mg/kg/day
in a single or 2 divided doses with food. Adjust after 2 - 4
weeks, if necessary, according to response and adverse effects.
If the response is slight, increase up to a maximum of 1
mg/kg/day, if well tolerated.Maintenance: 0.5 - 1 mg/kg/day for
a further 12 weeks. In the event of intolerance of the initial
dose, reduce to 0.1 - 0.2 mg/kg/day with longer duration of
therapy. Total dose 120 mg/kg.Usual treatment period, 16 - 24
weeks.Repeat treatment: allow an interval of 3 - 4 months (at
least 8 weeks) as improvement may continue despite stopping
therapy.
889

18. Dermatological Agents

Storage: store at room temperature.

Methylprednisolone
Tablet, 4mg
Indications:suppression of inflammatory and allergic disorders;
severe inflammatory bowel disease
Cautions, Contraindications, Side effects: see notes
Dose and Administration:Oral: usual range 240 mg daily
Prednisolone
Tablets, 1mg, 2mg, 5mg
Indications: short-term suppression of inflammation in allergic
disorders.
Cautions: tuberculosis, amaebiasis, strongyloidiasis, risk of
severe chicken pox in non-immune patient, avoid exposure to
measles, diabetes mellitus; peptic ulcer; hypertension.
Contraindications: untreated systemic infection; administration
of live virus vaccines.
Side effects: nausea, dyspepsia, malaise, hiccups,
hypersensitivity reactions including anaphylaxis.
Dose and Administration: Adult and Child:Oral: initially up
to 10 - 20 mg daily as a single dose in the morning (in severe
allergy up to 60 mg daily as a short course of 5 - 10 days).
Storage: store at room temperature.
18.10. Skin Disinfecting Agents
The choice of disinfectant is an important factor in treating skin
conditions. For example, scaling disorders are best treated with
emulsifying ointment or other disinfectants that do not irritate
the skin. Some of the useful disinfectants for skin cleansing
available at district hospital level include Chlorhexidine;
Potassium permanganate and Povidone - iodine. Povidoneiodine is preferred to chlorinated solutions (such as dilute
890

18. Dermatological Agents

sodium hypochlorite solution; not described here) which are too

irritant and are no longer recommended. Astringent
preparations, such as potassium permanganate solution are
useful for oozing eczematous reactions.
Chlorhexidine Gluconate + Cetrimide
Solution 1.5 % + 15 %, 0.3% + 3%w/v
Indications: for skin disinfection and wound cleansing, and also
for the cleansing and disinfection of equipments.
Side effects: skin sensitivity may occur rarely. Strong solutions
may cause irritation of the conjunctiva and other sensitive
tissues.
Dose and Administration: TopicallyFor skin disinfection and
wound cleansing:Apply to the affected area the diluted solution
(1 in 100 (1%) with water).
For disinfection of equipment (e.g bowls, tables), spraying
wards: Use 1 in 2000 dilution with water.
Storage: at room temperature protected from light.
Ethyl Alcohol
Solution, 70 %
Indications: for disinfection of the skin in preparation for
injections.
Cautions: it should not be applied to fresh wounds.
Dose and Administration: Topical, to the skin.
Storage: in airtight containers, in a cool place.
Hydrogen peroxide
3 %, 6 %
Indications: skin disinfectant, particularly cleansing and
deodorizing wounds and ulcers.
Cautions: in large and deep wounds, avoid use in normal skin.
891

18. Dermatological Agents

Dose and Administration: topically, apply to the wound to

cleanse.
Iodine
Solution, 2 %
Indications: for the disinfection of minor superficial skin
wounds.
Cautions: do not apply to sensitive area such as the axillary,
perianal, or genitalia.
Side effects: skin sensitivity, irritation, sloughing of soft tissues
and staining of the skin may occur.
Dose and Administration: Topical to the affected areas as
necessary. Do not cover with a tight bandage.
Storage: at room temperature. In yellowish brown coloured
glass bottles, preferably glass stoppered.
Potassium permanganate
Tablet (for solution), 50 mg, 120 mg, 200 mg, 250 mg, 300 mg
Indications: as skin disinfectant for cleansing and deodorizing
suppurating eczematous reactions and wounds.
Cautions: irritant to mucous membrane and it stains skin and
clothing
Side effect: irritation to tissues, corrosive burns,
Dose and Administration: 1 tablet dissolved in suitable
amount of water to provide a 0.01% solution. It is applied as wet
dressings or baths, approximately of 0.01% solution.
Povidone - Iodine
Solution (aqueous), 4 %, 7.5 %, 10 %
Indications: as skin disinfectant and antiseptic mainly for the
treatment of contaminated wounds and pre-operative
preparation of the skin and mucous membranes.
892

18. Dermatological Agents

Cautions: during pregnancy and breast-feeding, in patients with

broken skin and renal impairment. The application of povidone iodine to large wounds or severe burns may produce systemic
adverse effects such as metabolic acidosis, hypernatremia and
impairment of renal function.
Contraindications: avoid regular use in patients with thyroid
disorders or those receiving lithium therapies, very low birth
weight infants.
Side effects: rarely sensitivity may interfere with thyroid
function tests; see also caution.
Dose and Administration:Alcoholic solution, povidone iodine
10%: Adult: to be applied undiluted in pre- and post-operative
skin disinfection. Child: not recommended for regular use in
neonates (and contraindicated in very low birth weight infants)
Antiseptic solution, povidone - iodine, 10% in aqueous solution:
Adult: to be applied undiluted in pre-and postoperative skin
disinfection. Child: not recommended for regular use in
neonates (and contraindicated in very low birth weight infants).
Scalp and skin cleanser solution, povidone - iodine, 7.5%, in a
surfactant basis:
Adult: use of seberrhoeic condition of scalp and acne vulgaris
of face and neck 1-2 times daily child dose. Child under 2 years
not recommended.Skin cleanser solution, providone - iodine,
4% in a surfactant basis:
Adult: for infective condition of the skin. Retain on skin for 3-5
minutes before rinsing, repeat twice daily. Child under 2 years
not recommended
18.11. Dermatologicals, Others
Aluminum Chloride
Solution (alcoholic), 20%, 25%
893

18. Dermatological Agents

Indications: used for control of hyperhidrosis.

Dose and Administration: Applied to dry skin at night (and
washed off in the morning); especially if occluded and the
patient sedated.
Betamethasone Dipropionate + Salicylic Acid
Ointment and Lotions, 0.064%+2%
Indications: Subacute and chronic hyperkeratotic and dry
dermatoses.Betamethasone Dipropionate is a synthetic
fluorinated corticosteroid. In combination with salicylic acid it
is indicated for the treatment of chronic lichenified eczema,
lichen planus, lichen simplex and non bullous ichthyosiform
erythroderma. It is also effective in the less responsive
conditions such as psoriasis of the scalp and chronic plaque
psoriasis of the hands and feet but excluding widespread plaque
psoriasis. Topical salicylic acid softens keratin, loosens
cornified epithelium and desquamates the epidermis.
Cautions: Pregnancy and breast feeding mother. Not to be used
in or near the eyes. Avoid contact with mucous membranes.
Prolonged topical corticosteroid treatment may result in systemic
corticosteroid effects; may also lead to formation of striae or atrophy
of the skin or subcutaneous tissue. Absorption of corticosteroid
through the skin is increased when used with occlusive dressings.
Caution when used in patients with stasis dermatitis or other skin
diseases with impaired blood circulation.

Contraindications:Rosacea, acne, perioral dermatitis, perianal

and genital pruritus. Hypersensitivity to any of the ingredients
of the preparations contra-indicates their use as does
tuberculosis and most viral lesions of the skin, particularly
herpes simplex, vacinia, varicella. It should not be used in
napkin eruptions, fungal or bacterial skin infections without
suitable concomitant anti-infective therapy.
894

18. Dermatological Agents

Side effects: Pruritus, irritation, folliculitis, maceration of skin,

skin atrophy, hypertrichosis, acneiform eruptions, secondary
infection, hypopigmentation, perioral dermatitis, allergic contact
dermatitis, striae and miliaria.
Dose and administration: Adults: In most cases a few drops
should be applied to the affected areas once or twice daily and
massaged gently and thoroughly into the skin. For some patients
adequate maintenance therapy may be achieved with less
frequent application.It is recommended that preparations are
prescribed for two weeks. The maximum weekly dose should
not exceed 60g.Children: Dosage in children should be limited
to 5 days.
Storage:Do not store above 25C.
Imquimod
Cream, 5%
Indication: Imiquimod cream is used to treat certain types of
actinic keratoses (flat, scaly growths on the skin caused by too
much sun exposure) on the face or scalp. Imiquimod cream is
also used to treat superficial basal cell carcinoma (a type of skin
cancer) on the trunk, neck, arms, hands, legs, or feet and warts
on the skin of the genital and anal areas. It treats genital and
anal warts by increasing the activity of the body's immune
system.
Contraindication: allergic to imiquimod or any ingredients in
imiquimod cream.
Dose and administration:Actinic keratoses: apply it once a day
for 2 days a week, 3 to 4 days apart
Superficial basal cell carcinoma: apply once a day for 5 days a
week. Genital and anal warts: apply once a day for 3 days a
week.
895

18. Dermatological Agents

Side effects: redness, itching, burning, or bleeding of the treated

area; flaking, scaling, dryness, or thickening of the skin;
swelling, stinging, or pain in the treated area; blisters, scabs, or
bumps on the skin; headache; diarrhea; back pain; tiredness
Storage: Store it at room temperature
Methylsalicylate
Methyl salicylate is irritant to the skin and is used topically in
rubefacient preparations in musculoskeletal, joint and soft-tissue
disorders and for minor peripheral vascular disorders such as
chilblains. It is absorbed through intact skin and can produce
effects typical of systemic salicylates.
Minoxidil
Solution, 20mg/ml (2%), 5%)
Indications: The treatment of alopecia androgenetica (male
pattern baldness).
Contraindications: Hypersensitivity to minoxidil, propylene
glycol or ethanol; Pregnancy and Lactation.
Side effects: Local irritation is the most common, including
scaling, erythema/flushing, dermatitis, dry skin, hypertrichosis,
burning sensation and rash.
Dose and Administration:A total dose of 1 mL minoxidil
topical solution should be applied twice per day to the scalp,
beginning at the centre of the affected area.
Paraffin Gauze Dressing
Paraffin Gauze Dressing - is Fabric of Leno weave, weft and
warp threads of cotton and/or viscose yarn, impregnated with
white or yellow soft paraffin.

Any other rubefacient proven to be therapeutically effective can be used

896

18. Dermatological Agents

Indications: treatment of abrasions, burns, and other injuries

of skin, and ulcerative conditions; post-operatively as a penile
and vaginal dressing and for sinus packing; heavier loading for
skin graft transfer.
Pimecrolimus
Cream, 1%
Indications: short-term treatment of mild to moderate atopic
eczema (including flares) when topical corticosteroids cannot be
used.
Cautions: UV light (avoid excessive exposure to sunlight and
sunlamps), avoid other topical treatments except emollients at
treatment site; alcohol consumption (risk of facial flushing and
skin irritation)
Contraindications: contact with eyes and mucous membranes,
application under occlusion, infection attreatment site;
congenital epidermal barrier defects; generalised erythroderma;
immunodeficiency; concomitant use with drugs that cause
immunosuppression (may be prescribed in exceptional
circumstances by specialists); application to malignant or
potentially malignant skin lesions
Side effects: burning sensation, pruritus, erythema, skin
infections (including folliculitis and less commonly impetigo,
herpes simplex and zoster, molluscum contagiosum); rarely
papilloma, skin discoloration, skin local reactions including
pain, paraesthesia, peeling, dryness, oedema, and worsening of
eczema; skin malignancy reported
Dose and Administration: Apply twice daily until symptoms
resolve (stop treatment if eczema worsens or no response after 6
weeks); child under 2 years not recommended

897

18. Dermatological Agents

Talc Dusting powder

Indications: used in folds where a friction may occur between
opposing skin surfaces.
Cautions: they should not be applied in areas that are very
moist as they tend to take and abrade the skin.
Urea
Cream, 10%, 15%, 20%, 40%
Indications:hydrating agent and keratolytic for dry, scaling and
itching skin conditions, including mild psoriasis.
Cautions:avoid application to face or broken skin; avoid
contact with eyes.
Side effects:transient stinging and local irritation.
Dose and Administration: Adult and Child: Dry, scaling skin
disorders, apply directly to the affected area twice daily,
preferably to damp skin.

898

19. Antidotes And Other Substances Used In Poisoning

19. ANTIDOTES
POISONING

and

SUBSTANCES

USED

in

In the treatment of acute poisoning most patients require only

supportive and symptomatic therapy. The active removal of
poisons from the stomach by gastric lavage or emesis induction
may be considered, as should the administration of substances
like activated charcoal by mouth to reduce their absorption.
However, the use of emetics and gastric lavage has been
questioned and these measures, including the administration of
charcoal are for instance inappropriate in corrosive poisoning,
and aspiration should only be carried out with great care. Some
poisons, in particular pesticides, may be absorbed through the
skin and clothing should be removed and the skin thoroughly
washed to avoid continued absorption.Techniques such as
forced diuresis, haemodialysis, or haemoperfusion are only of
value for a limited number of poisons in a few severly poisoned
patients.
The drugs included in this section act in a variety of ways.
These are the antagonists, such as the opioid antagonist
naloxone hydrochloride, that compete with the poison for the
receptor sites. There are compounds that inhibit the poison by
reacting with it to form less active or inactive complexes or by
interfering with its metabolism; a typical examples of the first
group.
Atropine sulphate is given in the case of organo-phosphorus
poisoning which is characterized by intense muscarinic effects
by inhibiting cholinesterase activity thereby prolonging and
intensifying the effects of acetylcholine. Atropine will reverse
the muscarinic effects of acetylcholine and is given in a dose of
2 mg as atropine sulphate (intramuscularly or intravenously
according to the severity of poisoning) every 20 to 30 minutes
899

19. Antidotes And Other Substances Used In Poisoning

until the skin becomes flushed and dry, the pupils dilate, and
tachycardia develops.
Pralidoxime mesylate, a cholinesterase reactivator, is
indicated, as an adjunct to atropine, in moderate or severe
poisoning but is any effective if given within 24 hours.
Other specific antagonists include acetylcysteine used in
paracetamol poisoning. Sodium nitrite is used in the treatment
of cyanide poisoning in conjunction with sodium thiosulphate.
And Flumazenil, a benzodiazepine antagonist, is used in
anesthesia and intensive care to reverse benzodiazepine
induced sedation; it is also used to treat benzodiazepine over
dosage.
Acetylcysteine
Injection, 200 mg/ml in 10 ml ampoule
Indications: antidote to acetaminophen overdose, to protect
against hepatotoxicity.
Cautions: patients with history of asthma, conditions
predisposing to gastrointestinal hemorrhage such as esophageal
varices, peptic ulceration, and in patients sensitive to
acetylcysteine.
Side effects: drowsiness, fever, nausea, or vomiting,
bronchospastic allergic reaction (troubled breathing, tightness
in chest, wheezing), skin rash or hives.
Dose and Administration:Adult and Child: Antidote: IV:
300mg per kg of body weight administered over twenty hrs and
fifteen minutes, divided as follows:
Initial loading dose - 150mg per kg of body weight in up to
200ml of 5% dextrose injection, administered over fifteen
minutes.Second infusion- 50mg per kg of body weight in 500ml
of 5% dextrose injection, administered over four hours.Third

900

19. Antidotes And Other Substances Used In Poisoning

infusion - 100mg per kg of body weight in 1000ml of 5%

dextrose injection, administered over the next sixteen hours.
Activated Charcoal
Tablet, 125mg, 250mg
Powder for reconstitution, 15gm/120ml, 25gm
Gel, 300ml
Indications: treatment of acute poisoning.
Cautions: intestinal obstructions, drowsy or unconscious
patients (risk of aspiration; intubate before administration via
nasogastric or gastric tube); not effective for poisoning with
alcohols, clofenotane (dicophane, DDT), cyanides, malathion,
and metal salts including those of iron and lithium.
Drug interactions: charcoal decreases the effect of Ipecac
syrup.
Contraindications: poisoning by hydrocarbons with high
potential for harm if aspirated; poisoning by corrosive
substances (may prevent visualization of lesions caused by the
poison).
Side effect: black stools; vomiting, constipation or diarrhoea;
bowel obstruction pneumonitis (due to aspiration).
Dose and Administration:Poisoning (reduction of absorption),
Oral: as soon as possible after ingestion of poison, Adult, 50
100 g as a single dose; Infant, 1 g/kg as a, single dose; Child 1
12 years, 25 g as a single dose (50 g in severe
Poisoning).Poisoning (active elimination), Oral: Adult, 50 g
every 4 hours (in case of intolerance 25 g every 2 hours);
Infant, 1 g/kg every 46 hours; Child Over 1 year, 2550 g
every 46 hours.
Apomorphine Hydrochloride
Injection, 3 mg/ml in 1 ml ampoule
901

19. Antidotes And Other Substances Used In Poisoning

Indications: emetic in the treatment of acute poisoning;

diagnosis and management of parkinsonism.
Cautions: if vomiting does not result from the first dose of
apomorphine, then a second dose should not be given. Caution
should be taken in children debilitated or elderly patients or
those with cardiac decomposition.
Drug interactions: the effectiveness of apomorphine as an
emetic is diminished by drugs that depress the vomiting center
and they in turn may enhance its central depressant effects.
Contraindications: respiratory or central nervous system
depression, in shock or seizure, or in patients suffering from the
effects or corrosive poisons.
Side effects: protracted vomiting, shock, CNS stimulation,
depression and respiratory depression.
Dose and Administrations:Adult:subcutaneous 5 or 6 mg as a
single dose; Child:subcutaneous 70 to 100 mcg per Kg body
weight as a single dose:
Note: A glass of water being given before injection.

Storage: store in tight container. Protect from light.

Atropine Sulphate
Injection, 1 mg/ml in 1 ml ampoule
Indications: for the treatment of poisoning from cholinesterase
inhibitors such as neostigmine, pilocarpine, physiostigmine, and
methacholine, and in the treatment of the rapid type of
mushroom (muscarine) poisoning.It is also indicated in the
treatment of poisoning caused by pesticides that are
organophosphate cholinesterase inhibitors, chemical warfare,
and nerve gases.
Cautions: pregnancy and breastfeeding in children and in
elderly, urinary retention, prostatic enlargement, tachycardia,

902

19. Antidotes And Other Substances Used In Poisoning

cardiac insufficiency, paralytic ileus, ulcerative colitis, and

pyloric stenosis.
Drug
interactions:
antacids,
antidiarrhoeals,
other
anticholinergics, cyclopropane, ketoconazole, haloperidol.
Contraindications: closed angle glaucoma.
Side effect: dryness of mouth, skin, blurred vision, loss of
accommodation constipation, bradycardia followed by
tachycardia, difficulty with micturation, flushing.
Dose and Administration:Adult: Antidote to cholinesterase
inhibitors: IV: 2-4mginitially, then 2mg repeated every five to
ten minutes until muscarinic symptoms disappear or signs of
atropine toxicity appears.Antidote to muscarine in mushroom
poisoning:IM, or IV: 1 to 2mg every hour until respiratory
effects subside.Antidote to organophosphate pesticides:IM or
IV: 1 to 2mg repeated in twenty or thirty minutes as soon as
cyanosis has cleared. Continue dosage until definite
improvement occurs and is maintained, sometimes for two days
or more.Child:Antidote to cholinesterase inhibitors:IV or IM:
1mg initially, then 0.5 - 1mg every five to ten minutes until
muscarinic symptoms disappear or signs of atropine toxicity
appear.
Storage: at room temperature, protect from freezing
Calcium folinate and Folinic acid (See section 12.4)
Calcium Gluconate (Levulinate, or Chloride)
Injection, 10 % in 10 ml ampoule
Indications: fluoride toxicity; hypocalcaemia and of calcium
deficiency states (see sec.11.2)
Side effects, Drug interactions, Cautions, Contraindications:
see sec. 11.2

903

19. Antidotes And Other Substances Used In Poisoning

Dose and Administrations:10 ml of Calcium gluconate 10 %

IVrepeated after one hour; 30 ml should be given if tetany is
present. The short term affected skin and tissue should be
injected with a 10 % solution of calcium gluconate at a dose of
0.5 ml per cm2.
Note: Inorganic fluoride is corrosive to skin and mucous membranes and
acute intoxication disrupts many physiological systems and severe burns and
profound hypocalcaemia may ensure. Absorption of the fluoride can be
prevented by conversion to an insoluble form such as calcium fluoride and
thus irrigation with limewater, milk, or a 1 % solution of calcium chloride or
gluconate at the portable of entry (mouth, skin, stomach) is recommended.

Desferrioxamine Mesylate
Powder for injections, 0.5 g in vial
Indications: it is a chelating agent used in the treatment of
acute iron poisoning, and chronic iron or aluminium over load.
Cautions: impaired renal function, if infection is suspected
treatment with desferroxamine should be stopped and
appropriate antimicrobial treatment given.
Drug interactions: prochlorperazine
Contraindications: severe renal disease or anuria, pregnant
women or women who may become pregnant.
Side effects: anaphylactic reactions, and hypotension when
given too rapidly by intravenous injection
Dose and Administration:Continuous IV infusion: up to 15
mg/kg /hour; maximum 80mg /kg in 24 hours.
IM: 1 - 2 g in 10 - 20 ml of water for injections every 3 - 12
hours; maximum 6g in 24 hours.
Storage: reconstituted solutions of desferrioxamine mesylate
are stable for 1 week at room temperature when protected from
light.
Note: Inform the patient that the drug may colour the urine reddish
brown
904

19. Antidotes And Other Substances Used In Poisoning

Digoxin Immune Fab (Ovine)/Digoxin-specific, Antibody

fragments
Powder for injection, 40mg
Indications: treatment of life-threatening or potentially life
threatening digoxin intoxication, associated with hyperkalaemia,
life- threatening cardiac dysrhythmias or digoxin levels >
6ng/ml.
Cautions: renal or cardiac failure.
Drug interaction: digoxin.
Contraindications: hypersensitivity to sheep products or any
component of the formulation.
Side effects: hypersensitivity reactions and hypokalemia.
ose and Administration: Each vial of 40mg will
ind 0.5 mg of digoxin or digitoxin.Estimation of
he dose is based on the body burden of digitalis.
his may be calculated if the amount ingested is
nown or the post distribution serum drug level is
nown (round dose to the nearest whole vial). See
he next table. Digoxin Immune Fab
Tablet Ingested (0.25 mg)

Fab Dose(Vials)

5
10
25
50
75
100
150
200

2
4
10
20
30
40
60
80

If neither amount ingested nor drug level are known, dose

empirically as follows: For acute toxicity: 20 vials,
administered in 2 divided doses to decrease the possibility of a
febrile reaction, and to avoid fluid overload in small children.
905

19. Antidotes And Other Substances Used In Poisoning

For chronic toxicity: 6 vials, for infants and small children (

20kg), a single vial may be sufficient.
Storage: store in refrigerator (2 to 8oC).
Dimercaprol
Injection, 5% in 2ml ampoule.
Indications: antidote to gold, arsenic, mercury poisoning;
adjunct to edetate calcium disodium in lead poisoning; possibly
effective for antimony, bismuth, chromium, copper, nickel,
tungsten, or zinc.
Cautions: oliguria; glucose 6-phosphate dehydrogenase
deficiency.
Drug interactions: toxic complexes with iron, cadmium,
selenium, or uranium.
Contraindications: hepatic insufficiency (unless due to arsenic
poisoning); iron, cadmium, or selenium poisoning.
Side effects: hypertension, headache, nausea, vomiting.
Dose and Administration: Adult and Children: Deep
I.M:Arsenic, mercury, and gold poisoning: 3mg /kg every 4 - 6
hours for 2 days, then every 12 hours for 7 - 10 days or until
recovery (initial dose may be up to 5mg if severe
poisoning).Lead poisoning (in conjunction with calcium EDTA):
For symptomatic acute encephalopathy or blood level > 100
mcg/dl: 4 - 5mg/kg every 4 hours for 3 - 5 days.
Storage: store at 2-8 oC; protect from light.
Flumazenil
Injection, 0.1 mg/ml in 5 ml ampoule
Indications: flumazenil is indicated for the management of
benzodiazepine over dose.

906

19. Antidotes And Other Substances Used In Poisoning

Cautions: hypersensitivity to benzodiazepines; patients

receiving benzodiazepines for prolonged periods; pediatrics,
elderly; pregnant and breast-feeding women.
Drug interactions: cyclic (tricyclic or tetracyclic)
antidepressants
Contraindications:
cyclic
(tricyclic
or
tetracyclic)
antidepressant; status epilepticus severe head injury
Side effects: nausea, vomiting, flushing and very occasionally
convulsions
Dose and Administration: Adult: IV:0.2mg over 15 seconds;
if a response is not achieved within 60 seconds; 0.1mg may be
repeated at 60-second intervals as required to a total dose of
1mg (2mg in intensive care). Usual range 0.3-0.6 mg. If there is
no response, aetiology should be questioned.
Storage: at room temperature.
Ipecac
Syrup, 7% powdered Ipecac
Indications: an emetic for emergency use in the treatment of
drug overdose and in some cases of poisoning
Cautions: children under 1 year of age; heart disease active or
impending seizures and in conditions of strychnine poisoning or
ingestion of petroleum distillates, such as kerosene, gasoline,
coal oil, fuel oil, paint thinner, or cleansing fluid.
Drug interactions: activated charcoal, milk or milk products,
carbonated beverages, antiemetics.
Contraindications: impending coma, severe inebriation,
corrosive poisoning with alkali and strong acids, depressed gag
reflex, impending shock states.
Side effect: diarrhoea, fast or irregular heartbeat, nausea or
vomiting, stomach cramps or pain, troubled breathing, unusual

907

19. Antidotes And Other Substances Used In Poisoning

tiredness or weakness, aching, and stiffness of muscles,

especially those of the neck, arms, and legs.
Dose and Administration: Oral:Adult: emetic: 15 to 30ml
followed immediately by one glass (240ml) of water. Dose may
be repeated in twenty minutes if emesis does not occur. The
dosage should be reversed by gastric lavage if emesis does not
occur after the second dose.
Child:Emetic:Children up to 1 year of age: 5 to 10ml
Children 1-12 years of age: 15 ml, preceded or followed by -1
full glass (120-240ml) of water.
Storage: at a temperature below 250c.
Methionine
Tablet, 250mg
Indications: management of paracetamol (acetaminophen)
overdose. The efficacy and safety of late (> 15 hours post
ingestion) or prolonged administration (> 16 hours) have not
been sufficiently explored.
Dose and Administration: Oral: 2.5g 4 hourly for a total of 4
doses, started within 10 - 12 hours after paracetamol ingestion.
Storage: protect from light.
Methylene Blue
Injection, 1% in 10ml ampoule.
Indications: antidote for cyanide poisoning and drug-induced
methemoglobinemia.
Cautions: G6PD deficiency, pregnancy and breastfeeding.
Contraindication: renal insufficiency.
Side effects: hypertension, precordial pain, dizziness, mental
confusion, headache, fever, staining of skin, fecal discoloration,
nausea, vomiting, abdominal pain, discoloration of urine,
bladder irritation, anemia, diaphoresis.
908

19. Antidotes And Other Substances Used In Poisoning

Dose and Administration: Adult and Child:IV:

Methemoglobinemia: 1 - 2 mg/kg over several minutes; may be
repeated in 1 hour if necessary.
Naloxone Hydrochloride
Injection, 0.02 mg/ml in 2 ml ampoule. 0.4 mg/ml in 1 ml and 10
ml ampoule, 1mg/ml
Indications: over dosage with opioids; postoperative respiratory
depression
Cautions: physical dependence on opioids, cardiac problems or
those patients receiving cardiotoxic drugs.
Dose and Administrations:By IV, 0.8 to 2 mg repeated at
intervals of 2 - 3 minutes to maximum of 10 mg if respiratory
function does not improve (then question diagnosis); Child 10
microgram/kg; subsequent dose of 100 micrograms/kg if no
response.
SC or IM: as intravenous injection but only if intravenous route
not feasible (onset of action slower).
Continuous IV infusion: 2 mg diluted in 500 ml intravenous
infusion solution at a rate adjusted according to the response
Storage: in airtight containers. Protect from light
Penicillamine
Capsule, 250mg
Indications: treatment of copper, mercury, arsenic, lead and
zinc poisoning; Wilson's disease and cystinuria; adjunctive
treatment of rheumatoid arthritis.
Caution: penicillin allergy.
Drug interactions: antacids, iron salts, digoxin.
Contraindications: renal insufficiency and pregnancy (in
patients with rheumatiod arthritis); patients with previous
penicillamine-related aplastic anemia or agranulocytosis; breastfeeding.
909

19. Antidotes And Other Substances Used In Poisoning

Side effects: vasculitis, anxiety, agitation, fever, psychiatric

disturbances, alopecia, rash, urticaria, wrinkling, anorexia,
diarrhea, hematuria, nephrotic syndrome and renal failure.
Dose and Administration: Oral:Rheumatoid arthritis:
Adult: 125 - 250mg/day, may increase dose at 1- 3 month
intervals up to 1 1.5g/day;Wilson's disease:Adult: 250 mg/4
times /day.Child< 12 years: 20mg/kg/day in 2-3 divided doses,
round off to the nearest 250 mg dose; maximum 1g/day.
Cystinuria:Adult: 1-4g/day in divided doses every 6 hours;
usual dose: 2g/day.Child: 30mg/kg/day in 4 divided doses.
Chelation therapy:Adult: 0.5 - 1.5 g daily in 4 divided doses.
Child: 20 - 40 mg/kg daily in 4 divided doses.
Storage: store in tight, well - closed containers.
Physostigmine salicylate
Injection, 1mg/ml in 1ml and 2ml ampoule
Indications: reverse toxic CNS effects caused by
anticholinergic drugs.
Cautions: epilepsy, asthma, diabetes, gangrene, cardiovascular
disease, bradycardia.
Drug interactions: bethanechol, methacholine, succinylcholine.
Contraindications: GI or GU obstruction.
Side
effects:
bradycardia,
palpitations,
restlessness,
nervousness, hallucinations, seizure, nausea, salivation,
diarrhea, stomach pain, frequent urge to urinate, muscle
twitching, lacrimations, miosis, dyspnea, bronchospasm,
respiratory paralysis, pulmonary edema, diaphoresis.
Dose and Administration: Adult:IM, IV, SC: 0.5 - 2mg to
start, repeat every 20 minutes until response occurs or adverse
effect occurs. Repeat 1- 4mg every 30 to 60 min as life threatening signs.Child: IV: 0.01 - 0.03 mg/kg /dose
(maximum: 0.5 mg/min); may repeat after 5 - 10 minutes to a
maximum total dose of 2mg.
910

19. Antidotes And Other Substances Used In Poisoning

Storage: store at controlled room temperature.

Phytomenadiaone (Vitamin k1)
Injection, 10mg/ml in 1ml ampoule
Indications: overdose of warfarin and related agents used in
rodent poisons.
Cautions: G6PD deficiency.
Drug interactions: warfarine.
Contraindications: impaired hepatic function.
Side effects: shock- like reactions with bronchospasm,
cyanosis, tachycardia and vascular collapse.
Dose and Administration:Adult: IM: 10mg. Child: IM: 15mg. With severe toxicity, vitamin k1 may be given I.V.
Storage: store in airtight containers.
Protamine Sulphate
Injection, 10mg/ml in 5ml ampoule, 250mg (10mg/ml), 25ml
Indications: treatment of heparin overdosage.
Cautions: allergic to fish, vasectomised or infertile males, and
prior exposure to protamine or protamine containing insulin;
porphyria.
Side effects: anaphylaxis, transient neutropenia, bradycardia,
flushing, systemic hypotension and pulmonary hypertension.
Dose and Administration:
Heparin
route
IV

Time elapsed since

heparin given
<15 minutes

Protamine Sulfate Per 100u

heparin
1mg

IV
IV
SC

30 -60 minutes
> 2 hours
_

0.5 - 0.75mg
0.25 - 0.375mg
1mg

911

19. Antidotes And Other Substances Used In Poisoning

Protamine sulphate usually is administered by very slow IV

injection over 10 minutes. No more than 50mg of the drug
should be administered in any 10 minute period.
Storage: store at 2-8 oC.
Pralidoxime Chloride
Tablet, 500 mg
Powder for injection, 1 g in vial
Indications: It is used as an adjunct to but not as a substitute for
atropine in the treatment of poisoning by certain cholinesterase
inhibitors.
Its main indication is in poisoning due to
organophosphorus pesticides or related compounds.
Cautions: It should be used cautionly in patients with impaired
renal function (a reduction in dosage may be necessary);
myasthenia gravis. It should not be used to treat poisoning by
carbamate pesticides.
Drug
interactions:
succinylcholine,
theophylline,
aminophylline and respiratory depressants.
Side effects: drowsiness, dizziness, disturbances of vision,
nausea, tachycardia, headache, hyperventilation, and muscle
weakness; laryngospasm, muscle rigidity (due to rapid IV
injection of pralidoxime)
Dose and Administration:The usual initial parenteral dose of
pralidoxime chloride is 1 2 g for adult, or 20-40 mg/kg for
children; repeat the dose in about 1 hour if muscle weakness
has not been relieved (IV infusion of 500mg of the drug per hrs).
For prophylactic use in workers exposed to organophosphate
insecticides: 1-3g of pralidoxime chloride has been given orally
just before exposure to the organophosphate and a second dose
has been given after conclusion of exposure or 5 hours after the
first dose whichever came first.

912

19. Antidotes And Other Substances Used In Poisoning

Sodium Calcium Edetate

Injection, 200 mg/ml in 5 ml ampoule.
Indications: treatment of symptomatic acute and chronic lead
poisoning.
Cautions: severe renal disease, anuria.
Drug interactions: zinc insulin preparation: do not mix in the
same syringe with dimercaprol.
Side effects: arrhythmias, hypotension, chills, skin lesions,
hypercalcemia, anorexia, anemia, renal tubular necrosis,
sneezing, nasal congestion.
Dose and Administration: Adult: IV infusion or IM: usually
1g twice daily or 50-75mg/kg/day for 5 days, followed by a 2day interruption if a repeat dose is considered.Child: IV infusion
(over 8 - 12 hours) or IM: usually 1000 - 1500 mg/m2 /day for
3- 5 days, followed by a 2-day interruption if a repeat course of
therapy is necessary.
Storage: store at controlled room temperature.
Sodium Nitrite
Injection, 3 % (30 mg/ml)
Indications: sodium nitrite is used in the treatment of cyanide
poisoning in conjunction with sodium thiosulphate.
Side effects: nausea and vomiting, abdominal pain, dizziness,
headache, cyanosis, tachypnoea, and dyspnea; flushing and
headache due to vasodilatation.
Dose and Administration:10 ml by intravenous injection over
3 minutes, followed by 25 ml of sodium thiosulphate injection
50 % by intravenous injection over 10 minutes. The usual
dosage regimen in children is 0.15 to 0.33 ml (approximately
4.5 to10.0 mg per kg) followed by 1.65 ml per kg of a 25 %
solution of sodium thiosulphate.
Storage: store in airtight container.
913

19. Antidotes And Other Substances Used In Poisoning

Sodium Polystyrene Sulphonate

Powder, 15g
Indications: treatment of hyperkalemia.
Cautions: severe CHF, hypertension, edema, or renal failure.
Drug interactions: antacids, laxatives (magnesium hydroxide,
aluminum carbonate), digitalis.
Contraindications: hypernatremia, hypokalemia, obstructive
bowel disease.
Side effects: hypernatremia, hypokalemia, hypocalcemia,
hypomagnesemia, anorexia, constipation, fecal impaction,
intestinal obstruction, nausea, vomiting.
Dose and Administration:Adult:Oral: 15g (60ml) 1 - 4 times
per day.Rectal: 30 - 50g every 6 hours.Child:Oral: 1g/kg/dose
every 6 hours.Rectal: 1g/kg /dose every 2 - 6 hours.
Storage: store prepared suspensions at 15-30 oC, store
repackaged product in refrigerator and use within 14 days.
Sodium Thiosulphate
Injection, 10 % in 50 ml ampoule
Indications: poisoning with cyanides (used in conjunction with
sodium nitrite)
Dose and Administration: See under sodium Nitrite
Universal Antidote(charcoal+tannic acid+magnesium oxide)
Powder, 2 parts + 1 part + 1 part
Indications: treatment of selected cases of acute poisoning to
adsorb the toxic substance and thereby reduces its systemic
absorption.
Note: The "Universal antidote" is inferiors to activated charcoal alone. In
addition, the tannic acid component is potentially hepatotoxic. Thus, there is
no justification for the use of the "Universal antidote".

914

20. Immunological Preparations

20. IMMUNOLOGICAL PREPARATIONS

Immunoglobulins
Immunoglobulins are preparations containing antibodies
against infectious micro-organisms and are prepared usually
from human plasma or serum. They are used for passive
immunization, thus conferring immediate protection against
some infectious diseases. They are preferred to antisera of
animal origin as the incidence of adverse reactions is less.
Side effects: Local reactions with pain and tenderness at the site
of intramuscular injection; hypersensitivity reactions, including
rarely anaphylactic reactions, have also been reported; systemic
reactions with fever, chills, facial flushing, headache, and
nausea may occur following intravenous administration,
particularly at high rates of infusion.
Cautions: If immunoglobulins are given after administration of
a live vaccine at interval of at least 3 weeks should be allowed
to elapse. An interval of 3 months should be allowed between
the use of live vaccines and the prior administration of
immunoglobulins.
Antisera: Antisera (immunosera) are sterile preparations
containing immunoglobulins obtained from the serum of
immunised animals by purification. Antisera have the specific
power of neutralising venoms or bacterial toxins, or combining
with the bacterium, virus, or other antigen used for their
preparation.
Side effects and cautions: Anaphylactic reaction may occur,
with hypotension; dyspnoea, urticaria, and shock; serum
sickness frequently 7 to 10 days after the injection of serum of
animal origin.
Before injecting serum, information should be obtained
whenever possible as to whether previous injections of serum
915

20. Immunological Preparations

have been received and whether the patient is subject to

hypersensitivity disorders.
Sensitivity testing should be
performed before the administration of antisera.
Vaccines: Vaccines are preparations of antigenic materials
which are administered with the object of inducing in the
recipient active immunity to specific bacteria or viruses. They
may contain living or killed microorganisms, bacterial toxoids,
or antigenic material from particular parts of the bacterium,
ricketssia or virus.
The term vaccination and immunization are often used
synonymously and interchangeably. Vaccination is strictly only
the administration of a vaccine whereas immunization results in
the demonstrable presence of protective levels of antibodies
confirmed usually by serological testing.
Cautions: Vaccination should be postponed in patients
suffering from any acute illness although minor infections
without fever or systemic upset are not regarded as contraindications. Before injection of a vaccine any alcohol or
disinfectant used for cleansing the skin should be allowed to
evaporate otherwise inactivation of live vaccines may occur.
Contraindications: Vaccines are contra-indicated in those who
have a confirmed anaphylactic reaction to a preceding dose of a
vaccine containing the same antigens or vaccine component
(such as antibacterial in viral vaccines).
Hypersensitivity to egg with evidence of previous anaphylactic
reaction, contra-indicates influenza vaccine (prepared in hens
eggs), tick-borne encephalitis vaccine, and yellow fever vaccine.
Live vaccines may be contra-indicated temporarily in
individuals who are:immunosuppressed (see Impaired immune
response, below);Pregnant (see Pregnancy and breast-feeding,
below).
916

20. Immunological Preparations

Impaired immune response: Immune response to vaccines

may be reduced in immunosuppressed patients and there is also
a risk of generalized infection with live vaccines. Severely
immunosuppressed patients should not be given live vaccines
(including those with severe primary immunodeficiency).
Specialist advice should be sought for those being treated with
high doses of corticosteroids (dose equivalents of prednisolone:
adults, at least 40 mg daily for more than 1 week; children,
2 mg/kg daily for at least 1 week or 1 mg/kg daily for 1 month),
or other immunosuppressive drugs and those being treated for
malignant conditions with chemotherapy or generalised
radiotherapy
Pregnancy:Live vaccines should not be administered routinely
to pregnant women because of the theoretical risk of fetal
infection but where there is a significant risk of exposure to
disease (e.g. to yellow fever), the need for vaccination usually
outweighs any possible risk to the fetus. Termination of
pregnancy following inadvertent immunisation is not
recommended. There is no evidence of risk from vaccinating
pregnant women with inactivated viral or bacterial vaccines or
toxoids. For use of specific vaccines during pregnancy, see
under individual vaccines.
Breast-feeding: Although there is a theoretical risk of live
vaccine being present in breast milk, vaccination is not contraindicated for women who are breast-feeding when there is
significant risk of exposure to disease. There is no evidence of
risk from vaccinating women who are breast-feeding, with
inactivated viral or bacterial vaccines or toxoids. For use of
specific vaccines during breast-feeding, see under individual
vaccines.
Side effects:Injection of a vaccine may be followed by local
reactions such as pain, inflammation, redness, and lymphangitis.
917

20. Immunological Preparations

An induration or sterile abscess may develop at the injection

site. Gastro-intestinal disturbances, fever, headache, irritability,
loss of appetite, fatigue, myalgia, and malaise are among the
most commonly reported side-effects. Other side-effects include
influenza-like symptoms, dizziness, paraesthesia, asthenia,
drowsiness,
arthralgia,
rash,
and
lymphadenopathy.
Hypersensitivity reactions, such as bronchospasm, angioedema,
urticaria, and anaphylaxis, are very rare but can be fatal.
Oral vaccines such as cholera, live poliomyelitis, rotavirus, and
live typhoid can also cause gastro-intestinal disturbances such as
nausea, vomiting, abdominal pain and cramps, and diarrhoea.
Route of administration: Vaccines should not be given
intravenously. Most vaccines are given by the intramuscular
route; some vaccines are given by others routesthe
intradermal route for BCG vaccine, and the oral route for
cholera, live poliomyelitis, rotavirus, and live typhoid vaccines.
The intramuscular route should not be used in patients with
bleeding disorders such as haemophilia or thrombocytopenia.
Vaccines usually given by the intramuscular route.
Storage and use:Care must be taken to store all vaccines and
other immunological products under the conditions
recommended in the product literature; otherwise the
preparation may become ineffective. Refrigerated storage is
usually necessary; many vaccines and immunoglobulins need to
be stored at 28C and not allowed to freeze. Vaccines and
immunoglobulins should be protected from light. Reconstituted
vaccines and opened multi-dose vials must be used within the
period recommended in the product literature. Particular
attention must be paid to instructions on the use of diluents.
Vaccines which are liquid suspensions or are reconstituted
before use should be adequately mixed to ensure uniformity of
the material to be injected.
918

20. Immunological Preparations

Indications: to prevent a rhesus (Rh) negative mother actively

forming antibodies to fetal rhesus positive (Rh+) red blood cells
that may pass into the maternal circulation during child birth,
abortion, or certain other sensitizing events causing disease of
the new born (erythroblastosis fetalis).Anti-D immune
globulune should be administered following any sensitizing
episode(e.g .abortion ,miscarriage and birth), it should be
injected within 72 hours of the episode but even if a longer
period has elapsed it may still give protection and should be
administered. The dose of Anti-D immunoglobuline is
determined according to the level of exposer to rhesus- positive
blood.Routine antenatal anti D prophylaxisshouldbe offerd to
all non-sensitised pregnant women who are rhesus negative.
Anti-Rho (D) Immune Globulin
Injection, 2ml in vial, 120mcg, 300mcg
Indications: see notes above
Cautions: as for immunoglobuline in general; Rho (D) immune
globulin should be used with caution in individuals with a
history of prior allergic reactions to preparation containing
human immune globulins.Caution also in those with
thrombocytopenia or bleeding disorders.
Contraindications: Rho (D)-positive individuals, Rho (D)negative individuals who have been previously sensitized to
Rho (D) antigens, anaphylactic reaction to preparation
containing human immune globulins.
Side effects: as for immunoglobulin in general; pain tenderness,
and discomfort at site of injection, slight temperature elevations,
fever, myalgia, lethargy.
Dose and Administration:After full-time delivery:IM: 500 units
(100ug). A higher dose may be required depending on the
amount of transplacental bleeding.
919

20. Immunological Preparations

Termination of pregnancy: Rh-negative women having

spontaneous or induced up to 13 weeks of gestation or more:IM:
250 units (50mcg) of anti-DImmunoglobulin.
Occurrence of risk of sensitization during pregnancy from
threatened abortion, amniocentesis or external version: IM:
250-500 units (50-100mcg) of anti Rho (D) immunoglobulin.
Storage: at a temperature between 2oc and 80c.
BCG Vaccine
Injection, 500,000 organisms /ml in 0.05ml and 0.1ml
Indications: active immunization against tuberculosis.
Cautions: pregnancy, eczema, scabies-vaccine site must be
lesion-free; see also notes above.
Drug interactions: asparginase, azathioprine, bleomycin,
ciclosporin,
daunorubicin,
dactinomycin,
fluorouracil,
vinblastin, vincristine.
Contraindications: generalized edema, children with
symptomatic HIV, antimycobacterial treatment see also notes
under general description above.
Side effects: lymphadenitis and keloid formation; osteitis and
localized necrotic ulceration, rarely, disseminated BCG
infection in immunodeficient patients.
Dose and Administration: Intradermal injection:Adult and
Child > 3 month: 0.1 ml; Infants up to 3 months: 0.05ml.
Storage: store in refrigerator.
Botulism Antitoxin, polyvalent types A, B and E
Indications: treatment of botulism, caused by the injection of
infected food.
Note: Treatment should be given as early as possible in the
course of the disease. Botulism antitoxins are generally not
effective for infant botulism.
920

20. Immunological Preparations

Cautions, Contraindications, Side effects: see notes above, as

for antisera in general.
Dose and Administrations:Prophylaxis: IM: 20 ml as soon as
possible after exposure.Treatment: 20 ml (diluted to 100 ml with
sodium chloride 0.9%), slow IV infusion followed by 10 ml 2 - 4
hours later if necessary, and further doses at intervals of 12 - 24
hours.
Storage: store at 2o to 8o c in single use containers.
Cyclosporin A
Capsules, 10mg, 25mg, 50mg, 100mg
Oral solution, 100mg/ml
IV infusion (oily), 50mg/ml
Indications: prevention and treatment of graft rejection
following organ and tissue transplantation; severe chronic
plaque - type psoriasis, and severe atopic dermatitis.
Cautions: renal or hepatic disease; porphyria.
Contraindications: hypersensitivity to ciclosporin, malignancy,
uncontrolled hypertension, or uncontrolled infections.
Drug interactions: amphotericin B, cimetidine, omeprazole,
ketoconazole,
itraconazole,
fluconazole,
erythromycin,
doxycycline, diltiazem, verapamil, metoclopramide, colchicine,
methyl
prednisolone,
oral
contaceptives,
danazol,
norethisterone, androgens, alopurinol, amiodarone, and
grapefruit juce, rifampicin, carbamazepine, phenytoin,
phenobarbital, isoniazid, prubucol, ACE inhibitors, potassiumsparing
diuretics,
aminoglycosides,
amphotericin
B,
ciprofloxacin, vancomycin, co-trimoxazole, NSAIDs, digoxin,
colchicine, simvastatin, pravastatin, other immuno suppressants,
fat rich meal.
Side effects: nephrotoxicity, hyperkalaemia, hyperuricaemia,
hypomagnesaemia and hyperlipidaemia, microangiopathic
921

20. Immunological Preparations

haemolytic anaemia, hypertension, nausea, vomiting, headaches,

hepatotoxicity, neurotoxicity includes tremor, seizures,
dysarthria, confusion, drowsiness, hallucinations, visual
disturbances and mental changes.
Dose and Administration: Adult:Organtransplantation (single
therapy): Oral: 10 - 15 mg/kg/day in 2 divided doses, reduced
gradually according to blood levels; maintenance 2 - 6
mg/kg/day in 2 divided doses.IV infusion: 2 - 6 mg/kg/day
(diluted in 0.9% sodium chloride solution or 5% glucose and
given as a continuous infusion over 24 hours) continued until
patient can take oral therapy.Severe psoriasis: Oral: 2.5
mg/kg/day in 2 divided doses; may be increased gradually up to
maximum of 5mg /kg/day if no improvement after 1 month.
Discontinue if response still not adequate within 6 weeks on
5mg/kg /day.
Severe atopic dermatitis: Oral: initially 2.5mg/kg/day in 2
divided doses; may be increased rapidly if response inadequate
in 2 weeks, up to a maximum of 5mg/kg day. If very severe,
initiate with 5 mg/kg/day and reduce gradually once response is
satisfactory. Duration of treatment should not exceed 8
weeks.Child: organ transplantation: As for adults. Higher or
more frequent doses may be required.
Storage: store at room temperature.
Diphtheria Antitoxin
Injection, 2000 units/ml in 5ml
Indications: for passive immunization in suspected cases of
diphtheria and should be given without waiting for
bacteriological confirmation of the infection.
Note: An antibacterial agent such as erythromycin or benzyl penicillin
is usually given concomitantly. Diphtheria antitoxin is generally not
used for the prophylaxis of diphtheria because of the risk of provoking
a hypersensitivity reaction.Contacts of a diphtheria case should be
922

20. Immunological Preparations

promptly investigated, given a prophylactic course of erythromycin

and active immunization with a suitable diphtheria containing vaccine
as appropriate and kept under observation.

Cautions, Contraindications, Side effects; as for antisera in

general, see notes above.
Dose and Administration: Note: A test dose of diphtheria
antitoxin should always be given to eliminate hypersensitivity.
10,000 - 30,000 units increased to 40,000 - 100,000 units in
severe cases: doses of up to 30,000 units should be given
intramuscularly but for those over 40,000 units a portion is
given intramuscularly followed by the bulk of the dose
intravenously after an interval of to 2 hours.
Note: children require the same dose as adults, depending on
the severity of the awe.
Storage: store at 2o to 8oc, do not freeze.
Diphtherial and Tetanus Toxoid
Injection, 0.5 ml
Indications:Infants and Children through 6 years of age: Active
immunity against diphtheria and tetanus when pertussis vaccine
is contraindicated.Children 7 years of age and Adults: Active
immunity against diphtheria and tetanus; tetanus prophylaxis in
wound management.
Cautions: bleeding disorders or anticoagulant therapy.
Drug interactions: antimetabolites, alkylating agents, cytotoxic
drugs, corticosteroids, irradiation.
Contraindications: hypersensitivity to diphtheria, tetanus
toxoid.
Side effects: dizziness, seizure, rash, nausea, vomiting, local
reactions, myalgia, arthralgia.
Dose and Administration: I.M:Infants and Child 6 years
(DT):Primary immunization: 6 weeks to 1 year: three 0.5 ml
923

20. Immunological Preparations

doses at least 4 weeks apart; administer reinforcing doses 6 - 12

months after the third injection.
1 - 6 years: two 0.5 ml doses at least 4 weeks apart, reinforcing
dose 6 - 12 months after second injection;
Booster immunization: 4 - 6 years: 0.5 ml; not necessary if the
fourth dose was given after fourth birthday; routinely administer
booster doses at 10 -year intervals with the adult preparation.
Child > 7 years and Adult:
Primary immunization: Patients previously not immunized
should receive 2 primary doses of 0.5ml each, given at an
interval of 4 - 6 weeks; third (reinforcing) doses of 0.5ml 6 - 12
months later.
Booster immunization: 0.5ml every 10 years; to be given to
children 11 - 12 years of age if at least 5 years have elapsed
since last dose of toxoid containing vaccine.
Storage: store at 2 - 8 oC. Do not freeze.
Diphtheria, Tetanus Toxoid and Pertussis Vaccine
Injection, 0.5ml
Indications: active immunization against diphtheria, tetanus,
and pertussis from age 6 weeks through seventh birthday.
Cautions: children with coagulation disorders; seizure disorder.
Drug interactions: anticoagulants, corticosteroids and
immunosuppressant agents.
Contraindications: children > 7 years of age.
Side effects: drowsiness, irritability, decreased appetite,
redness, swelling, fever, vomiting, pain, redness, and
tenderness.
Dose and Administration:Child 6 weeks to < 7 years: I.M:
0.5ml.Primary series: Three doses, usually given at 2, 4, and 6
months of age; may be given as early as 6 weeks of age and
repeated every 4 - 8 weeks, use same product for all 3
924

20. Immunological Preparations

doses.Booster series: Fourth dose: given at 15-20 months of

age, but at least 6 months after third dose. Fifth dose: Given at 5
- 6 years of age, prior to starting school or kindergarten; If the
fourth dose is given at 4 years of age, the fifth dose may be
omitted.
Storage: store in refrigerator at 2 to 8 oC; do not freeze.
Gas Gangrene Antitoxin, Mixed
Injection, 25,000 units in 20 ml
Indications: treatment of gas gangrene and for prophylaxis in
patients at risk following injury.
Note: They are now seldom used and have been superseded by
antibacterials such as benzyl penicillin or metronidazole.

Cautions, Contraindicationand Side effects; as for antisera in

general,
Storage: Store at 20 to 80C, and not be allowed to freeze.
Haemophilus Influenza type B (Hib) vaccine
Injection, 0.5 ml
Indications: for active immunization against Haemophilus
influenzas type b infections, one of the major causes of
meningitis and other sever systems illnesses in young children.
Cautions, Contraindicationsand Side effects: As for vaccines
in general, see notes above; and Erythemamultiforme has been
reported rarely in children.
Note: Different proprietary vaccines may be conjugated to differing
proteins and therefore the same vaccine should be used for an
immunization course; if a different vaccine needs to be employed the
entire primary course should be repeated.

Dose and Administrations:By deep SC or IM injection in doses

of 0.5 ml; doses are given at 2, 3 and 4 months of age.Note: The
vaccine may be administered at the same time as combined
diphtheria, tetanus, and pertusis vaccines of the primary
925

20. Immunological Preparations

immunization schedule children aged under 13 months who have

already commenced or completed their primary immunization
schedule should receive three doses of Hib at intervals of one month.
Children aged 13 to 48 months should be given a single dose as they
are at lower risk and the vaccine is effective after a single dose in this
age group.

Hepatitis B Vaccine, inactivated

Injection, 16.5 % in 2 ml and 10 ml.
Indications: for active immunization against hepatitis B
infections in persons at high risk of contracting the disease.
Cautions; Side effects; see notes above.
Note: The high risk group include: health care personnel, laboratory
workers, or any other personnel who have direct contact with patients
or their body fluids; patients requiring haemodialysis; haemophiliacs
and those receiving regular blood transfusions or blood products;
contacts or sexual partners of cases or carriers of hepatitis B;
individuals who frequently change sexual partners; parenteral drug
abusers; and some travelers to areas where hepatitis B is endemic.

Dose
and
Administrations:Note:
refere
Ethiopian
Immunization schedules. Immunization of Children against
hepatitis B: IM: infant 0.5 ml either at birth Or at 6 and 14
weeks of age, or at 6, 10 and 14 weeks of age.
Immunization of unimmunized high risk persons against
hepatitis B: IM: Adult and child over 15 years of age 3 doses of
1 ml, with an interval of 1 month between the first and second
dose and 5 months between the second and third doses; child
under 15 years, 0.5 ml.
Note: Different products may contain different concentrations of antigen per
ml. Consult manufacturers literature.The vaccine should be given in the
deltoid region in adults; anterolateral thigh is the preferred site in infants
and children; it should not be injected into the buttock (vaccine efficacy
reduced); subcutaneous route used for patients with hemophilia.

Storage: store at 2o to 8o c, not be allowed to freeze.

926

20. Immunological Preparations

Hepatitis B vaccine, Recombinant yeast DNA

Injection, 0.5ml
See under Hepatitis B Vaccine, Inactivated.
Dose and Administration: The basic immunization schedule
consists of 3 doses of a hepatitis schedule consists of 3 doses of
a hepatitis B vaccine, with the second and third doses 1 and 6
months, respectively, after the first. Typical doses for adults are
10 or 20mcg and for children 2.5 to 10mcg.
Storage: store at 2o to 8o c, not be allowed to freeze, and be
protected from light. Under these conditions it may be expected
to retain its potency for months.
Human Antirabies Immunoglobulin
Injection, 150 IU/ml, in 2 ml
Indications: Passive immunization either post-exposure or in
suspected exposure to rabies in high-risk countries in
unimagined individuals (in conjunction with rabies vaccine).
Cautions, Side effects: see notes above, as for immunoglobulin
in general.
Contraindications: see notes above; avoid repeat doses after
vaccine treatment initiated; intravenous administration.Note: If
schedule requires rabies vaccine and rabies immunoglobulin to be
administered at the same time, they should be administered using
separate syringes and separate sites.

Dose and Administration:Immunization against rabies: Postexposure (or suspected infiltration): Adult and Child: 20
units/kg (half by intramuscular injection and half by wound
infiltration)
Storage: store at 2o to 8oC.
Human Papiloma Virus Vaccine:
Injection, HPV6L1 20mcg +HPV11L140mcg + HPV16L1
20mcg +HPV18L120mcg /0.5mldose.
927

20. Immunological Preparations

Human papiloma virus vaccine is available as a bivalent vaccine

or a quadrivalent vaccine. Bivalent vaccine is licensed for use in
females for the prevention of cervical cancer and other precancerous lesions caused by human papilloma virus types 16
and 18. Quadrivalent vaccine is licensed for use in females for
the prevention of cervical cancer, genital warts and precancerous lesions caused by human papilloma virus types 6, 11,
16, and 18. The two vaccines are not interchangeable and one
vaccine product should be used for an entire course.
Indications: prevention of cervical cancer, genital warts and
other pre-cancerous lesions caused by human papilloma virus
types 6, 11, 16 and 18.
Cautions: See notes above
Contraindications: See notes above
Pregnancy: not known to be harmful, but vaccination should be
postponed until completion of pregnancy
Side effects: See notes above
Dose and administration: Human papilloma virus vaccine will
be most effective if given before sexual activity starts. The first
dose is given to females aged 12 to 13 years, the second and
third doses are given 12 and 6 months after the first dose; all 3
doses should be given within a 12-month period. If the course is
interrupted, it should be resumed but not repeated, allowing the
appropriate interval between the remaining doses. Where there
are significant challenges in scheduling vaccinations, or a high
likelihood that the third dose will not be given, the third dose of
bivalent vaccine can be given 3 months after the second dose.
The duration of protection has not been established, but current
studies suggest that protection is maintained for at least 6 years
after completion of the primary course. As the vaccines do not
protect against all strains of human papilloma virus, routine
cervical screening should continue.
928

20. Immunological Preparations

Immune Serum Globulin,Human(GammaGlobulin, Human)

Injection, 16.5% in 2ml, 5ml and 10ml
Indications: for replacement therapy in patients with immune
deficiency
states,
e.g.
agammaglobulinaemia
or
hypogammaglobulinaemia, and for the immediate protection of
susceptible contacts against hepatitis A or measles.
Cautions: thrombocytopenia or coagulation disorders.
Drug interactions: Live virus, vaccines (measles, mumps,
rubella).
Contraindications: IgA deficiency.
Side effects: flushing, angioedema, chills, lethargy, fever,
urticaria, erythema, nausea, vomiting, local (myalgia, pain,
tenderness, muscle stiffness at I.M site), hypersensitivity.
Dose and Administration: IM:Hepatitis A prophylaxis:
Contacts: 0.02 - 0.04 ml/kg within 1 week of exposure.
Pre-exposure prophylaxis for travellers: Period of stay < 3
months, 0.02 ml/kg.Period of stay > 3 months (continued
exposure), 0.06 ml/kg 4-6 monthly.
Measles prophylaxis: within 1 week of contact: 0.2 - 0.25 ml/kg
(maximum 15 ml).
Immuncompromised patients: 0.5 ml/kg (maximum 15 ml).
Follow after 3 months with active immunisation in patients 15
months of age, unless contraindicated.
Replacement therapy: congenital immunoglobulin deficiencies:
0.2 - 0.5 ml/kg, repeated 4 - 8 weekly.
Transient hypogammaglobulinaemia: 0.2 - 0.5 ml/kg, repeated
when necessary.
Storage: store in refrigerator, do not freeze.
Influenza Virus Vaccine, Polyvalent
Injection, 0.5 ml
929

20. Immunological Preparations

Indications: provide active immunity to influenza virus strains

contained in the vaccine.
Cautions: thrombocytopenia or any coagulation disorder.
Drug interactions: DTP
Contraindications: hypersensitivity reaction.
Side effects: fever, malaise, angioedema, urticaria, local
(tenderness, redness, or induration at the site of injection),
myalgia, allergic or anaphylactoid reactions.
Dose and Administration:Adult:I.M.ordeep SC, 0.5 ml.
Storage: store between 2-8oC.
Interferon Alpha
Injection, 3, 5, 10 million units.
Indications: treatment of malignant neoplasms such as nonHodgkins lymphoma, hairy-cell and chronic myeloid
leukaemias, and renal cell carcinoma. Has some efficacy in
chronic viral hepatitis B and C.
Cautions: depression, autoimmune disease, preexisting cardiac
disease, renal and hepatic impairment, myelosuppression,
diabetes, thyroid disease.
Drug interactions: theophylline, ACE inhibitors, melphalan,
prednisolone, clozapine, warfarin and zidovudine.
Contraindications: hypersensitivity reaction, autoimmune
hepatitis.
Side effects: fever, chills, myalgia, depression, unusual
tiredness, hypo and hypertension, arrhythmias, transient
confusion, somnolence, delirium, extrapyramidal symptoms,
mania and neurasthenia with catatonic episodes. Clinical
hypothyroidism preceded by appearance in the blood of thyroid
autoantibodies
reported
with
long-term
interferon.
Myelosuppression (granulocytopenia and thrombocytopenia);
GI effects and elevation of liver enzymes reported.
930

20. Immunological Preparations

Dose and Administration: Doses for individual products may

differ; package insert should be consulted.
Hairy-cell leukaemia:SC, 2 million IU/M2 administered (on
alternate days) 3 times a week;
Chronic viral hepatitis: Chronic Hepatitis B is usually treated
with 5 - 10 million IU thrice weekly for 16 weeks.Chronic
hepatitis C is usually treated with 3 - 5 million IU thrice weekly
for 24 weeks.
Storage: store in refrigerator at 2-8 oC; do not freeze.
Interferon Gamma
Injection, 3, 5, million units / 0.5ml
Indications: reduce frequency and severity of serious infections
associated with chronic granulomatous disease; delay time to
disease progression in patients with severe malignant
osteopetrosis.
Cautions: cardiac disease, seizure disorders, CNS disturbances,
or myelosuppression.
Contraindications: hypersensitivity reaction.
Side effects: fever, headache, chills, fatigue, rash, diarrhea,
vomiting, injection site erythema or tenderness (local),
depression, nausea, abdominal pain, myalgia, arthralgia, back
pain.
Dose and Administration:Chronic granulomatous disease:
Child > 1 year and Adult: SC:BSA 0.5 m2: 1.5 mcg /kg/dose 3
times /week.BSA > 0.5 m2: 50 mcg/m2 (1 million int. units/m2)
3 times/week. Severe, malignant osteopetrosis: Child > 1 year:
SC: BSA 0.5m2: 1.5mcg/kg/dose 3 times /week. BSA >
0.5m2: 50mcg/m2 (1 million int. units/m2) 3 times/week.
Storage: store in refrigerator. Do not freeze.

931

20. Immunological Preparations

Measles Virus Vaccine, Live Attenuated

Injection, 0.5 ml
Indications: active immunization against measles.
Side effects: as for vaccines in general, see notes above, and
fever and skin rashes may occur following the administration of
measles vaccines. The fever generally starts 5 to 10 days after
the injection, lasts for about 1 or 2 days, and has sometimes
been accompanied by convulsions. Conjunctivitis, coryza,
pharyngitis, and cough may also occur. More serious effects
reported rarely after the use of the vaccine include encephalitis
and thrombocytopenic purpura.
Cautions: see notes above; pregnancy
Contraindications: see notes above; hypersensitivity to any
antibiotic present in vaccine - consult manufacturer's literature;
hypersensitivity to egg.
Dose and Administration:Immunization of children against
measles:IM or deep SC injection: infant at 9 months of age, 0.5
ml. Prophylaxis in susceptible children after exposure to
measles:IM or deep SC injection within 72 hours of contact,
child over 9 months of age 0.5 ml
Storage: store at 2o to 8o c and be protected from light.
Meningococcal polysaccharide vaccine
Injection, 0.5ml
Indications:for active immunization against Neisseria
meningitidis infections which include meningitis and
septicaemia. Note: Meningococcal vaccines are indicated in persons
at risk, in epidemic or endemic areas, of meningococcal disease
caused by the specific serotypes contained in the vaccine. It is given
as an adjunct to chemoprophylaxis in close contacts of persons
traveling to countries where the disease is endemic. Asplenic persons
or those who have terminal complement component deficiencies are at
higher than normal risk of acquiring meningococcal infection.
932

20. Immunological Preparations

Cautions: as for vaccines in general; Immunity to some

meningococcal vaccines may be insufficient to confer adequate
protection against infection in infants under 2 years of age.
Contraindications:contraindacted for children under 2years of
age. Other contraindications and Side effects; as for vaccines in
general.
Dose and Administration:SC or IM: A single injection of
0.5ml.
Storage: store both the freeze-dried and the reconstituted
vaccine between 2 and 8oc. Protect from freezing.
Mycophenolic Acid (as Mycophenolate odium/Mofetil)
Tablet (e/c), 180mg, 360mg (as Mycophenolate Sodium),
250mg, 500mg, 1gm (as Mycophenolate Mofetil equivalent to
720mg Mycophenolic Acid)
Capsule, 250mg
Indications: prophylaxis of acute renal, cardiac, or hepatic
transplant rejection (in combination with ciclosporin and
corticosteroids) under specialist supervision
Cautions:full blood counts every week for 4 weeks then twice a
month for 2 months then every
month in the first year
(consider interrupting treatment if neutropenia develops);
elderly(Increased
risk
of
infection,
gastro-intestinal
haemorrhage and pulmonary oedema); children (higher
incidence of side-effects may call for temporary reduction of
dose or interruption); active serious gastro-intestinal disease
(risk of haemorrhage, ulceration and perforation); delayed graft
function; increased susceptibility to skin cancer (avoid exposure
to strong sunlight); bone marrow suppressionPatients should be
warned to report immediately any signs or symptoms of bone
marrow suppression e.g. infection or inexplicable bruising or
bleeding
933

20. Immunological Preparations

Contraindications:pregnancy (exclude before starting and

avoid for 6 weeks after discontinuation), breast-feeding.
Drug interactions:antacids, metronidazole, norfloxacin,
rifampicin, phenytoin, clozapine, aciclovir, ganciclovir,
digoxin,iron, colestyramine sevelamer.
Side effects:gastro-intestinal disturbances (including diarrhoea,
vomiting, and abdominal pain), gastrointestinal ulceration and
bleeding, abnormal liver function tests, hepatitis, jaundice,
pancreatitis;
oedema,
tachycardia,
hypertension,
hypotension,vasodilatation; cough, dyspnoea; insomnia,
agitation, tremor, dizziness, headache; influenza-like syndrome,
infections (viral, bacterial, and fungal); hyperglycaemia; renal
impairment; increased risk of malignancies, particularly of the
skin; blood disorders (including leucopenia, anaemia,
thrombocytopenia,pancytopenia), disturbances of electrolytes
and blood lipids; arthralgia; alopecia, acne, and rash;
progressive multifocal leucoencephalopathy reported
Dose and administration:Renal transplantation, by mouth, 1 g
twice daily starting within 72 hours of transplantation or by
intravenous infusion, 1 g twice daily starting within 24 hours of
transplantation for max. 14 days (then transfer to oral therapy);
Child and adolescent: 218 years, by mouth600 mg/m2/dose
twice daily (max. 2 g daily), Note :Tablets and capsules not
appropriate for dose titration in children with body surface area
less than 1.25m2 .Cardiac transplantation, by mouth, 1.5 g
twice daily starting within 5 days of transplantation. Hepatic
transplantation,by intravenous infusion, 1g twice daily starting
within 24 hours of transplantation for 4 days (up to max. 14
days), then by mouth, 1.5 g twice daily as soon as is tolerated.
Storage: see notes above

934

20. Immunological Preparations

Pentavalent (Diphtheria, Pertusis, Tetanus, Hepatitis B,

Haemophilus InfluenzaeB) Vaccine
Injection, 0.5 ml
Indications: Active immunization against diphtheria, tetanus,
pertussis, hepatitis B and Haemophilus Influenzae B at
completion of 2, 4 and 6 months of age.
Cautions: Administration of any subsequent dose of Pentavalent
should be carefully considered if, in connection with the
administration of vaccine, one or more of the following effects
have been observed: 40C temperature within 48 hours
following vaccination (not due to other identifiable causes);
collapse or shock (hypotonic hyporesponsive episodes) within
48 hours following vaccination; persistent crying lasting more
than 3 hours during the 48 hours following vaccination;
convulsions, with or without fever, within 3 days following
vaccination;subjects with thrombocytopenia or a bleeding
disorder.
Contraindications:avoided only for children with:
A history of a severe allergic reaction (e.g. generalized urticaria,
difficulty in breathing, swelling of mouth and throat, shock) to a
previous dose of Pentavalent vaccine or with known
hypersensitivity to any vaccine component. A history of an
encephalopathy of unknown aetiology after a previous
immunization with a vaccine containing pertussis.In these
circumstances, the vaccination course should be continued with
Diphtheria and Tetanus Toxoid (DT) and Hepatitis B.
o

A severe acute illness with temperature above 38.5 C. As with

other vaccines, vaccination should be postponed in children
suffering from acute febrile illness
A progressive neurological disease.
The following are NOT contraindications; Minor illnesses such
as respiratory tract infection or diarrhea with temperature below
935

20. Immunological Preparations

38.5 C. Allergy or asthma, family history of convulsions,

Treatment with antibiotics, Treatment with topical
corticosteroids or systemic use of corticosteroids at low dosage
(<0.5 mg/kg of prednisone or equivalent) in case of skin
diseases like dermatitis, eczema, or other localized skin
disorders, Infection with HIV. Breast feeding, History of
seizures (Convulsions, fits). Chronic illnesses such as those of
heart, lung, kidney or liver, Stable neurological conditions e.g.
cerebral palsy, Down syndrome ,Prematurity or low birth
weight, History of jaundice at birth.
Dose and administration:The standard dose for infants and
children is 0.5 ml. 4 Pentavalent vaccine should be given as an
Intramuscular (IM) injection to the anterolateral aspect of the
thigh in infants. Pentavalent vaccine SHOULD NOT be given
in the buttock or administered intradermally because this route
of administration does not produce an adequate antibody
response. In addition there may be a risk of injury to the sciatic
nerve, if it is given in the buttock. Unlike the present practice of
administering two injectable vaccines (DPT and Hep.B) in the
same clinic session, where it is advised that the two injections
are administered in different sites/thighs, in Pentavalent there is
no special concern of which side/site to be used. However, it is
advisable to use the left thigh/deltoid muscle to maintain a
uniform practice.
Storage:Pentavalent vaccine should be stored and transported
o

between 2 C to 8 C. It should not be frozen. Hence this vaccine

should never be stored in the freezer and should preferably be
kept in the middle shelf of the main compartment of the
refrigerator in all places. While transporting the vaccine vials
should not be kept in contact with ice in vaccine carriers and
936

20. Immunological Preparations

during clinic sessions Pentavalent vials should not be kept in

contact with ice.
Pneumoccocal Polysaccharide Vaccine
Injection, 0.5ml
Indications: people at risk of developing serious pneumococcal
infection, such as patients with chronic cardiac or pulmonary
disease, and with illnesses or conditions known to predispose to
pneumoccal infection (such as sickle cell disease, nephritic
syndrome, previous splenectomy, multiple myeloma and
Hodgkin's disease); also in immunocompromised patients,
including those with HIV infection.
Contraindications: pregnancy, active infection and children
under 2 years old.
Side effects: transient, local pain and erythematic at the
injection site, fever may occur occasionally.
Dose and Administration:SC or IM, 0.5 ml.
Storage: store in refrigerator at 2- 8oC.
Poliomyelitis Vaccines
Poliomyelitis is an acute viral infection spread by the faecal-oral
route, which can cause paralysis of varying degree. There are
two types of vaccine against poliomyelitis: oral and injectable.
Oral poliomyelitis vaccine (OPV) is composed of three types of
live attenuated poliomyelitis viruses.
Poliomyelitis vaccine, Trivalent
Types I, II, III
Oral suspension, 0.5 ml, 10ml and 20 ml.
Indications: active immunization against Poliomyelitis.
Cautions: pregnancy
Drug interactions: asparginase, azathioprine, ciclosporin,
immunoglobulin.
937

20. Immunological Preparations

Contraindications: patients with diarrhea or vomiting; food

which contains a preservative.
Side effects: rarely, vaccine-associated poliomyelitis in
recipients of vaccine and contacts of recipients.
Dose and Administration:Oral:Adult:Primary immunization of
unimmunized adults: 3 doses each of drops with an interval of at
least 4 weeks between each dose.Reinforcing immunization: 3
drop 10 years after completion of primary course.Child:Primary
immunization: 3 drops at birth and at 6, 10 and at 14 weeks of
age.Reinforcing immunization: 3 drops at least 3 years after
completion of primary course and a further 3 drops at 15 - 19
year of age.
Storage: store between 2-8 oC or in the frozen state.
Rabies Antiserum, Equine
Injection, 200 units in 5ml
Indications: rabies antiserum, equine is used to provide passive
immunization to Rabis in patients who have received bites from
rabid animals or animals suspected of being rabid.
Cautions: as for antisera in general; caution should be taken in
allergic patients. The patient must be kept under observation
after the administration of full doses of antisera and adrenaline
injection kept in readiness for emergency use.
Side effects: as for antisera in general; nephritis, myocarditis,
polyarthritis, neuritis and ureitis.
Dose and Administration: usual dose 40 units per kg of body
weight given at the same time, but at different sites, as the first
dose of a Rabis vaccine. It has been recommended that 50% of
the dose should be administered by local infiltration at the site
of the wound and the remainder given by IM injection unless the
wound involves mucous membranes when the entire dose
should be given intramuscularly.
938

20. Immunological Preparations

Storage: between 2o and 80C.

Rabies Vaccine
Injection, 100 ml in vial
Indications: for active immunization against rabies. They are
given, with rabies immunoglobulin or antisera, for post
exposure treatment to patient who have been bitten by rabid
animals or animals suspected of being rabid. They are also used
for pre-exposure prophylaxis against rabies in persons at high
risk of exposure to rabies vaccine.
Cautions: as for vaccines in general; see notes above.
Note: when this vaccine is injected into the gluteal region, there is a
poor response. Concomitant administration of chloroquine may also
affect the antibody response. Because of the potential consequences
of inadequately treated rabies exposure and because there is no
indication that fetal abnormalities have been associated with rabies
vaccination, pregnancy is not considered a contraindication to post
exposure prophylaxis. If there is substantial risk of exposure to
rabies, pre-exposure prophylaxis may also be indicated during
pregnancy.

Side effects: as for vaccines in general, see notes above; and

patients may experience pain, eurhythmic, and in duration at the
injection site after the use of any type of rabies vaccine; nausea,
headache, fever, malaise, or myalgia may also
occur.Neuroparalytic and hypersensitivity reactions have been
associated with the vaccines derived from animal nerve tissues
or duck embryos.
Dose and Administration: Prophylactic: deep SC or IM
injection in the deltoid region, 1 ml on days 0, 7, and 28; also
booster doses every 2 3 years to those continued risk.
Storage: store at 2o to 8oC, not be allowed to freeze, and be
protected from light. Under these conditions it may be expected to
retain its potency for at least 2 years.
939

20. Immunological Preparations

Rabies Vaccine, Duck Embryo

Injection; 100 ml in vial
See under Rabies vaccine
Dose Administration: Prophylactic,IM injection in the deltoid
muscle or anterolateral thigh in small children, 1 ml on days 0,7
and 21 or 28; also booster doses every 2 - 5 years for those at
continued risk.Post exposure, IM injection in the deltoid muscle
or anterolateral thigh in small children, 1ml.
Storage: store at 2o to 8oC.
Rabies (Human diploid cell) vaccine
Injection, 2.5IU/ml
Indications: rabies human diploid cell vaccine is used for active
immunization against rabies. They are used as a part of post
exposure treatment, for the prevention of rabies in patients who
have been bitten by rabid animals or animals suspected of being
rabid.
Cautions: as for vaccine in general; the vaccine should be
administered with caution in patients with a history of allergic
disorders or who have exhibited previous systemic allergic
reaction to human diploid cell vaccine.
Drug interactions: rabies immunoglobulin, antimalarial agents,
corticosteroids immuno suppressive agents.
Side effects: as for vaccine in general; pain, erythema and
induration at injection site, pruritis, nausea, headache, fever.
Dose and Administration:For post exposure therapy: deep SC
or IM: 6 doses of human diploid cell vaccine, each of 1ml on
days 0,3,7,14, 30 and 90.
For pre-exposure prophylaxis against rabis:IM or ID: 2 doses
of human diploid cell vaccine given 4 weeks apart with a third
dose after 12 months, either 1ml may be given by deep SC or
IM injection or 0.1ml ID. Booster doses should be given every 1
to 3 years depending upon the risk of exposure.
940

20. Immunological Preparations

Storage: between 2o and 80C.

Rota Virus Vaccine Monovalent (P1 [8], G1]), Bivalent,
Pentavalent (G1, 2, 3, 4, 5 and P1 [8])
Oral solution, 2ml
Indications: immunization against gastro-enteritis caused by
rotavirus
Cautions: see notes above, also diarrhoea or vomiting
vaccination);
immunosuppressed.
(postpone
Contraindications: see notes above, also predisposition to, or
history of intussusceptions.
Scorpion Venom Antisera (Scorpion Antivenom)
Injection, 0.5ml
Indications:to neutralize the venom of one or more species of
scorpion
Cautions: allergic to the antivenin, sensitivity testing should be
preformed.
Side effect: as for antisera in general; urticaria, nephritis,
myocarditis, polyarthritis, neuritis, ureitis.
Dose and Administration: The use of a scorpion antiserum
suitable for the species of scorpion can prevent symptoms
provided it is done with the least possible delay, other general
supportive measures may also be needed. The volume stated on
the label as the dose, should preferably be made directly into the
site of the sting but if this cannot be done, as much as possible
should be injected into the site and the remainder
intramuscularly into a convenient proximal position.
Snake Venom Antiserum Polyvalent
Injection, 10ml
Indications: antivenin (crotalidae) polyvalent neutralizes
absorbed venom of crotalid snakes (pit vipers), including the
rattlesnake, copperhead, water moccasin and tropical and asiatic
941

20. Immunological Preparations

crotalids, and is used to prevent or minimize the effects of

poisoning by these snakes.
Cautions: in people who have been snake-bitten if they have a
history of asthma hay fever, urticaria, or other allergic
manifestation. Intradermally sensitivity testing should be
performed before administration.
Side effect: as for antisera in general; itching, edema of the
face, tongue and throat, cough, vomiting, cardiovascular
collapse.
Dose and Administration: For IV infusion, a 1:1 to 1:10
dilution of reconstituted antivenin in 0.9% sodium chloride or
5% dextrose injection is prepared. Usual dose IV infusion, 510ml of diluted antivenin, infused over 3-5 minutes with careful
observation of the patient.
Tacrolimus
Capsule, 500mcg, 1mg, 2mg, 5mg Infusion, 5mg/ml
Indications: prophylaxis of organ rejection in liver, kidney, and
heart allograft recipients and allograft rejection resistant to
conventional immunosuppressive regimens, moderate to severe
atopic eczema
Cautions: pregnancy; see under Cyclosporin A (section 19);
also monitor ECG (important: also echocardiography, visual
status, blood glucose, haematological and neurological
parameters and whole-blood trough concentrations (especially
during episodes of diar rhoea); prolonged QT interval; hepatic
impairment; if contraception needed non-hormonal methods
should be used.
Drug interactions: NSAIDs; Angiotensin-II Receptor
Antagonists: Antibacterials: (.clarithromycin; rifampicin;
aminoglycosides;chloramphenicol
and
vancomycin);
Antidepressants; Antiepileptics; Antifungals
(uconazole,
itraconazole, ketoconazole and .voriconazole; amphotericin;
942

20. Immunological Preparations

imidazoles and triazoles); Antipsychotics: droperidol;

Antivirals: aciclovir or ganciclovir; atazanavir, nelnavir and
ritonavir; efavirenz; saquinavir; Barbiturates:phenobarbital;
Calcium-channel Blockers: felodipine, nicardipine and
verapamil ; diltiazem and nifedipine; Cyclosporin; potassiumsparing diuretics and aldosterone antagonists; Hormone
Antagonists: ethinylestradiol; Potassium Salts; Progestogens;
omeprazole
Contraindications: hypersensitivity to macrolides; breastfeeding; avoid concurrent administration with cyclosporin A
(care if patient has previously received cyclosporine A)
Side effects:For Kidney Transplant Patients:infection,
headache, tremors, diarrhea, constipation, nausea, high blood
pressure, changes in the amount of urine, and trouble sleeping.
For Liver Transplant Patients: headache, tremors, diarrhea,
high blood pressure, nausea and changes in the amount of urine.
Dose and Administration:Liver transplantation: Adult:
starting 12 hours after transplantation, by mouth, 100200
micrograms /kg daily in 2 divided doses or by intravenous
infusion over 24 hours, 1050 micrograms /kg daily for up to
max. 7 days (then transfer to oral therapy); CHILD: by mouth,
300 micrograms/kg daily in 2 divided doses or by intravenous
infusion over 24 hours, 50 microgram s/kg daily for up to max.
7 days (then transfer to oral therapy).
Renal transplantation: Adult: starting within 24 hours of
transplantation, by mouth, 200300 micrograms /kg daily in 2
divided doses or by intravenous infusion over 24 hour s, 50100
microgram s/kg daily for up to max. 7 days (then transfer to oral
therapy); CHILD: by mouth, 300 micrograms/kg daily in 2
divided doses or by intravenous infusion over 24 hour s, 75100
micrograms/kg daily for up to max. 7 days (then transfer to oral
therapy).
943

20. Immunological Preparations

Heart transplantation (with or without antibody induction):

starting within 5 days of transplantat ion, by mouth , 75
microgram s/kg daily in 2 divided doses or by intravenous
infusion over 24 hours, 1020 micrograms /kg daily for up to
max. 7 days (then transfer to oral therapy); child, without
antibody induction, initially by intravenous infusion over 24
hour s, 3050 micrograms /kg daily, then by mouth, 300
microgram s/kg daily in 2 divided dose s as soon as clinically
possible (give 812 hours after discontinuing intravenous
infusion); following antibody induction, by mouth, 100300
micrograms /kg daily in 2 divided doses.
Storage:store at 20-25C.
Tetanus Antitoxin, Equine
Injection, 1500 units, 3000 units, 20,000 units
Indications: tetanus antitoxin, equine is indicated for temporary
passive immunization against tetanus and also to prevent tetanus
infection that arise from the toxins produced by Clostridium
tetani.
Cautions: allergic to the antitoxin. For this sensitivity testing
should be performed.
Side effects: Anaphylaxis (with hypotension, dyspnoea,
urticaria, shock), serum sickness (fever, vomiting, diarrhoea,
bronchospasm, urticaria).
Dose and Administration:Adult: prophylaxis after injury of
non-immune or partially immune persons: SC, or IM: 3000 5000 units of tetanus antitoxin.
Treatment of established tetanus: 50,000 - 100,000 units part of
which is administered by IV injection with the remainder being
given intramuscularly.
Tetanus Immune-Human Globulin
Injection, 3000 units
944

20. Immunological Preparations

Indications:for passive immunization against tetanus.

Note:The use of tetanus immunoglobulins is recommended as part of
the management of tetanus-prone wounds in persons unimmunized or
incompletely immunized against tetanus, in persons whose
immunization history is unknown, and in persons who received the
last dose of tetanus vaccine more than 10 years previously.

Cautions: as for immunoglobulin in general; tetanus

immunoglobulins should not be injected in to the same site or in
the same syringe.
Contraindications and Side effects; see notes under general
description above.
Dose and Administration: The usual dose of tetanus
immunoglobulin is 250 units by intramuscular injection but if
more than 24 hours have elapsed since the wound was
sustained, if there is a risk of heavy contamination, or following
burns 500 units should be given irrespective of the
immunization history.Tetanus immunoglobulin is also used in
the treatment of tetanus, a recommended dose being 150 units
per kg body-weight given intramuscularly in to different
sites.Note: The pediatric dose is the same as for adults. Alternatively,
in children younger than 7 years of age, tetanus immunoglobulin can
be given in doses of 4 units per kilogram of body weight.

Storage: store between 2 and 8oc. Do not freeze.

Tetanus Toxoid
Injection, 0.5 ml, 1ml
Indications: active immunization against tetanus and neonatal
tetanus; wound management (tetanus - prone wounds and clean
wounds).
Cautions: patients on anticoagulants.
Drug interactions: anticoagulants, corticosteroids.
Contraindications: hypersensitivity to tetanus toxoid.
945

20. Immunological Preparations

Side effects: hypotension, fever, rash, urticaria, nausea, local

(edema, redness, warmth), arthralgia.
Dose and Administration:Unimmunized patients: IM, 2 doses
of 0.5ml, 6 8 weeks apart. A third dose is recommended 6 -12
months after the second dose, and is essential when tetanus
immunoglobulin was given at the time of the first injection. In
these cases the interval between the first and second doses
should be reduced to 4 weeks.A booster should be given every
10 years, or following an injury.
Storage: store in refrigerator at 2-8 oC.
Yellow fever Vaccine
Injection, 500LD, 50 Doses
Indications: active immunization against yellow fever.
Cautions: pregnancy.
Contraindications: infants under 6 months of age;
hypersensitivity to any antibiotic present in vaccine and egg.
Side effects: rarely encephalitis, generally in infants under 9
months.
Dose and Administration: Child 9 months and Adult: SC:
one dose (0.5ml). Infant 6-9 months of age: 0.5ml, only if risk
of yellow fever is unavoidable.
Booster: Every 10 years.
Storage: store at a temperature between 0- 5 oC. Do not freeze.

946

21. Miscellaneous

21. MISCELLANEOUS
Aluminum Sulphate + Calcium Hypochlorite + Sodium
Carbonate
Water treatment powder in the ratio of 23:1:1 by weight
Indications: used as a disinfectant in water.
Anticoagulant Citrate Dextrose solution (ACD Solution)
Sodium Citrate + Citric Acid + Dextrose
Solution, 1.32g +0.44g +1.47g
Barium Sulfate
Powder in Sachet
Indications: use as a contrast medium in x-ray photography of
the digestive tract.
Contraindications: in patients with known or suspected
obstruction of the colon, known or suspected gastrointestinal
tract perforation, suspected tracheoesophageal fistula,
obstructing lesions of the small intestine, pyloric stenosis or
known hypersensitivity to barium sulfate formulations.
Side effects: Constipation, cramping, diarrhea
Storage: Store at room temperature and Keep out of reach of
children.
Calcium Hypochlorite+IronSulphate+ Bentonite+Potassium
Permanganet Polyacrylamide + Sodium Carbonate
Water treatment Powder
Indications: used as a disinfectant in water.
Dicophane (DDT)
Dusting Powder, 10%
It is an effective pediculocide. Its prolonged residual effect
makes it lethal to the larva which hatches out later.
Formaldehyde Solution
947

21. Miscellaneous

Solution, 3%, 8% (w/w, v/v)

Indications: It is a disinfectant active against bacteria, fungi,
and many viruses, with a slow action against bacterial spores. It
is used for the disinfection of the blankets, bedding, and
membranes in dialysis equipment.
Cautions and Side effects: Ingestion of formaldehyde solution
causes intense pain, with inflammation, ulceration, and necrosis
of mucous membranes. There may be vomiting, haematemesis,
blood-stained diarrhoea, haematuria, and anuria; metabolic
acidosis, vertigo, convulsions, loss of consciousness, and
circulatory failure may occur. Death has occurred after the
ingestion of the equivalent of about 30ml of formaldehyde
solution. If the patient survives 48 hours, recovery is probable.
Formaldehyde vapour is irritant to the eyes, nose, and upper
respiratory tract, and may cause coughing, dysphagia, spasm
and oedema of larynx, bronchitis, pneumonia, and rarely,
pulmonary oedema. Asthma has been reported after repeated
exposure.
Storage: at temperature between 15 and 25oc in airtight
containers. Avoid contact with plastics.
Gadodamide
Injection 0.5mmol/ml
Indication: It is a gadolinium-based MRI contrast agent, used
to diagnose problems in the brain, spine, chest, stomach, hip
area, and other parts of the body.
Cautions: In patients with history of asthma, infection, kidney
or liver impairment, seizures, diabetes, high blood pressure, any
allergy, during pregnancy and breastfeeding.Note: It may cause
dizziness or lightheadedness, do not drive a car or operate machinery
while taking this medication. Patient may develop with increased risk
of nephrogenic systemic fibrosis (NSF), if it is so consult with your
healthcare provider.
948

21. Miscellaneous

Contra-indications: Hypersensitivity to the medicine and in

patient with severe kidney disease.
Side-effects: Nausea, headache and dizziness.
Dose and Administration: CNS Adults: The recommended
dose is 0.2 ml/kg (0.1mmol/kg) administered as a bolus
intravenous injection. The recommended dose is 0.1 ml/kg
(0.05mmol/kg).
Storage: Store at room temperature (20-25C).
Glutaraldehyde
Solution, 2%
Indications: It is a bactericidal disinfectant which is rapidly
effective against Gram-positive and Gram-negative bacteria. It
is also effective against mycobacterium tuberculosis, some
fungi, and viruses, including hepatitis B virus and HIV, and is
slowly effective against bacterial spores.
Side effects: as for Formaldehyde solution.
Glycine
Bladder irrigation solution, 1.5%
Indications: used as urogenital irrigation solutions during
certain surgical procedures, particularly transurethral resection
of the prostate.
Cautions: hepatic and renal impairment, cardiopulmonary.
Contraindications: anuric patients.
Side effects: systemic absorption of glycine irrigation solutions
can lead to disturbances of fluid and electrolyte balance and
cardiovascular and pulmonary disorders.
Halazone
Tablet, 4mg
Indications: Halazone is a disinfectant with the general
properties of chlorine in aqueous solution and is used for the
949

21. Miscellaneous

disinfection of drinking water. One tablet containing 4mg of

Halazone, stabilized with sodium carbonate and sodium
chloride, is sufficient to treat about a litre of water in about 30
minutes to 1hour, more being required for heavily contaminated
water. The taste of residual chlorine may be moved by adding
sodium thiosulphate.
Storage: in airtight containers. Protect from light.
KY Jelly (Hydroxyethyl cellulose)
Indications: It is present in lubricant preparations, some of
which are used as artificial tears in ocular disorder or dry eye.
Iodized Salt
Indications: prevention and treatment of iodine deficiency.
Cautions: those over 45 years old or with nodular goiter
(especially susceptible to hyperthyroidism when given iodine
supplements); pregnancy
Side effects: hypersensitivity reactions; goiter and
hypothyroidism; hyperthyroidism
Oxidized Cellulose
Indications: Oxidized cellulose is absorbable haemostatics,
when applied to bleeding surface; it swells to form a gelatinous
mass that is gradually absorbed by the tissues, usually within 2
to 7 days. Complete absorption of large amounts of such
material may take 6 weeks or more.
Cautions: Oxidized cellulose should not be used as a surface
dressing, except for immediate control of bleeding, as it inhibits
epitheliasation. It should not be used for packing or implantation
in bone surgery
Drug interactions: silver nitrate or other escharotic chemicals
should not be applied prior to use as cauterization might inhibit

950

21. Miscellaneous

absorption of oxidized cellulose. It should not be impregnated

with other haemostatic or antibiotics.
Contraindication: use should be avoided in infected wounds.
Side effects: foreign body reaction, headache, burning, stinging,
sneezing.
Dose and Administration: the guaze, lint or knitted material
should be laid on the bleeding surface or held firmly against the
tissue until haemostasis is achieved. Removal of excess
oxidized cellulose should then be considered.
Oxygen (white-colored cylinder)
Indications: oxygen is given by inhalation to correct hypoxia in
conditions causing under ventilation of the lungs, such as
exacerbations of chronic bronchitis, pneumonia, or pulmonary
oedema, where bronchospasm causes hypoxia, as in asthma, in
extensive fibrosing alveolitis after general anaesthesia and in
conditions where the oxygen content of the air breathed is
inadequate as at high altitudes.
Cautions: any fire or spark is highly dangerous in the presence
of increased oxygen concentrations especially when oxygen is
used under pressure.
Metal cylinders containing oxygen should be fitted with a
reducing valve by which the rate of flow can be controlled.
Side effects: CNS, toxicity (nausea, mood change, vertigo,
twitching, convulsions, loss of consciousness), pulmonary
toxicity (decrease in vital capacity, cough, substernal distress,
and later atelectasis), retinopathy of prematurity.
Dose and Administration: by inhalation. It is administered by
means of nasal catheter, facemask, endotracheal tube, or oxygen
tent. Concentration of oxygen in inspired anesthetic gases
should never be less than 21 % sideline (carbondioxide
absorbent).
951

21. Miscellaneous

Saccharin
Tablet
Indications: Saccharin and its salts (sodium, calcium, and
potassium) are intense sweeteners being several hundred times
sweeter than sucrose and are used as food additives and artificial
sweetener for diabetes. The salts are more often used as they are
considered to be the most palatable.
Side effects: allergic and photosensitivity reaction.
Dose and Administration: 5mg per kg of saccharine salt taken
daily.
Sodium Chloride Free Salt
Indications: treatment of extracellular volume depletion and
sodium depletion
Cautions: Sodium chloride should be used with extreme
caution, if at all, in patients with hypertension, congestive heart
failure, or other edematous or sodium-retaining conditions, in
patients with liver cirrhosis and in patients receiving
corticosteroids or corticotropin. Particular caution is necessary
in geriatric and post-operative patients.
Contraindications: sodium chloride is contraindicated in
patients with conditions in which administration of sodium and
chloride is detrimental.
Side effects: nausea, vomiting, diarrhoea, abdominal cramps,
thirst, reduce salivation and lachrymation, sweating, fever,
tachycardia, hypertension, renal failure, peripheral and
pulmonary oedema, respiratory arrest, headache.
Dose and Administration:Oral: 1-2 gm 3 times daily
depending on individual needs either with food or as a solution;
doses of up to 12g daily may be necessary in severe cases.

952

21. Miscellaneous

Sodium Dichloroisocyanurate
Tablet, 67mg, 75mg
Indications: used as a disinfectant in water. It dissociates in
water to form a number of chemical species, notably free
chlorine and cyanuric acid.
Cautions: Harmful if swallowed, contact with the skin or eyes,
or if inhaled. Do not expose the product to flames, do not mix
with detergents
Storage: Store in a dry, well-ventilated area.
Sorbitol
Indications: Sorbitol is used in limited quantities either as a
sweetening agent or as a source of carbohydrate in diabetic food
products. It is also used as a sweetening agent instead of sucrose
in many sugar-free oral liquid preparations and in sugar freepreparation of dental caries.
Cautions: impaired kidney function or severe liver damage.
Side effects: flatulence, abdominal pain, diarrhoea, and lactic
acidosis hyperuricemia.
Storage: store in airtight container.
Supportive hepatic preparations that contain Essential
Phospholipids and Vitamins
Water for injections
In 2ml, 5ml, 10ml
Water for injection is distilled water free from pyrogens used to
produce solutions for injections.

953

GLOSSARY

Abstinence syndrome: symptoms that occur if a drug causing

physical or psychological dependence is suddenly discontinued
Active immunity: occurs when the person is exposed to a disease and
develops the disease, and the body makes antibodies toprovide future
protection against the disease
Addiction: a compulsive desire or craving to use a drug or chemical
with a resultant physical dependence
Adrenergic drug: a drug that acts like or mimics the actions of
thesympathetic nervous system
Aerobic: organisms that require oxygen to live
Agonist: drug that binds with a receptor to produce a therapeutic
response
Agonist-antagonist: drug with both agonist and antagonist properties
Agranulocytosis: a decrease or lack of granulocytes (type of white
bloodcell)
Aldosterone: hormone secreted by the adrenal cortex and
contributing to a rise in blood pressure
Alopecia: abnormal loss of hair; baldness
Amenorrhea: absence or suppression of menstruation
Anaerobic: organisms that do not require oxygen to live
Analgesic: a drug that relieves pain
Anaphylactic reaction: a sudden, severe hypersensitivity reaction
with symptoms that progress rapidly and may result in death if not
treated
Anemia: a decrease in the number of red blood cells and hemoglobin
value below normal
Androgens: testosterone and its derivatives
Angina pectoris (angina): acute pain in the chest resulting from
decreased blood supply to the heart muscle
Angioedema: localized wheals or swellings in subcutaneous tissues
or mucous membranes, which may be due to an allergic response; also
called angioneurotic edema anorexia: loss of appetite
Anorexiant: a drug used to suppress the appetite
954

Antagonist: drugs that join with a receptor to prevent the action of

anagonist
Anthelmintic: a drug used to treat helminthiasis (worms)
Antibacterial: active against bacteria
Antibody: molecule with the ability to bind with a specific antigen
responsible for the immune response
Antiemetic: drug that is used to treat or prevent nausea
Antiflatulent: drug that works against flatus (gas)
Antigen: substance that is capable of inducing a specific immune
response
Anti-infective: a drug used to treat infection
Antipsoriatics: drugs used to treat psoriasis
Antipyretic: a drug that lowers an elevated body temperature
Antiseptic: an agent that stops or slows, or prevents the growth of
microorganisms
Anxiolytics: term used to describe the antianxiety drugs
Aplastic anemia: a blood disorder caused by damage to the bone
marrow resulting in a marked reduction in the number of red blood
cells and some white blood cells
Arrhythmia: abnormal heart rate or rhythm; also called dysrhythmia
Asthenia: weakness; loss of strength
Ataxia: unsteady gait; muscular incoordination
Atherosclerosis: a disease characterized by deposits of fatty plaques
on the inner walls of arteries
Atrial fibrillation: quivering of the atria of the heart
Attenuate: weaken
Aura: sense preceding a sudden attack, as in the aura that occurs
before a convulsion
Auscultation: the process of listening for sounds within the body
Autonomic nervous system: a division of the peripheral nervous
system concerned with functions essential to the life of the organism
and not consciously controlled (ie, blood pressure, heart rate,
gastrointestinal activity)

955

Azotemia: retention of excessive amounts of nitrogenous compounds

in the blood caused by failure of the kidney to remove urea from the
blood
Bactericidal: a drug or agent that destroys or kills bacteria
Bacteriostatic: a drug or agent that slows or retards the multiplication
of bacteria
Biliary colic: pain caused by the pressure of passing gallstones
Bloodbrain barrier: ability of the nervous system to prohibit large
and potentially harmful molecules form crossing into the brain
Bone marrow suppression: a decreased production of all blood cells
Booster: an immunogen injected following a specified interval; often
after the primary immunization to stimulate and sustain the immune
response
Bradycardia: slow heart rate, usually at a rate below 60 beats per
minute
Bronchospasm: spasm or constriction of the bronchi resulting in
difficulty breathing
Bulla: blister or skin vesicle filled with fluid
Bursa: pad-like sac found in connecting tissue usually located in the
joint area
Candidiasis: infection of the skin or mucous membrane with the
species Candida
Cardiac output: amount of blood discharged from the left or right
ventricle per minute
Central nervous system: one of two main divisions of the nervous
system consisting of the brain and spinal cord
Cervical mucorrhea: increased cervical discharge
Cheilosis: cracking of the edges of the lips
Chemoreceptor trigger zone: a group of nerve fibers located on the
surface of the fourth ventricle of the brain that, when stimulated,
results in vomiting
Chemotherapy: drug therapy with a chemical, often used when
referring to treatment with an antineoplastic drug
Cholesterol: a fat-like substance produced mostly in the liver of
animals
956

Cinchonism: quinidine toxicity or poisoning

Conjunctivitis: inflammation of the conjunctiva (mucous membrane
lining the inner surfaces of the eye)
Convulsions: paroxysm (occurring suddenly) of involuntary muscular
contractions and relaxations
Crohns disease: inflammation of the terminal portion of
The ileum
Cross-allergenicity: allergy to drugs in the same or related groups
Cross-sensitivity: see cross allergenicity
Crystalluria: formation of crystals in the urine
Cumulative drug effect: occurs when the body is unable to
metabolize and excrete one dose of a drug before the next dose is
given
Cushings syndrome: a disease caused by the overproduction of
endogenous glucocorticoids
Cyanosis: bluish, grayish, or dark purple discoloration of the skin due
to abnormal amounts of reduced hemoglobin in the blood
Cycloplegia: paralysis of the ciliary muscle resulting in an inability to
focus the eye
Cytomegalovirus (CMV): any of a group of herpes viruses infecting
man, monkeys, or rodents; the human CMV is found in the salivary
glands and causes cytomegalic inclusion disease
Debridement: removal of all foreign material and dead or damaged
tissue from a wound or infected lesion
Delirium tremens: signs and symptoms of withdrawal from a drug or
chemical including tremors, weakness, anxiety, restlessness, excessive
perspiration, nausea, and vomiting
Diabetes insipidus: a disease resulting in the failure of the pituitary to
secrete vasopressin or from the surgical removal of the pituitary gland
Diaphoresis: increased sweating or perspiration
Digitalization: administration of digitalis at intervals to produce and
maintain a therapeutic blood level
Diluent: a fluid that dilutes
Diuretic drug: drug that produces urine secretion
Dyskinesia: impairment of voluntary movement
957

Dyspnea: labored or difficult breathing

Dystonia: prolonged muscle contractions that may cause twisting and
repetitive movements of abnormal posture
Dysuria: painful or difficult urination
Edema: accumulation of excess water in the body
Emetic: drug that induces vomiting
Endogenous: normally occurring within the organism
Epilepsy: a permanent, recurring seizure disorder
Epiphysis: a center of ossification (conversion of tissue to bone) at
each extremity of long bone
Epistaxis: nosebleed
Erythrocytes: red blood cells; one of several formed elements in the
blood
Escherichia coli: a nonpathogenic colon bacillus; when found outside
of the colon may cause infection
Estrogens: female hormones
Exacerbation: increase in severity
Exfoliative dermatitis: reddish rash in which scaling occurs
following the erythema
Exogenous: normally occurring outside of the organism or
community
Expectorant: drug that aids in raising thick, tenacious mucus from
the respiratory tract
Extrapulmonary: occurring outside of the respiratory systems (ie,
lungs)
Extrapyramidal effects: a group of adverse reactionsoccurring on
the extrapyramidal portion of the nervous system causing abnormal
muscle movements, akathisia and dystonia
Extravasation: escape of fluid from a blood vessel intosurrounding
tissue
Fibrolytic: term used to describe a drug that dissolves clots already
formed within the vessel walls
Germicide: an agent that kills bacteria
Gingival hyperplasia: overgrowth of gum tissue
Gingivitis: inflammation of the gums
958

Glaucoma: a group of diseases of the eye characterized by increased

intraocular pressure; results in changes within the eye, visual field
defects, and eventually blindness (if left untreated)
Globulin: proteins that are insoluble in water and present in the
plasma
Glossitis: inflammation of the tongue
Goiter: enlargement of the thyroid gland causing a swelling in the
front part of the neck, usually caused by a lack of iodine in the diet
Gonadotropin: hormone that stimulates the sex glands(gonads)
Gonad: glands responsible for sexual activity and characteristics
Granulocytopenia: a reduction or decrease in the number of
granulocytes (a type of white blood cell)
Gynecomastia: breast enlargement in the male
Habituation: a desire to continually use a drug or chemical for the
desired effect with no physical dependence but some psychological
dependence
Hallucinogen: drug capable of producing a state of delirium
characterized by visual or sensory disturbances
Helminthiasis: invasion by helminths (worms)
Hemolytic anemia: disorder characterized by chronic premature
destruction of red blood cells
Herb: plant used in medicine or as seasoning
High-density lipoproteins (HDL): macromolecules that carry
cholesterol from the body cells to the liver to be excreted
Hirsutism: excessive growth of hair or hair growth in unusual places,
usually in women
Histamine: a substance found in various parts of the body (ie, liver,
lungs, intestines, skin) and produced in excess in response to a
substance to which the body is sensitive
Humoral immunity: antibody-mediated immune response of the
body
Hyperglycemia: high blood glucose (sugar) level
Hyperinsulinism: elevated levels of insulin in the body
Hyperkalemia: increase in potassium levels in the blood
Hyperlipidemia: an increase in the lipids in the blood
959

Hypersensitivity: allergic reaction to a drug orothersubstance

Hypertension: high blood pressure
Hypnotic: drug that induces sleep
Hypoglycemia: low blood glucose (sugar) level
Hypoinsulinism: low levels of insulin in the body
Hypokalemia: low blood potassium level
Hyponatremia: low blood sodium level
Hypotension: abnormally low blood pressure
Hypotension, orthostatic: a decrease in blood pressureoccurring
after standing in one place for an extended period
Hypotension, postural: a decrease in blood pressure after a sudden
change in body position
Hypoxia: inadequate oxygen at the cellular level
Idiosyncrasy: unusual or abnormal drug response
Immunocompromised: having a immune system incapable
of fighting an infection
Infiltration: the collection of fluid into tissue
Intraocular pressure: the pressure within the eye
Iritis: inflammation of the iris of the eye
Jaundice: yellow discoloration of the skin
Keratolyte: an agent that removes excessive growth of theEpidermis
(top layer of skin)
Ketoacidosis: a type of metabolic acidosis caused by an accumulation
of ketone bodies in the blood
Ketonuria: presence of ketones in the blood
Laryngospasm: spasm of the larynx resulting in dyspnea andnoisy
respirations
Lethargic: sluggish, difficult to rouse
Leukopenia: a decrease in the number of leukocytes (white blood
cells)
Lipids: a group of fats or fat-like substances
Lipodystrophy: atrophy of subcutaneous fat
Low-density lipoproteins (LDL): macromolecules thatcarry
cholesterol from the liver to the body cells
Lumen: inside diameter, the space/ opening within an artery
960

Lupus erythematosus: A chronic inflammatory connective tissue

disease affecting skin, joints, kidneys, nervous system, and mucous
membranes. A butterfly rash or erythema may be seen on the face,
particularly across nose
Malaise: discomfort, uneasiness
Megacolon: dilatation and hypertrophy of the colon
Megaloblastic anemia: anemia characterized by the presence of
large, abnormal, immature erythrocytes circulating in the blood
Melasma: discoloration of the skin
Melena: blood in the stools
Merozoites: cells formed as the result of asexual reproduction
Methemoglobinemia: clinical condition in which more than 1% of
hemoglobin in the blood has been oxidized to the ferric form
Micturition: voiding of urine
Miosis: constriction of the pupils
Mucolytic: drug that loosens and thins respiratory secretions (lessens
the viscosity of the secretions)
Myasthenia gravis: condition characterized by weakness and
fatigability of the muscles
Mycotic: pertaining to a fungus or fungal infection
Mydriasis: dilation of the pupil
Myocardial infarction: heart attack
Myopia: nearsightedness
Myxedema: condition caused by hypothyroidism or deficiency of
thyroxine and characterized by swelling of the face, periorbital
tissues, hands, and feet.
Narcolepsy: a chronic disorder that results in recurrent attacks of
drowsiness and sleep during daytime
necrosis: death of tissue (as adjective, necrotic)
Nephrotoxic: harmful to the kidney
Nephrotoxicity: damage to the kidneys by a toxic substance
Neurohypophysis: posterior lobe of the pituitary gland
Neuroleptic: drug that causes altered state ofconsciousness(ie,
antipsychotic)
Neuromuscular blockade: acute muscle paralysis and apnea
961

Neurotoxicity: damage to the nervous system of a toxic substance

Neurotransmitter: chemical substances released at the nerve ending
that facilitate the transmission of nerve impulses
Neutropenia: abnormally small number of neutrophil cells (type of
white blood cell)
Objective data: information obtained by means of a physical
assessment or physical examination
Oliguria: a decrease in urinary output
Ophthalmic: pertaining to the eye
Opportunistic infection: infection resulting from MOs commonly
found in the environment, which normally do not cause an infection
unless there is an impaired immune system
Orthostatic hypotension: see hypotension, orthostatic
Osteomalacia: a softening of the bones
Osteoporosis: a loss of calcium from the bones, resulting in a
decrease in bone density
Otic: pertaining to the ear
Ototoxic: harmful to the ear
Ototoxicity: damage to the organs of hearing by a toxic substance
Overt: not hidden, clearly evident
Oxytocic: agent that stimulates contractions of the uterus resulting in
labor
Palliative: therapy designed to treat symptoms, not to produce a cure
Pancytopenia: a reduction in all cellular elements of the blood
Paralytic ileus: paralysis of the bowel resulting in lack of movement
of the bowel contents
Parasite: an organism living in or on another organism (host) without
contributing to the survival or well-being of the host
Parenteral: administration of a substance, such as a drug, by any
route other than the oral route
Paresthesia: an abnormal sensation such as numbness, tingling,
prickling, or heightened sensitivity
Parkinsonism: referring to the symptoms of Parkinsons disease (ie,
fine tremors, slowing of the voluntary movements, and muscular
weakness)
962

Passive immunity: a type of immunity occurring from the

administration of ready-made antibodies from another individual or
animal
Pathogenic: disease producing
Peripheral: pertaining to the outward surface; away from the center
Petechiae: tine purple or red spots that appear on the skin as a result
of pinpoint hemorrhages within outer layers of the skin
Phenochromocytoma: tumor of adrenal medullacharacterized by
hypersecretion of epinephrine and norepinephrine
Phlebitis: inflammation of a vein
Phenylketonuria (PKU): a congenital disease due to a defect in the
metabolism of phenylalanine (an amino acid); results from the lack of
an enzyme necessary for the conversion of phenylalanine into
tyrosine; untreated, the condition leads to mental retardation
Photophobia: an aversion to or intolerance of light
Photosensitivity: exaggerated sunburn reaction when the skin is
exposed to sunlight or ultraviolet light
Physical dependence: compulsive need to use a substance repeatedly
to avoid withdrawal symptoms
Plasma expanders: IV solutions used to expand plasma volume with
shock due to burns, hemorrhage, or other trauma
Polydipsia: excessive thirst
Polyphagia: eating large amounts of food
Polypharmacy: taking a large number of drugs (may be prescribed or
over-the-counter drugs)
Prepubertal: before puberty
Progesterone: a female hormone produced by the corpus luteum that
works in the uterus (along with estrogen) to prepare the uterus for
possible conception
Progestins: natural and synthetic progesterones
Prophylaxis: prevention
Prostaglandins: a fatty acid derivative found in almost every tissue
of the body and body fluid that affects the uterus and other smooth
muscles; also thought to increase the sensation of peripheral pain
receptors to painful stimuli
963

Prostatic hypertrophy: abnormal enlargement of the prostate gland

Protein substrates: amino acids essential to life
Pruritus: itching
Pseudomembranous colitis: a severe, life-threatening form of
diarrhea
Psychological dependence: compulsion to use a substance to obtain a
pleasurable experience
Ptosis: drooping of the upper eyelid
Purpura: condition characterized by various degrees of
hemorrhaging into the skin and/or mucous membranes producing
ecchymoses (bruises) and petechiae (small red patches) on the skin
QT interval: is a measure of the time between the start of the Q wave
and the end of the T wave in the heart's electrical cycle
(depolarization and repolarization) of the left and right ventricles.
Dependent on the heart rate (the faster the heart rate the shorter the
QT interval). A lengthened QT interval is a biomarker for ventricular
tachyarrhythmias like torsades de pointes and a risk factor for sudden
death.
Remission: periods of partial or complete disappearance of signs and
symptoms
Retinitis: inflammation of the retina of the eye
Reyes syndrome: acute and potentially fatal disease of childhood;
associated with a previous viral infection
Rheumatic fever: a disease associated with a delayed response to a
prior streptococca infection in the body and characterized by fever
and pain in the joints
Rheumatoid arthritis: a type of arthritis marked by inflammation,
degeneration, and derangement of the joints and related structures
resulting in contractures and deformities of the joints
Rhinitis: inflammation of the nasal passages resulting in increased
nasal secretions
Sedative: a drug producing a relaxing, calming effect
Somatotropic hormone: growth hormone produced by the anterior
pituitary gland
Somnolence: prolonged drowsiness; sleepiness
964

Sprue: a disease characterized by weakness, anemia, weight loss, and

malabsorption of essential nutrients
Status epilepticus: an emergency situation characterized by continual
seizure activity
Stevens-Johnson syndrome: fever, cough, muscular aches and pains,
headache, and lesions of the skin, mucous membranes and eyes. The
lesions appear as red wheals or blisters, often starting on the face, in
the mouth, or on the lips, neck, and extremities.
Stomatitis: inflammation of the mouth
Sublingual: under the tongue
Sulfonylurea: a type of drug used to lower blood sugar in persons
with noninsulin-dependent diabetes
Superinfection: an overgrowth of bacterial or fungal microorganism
not affected by the antibiotic being administered
Sympathomimetic: acting like the sympathetic nervous system
Synergistic: a drug interaction occurring when two drugs interact to
produce an effect that is greater than the sum of their separate actions
Tachycardia: heart rate above 100 beats/minute
Tardive dyskinesia: rhythmic, involuntary movements of the tongue,
face, mouth, jaw, and sometimes the extremities
Testosterone: the most prominent male sex hormone that acts to
stimulate development of the male reproductive organ and the
secondary sex characteristics
Tetany: nervous condition characterized by sharp flexion of the wrist
and ankle joints, muscle twitching, cramps, and possible convulsions,
usually caused by abnormal levels of calcium, vitamin D, and
alkalosis
Thrombocytopenia: low platelet count
Thrombus: a blood clot (pl. Thrombi)
Thyroid storm: see thyrotoxicosis
Thrombocytopenia: low number of the platelets in the blood
Thyrotoxicosis: severe hyperthyroidism that is characterized by
symptoms such as high fever, extreme tachycardia, and altered mental
status (also called thyroid storm)
Tinnitus: ringing in the ears
965

Tolerance: decreased response to a drug, usually requiring an

increase in the dosage to give the desired effect
Tonic-clonic seizure: generalized seizure consisting of alternate
contraction (tonic) and relaxation of muscles (clonic)
Toxicity: poisonous or harmful
Toxoid: an attenuated toxin that is capable of stimulating the
formation of antitoxins
Transient ischemic attack (TIA): temporary interference with blood
supply to the brain causing symptoms related to the portion of the
brain affected (ie, temporary blindness, aphasia, dizziness, numbness,
difficulty swallowing or paresthesias); may last from a few moments
to several hours, after which no residual neurologic
Tyramine: substance found in most cheeses and in beer, bean pods,
yeast, wine, and chicken liver; individuals taking the antidepressant
MAOs and eating foods containing tyramine may experience severe
hypertension
Unlabelled (off-label or unapproved) Use: use of an approved
product in a scenario that is not included or is disclaimed in the
product information.
Urticaria: hives; itchy wheals on the skin resulting from contact with
or ingestion of an allergic substance or food
Uveitis: a nonspecific term for any intraocular inflammatory disorder
Vaccine: substance with either weakened or killed antigens developed
for the purpose of creating resistance to disease
Vasodilatation: an increase in the size of the blood vessels, which
when widespread results in a rise in blood pressure
Vertigo: a feeling of a spining or rotation-type motion
Vitamin: organic substance needed by the body in small amounts
fornormal growth and nutrition

966

APPENDIXES
APPENDIX I: Medicines Dose Calculation for Children
Age
Mean weight approximate % of
Age
Body weight (Kg)
Adult dose
Newborn (full term)
3.5
12.5
2 months
4.5
15
4 months
6.5
20
1 year
10
25
3 years
15
33.3
7 years
23
50
10 years
30
60
12 years
39
75
14 years
50
80
16 years
58
90
Adult
68
100
N.B.: The percentage method is derived from the surface area
formula for children. This table is to be used only for drugs with
a high therapeutic index. The clinical response of the child, ageor disease-related changes in drug clearance and any adverse
effects that might present should be given due consideration
when calculating doses.
Approximate Measures
1 teaspoonful = 5ml
1 dessertspoonful = 10ml
1 tablespoonful = 15ml
Drugs Formulary for Health Centers

967

APPENDIX II: Body Weight to Surface Area

968

APPENDIX III: Medicines Adverse Events

An adverse drug reaction (ADR) may be defined as any
response to a drug which is noxious, unintended and occurs at
doses normally used for prophylaxis, diagnosis, or therapy.
ADRs are therefore unwanted or unintended effects of a
medicine, including idiosyncratic effects, which occur during its
proper use. They differ from accidental or deliberate excessive
dosage or drug maladministration. ADRs may be directly linked
to the properties of the drug in use, the so-called A type
reactions. An example is hypoglycaemia induced by an
antidiabetic drug. ADRs may also be unrelated to the known
pharmacology of the drug, the B type reactions including
allergic effects, for example anaphylaxis with penicillins. Any
drug may produce unwanted or unexpected adverse reactions.
Detection and recording of these is of vital importance.
In Ethiopia we use passive form of reporting of ADR to
pharmacovigillance center using pre-paid yelow postage which
is avalable in every health facility. Any health professional who
encounterd any type of ADR can fill and send the case free of
charge to FMHACA through nearby post office to:
Food, Medicine and Healthcare Administration and Control
Authority (FMHACA) of Ethiopia
Pharmacovigillance Center, P.o.Box 5681; Addis Ababa
Fax. 251-115-521392
E-mail: [email protected]
Reporting format as shown below

969

970

APPENDIX IV: Medicines Storage Condition

Terms used
1 Store frozen
(in a deep
freezer) (-

Applications
For products, such as certain vaccines,
need to be transported within a cold chain.

20 C
a For products which are very heat sensitive
2 "..in
refrigerator"
but must not be frozen. Appropriate of
or Store at storing vaccines for a short period of time
0

2C

8C

(36 -46 F)
3 in a cool/cold For products labeled to be kept between
0
0
0 0
place
8 -15 C (45 59 F)
4 ".. at room For products labeled to be kept between
0
0
0
0
temperature"
15 -25 C (59 -77 F)
at Store at the surrounding temperature. It
5 Store
ambient
means room temperature or normal
storage conditions, i.e. storage in a dry,
temperature
clean,
well-ventilated
area
room
0

0-

temperature between 15 -25 C (59 77 F)

0

"..protect
from heat"
".. in a dry
place"

or up to 30 C , depending on climatic
conditions
not more than 30oc

relative humidity less than 5%

971

INDICES
Abacavir (ABC), 477
Abacavir sulphate + Lamivudine
+Zidovudine, 494
Abacavir sulphate +Lamivudine,
496
Acarbose, 573
Aceclofenac, 215
Acemetacin, 345
Acetaminophen+Pseudoephedrine
Hydrochloride+Chlorphenira
mine, 185
Acetazolamide, 282, 766
Acetic Acid, 835
Acetylcholine Chloride, 811
Acetylcysteine, 900
Acetylcysteine + Hypermellose,
812
Acetylsalicylic acid, 345
Acetylsalicylic Acid, 682
Acetylsalicylic acid (Aspirin), 215
Acetylsalycilic acid + Caffeine +
Paracetamol, 346
Acitretin, 885
Actinomycin-D
(Dactinomycin,
646
Activated Charcoal, 56, 901
Acyclovir, 501, 788, 861
Acyclovir Cream, 822
Adapalene, 873
Adefovir dipivoxil, 498
Adenine Arabinoside, 503
Adenosine, 84
Adrenaline, 823
Adrenaline (Epinephrine), 172,
195, 759
Albendazole, 544
Albumin, Salt-free, 702
Alendronate Sodium, 374

Alfacalcidol
(1
ahydroxycholecalciferol), 730
Alfuzosin, 63
Allopurinol, 358
Alpha, Beta Arteether, 514
Alphachymotrypsin, 813
Alprazolam, 242
Alteplase, 177
Aluminium Hydroxide, 3
Aluminium
Hydroxide
+
Magnesium
Hydroxide
+
Simethicone, 5
Aluminium
Hydroxide
and
Magnesium Hydroxide, 4
Aluminum Chloride, 893
Aluminum Sulphate + Calcium
Hypochlorite
+
Sodium
Carbonate, 947
Amantadine hydrochloride, 503
Amantadine Hydrochloride, 299
Amiloride, 163
Amiloride
and
Hydrochlorthiazide, 132, 163
Aminocaproic Acid, 616, 684
Aminophylline, 195
Amiodarone, 86
Amitriptyline, 266
Amlodipine, 133
Ammonium Chloride, 708
Amoxicillin, 379
Amoxicilline and Clavulanic acid,
381
Amphotericin B, 464, 527
Ampicillin, 382
Ampicillin sodium and sulbactam
sodium, 383
Ampicillin Sodium and Sulbactam
Sodium double ester), 393
Amrinone Lactate, 73

972

Betamethason, 556
Betamethasone, 835, 864
Betamethasone Dipropionate +
Salicylic Acid, 894
Betamethasone Sodium Phosphate
+
Betamethasone
Dipropionate, 557
Betaxolol, 762
Bethanechol, 368
Bevacizumab, 663, 813
Bicalutamide, 659
Bimatoprost, 769
Biphasic Insulin, 574
Biphasic Isophane Insulin, 575
Bisacodyl, 44
Bismuth compounds, 22
Bismuth Subgallate, 59
Bismuth Subgallate + Bismuth
Oxide + Peru Balsam, 59
Bismuth Subgallate + Bismuth
Oxide +Peru Balsam + Zinc
Oxide), 59
Bismuth subsalicylate, 22
Bleomycin, 646
Bretylium Tosylate, 87
Brimonidine, 764
Brinzolamide, 767
Bromazepam, 243
Bromhexine Hydrochloride, 185
Bromocriptine, 300
Bromocriptine Mesylate, 617
Bromofenac, 793
Budesonide, 197, 749
Budesonide
+
Formoterol
Fumarate, 198
Bupivacaine, 341
Bupivacaine Hydrochloride, 618,
809
Bupropion, 277, 308
Buspirone, 253
Busulfan, 639
C3F8 Gas Injection, 815

Amyl
Meta-cresol
+
Dichlorobenzyl Alcohol, 823
Anastrazole, 658
Antazoline + Naphazoline, 797,
824
Anticoagulant Citrate Dextrose
solution
(ACD
Solution)
Sodium Citrate + Citric Acid +
Dextrose, 947
Anti-Rho (D) Immune Globulin,
919
Apomorphine Hydrochloride, 901
Apraclonidine HCL, 763
Artemether, 514
Artemether + Lumfantrine, 516
Artesunate, 515
Ascorbic Acid (Vitamin C), 731
Atazanavir, 486
Atenolol, 121, 133
Atomoxetine, 305
Atorvastatin, 105
Atracurium Besylate, 326
Atropine Sulphate, 26, 332, 777,
902
Azathioprin, 664
Azelaic Acid, 873
Azithromycin, 412
Baclofen, 363
Barium Sulfate, 947
BCG Vaccine, 920
Beclomethasone
Dipropionate,
196, 824
Benoxinate hydrochloride, 809
Benzhexol
(Trihexyphenidyl
Hydrochloride), 299
Benzodiazepine therapy, 241
Benzoic Acid + Salicylic Acid
(Whitfields Ointment), 842
Benzoyl peroxide, 874
Benztropine Mesylate, 301
Benzyl Benzoate, 857

973

Calamine, 882
Calamine + Zinc Oxide, 882
Calciferol (Ergocalciferol/Vitamin
D2), 732
Calcipotriol, 879
Calcium, 709
Calcium Carbonate, 6
Calcium Caseinate, 727
Calcium Chloride, 717
Calcium Folinate, 710
Calcium Folinate (Leucovorin
calcium, 687
Calcium Folinate (Leucovorin
Calcium, 655
Calcium folinate and Folinic acid,
903
Calcium Glubionate + Calcium
Galacto gluconate, 711
Calcium Gluconate, 711
Calcium gluconate (levulinate),
718
Calcium Gluconate (Levulinate,
or Chloride), 903
Calcium
Hypochlorite+Iron
Sulphate+
Bentonite+Potassium
Permanganet Polyacrylamide
+ Sodium Carbonate, 947
Calcium Lactate, 712
Candesartan, 134
Candesartan
and
Hydrochlorothiazide, 136
Capecitabine, 651
Capreomycin, 444
Captopril, 74, 136
Captopril + Hydrochlorthiazide,
137
Carbamazepine, 282
Carbenicillin, 384
Carbimazole, 567
Carbocisteine, 186
Carvedilol, 138

Cascara Sagrada, 45
Castellani's paint (Magenta +
Boric Acid + Phenol +
Resorcinol + Alcohol 90 % +
Acetone), 843
Castor oil, 45
Cefaclor, 398
Cefadroxil, 394
Cefditoren, 401
Cefepime, 402
Cefixime, 403
Cefotaxime, 404
Cefpodoxime, 405
Cefprozil, 399
Ceftazidime, 406
Ceftriaxone, 407
Cefuroxime, 400
Celecoxib, 217
Cephalexin, 395
Cephazoline Sodium, 396
Cephradine, 397
Cetirizine, 749
Chloral Hydrate, 248
Chlorambucil, 640
Chloramphenicol, 430, 782, 836
Chloramphenicol
+
Dexamethasone, 805
Chloramphenicols, 430
Chlordiazepoxide, 243
Chlordiazepoxide + Clidinium
Bromide, 26
Chlorhexidine Gluconate, 824
Chlorhexidine
Gluconate
+
Cetrimide, 891
Chlormezanone + Paracetamol,
364
Chloroquine Phosphate, 517, 523
Chlorpheniramine Maleate, 749
Chlorpromazine Hydrochloride,
32, 254
Chlorpropamide, 581

974

Cholecalciferol (Vitamin D3), 734

Cholestyramine, 107
Chorionic Gonadotrophin, 587
Cimetidine, 10
Ciprofloxacin, 421, 783, 836
Cisatracurium, 327
Cisplatin, 665
Clarithromycin, 414
Clindamycin, 432, 534
Clindamycin Phosphate, 851
Clioquinol, 851
Clioquinol +Flumethasone, 837
Clioquinol+ Hydrocortisone, 869
Clobetasol Propionate, 864
Clofazimine, 461
Clomiphene Citrate, 618
Clomipramine
Hydrochloride,
268
Clonazepam, 284
Clonidine Hydrocloride, 138
Clopidogrel, 683
Clotrimazole, 465, 619, 825, 837,
844
Cloxacilline sodium, 385
Clozapine, 256
Coal Tar + Salicylic Acid, 874
Cocain Hydrochloride, 837
Cocaine Hydrochloride, 342, 810
Codeine Phosphate, 186, 230
Colchicine, 359
Conjugated estrogens (equine,
587
Conjugated estrogens (equine)
(initial phase) + Conjugated
estrogens
(equine)
and
Medroxyprogesterone acetate
(second phase), 589
Conjugated
estrogens
and
Medroxyprogesterone acetate,
589
Copper T 380 A, 606

Crotamiton, 857, 882

Cyanocobalamin (Vitamin B12),
688
Cyanocobalamine (vitamin B12),
734
Cyclopentolate
Hydrochloride,
778
Cyclophosphamide, 641
Cycloserine, 445
Cyclosporin A, 921
Cyclosporine, 793
Cyproheptadine Hydrochloride,
750
Cyproterone acetate and Ethinyl
estradiol, 886
Cytosine
Arabinoside
(Cytarabine), 651
Dacarbazine, 665
Dalteparin, 673
Dantrolene sodium, 364
Dapsone, 461
Darunavir, 491
Daunorubicin Hydrochloride, 647
Dehydroemetine, 524
Dequalinium chloride, 826
Desferrioxamine Mesylate, 904
Desloratadine, 750
Desmopressin Acetate, 552
Desoximethasone, 864
Dexamethasone, 559, 803
Dexamethasone
Acetate
+
Clotrimazole, 869
Dexamethasone
sodium
Phosphate, 865
Dexchlorpheniramin, 187
Dexchlorpheniramine
+
Guaifenesin
+
Pseudoephedrine, 188
Dexchlorpheniramine
Maleate,
751
Dexchlorpheniramine Maleate+
Betamethasone, 752

975

Dextran (MW 40, 000), 703

Dextran (MW 70,000), 704
Dextroamphetamine, 306
Dextromethorphan
Hydrobromide, 188
Dextrose, 720
Dextrose in Normal Saline, 720
Diaphragm with spermicides, 607
Diazepam, 243, 285, 365
Dichlorobenzene + Chlorobutol +
Turpentine oil, 838
Diclofenac Diethylamine, 346
Diclofenac sodium, 347, 794
Diclofenac Sodium, 218
Diclofenac sodium + misoprostol,
220
Diclofenac sodium + Misoprostol,
348
Dicophane (DDT), 947
Didanosine (DDI, ddI), 477
Dienogest, 620
Diensterol, 589
Diethyl Carbamazine Citrate, 539
Digoxin, 75
Digoxin
Immune
Fab
(Ovine)/Digoxin-specific,
Antibody fragments, 905
Dihydroartemisinin, 518
Diloxanide Furoate, 524
Diltiazem Hydrochloride, 121
Dimenhydrinat, 32
Dimercaprol, 906
Dinoprostone (prostaglandin, 621
Dioctyl sodium Sulphosuccinate
(Docusate Sodium), 46
Diphenhydramine Hydrochloride,
301, 753
Diphenoxylate with Atropine
Sulphate, 52
Diphenylhydantoin (Phenytoin),
286

Diphtheria Antitoxin, 922

Diphtheria, Tetanus Toxoid and
Pertussis Vaccine, 924
Diphtherial and Tetanus Toxoid,
923
Disulfiram, 308
Dithranol, 880
Dobutamine, 173
Domperidone, 33
Dopamine Hydrochloride, 174
Dorzolamide, 768
Doxazosin, 63
Doxorubicin (Liposomal), 649
Doxorubicin
hydrochloride
(Adriamycin), 648
Doxycycline, 426
Droperidol, 333
Drospirenone+Ethinyl Estradiol,
600
Drotaverine, 27
Duloxetin, 276
Dutasteride, 65
Econazole, 792
Edrophonium, 369
Efavirenz (EFV, EFZ), 483
Emtricitabine (FTC, 478
Emtricitabine + Tenofovir, 496
Enalapril Maleate, 78, 140
Enalapril
Maleate
+
Hydrochlorothiazide, 79
Enalapril
Maleate
and
Hydrochlorothiazide, 141
Enalaprilat, 140
Enflurane, 320
Entacavir, 498
Ephedrine + Theophyline, 199
Ephedrine sulphate, 198
Ephedrine Sulphate, 826
Epirubicin, 650
Epoetin alfa and beta, 689
Ergometrine maleate, 622

976

Ergotamine Tartrate, 237

Ergotamine Tartrate + Cyclizine
Hydrochloride + Caffeine
Hydrate, 240
Ergotamine Tartrate + Caffeine,
239
Erythromycin, 415, 784, 852
Escitalopram, 272
Esomeprazole, 18
Estradiol + Estriol +Estrone, 591
Estradiol Valerate, 591, 623
Estraiol, 591
Ethambutol, 446
Ethambutol + Isoniazid, 447
Ethanolamine Oleate, 169
Ether, anesthetic, 321
Ethinyl estradiol, 592
Ethionamide, 447
Ethosuximide, 288
Ethyl Alcohol, 891
Ethyl Chloride, 342
Etofenamat, 349
Etomidate, 316
Etonogestrel, 605
Etonogestrol+ Ethinyl estradiol,
592
Etoposide (Phosphate), 656
Etretinate, 887
Ezetimibe, 108
Famciclovir, 504
Famotidine, 12
Famotidine + calcium carbonate +
Magnesium hydroxide, 6
Fenofibrate, 109
Fentanyl, 230, 333
Ferrous Salt, 692
Ferrous salt + Folic Acid, 693
Fexofenadine, 754
Fibrinogen, 684
Filgrastin, 668
Finasteride, 66, 887

Flucinolone Acetonide, 865

Flucloxacillin, 386
Fluconazole, 466
Fluconazole in Sodium Chloride,
467
Flucortolone
Pivalante
+
Chloramphenicol, 805
Flucytosine, 467
Fludrocortisone Acetate, 560
Flumazenil, 906
Fluocinolone
Acetonide
+
Neomycin, 869
Fluorescein sodium, 815
Fluorouracil, 652, 861
Fluoxetine, 273
Fluoxymesterone, 694
Fluphenazine decanoate, 257
Fluphenazine Hydrochloride, 257
Flurazepam, 245
Flurbiprofen, 794
Flurometholone, 803
-Flurouracil, 816
Fluticasone furoate, 200
Fluticasone Furoate, 560, 826
Fluvastatin, 110
Fluvoxamine maleate, 273
Folic acid, 735
Folic Acid, 734
Folinic acid, 695
Fondaparinux, 178
Formaldehyde Solution, 947
Formoterol fumarate, 202
Fosinopril, 141
Furosemide, 164
Fusidic Acid, 852
Fusidic Acid/ Sodium Fusidate +
Bethamethasone, 870
Gadodamide, 948
Gamabenzene
Hexachloride
(Lindane), 858
Ganciclovir, 505

977

Gancyclovir, 789
Gas Gangrene Antitoxin, Mixed,
925
Gemfibrozil, 111
Gemifloxacin, 411
Gentamicin, 417, 784, 838, 853
Gentamycine
+Betamethasone,
805
Gentamycine
+Dexamethasone,
806
Gentian Violet, 827
Glaucoma Filtration tube, 815
Glibenclamide, 581
Gliclazide, 585
Glimepiride, 579, 582
Glipizide, 582
Glutaraldehyde, 875, 949
Glycerin (Glycerol, 47
Glycerol, 770
Glyceryl
trinitrate
(Nitroglycerine, 122
Glycine, 949
Glycopyrronium Bromide, 334
Granisetron Hydrochloride, 33
Granisetrone Hydrochloride, 669
Griseofulvin, 468
Guaifenesin, 189
Haemophilus Influenza type B
(Hib) vaccine, 925
Halazone, 949
Haloperidol, 259
Haloperidol Decanoate, 260
Halothane, 321
Hdroxyethyl starch, 720
Heparin, 677
Hepatitis B Vaccine, inactivated,
926
Hepatitis B vaccine, Recombinant
yeast DNA, 927
Hexetidine, 827
Hexidine, 827

Homatropine Hydrobromide, 778

Human
Antirabies
Immunoglobulin, 927
Human Papiloma Virus Vaccine,
927
Hyaluronidase, 373
Hydralazine, 79, 142
Hydralazine
+Isosorbide
Dinitrate, 80
Hydrochlorothiazide, 143, 166
Hydrocortisone, 561, 760
Hydrocortisone Acetate, 865
Hydrogen peroxide, 828, 838,
891
Hydroquinone, 883
Hydroxycarbamide (hydroxyurea,
666
Hydroxychloroquine, 887
Hydroxyethyl Starch, 705
Hydroxyprogesterone Caproate,
593
Hyoscine
(scopolamine)
Hydrobromide, 779
Hyoscine Hydrobromide, 336
Ibandronate, 375, 671
Ibuprofen, 220, 350, 360
Ichthammol, 881
Idoxuridine, 790
Imipenem and Cilastatin, 408
Imipramine, 269
Immune Serum Globulin, Human
(Gamma Globulin, Human),
929
Imquimod, 895
Indapamide, 144
Indinavir (IDV), 487
Indomethacin, 350, 361
Influenza
Virus
Vaccine,
Polyvalent, 929
Insulin soluble, 575

978

Ketorolac, 795
Ketotifen, 796
KY Jelly (Hydroxyethyl cellulose),
950
Labetalol Hydrochloride, 146
Lactated
potassium
saline
injection (Darrow's solution),
721
Lactated
Ringer's
injection
(Hartmann's solution, 721
Lactulose, 48
Lamivudine (3TC, 479
Lamivudine +Stavudine, 495
Lamivudine
+Zidovudine
+
Nevirapine, 493
Lamivudine+
Zidovudine
(Combivir), 495
Lamotrigine, 289
Lamuvidine
+
Nevirapine
+Stavudine, 493
Lansoprazole, 19
Latanoprost, 770
Leflunomide, 351, 372
Levamisole, 545
Levarterenol
(Noradrenaline)
Tartarate, 175
Levobunolol, 762
Levocabastine, 796
Levocetrizine, 754
Levodopa, 302
Levodopa + benserazide, 303
Levodopa + Carbidopa, 303
Levofloxacin, 450
Levonorgestrel
(D-Norgestrel),
605
Levonorgestrel
(D-Norgestrel)
+Ethinylestradiol and, 601
Lidocaine + Aluminium Acetate +
Zinc Oxide + Hydrocortisone
Acetate, 60
Lidocaine hydrochloride, 90
Lidocaine Hydrochloride, 343

Insulin Zinc suspension/Insulin

Lente, 576
Interferon Alpha, 930
Interferon Gamma, 931
Iodine, 892
Iodine + Potassium Iodide (Aqueous
Iodine oral solution or Lugol's,
566
Iodized Salt, 950
Iohexol, 182
Ipecac, 907
Ipratropium Bromide, 203
Irbesartan, 145
Iron Complex, 698
Iron gluconate + Manganese
gluconate + copper gluconate,
699
Iron sucrose, 699
Isoconazole, 624, 845
Isoflurane, 322
Isoniazid, 448
Isophane/NPH insulin (, 576
Isoplasma, 706
Isoprenaline Sulphate, 203
Isoprenaline(Isoproproterenol)
hydrochloride, 175
Isoproterenol, 89
Isosorbide, 771
Isosorbide dinitrate, 124
Isosorbide Dinitrate, 81
Isosorbide mononitrate, 125
Isotretinoin, 889
Isradipine, 146
Itraconazole, 469, 845
Ivermectin, 540
Kanamycin, 449
Ketamine Hydrochloride, 316
Ketoconazole, 470, 845
Ketoconazole + Zinc Pyrithione,
846
Ketoprofen, 221

979

Mefloquine hydrochloride, 519

Melarsonyl potassium, 532
Melarsoprol, 532
Meloxicam, 352
Melphalan, 643
Menadiol Sodium Diphosphate,
736
Meningococcal
polysaccharide
vaccine, 932
Menthol + Eucalyptus oil + Light
Magnesium carbonate, 828
Mercaptopurine, 653
Meropenem, 410
Mesterolone, 594
Metformin, 580
Methadone, 309
Methadone hydrochloride, 231
Methazolamide, 769
Methionine, 908
Methocarbamol, 366
Methotrexate, 372, 653
Methoxsalen
(8Methoxypsoralen), 884
Methyl Cellulose, 50
Methyldopa, 149
Methylene Blue, 908
Methylergometrine Maleate, 625
Methylphenidate, 307
Methylprednisolone, 890
Methylprednisolone Acetate, 562
Methylrosanilinium
chloride
(Genitian Violet), 844
Methylsalicylate, 896
Metoclopramide Hydrochloride,
35
Metolazone, 167
Metoprolol, 91, 126
Metoprolol Tartrate, 150
Metrifonate, 542
Metronidazole, 433, 524, 626,
853

Lidocaine
Hydrochloride
+
Adrenaline, 810
Lidocaine Hydrochloride and
Adrenaline, 344
Lignocaine + Tribenoside, 60
Liquid parafin, 48
Lisinopril, 82, 147
Lisinopril
and
Hydrochlorothiazide, 148
Lisseman Green, 817
Lithium carbonate, 278
Lodoxamide Tromethamine, 798
Loperamide, 53
Lopinavir +Ritonavir, 496
Loratadine, 754
Loratadine+
Pseudoephedrine,
755
Lorazepam, 291
Losartan, 148
Loteprednol, 803
Lovastatin, 112
Magnesium Chloride, 712
Magnesium Hydroxide, 7
Magnesium Sulfate, 292, 624
Magnesium sulphate, 49
Magnesium Trisilicate, 7
Malathion, 859
Mannitol, 166, 772
Marcaine Hydrochloride, 810
Measles Virus Vaccine, Live
Attenuated, 932
Mebendazole, 546
Mechlorethamine
Hydrochloride(Nitrogen
Mustard, 642
Meclizine Hydrochloride, 35
Mecobalamine, 736
Medazepam, 246
Medroxyprogesterone
Acetate,,
604
Mefenamic Acid, 223

980

Metronidazole + Miconazole, 628

Mexiletin Hydrochloride, 93
Mezlocillin, 387
Miconazole, 471, 828
Miconazole Nitrate, 629, 846
Midazolam Hydrochloride, 246
Mifepristone, 629
Minocycline hydrochloride, 427
Minoxidil, 896
Misoprostol, 15, 630
Mitomycin C, 817
Mometasone furoate, 829, 866
Montelukast, 204
Morphine Sulphate, 232
Moxifloxacin, 785
Moxifloxacin Hydrochloride, 451
Mupirocin, 854
Mupirocin+BetamethasoneDiprop
ionate, 871
Mycophenolic
Acid
(as
Mycophenolate
odium/Mofetil), 933
Nalidixic acid, 423
Naloxone Hydrochloride, 909
Naltrexone Hydrochloride, 309
Naproxen, 353
Naproxen + Esomeprazole, 224
Natamycin, 792
Nedocromil Sodium, 799
Nelfinavir (NFV), 488
Neomycin, 418
Neomycin + Bacitracin, 854
Neomycin
+
Dexamethasone
phosphate, 806
Neomycin + Hydrocortisone +
Polymixin B Sulphate, 807
Neomycin + Polymixin B +
Nystatin, 631
Neomycin Sulphate, 785
Neomycin
Sulphate
+
Hydrocortisone + Polymixin B
Sulphate, 839

Neomycin Sulphate + Polymixin B

Sulphate + Dexamethasone,
807
Neostigmine, 337, 371
Nevirapine, 484
Nicardipine, 150
Niclosamide, 547
Nicotinamide, 737
Nicotine replacement therapy,
310
Nicotinic Acid, 738
Nifedipine, 126, 151
Nimesulide, 354, 867
Nimodipine, 127
Nitrofurantoin, 434
Nitrofurazone, 854
Nitrous oxide, 323
Nizatidine, 13
Nonoxinol, octoxinol, 609
Nonoxynol, 610
Norethindrone (Norethisterone,
604
Norethindrone (Norethisterone) +
Ethinylestradiol, 601
Norethindrone (Norethisterone) +
Mestranol
and
iron
tabletsTablet, 1mg + 0.05mg),
601
Norethindrone (Norethisterone)
Enanthate, 604
Norethisterone (Norethindrone),
593
Norfloxacin, 424
Nortriptyline, 271
Nystatin, 472, 631, 830, 847, 849
Ofloxacin, 785, 839
Olanzapine, 261
Olopatadine, 800
Omeprazole, 19
Ondansetron, 670
Ondansetrone, 37

981

Oral Rehydration salt, 54

Oral Rehydration Salts, 713
Orlistat, 113
Ornidazole, 526
Orphenadrine Citrate, 367
Orphenadrine
citrate
+
Paracetamol, 367
Orphenadrine hydrochloride, 304
Oseltamivir Phosphate, 506
Oxamniquine, 543
Oxazepam, 247
Oxidized Cellulose, 950
Oxygen, 338
Oxygen (white-colored cylinder,
951
Oxymetazoline
Hydrochloride,
797, 830
Oxymetholone, 700
Oxytetracycline, 840
Oxytetracycline Hydrochloride,
786
Oxytetracycline Hydrochloride +
Hydrocortisone Acetate +
Polymyxin B sulphate, 840
OxytetracyclineHydrochloride+
Hydrocortisone Acetate +
Polymixin B sulphate, 807
Oxytocin, 632
Oxytocin + Ergometrine Maleate,
634
Pamidronate, 376
Pancreatin, 57
Pancuronium bromide, 327
Pantoprazole, 20
Para-Amino Salicylic Acid, 451
Paracetamol, 226
Paracetamol + Pseudoephedrine
Hydrochloride
+
Chlorpheniramine, 227
Paracetamol+Acetylsalycilic
acid+Caffeine, 237
Paraldehyde, 293

Paramomycine, 528
Paroxetine, 275
Pemirolast potassium, 800
Penicillamine, 909
Penicillin G, Benzathine, 388
Penicillin G, Sodium crystalline,
388
Pentaerythritol Tetranitrate, 129
Pentamidine Isethionate, 529,
532
Pentamidine Isothionate, 435
Pentavalent (Diphtheria, Pertusis,
Tetanus,
Hepatitis
B,
Haemophilus
InfluenzaeB)
Vaccine, 935
Pentazocine, 233
Pentobarbitone (pentobarbital),
249
Perfluorocarbon liquids, 817
Peritoneal dialysis fluid No, 722
Peritoneal dialysis fluid No., 723
Permethrine, 860
Pethidine Hydrochloride, 234
Phenazopyridine, 235
Pheniramine
Aminosalicylate,
756
Phenobarbitone (Phenobarbital,
293
Phenobarbitone (Phenobarbital),
250
Phenoxybenzamine
Hydrochloride, 152
Phenoxymethyl penicillin, 391
Phenoxymethyl Penicillin, 390
Phentolamine mesilate, 153
Phenylephrine, 779, 831
Phenylephrine
Hydrochloride,
176
Phenytoin
(Diphenylhydantoin
sodium), 94
Pholcodine, 190

982

Physostigmine salicylate, 910

Phytomenadiaone, 911
Phytomenadione (vitamin K1),
685
Phytomenadione (Vitamin K1),
739
Pilocarpine hydrochloride, 765
Pimecrolimus, 868, 897
Pimozide, 261
Pioglitazone, 582
Piperacillin, 391
Piperazine, 548
Piroxicam, 355
Plasma
Antihaemophillic
(Human), 706
Pneumoccocal
Polysaccharide
Vaccine, 937
Podophyllin Paint, 875
Poliomyelitis vaccine, Trivalent,
937
Polygeline + Na+ + K+ + Ca++ + Cl, 707
Polymyxin B + Bacitracin, 786
Polyvinyl Chloride, 817
Potassium chloride, 714, 723
Potassium permanganate, 892
Povidone - Iodine, 831, 892
Povidone Iodine Solution, 818
Pralidoxime Chloride, 912
Praziquantel, 543
Prazosin Hydrochloride, 67, 154
Prednisolone, 562, 804, 890
Prednisolone
Caproate
+
Dibucaine Hydrochloride +
Hexachlorophene + Clemizole
undecenoate, 61
Primaquine, 541
Primaquine phosphate, 520
Primaquine Phosphate, 535
Primidone, 295
Probenecid, 361

Procainamide hydrochloride, 94
Procaine Hydrochloride, 811
Procaine Penicillin, Fortified, 392
Procarbazine, 667
Procyclidine, 304
Progestogen - only contraceptives,
603
Progestogen-only contraceptives,
599
Promethazine, 252
Promethazine Hydrochloride, 39,
756, 761
Propanocaine Hydrochloride, 811
Propantheline Bromide, 29
Propofol, 317
Propranolol, 96, 129, 155, 240,
567
Propylthiouraci, 567
Protamine Sulphate, 911
Protionamide, 452
Pseudoephedrine + Loratadine,
832
Pseudoephedrine Hydrochloride,
832
Psyllium, 50
Pyrantel Pamoate, 549
Pyrazinamide, 453
Pyridostigmine bromide, 371
Pyridoxine
Hydrochloride
(Vitamin B6), 739
Pyrimethamine, 535
Quinidine sulphate, 98
Quinine Dihydrochloride, 521
Rabies (Human diploid cell)
vaccine, 940
Rabies Antiserum, Equine, 938
Rabies Vaccine, 939
Rabies Vaccine, Duck Embryo,
940
Raloxifene Hydrochloride, 662
Raltegravir, 492

983

Ramipril, 155
Ranibizumab, 818
Ranitidine, 13
Reserpine, 156
Reteplase, 180
Retinoic Acid, 876
Ribavirin, 499, 507
Rifabutin, 454
Rifampicin, 455, 462
Rifampicin + Isoniazid, 456
Rifampicin
+
Isoniazid
+
Pyrazinamide, 456
Rifampicin
+
Isoniazid
+
Pyrazinamide + Ethambutol,
457
Rifamycin, 787
Ringer's injection, 724
Risperidone, 262
Ritodrine Hydrochloride, 634
Ritonavir (RTV), 488
Rituximab, 663
Rivaroxaban, 181
Rose benegal, 819
Rosiglitazone maleate, 583
Rosuvastatin, 114
Rota Virus Vaccine Monovalent
(P1
[8],
G1]),
Bivalent,
Pentavalent (G1, 2, 3, 4, 5 and
P1 [8]), 941
Saccharin, 952
Salbutamol, 635
Salbutamol (Albuterol), 205
Salbutamol + Bromhexine +
Guaifenesine + Menthol, 206
Salicylic Acid, 847, 876
Salicylic Acid +Betamethasone
Dipropionate, 877
Saline Solution, 832
Salmeterol + Fluticasone, 201
Saquinavir (SQV), 489
Saxagliptin+ Metformine, 584

Scopolamine
(Hyoscine)
Butylbromide, 27
Scopolamine
(hyoscine)
Hydrobromide, 28
Scorpion
Venom
Antisera
(Scorpion Antivenom), 941
Selenium Sulphide, 848
Senna, 51
Sertaconazole Nitrate, 473
Sertraline hydrochloride, 276
Sevelamer hydrochloride, 69
Sevoflurane, 324
Sildenafil Citrate, 612
Silicon oil, 820
Silver Nitrate + Potassium
Nitrate, 878
Silver Sulphadiazine, 855
Simethicone, 56
Simvastatin, 117
Snake
Venom
Antiserum
Polyvalent, 941
Soda lime, Carbon Dioxide, 339
Sodium
Alginate+Magnesium
Hydroxide+Aluminum
Hydroxide+Siimethicone, 8
Sodium Bicarbonate, 715, 724
Sodium Calcium Edetate, 913
Sodium chloride, 725
Sodium Chloride, 716
Sodium Chloride Free Salt, 952
Sodium Chromoglycate, 832
Sodium cromoglycate, 799
Sodium Cromoglycate, 207
Sodium
Dichloroisocyanurate,
953
Sodium Fusidate, 856
Sodium Hyaluronate, 820
Sodium lactate, 726
Sodium Nitrite, 913
Sodium Nitroprusside, 157
Sodium Polystyrene Sulphonate,
914

984

Sodium Stibogluconate, 530

Sodium Tetradecyl Sulphate, 171
Sodium Thiosulphate, 914
Sodium Valproate, 295
SodiumMorrhuate, 170
Sorbitol, 953
Sotalol, 99
Sparfloxacin, 425
Spectinomycin, 437
Spiramycin, 536
Spironolactone, 168
Stavudine (d4T), 480
Streptomycin Sulphate, 457
Sucralfate, 23
Sulfadiazine, 536
Sulfadoxine +Pyrimethamine, 537
Sulphamethoxazole
and
Trimethoprim, 437
Sulphasalazine, 355
Sulphur, 860
Sumatriptan, 240
Suprofen, 795
Suramin Sodium, 533, 541
Suxamethonium Chloride, 329
Tacrolimus, 942
Tadalafil, 612
Tamoxifen Citrate, 660
Tamsulosin, 68
Telbivudine, 501
Temazepam, 247
Temozolomide, 643
Tenecteplase, 182
Tenofovir (TDF, 482
Tenofovir +Lamivudine, 495
Tenoxicam, 356
Terbinafine HCL, 473
Terfenadine, 757
Terizidone, 458
Testosterone, 595
Testosterone propionate, 595
Testosterone Propionate, 661

Testosterone
propionte
+
Testosterone
phenyl
propionate
+Testosterone
isocaproate + Testosterone
decanoate, 596
Tetanus Antitoxin, Equine, 944
Tetanus
Immune-Human
Globulin, 944
Tetanus Toxoid, 945
Tetracaine hydrochloride, 344
Tetracaine Hydrochloride, 811
Tetracycline, 787, 856
Tetracycline hydrochloride, 428
Tetracyclines, 426
Theophylline and Guaifenesin,
209
Thiabendazole, 550
Thiamine
Hydrochloride
(Vitamin, 740
Thiamphenicol, 431
Thiethylperazine Maleate, 40
Thiopental sodium, 318
Thioridazine Hydrochloride, 263
Thiotepa, 644
Thyroxin Sodium, 568
Timolol + Bimatoprost, 772
Timolol + Brimonidine, 774
Timolol + Brinzolamide, 774
Timolol + Dorzolamide, 774
Timolol + Latanoprost, 775
Timolol + Pilocarpine, 775
Timolol + Travoprost, 775
Timolol Maleate, 763
Tinidazole, 525
Tobramycin, 419, 787
Tobramycin + Dexamethason,
808
Tolazoline, 158
Tolbutamide, 585
Tolmetin sodium, 357
Tolnaftate, 849

985

Topiramate, 297
Tramadol, 235
Travoprost, 770
Triamicinolone, 868
Triamicinolone Acetonide, 563,
833
Trichloroethylene, 325
Trifluoperazine
hydrochloride,
264
Trifluridine, 791
Trimetazidine, 129
Trimethoprim, 439
Tripotassium
Dicitratobismuthate, 23
Triprolidine Hydrochlorides, 758
Tropicamid + Phenylephrine, 780
Tropicamide, 780
Trypan Blue, 820
Universal Antidote (charcoal +
tannic acid + magnesium
oxide), 914
Urea, 898
Ursodeoxycholic Acid, 118
Valaciclovir, 508
Valsartan, 158
Valsartan +Hydrochlorthiazide,
159
Vancomycin, 440

Vardenafil, 613
Vasopressin, 553
Vecuronium Bromide, 328
Verapamil, 160
Verapamil Hydrochloride, 102
Vidarabine, 791
Vinblastine (Sulphate), 657
Vincristine Sulfate, 658
Vitamin A, 741
Vitamin A + D, 744
Vitamin B complex preparations,
744
Vitamin E, 743
Warfarin Sodium, 680
Water for injections, 953
Xylometazoline
Hydrochloride,
834
Yellow fever Vaccine, 946
Zalcitabine (ddC, DDC), 480
Zidovudine / Azidothymidine, 481
Zinc Oxide, 881
Zinc oxide + Talc, 881
Zinc Sulphate, 55
Zinc undecenoate + Undecenoic
Acid, 850
Zoledronic acid, 671
Zolpidem, 248

986

987